<SEC-DOCUMENT>0001741830-20-000018.txt : 20201118
<SEC-HEADER>0001741830-20-000018.hdr.sgml : 20201118
<ACCEPTANCE-DATETIME>20201118080500
ACCESSION NUMBER:		0001741830-20-000018
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201118
DATE AS OF CHANGE:		20201118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kronos Bio, Inc.
		CENTRAL INDEX KEY:			0001741830
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39592
		FILM NUMBER:		201323013

	BUSINESS ADDRESS:	
		STREET 1:		1300 S. EL CAMINO REAL
		STREET 2:		SUITE 300
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94402
		BUSINESS PHONE:		212-871-7920

	MAIL ADDRESS:	
		STREET 1:		1300 S. EL CAMINO REAL
		STREET 2:		SUITE 300
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94402
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>kron-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:24f323b6-3e05-4299-b60b-ed7d0f94eb5e,g:b8dc781a-ce5b-4a7b-a930-702eddd4413f,d:d4bb4e4f9863422ab5c3f3e7868262d4--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:kron="http://www.kronosbio.com/20200930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kron-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzMtMS0xLTEtMjIwNA_5c7ea0df-1340-496a-be95-43aba84ffc40">0001741830</ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzQtMS0xLTEtMjIwNA_85f1a89b-fab3-4e72-9407-aba8ccd70fca">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzUtMS0xLTEtMjIwNA_20cb3805-01ed-4075-af6e-3bead042d50e">2020</ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzYtMS0xLTEtMjIwNA_a647f88a-2b08-433c-8aac-bd76fde83842">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzctMS0xLTEtMjIwNA_b5a44acb-1636-4bca-b801-d0d86c3b4efd">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84MzkvZnJhZzo0YzcwMmZlZTU3Zjk0OTRkYTY3YTEzYjdkNDI2N2QwZi90YWJsZTpjODJiZjQxYTdjZTE0YTMyOTIzODJkOGIxMTUzNjVlZi90YWJsZXJhbmdlOmM4MmJmNDFhN2NlMTRhMzI5MjM4MmQ4YjExNTM2NWVmXzItMS0xLTEtMTA0OTY_145d7972-71a7-4821-980c-6bbdef49232d">10.5</ix:nonNumeric><ix:nonNumeric contextRef="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84MzkvZnJhZzo0YzcwMmZlZTU3Zjk0OTRkYTY3YTEzYjdkNDI2N2QwZi90YWJsZTpjODJiZjQxYTdjZTE0YTMyOTIzODJkOGIxMTUzNjVlZi90YWJsZXJhbmdlOmM4MmJmNDFhN2NlMTRhMzI5MjM4MmQ4YjExNTM2NWVmXzQtMS0xLTEtMTA1MTk_b701b4c6-8e94-4c2f-bd6d-2f93001e8c5b">4.7</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kron-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic875b4ec6f6440d5a5659f163d10c799_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2277693b6fbc4690a6679221de27b1a2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f8e95f9bad0404484cd92bc97317806_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fc452a116164f07ab8c6db2e41a54a2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21cf7c43c804ff58bb10d3f479807f1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b70948b6ee4fedbe87831200d026b1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id950e5b1ee3743abb012a5fa0a2d1172_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87511770e86434c8b397546525820c3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc0f3c260074cab9565bcf4c504aca2_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03886d7b8ad440cf91b6f137373f3fe4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d088ea318046c28ff574bbc24a4539_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3ddd1ef68df4a7491812cbb786883ba_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa65bad82b9e4ad2a2bd21cd489827cd_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96feaae211f5437abfe5df9cb2556889_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i398f3cb912cc4c3b8389921c5e59690d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a73e8597e49499c83e7d630d13b969f_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215f3d19ff10462fac7d04a82c46e12b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4b14f7eb2344feb5abbff653d77cc3_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e94cc8395934b1f8041da5f310ddcd6_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf12f6d5105c4cb49c04cb538332565f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33964ca9f59949bd8a0dad9cc8ddf198_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fa48a0f98ad4d87aab5fba5718268f5_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87fb0d1895c24824b9493d143c45cf5f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i765953ff2adb498fa37b7ff3e73d477d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7da5cd1e28af4f31bab4ef99a9a22778_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4488d94b40c645b8b0eec4586e9ffaa1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3d2666a19540bd8e3b415b1e862d28_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47a2ad7dc20e45f8a10245fcd852cd7f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia81288a6a3fa4a88a8f294d3b0df8299_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7b7bb754ddc40bbbd810ba27db95742_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7a3a26575a447b0a22f44539d68c78f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08a06283a2d4d1391878f6cd94cc735_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i873ef3d6e24746a29e6379448312fad6_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50164c6c882d42f3919eca44154397d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f99d002a8a4eaaa64cf919ecdea498_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1dd1ee47d2a4d7e94466a527f95e4dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3528d13cf33844ac95aedb7d3764991c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07bca622fbaa4a77834306e2dc4158cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c535b861b90421a981086e2092d7c25_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i115b646974a740c39cf4aca40b4727a2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30a2c5294eeb4d659c07857d5b23eecc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae1bc220d124171941ce912959a757d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i843c9dde5a3b4b64b5716b83abdb8982_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1fcf856179f4d0a8fb0794daa7e6d02_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7b0100128e94091ac9bab9b50f79c03_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8deeaad6f2634e11b9f9c0316139d717_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6646e83b8de940969fc96333ff6a7d2a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c5ebc92f654f8491c5de314a112730_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b83d5eb6d345538b2d5d4cb90f98e1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07042dba8294acc85fb47df8bbcc218_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7555544cb3f7417ab92209c0d2f251b7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1310705bc7ae4f78af0e8a824858b5c5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie28a26a8d7224bd8901bf199a0538658_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40dd880b211e46408cac612575b17ac5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a6843fec8241b0882996b9484b444f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09b579f33f344c7b796c94598c93ab2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie598b98bcf9d47bd8f9ada78c710b752_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad6f77124e9847649d247673b804dde9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc2dc2098a3453c85866e5fdf18f779_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e14aee510204c7b89e48f9e27f07afc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd881c372af5476a8da370cfe8309eeb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia328bcbcb2f049488186eac987fe0643_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c4ed6efa7740e18904bfe97dd36b05_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>kron:segment</xbrli:measure></xbrli:unit><xbrli:context id="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47233a942abf4a268c14b15bafb9f5e0_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312337076930421489dbae527af0c6a2_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba04a0b8630a43e7a31aa41fb7a542f6_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib50ec0c321854506a6168bb676c9bb98_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ec867a047842948219312d9ab1388e_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb3c774af9d4c178d3cac868b3c195a_D20170602-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-02</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i5c23b681d5c84ca1bf3cfe7435c3e188_D20201002-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-02</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58709a1025434a858b79101128c97c2e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:AssetAcquisitionAxis">kron:GileadAssetPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaddbc37c40784a41b4cba75355474170_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:AssetAcquisitionAxis">kron:GileadAssetPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7368251cdbf04660970e56374215be24_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica62b3a4be464cb3bc3599acf158c2ae_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icebd3a6e85524ddfae7ab2d335391a20_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3525e299a5b4af0be5bf6819c729869_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefc9cad03a70461aa7360544a7db02b8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3880408e89894aeda2c8f29fbbd3aabb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf34c2cfcabc444f928cf7c4d4f21f48_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0ea2ec1be444c429b071d6fbb31c541_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34a2a0c9723b4043be099d02b2adcda9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31eb8916a43d46619bd5de6a14b21fcf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1322d5329804324b8862de983107090_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d7755090cf442b9c9553d09c0c78e4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3736170b03754b159e40f2cbb89bdfc6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i680604ecdff84d6583da30f5932ef047_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98808ce4a14e4f6d9893eafb8348f14f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae3269eca18443ca8f367f8ca760d4d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fc21197ebfa4519b5f3821c2e7bd9cd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c6f85d2f9144b0f9c6655f0a45deb0b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i573369416f3145549249238391de4f54_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2166333152034a59828414d7b029805f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c12e5ec7e247b29b2dbcedcb33e438_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474c4138d7474661a524846e44986c19_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb3393bbb6f14657970ffb6c3b9bf796_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ed0d5b5fee34c9da760299481d92409_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3e139b86417413ba1c2ca3b42137fc7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35673f0d42234a1a87f1a231ace9457d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5bdf1d474b04179a7a68c046db8a473_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd30a89a052a4593801ad15c7befa88a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd9407ea32a46d29a98b1840c00b5e5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bf649645154449d937a12dc7b650d3b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if583afaf5b244bcca3ee512b9be88c54_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84e2789cb4b74177b02829790b3e940d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37461a4dccc543c794502b870925d09a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia34dc0fe00ef4ae7b9326ac0de29b988_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f8d077e88bd4026bd1bb0363cba99a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a45a3c22d2a4df687077e2744eeadf4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1d31ded16544421a9103017ada1e3d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8e7dcee3fb74a77a44721d2eede0234_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4076df8add474ba29dc5b999506194be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e6b6f0456e4402a51dcd58d9f97704_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideaf848d46684b1688cbb86308ac9126_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2dff33c792e472cb04f1f4a0c4177c6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230135e8439a495f98bb16d12950f814_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f054c8a6945414f871dddd891074dfd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i779c812cecca45018028a8b1b19645f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fbc7564af4d4ca8ab0b6d6ee3eca9e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4779748a74d4a69825b5e0020c5ba68_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93643158b5c54d28a5f5e8c68a1277e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6335bb67f9274f448c80b37b25c8a24b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799ef75758464399a4c6a7a23c3f174d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b6a69f036854687b46ff68bdaa0cd34_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf3accbd97d64e20abccd18a3f976641_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9ccd829968847d0a85a4e061e73e94a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4218d1af33444d8792019dd29458c211_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bef37ea13804aa98d20b37c8a9755f2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc6a9845420549d1b467cec0513db1ff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia172359196044363a8d21deea37250a0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica89d2973d6e42c69a454cbcfad99204_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76a3c48f37e74d588132870025f958b3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i903c1dd51d3f4f3294ec6e9659628839_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1522d2b251964ba5a986cdf9d5591a43_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if34c5b72f428403a99b45063852c073b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b10d2d52aec4721944b453f9433b17a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62e3f25eb0c84772add6ec6f825655e0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc04e4557db74cd5a579218a21c7f715_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee26b5d7183c4798998478356fcefae4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie80dcec257aa4382b7cd1712a6f7b431_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c206960ada7462e824eea778e31e777_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23250faf272245f5a94cf235af7afc83_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32dc3ea144344868a7ed2a838d5f9fc6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3898290b234512a7b35eb92edd64fb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1515d6ea7fa64e37b804f072218ceeaa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd7af7df3693489cbbd3c087fa18aa9b_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kron:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1737f19c2c5741778344526c60c0bf8b_I20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kron:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacd7aa366554a0abf8c53a9d66b1c77_D20190701-20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ce35e12ca14274b80c3a91dc888b6c_I20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kron:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72eae238362f4c8b8de479d633195c0d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfef7d206519439a936e6eb262b31e71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kron:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dc130be29104c028617076697807621_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3690868d9bd846d58fea672236b4ef2f_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc479aee05e472aaa0315eec9166109_I20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13481663bdd345c8b1e8be6825bfce9d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9c2bbd688841678d9a85d7983c2cfd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0730288162bf44dea2732ca595d2a797_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d5a83c4e52a4e4b837319163fdc11bd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6347ac3253f4253ba6ddc43e9544f3d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608787e5e840492dac11e9916bd81793_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c0d6cc50b8e49aca2ce81649e3efb0a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id555f67142ab472db96a2d992d964d82_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb629f251d5f424b8c936814babcc4f6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b76d71920eb47b9b25ad42914b7f4b0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fa6a9b2386942c4a674dfa9c9918c8a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb0c54a250748e2bd702dfc80c5dca5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6bc89ef445474790f3d6a61419f2a0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic510c74d485b4029bb4fefcd43dd7a70_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ef266f587f64a7798fcaaa861326c3c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b5e3dc5e7d94133a087d964992323e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38dd8b9841e644e0a406a3e2b3439dec_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08c6c6f783f041ae92c761672b2966aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb0ef90a61349be85e69f64dcaf4055_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ebb89160a743719ce7b11be1918ff8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:ExecutiveEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eea990477a54f47bacea5aed627224f_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:ExecutiveEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd203f8d19ab4cb7ba2e8763e4797437_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a4a632dbe23409c87fb1cb29d8c6158_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i694e0708e4ee460d962dcdf8b06c84b3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic973ed0f6744448cac474a05a81e7803_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b46cef6f87e4fecbc3caaa9619f38f5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3fb6aa27992434fbc43f1d769315cae_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ba0aba4eac64967a28041b82683a193_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i223930fbcee8485494d93864723c1094_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff773b2225814be2bd54a5fabb6156f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i987eec82cc864592a298066957f8a94b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24fc0801a2ef47149bd82ac3437499a4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ca6bc47f334d828c27e5e2e5f3288d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21e4dfab6f3d4306b4f260d7d24f30cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e439c793aa6461ba7288faa23830525_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">kron:StockOptionsEarlyExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bc87606b0ba41f9a3cf5ea58af93b90_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">kron:StockOptionsEarlyExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5bab20c255c46269a25294cdd840266_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bef5ce38731457493cfc788f479063e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4dd19cf017640d5a992af85e6743b2b_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:AssetAcquisitionAxis">kron:GileadAssetPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcdc628eb6df4f0bb5c79f1d07222825_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aa8d7617e6248f49f8f5e9c3f2f946d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b189c5eff6848ada547002d5d66c700_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486cac36f7944dbfbac5953889346c1e_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib714cc1a7a1046e1bed70ca7b135cbda_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88cd4588864e407facd4e99fbcae11bc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51068c8029ef42c399d8e6f8a7fe8997_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b0031b2310d43fd96017f1c5a5a7ecd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc78d3feb68447fad1581a1f5d31298_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a405d92641543f7bddb7edda6fa1ae2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a507464b5342f5bf93741aebc293b7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e7237fee96140989757ebe5aca441fa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb97e3d8c6848998adba729a721a4cc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb03e961bb854f9fa74406cd020a41d8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d9088eb63e343bf87263a6d2eacd1cc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i620aab95020a4e98b682a7a22af3c0a7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f897da9f4b94b72b44c2e02de325360_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c0e7dc1935d48da9c69163a1164cb59_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac4e5e570b0944eaa1dd8ba60b2886df_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ced39808984c03a296264c3ea65adc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i851ff4900ea249cda09f664b0212918d_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99e131dd6404121b4e194d9356f67ad_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616172ed102541feb61d3c1b5cead753_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib79a6a6966a34788a0429125557e239f_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd88330648594bcabdc951197524d855_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i631c46c59d354aa580f1ad4e832c8861_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2666b9ac19e49baab7aca87809bf7c6_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib728710261c742538e0fcb8346b1c830_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86502c45f58b4b9f9337f25a9ea085a3_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcfcef6f36724f44b53de7181f6c587d_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i001fd52a7b1e4106a06c40add33e03e1_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17af873f453147b4b57bd13a9c4f867d_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i163397f07fc24c7fa96b425b3dae61a6_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a50cdf7028c44ca97bad3a2559a8ea7_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c37e34655d34543ac8add2eaa2cbb87_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib041367f98b84d5faa59bdf5673a3592_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:A21ErieStreetCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a92a2894224488c9e94058000096ced_I20200301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:A301BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i8f951b9cc2d342b394ec7ff04e4d40a9_D20200301-20200301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:A301BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b773488624d4ae486e3123cdebd12c2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:A301BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3234c4fd018b4ff6ae61cebd2fd7b666_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad0893c755d45138461981a7756615e_I20180801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icffc314b519d440aa9f7fa06b641a760_D20180801-20180801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6517aa7d879f44528a2d88e8c188d509_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676113738ba64cf9bfb99cf6d7419962_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i623e9b9d16b249bda0eeafb5a7270517_I20200701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaAdjacentSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b09b6cd908145558102a1d2ebca38a9_D20200701-20200701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaAdjacentSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaAdjacentSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbecda89de7840548904aa4dd3124d22_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:RDEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77faf9def6034a17a43362f8c79b789c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">kron:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a7c2fa9dca4beab08872d278639b3d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">kron:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff1ad401e98742ddb6abcc5503e71ad1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">kron:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id688172e6cde48eeae48e9a213f81cb5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">kron:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieed7f26a9c4d41b290ef0ca4f65ed6b7_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b7d39d86434ec791e9c67d78593194_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5ac0bb41ed144069f9ed35f0501c5ff_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea6fedb22e248bdb67c280feee123df_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f6001b206b54c728c11f91d8f95efb7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32a5d81edc2c45aaa7af987dd2ec57b2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:SeriesBScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8c0d66302445e9a58d268bbad55dc8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FinancingScenarioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d56dfa261f8415b8e8a2412f974446b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c80af886534e0e839a947a487fabc6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:SeriesBScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15541111cc0147dcaa8140563fa4f2f2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FinancingScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23666d2a49a44d07afcdc32b368ec048_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81df50dc201b4b8ea1c8247921d8ca17_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:SeriesBScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35f23e6018f34b819e4f9ad667f5b07e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FinancingScenarioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c9e8411b1234b0ea5b11006c170b729_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19dd6da6c7b34b17b50df3ce81d9dd81_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i732fa4350e424f4bb60a16a35c6aa5cf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013165bd63c141f78e3b0ec48d6aeb39_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:TwoRiverConsultingLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1c4ce7e09f4609b89a6586759b8444_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:TwoRiverConsultingLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2997d3b39e44c049e46716565e334c4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:TwoRiverConsultingLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e930125986d43ccab7955e01aa7d87f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:TwoRiverConsultingLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef3396d498f4831ab1ac220e09caad2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e707633da84487498c2674c190517d8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d8ea9d54ffb45dc8de4f5d3a62c8776_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51fbcc82facb4e78bbf3571c3a7b333b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2696f8ecf0246daa8d17d75de9abb4d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fbdca86d2ea46a5a02388d0823daea8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc38fa9749f94b56b8bd462c4e5b894b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447ffc13a5e74bdf9f0ed1c954749058_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3abdc990ab4085bba504ea15586fb0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6bc7aed10264332996827a2e1c4b226_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75d1b3f7102a450088f5769228278051_I20201014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i354b6c38321f418e8ea03e729e783986_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide813d6d56e94d6eab30a8e7472b2e0d_I20201008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:A2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5bf533181c044de8807c924d489d6e6_I20201008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63f36e0c9f049a4a09953343fbdb606_D20201001-20201118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd40f9ae2ea3456890d775273e5e0e55_D20201001-20201118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac6a536633140c584616f4aaff231e3_I20201118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001741830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kron:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-18</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTItMy0xLTEtMA_c5bdbdb7-9e21-44ad-8ac8-e2ab8ec88e9e id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtMA_d05a5384-e248-4030-a9cf-17cdd1ccf138 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjgtMy0xLTEtMA_303524e9-a85d-41a3-bff2-33bd1fe342e2 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjEtMy0xLTEtMA_f84feb2d-73c3-4aba-9559-c0ead7335b39 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTMtMy0xLTEtMA_9276a3d8-cc19-42c6-b38f-6cfc9f4c097f id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOC0zLTEtMS0w_5b95e419-e2ea-434e-833a-e07994cad3b6 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTgtMy0xLTEtMA_414422d2-b987-4a31-90f8-d3a1822608ff id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTEtMy0xLTEtMTc1_238e1a5e-cfcb-4dfc-93ac-9e82ee1ea9b1 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjItMy0xLTEtMA_7336a50e-0972-47cb-b658-c50350b82e43 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTktMy0xLTEtMA_5df9ec80-449c-4bc2-9cd5-fde54eefbebe id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNy0zLTEtMS0w_7b294014-cf51-4f5d-abac-68c1e70d5d4a id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzEtMy0xLTEtMA_0ca701ee-1ad6-4424-b3dd-17217e95139c id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtODQ2_252d2175-5e02-4f30-827b-5a392ef0b3fe id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjQtMy0xLTEtMjMyNg_adb29f22-92ac-48ab-ad38-e05bc106e22c id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjMtMy0xLTEtMA_6db15a62-3bd4-461c-a3e1-cfe3c6484b36 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjAtMy0xLTEtMA_6d8f280b-3a43-4309-a1c7-f19dde7db983 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTAtMy0xLTEtMA_8f4a915b-acb5-498f-bbff-81d6ed20c39c id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNS0zLTEtMS0w_752d2bc5-71cf-447b-a301-5119a2ce6b62 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzItMy0xLTEtMA_a61ba345-c4d1-4570-b74e-56cf78a59d83 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTYtMy0xLTEtMA_8035d86e-f487-45d9-8e4b-7ecba505e96e id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzAtMy0xLTEtMA_87a8dcbc-3d64-46d4-9cc5-e3d3fcc55f25 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNC0zLTEtMS0w_398e2a31-5dad-4e0e-a749-cfb32aafa8c2 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMy0xLTEtMA_45216b21-6194-4072-a7f8-9dee72f84077 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjktMy0xLTEtMA_f4797447-8a55-441e-9d79-ec2e08d271ea id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOS0zLTEtMS0w_af194b14-52ad-4435-8abc-ada345b8a0a3 id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNi0zLTEtMS0w_df2df7a5-df8d-4c50-b410-d192c470f3ba id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMy0xLTEtMA_c07a24f2-af19-4588-ae47-664036655373" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524" order="1"></ix:relationship></ix:resources></ix:header></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:17.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA4OTI1_bc86c5b7-87ef-449c-b29b-3ee55d6b5c07">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:17.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4MQ_1f726a62-ba3d-4163-a2ef-5ab3e98543aa">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA4OTI4_b325ed50-00ef-4ead-8b06-8972107f7af5">September 30, 2020</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4Mg_bd27019c-f65d-4471-8c43-6a9a85183ee0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from  _______to _______</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA5Njc2_656be3b3-0b8a-450a-ba2f-3a4d18043734">001-39592</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:17.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA4OTI2_91c60985-a4c0-4b60-9473-8e1d855053fa">Kronos Bio, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:17.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDIyYTU4NjQzMGM2NGU1MTliZWZhNjMxYjE4NGQ4YjUvdGFibGVyYW5nZTpkMjJhNTg2NDMwYzY0ZTUxOWJlZmE2MzFiMTg0ZDhiNV8wLTAtMS0xLTIxODI_fd9b3512-7e2f-495c-9390-bcea504ccffe">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDIyYTU4NjQzMGM2NGU1MTliZWZhNjMxYjE4NGQ4YjUvdGFibGVyYW5nZTpkMjJhNTg2NDMwYzY0ZTUxOWJlZmE2MzFiMTg0ZDhiNV8wLTEtMS0xLTIxODI_7b47963c-fb24-41a3-ba28-85ac2431b818">82-1895605</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4Mw_8bfe4e9e-25d5-418f-9d13-28c211fea704">1300 So. El Camino Real</ix:nonNumeric>, <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4NA_a8b7ea4c-a080-4e61-aa66-1f0b1bf06500">Suite 300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4NQ_97570029-bf73-4294-b4fe-a49eb205d3dc">San Mateo</ix:nonNumeric>, <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4Ng_c1901580-d8ca-42d9-bf1a-d3f513586556">California</ix:nonNumeric> <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4OA_323436bd-548b-41b6-b92e-0982509f6fa4">94402</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI5NQ_24fcad6f-da45-4046-91b4-fcf6921add6c">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI5OQ_8271fed2-eaee-4365-a006-01413c554655">781-5200</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:17.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:36.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDYzMDg4OTRkZTdjNGYyYTkyNDNkZWU1ZjM4NjM5YjAvdGFibGVyYW5nZTpkNjMwODg5NGRlN2M0ZjJhOTI0M2RlZTVmMzg2MzliMF8xLTAtMS0xLTIyODA_a48193e4-ee07-4a02-990d-86883c32d99f">Common stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDYzMDg4OTRkZTdjNGYyYTkyNDNkZWU1ZjM4NjM5YjAvdGFibGVyYW5nZTpkNjMwODg5NGRlN2M0ZjJhOTI0M2RlZTVmMzg2MzliMF8xLTEtMS0xLTIyODA_56d2727a-4565-49a9-891f-c39a0d19975a">KRON</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDYzMDg4OTRkZTdjNGYyYTkyNDNkZWU1ZjM4NjM5YjAvdGFibGVyYW5nZTpkNjMwODg5NGRlN2M0ZjJhOTI0M2RlZTVmMzg2MzliMF8xLTItMS0xLTIyODA_a388e54c-cc60-4d37-a901-e75caa11cea8">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#9744; Yes or  &#9746;  <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA5NzE5_06546c8e-aa5c-4cd1-8a92-54ff41b13716">No</ix:nonNumeric>.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  &#9746; <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjMxMg_e0d2a824-8274-490c-a19e-551fb1e37f12">Yes</ix:nonNumeric> or &#9744; No.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6YTBmOTQ4OGI5ZTNlNDk2ZTllZmUxODBiNzhlMWQ4ZmYvdGFibGVyYW5nZTphMGY5NDg4YjllM2U0OTZlOWVmZTE4MGI3OGUxZDhmZl8wLTMtMS0xLTIyNjg_d4074c26-2eec-4484-8352-89302a1ebd36">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6YTBmOTQ4OGI5ZTNlNDk2ZTllZmUxODBiNzhlMWQ4ZmYvdGFibGVyYW5nZTphMGY5NDg4YjllM2U0OTZlOWVmZTE4MGI3OGUxZDhmZl8xLTAtMS0xLTIxODU_f957bdbd-1d58-4241-9d87-f288109257b5">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6YTBmOTQ4OGI5ZTNlNDk2ZTllZmUxODBiNzhlMWQ4ZmYvdGFibGVyYW5nZTphMGY5NDg4YjllM2U0OTZlOWVmZTE4MGI3OGUxZDhmZl8yLTMtMS0xLTIyNjE_0fe14b87-3bb2-4c41-8c55-e8bf51a13f8a">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjMxMw_d44f9000-cf5a-493f-94de-46b83a2b423c">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjMxMA_f3a80d41-37cb-4812-b121-49f004226dcf">&#9744;</ix:nonNumeric> Yes or &#9746; No</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of November 16, 2020, the registrant had <ix:nonFraction unitRef="shares" contextRef="ic875b4ec6f6440d5a5659f163d10c799_I20201116" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8yNzQ4Nzc5MDg0Njgy_1b8a6ad7-4541-414d-b364-93ba149f2021">56,033,504</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-bottom:3pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PART I. FINANCIAL INFORMATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Statements (Unaudited):</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_88">Condensed Balance Sheets as of September 30, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_88">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_91">Condensed Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_91">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_94">Condensed Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit for the Three and Nine Months Ended September 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_94">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_97">Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_97">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_875">Notes to </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_875">Con</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_875">densed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_875">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_875">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_43">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_617">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_617">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_612">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_612">45</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PART II. OTHER INFORMATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_634">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_634">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_19">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_832">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_832">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_172">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_172">112</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_178">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4bb4e4f9863422ab5c3f3e7868262d4_178">113</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_558"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART 1. FINANCIAL INFORMATION</span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_85"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_88"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNC0xLTEtMS0w_fbbeefba-e23e-4c5c-9f0d-fa990c2632b7">156,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNC0zLTEtMS0w_398e2a31-5dad-4e0e-a749-cfb32aafa8c2">32,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNS0xLTEtMS0w_c22331bb-5b5f-45d3-9e43-d49766fdc063">55,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNS0zLTEtMS0w_752d2bc5-71cf-447b-a301-5119a2ce6b62">59,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNi0xLTEtMS0w_0738f9e2-da26-44d7-860a-4897e688b662">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNi0zLTEtMS0w_df2df7a5-df8d-4c50-b410-d192c470f3ba">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNy0xLTEtMS0w_f25e69b7-c79b-4f8b-bdb2-52480cccc52d">212,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNy0zLTEtMS0w_7b294014-cf51-4f5d-abac-68c1e70d5d4a">93,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOC0xLTEtMS0w_fa966a65-0f96-45d9-a427-b91ea253adf6">4,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOC0zLTEtMS0w_5b95e419-e2ea-434e-833a-e07994cad3b6">4,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOS0xLTEtMS0w_e997dc1b-20f1-4df2-ab4c-aed400da5ea7">10,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOS0zLTEtMS0w_af194b14-52ad-4435-8abc-ada345b8a0a3">3,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTAtMS0xLTEtMA_53b1dc3f-64db-41d8-9ba0-6412f1415ea4">29,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTAtMy0xLTEtMA_8f4a915b-acb5-498f-bbff-81d6ed20c39c">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTEtMS0xLTEtMTcx_577cdd16-eb01-4310-9471-49272cc0d7dd">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTEtMy0xLTEtMTc1_238e1a5e-cfcb-4dfc-93ac-9e82ee1ea9b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTItMS0xLTEtMA_55afc55a-8259-49ed-ab01-f91a57785470">3,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTItMy0xLTEtMA_c5bdbdb7-9e21-44ad-8ac8-e2ab8ec88e9e">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTMtMS0xLTEtMA_b4a63fc9-2b36-4774-8b82-75391ddf5a47">262,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTMtMy0xLTEtMA_9276a3d8-cc19-42c6-b38f-6cfc9f4c097f">102,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, convertible preferred stock and stockholders' deficit</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTYtMS0xLTEtMA_5c578959-5ea6-4e7c-bd9a-4b6a1ca9f980">4,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTYtMy0xLTEtMA_8035d86e-f487-45d9-8e4b-7ecba505e96e">1,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMS0xLTEtMA_bc21192b-e6d5-4628-92b3-20d15845aa3d">1,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtMA_d05a5384-e248-4030-a9cf-17cdd1ccf138">818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes payable, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMS0xLTEtODQ2_3d241ef7-eaea-4c61-8eca-43fe73b163ba">173,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtODQ2_252d2175-5e02-4f30-827b-5a392ef0b3fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTgtMS0xLTEtMA_2cdffab6-3cf7-42d4-a298-684fbef2db12">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTgtMy0xLTEtMA_414422d2-b987-4a31-90f8-d3a1822608ff">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTktMS0xLTEtMA_cf4a583d-3795-4a8f-b59a-20854a1b3b17">2,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTktMy0xLTEtMA_5df9ec80-449c-4bc2-9cd5-fde54eefbebe">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjAtMS0xLTEtMA_574b665f-c3ff-46e1-8ac9-91e8f3fe82ed">183,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjAtMy0xLTEtMA_6d8f280b-3a43-4309-a1c7-f19dde7db983">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjEtMS0xLTEtMA_6c878bd8-c949-4e68-a7a1-8cf8530c871b">29,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjEtMy0xLTEtMA_f84feb2d-73c3-4aba-9559-c0ead7335b39">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjItMS0xLTEtMA_989009cf-2e07-4d7d-b1eb-057726473ccb">2,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjItMy0xLTEtMA_7336a50e-0972-47cb-b658-c50350b82e43">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjMtMS0xLTEtMA_9b6cd3ef-875d-436c-a57c-1d0bbf0d05c0">215,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjMtMy0xLTEtMA_6db15a62-3bd4-461c-a3e1-cfe3c6484b36">2,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 13)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjQtMS0xLTEtMjMyNg_d80f4d6a-ae69-4b1b-87fe-2afe6ed70180"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjQtMy0xLTEtMjMyNg_adb29f22-92ac-48ab-ad38-e05bc106e22c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTMx_b659a2f7-54ab-4fe5-bdc7-677c467b986f"><ix:nonFraction unitRef="usdPerShare" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTMx_fbd37fdd-7d4a-411b-9ff7-7038f049aa5d">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTQ0_9f47fabd-94e9-4b18-8edf-fea021dcb145">21,506,977</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTU3_caac549b-9462-47a8-a19e-ab521f5e010b">21,506,977</ix:nonFraction> shares authorized as of September 30, 2020 and December 31, 2019, respectively; <ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTY5_0f275e9b-ee6d-40ff-a3da-8e2c1be3520d"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTY5_332d7641-032a-46e2-a61a-a4f516d37d7d">21,504,893</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTgz_b83fbdfb-21b4-49dc-ad9b-b6e69c7a7a31"><ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTgz_c678ef70-5044-4789-a0ea-8fe3f5224199">21,504,893</ix:nonFraction></ix:nonFraction> share issued and outstanding as of September, 2020 and December 31, 2019, respectively; $<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTk0_9bfae45e-1480-46ef-a5a2-cfa8940e5343">123,016</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MjA1_a523fa16-3acd-4bf6-8842-b83a01e29fd3">123,016</ix:nonFraction> liquidation preference as of September 30, 2020 and December 31, 2019, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMS0xLTEtMA_c17b20c9-e158-4ab9-88e1-1fa86019de4c">122,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMy0xLTEtMA_c07a24f2-af19-4588-ae47-664036655373">122,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholder's equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzEwOTk1MTE2Mjc4MTAw_a0ebb75e-830c-4223-8690-5663fe047e00"><ix:nonFraction unitRef="usdPerShare" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzEwOTk1MTE2Mjc4MTAw_b0b88bd1-0730-4f95-b7b5-a773de1b394e">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzI3NDg3NzkwNjk3MDk_0f4bd288-aa25-4bdd-b902-704780699eb8">40,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzI3NDg3NzkwNjk2OTY_c0fb3cd9-6f60-4b09-99c8-80de2f30ac46">40,000,000</ix:nonFraction> shares authorized as of September 30, 2020 and December 31, 2019 respectively; <ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzMyOTg1MzQ4ODM2MzQ_710c7f4e-5cb0-4eb5-8489-33759bb2ce58"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzMyOTg1MzQ4ODM2MzQ_81e42231-5184-4ee5-9738-73eacfa3078c">6,284,326</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzMyOTg1MzQ4ODM2NDY_b1a4f1c4-65c3-4873-990d-f540cf8f64a4"><ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzMyOTg1MzQ4ODM2NDY_c2968248-1163-4492-8d5b-2fbed1dbf96e">5,660,391</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMS0xLTEtMA_bed538c9-f98f-4b0a-9c8b-cb44932eb3f5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMy0xLTEtMA_45216b21-6194-4072-a7f8-9dee72f84077">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjgtMS0xLTEtMA_fea2efbf-1558-4020-ab93-56e6243c62c2">2,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjgtMy0xLTEtMA_303524e9-a85d-41a3-bff2-33bd1fe342e2">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjktMS0xLTEtMA_671f5bf9-f968-4b57-b8f0-77b6355c92aa">78,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjktMy0xLTEtMA_f4797447-8a55-441e-9d79-ec2e08d271ea">23,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzAtMS0xLTEtMA_8383369e-2487-49f5-91a4-61efa1536427">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzAtMy0xLTEtMA_87a8dcbc-3d64-46d4-9cc5-e3d3fcc55f25">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzEtMS0xLTEtMA_92cdf59e-e33d-4c27-8e67-c49baa4109f4">76,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzEtMy0xLTEtMA_0ca701ee-1ad6-4424-b3dd-17217e95139c">23,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzItMS0xLTEtMA_d9f897c5-4a76-4f6d-be48-a80e5f6045a5">262,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzItMy0xLTEtMA_a61ba345-c4d1-4570-b74e-56cf78a59d83">102,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524" footnoteRole="http://www.xbrl.org/2003/role/footnote">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</ix:footnote></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_91"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNC0xLTEtMS0w_dc61e6fe-6b93-4b00-82d9-20b50213f60a">16,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNC0zLTEtMS0w_b677717b-49a2-4669-af68-5cc62f322972">3,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNC01LTEtMS0w_17414d4f-5ed9-4b69-97d8-52d24e96d79d">30,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNC03LTEtMS0w_6e57eb4a-cfa5-4231-887c-037b8a7cd753">8,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNS0xLTEtMS0w_ab3912ce-cd26-4742-9bc8-db57e650fa5e">4,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNS0zLTEtMS0w_a30394c6-f6f4-44ec-b581-040aec78d21f">797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNS01LTEtMS0w_e383d446-ac1e-4145-8083-a34d77ef9ea6">6,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNS03LTEtMS0w_9d6538a3-3f17-4aa5-a18d-1177ca734f7c">2,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNi0xLTEtMS0w_0c6e829a-bc7a-4885-9f6d-7d1fb9d557fa">20,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNi0zLTEtMS0w_b773b31b-4b18-4f1c-875d-32b729ef46bc">4,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNi01LTEtMS0w_aa8ccc8d-4f79-409c-be6f-c8ba7e25c71f">36,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNi03LTEtMS0w_80bd24eb-d386-41d3-b3a2-1ad110ffabb4">10,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNy0xLTEtMS0w_eba211b4-6161-43bc-97cb-ad3f2f25b464">20,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNy0zLTEtMS0w_c5667a4b-b9e1-43a9-9da5-df93398e6bd0">4,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNy01LTEtMS0w_60aeaf38-4d8c-4760-8208-7e0d58c9565d">36,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNy03LTEtMS0w_55c48669-73c5-4500-8063-8bb93b26589e">10,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="kron:NotesPayableFairValueGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC0xLTEtMS0yOTg3_cc825369-182a-4330-b128-3b6355a2494b">15,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="kron:NotesPayableFairValueGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC0zLTEtMS0yOTg3_5360de3b-7377-4f49-a180-83a5d3cc4807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="kron:NotesPayableFairValueGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC01LTEtMS0yOTg3_51045922-41e6-4f26-863b-8804af682d29">15,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="kron:NotesPayableFairValueGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC03LTEtMS0yOTg3_1fed9771-4b4b-439f-8f52-025fecd447eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS0xLTEtMS00ODU5_1629a4a9-111c-4978-934d-accf05cff5b7">3,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS0zLTEtMS00ODU5_0e3aa208-4671-4ef9-86f2-c30de168713c">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS01LTEtMS00ODU5_e86f340e-de74-4edc-b16a-8974c30c5018">3,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS03LTEtMS00ODU5_edd65273-d99a-447a-a8b5-5436176115ab">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC0xLTEtMS0w_fe1f8511-344a-4263-98d6-06e05f2bd78b">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC0zLTEtMS0w_dca4cfa7-905a-4364-a262-8e1c7d150063">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC01LTEtMS0w_4f61f360-2f56-4298-b360-6bf93e1225b6">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC03LTEtMS0w_290a262c-a205-4d7d-9a19-63aeccbcd6c9">311</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTAtMS0xLTEtMjk4Nw_80e5740e-65af-44a8-8d24-104b0906a753">18,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTAtMy0xLTEtMjk4Nw_31b50767-e752-4641-80e1-54f674a57d05">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTAtNS0xLTEtMjk4Nw_5e3b47d1-a0db-4032-88c8-41534aaa03c7">18,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTAtNy0xLTEtMjk4Nw_2235932e-af25-4f20-996d-ec93c0216d31">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS0xLTEtMS0w_88f77181-d567-4cc3-9334-bfcb523f9219">39,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS0zLTEtMS0w_c5072f48-1bb0-4355-b34f-97a3eb4657eb">4,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS01LTEtMS0w_5796d762-6a4b-48e5-a6a4-dd121865e471">55,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS03LTEtMS0w_c0813a67-76bb-4c30-9a01-95b527db52f4">10,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTEtMS0xLTEtMA_bf7d46b9-6f33-423e-89ce-102bf370a95c">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTEtMy0xLTEtMA_3961fd05-80b0-4fa3-86d3-a602421bd477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTEtNS0xLTEtMA_b05de2f2-6522-469a-8d42-e7050666380c">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTEtNy0xLTEtMA_e6bfe4b0-0ca8-4b69-8e9a-af97095fb2fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTItMS0xLTEtMA_19c68600-c986-49af-b96e-f22158383b66">39,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTItMy0xLTEtMA_9f9ea0e2-8197-44da-879e-c5211c23d1ea">4,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTItNS0xLTEtMA_8f3181ab-4e6e-4fd7-bdb1-0b448c8e17c2">55,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTItNy0xLTEtMA_044a5525-f826-4b2a-a022-9b65c2e4aa72">10,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTMtMS0xLTEtMA_2eb7b5fe-9138-4cae-8f72-ed0bada4381e">6.48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTMtMy0xLTEtMA_2502b6fe-52f5-4ffd-8c9f-2837bd017e46">0.74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTMtNS0xLTEtMA_1ce587b1-0429-40ea-ac62-e3b90a5d9eb1">9.39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTMtNy0xLTEtMA_bf69a86d-279d-4904-bdbe-64cb99e02015">2.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTQtMS0xLTEtMA_23aa5311-491d-4bc7-95bd-48262c6c2042">6,127,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTQtMy0xLTEtMA_4d5648a6-9cb1-4ba0-9f62-758a0193949a">5,409,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTQtNS0xLTEtMA_6576a178-862c-453e-ad34-e846a0be79d0">5,886,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTQtNy0xLTEtMA_4e780dee-bfba-4d67-b42a-88f22c69e106">5,196,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_94"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.913%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Deficit</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f8e95f9bad0404484cd92bc97317806_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xLTEtMS0w_984e4b30-98f7-4617-8900-12b255e52cf8">7,806,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f8e95f9bad0404484cd92bc97317806_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0zLTEtMS0w_6091afd9-2552-4f9a-9b99-d1ff389eb878">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fc452a116164f07ab8c6db2e41a54a2_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi02LTEtMS0w_edf40f62-cbc9-47e7-88c8-898b0ef9508a">4,966,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc452a116164f07ab8c6db2e41a54a2_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi04LTEtMS0w_c06c4e2a-9169-4982-9903-a8d0415c1a60">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21cf7c43c804ff58bb10d3f479807f1_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xMC0xLTEtMA_21952b69-be67-4270-a649-b9bc6f811eff">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0b70948b6ee4fedbe87831200d026b1_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xMi0xLTEtMA_0a12e6c2-cef6-4918-b422-5f6d3c66764b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id950e5b1ee3743abb012a5fa0a2d1172_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xNC0xLTEtMA_ede0694b-8b3a-45a5-8927-6002e1335c5f">7,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f8e95f9bad0404484cd92bc97317806_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xNi0xLTEtMA_9a404019-2c26-4e1c-a4ff-4cc8289ca05c">7,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id87511770e86434c8b397546525820c3_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMy02LTEtMS0w_938e94c7-65b1-4942-bb85-7528be0c0b0f">29,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc0f3c260074cab9565bcf4c504aca2_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMy0xMC0xLTEtMA_ba1792c0-6c4e-46a2-93b3-9d0ba8ede06e">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03886d7b8ad440cf91b6f137373f3fe4_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMy0xNi0xLTEtMA_f5a90754-fab8-45da-bfd8-f8be59c8bcde">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc0f3c260074cab9565bcf4c504aca2_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNC0xMC0xLTEtMA_143ca5cb-d1d1-4925-b8af-2856be07e3f1">16</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03886d7b8ad440cf91b6f137373f3fe4_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNC0xNi0xLTEtMA_260e2104-13f7-4ad1-9065-abf2d1c2c169">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4d088ea318046c28ff574bbc24a4539_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNS0xNC0xLTEtMA_27340155-582b-46e9-b9ba-9e203cafe8f0">3,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03886d7b8ad440cf91b6f137373f3fe4_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNS0xNi0xLTEtMA_efc42f6e-f3d7-456f-921d-baf90000782b">3,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3ddd1ef68df4a7491812cbb786883ba_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xLTEtMS0w_12eb3266-ed6b-4660-a415-232297aa9a6f">7,806,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3ddd1ef68df4a7491812cbb786883ba_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0zLTEtMS0w_43d88cb7-7017-4f14-9076-a422f764a5d7">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa65bad82b9e4ad2a2bd21cd489827cd_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi02LTEtMS0w_eff8655c-a10b-4245-868e-9a6c6d20a7b2">4,995,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa65bad82b9e4ad2a2bd21cd489827cd_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi04LTEtMS0w_269dfbf6-bf1c-49e3-94ed-ee8aa20fb602">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96feaae211f5437abfe5df9cb2556889_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xMC0xLTEtMA_58b0f0d2-079f-4fb4-a966-f417c99bdaba">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i398f3cb912cc4c3b8389921c5e59690d_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xMi0xLTEtMA_5952dd7c-accc-489e-a92a-c5ac938250e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a73e8597e49499c83e7d630d13b969f_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xNC0xLTEtMA_42c979d3-31fd-4508-b54f-30bacbb2e9a8">10,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3ddd1ef68df4a7491812cbb786883ba_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xNi0xLTEtMA_4e4c7985-e541-4a8a-9125-87bb4410ce25">10,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i215f3d19ff10462fac7d04a82c46e12b_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNy02LTEtMS0w_0d5bf34e-b2e2-4000-b14c-11cf963e73be">386,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4b14f7eb2344feb5abbff653d77cc3_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNy0xMC0xLTEtMA_60a6e48a-0886-4882-a8de-ec51c5a2685f">45</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNy0xNi0xLTEtMA_9fa7d169-0274-45eb-9c29-65dee8be0623">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4b14f7eb2344feb5abbff653d77cc3_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOC0xMC0xLTEtMA_74b8b0ab-b42b-4acf-a5ff-e6b1a87c4747">21</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOC0xNi0xLTEtMA_2b9af085-b555-42f3-bb2d-38869caf10d1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Series A convertible preferred stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i6e94cc8395934b1f8041da5f310ddcd6_I20190630" decimals="2" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOS0wLTEtMS0yNTUvdGV4dHJlZ2lvbjozMmI2MzlhN2FiZmI0YWUxYTEyMzU1Njk1ZWZjNDU1Zl83Njk2NTgxMzk0NTM4_59dddc61-c7d7-448e-8c8d-c6c9ab5102d9">7.67</ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="icf12f6d5105c4cb49c04cb538332565f_D20190401-20190630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOS0wLTEtMS0yNTUvdGV4dHJlZ2lvbjozMmI2MzlhN2FiZmI0YWUxYTEyMzU1Njk1ZWZjNDU1Zl83Njk2NTgxMzk0NTQ0_adde5abb-70f6-46bd-b2fd-c945b4fea0dc">70</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="kron:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOS0xLTEtMS0w_5dfc7f83-42e8-4d87-96e9-826ac6e1f47d">7,142,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOS0zLTEtMS0w_a474c307-e631-486c-9da0-e70458942334">54,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33964ca9f59949bd8a0dad9cc8ddf198_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTAtMTQtMS0xLTA_09d12a05-8618-4258-9ed0-95109971a4bd">3,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTAtMTYtMS0xLTA_de6a4b8d-1b96-4e95-b450-52f8d78cb8c7">3,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e94cc8395934b1f8041da5f310ddcd6_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMS0xLTEtMA_82e17432-f720-4f3c-8631-89762830a5fd">14,949,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e94cc8395934b1f8041da5f310ddcd6_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMy0xLTEtMA_66cac36a-602f-49e5-9dc7-844f2ca9865d">72,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fa48a0f98ad4d87aab5fba5718268f5_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtNi0xLTEtMA_bce12331-2dff-49fc-958e-7273e670a297">5,382,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fa48a0f98ad4d87aab5fba5718268f5_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtOC0xLTEtMA_719aa294-cb84-4c87-a48d-6fc45495ad7c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fb0d1895c24824b9493d143c45cf5f_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMTAtMS0xLTA_43b50502-0873-40aa-84b2-05af0d390ebc">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765953ff2adb498fa37b7ff3e73d477d_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMTItMS0xLTA_ef10b6f4-00d0-49cb-9ff2-bc0c6770a67e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7da5cd1e28af4f31bab4ef99a9a22778_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMTQtMS0xLTA_aaa8b0f0-8e82-44ba-ac1f-b4ee5475ca03">13,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e94cc8395934b1f8041da5f310ddcd6_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMTYtMS0xLTA_08e7db54-0062-4ea0-8feb-bb784cea3527">13,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4488d94b40c645b8b0eec4586e9ffaa1_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTItNi0xLTEtMA_03dd3b52-7886-4067-876f-dded44a9e39c">106,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3d2666a19540bd8e3b415b1e862d28_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTItMTAtMS0xLTA_18d9bef3-dc5b-440e-bfd0-81763f2ecefa">11</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTItMTYtMS0xLTA_fccab8c7-ba40-4adf-8a7d-336344bca669">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3d2666a19540bd8e3b415b1e862d28_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTMtMTAtMS0xLTA_5388efa5-7b67-4459-98ad-8080bcf9c6e1">23</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTMtMTYtMS0xLTA_1ea1045e-63b4-425a-b101-f1ac1d1e182e">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Series A convertible preferred stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930" decimals="2" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTQtMC0xLTEtMjU1L3RleHRyZWdpb246MTAwMTM0ZjY2ZWNmNGE0NzhlNzhiMzQ1MjRjMmVkMDBfNzY5NjU4MTM5NDUzOA_42a5c064-ee6e-4ac4-b302-d797c6ef930b">7.67</ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i47a2ad7dc20e45f8a10245fcd852cd7f_D20190701-20190930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTQtMC0xLTEtMjU1L3RleHRyZWdpb246MTAwMTM0ZjY2ZWNmNGE0NzhlNzhiMzQ1MjRjMmVkMDBfNzY5NjU4MTM5NDU0NA_0c5be8ea-99b2-409e-9c7f-202184384a49">78</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="kron:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTQtMS0xLTEtMA_bc71a0c2-8a20-45b8-9d01-4823e43cb6c6">6,555,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTQtMy0xLTEtMA_e5c693df-0b3b-4c7e-aac8-972c5f073f70">50,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia81288a6a3fa4a88a8f294d3b0df8299_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTUtMTQtMS0xLTA_e0acb646-84e8-4b1b-88e3-75d3df61980a">4,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTUtMTYtMS0xLTA_6dd2ba3e-cde9-44bf-b767-090fd898fd58">4,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMS0xLTEtMA_2b8bc96f-7d3a-4af3-a34e-0c867a9485de">21,504,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMy0xLTEtMA_6b640f61-3fee-4637-9195-23f22bc96111">122,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7b7bb754ddc40bbbd810ba27db95742_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtNi0xLTEtMA_b1d45022-6422-4a90-94fb-5c5af5aa0336">5,488,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b7bb754ddc40bbbd810ba27db95742_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtOC0xLTEtMA_407df4d3-5d80-464a-a545-008ff4aa2a33">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a3a26575a447b0a22f44539d68c78f_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMTAtMS0xLTA_54f26a71-f2b0-473c-9840-20db9cc96880">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08a06283a2d4d1391878f6cd94cc735_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMTItMS0xLTA_87955abe-25d2-44ea-b9a6-30097136a2c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i873ef3d6e24746a29e6379448312fad6_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMTQtMS0xLTA_cef70120-c133-441a-9c78-63c96722514e">17,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMTYtMS0xLTA_99ff3d0c-fa66-4d4a-b2ca-08d3be539c37">17,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.913%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Deficit</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xLTEtMS0xMTQ2_9b8830aa-1197-4c71-a500-4f3f77e6bb47">21,504,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0zLTEtMS0xMTQ2_5370c25e-5ec1-487d-b0cc-a4c4dc0a1b7b">122,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50164c6c882d42f3919eca44154397d9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi02LTEtMS0xMTUw_65e8b780-dd94-468a-a5d1-703711c38bb1">5,660,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50164c6c882d42f3919eca44154397d9_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi04LTEtMS0xMTUw_fbb80d63-04dc-4276-a821-cf3737378c91">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f99d002a8a4eaaa64cf919ecdea498_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xMC0xLTEtMTE1MA_505df8d6-90dc-4533-b457-3cddbec51a1a">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dd1ee47d2a4d7e94466a527f95e4dd_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xMi0xLTEtMTE1MA_bbab05c3-12d2-4e1c-b314-b1529a21882e">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3528d13cf33844ac95aedb7d3764991c_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xNC0xLTEtMTE1MA_45c19956-2769-4b80-8c40-38797b8d6ddd">23,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xNi0xLTEtMTE1MA_c35b8d0c-dcfa-4f6b-9d0d-fdc81c4c01af">23,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07bca622fbaa4a77834306e2dc4158cf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMy02LTEtMS0xMTUw_f016818e-27e4-486d-b3e8-bf1a3564fda0">119,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c535b861b90421a981086e2092d7c25_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMy0xMC0xLTEtMTE1MA_1355ebb0-3484-464e-85ee-4f09aa5b35aa">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMy0xNi0xLTEtMTE1MA_29b332b6-b66b-4931-b61b-d9e1e1bef2ba">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c535b861b90421a981086e2092d7c25_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNC0xMC0xLTEtMTE1MA_e9e3b9f3-5bda-46fd-bce2-e83968328bf8">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNC0xNi0xLTEtMTE1MA_975b043f-5918-4f95-9240-0eece4a0ebfe">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i115b646974a740c39cf4aca40b4727a2_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNS0xMi0xLTEtMTE1MA_fda953b2-c187-4855-a7e2-7d17b182661f">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNS0xNi0xLTEtMTE1MA_1ddff845-5bb3-40fb-9825-d4bde8c5b08c">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a2c5294eeb4d659c07857d5b23eecc_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNi0xNC0xLTEtMTE1MA_363a890c-7690-43f8-a8d1-c4ae24678e96">6,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNi0xNi0xLTEtMTE1MA_614e7b7c-c1fc-47eb-bc32-c42ec7f10eab">6,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ae1bc220d124171941ce912959a757d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xLTEtMS0xMTQ2_fbb97f0e-f3ce-4f62-b1d6-a733cff1bcbb">21,504,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ae1bc220d124171941ce912959a757d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0zLTEtMS0xMTQ2_55c6393f-b240-406c-9dc0-1489e4d11f76">122,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i843c9dde5a3b4b64b5716b83abdb8982_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy02LTEtMS0xMTUw_5035d88e-a172-4934-920c-775538c1f06a">5,780,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843c9dde5a3b4b64b5716b83abdb8982_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy04LTEtMS0xMTUw_96cc1488-a787-4515-b287-039b436ca28c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcf856179f4d0a8fb0794daa7e6d02_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xMC0xLTEtMTE1MA_b39deb7c-fda7-442f-8265-57bf47b97038">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b0100128e94091ac9bab9b50f79c03_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xMi0xLTEtMTE1MA_1e46de9a-f750-4925-a3a6-6a594eb888de">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8deeaad6f2634e11b9f9c0316139d717_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xNC0xLTEtMTE1MA_da69a066-c14d-40a4-9f1f-cf657447e136">30,457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ae1bc220d124171941ce912959a757d_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xNi0xLTEtMTE1MA_26626df9-8c03-4b5d-be09-c41391fa1f13">29,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6646e83b8de940969fc96333ff6a7d2a_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOC02LTEtMS0xMTUw_699b74f5-7386-41e4-9fcd-cb992681d915">171,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c5ebc92f654f8491c5de314a112730_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOC0xMC0xLTEtMTE1MA_9ad9fa81-bffe-4a38-b98a-0db11591f0b6">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOC0xNi0xLTEtMTE1MA_8482a930-8cf3-43ae-9e72-58ce89f05708">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c5ebc92f654f8491c5de314a112730_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOS0xMC0xLTEtMTE1MA_92b71544-72e4-4d3c-896c-a58d66da718e">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOS0xNi0xLTEtMTE1MA_03684022-13dc-41d0-a775-104751988550">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b83d5eb6d345538b2d5d4cb90f98e1_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTAtMTItMS0xLTExNTA_28ea48e2-6014-4066-bb03-d3a124740b2d">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTAtMTYtMS0xLTExNTA_13f94570-1a7b-4c70-b6d6-4e17df79d66a">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07042dba8294acc85fb47df8bbcc218_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTEtMTQtMS0xLTExNTA_8d023b0f-fddf-418d-95c4-68e80309d01a">8,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTEtMTYtMS0xLTExNTA_df7cf200-d18b-4bc9-9038-4252415055a8">8,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7555544cb3f7417ab92209c0d2f251b7_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMS0xLTEtMTE0Ng_7bce5ca6-2fe9-4ab8-8ab6-8cebb01b3111">21,504,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7555544cb3f7417ab92209c0d2f251b7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMy0xLTEtMTE0Ng_4a74c7f7-f784-4fe1-b0a3-545921010c19">122,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1310705bc7ae4f78af0e8a824858b5c5_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItNi0xLTEtMTE1MA_bcc91295-8ea5-4406-9f65-76b9bd1af6a1">5,952,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1310705bc7ae4f78af0e8a824858b5c5_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItOC0xLTEtMTE1MA_896b8c63-20ca-4eca-9949-fd45aab60967">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28a26a8d7224bd8901bf199a0538658_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMTAtMS0xLTExNTA_ec29ae44-fa65-4040-8408-950c3f274ad7">885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40dd880b211e46408cac612575b17ac5_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMTItMS0xLTExNTA_fc276c28-9af8-4470-abb0-b4193a9128d6">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35a6843fec8241b0882996b9484b444f_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMTQtMS0xLTExNTA_b6444a50-05b0-4434-8fff-bd592fb536ab">39,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7555544cb3f7417ab92209c0d2f251b7_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMTYtMS0xLTExNTA_062f44ee-09c5-44cc-9d1d-6c763d68e15b">37,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id09b579f33f344c7b796c94598c93ab2_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTMtNi0xLTEtMTE1MA_5daae430-d866-4f11-ada6-eddeef7a1352">332,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie598b98bcf9d47bd8f9ada78c710b752_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTMtMTAtMS0xLTExNTA_81528156-c2a8-47bb-b18d-1c6502103886">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTMtMTYtMS0xLTExNTA_512ac89b-c671-4c09-9486-cc535ca70a49">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie598b98bcf9d47bd8f9ada78c710b752_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTQtMTAtMS0xLTExNTA_bc05e69c-d95b-410a-8ed4-eb0b026b14ed">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTQtMTYtMS0xLTExNTA_e98ef1d6-8d0b-4293-97d6-16965b3ce368">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad6f77124e9847649d247673b804dde9_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTUtMTItMS0xLTExNTA_b0404d15-4db6-412a-a9b1-4a44230e0129">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTUtMTYtMS0xLTExNTA_952fff3d-b3b8-4f03-a38b-7ac6f57aafda">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dc2dc2098a3453c85866e5fdf18f779_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTYtMTQtMS0xLTExNTA_101fea20-beb7-4101-bab0-11480196121c">39,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTYtMTYtMS0xLTExNTA_9dbab2fd-5367-449e-aaf8-251699527e12">39,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMS0xLTEtMTE0Ng_12bb57e6-c5fd-4fd0-adf0-81ad4837ddc6">21,504,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMy0xLTEtMTE0Ng_3dc50dcc-35a0-48da-bcac-07ef3df99ec4">122,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e14aee510204c7b89e48f9e27f07afc_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctNi0xLTEtMTE1MA_0ab90013-bc82-437b-96dd-53f4af2ef04e">6,284,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e14aee510204c7b89e48f9e27f07afc_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctOC0xLTEtMTE1MA_d7c506d9-97f4-4ced-83ac-6ac383bd804b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd881c372af5476a8da370cfe8309eeb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMTAtMS0xLTExNTA_11e25ea7-89ed-4613-ba11-0f8016a2c80d">2,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia328bcbcb2f049488186eac987fe0643_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMTItMS0xLTExNTA_6d0e5e6d-7af8-4a27-bde8-4742392a85ef">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96c4ed6efa7740e18904bfe97dd36b05_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMTQtMS0xLTExNTA_0d357146-243a-4ab8-83c6-28e11b30119e">78,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMTYtMS0xLTExNTA_6019f086-0135-43d5-af0a-6e084bbfbde3">76,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_97"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNC01LTEtMS0w_b0e49f7f-90dc-4a20-af57-d6f227759a80">55,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNC03LTEtMS0w_f01e70dd-e450-48b2-a779-996e36e73f82">10,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNi01LTEtMS0w_4f1002c8-1d46-45b2-b5a5-fc607d7e0bed">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNi03LTEtMS0w_8b4118a3-ffa4-4715-8a25-17af94597a50">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amortization/accretion on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNy01LTEtMS0w_1ab40832-9d51-48e3-a5bd-1ea07d1ddd96">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNy03LTEtMS0w_11083501-83a7-4c7d-98b9-992fb97059c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in accrued interest on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfOC01LTEtMS0w_d93ad85c-ed1c-4190-87d6-24e842acf5a4">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfOC03LTEtMS0w_4fd24cdd-1aac-4739-bd28-7072c5fbe896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTAtNS0xLTEtMA_b5f0bd5d-92c5-4348-89f8-0f40373794dc">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTAtNy0xLTEtMA_4ff328b6-207c-4f2c-b0cb-9f8b7f3b79c9">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="kron:LeaseExpenseNoncash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTEtMS0xLTEtMjg0_f869cbba-1135-4868-be32-26618f6a0ee7">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="kron:LeaseExpenseNoncash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTEtMy0xLTEtMzA1_a756c535-6e55-47cd-81aa-693e640be9fd">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTItMS0xLTEtNDA1Ng_eb03b550-47ea-4d95-a227-a1f1a575a8b5">15,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTItMy0xLTEtNDA3Mw_75724472-be9d-4729-b7ba-179c80e40233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs on convertible notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtMS0xLTEtNDA1Ng_f6200b57-44e1-49df-b793-40a547f2ff34">3,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtMy0xLTEtNDA3Mw_ce3f1b2a-5426-472c-8b06-d35367cae861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtMS0xLTEtNzk0Mg_a7edca72-4475-4ed6-98a1-6f3576ca584d">3,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtMy0xLTEtNzk0Mg_fd0f430e-1025-468c-8ec7-30394ea94366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtNS0xLTEtMA_cfacfc8b-110a-454f-8e7d-f324dabdebd9">493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtNy0xLTEtMA_5894591c-7df5-479d-a75b-d68d2929e166">271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTQtNS0xLTEtMA_097f222d-7788-416b-bc83-f52ddff0962d">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTQtNy0xLTEtMA_c38721c6-ba15-418d-b3e8-3948ec63dbb8">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTUtNS0xLTEtMA_179ba853-4b08-48b5-ad19-b935716878e0">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTUtNy0xLTEtMA_2c93cc9a-3150-4c6b-97fd-678fa6f3bcb7">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTYtNS0xLTEtMA_a345a59a-b9e1-4adb-aea0-98832c9fab6c">879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTYtNy0xLTEtMA_bc2ec257-ddd3-4671-a069-92aba3281443">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="kron:IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTctNS0xLTEtMA_da9e33ba-cef6-4159-baf0-faacb6fb9bd6">588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="kron:IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTctNy0xLTEtMA_02667a17-9c4c-4a80-8cce-efdc41c0a7c3">183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTgtNS0xLTEtMA_bced80c1-81a6-49f8-923d-0c92adc7db90">4,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTgtNy0xLTEtMA_57af7d76-4c2b-4344-b3da-62682e9d7f06">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTktMS0xLTEtMjg0_63fa3716-6c5e-4d7c-bee1-a5908b022b06">22,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTktMy0xLTEtMzA1_1f3630f9-c29f-4013-b506-4780e8bb7740">10,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjItNS0xLTEtMA_22ad3250-cfa6-4b33-9f60-a4facd175028">5,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjItNy0xLTEtMA_04ab1d3e-83fc-430b-8fbd-9d3327b81abf">2,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjMtNS0xLTEtMA_01b29326-3cb0-4148-9ccf-8de0283b0c40">41,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjMtNy0xLTEtMA_498979d7-c0da-4573-a751-1a5b25d2894b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjQtMS0xLTEtMjg0_28b11bab-0f3d-45e4-bcbf-96571edfc17e">45,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjQtMy0xLTEtMzAy_003f7668-cafe-408d-8c7f-81496eb6f665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjUtNS0xLTEtMA_c59ebb1c-94c9-4e34-93e6-d561df24a29f">1,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjUtNy0xLTEtMA_255c5a2c-e2e7-41ae-8ddc-e005af372f67">2,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjgtNS0xLTEtMA_3d900b16-5fa1-4410-b334-b154ba6446cb">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjgtNy0xLTEtMA_d1ff8ff7-392d-40e3-a927-ad45c5034e3e">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjktNS0xLTEtMA_165676aa-8a0e-43a6-aeda-9c8be0cfa3e7">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjktNy0xLTEtMA_aa8d62d7-0d8d-48d9-87e7-8ed0e62e4b66">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of preferred stock, net of financing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzAtNS0xLTEtMA_245fb5dd-d786-43f6-98ec-cabe34dcf56f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzAtNy0xLTEtMA_8d79b160-aab0-40f8-b735-a63ded4d8452">104,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of convertible notes, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzMtMS0xLTEtNDA3Nw_acb8d2ab-55cc-4014-b59c-257b494a2b8a">151,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzMtMy0xLTEtNDA4MQ_14498745-0409-4065-ba7a-d161aded5cb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzQtMS0xLTEtNzk0OQ_82571e6b-b569-4b85-afa5-782cf0857438">2,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzQtMy0xLTEtNzk1Nw_c1463289-3001-4f6b-9ae0-bb13cee3394e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzEtNS0xLTEtMA_18b446b5-1c75-49ba-baf0-0e60b3f0679b">149,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzEtNy0xLTEtMA_bce83539-a7d1-4520-9872-7db9b209b40d">104,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzItMS0xLTEtMjg0_f7fbe6ff-30ac-4c0c-887e-777d0ddb9e91">125,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzItMy0xLTEtMzEw_bd7fe038-47c7-4746-8cda-d367653549ab">92,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzMtNS0xLTEtMA_cfa7d105-37f7-4d12-b71f-84347ca341a0">32,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f8e95f9bad0404484cd92bc97317806_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzMtNy0xLTEtMA_9d21c4cb-57bd-4748-8726-cf3e611e9804">10,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzQtMS0xLTEtMjg0_5be3bfe2-482a-4d23-a27f-3506f3894f87">158,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzQtMy0xLTEtMzEw_bc21e6ce-d0ec-4d86-8363-f5ce4338ae74">102,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment additions included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDAtMS0xLTEtNzg1MQ_1ad031e5-b688-462b-9574-abd6ffdcd08c">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDAtMy0xLTEtNzg1MQ_1305f929-550c-434d-baf7-df224adea2f4">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset obtained in exchange for operating lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDEtMS0xLTEtNjc1OA_92e3d03f-c3d1-4fa1-8b8c-8714c344e412">30,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDEtMy0xLTEtNzg1NQ_9f1b097f-52ba-437a-a129-cd87f675a861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="kron:DeferredOfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDItMS0xLTEtNzg0Nw_4ef6492d-3dd7-4611-9851-a91079087705">682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="kron:DeferredOfferingCostsIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDItMy0xLTEtNzg0Nw_23af3fe5-9fb6-4466-93d3-23e4bff5f7b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock issuance costs in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="kron:TemporaryEquityIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDMtMS0xLTEtNzg0Nw_985fb286-f7c4-4023-ae26-b0864ad05523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="kron:TemporaryEquityIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDMtMy0xLTEtNzA1Mg_164b64d9-6ccf-479d-bc32-d79b78088814">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_875"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_103"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzc2OTY1ODE0MDAzNzE_5bbcea6f-d913-43df-9ee5-b13a90401c5d" continuedAt="i3d4815140e874cc395d15424fda98c8a" escape="true">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i3d4815140e874cc395d15424fda98c8a" continuedAt="ic4db71748ecb45adaa9a6b04d528ba91"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kronos Bio, Inc. (Kronos or the Company), a Delaware corporation, was incorporated on June 2, 2017. The Company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="segment" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzc2OTY1ODE0MTUxNjI_165fd8a8-5dac-4722-bb62-7143f58d2823">one</ix:nonFraction> business segment, the development of biopharmaceutical products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company completed an initial public offering (IPO) of its common stock.  In connection with its IPO, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0MzM_b8192982-634a-4e19-a58a-eb0f7a8c75db">15,131,579</ix:nonFraction> shares of its common stock, which included <ix:nonFraction unitRef="shares" contextRef="i47233a942abf4a268c14b15bafb9f5e0_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0Mzk_dbcdeb4b-c625-476d-b8cc-735690f003ce">1,973,684</ix:nonFraction> shares of its common stock issued and sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i312337076930421489dbae527af0c6a2_I20201031" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0NDU_ba6f9d10-8036-4b9d-85ed-6046308169a1">19.00</ix:nonFraction> per share.  As a result of the IPO, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzM4NDgyOTA3MDczMDA_4042688d-aca6-420d-95eb-bd876bb9fea0">263.9</ix:nonFraction> million in net proceeds, after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="usd" contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="kron:PaymentsOfUnderwritingDiscountsAndCommissions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0NTE_a0964054-68d8-4b40-a6b5-025efe331a9d">20.1</ix:nonFraction> million and offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="kron:PaymentsOfOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4OTM0MDU_1f5561df-db14-44c0-811a-ef81505ac4ad">3.5</ix:nonFraction> million payable by the Company.  At the closing of the IPO, <ix:nonFraction unitRef="shares" contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0ODE_8ba57036-aec7-481f-a95b-00aff1701f22">21,504,893</ix:nonFraction> shares of outstanding convertible preferred stock were automatically converted to <ix:nonFraction unitRef="shares" contextRef="iba04a0b8630a43e7a31aa41fb7a542f6_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0ODY_bf49b9c2-8ccc-463c-ba55-7ec596e61234">22,687,625</ix:nonFraction> shares of common stock and the 2020 Notes (See Note 15) were automatically converted into <ix:nonFraction unitRef="shares" contextRef="ib50ec0c321854506a6168bb676c9bb98_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0OTI_0d33dbed-2537-4164-b306-a08a6ac9333e">9,610,713</ix:nonFraction> shares of common stock.  At the closing of the IPO, the Gilead Note (See Note 13) was also converted into <ix:nonFraction unitRef="shares" contextRef="if9ec867a047842948219312d9ab1388e_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzQzOTgwNDY1MjE0MDU_c91d48ad-01b9-4266-8166-0926291bb620">188,567</ix:nonFraction> shares of common stock. Following the IPO, there were <ix:nonFraction unitRef="shares" contextRef="i312337076930421489dbae527af0c6a2_I20201031" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzc2OTY1ODE0MTM0MTA_ef8fffc5-65dc-490d-b21d-766e272888f1">no</ix:nonFraction> shares of convertible preferred stock outstanding.  As of September&#160;30, 2020, the Company had incurred $<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzI3NDg3NzkwODgzOTg_0a0ff5ee-6ff8-4093-8bc5-8ec27aa9c8c3">2.9</ix:nonFraction> million of deferred offering costs, which will be offset against the net proceeds received from the sale of common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses since its inception of $<ix:nonFraction unitRef="usd" contextRef="iafb3c774af9d4c178d3cac868b3c195a_D20170602-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODk4NDA_b623c964-db76-4816-9c2b-db7fba50d147">78.7</ix:nonFraction> million as of September&#160;30, 2020.  The Company expects that its cash, cash equivalents and investments as of September&#160;30, 2020, in addition to its approximate net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzM4NDgyOTA3MDczMTg_4042688d-aca6-420d-95eb-bd876bb9fea0">263.9</ix:nonFraction> million from the Company&#8217;s IPO, which closed on October 14, 2020, will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of issuance of these condensed financial statements.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the global novel coronavirus disease (COVID-19) outbreak a pandemic. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ic4db71748ecb45adaa9a6b04d528ba91"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations.  The Company&#8217;s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue business strategies.  The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaboration arrangements or obtain government grants.  The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders.  If the Company is unable to obtain funding, the Company could be forced to delay, reduce, or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.  In the event that the Company requires additional funding, there can be no assurance that it will be successful in obtaining sufficient funding on terms acceptable to the Company to fund its continuing operations, if at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward Stock Split</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&#8217;s common stock on a <ix:nonFraction unitRef="number" contextRef="i5c23b681d5c84ca1bf3cfe7435c3e188_D20201002-20201002" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzI3NDg3NzkwOTIzMjI_f4f07e72-81f0-48a5-81f3-b3bf204cf1aa">1.055</ix:nonFraction>-for-1 basis (the Forward Stock Split).  In connection with the Forward Stock Split, the conversion ratio for the Company&#8217;s outstanding convertible preferred stock was proportionally adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split.  The par value of the common stock was not adjusted as the result of the Forward Stock Split.  All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these condensed financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.</span></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTI3_bb47ba20-c3fa-4f6e-862d-46c07e4e65c1" continuedAt="ife3a947e061842e8b27b1a18ec2ec75f" escape="true">SIGNIFICANT ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS </ix:nonNumeric></span></div><ix:continuation id="ife3a947e061842e8b27b1a18ec2ec75f" continuedAt="iebeb9d9620cd44079421fecb6994051f"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzc2OTY1ODE0NDQ5MDc_a8a30b00-ce82-4296-a60d-bc29b668ee29" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying balance sheet as of September&#160;30, 2020, the statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019, the statements of convertible preferred stock and stockholders&#8217; deficit as of September&#160;30, 2020 and 2019, the statements of cash flows for the nine months ended September&#160;30, 2020 and 2019, and the financial data and other financial data and other information disclosed to in the notes to the condensed financial statements are unaudited.  The unaudited interim financial statements have been prepared on a basis consistent with the Company&#8217;s audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of September&#160;30, 2020 and the results of its operations the three and nine months ended September&#160;30, 2020 and 2019. The results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2020, any other interim periods, or any future year or period.  These financial statements should be read in conjunction with the Company's audited financial statements included in the prospectus dated October 8, 2020 that forms a part of the Company's Registration Statements on Form S-1 (File No. 333-248925), as filed with the SEC pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended, on October 9, 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTI4_19852236-bdc9-437a-9d13-687358717366" continuedAt="id2e198c1f9834c3995e399b3698d966d" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="iebeb9d9620cd44079421fecb6994051f" continuedAt="i960c26d79d4147a6872b89a96ee0ad0c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id2e198c1f9834c3995e399b3698d966d" continuedAt="ifa935f1417a1453fae47c862ab6daed6">Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of convertible notes and investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  Actual results could differ from the Company&#8217;s estimates.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifa935f1417a1453fae47c862ab6daed6">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets.</ix:continuation> </span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTI5_21e64dff-f0cc-4a99-9bc9-4eb52ed0b245" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, discovery research performed by contract research organizations (CROs), materials and supplies, licenses and fees and overhead allocations consisting of various support and facility-related costs. The Company expenses R&amp;D costs as the services are performed or the goods are received.  Research and development expenses for the three and nine months ended September&#160;30, 2020 included $<ix:nonFraction unitRef="usd" contextRef="i58709a1025434a858b79101128c97c2e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzQzOTgwNDY1Mzk4NzA_0ab26e4e-24a8-49cb-9564-f751f3d34701"><ix:nonFraction unitRef="usd" contextRef="iaddbc37c40784a41b4cba75355474170_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzQzOTgwNDY1Mzk4NzA_60bf892f-92bc-479a-8b68-3d8aff16da11">6.6</ix:nonFraction></ix:nonFraction> million related to acquired intangible assets as research and development costs pursuant to the Asset Purchase Agreement with Gilead (See Note 13) as, at the time of acquisition of the asset, the technology was under development; was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing; had not reached technical feasibility; or otherwise had no foreseeable alternative future use.  There were no acquired intangible assets expensed for the three and nine months ended September&#160;30, 2019.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRO costs are a significant component of R&amp;D expenses. The Company monitors levels of performance under each significant contract through communications with its CROs. The Company accrues costs for discovery research performed by CROs over the service periods specified in the contracts and adjusts our estimates, if required, based upon its ongoing review of the level of effort and costs actually incurred by the CROs. All of the Company&#8217;s material CRO contracts are terminable by the Company upon written notice and it is generally only liable for actual services completed by the CRO and certain non-cancellable expenses incurred at any point of termination.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTMw_d1f601ff-a955-4cef-84d0-d0088a5605b9" continuedAt="i69db75dbf2174b83a93201513c808489" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i69db75dbf2174b83a93201513c808489">The Company has deposited cash of $<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzk4OTU2MDQ3MDE5NzA_eb5ab7e2-10f1-424d-a3fe-7fe6480e9a8f">2.0</ix:nonFraction> million as of September&#160;30, 2020 to secure a letter of credit in connection with the lease of the 301 Binney facility (See Note 14).  The Company has classified the restricted cash as a noncurrent asset on its balance sheets.</ix:continuation> </span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTMz_46a53a5c-64fa-4287-b093-7c1515f27a5c" continuedAt="ib28075825eb64283a31b13d9ed2f5790" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i960c26d79d4147a6872b89a96ee0ad0c" continuedAt="i6b69efaaa8684a8497566acda435aaea"><ix:continuation id="ib28075825eb64283a31b13d9ed2f5790"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks common for biopharmaceutical companies, including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition, and untested manufacturing capabilities.</span></div></ix:continuation><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM0_54f6622a-fd24-4a6a-a5bc-28fc3874f64c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are available-for-sale and are carried at estimated fair value. The Company&#8217;s valuations of available-for-sale securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the balance sheet date are classified as short-term investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are excluded from earnings and are reported as components of comprehensive loss. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income (expense), net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest income (expense), net on the Company&#8217;s statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM1_9086bc3e-687e-40c7-8d0c-a1acf46331a5" continuedAt="i7aea43219bcc46eda8ef0445eb93bbea" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6b69efaaa8684a8497566acda435aaea" continuedAt="i66cd8af6cf9a47efb6678213ac0ad322"><ix:continuation id="i7aea43219bcc46eda8ef0445eb93bbea"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value estimates are made at a discrete point in time based on relevant market information and information about the financial instruments. Fair value estimates are based on judgments regarding future expected loss experience, current economic conditions, risk characteristics of various financial instruments, and other factors. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company recorded both financial assets and financial liabilities requiring fair value measurement.  The financial assets include cash equivalents and investments.  The financial liabilities consist of the convertible promissory note (Gilead Note) from the Gilead Asset Purchase Agreement (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15).  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, the Company recorded financial assets, including cash equivalents, and investments, requiring fair value measurement.  There were no financial liabilities as of December&#160;31, 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, the Company has the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument by instrument basis, with changes in fair value reported in the statements of operations.  The option was elected for the treatment of the Company&#8217;s convertible promissory note from the Gilead Asset Purchase Agreement entered into in July 2020 (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15) in order to more accurately reflect the economic value of the notes.</span></div></ix:continuation><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM2_0e943087-8190-4a27-9bb2-899fd24f3340" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over the estimated useful lives of the respective assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Repairs and maintenance costs are expensed as incurred.  </span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTc1_21d48bde-6e0e-4558-8552-d3770aa664c7" continuedAt="i87f2d46411844666a8bbd7c5a0ee2de6" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives in years are generally as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7368251cdbf04660970e56374215be24_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZTplNTc0ZTk0MmY1NmE0ODgwOWNjNGJiNjllZTc3MjU3ZC90YWJsZXJhbmdlOmU1NzRlOTQyZjU2YTQ4ODA5Y2M0YmI2OWVlNzcyNTdkXzEtMi0xLTEtMzI2Ny90ZXh0cmVnaW9uOmVlM2RiNDJlYzZmMTQ3YTZiNWI1YmI0ZDkzYzUwZDllXzk4OTU2MDQ2NTAwMDE_ac875c3e-a856-420a-9480-d752d06998ba">3</ix:nonNumeric> to <ix:nonNumeric contextRef="ica62b3a4be464cb3bc3599acf158c2ae_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZTplNTc0ZTk0MmY1NmE0ODgwOWNjNGJiNjllZTc3MjU3ZC90YWJsZXJhbmdlOmU1NzRlOTQyZjU2YTQ4ODA5Y2M0YmI2OWVlNzcyNTdkXzEtMi0xLTEtMzI2Ny90ZXh0cmVnaW9uOmVlM2RiNDJlYzZmMTQ3YTZiNWI1YmI0ZDkzYzUwZDllXzk4OTU2MDQ2NTAwMDc_5314dbe4-1fa4-45cd-96bd-ae3cdaf6cca4">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or lease term</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzc2OTY1ODE0MzEwMjg_c09b1faf-bcd3-4e71-b33c-a2013501dc36" continuedAt="ib392275f19114b408cf4f5890172a9b4" escape="true">Deferred Offering Costs</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib392275f19114b408cf4f5890172a9b4">Offering costs, including legal, accounting, and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO.</ix:continuation>  As of September&#160;30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzI3NDg3NzkxMTIzMTQ_0a0ff5ee-6ff8-4093-8bc5-8ec27aa9c8c3">2.9</ix:nonFraction> million of deferred offering costs have been capitalized, which are included in the accompanying balance sheet within other noncurrent assets.  There were no deferred offering costs recorded as of December&#160;31, 2019.</span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM4_fa725879-6153-457f-ae52-24daab7d6028" continuedAt="i8ed66b56ddfa46179acc0e16e62054fe" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and noncurrent operating lease liabilities on the Company&#8217;s balance sheet. Finance leases are included in property and equipment, current portion of other liabilities, and other noncurrent liabilities on the balance sheet. </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i66cd8af6cf9a47efb6678213ac0ad322" continuedAt="i95b7993ae13c4ec884bdc78c70800f11"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8ed66b56ddfa46179acc0e16e62054fe">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments and initial direct costs incurred, net of lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.</ix:continuation></span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM5_1a1c5026-71ec-4600-9349-551978721b31" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQw_f7956c08-2e9c-4f02-9240-0ca66d756805" continuedAt="ibaf72626d249487aba450ee236ebf30c" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:continuation id="ibaf72626d249487aba450ee236ebf30c" continuedAt="i2e2a24d8ca704519a244997c6377a7f8"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock-based awards granted to employees and nonemployees based on the fair value on the date of the grant and recognizes stock-based compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value measurement of stock options using the Black-Scholes option-pricing model. </span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2e2a24d8ca704519a244997c6377a7f8">Forfeitures are accounted for as they occur. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has only issued stock options with service-based vesting conditions and records the expense for these awards using the straight-line method.</ix:continuation> </span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQx_aecbc2d5-ae04-4b34-a3c8-b92a433c918d" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQy_26de2fd3-b30e-4870-9cdd-4a9f55509f70" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the three and nine months ended September&#160;30, 2020, other comprehensive loss consisted of unrealized gains and losses from available-for-sale securities. There was no difference between net loss and comprehensive loss for the three and nine months ended September&#160;30, 2019.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i95b7993ae13c4ec884bdc78c70800f11" continuedAt="ib8fdc407b1a845bcb1e0d712d6049456"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQz_8ddaa98f-9c2a-4cde-90e3-1c22adf23ab0" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and the effect of dilutive securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect on net loss per share is anti-dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQ0_80f10a7e-edae-453e-ade2-08ca079e1adc" continuedAt="ic276e0a896f64dcfaecda30647d9982a" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).  The Company adopted ASU No. 2018-13 on January 1, 2019. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the FASB issued ASU No. 2016-18, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows, Restricted Cash </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-18). This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet.  The Company elected to adopt ASU 2016-18 on January 1, 2019 and has reflected the adoption in its financial statements. <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTc2_2417de02-15d9-4c81-8e94-0f2a6d6cef45" continuedAt="i897aea2a0dff44878f791ad13a455c41" escape="true">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="i897aea2a0dff44878f791ad13a455c41"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzMtMS0xLTEtMjA2OQ_fcf60f0c-eed9-447e-8ee2-023efbe0cbd9">156,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzMtMy0xLTEtMjA2OQ_90f036fc-bf49-4647-afcf-5696462c76a8">102,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzQtMS0xLTEtMjA2OQ_1ae391e4-e711-4911-a679-37b5e9b7826c">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzQtMy0xLTEtMjA2OQ_dc7e478e-a8f9-435e-a528-0c70f8b17b03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as shown on the statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzUtMS0xLTEtMjA2OQ_a6b9b747-c642-4f2b-9b37-de722c2cc54b">158,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzUtMy0xLTEtMjA2OQ_352c07c0-7e38-454d-a33f-afa69af07350">102,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company adopted ASU No 2016-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flow</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2016-15) in 2019. The guidance reduces diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The adoption of ASU 2016-15 did not have a material impact on the Company&#8217;s condensed financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The standard will become effective for the Company in the first quarter of 2020, with early adoption permitted beginning the first quarter of 2019. The modified retrospective approach should be applied upon adoption of this new guidance. The Company&#8217;s financial instruments that are in the scope of ASU 2016-13 include available-for-sale debt securities. The Company adopted this standard on January&#160;1, 2020 and this amendment did not have a material impact on its financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:continuation id="ib8fdc407b1a845bcb1e0d712d6049456" continuedAt="i31c655012e184b8f9d51af78c910518c"><ix:continuation id="ic276e0a896f64dcfaecda30647d9982a" continuedAt="i36da1a9e5cc6444188d06d728cd24632"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i31c655012e184b8f9d51af78c910518c"><ix:continuation id="i36da1a9e5cc6444188d06d728cd24632">, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company has adopted this standard as of January 1, 2020, which did not have a material impact on its financial statements.</ix:continuation></ix:continuation> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_109"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90ZXh0cmVnaW9uOjZmYzliMDk0M2QwYjQ0OTU4Y2RlYjc5MDQ4ODQ4ODlmXzk4OTU2MDQ2NTMxNDQ_b25c4dc1-229d-4216-a442-b58e1ee16aa7" continuedAt="i05b2497b1d784e4287cf7fa7fadf7c76" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i05b2497b1d784e4287cf7fa7fadf7c76" continuedAt="i3320b1f882e3435396ee018de269029b"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports its cash equivalents, investments, and convertible notes at fair value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds are measured at fair value on a recurring basis used quoted prices and are classified as Level 1.  Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classed as Level 2 inputs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 liabilities consist of the Company&#8217;s convertible notes payable.  The determination of the fair values for the Gilead Note and the 2020 Notes and the change in the fair value of these notes are discussed in Note 13 and Note 15, respectively.</span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90ZXh0cmVnaW9uOjZmYzliMDk0M2QwYjQ0OTU4Y2RlYjc5MDQ4ODQ4ODlmXzk4OTU2MDQ2NTMxNDU_0dcc867c-f6d0-44ad-88be-4898826cf556" continuedAt="ia21a7bff3f5240aa838ca5a74e2e30d0" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icebd3a6e85524ddfae7ab2d335391a20_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzUtMS0xLTEtMzUy_1ce657ca-cd90-4ba1-8692-9dd965ff7e42">84,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3525e299a5b4af0be5bf6819c729869_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzUtMy0xLTEtMzUy_ea5c0a28-0dbc-4a54-b20c-83080ef4be05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefc9cad03a70461aa7360544a7db02b8_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzUtNS0xLTEtMzUy_ad2d64b4-2f1f-494f-a4b3-7a8846e9823c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3880408e89894aeda2c8f29fbbd3aabb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzUtNy0xLTEtMzUy_dfa8cfcd-dabb-48a2-ae4a-9910955b46e5">84,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf34c2cfcabc444f928cf7c4d4f21f48_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzYtMS0xLTEtMzUy_b0bd9508-3901-42f8-ae9c-e99f573f8a9d">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ea2ec1be444c429b071d6fbb31c541_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzYtMy0xLTEtMzUy_1f837ec1-183e-4ea7-8842-7230eaef1d90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a2a0c9723b4043be099d02b2adcda9_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzYtNS0xLTEtMzUy_dedbdf32-9533-4f9f-9607-73a7477f9ffa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31eb8916a43d46619bd5de6a14b21fcf_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzYtNy0xLTEtMzUy_e477d8d5-d0bc-4957-8a68-01d9c4c81339">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1322d5329804324b8862de983107090_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzctMS0xLTEtMzUy_99decda2-6251-450c-a001-7f81f3632f5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d7755090cf442b9c9553d09c0c78e4_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzctMy0xLTEtMzUy_7d0de2b5-6de5-472f-bb84-6cf2255979be">18,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3736170b03754b159e40f2cbb89bdfc6_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzctNS0xLTEtMzUy_bdf596dd-11d7-40e4-a6f4-ff41015ee75e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i680604ecdff84d6583da30f5932ef047_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzctNy0xLTEtMzUy_4398d604-4290-4194-bdb7-beca28600475">18,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98808ce4a14e4f6d9893eafb8348f14f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzgtMS0xLTEtMzUy_f71ed7ad-dba0-49b4-ae14-7fad7c031510">40,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae3269eca18443ca8f367f8ca760d4d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzgtMy0xLTEtMzUy_0f53685f-b069-42bd-8384-228ddd18d8ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fc21197ebfa4519b5f3821c2e7bd9cd_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzgtNS0xLTEtMzUy_d32caefb-ccc5-4b95-90de-eddd36e72abd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6f85d2f9144b0f9c6655f0a45deb0b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzgtNy0xLTEtMzUy_94b3f81a-88bf-431a-bcc5-fdfd7a5d859b">40,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573369416f3145549249238391de4f54_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzktMS0xLTEtMzUy_0d26171b-290f-4468-a8d1-85e14540f886">126,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2166333152034a59828414d7b029805f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzktMy0xLTEtMzUy_4eb04697-3bb0-430b-a473-d59ad05451a2">18,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c12e5ec7e247b29b2dbcedcb33e438_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzktNS0xLTEtMzUy_f6cde3a7-a1c4-4e75-b040-d03a07c03e1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i474c4138d7474661a524846e44986c19_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzktNy0xLTEtMzUy_c68131ca-9b98-4d55-a758-a2034aeeab35">144,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3393bbb6f14657970ffb6c3b9bf796_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEyLTEtMS0xLTI1OTE_aebac88c-d517-40a4-a51d-48cdc861301a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0d5b5fee34c9da760299481d92409_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEyLTMtMS0xLTI1OTE_c9b173dc-5619-4500-9ecd-b897c832920a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e139b86417413ba1c2ca3b42137fc7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEyLTUtMS0xLTI1OTE_380bb05a-59fd-4e61-ae95-b694ad94a7d5">168,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35673f0d42234a1a87f1a231ace9457d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEyLTctMS0xLTI1OTE_a859e3f5-d71c-40c6-81ff-53c295189800">168,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bdf1d474b04179a7a68c046db8a473_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEzLTEtMS0xLTI1OTE_7e22c3d6-d8fa-40ca-844f-a5e763771029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd30a89a052a4593801ad15c7befa88a_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEzLTMtMS0xLTI1OTE_e4fac8e4-f020-4b8b-9dac-22a57340b8b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd9407ea32a46d29a98b1840c00b5e5_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEzLTUtMS0xLTI1OTE_2568ee69-fbd9-4267-b25c-3c3eda5d09bd">5,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf649645154449d937a12dc7b650d3b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEzLTctMS0xLTI1OTE_0856c30a-a12d-42fa-85ee-d0c1adce30e9">5,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573369416f3145549249238391de4f54_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzE0LTEtMS0xLTI1OTE_dd6006b9-c70a-49cf-ac2f-7cf18fac9994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2166333152034a59828414d7b029805f_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzE0LTMtMS0xLTI1OTE_8da6f045-0a1d-4157-87ef-f5b348761c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c12e5ec7e247b29b2dbcedcb33e438_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzE0LTUtMS0xLTI1OTE_f2dc0b1f-52b8-4b9f-9e9c-9fd055c9a851">173,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i474c4138d7474661a524846e44986c19_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzE0LTctMS0xLTI1OTE_c237892a-7107-4edd-b442-3ae195183526">173,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3320b1f882e3435396ee018de269029b"><ix:continuation id="ia21a7bff3f5240aa838ca5a74e2e30d0"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if583afaf5b244bcca3ee512b9be88c54_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzQtMS0xLTEtMzYw_3b7de633-c17f-4e36-b3f3-35e0e98afd80">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e2789cb4b74177b02829790b3e940d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzQtMy0xLTEtMzYw_b07ea56c-df13-44af-9348-acd82bf56048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37461a4dccc543c794502b870925d09a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzQtNS0xLTEtMzYw_c7da6274-d06e-4f85-9fba-4871d5ddc558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34dc0fe00ef4ae7b9326ac0de29b988_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzQtNy0xLTEtMzYw_a33ce441-ce13-4956-9669-d5885d3b7156">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8d077e88bd4026bd1bb0363cba99a1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzUtMS0xLTEtMzYw_170593c8-07f6-40d9-bbff-756b05e742fc">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a45a3c22d2a4df687077e2744eeadf4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzUtMy0xLTEtMzYw_f475524e-3291-4e1b-920c-04a3ff6cd1c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d31ded16544421a9103017ada1e3d8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzUtNS0xLTEtMzYw_2daab628-166b-450e-aa9a-d7e23657ecbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e7dcee3fb74a77a44721d2eede0234_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzUtNy0xLTEtMzYw_4f28ee60-b7c1-4d71-8fe6-804b039e78a6">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4076df8add474ba29dc5b999506194be_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzYtMS0xLTEtMzYw_bb664d4a-92c5-4340-ab13-81040a199f60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e6b6f0456e4402a51dcd58d9f97704_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzYtMy0xLTEtMzYw_e5815385-d93a-4c66-bd16-040581476ddd">4,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideaf848d46684b1688cbb86308ac9126_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzYtNS0xLTEtMzYw_ce192758-0751-4354-bb14-2e968e6c33bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2dff33c792e472cb04f1f4a0c4177c6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzYtNy0xLTEtMzYw_3c6ff3a2-b680-4b72-b712-40d5b0f8a5df">4,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230135e8439a495f98bb16d12950f814_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzctMS0xLTEtMzYw_efcf1707-365e-44ff-8dcd-29373dd904ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f054c8a6945414f871dddd891074dfd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzctMy0xLTEtMzYw_d7f42b09-979e-4a8b-a943-f059d5fbbaf1">26,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i779c812cecca45018028a8b1b19645f8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzctNS0xLTEtMzYw_0875e54f-86b5-49a0-8435-e57a8604a3ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fbc7564af4d4ca8ab0b6d6ee3eca9e4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzctNy0xLTEtMzYw_b0735ca0-3963-43fc-b595-dd1caedb3ce6">26,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4779748a74d4a69825b5e0020c5ba68_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzgtMS0xLTEtMzYw_2289558c-3b42-425d-bd80-ab41a96b95b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93643158b5c54d28a5f5e8c68a1277e1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzgtMy0xLTEtMzYw_9035aa6c-aead-4024-8a01-618953bc654e">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6335bb67f9274f448c80b37b25c8a24b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzgtNS0xLTEtMzYw_83f05b75-83a8-4f5b-9004-ac7ee51277d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799ef75758464399a4c6a7a23c3f174d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzgtNy0xLTEtMzYw_9c097d82-cb64-47b2-b35e-69986d6df3eb">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b6a69f036854687b46ff68bdaa0cd34_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzktMS0xLTEtMzYw_51bc6336-9756-4642-9f2d-3bd5ff3b3f55">36,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3accbd97d64e20abccd18a3f976641_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzktMy0xLTEtMzYw_31c09bc9-2665-4ca3-aaae-33f1f1ab4491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9ccd829968847d0a85a4e061e73e94a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzktNS0xLTEtMzYw_e66311ba-ebdd-46c6-8374-f23d0141764e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4218d1af33444d8792019dd29458c211_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzktNy0xLTEtMzYw_605c5700-af9b-4292-89d5-e740867ee613">36,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bef37ea13804aa98d20b37c8a9755f2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzEwLTEtMS0xLTM2MA_dc5b8364-e80d-4891-917f-53bc9a9c419d">38,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6a9845420549d1b467cec0513db1ff_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzEwLTMtMS0xLTM2MA_6c56e660-7c24-4705-90cb-379861ebc5c9">32,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia172359196044363a8d21deea37250a0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzEwLTUtMS0xLTM2MA_e7b2b9ba-ab83-446b-a5f1-56df38660aae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica89d2973d6e42c69a454cbcfad99204_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzEwLTctMS0xLTM2MA_eff53d5f-4c51-40cd-ac21-e912eeb790bf">71,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities. The Company&#8217;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category as of September&#160;30, 2020.  Recorded losses associated within the Level 3 category include changes to fair value and are recorded within change in fair value of convertible notes in the statement of operations. Refer to Note 13 and Note 15 for the fair value determination of the Level 3 financial liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any financial assets or liabilities as of December 31, 2019 that required Level 3 inputs. There were no transfers of assets between the fair value measurement levels during any of the periods presented in the accompanying financial statements.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_112"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90ZXh0cmVnaW9uOmE5MDliZDExYmU1MDQ5Zjk5MmMwOTFkM2U1Y2M4ZmYzXzEyNjQ0MzgzNzIxMDk3_7013b126-ae92-416d-bfd2-92dbce038bf3" continuedAt="if391b875f0664334b762af84b9dcd87b" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="if391b875f0664334b762af84b9dcd87b" continuedAt="id366e27b2d85472485987254dce5b6d2"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90ZXh0cmVnaW9uOmE5MDliZDExYmU1MDQ5Zjk5MmMwOTFkM2U1Y2M4ZmYzXzEyNjQ0MzgzNzIxMDk5_4c859e90-d56f-4f2b-a00e-c606e2b7b328" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of available-for-sale securities by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a3c48f37e74d588132870025f958b3_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzQtMS0xLTEtMzkx_80332d35-e928-476d-9321-704e040ee8e7">84,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a3c48f37e74d588132870025f958b3_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzQtNy0xLTEtMzkx_0ae33e3e-878e-4c54-ae3f-196969eac8bc">84,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i903c1dd51d3f4f3294ec6e9659628839_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzUtMS0xLTEtMzkx_da1d4acd-29aa-449e-82ed-599d9d49b3c4">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i903c1dd51d3f4f3294ec6e9659628839_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzUtMy0xLTEtMzkx_7c074357-7a73-4145-863b-0a57d37a8ec0">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i903c1dd51d3f4f3294ec6e9659628839_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzUtNS0xLTEtMzkx_4f4e3e04-853d-4a90-bfe1-c0eac60093d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i903c1dd51d3f4f3294ec6e9659628839_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzUtNy0xLTEtMzkx_650d8681-931e-4286-89a7-fb8fea79d41a">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzYtMS0xLTEtMzkx_0ca0e8ca-aa67-4c70-aeea-9b7b9c4d509b">18,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzYtMy0xLTEtMzkx_93ffdd9e-9c9a-46f9-bc2e-8914784bfdfd">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzYtNS0xLTEtMzkx_a5f58392-d5d9-4b6d-ad2f-66653e16eefc">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzYtNy0xLTEtMzkx_b5ff777f-14be-4d33-8f43-312c2f5288d9">18,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1522d2b251964ba5a986cdf9d5591a43_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzctMS0xLTEtMzkx_f1776be6-5c0f-4ea3-b798-e94a6320fca8">40,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1522d2b251964ba5a986cdf9d5591a43_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzctMy0xLTEtMzkx_c5345440-488e-46b0-8d17-c74ed6450a71">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1522d2b251964ba5a986cdf9d5591a43_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzctNS0xLTEtMzkx_36e6808f-3979-42c5-848d-5c44613a2059">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1522d2b251964ba5a986cdf9d5591a43_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzctNy0xLTEtMzkx_2b2c1961-fa8e-4ea8-8eef-7f078bfaf1ff">40,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzgtMS0xLTEtMzkx_0bf77d55-1e3c-4d4c-a2b9-5a932ea1a657">144,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzgtMy0xLTEtMzkx_09e42bfe-2327-4ca6-a4f0-aa373695320a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzgtNS0xLTEtMzkx_04df060a-f89d-4cdc-b0e4-da42da063b90">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzgtNy0xLTEtMzkx_87ccfe6d-d254-4adb-a395-4c07ec2c668a">144,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34c5b72f428403a99b45063852c073b_I20191231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzMtMS0xLTEtMzk2_eb824c45-68ec-4c00-80a5-dcf4a67bb914">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34c5b72f428403a99b45063852c073b_I20191231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzMtNy0xLTEtMzk2_b55745d7-36a9-4f2c-91a8-d22ab6c89204">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b10d2d52aec4721944b453f9433b17a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzQtMS0xLTEtMzk2_1e5cedc9-dc19-4623-a346-83bfc861e21e">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b10d2d52aec4721944b453f9433b17a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzQtMy0xLTEtMzk2_efc47cbd-cf53-4e8f-9c4e-d51292e530ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b10d2d52aec4721944b453f9433b17a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzQtNS0xLTEtMzk2_aa5a188c-0624-4aa7-9064-2277c17609b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b10d2d52aec4721944b453f9433b17a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzQtNy0xLTEtMzk2_ae73db06-a8ba-4b26-a727-66fae5c6cbfa">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e3f25eb0c84772add6ec6f825655e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzUtMS0xLTEtMzk2_c6c7439b-3fa1-4ea8-b58d-da19e3b36d3c">4,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e3f25eb0c84772add6ec6f825655e0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzUtMy0xLTEtMzk2_e8c16751-e654-41b4-8e1a-f47ae90520a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62e3f25eb0c84772add6ec6f825655e0_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzUtNS0xLTEtMzk2_0568dc53-e7fb-4232-87db-dc76969c73fe">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e3f25eb0c84772add6ec6f825655e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzUtNy0xLTEtMzk2_aa03a50f-0c2e-4c2e-88d6-e4ae434ed69c">4,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc04e4557db74cd5a579218a21c7f715_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzYtMS0xLTEtMzk2_92d84224-285a-47e9-be77-e2da7c5e41aa">26,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc04e4557db74cd5a579218a21c7f715_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzYtMy0xLTEtMzk2_2a94dacd-f854-4dab-ad34-3f32a0dac4be">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc04e4557db74cd5a579218a21c7f715_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzYtNS0xLTEtMzk2_6710c6d0-65d5-46ea-8728-04ddafdcb740">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc04e4557db74cd5a579218a21c7f715_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzYtNy0xLTEtMzk2_3039e508-84da-4cea-b98e-b2b4715d5bd2">26,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee26b5d7183c4798998478356fcefae4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzctMS0xLTEtMzk2_9f6bcfdc-f8be-45f9-a3a5-ce3995c8b24b">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee26b5d7183c4798998478356fcefae4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzctMy0xLTEtMzk2_38eca6ef-b520-4f10-8fe0-f0a56d8af7bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee26b5d7183c4798998478356fcefae4_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzctNS0xLTEtMzk2_8ff47623-f8dd-45e9-8d50-d69e36997030">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee26b5d7183c4798998478356fcefae4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzctNy0xLTEtMzk2_313982c8-554f-4b96-b611-7e6130210a8d">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80dcec257aa4382b7cd1712a6f7b431_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzgtMS0xLTEtMzk2_383e5262-3d73-4101-aed0-eaf5a11c2bbe">36,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80dcec257aa4382b7cd1712a6f7b431_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzgtMy0xLTEtMzk2_2c1d9265-a2f5-45f2-a536-ab742fbecae5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie80dcec257aa4382b7cd1712a6f7b431_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzgtNS0xLTEtMzk2_80f41967-ef1e-40f4-8bf9-bc0b13d0e536">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80dcec257aa4382b7cd1712a6f7b431_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzgtNy0xLTEtMzk2_5d119104-bd4f-4e38-893e-ee76db7c9685">36,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzktMS0xLTEtMzk2_b4335340-519c-4251-9306-a617cc38fd41">71,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzktMy0xLTEtMzk2_5a1bf0e8-cdcb-4c80-85fa-73584b4f290b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzktNS0xLTEtMzk2_33bb65ab-acf8-42e2-8c40-2c8e877d07ca">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzktNy0xLTEtMzk2_fb4759b4-d2c7-402d-854a-82be44a14a77">71,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These available-for-sale securities were classified on the Company&#8217;s balance sheets as of September&#160;30, 2020 and December&#160;31, 2019 as:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzMtMS0xLTEtNDA5_9e902398-5560-4da7-9d8c-cc401764c998">84,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzMtMy0xLTEtNDA5_e3a875df-dd61-4248-b1f6-ba4f89ccb3d2">6,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzQtMS0xLTEtNDA5_875dd458-2a78-430c-97e3-9a24ae485a50">55,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzQtMy0xLTEtNDA5_72fb0596-2949-4339-b7d4-bc840feefecb">59,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzUtMS0xLTEtNDA5_e349331a-1b57-424f-8435-469a44bb931d">4,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzUtMy0xLTEtNDA5_7263bc82-622b-49ff-95ec-06bd55df2c31">4,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsAndCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzYtMS0xLTEtNDA5_99dd6046-b544-4841-918a-a37cf09c89c6">144,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsAndCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzYtMy0xLTEtNDA5_183b67e3-946c-4808-b8fe-48f3d6124162">71,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale securities by contractual maturity as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzItMS0xLTEtNDE3_6a04155c-427a-4cf4-97d3-ae00499a41ea">55,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzItMy0xLTEtNDE3_4efd0a3c-5a60-4be4-a114-cac01c66b971">66,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzMtMS0xLTEtNDE3_1814edf7-da1f-45d1-b443-4b5b5e0e3044">4,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzMtMy0xLTEtNDE3_3eccea42-2e24-477a-8d34-033f8ff02abd">4,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments not due at a single maturity date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzQtMS0xLTEtNDE3_a419f831-6322-408d-9ee9-61c408312495">84,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzQtMy0xLTEtNDE3_f4a8f13b-c52b-4915-89a4-e8abc0dd08b0">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsAndCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzUtMS0xLTEtNDE3_c5a63243-8ca1-4fbb-ace0-3191437c8f5c">144,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsAndCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzUtMy0xLTEtNDE3_c2fa3622-748c-4aa8-8ca9-5ae33e428739">71,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id366e27b2d85472485987254dce5b6d2">As of September&#160;30, 2020 and December&#160;31, 2019, the remaining contractual maturities of available-for-sale securities were less than <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:durmonth" name="kron:DebtSecuritiesAvailableForSaleRemainingContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90ZXh0cmVnaW9uOmE5MDliZDExYmU1MDQ5Zjk5MmMwOTFkM2U1Y2M4ZmYzXzEyNjQ0MzgzNzIxMTA2_edb21eaa-cef0-456e-ac9a-9e56fffb3496">23</ix:nonNumeric> months and <ix:nonNumeric contextRef="i6c206960ada7462e824eea778e31e777_D20190101-20191231" format="ixt-sec:durmonth" name="kron:DebtSecuritiesAvailableForSaleRemainingContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90ZXh0cmVnaW9uOmE5MDliZDExYmU1MDQ5Zjk5MmMwOTFkM2U1Y2M4ZmYzXzEyNjQ0MzgzNzIxMTIy_2c017393-705c-4f66-bb39-5922e22d043e">18</ix:nonNumeric> months, respectively. There have been no significant realized losses on available-for-sale securities for any of the periods presented in the accompanying financial statements. Based on the Company&#8217;s review of its available-for-sale securities, the Company believes that it had no other-than-temporary impairments on these securities as of September&#160;30, 2020 and December&#160;31, 2019 because the Company does not intend to sell these securities nor does it believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for any of the periods presented in the accompanying financial statements.</ix:continuation></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_115"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90ZXh0cmVnaW9uOjE2NjhjMzc0ZmI5ZTQ1OTU4ZTYwNjgxMGMwYzQ4ZTRkXzEzMTk0MTM5NTMzNTMz_0d2a5daf-93e1-459e-ac64-157f7ad2e20c" continuedAt="id01f1cdf26d1452fbd777a024fdea9fb" escape="true">PREPAID EXPENSES AND OTHER CURRENT ASSETS </ix:nonNumeric></span></div><ix:continuation id="id01f1cdf26d1452fbd777a024fdea9fb"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90ZXh0cmVnaW9uOjE2NjhjMzc0ZmI5ZTQ1OTU4ZTYwNjgxMGMwYzQ4ZTRkXzEzMTk0MTM5NTMzNTM0_230bfc93-93a1-4754-b5b5-c38c970b8a5a" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on short-term available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="kron:DebtSecuritiesAvailableForSaleAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzItMS0xLTEtNDQ2_91f95ce4-212c-4d3d-9788-d590eaeb0ff3">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="kron:DebtSecuritiesAvailableForSaleAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzItMy0xLTEtNDUy_b1d7c133-863b-433c-ab46-e82c2bb320e4">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid equipment service contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="kron:PrepaidEquipmentServiceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzMtMS0xLTEtNDQ5_254434c1-7ca3-413b-ac7a-aac8f02e82a9">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="kron:PrepaidEquipmentServiceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzMtMy0xLTEtNDUy_bea6518a-b976-48ee-b5f7-7916e8e15ccd">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid external research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="kron:PrepaidExternalResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzQtMS0xLTEtNDQ2_c3a66a3d-ebc9-40d2-a1fb-f858cb85be5f">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="kron:PrepaidExternalResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzQtMy0xLTEtNDUy_591d3c98-f392-459c-80f5-b40c9bdb23b9">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="kron:PrepaidSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzUtMS0xLTEtNDQ5_94ffd776-4699-4ab9-9a39-09b82d6b6209">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="kron:PrepaidSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzUtMy0xLTEtNDUy_2c93fe78-c7f8-420b-8248-c927ff494b41">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzYtMS0xLTEtNDQ5_6c9a01c1-74e8-4b4f-91c7-da54b9d35ed8">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzYtMy0xLTEtNDUy_c9e13ac2-7d4b-477b-85cc-e0fbfa8f2b71">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:PrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzctMS0xLTEtNDQ2_04e9c18b-cde1-4ee6-b0dd-e3a11d404ea1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:PrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzctMy0xLTEtNDUy_764b76ba-7c4e-48e9-a654-6ef2096535da">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzgtMS0xLTEtNDQ5_3f2273e8-5800-4587-98d4-63283d18d4d4">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzgtMy0xLTEtNDUy_18318cb4-b897-4588-866b-223d47740138">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzktMS0xLTEtNDQ2_264e6031-7654-4a0d-90c1-3382a6f26544">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzktMy0xLTEtNDUy_60f19a2b-0c34-4a33-b344-99c2ab37f21d">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_118"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzEzMTk0MTM5NTMzOTQx_536393ee-c2e1-4f98-8a8a-7f8b07f93a0d" continuedAt="i66cbc170ef454ed3953cfb8eef8c6d0c" escape="true">PROPERTY AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="i87f2d46411844666a8bbd7c5a0ee2de6"><ix:continuation id="i66cbc170ef454ed3953cfb8eef8c6d0c" continuedAt="i27038577a44b492bb267040fbaa6cde5"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23250faf272245f5a94cf235af7afc83_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzMtMS0xLTEtNDY4_2da96ad0-3ae5-4ade-8179-e7c1f2f02a28">5,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32dc3ea144344868a7ed2a838d5f9fc6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzMtMy0xLTEtNDY4_1824853e-ba07-4b0f-8b7a-40d7f985e72a">3,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease on R&amp;D equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzQtMS0xLTEtNDY4_653c686c-8df9-470d-984e-1eaf2b046180">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzQtMy0xLTEtNDY4_58e02bb3-0959-4b84-8c68-73fcf598cf72">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3898290b234512a7b35eb92edd64fb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzUtMS0xLTEtNDY4_843c5dc7-4bf9-4217-98b0-8a92814f9d76">5,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1515d6ea7fa64e37b804f072218ceeaa_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzUtMy0xLTEtNDY4_1447ef74-0020-45ce-a304-3c3e105e452e">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzYtMS0xLTEtNDY4_ea2f9d5b-7676-4b02-a86d-e5ee1b17457a">11,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzYtMy0xLTEtNDY4_279ea4b2-1ef4-42fc-8f52-197750cb3f3b">4,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzctMS0xLTEtNDY4_4db4f5a6-7aaa-40b2-b9e3-488ac7ebd143">985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzctMy0xLTEtNDY4_6431d8a1-c3a1-4217-8bd1-8f7107d71820">446</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzgtMS0xLTEtNDY4_af23f6bf-ffc4-4726-b86c-ca4f34d5de34">10,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzgtMy0xLTEtNDY4_b609d13b-500d-4ed5-8be4-da4b55d95d7e">3,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i27038577a44b492bb267040fbaa6cde5">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzMyOTg1MzQ4ODM3NDY_3592eba5-a860-4cdd-8105-ae85884b720d">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzMyOTg1MzQ4ODM3NjY_d184ae35-9cc0-4edc-a542-a290e5bf107e">0.1</ix:nonFraction> million for the three months ended September&#160;30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzMyOTg1MzQ4ODM5NDI_a5ceb7f5-e58b-4cde-830c-804ec7702b2f">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzMyOTg1MzQ4ODM5NTA_f54f0158-5148-44e9-985a-3f71fcc11475">0.2</ix:nonFraction> million for the nine months ended September&#160;30, 2020 and 2019, respectively.</ix:continuation>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_121"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90ZXh0cmVnaW9uOjFlYWI0ODU1NmFlNDQ0YzNiZTBiYjg0ZGY5NTA4Mzc5Xzk4OTU2MDQ2NTAzNjI_bee88d1b-2290-4992-8b6e-04895743a34e" continuedAt="i39103be8887c4e7c9f9d2da07ce1b9a2" escape="true">ACCRUED EXPENSES AND CURRENT PORTION OF OTHER LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i39103be8887c4e7c9f9d2da07ce1b9a2" continuedAt="i59de0f31d6e542ad94d67ce13a60d451"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90ZXh0cmVnaW9uOjFlYWI0ODU1NmFlNDQ0YzNiZTBiYjg0ZGY5NTA4Mzc5Xzk4OTU2MDQ2NTAzNjA_46b729de-887e-419d-b922-aac0c7f51db1" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzItMS0xLTEtNDg4_be47b987-41d8-461b-9069-935722ad022f">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzItMy0xLTEtNDk1_53ed6c70-e4c8-4279-8830-dcfdb065c845">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued franchise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzMtMS0xLTEtNDkx_ec08ca8e-8ceb-4e6e-95e3-43a8221ec95b">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzMtMy0xLTEtNDk1_8239f197-44e5-479b-bd2f-95738b025955">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="kron:AccruedExternalResearchAndDevelopmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzQtMS0xLTEtNDkx_894c5593-f7eb-4f87-ab6a-eadba411aff6">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="kron:AccruedExternalResearchAndDevelopmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzQtMy0xLTEtNDk1_efbec855-85cd-49e7-a60b-774bf89c88ba">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="kron:AccruedOfferingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzUtMS0xLTEtNzI5MA_77a45231-c885-4d23-bc3f-eb0311b49467">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:zerodash" name="kron:AccruedOfferingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzUtMy0xLTEtNzI5MA_20ad7c5e-6797-4c6e-bce9-faf7364eba70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzUtMS0xLTEtNDkx_311ece8b-017e-461a-82c1-8041df7f13aa">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzUtMy0xLTEtNDk1_540b5283-30d9-49f2-8f21-143e7c260384">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzYtMS0xLTEtNDg4_9a71bf37-0924-4628-8fc7-73c4e008f449">1,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzYtMy0xLTEtNDk1_8281dc73-1b14-4f4a-923a-673003211c8d">818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90ZXh0cmVnaW9uOjFlYWI0ODU1NmFlNDQ0YzNiZTBiYjg0ZGY5NTA4Mzc5Xzk4OTU2MDQ2NTAzNjE_ed028b70-41f1-4b11-8f74-7f5c6c4b4676" continuedAt="ie4f3a1cac9b74a45a623380e22b3a645" escape="true">Current portion of other liabilities consist of the following as of September&#160;30, 2020 and December&#160;31, 2019:</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:9pt"><ix:continuation id="i59de0f31d6e542ad94d67ce13a60d451"><ix:continuation id="ie4f3a1cac9b74a45a623380e22b3a645"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzItMS0xLTEtNTAz_09c3a1d1-edb4-4717-85ba-38a8c70b1ddc">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzItMy0xLTEtNTA2_c8d5e576-32bb-4e07-b94a-6393d5e4d433">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of unvested early exercised share liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzMtMS0xLTEtNTAz_c4174ead-b4df-4d7f-825c-08ecec6e889c">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzMtMy0xLTEtNTA2_9b0bf884-8139-4242-a119-6ff0f3dcd938">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current portion of other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzQtMS0xLTEtNTAw_8054924a-78fc-4bac-9e6f-7ba2813ec274">2,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzQtMy0xLTEtNTA2_3e668506-f24e-4351-a1ef-c580cb852521">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_124"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="kron:TemporaryEquityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzE0MjkzNjUxMTgxNTYw_18b82db2-6c55-4286-8cdb-fadb6b4e5470" continuedAt="i827ecbb1723e40eca35b589d3b61a78f" escape="true">PREFERRED STOCK</ix:nonNumeric></span></div><ix:continuation id="i827ecbb1723e40eca35b589d3b61a78f" continuedAt="ie962cde2719f4169960333dca0064437"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2018, the Company completed a private placement (Series Seed Financing) in which it issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="ibd7af7df3693489cbbd3c087fa18aa9b_D20180522-20180522" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODgyNTY_47a5f219-52d4-45e1-919b-0dbf8772f5e2">7,806,977</ix:nonFraction> shares of its Series Seed Convertible Preferred Stock (Series Seed Preferred Stock) at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1737f19c2c5741778344526c60c0bf8b_I20180522" decimals="5" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkxMDIwMjc_e700a422-9a78-4e8e-b3e3-d3f05ed846e0">2.30769</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ibd7af7df3693489cbbd3c087fa18aa9b_D20180522-20180522" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODgzNzY_d289e135-87eb-4ba9-9a63-ca1cd897023f">18.0</ix:nonFraction> million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2019, the Company completed a private placement (the Series A Financing) in which it issued <ix:nonFraction unitRef="shares" contextRef="icacd7aa366554a0abf8c53a9d66b1c77_D20190701-20190701" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk0NTU_31114f4b-cf06-4c65-9a88-bdfdcf578035">13,697,916</ix:nonFraction> shares of its Series A Convertible Preferred Stock (Series A Preferred Stock) at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i20ce35e12ca14274b80c3a91dc888b6c_I20190701" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk1NjA_63602ad1-5fef-40a2-a361-09793a684262">7.6654</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="icacd7aa366554a0abf8c53a9d66b1c77_D20190701-20190701" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk2MDc_e5492934-2181-4774-a47e-dc81dcff27e0">105.0</ix:nonFraction> million less issuance costs of $<ix:nonFraction unitRef="usd" contextRef="icacd7aa366554a0abf8c53a9d66b1c77_D20190701-20190701" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk5NTk_367ac3b7-4451-4647-a10c-885a756e5d47">0.1</ix:nonFraction> million. </span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:TemporaryEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzE0MjkzNjUxMTgxNTYx_df7e28db-f7a4-4da5-b2d6-aa2614efdba7" continuedAt="i4a44182aac1e42e38a93aa9af7272ea9" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Preferred Stock (as defined below) consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred<br/>Stock<br/>Issued and<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Stock<br/>Issuable Upon<br/>Conversion</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series Seed Preferred Stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtMS0xLTEtNTI1_d3dd6184-ccde-415e-9d98-01829376839d">7,806,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtMy0xLTEtNTI1_2031a361-72df-47b0-b72f-574688cbe3b5"><ix:nonFraction unitRef="shares" contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtMy0xLTEtNTI1_d555fce0-beb6-4e27-b340-d05824fe829a">7,806,977</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtNS0xLTEtNTI1_51316d32-784c-495d-b5e2-72f8b9e5b53b">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtNy0xLTEtNTI1_d1e4f839-cada-4b42-9d55-e284ba2513b1">18,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtOS0xLTEtNTE0_07e65d61-c3d8-442d-bf22-fce855d8becd">8,236,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series A Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtMS0xLTEtNTI1_4ff916c4-d4d2-47cf-bb71-f7d4798ca8ea">13,700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtMy0xLTEtNTI1_1e7aa695-e790-4532-801e-8178bc48f332"><ix:nonFraction unitRef="shares" contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtMy0xLTEtNTI1_79f0c871-de53-4b1e-bd62-e2847d42da52">13,697,916</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtNS0xLTEtNTI1_69cbb07a-dc46-4816-b689-52eaf2e9c2d3">104,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtNy0xLTEtNTI1_de90bc5d-b98e-4fe5-86e7-9832a3e6e23e">105,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtOS0xLTEtNTE0_5c8a78b8-9901-4d17-9626-0692b577e184">14,451,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtMS0xLTEtNTI1_dd3c477e-4c69-4ca5-a19a-ff734179f609">21,506,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtMy0xLTEtNTI1_cf47ce55-99d8-45c0-9dc1-5123b423167b"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtMy0xLTEtNTI1_ef3469c7-f58d-4c6c-bc0c-f5b09b579aa8">21,504,893</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtNS0xLTEtNTI1_4b53ce29-7bc8-42c3-8787-9c64d7eec964">122,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtNy0xLTEtNTI1_37887ec7-4f87-4721-b8b6-27a7ffa66032">123,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtOS0xLTEtNTE0_9eb5a1b7-b7d3-4ecb-aae3-b5bf10f03b89">22,687,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie962cde2719f4169960333dca0064437"><div style="margin-bottom:9pt"><ix:continuation id="i4a44182aac1e42e38a93aa9af7272ea9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred<br/>Stock<br/>Issued and<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Stock<br/>Issuable Upon<br/>Conversion</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series Seed Preferred Stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="idfef7d206519439a936e6eb262b31e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtMS0xLTEtNTMx_4e4da09a-35c1-49ad-89ef-0209fb6380d4">7,806,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="idfef7d206519439a936e6eb262b31e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtMy0xLTEtNTMx_1c517f19-8305-4e02-af25-9d96efdce4cd"><ix:nonFraction unitRef="shares" contextRef="idfef7d206519439a936e6eb262b31e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtMy0xLTEtNTMx_37200905-44f3-4e3f-96ea-34f53281c482">7,806,977</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idfef7d206519439a936e6eb262b31e71_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtNS0xLTEtNTMx_3dc383e5-550a-465c-b003-2982c436f21a">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idfef7d206519439a936e6eb262b31e71_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtNy0xLTEtNTMx_68bfa5bc-57a3-488b-a512-21fc5da260fb">18,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfef7d206519439a936e6eb262b31e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtOS0xLTEtMA_560ccd4b-079c-4ec6-a4f7-dc2ea2262e13">8,236,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series A Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i1dc130be29104c028617076697807621_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtMS0xLTEtNTMx_5ceae56c-9933-4086-8ebe-f8a149f569b7">13,700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i1dc130be29104c028617076697807621_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtMy0xLTEtNTMx_0ca4770d-5b32-4c6d-aae0-4ee798a99010"><ix:nonFraction unitRef="shares" contextRef="i1dc130be29104c028617076697807621_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtMy0xLTEtNTMx_d7db5187-161a-4bba-aa59-324f7df3501c">13,697,916</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1dc130be29104c028617076697807621_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtNS0xLTEtNTMx_67887f4a-b0da-4431-8d71-95c4c6f280e9">104,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1dc130be29104c028617076697807621_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtNy0xLTEtNTMx_e9062cf4-3b86-4f7d-91b1-08b024fded76">105,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1dc130be29104c028617076697807621_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtOS0xLTEtMA_363084c3-4bbf-4c6b-98b5-ef69418d5e60">14,451,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtMS0xLTEtNTMx_00fe17a1-aa22-4527-86a0-c50a419e90ab">21,506,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtMy0xLTEtNTMx_87ff17ac-d723-4893-8f99-81b2033dfd47"><ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtMy0xLTEtNTMx_b9c08e55-0cfd-4055-89c7-6004d0525f3a">21,504,893</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtNS0xLTEtNTMx_ed07a317-f838-4712-b4f8-5ce692498da0">122,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtNy0xLTEtNTMx_05bb1ed1-eb75-4a01-94de-1a00bb54ef5b">123,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtOS0xLTEtMA_426c93fb-6419-4f44-b08a-69ea64473612">22,687,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the IPO (See Note 1), all outstanding shares of convertible preferred stock were automatically converted into <ix:nonFraction unitRef="shares" contextRef="i3690868d9bd846d58fea672236b4ef2f_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk4Nzk_ba03fcfe-7cfb-41ed-a0e5-a9eb0cb6656d">22,687,625</ix:nonFraction> shares of common stock.</span></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_127"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzEzMTk0MTM5NTMzOTMz_8eea75ec-abf6-401a-a122-1261f22f0b45" continuedAt="ic0d090052ba847f382b4c85d277b1ebc" escape="true">COMMON STOCK</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0d090052ba847f382b4c85d277b1ebc" continuedAt="ife68595b4c1e4266bbd4c47964b7fa20">Pursuant to the Company&#8217;s amended and restated certificate of incorporation, filed on July 1, 2019, the Company was authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i0bc479aee05e472aaa0315eec9166109_I20190701" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzEzMTk0MTM5NTMzOTIy_93c4bd76-1c48-4e65-b9ac-bae178adbe46">40,000,000</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i0bc479aee05e472aaa0315eec9166109_I20190701" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzEzMTk0MTM5NTMzOTAz_45772285-ee3d-4872-ab50-d7e510388c3b">0.001</ix:nonFraction>.  As of September&#160;30, 2020 and December&#160;31, 2019, there were <ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzMyOTg1MzQ4ODM4NjE_710c7f4e-5cb0-4eb5-8489-33759bb2ce58"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzMyOTg1MzQ4ODM4NjE_81e42231-5184-4ee5-9738-73eacfa3078c">6,284,326</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzI3NDg3NzkwNzAyMjY_b1a4f1c4-65c3-4873-990d-f540cf8f64a4"><ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzI3NDg3NzkwNzAyMjY_c2968248-1163-4492-8d5b-2fbed1dbf96e">5,660,391</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ife68595b4c1e4266bbd4c47964b7fa20">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Subject to the rights of the Preferred Stock, holders of the Company&#8217;s common stock are entitled to receive dividends, as may be declared by the Board of Directors.</ix:continuation> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_130"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzE0MjkzNjUxMTczMjQ1_127c5737-eca5-43be-874e-797d7e49cb93" continuedAt="i639d334f7dfe4525b56a18edba3980f7" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i639d334f7dfe4525b56a18edba3980f7" continuedAt="i3401d3902c864c429e9b2661cac8982b"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2017 Equity Incentive Plan, as amended (the 2017 Plan), provides that the Company may sell or issue shares of common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of shares of common stock, to employees, members of the Board of Directors, and consultants of the Company. The exercise prices, vesting, and other restrictions are determined at the discretion of the Board of Directors, or a designated committee thereof, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the common share on the date of grant and the term of stock option may not be greater than <ix:nonNumeric contextRef="i13481663bdd345c8b1e8be6825bfce9d_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzExNTQ0ODcyMTA2MDA2_b1afa8cf-dc95-4a35-b2d3-1d556bc6844c">10</ix:nonNumeric> years. The Company recognizes the impact of forfeitures on stock-based compensation expense as forfeitures occur. The Company applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Vesting periods are determined at the discretion of the Board of Directors. Stock options typically vest over <ix:nonNumeric contextRef="i0f9c2bbd688841678d9a85d7983c2cfd_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzExNTQ0ODcyMTA2MDIz_9c509229-0280-49af-983d-fc91e686ef5a">four years</ix:nonNumeric>. The maximum contractual term is <ix:nonNumeric contextRef="i0730288162bf44dea2732ca595d2a797_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzExNTQ0ODcyMTA2MDM5_3a2bec3a-d892-437e-b2d9-afaff5d4d934">10</ix:nonNumeric> years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, t</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he total number of shares of the Company&#8217;s common stock that may have been issued was <ix:nonFraction unitRef="shares" contextRef="i0d5a83c4e52a4e4b837319163fdc11bd_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODA0Nzk_3ff648cd-21ed-4100-9c7c-d84fec326458">6,857,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if6347ac3253f4253ba6ddc43e9544f3d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODA0NDE_15e8b762-b3f1-4b54-9787-826deaaabae2">3,692,500</ix:nonFraction> shares, respectively.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, there were</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="i0d5a83c4e52a4e4b837319163fdc11bd_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODA1MDU_2ee35b18-d11b-4c99-a54a-abfbfd1aa8f3">358,596</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if6347ac3253f4253ba6ddc43e9544f3d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODA0OTI_6f0858fe-c4d2-4d54-a8fc-01ac64eca7b8">1,365,647</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares, respectively, reserved by the Company under the 2017 Plan for the future issuance of equity awards.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3401d3902c864c429e9b2661cac8982b" continuedAt="ibacb034498d04446a2744bc19838588a"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model. This model requires the use of highly subjective assumptions to determine the fair value of stock-based awards, including:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In order to determine the fair value of the Company&#8217;s common stock underlying option grants, the Board of Directors considered, among other things, valuations of the Company&#8217;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Other objective and subjective factors considered included the Company&#8217;s stage of development and material risks related to its business, the progress of its research and development programs, its business conditions and projections, its financial position and its historical and forecasted performance and operating results, the lack of an active public market for its securities, its Preferred Stock, biopharmaceutical company performance, the likelihood of achieving a liquidity event, the hiring of key personnel and the experience of management, industry trends and developments, and external market conditions and industry trends. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expected Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of the options. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expected Volatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Since the Company is not yet a public company and does not have any trading history for its common stock, the expected volatility is estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies are chosen based on their size, stage in the product development cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the awards.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expected Dividend</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzE0MjkzNjUxMTczMjQy_066cc48e-53f6-4332-b7e3-8256a11b0200" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model assumptions that the Company used to determine the grant-date fair value of stock options for the three and nine months ended September&#160;30, 2020 and 2019 were as follows, presented on a weighted-average basis:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of common stock per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930" decimals="2" name="kron:SharePriceFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzItMS0xLTEtNTQ4_76de46c4-133b-4021-a508-d032efe2f624">6.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930" decimals="2" name="kron:SharePriceFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzItMy0xLTEtNTUx_72cce877-84c3-47e1-85a4-cf30fea80a4f">2.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930" decimals="2" name="kron:SharePriceFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzItNS0xLTEtNTU3_02c59122-9690-4aee-89e1-33496b91580f">4.70</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930" decimals="2" name="kron:SharePriceFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzItNy0xLTEtNTYw_38afc2e3-f146-401a-b42e-42765ca95ce9">1.35</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzMtMS0xLTEtNTQ0_6b3da980-52e4-464e-8a34-b8bf61f0d06f">5.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzMtMy0xLTEtNTUx_55b18a2e-471a-48b0-87c7-94ce8856850b">6.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzMtNS0xLTEtNTU0_2b3f8e99-8baa-4900-9d10-ed647db41771">5.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzMtNy0xLTEtNTYw_f095c0f7-9ccb-43b5-8329-e485d1de656b">6.06</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzQtMS0xLTEtNTQ4_706b11cd-417f-4bbe-89cc-84639def498a">81.72</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzQtMy0xLTEtNTUx_a081a386-b2ef-4839-a2d8-de10d3cd3c48">66.88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzQtNS0xLTEtNTU3_3309863b-8966-40d2-a298-23ef5e5ee680">76.93</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzQtNy0xLTEtNTYw_405630b1-3fb4-46c6-b818-7fd010b54495">76.97</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzUtMS0xLTEtNTQ4_cd653b5a-6396-4eb1-a915-36754bca287b">0.36</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzUtMy0xLTEtNTUx_e2af4cf3-7a52-4547-9436-b807bcef05ee">1.67</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzUtNS0xLTEtNTU3_9b8e9c94-b16d-46fc-b818-17966207575b">0.73</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzUtNy0xLTEtNTYw_d2580f2e-33bf-4e91-9da4-2d5a04c67312">2.15</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzYtMS0xLTEtNTQ0_6e11a84a-c82a-411e-8c03-4febbe7b1e4b">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzYtMy0xLTEtNTUx_605a46ed-1f1a-4ce0-87ac-96decf65c19b">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzYtNS0xLTEtNTU0_50055abe-b098-4394-8f84-8fe265036a87">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzYtNy0xLTEtNTYw_e9592ad8-2127-43b9-93b9-ecc569ecda1d">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of stock options granted, using the assumptions listed above, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzk5ODY_741f700d-2e4a-4627-b436-86b406667c38">4.66</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzk5OTk_24dfac1c-2ef6-46fd-91d2-2706e04f86ef">1.54</ix:nonFraction> during the three months ended September&#160;30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODAwMTA_ab61c3f3-29f2-4fe0-8a97-bdc3f54a4818">3.16</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODAwMjQ_c51ec624-e6d5-4924-939c-1dffc7e3710d">0.88</ix:nonFraction> during the nine months ended September&#160;30, 2020 and 2019, respectively. The weighted-average grant-date fair value per share of stock options vested was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4MTE_dc791821-946e-4b66-92b5-69c1c63929bd">0.69</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4MTU_337bae59-f0f5-4a8f-81a3-2b566fa0884a">0.09</ix:nonFraction> during the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ibacb034498d04446a2744bc19838588a" continuedAt="i1790f6b3379b4b48bcb10ae29441e595"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzE0MjkzNjUxMTczMjQz_bac2daf7-1157-4f14-adc2-7e01ded406d9" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the 2017 Plan as of September&#160;30, 2020 is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEwLTEtMS0xLTA_1603cd0f-781f-4448-94ce-a270629a50bf">1,726,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEwLTMtMS0xLTA_2e5839fc-9c0c-4e36-805a-75e9520b187b">1.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c206960ada7462e824eea778e31e777_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzItNS0xLTEtNTc3_a91b6290-a3ca-4cc0-b77c-856f1478e549">9.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzItNy0xLTEtNTc3_1d307fc5-bd51-4f80-843a-ff840fc2739e">27,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzExLTEtMS0xLTA_65aae4f9-95ac-46f1-badf-9b4f9fd5155c">4,015,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzExLTMtMS0xLTA_fbbd83f2-eb3a-456a-a164-3b51cc2ca760">4.70</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzQtMS0xLTEtNTc3_a8666d72-3c5b-4a1b-b825-40d95e721b3c">117,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzQtMy0xLTEtNTc3_e2471de3-ddfc-4eb5-a2a6-00ac89240fa2">0.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEyLTEtMS0xLTA_23ed87e0-681e-4679-b18c-ba3eeb698e68">406,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEyLTMtMS0xLTA_33e87631-f33f-431b-9688-28f3dd2b7598">1.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEzLTEtMS0xLTA_fc4ada6a-4a3c-4c52-8f71-b84800f44d4f">5,217,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEzLTMtMS0xLTA_579e91c6-8b30-46aa-913a-23b12d8da8fb">3.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzYtNS0xLTEtNTc3_dd7e0984-4698-4f4f-b5a9-d45398d9f8c7">9.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzYtNy0xLTEtNTc3_6bf47815-ec8e-48ac-8e27-1477bdd1e779">68,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzE0LTEtMS0xLTA_75b752e2-1e91-4eba-9a75-e2d6b48d656c">69,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzE0LTMtMS0xLTA_1bdd7535-d84a-46f9-a0bc-d96f2957ec7f">1.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzctNS0xLTEtNTc3_06b5f9cf-ba0e-438c-b279-9de4677c7cda">8.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzctNy0xLTEtNTgz_d72a02a6-bed1-4084-86ae-1ad2ecee7a3d">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and expected to vest at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzE1LTEtMS0xLTA_8205bd0e-7eba-4c29-8820-f1f71fa3bb16">5,147,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzE1LTMtMS0xLTA_30595b79-6678-41c5-aaae-6a48fdb247a5">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzgtNS0xLTEtNTc3_2cae472b-e0fd-4726-b5e8-3812acdf5741">9.36</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzgtNy0xLTEtNTgz_76f15965-6fde-4bfe-a3f4-66d7dc2e4dfb">67,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock, as determined by the Board of Directors, as of the end of the respective period.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The intrinsic value of options exercised for the three months ended September&#160;30, 2020 and 2019 </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE1NzQ_376f6a5b-257f-4727-8303-af47cd94fced">1.5</ix:nonFraction> million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd $<ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE1ODk_e1b73b0f-75a9-416f-ae49-09c0dc2fa80e">0.2</ix:nonFraction> million, respectively, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE1NDE_bd600970-d175-4c7b-9489-d303052fbf69">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE1NTY_c124fbf1-6055-4521-89a7-11720d4281f0">0.4</ix:nonFraction> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the nine months ended September&#160;30, 2020 and 2019 respectively, determined as of the applicable date of exercise.  There was no future tax benefit related to options exercised, as the Company had accumulated net operating losses as of September&#160;30, 2020 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzE0MjkzNjUxMTczMjQ0_12945a49-5028-4100-b478-8dd27326510b" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019 as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0d6cc50b8e49aca2ce81649e3efb0a_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzMtMS0xLTEtNTk1_dc729a79-f156-484f-9786-6e05f82c36cf">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id555f67142ab472db96a2d992d964d82_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzMtMy0xLTEtNTk1_a07a262d-ab13-4932-b85b-956439ada691">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb629f251d5f424b8c936814babcc4f6_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzMtNS0xLTEtNTk1_bbe0de6e-5f06-4d50-b8b3-59cd54b8fb0e">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b76d71920eb47b9b25ad42914b7f4b0_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzMtNy0xLTEtNTk1_dc9c0594-23d0-40c1-a5de-4192bf229914">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa6a9b2386942c4a674dfa9c9918c8a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzQtMS0xLTEtNTk1_75ac4545-745a-4199-ae21-8e174f4324c9">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb0c54a250748e2bd702dfc80c5dca5_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzQtMy0xLTEtNTk1_3138ceac-dd11-457d-9677-ca1bc807aa6d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6bc89ef445474790f3d6a61419f2a0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzQtNS0xLTEtNTk1_6f0de992-de9c-453c-a4c2-0a3079be0ce8">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic510c74d485b4029bb4fefcd43dd7a70_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzQtNy0xLTEtNTk1_d13a3d68-796e-4354-bd37-a41dae95e744">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzUtMS0xLTEtNTk1_64727aea-c8a6-43c4-8cce-0a2af8cacf36">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzUtMy0xLTEtNTk1_a1829510-79fa-43d9-8e9c-58b5b0bff39f">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzUtNS0xLTEtNTk1_ef559dd3-4b24-41ee-ad44-d0e972524d49">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzUtNy0xLTEtNTk1_b99fa141-ab30-4631-a9e2-f7dc1639525d">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, total unrecognized compensation cost related to the unvested share-based awards was $<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE3OTU_d9c9a0fc-4bf0-446f-ba7f-40ba46698089">14.1</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4MDM_ae2c2632-62bc-4711-9741-4a7f147e8364">3.53</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercised Options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows certain of its employees and its consultants to exercise options granted under the 2017 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company.  The early exercise by an employee or consultant of a stock option is not considered to be a substantive exercise for accounting purposes, and therefore the payment received by the employer for the exercise price is recognized as a liability.  For accounting purposes, unvested early exercised shares are not considered issued and outstanding and therefore not reflected as issued and outstanding in the accompanying statements of convertible preferred stock and stockholders' deficit until the awards vest. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i1790f6b3379b4b48bcb10ae29441e595" continuedAt="ic940cc8176f84b42bb754d2421319a6b"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposits received are initially recorded in current portion of other liabilities and other noncurrent liabilities for the noncurrent portion. The liabilities are reclassified to common stock and paid-in capital as the repurchase right lapses. During the three months ended September&#160;30, 2020 and 2019, and nine months ended September&#160;30, 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzMyOTg1MzQ4OTU2MjI_0e809c12-a4cf-4698-a0e5-1d437bb083f0">850,937</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzMyOTg1MzQ4OTU2MzI_ed90abbd-1352-4115-8acf-c6749c7d1d4f">60,924</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzMyOTg1MzQ4OTU2MDk_bd9ac610-125f-4c3e-ac2d-736ae85224f9">1,551,361</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzMyOTg1MzQ4OTU2NjY_8bedbfc8-c72c-41ea-bfc7-4e3baa83b33b">60,924</ix:nonFraction> shares of the Company&#8217;s common stock were early exercised, respectively.  At September&#160;30, 2020 and December&#160;31, 2019, there was $<ix:nonFraction unitRef="usd" contextRef="i7ef266f587f64a7798fcaaa861326c3c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDkzODI_e379b937-61e6-4a00-8c0d-db9bcd69594e">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8b5e3dc5e7d94133a087d964992323e8_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDkzOTM_6814796c-27cd-474d-b740-d6f06b7fede5">0.1</ix:nonFraction> million recorded in current portion of other liabilities, and $<ix:nonFraction unitRef="usd" contextRef="i38dd8b9841e644e0a406a3e2b3439dec_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0MDM_9b854586-08c9-4429-b682-8391accd2f1a">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i08c6c6f783f041ae92c761672b2966aa_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0MTQ_5fbccd43-9fec-429d-b0b5-8d4598ef92b0">0.1</ix:nonFraction> million recorded in other noncurrent liabilities, respectively, related to shares held by employees and nonemployees that were subject to repurchase.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic940cc8176f84b42bb754d2421319a6b">In 2017, the Company issued <ix:nonFraction unitRef="shares" contextRef="iffb0ef90a61349be85e69f64dcaf4055_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzk0MDY_be5bdacf-aa0d-400b-81e8-efaf5fe2ee88">538,050</ix:nonFraction> restricted stock awards to a non-employee at a fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="iffb0ef90a61349be85e69f64dcaf4055_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4NjQ_014b088c-6c49-4a76-88f5-e33bc5f1f099">0.05</ix:nonFraction> per share. In July 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i36ebb89160a743719ce7b11be1918ff8_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzkzOTI_3923940c-422d-44b1-bef8-35b5fa360397">274,341</ix:nonFraction> restricted stock awards to an executive employee at a fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3eea990477a54f47bacea5aed627224f_D20200701-20200731" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4NDY_de3e6aef-48e6-4005-99a5-3bb32a057e9c">4.14</ix:nonFraction> per share.  As of September&#160;30, 2020, the restricted stock awards outstanding were <ix:nonFraction unitRef="shares" contextRef="icd203f8d19ab4cb7ba2e8763e4797437_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzkzOTY_36d0a9b2-85bb-4b2c-9ba6-869e08581a7a">271,683</ix:nonFraction> which are subject to lapsing repurchase rights. In order to vest, the holder is required to provide service to the Company. For accounting purposes, unvested restricted stock awards are not considered issued and outstanding and therefore are not reflected as issued and outstanding in the accompanying statements of convertible preferred stock and stockholders&#8217; deficit until the awards vest.  The Company recorded stock-based compensation expense for these awards of $<ix:nonFraction unitRef="usd" contextRef="i7a4a632dbe23409c87fb1cb29d8c6158_D20200701-20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0Mjk_366ec6fc-b2bf-4793-86af-e2b27ffd523f">599.1</ix:nonFraction> thousand, $<ix:nonFraction unitRef="usd" contextRef="i694e0708e4ee460d962dcdf8b06c84b3_D20190701-20190930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0Mzg_8a8c7bf9-7dd8-46b2-a73e-8e629eb06efa">1.3</ix:nonFraction> thousand, $<ix:nonFraction unitRef="usd" contextRef="ic973ed0f6744448cac474a05a81e7803_D20200101-20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0NDc_b8fab1ec-cb68-490d-aba6-848ff652dd05">601.7</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i0b46cef6f87e4fecbc3caaa9619f38f5_D20190101-20190930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0NTY_8dabaf8d-d34d-49a0-9b83-d46e14365f5d">3.8</ix:nonFraction> thousand for the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, respectively, in research and development in the statements of operations and comprehensive loss.</ix:continuation>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_133"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzEzMTk0MTM5NTM4Mjgx_3c8970a2-f74c-421d-b0b7-f3564ff1b3db" continuedAt="iaffc35817e2e43729dfdd6916d8abae0" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="iaffc35817e2e43729dfdd6916d8abae0"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzc2OTY1ODE0MDI0Mzg_24f96769-4e65-4a29-acd0-e0e4fa676026"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzc2OTY1ODE0MDI0Mzg_6aa6fd09-f472-48d6-b00f-3434a16a2637"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzc2OTY1ODE0MDI0Mzg_b2ecd64e-c61d-47d3-b80a-4399a0694a35"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzc2OTY1ODE0MDI0Mzg_c5c1d2d3-e81c-49ea-a13d-93abb9108378">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t recorded any income tax expense for the three and the nine months ended September&#160;30, 2020 and 2019. The Company has incurred net operating losses for all the periods presented and has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has recorded a full valuation allowance against all of its deferred tax assets as it is not more likely than not that such assets will be realized in the near future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to record penalties and interest related to income taxes as a component of income tax expense.  The Company has not recorded any interest or penalties related to income taxes during the three and nine months ended September&#160;30, 2020 and 2019.  The Company has not identified any new uncertain tax positions as of September&#160;30, 2020.  Unrecognized tax benefits are not expected to change during the next 12 months.  The reversal of the unrecognized tax benefits would not affect the effective tax rate.  The Company is subject to examination by U.S. federal and state tax authorities for all years since its inception.</span></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_136"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90ZXh0cmVnaW9uOjRhM2IxMTI5ZDA4ZDQ1MjRiMzk0YmRkMGE5ODI4NmJhXzk4OTU2MDQ2NTExOTM_5049b20f-4b61-4a69-ba8e-7a8da06165c6" continuedAt="i6b546fae190d405e8493a225408fa015" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i6b546fae190d405e8493a225408fa015" continuedAt="i6d3d01e808ae47769d0112675ad67267"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90ZXh0cmVnaW9uOjRhM2IxMTI5ZDA4ZDQ1MjRiMzk0YmRkMGE5ODI4NmJhXzk4OTU2MDQ2NTExOTQ_27e7a03d-8f37-4203-b7d6-b084ec39b9b0" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share of the Company for the three and nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share and per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzQtMS0xLTEtMA_e0324f33-f3af-4d50-b299-becd46d05743">39,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzQtMy0xLTEtMA_c960c16e-f36e-41c9-840f-0d4e8cdb8cd1">4,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzQtNS0xLTEtMA_14c587ce-ea10-44a2-bfaf-af3a6f33dfc7">55,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzQtNy0xLTEtMA_fa5f737c-31e5-4f62-b81b-0676e1168d22">10,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzUtMS0xLTEtMA_0df1194b-ceda-482b-8343-08ed33c04e46">6,127,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzUtMy0xLTEtMA_ee763d33-47c8-4714-bbf1-3802449651e9">5,409,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzUtNS0xLTEtMA_05bd9e82-89eb-4b6f-a390-44d1f9143927">5,886,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzUtNy0xLTEtMA_2520efc0-57c5-462b-869f-ad79482a61a4">5,196,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzYtMS0xLTEtMA_9e80a320-2302-4334-a75f-c51f7df7913c">6.48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzYtMy0xLTEtMA_d2ccbb61-c40e-4381-8c5e-821472ba28dc">0.74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzYtNS0xLTEtMA_942a6ff7-67e7-493e-8fbf-41d571f405db">9.39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzYtNy0xLTEtMA_a68160e5-654c-46be-b05c-d9226f002299">2.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6d3d01e808ae47769d0112675ad67267"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include the Preferred Stock and options to purchase shares of the Company's common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90ZXh0cmVnaW9uOjRhM2IxMTI5ZDA4ZDQ1MjRiMzk0YmRkMGE5ODI4NmJhXzk4OTU2MDQ2NTExOTU_946302ae-e548-423b-9cbd-63c770bfc12f" continuedAt="i4b91c144454540ca86c1aafcc977dd21" escape="true">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="i4b91c144454540ca86c1aafcc977dd21"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3fb6aa27992434fbc43f1d769315cae_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzMtMS0xLTEtMA_33f17b37-7026-4834-8d8d-cdda43e60b50">22,687,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ba0aba4eac64967a28041b82683a193_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzMtMy0xLTEtMA_af1be9dd-b010-46dd-8afa-b29a6853ba7a">22,687,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i223930fbcee8485494d93864723c1094_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzItMS0xLTEtMjY0NA_70746e64-38c6-4d32-a3b1-7eb924ebe7ce">10,741,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff773b2225814be2bd54a5fabb6156f0_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzItMy0xLTEtMjY0NA_329fb598-6ef4-4edc-b32f-e813e3ae002e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i987eec82cc864592a298066957f8a94b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzMtMS0xLTEtMzQzOA_9d17bc4b-2a9b-4c6e-a4e3-8c6fd6930931">210,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24fc0801a2ef47149bd82ac3437499a4_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzMtMy0xLTEtMzQ0Mg_c071d12a-95cc-4585-8841-68ce7db1ecfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7ca6bc47f334d828c27e5e2e5f3288d_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzQtMS0xLTEtMA_f789597f-11c6-4212-9833-4d4449484de4">3,359,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21e4dfab6f3d4306b4f260d7d24f30cd_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzQtMy0xLTEtMA_7cff470d-0b73-40a9-a5c8-410830d28695">389,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e439c793aa6461ba7288faa23830525_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzUtMS0xLTEtMA_20d76afa-2657-45da-8bba-2293c3e23719">1,858,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bc87606b0ba41f9a3cf5ea58af93b90_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzUtMy0xLTEtMA_0d1520c4-4fc7-4681-975b-8b83790de5b9">854,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock award subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5bab20c255c46269a25294cdd840266_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzQtMS0xLTEtNjM1_4f7fad0b-d197-4670-a990-9360890c0179">271,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bef5ce38731457493cfc788f479063e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzQtMy0xLTEtNjM5_9c5f634d-6641-4edb-b671-43b52c1283a7">242,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzUtMS0xLTEtNjMx_8071cf92-4503-4d94-b281-7221ed8f4c80">39,129,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c206960ada7462e824eea778e31e777_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzUtMy0xLTEtNjM5_11e88443-6d93-40ff-bf2d-b795723d63d8">24,172,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_142"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzEzNzQzODk1MzU5MzYw_7b17923b-d95a-4c15-a85f-5d077a9628dc" continuedAt="ieb5d5483944b43a0873ae9c4fe24b49e" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ieb5d5483944b43a0873ae9c4fe24b49e" continuedAt="i086e0c3c1e0349838cb3671f7c267dc5"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Purchase Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into an asset purchase agreement (Gilead Asset Purchase Agreement) with Gilead Sciences, Inc. (Gilead), pursuant to which the Company acquired certain assets from Gilead related to entospletinib (ENTO) and lanraplenib (LANRA), and patents and other intellectual property covering or related to the development, manufacture and commercialization of ENTO and LANRA. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for such assets, on the date of the Gilead Asset Purchase Agreement, the Company made a $<ix:nonFraction unitRef="usd" contextRef="ia4dd19cf017640d5a992af85e6743b2b_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="kron:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTA1MDA_abfb31c4-53ee-4cfb-8de5-da111e22d096">3.0</ix:nonFraction> million upfront cash payment and issued a $<ix:nonFraction unitRef="usd" contextRef="ia4dd19cf017640d5a992af85e6743b2b_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="kron:AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODE2MTA_3bae8b4f-79a8-4dda-941a-2625d9830c87">3.0</ix:nonFraction> million principal amount convertible promissory note to Gilead (Gilead Note)The Company also made a $<ix:nonFraction unitRef="usd" contextRef="ia4dd19cf017640d5a992af85e6743b2b_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="kron:PaymentsForAssetAcquisitionsReimbursements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTA1MTU_164e7e57-3601-4de3-a7c0-e86e5c7a39b9">0.7</ix:nonFraction> million payment to reimburse Gilead for certain liabilities assumed by the Company pursuant to the Gilead Asset Purchase Agreement. In addition, the Company is required to make milestone payments upon successful achievement of certain regulatory and sales milestones for ENTO, LANRA and other selective spleen tyrosine kinase inhibitor compounds covered by the patent rights acquired pursuant to the Gilead Asset Purchase Agreement and developed by the Company as a back-up to ENTO or LANRA (Other Compounds). Upon initiation of the Company&#8217;s planned registrational Phase 2/3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations, the Company will be required to pay a milestone to Gilead of $<ix:nonFraction unitRef="usd" contextRef="idcdc628eb6df4f0bb5c79f1d07222825_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="kron:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTUxNjQ_6ae5df0f-7daa-4c67-ab9a-29d6e4dffb41">29.0</ix:nonFraction> million, and upon successful completion of certain other regulatory milestones in the United States, European Union and United Kingdom for ENTO, LANRA and any Other Compounds, across up to two distinct indications, the Company will be required to pay to Gilead an aggregate total of $<ix:nonFraction unitRef="usd" contextRef="idcdc628eb6df4f0bb5c79f1d07222825_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="kron:ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTUxODE_384f4d2b-c235-4143-acc6-de307b24c891">51.3</ix:nonFraction> million. Upon achieving certain thresholds for the aggregate annual net sales of ENTO, LANRA and any Other Compounds combined, the Company would owe to Gilead potential milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="idcdc628eb6df4f0bb5c79f1d07222825_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="kron:ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTUxOTk_40f7dea0-a670-4bb5-bf8f-979f25cde087">115.0</ix:nonFraction> million.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead is also eligible to receive (i) tiered marginal royalties ranging from the very low-teens to high-teens on annual worldwide net sales of ENTO, (ii) tiered marginal royalties ranging from high-single digits to the mid-teens on annual worldwide net sales of LANRA and (iii) tiered marginal royalties ranging from low single digits to mid-single digits on annual worldwide net sales of any Other Compounds. The royalties in the foregoing clauses are subject to reduction, on a country-by-country basis, for products not covered by certain claims within the assigned patents, for generic entry and, in the case of ENTO and LANRA, for any royalties paid for future licenses of third party intellectual property required to develop or commercialize ENTO or LANRA. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first commercial sale of such product in such country and ends on the latest of (i) expiration of the last claim of a defined set of the assigned patent rights covering such product in such country; (ii) loss of exclusive data or marketing rights to such product in such country; or (iii) 10 years from the first commercial sale of such product in such country.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i086e0c3c1e0349838cb3671f7c267dc5" continuedAt="ib610388546a84fdda93aefaba2baefcd"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Gilead Asset Purchase Agreement, the Company is required to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize either ENTO or LANRA.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Gilead Note accrues interest at a rate of <ix:nonFraction unitRef="number" contextRef="i7aa8d7617e6248f49f8f5e9c3f2f946d_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ5MDExNDU_ee5c4396-ea9b-4843-80a0-a19957418b9a">6</ix:nonFraction>% per year, compounded annually, and has a maturity date of July 14, 2020.  The Gilead Note provides that, upon the completion of the Company&#8217;s IPO, the Gilead Note will settle through the Company payment to Gilead of $<ix:nonFraction unitRef="usd" contextRef="i7b189c5eff6848ada547002d5d66c700_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="kron:RepaymentOfDebtPaymentToBeMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ5MDExNjA_a335ec6d-ba56-46db-a621-a046f3f43bd8">6.0</ix:nonFraction> million plus unpaid accrued interest unless Gilead elected, within a specified time, that the Gilead Note, including unpaid accrued interest, be converted into shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On issuance, the Company elected to account for the Gilead Note at fair value with any changes in fair value being recognized through the statements of operations until the Gilead Note settled. The fair value of the Gilead Note was determined to be $<ix:nonFraction unitRef="usd" contextRef="i486cac36f7944dbfbac5953889346c1e_I20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODEwNjY_63de18f6-cdc4-48ea-a5a3-9a392a294e7d">3.6</ix:nonFraction> million on issuance and $<ix:nonFraction unitRef="usd" contextRef="i7aa8d7617e6248f49f8f5e9c3f2f946d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODEwNzA_13c2a8b4-fc0a-4aaa-9103-90bb7ee21492">5.5</ix:nonFraction> million as of September&#160;30, 2020. For the three and nine months ended September&#160;30, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i7b189c5eff6848ada547002d5d66c700_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="kron:GainLossOnChangeInFairValueOfDebtInstrument" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODEyNDE_04dd2159-ffef-4850-ab00-993450ea4268"><ix:nonFraction unitRef="usd" contextRef="ib714cc1a7a1046e1bed70ca7b135cbda_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="kron:GainLossOnChangeInFairValueOfDebtInstrument" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODEyNDE_dd558ea9-1048-401c-b3c4-c3b516505e69">1.9</ix:nonFraction></ix:nonFraction> million in the accompanying statements of operations and comprehensive loss as the change in fair value of the 2020 Gilead Note.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the Gilead Note as of September&#160;30, 2020 by determining the present value of the Gilead Note if they were to settle either upon closing of an IPO, a deemed liquidation, or a qualified or non-qualified equity fundraise.  <ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzEzNzQzODk1MzU5MzYx_db42e4d6-e76a-4f10-afbd-d2111534b256" continuedAt="ic98c73224a8f4efd8fbd3d1718406c64" escape="true">Key valuation assumptions are as follows:</ix:nonNumeric></span></div><ix:continuation id="ic98c73224a8f4efd8fbd3d1718406c64" continuedAt="id2678d485afa45ecb5667844c2c14630"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fundraise scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO conversion scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation conversion scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88cd4588864e407facd4e99fbcae11bc_I20200930" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItMS0xLTEtMTkyNQ_825bf1b3-9b9f-434b-ace6-509862d22987">1.78</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51068c8029ef42c399d8e6f8a7fe8997_I20200930" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItMy0xLTEtMTkyNQ_ac41e9cf-45ab-4c5b-b68a-37e5b4e29459">0.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b0031b2310d43fd96017f1c5a5a7ecd_I20200930" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItNS0xLTEtMTkyNQ_9fa2f198-200a-49a4-bae3-96ec75db8a45">0.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafc78d3feb68447fad1581a1f5d31298_I20200930" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItNy0xLTEtMTk2NQ_dcd929e6-b307-4713-b788-7d3ffa9a0f39">1.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a405d92641543f7bddb7edda6fa1ae2_I20200930" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItOS0xLTEtMTk2NQ_1935e6cc-c5c1-47ad-990f-44e367cd533c">1.79</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0a507464b5342f5bf93741aebc293b7_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtMS0xLTEtMTkyNQ_218d5d6e-fd3d-4b4c-bef5-a2964b32380f">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e7237fee96140989757ebe5aca441fa_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtMy0xLTEtMTkyNQ_7f7133a7-5199-4bb1-89bd-a25064a357c4">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcb97e3d8c6848998adba729a721a4cc_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtNS0xLTEtMTkyNQ_87eb8e97-a0a9-4e5c-94a5-ec1e1465ce25">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb03e961bb854f9fa74406cd020a41d8_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtNy0xLTEtMTk2NQ_a616866d-f5b4-46d3-90e9-be99ef348fa1">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d9088eb63e343bf87263a6d2eacd1cc_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtOS0xLTEtMTk2NQ_5dbb7319-d5ca-42d9-b7b6-7cc0862f9779">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i620aab95020a4e98b682a7a22af3c0a7_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtMS0xLTEtMTkyNQ_4f418a68-e634-4b96-8b6d-1abb857d8b1e">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f897da9f4b94b72b44c2e02de325360_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtMy0xLTEtMTkyNQ_f19adb5c-16e4-4784-bbf6-c0a3390f1823">95.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c0e7dc1935d48da9c69163a1164cb59_I20200930" decimals="3" format="ixt:zerodash" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtNS0xLTEtMTkyNQ_ff2f0e2b-6d16-47d3-9ec9-280a96934ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac4e5e570b0944eaa1dd8ba60b2886df_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtNy0xLTEtMTk2NQ_def2c6e4-d435-43ee-83de-2eefba6a0b07">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1ced39808984c03a296264c3ea65adc_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtOS0xLTEtMTk2NQ_017349ea-a71c-4e70-b571-df7ac27672eb">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the Gilead Note at inception by determining the present value of the Gilead Note if they were to settle either upon closing of an IPO, a deemed liquidation, or a qualified or non-qualified equity fundraise.  Key valuation assumptions are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At inception</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fundraise scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO conversion scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation conversion scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i851ff4900ea249cda09f664b0212918d_I20200731" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItMS0xLTEtMTAxNjU_bd9466fa-9a01-42e9-8fae-8b1fadabd0ae">2.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia99e131dd6404121b4e194d9356f67ad_I20200731" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItMy0xLTEtMTAxNjU_a3b3f27b-d37f-4f0e-8779-385648050a16">0.30</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i616172ed102541feb61d3c1b5cead753_I20200731" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItNS0xLTEtMTAxNjU_75d32b5e-6a52-438c-af91-bc137cec2aa8">0.30</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib79a6a6966a34788a0429125557e239f_I20200731" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItNy0xLTEtMTAxNjU_af41bb1b-c00c-4ae9-af42-d15e81067539">2.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd88330648594bcabdc951197524d855_I20200731" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItOS0xLTEtMTAxNjU_0ca9e782-574b-483e-bda9-2483e7c71387">2.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i631c46c59d354aa580f1ad4e832c8861_I20200731" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtMS0xLTEtMTAxNjU_ce1f3b77-0c7e-47f9-b93f-4846295c3bf9">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2666b9ac19e49baab7aca87809bf7c6_I20200731" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtMy0xLTEtMTAxNjU_a66524e9-1106-413e-9085-50766124f7b1">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib728710261c742538e0fcb8346b1c830_I20200731" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtNS0xLTEtMTAxNjU_0d305837-cf43-4d3b-801b-9543bfdced47">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86502c45f58b4b9f9337f25a9ea085a3_I20200731" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtNy0xLTEtMTAxNjU_254c12cc-de76-474b-8561-73f3e3278e63">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcfcef6f36724f44b53de7181f6c587d_I20200731" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtOS0xLTEtMTAxNjU_38e69d13-ef80-41c2-abb4-2eee96c5e381">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i001fd52a7b1e4106a06c40add33e03e1_I20200731" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtMS0xLTEtMTAxNjU_4091e513-9617-4c2c-94ef-55b013255dad">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17af873f453147b4b57bd13a9c4f867d_I20200731" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtMy0xLTEtMTAxNjU_d3119418-5eac-4d60-9a67-e58acd5e3023">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i163397f07fc24c7fa96b425b3dae61a6_I20200731" decimals="3" format="ixt:zerodash" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtNS0xLTEtMTAxNjU_3a401228-da13-4545-b563-a7969294990c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a50cdf7028c44ca97bad3a2559a8ea7_I20200731" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtNy0xLTEtMTAxNjU_755dab9b-1002-4b54-9a4d-6efc898fc273">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c37e34655d34543ac8add2eaa2cbb87_I20200731" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtOS0xLTEtMTAxNjU_dbc221b6-2221-4cb6-b047-f508318f6d70">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts with CROs for preclinical studies and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib610388546a84fdda93aefaba2baefcd"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Company&#8217;s amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. There have been no claims to date, and the Company has a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims.</span></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_145"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzE3NTkyMTg2MDUxODAy_c6a8ff2d-6208-408a-85f6-22b59f4febf5" continuedAt="i0334f210ab49491bb6c6df2101dc1866" escape="true"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzE3NTkyMTg2MDUxODAy_fa8c6dc5-bf15-4ef3-a4ff-1ffd3025e3d8" continuedAt="i671e6e0e55124d9f8d36ee550442db72" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i0334f210ab49491bb6c6df2101dc1866" continuedAt="ida30107ea85144c1ab64087338f114a3"><ix:continuation id="i671e6e0e55124d9f8d36ee550442db72" continuedAt="id0d42406a966479ebfafcd83ac3b0b4f"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company amended its month-to-month rental agreement for the 21 Erie Street, Cambridge, Massachusetts lab space, to extend its non-cancellable lease term.  The amendment was executed on May 5, 2020 and has a term expiration date of May 31, 2021.  As the lease term is longer than 12 months, the Company determined that this amendment requires assessment under ASC 842.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="ib041367f98b84d5faa59bdf5673a3592_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODgzMTM_ec5e2422-d0bd-4970-a96f-af550c484031">1.6</ix:nonFraction> million and an aggregate lease liability of $<ix:nonFraction unitRef="usd" contextRef="ib041367f98b84d5faa59bdf5673a3592_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODgzMjg_a813e38c-d900-4de3-b779-3a9c80741679">1.0</ix:nonFraction> million on the September&#160;30, 2020 balance sheet. The remaining lease term is <ix:nonNumeric contextRef="ib041367f98b84d5faa59bdf5673a3592_I20200930" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODgzNDI_69da84ac-ae50-4adc-8d41-85f3e0acd0b4">8</ix:nonNumeric> months, and the estimated incremental borrowing rate is <ix:nonFraction unitRef="number" contextRef="ib041367f98b84d5faa59bdf5673a3592_I20200930" decimals="4" name="kron:LesseeOperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODgzMzc_cf65139d-5ea9-4c03-b10b-11b0bdda110d">12.71</ix:nonFraction>%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into an <ix:nonNumeric contextRef="i1a92a2894224488c9e94058000096ced_I20200301" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0NjA_5fc32c1f-83cd-4994-b32d-c274f22c684a">11</ix:nonNumeric>-year lease agreement to move its research and development operations from 21 Erie Street, Cambridge, Massachusetts, to a <ix:nonFraction unitRef="sqft" contextRef="i1a92a2894224488c9e94058000096ced_I20200301" decimals="0" format="ixt:numdotdecimal" name="kron:OperatingLeaseFacilitySize" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0Njc_4cfdce3e-e7c7-4622-a1dc-87d61566d6f9">40,514</ix:nonFraction> square-feet facility at 301 Binney Street, Cambridge, Massachusetts.  The new lease commenced on March 1, 2020 with a monthly base rent of $<ix:nonFraction unitRef="usd" contextRef="i8f951b9cc2d342b394ec7ff04e4d40a9_D20200301-20200301" decimals="-5" format="ixt:numdotdecimal" name="kron:LesseeOperatingLeaseMonthlyBaseRent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzczMzA_edd06870-205d-463b-9335-fa9411020d06">0.3</ix:nonFraction> million. The initial rent payment was paid as of September&#160;30, 2020, with rent payments escalating <ix:nonFraction unitRef="number" contextRef="i8f951b9cc2d342b394ec7ff04e4d40a9_D20200301-20200301" decimals="3" name="kron:LesseeOperatingLeaseEscalatingRentPaymentsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzc5MTA_a53af824-607d-409f-ba1a-0aa7f2217649">3.0</ix:nonFraction>% annually after the initial 12 payments. As discussed in Note 2, the Company executed a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzc2NzE_69b11b42-24f8-4e2c-a72c-8ac92ec7bd46">2.0</ix:nonFraction> million in connection with the lease.  The lease includes $<ix:nonFraction unitRef="usd" contextRef="i1a92a2894224488c9e94058000096ced_I20200301" decimals="-5" format="ixt:numdotdecimal" name="kron:LesseeOperatingLeaseTenantImprovementAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzc0OTE_c6761030-cac8-448e-a6ca-f1ab69732ea0">3.7</ix:nonFraction> million in certain tenant improvement allowances, which the Company included in its calculation of the right-of-use asset in the lease at commencement. In connection with the lease, the Company recognized an operating lease right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg1NjU_9bbd3cac-11d3-4eec-b897-12942080fd96">25.7</ix:nonFraction> million and an aggregate lease liability of $<ix:nonFraction unitRef="usd" contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg1ODE_54a73d2b-c5a5-4e52-a785-07acdf808b36">27.7</ix:nonFraction> million on the September&#160;30, 2020 balance sheet. The remaining lease term is 10 years and 5 months, and the estimated incremental borrowing rate is <ix:nonFraction unitRef="number" contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930" decimals="4" name="kron:LesseeOperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg1ODk_179dd887-be24-4e63-a339-a709743b7fe5">8.50</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company entered into a lease agreement for a <ix:nonFraction unitRef="sqft" contextRef="i3234c4fd018b4ff6ae61cebd2fd7b666_I20180731" decimals="0" format="ixt:numdotdecimal" name="kron:OperatingLeaseFacilitySize" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0ODI_67e054ac-6ed9-42e9-80db-ba5bfef24f6c">4,661</ix:nonFraction> square-foot office space to be used for general and administrative activities in San Mateo, California. The lease commenced on August 1, 2018 and has a <ix:nonNumeric contextRef="idad0893c755d45138461981a7756615e_I20180801" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0ODk_4ab83732-2d27-45ae-8a34-8fc00fb45cc0">37</ix:nonNumeric>-month initial term expiring on August 31, 2021. The lease also contains an option for the Company to extend the lease upon its initial expiration. In connection with the lease, the Company made a one-time cash security deposit in the amount of $<ix:nonFraction unitRef="usd" contextRef="idad0893c755d45138461981a7756615e_I20180801" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxNzc_9aa83769-31b5-4cff-8bcf-bdeedb301bf9">27.8</ix:nonFraction> thousand. In May 2020, the Company amended its agreement to extend the lease for its office in San Mateo, California through April 2025. The initial annual base rent is $<ix:nonFraction unitRef="usd" contextRef="icffc314b519d440aa9f7fa06b641a760_D20180801-20180801" decimals="-2" format="ixt:numdotdecimal" name="kron:LesseeOperatingLeaseInitialAnnualBaseRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxNjI_f755c9f6-65d3-46be-baf6-f5e91eedf9c9">26.1</ix:nonFraction> thousand, and such amount will increase by <ix:nonFraction unitRef="number" contextRef="icffc314b519d440aa9f7fa06b641a760_D20180801-20180801" decimals="3" name="kron:LesseeOperatingLeaseEscalatingRentPaymentsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxNjc_feade6cd-b7bd-46bb-93ba-70275d37606c">3</ix:nonFraction>% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="i6517aa7d879f44528a2d88e8c188d509_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg2Mjg_da8ff37d-527d-45fe-b00c-03b70d302527">1.2</ix:nonFraction> million $<ix:nonFraction unitRef="usd" contextRef="i676113738ba64cf9bfb99cf6d7419962_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzM4NDgyOTA3MDc3ODc_07f89ca8-7867-48a5-9298-9c998b440403">0.5</ix:nonFraction> million and an aggregate lease liability of $<ix:nonFraction unitRef="usd" contextRef="i6517aa7d879f44528a2d88e8c188d509_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg2OTc_ce4dafbe-aefc-4261-be03-25cb34793529">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i676113738ba64cf9bfb99cf6d7419962_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzM4NDgyOTA3MDc3OTc_4ad538d6-35e9-4e66-b005-a9bbbb1a5b67">0.5</ix:nonFraction> million on the September&#160;30, 2020 and December&#160;31, 2019 balance sheets, respectively.  The Company expanded to an adjacent suite in July 2020, which is treated as a separate lease for accounting purposes.  The additional space is approximately <ix:nonFraction unitRef="sqft" contextRef="i623e9b9d16b249bda0eeafb5a7270517_I20200701" decimals="0" format="ixt:numdotdecimal" name="kron:OperatingLeaseFacilitySize" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0NzU_c92d92ab-2bc2-4d95-a159-bb5cc577cefd">3,414</ix:nonFraction> square feet and will similarly be used for general and administrative activities.  The lease commenced on July 1, 2020 and will expire on April 30, 2025.  In connection with the additional space leased, the Company made a one-time additional cash security deposit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i623e9b9d16b249bda0eeafb5a7270517_I20200701" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAyMDg_9e999671-dfa1-446f-8f07-f89f28b84cab">24.8</ix:nonFraction> thousand.  The initial base rent for the expansion is $<ix:nonFraction unitRef="usd" contextRef="i3b09b6cd908145558102a1d2ebca38a9_D20200701-20200701" decimals="-2" format="ixt:numdotdecimal" name="kron:LesseeOperatingLeaseInitialAnnualBaseRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxOTA_24f930ad-dd9b-46d7-bbbc-ee72df3e09f1">19.2</ix:nonFraction> thousand, and such amount will increase by <ix:nonFraction unitRef="number" contextRef="i3b09b6cd908145558102a1d2ebca38a9_D20200701-20200701" decimals="3" name="kron:LesseeOperatingLeaseEscalatingRentPaymentsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxOTU_194b5747-e098-4360-9a7f-dbdb80021041">3</ix:nonFraction>% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAwNjU_a650aaf1-25f1-4fdc-b629-da9df578889b">0.9</ix:nonFraction> million and an aggregate lease liability of $<ix:nonFraction unitRef="usd" contextRef="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxMDU_6d51f523-9f5e-484a-9bd0-b57c1f860f89">0.9</ix:nonFraction> million on the September&#160;30, 2020 balance sheet.  The remaining lease term is for both spaces is 4 years and 7 months, and the estimated incremental borrowing rate is <ix:nonFraction unitRef="number" contextRef="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930" decimals="4" name="kron:LesseeOperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODk4MjI_be8ca1ce-3248-4758-b00d-88bb995dced8">12.07</ix:nonFraction>%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company entered into a finance lease for R&amp;D equipment that has a bargain purchase option at the end of its <ix:nonNumeric contextRef="ifbecda89de7840548904aa4dd3124d22_I20180331" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA1MTY_8553eb74-8d1d-4511-8432-bcd5125fc2c4">three-year</ix:nonNumeric> term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finance lease is included in property and equipment, net, other current liabilities, and other noncurrent liabilities on the Company&#8217;s balance sheets. </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ida30107ea85144c1ab64087338f114a3" continuedAt="i50a96f2839574091acc91df2d2398ea1"><ix:continuation id="id0d42406a966479ebfafcd83ac3b0b4f" continuedAt="i68ff4ef512974fc1a194bfdf4740c015"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="kron:AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA1MTc_82899502-e9fd-46fd-a716-0341df359355" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the Company&#8217;s finance lease in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzMtMi0xLTEtNjU3_f80e86b8-e65b-4836-8c16-2020b35a6c1b">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzMtNC0xLTEtNjU3_dbc9a419-7eab-4b06-b022-1b83016200f3">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion of other liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzUtMi0xLTEtNjU3_907b4d98-1ca0-44ab-b442-28adcb509b6c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzUtNC0xLTEtNjU3_270d0337-6801-4148-aa72-e05637b59b12">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzYtMi0xLTEtNjU3_e90fef9f-f6d8-4d0f-90ea-41ea8ec8a42e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzYtNC0xLTEtNjU3_928fffcd-19d1-4009-9d14-772415876fee">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzctMi0xLTEtNjU3_987abf16-6382-4df5-a18d-3502f5e7d35b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzctNC0xLTEtNjU3_d8e86454-7e94-43d1-b76c-9fe2e0b564b2">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="kron:AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA1MTg_f54981e9-eea9-42c1-9e86-03774aaf4637" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the Company&#8217;s operating leases in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzMtMi0xLTEtNjY5_30b446e5-37f8-485f-9e29-20f6737b98c6">29,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzMtNC0xLTEtNjY5_ce138805-5af0-4a77-b0eb-de7f8fe3859f">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion of operating lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzUtMi0xLTEtNjY5_a5c13e4c-8aca-47bf-95d5-17ea15cedc5e">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzUtNC0xLTEtNjY5_fa122314-70c8-4d84-8be7-7dcddaed8f9c">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Noncurrent operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzYtMi0xLTEtNjY5_5b18ba05-f762-4016-81fb-2d9bfee565eb">29,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzYtNC0xLTEtNjY5_345bcfee-3718-490b-9145-3caaf1a77fce">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzctMi0xLTEtNjY5_8f88ac09-99e3-4f7f-a899-cf231b8256c5">30,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzctNC0xLTEtNjY5_bc06e36c-a096-4dc1-bf22-fe436b725e08">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzE3NTkyMTg2MDUxODA2_a6d7463f-c719-42a8-93ed-298ed32031e9" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of finance lease costs in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Statement of Operations and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive Loss Caption</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i77faf9def6034a17a43362f8c79b789c_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzMtMi0xLTEtNjg4_e54cb291-532b-41b9-abaa-ab58add1dc34">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i07a7c2fa9dca4beab08872d278639b3d_D20190701-20190930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzMtNC0xLTEtNjkx_b960b875-d63b-4460-b9be-110502ead129">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iff1ad401e98742ddb6abcc5503e71ad1_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzMtNi0xLTEtNjk0_36e61a28-3131-4791-937b-c5b22b842b32">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id688172e6cde48eeae48e9a213f81cb5_D20190101-20190930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzMtOC0xLTEtNjk3_d5abdfbe-5df3-4313-b1f9-6d89d07b4b5c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income (expense), net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzQtMi0xLTEtNjg1_ef0626bb-c4c2-444e-a1dc-f8eeb5227927">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzQtNC0xLTEtNjkx_606e6a3d-6350-4a2f-b0c1-e704ddd1bfb1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzQtNi0xLTEtNjk0_1536d4a6-7fb3-427e-b75e-aea723809028">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzQtOC0xLTEtNjk3_c10fbbfa-73e3-4d37-9bff-386a07970370">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzUtMi0xLTEtNjg1_609c9105-bb1d-4b5c-aed1-0c4fc85063a5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzUtNC0xLTEtNjkx_692f30b1-7f25-4d48-ae17-1e84d72d3922">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzUtNi0xLTEtNjk0_aa633199-c3cd-4392-8590-9dd22351cfdf">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzUtOC0xLTEtNjk3_4167d840-4e0b-4d70-b49a-afb5b5b5d7b8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of operating lease costs in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Statement of Operations and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive Loss Caption</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i77faf9def6034a17a43362f8c79b789c_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzMtMi0xLTEtNzAx_340ba2de-1d82-49cd-9efc-bb64607aa342">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i07a7c2fa9dca4beab08872d278639b3d_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzMtNC0xLTEtNzA0_f7f710a5-2a75-4cf8-9712-237a749584b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iff1ad401e98742ddb6abcc5503e71ad1_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzMtNi0xLTEtNzA3_3ebf0e3e-f6da-4826-9019-13018e3a7932">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id688172e6cde48eeae48e9a213f81cb5_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzMtOC0xLTEtNzEw_f45a3f35-88e6-41c7-82cb-23dbd43ebd15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1fa6a9b2386942c4a674dfa9c9918c8a_D20200701-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzQtMi0xLTEtNzAx_13c8366f-bdfb-4616-aa23-d26d5f3539ee">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0eb0c54a250748e2bd702dfc80c5dca5_D20190701-20190930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzQtNC0xLTEtNzA0_d97b6d13-4a33-41d9-ac23-9553c864f8fc">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ice6bc89ef445474790f3d6a61419f2a0_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzQtNi0xLTEtNzA3_13c535de-722e-447c-8e40-61fe95d3fd40">890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic510c74d485b4029bb4fefcd43dd7a70_D20190101-20190930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzQtOC0xLTEtNzEw_40d6182c-7a75-4d45-850a-6f6b45ee278d">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzUtMi0xLTEtNzAx_018f8b92-35b5-4ea4-8ec5-cd5b562cca1a">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzUtNC0xLTEtNzA0_8c83b8d6-9bc5-4c1a-81bd-8e2109a5cb95">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzUtNi0xLTEtNzA3_8cc08ca0-d408-4c1b-853c-c313b847fad5">3,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzUtOC0xLTEtNzEw_2649abcf-ce9b-46fc-a393-fe287f77a712">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i50a96f2839574091acc91df2d2398ea1"><ix:continuation id="i68ff4ef512974fc1a194bfdf4740c015"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments of $<ix:nonFraction unitRef="usd" contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzgwMDc_2cc441f6-547b-4918-b46f-728f943e7296">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzgwMjI_51e58484-d5b6-40b7-a71c-ee6a435333f1">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzgwMzc_8f37159b-279f-4ae0-af4b-e7bd14714546">1.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzgwNTI_d200f9cb-caad-4bd6-bf6e-ea5e3925dda9">0.2</ix:nonFraction> million under the lease agreements during the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzE3NTkyMTg2MDUxODA0_3bbda419-785e-41c0-b5b6-fdd6b5b32975" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> undiscounted future non-cancellable lease payments under the Company's operating leases </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of September&#160;30, 2020 for the next five years and thereafter is expected to be as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining three months of 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzItMi0xLTEtNzE1_533b986c-896c-4905-a547-783dde0f8f23">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzMtMi0xLTEtNzE1_558881f3-fb98-4e07-a335-bb4622cf3912">5,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzQtMi0xLTEtNzE1_364b4b5e-381d-45c6-a3bf-383b7b2259f2">4,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzUtMi0xLTEtNzE1_f0509d5f-9016-4362-ac9d-195dcd743702">4,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="kron:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzYtMi0xLTEtNzE1_a629bccc-5a49-428c-8b15-9c1b074709f6">35,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzctMi0xLTEtNzE1_0f266eb6-aa1c-4a80-a560-711f47b5f2c8">52,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzgtMi0xLTEtNzE1_4e2754ef-4696-4081-a40b-4b89b7e4abb9">18,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Tenant improvement allowance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzktMi0xLTEtNzE1_0b953257-8108-40ed-b94b-7bbd3630803d">3,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzEwLTItMS0xLTcxNQ_49796cdb-a513-4a23-9fbe-3533a2bc1e7f">30,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_747"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzEzNzQzODk1MzU0Nzc5_217bc05e-2ffe-4fbc-b77b-93ebd59f7675" continuedAt="ia6ae0a37da5b4fb18ccb73a441ba6d29" escape="true">2020 Notes</ix:nonNumeric></span></div><ix:continuation id="ia6ae0a37da5b4fb18ccb73a441ba6d29" continuedAt="i3f00e06519c644e4a301008e64510444"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a note purchase agreement pursuant to which it sold and issued and aggregate of $<ix:nonFraction unitRef="usd" contextRef="ieed7f26a9c4d41b290ef0ca4f65ed6b7_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzY3Nzg_d4f947b3-c8f1-45e7-8f37-25fade72b829">155.2</ix:nonFraction> million in convertible promissory notes (2020 Notes) and received net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie0b7d39d86434ec791e9c67d78593194_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwNjg_114441e8-06c8-4d1b-b856-cc7663c83b9a">151.3</ix:nonFraction> million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Notes do not accrue interest.  The 2020 Notes were settled in exchange for <ix:nonFraction unitRef="shares" contextRef="ib50ec0c321854506a6168bb676c9bb98_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTA0MzQ_c01a8960-d620-4c22-a87a-89d1f0ca4e40">9,610,713</ix:nonFraction> shares of common stock in connection with the closing of the Company&#8217;s IPO (See Note 1) at a settlement per share price equal to <ix:nonFraction unitRef="number" contextRef="ie5ac0bb41ed144069f9ed35f0501c5ff_D20200801-20200831" decimals="2" name="kron:SaleOfStockPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwNDg_f25df7e1-c6b9-436b-ae23-d1281fc47f42">85</ix:nonFraction>% of the IPO price per share.  The 2020 Notes also contained other settlement provisions if an IPO did not occur within 18-months of the 2020 Notes issuance date.  If the Company was acquired, completed a business combination resulting in a change of control or sold all or substantially all of its assets (each, a liquidation transaction) prior to the 18-month anniversary of the issuance dates of the 2020 Notes, the 2020 Notes unless previously settled into shares of common stock in the IPO, will settle into shares of the Company&#8217;s common stock at a price per share equal to <ix:nonFraction unitRef="number" contextRef="ie5ac0bb41ed144069f9ed35f0501c5ff_D20200801-20200831" decimals="2" name="kron:SaleOfStockPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwNTQ_f25df7e1-c6b9-436b-ae23-d1281fc47f42">85</ix:nonFraction>% of the estimated fair value of the consideration per share payable to the holders of its common stock in connection with such liquidation transaction.  If neither the IPO nor a liquidation transaction occurs prior to the 18th-month anniversary of the issuance dates of the 2020 Notes, the 2020 Notes will be converted into shares of newly designated Series B convertible preferred stock of the Company at a settlement price that will be determined based on a stipulation $<ix:nonFraction unitRef="usd" contextRef="i4ea6fedb22e248bdb67c280feee123df_I20200831" decimals="-5" format="ixt:numdotdecimal" name="kron:DebtConversionValuationOfCompany" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwMzU_ca895428-4a2f-4d5b-aaf3-a7bb9c0c0143">500.0</ix:nonFraction> million valuation of the Company and its fully diluted capitalization as of immediately prior to the conversion of the 2020 Notes.  The 2020 Notes contain additional redemption features contingent upon the occurrence of certain future events.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On issuance, the Company elected to account for the 2020 Notes at fair value with any changes in fair value being recognized through the statements of operations until the 2020 Notes settled.  On issuance, the fair value of the 2020 Notes was determined to be equal to $<ix:nonFraction unitRef="usd" contextRef="ieed7f26a9c4d41b290ef0ca4f65ed6b7_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTYzOTI_383033fd-28fb-42b0-958f-b604615f5f3a">155.2</ix:nonFraction> million, which is the principal amount of the 2020 Notes, and total debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ie0b7d39d86434ec791e9c67d78593194_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwNDE_89b4dee9-e0ce-4826-b76a-e4e9dd1ac856">3.9</ix:nonFraction> million were expensed and recognized as interest expense in the accompanying statements of operations and comprehensive loss.  An additional $<ix:nonFraction unitRef="usd" contextRef="ie0b7d39d86434ec791e9c67d78593194_D20200801-20200831" decimals="-3" format="ixt:numdotdecimal" name="kron:PaymentsForLegalCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzc2Njg_8bb0dfe3-6db4-4d3c-b9c4-5821946a75b6">50</ix:nonFraction> thousand was reimbursed to investors for legal costs incurred and netted against total proceeds received on the Company&#8217;s balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the 2020 Notes as of September&#160;30, 2020 by determining the present value of the 2020 Notes if they were to settle either upon closing of an IPO, in shares of Series B convertible preferred stock 18-months after issuance (February 2022), or upon a financing scenario.  <ix:continuation id="id2678d485afa45ecb5667844c2c14630" continuedAt="ie6a3198fa5934666a47d9aca30bd6e3b">Key valuation assumptions are as follows:</ix:continuation></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3f00e06519c644e4a301008e64510444"><div style="margin-bottom:9pt"><ix:continuation id="ie6a3198fa5934666a47d9aca30bd6e3b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO Scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing Scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f6001b206b54c728c11f91d8f95efb7_I20200930" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzItMS0xLTEtMTkxOQ_06773348-3726-4f87-871f-3260202b3211">0.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32a5d81edc2c45aaa7af987dd2ec57b2_I20200930" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzItMy0xLTEtMTkxOQ_c06a5256-f90a-4536-a9b5-32a7ec6da3a9">1.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee8c0d66302445e9a58d268bbad55dc8_I20200930" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzItNS0xLTEtMTkxOQ_e259d7cc-b34b-4f7d-83c7-4d12c7e8b74a">1.39</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d56dfa261f8415b8e8a2412f974446b_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzMtMS0xLTEtMTkxOQ_5b449bc2-2dfd-4ad5-9974-71da6d7a05f2">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i48c80af886534e0e839a947a487fabc6_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzMtMy0xLTEtMTkxOQ_52b52b6b-3de2-4f7f-8981-9005ea917f42">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15541111cc0147dcaa8140563fa4f2f2_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzMtNS0xLTEtMTkxOQ_966a380b-7f94-4b52-9a2e-b0f4f839379a">24.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23666d2a49a44d07afcdc32b368ec048_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzQtMS0xLTEtMTkxOQ_b16a9cb7-5c81-461d-98c0-fa2ab2511901">95.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81df50dc201b4b8ea1c8247921d8ca17_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzQtMy0xLTEtMTkxOQ_0967f423-f998-4cc3-b85c-290b2f15c568">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35f23e6018f34b819e4f9ad667f5b07e_I20200930" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzQtNS0xLTEtMTkxOQ_0c37bf3f-0abc-48d9-b91c-2d2513c05116">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the 2020 Notes was determined to be $<ix:nonFraction unitRef="usd" contextRef="ieed7f26a9c4d41b290ef0ca4f65ed6b7_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTU5NzI_383033fd-28fb-42b0-958f-b604615f5f3a">155.2</ix:nonFraction> million on issuance and $<ix:nonFraction unitRef="usd" contextRef="i0c9e8411b1234b0ea5b11006c170b729_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTU5OTI_472cbda8-f8fe-45be-89f1-b8b6135f6f41">168.5</ix:nonFraction> million as of September&#160;30, 2020. For the three and nine months ended September&#160;30, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i19dd6da6c7b34b17b50df3ce81d9dd81_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="kron:GainLossOnChangeInFairValueOfDebtInstrument" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTYwNzE_b3df546d-6cf6-44b2-810b-234c21e9ae78"><ix:nonFraction unitRef="usd" contextRef="i732fa4350e424f4bb60a16a35c6aa5cf_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="kron:GainLossOnChangeInFairValueOfDebtInstrument" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTYwNzE_e8c33b58-8ea5-4565-9ee7-4ce70d27070f">13.3</ix:nonFraction></ix:nonFraction> million in the accompanying statements of operations and comprehensive loss as the change in fair value of the 2020 Notes.</span></div></ix:continuation><div id="id4bb4e4f9863422ab5c3f3e7868262d4_148"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5Xzk4OTU2MDQ2NTI1ODE_7878f542-5945-43aa-a774-47d3a672690a" continuedAt="i7c9c41897d31468a825137c90e799c4c" escape="true">RELATED PARTIES</ix:nonNumeric></span></div><ix:continuation id="i7c9c41897d31468a825137c90e799c4c"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2017, the Company entered into a <ix:nonNumeric contextRef="i013165bd63c141f78e3b0ec48d6aeb39_D20200101-20200930" format="ixt-sec:durwordsen" name="kron:ServicesAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5Xzk4OTU2MDQ2NTI3NDc_4bb9562b-4c50-4365-9301-6562e1ab301b">three-year</ix:nonNumeric> services agreement with Two River Consulting, LLC (Two River) to provide various clinical development, operational, managerial, accounting and financial, and administrative services to the Company. Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman of Two River. Mr. Joshua Kazam and Mr. David Tanen, each a director of the Company, are each partners of Two River. Mr. Tanen additionally serves as our Corporate Secretary.  Mr. Christopher Wilfong, a strategic advisor to the Company, is an Operating Partner of Two River and Mr. Sean Algeo, serving as the Company&#8217;s Treasurer, is the Chief Financial Officer of Two River. During the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, the Company incurred expense of $<ix:nonFraction unitRef="usd" contextRef="i3b1c4ce7e09f4609b89a6586759b8444_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2MzM_aa79f470-cf77-49a8-93bf-27930d5ba38d">0.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id2997d3b39e44c049e46716565e334c4_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2Mzc_fa1b975d-8d3b-4fde-86d5-6d4e06df1491">0.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i013165bd63c141f78e3b0ec48d6aeb39_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2NDE_76033aae-e4da-4a46-8b22-aced219f8c4a">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9e930125986d43ccab7955e01aa7d87f_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2NDU_55c1b1bc-5229-4829-bdac-7a7361ae203a">0.6</ix:nonFraction> million respectively, for these services. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s expenses are periodically paid by Two River. The Company reimburses Two River for these expenses and no interest is charged on the outstanding balance.  These reimbursable expenses totaled $<ix:nonFraction unitRef="usd" contextRef="ifef3396d498f4831ab1ac220e09caad2_D20200701-20200930" decimals="-2" format="ixt:numdotdecimal" name="kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2OTk_3a68a8f2-1497-4af3-93e9-d798414b5938">15.0</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i7e707633da84487498c2674c190517d8_D20190701-20190930" decimals="-2" format="ixt:numdotdecimal" name="kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI3MDM_44a75082-3276-434c-be95-cbfc3dc52b09">7.4</ix:nonFraction> thousand for three months ended September&#160;30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i0d8ea9d54ffb45dc8de4f5d3a62c8776_D20200101-20200930" decimals="-2" format="ixt:numdotdecimal" name="kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI3MDk_b4661dcb-c82e-490d-acac-edc338d13df6">24.1</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i51fbcc82facb4e78bbf3571c3a7b333b_D20190101-20190930" decimals="-2" format="ixt:numdotdecimal" name="kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI3MTQ_bdd5fbc6-1a25-43f6-b1d9-3753ca9b29ab">44.9</ix:nonFraction> thousand for the nine months ended September&#160;30, 2020 and 2019, respectively.  As of September&#160;30, 2020 and December&#160;31, 2019, the Company had payables to Two River of $<ix:nonFraction unitRef="usd" contextRef="if2696f8ecf0246daa8d17d75de9abb4d_I20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2Mjk_5a05c247-de65-4e16-97ed-2b2ab2a7bcd5">92.5</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i1fbdca86d2ea46a5a02388d0823daea8_I20191231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2MjU_104d4813-82a5-4147-b35b-069cd3fbada2">75.0</ix:nonFraction> thousand, respectively. All balances owed as December 31, 2019 were paid in full during the first quarter of 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a consulting agreement with Bellco Capital, LLC (Bellco) to provide various executive services to the Company.  Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman of Bellco. Rebecka Belldegrun, M.D., a director of the Company, is the President and Chief Executive Officer of Bellco. During the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, the Company incurred expense of $<ix:nonFraction unitRef="usd" contextRef="idc38fa9749f94b56b8bd462c4e5b894b_D20200701-20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzMyOTg1MzQ4ODYwOTY_59209d8d-a77e-4630-893c-ed5f1f192df5">6.3</ix:nonFraction> thousand, $<ix:nonFraction unitRef="usd" contextRef="i447ffc13a5e74bdf9f0ed1c954749058_D20190701-20190930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzMyOTg1MzQ4ODYxMDE_a55ab796-0f21-4cff-ae1a-41f5fd6e32de">6.3</ix:nonFraction> thousand, $<ix:nonFraction unitRef="usd" contextRef="i3a3abdc990ab4085bba504ea15586fb0_D20200101-20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI0NTY_1b760a54-9b1c-4655-9fb9-4df87764af5f">18.9</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="ib6bc7aed10264332996827a2e1c4b226_D20190101-20190930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5Xzk4OTU2MDQ2NTM3ODc_a2c0aeee-ef9d-46f9-8f73-29c783a709fb">18.9</ix:nonFraction> thousand, respectively, for these services.</span></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_151"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt"><ix:nonNumeric contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzEzNzQzODk1MzU4ODg2_d0b3b6e4-771c-49ca-9538-6db329e5e20e" continuedAt="i8d020f6758ee488dab77cf67228a7109" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i8d020f6758ee488dab77cf67228a7109" continuedAt="i735a91301fcb4dd389973486673e929f"><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the interim financial statements as of September&#160;30, 2020 for the three and nine months periods then ended, the Company evaluated subsequent events for recognition and measurement purposes.  The Company concluded that no events or transactions have occurred that require disclosure in the accompanying financial statements, other than the following.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt">Authorization of Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2020, the Company amended and restated its certificate of incorporation.  Among other things, the amended and restated certification of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="i75d1b3f7102a450088f5769228278051_I20201014" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkwODExMDE_d6d075d4-449f-439b-a9ff-c99824e44e51">10,000,000</ix:nonFraction> shares of undesignated preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i75d1b3f7102a450088f5769228278051_I20201014" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkwODExMDY_bd3358c9-fd1e-493c-9544-769b2fe4d1a1">0.001</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt">Increase in Authorization of Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020, the Company amended its certificate of incorporation to, among other things, increase the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkwODEwOTY_0f4bd288-aa25-4bdd-b902-704780699eb8">40,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i354b6c38321f418e8ea03e729e783986_I20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkwODEwOTE_6669ee6f-0a82-462d-a6ff-94afd32c0969">200,000,000</ix:nonFraction>.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i735a91301fcb4dd389973486673e929f"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt">Amendments to Convertible Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2020, the required holders of the Company&#8217;s Convertible Preferred Stockholders authorized the automatic conversion of all shares of the Convertible Preferred Stock in the IPO.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt">Forward Stock Split</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020, the Company effected a <ix:nonFraction unitRef="number" contextRef="i5c23b681d5c84ca1bf3cfe7435c3e188_D20201002-20201002" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkxMDIzMDg_f4f07e72-81f0-48a5-81f3-b3bf204cf1aa">1.055</ix:nonFraction>-for-1 forward stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing ratios for each series of the Company&#8217;s Preferred Stock.  In addition, the number of shares subject to each stock option outstanding was proportionally increased by the forward stock split ratio, and the exercise price per share was proportionally decreased by the forward stock split ratio.  Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retrospectively, where applicable, to reflect this forward stock split and adjustment of the preferred stock conversion ratios.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt">2020 Equity Incentive Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company&#8217;s board of directors and stockholders approved the Company&#8217;s 2020 Equity Incentive Plan (the 2020 Plan), which became effective on October 8, 2020.  The 2020 Plan provides for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="ide813d6d56e94d6eab30a8e7472b2e0d_I20201008" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzMyOTg1MzQ4OTQ4NTM_cf45fd54-1967-4eda-9120-e48eafbfd0a2">11,938,152</ix:nonFraction> of share-based awards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">f.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.9pt">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company&#8217;s board of directors and stockholders approved the Company&#8217;s 2020 Employee Stock Purchase Plan (the ESPP).  The ESPP became effective October 8, 2020.  The ESPP provides for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="ia5bf533181c044de8807c924d489d6e6_I20201008" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzMyOTg1MzQ4OTQ4NTk_73b0ea1c-dcbd-4cb5-a8fc-fe2fa1b5ca48">688,000</ix:nonFraction> of share-based awards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt">Conversion of convertible notes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, upon the closing Company&#8217;s IPO, the 2020 Notes automatically converted into <ix:nonFraction unitRef="shares" contextRef="ib50ec0c321854506a6168bb676c9bb98_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzMyOTg1MzQ5MTM2MDc_0d33dbed-2537-4164-b306-a08a6ac9333e">9,610,713</ix:nonFraction> shares of common stock (See Note 15).  Upon the closing of the IPO, the Gilead Note was also converted into <ix:nonFraction unitRef="shares" contextRef="if9ec867a047842948219312d9ab1388e_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzMyOTg1MzQ5MTM3MTg_c91d48ad-01b9-4266-8166-0926291bb620">188,567</ix:nonFraction> shares of common stock as the result of Gilead&#8217;s election (See Note 13).  The Company will record a loss of $<ix:nonFraction unitRef="usd" contextRef="if63f36e0c9f049a4a09953343fbdb606_D20201001-20201118" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzM4NDgyOTA3Mjk0NjQ_1c41b87d-b12f-4cce-817f-d8dd6ad76210">14.1</ix:nonFraction> million and a gain of $<ix:nonFraction unitRef="usd" contextRef="ifd40f9ae2ea3456890d775273e5e0e55_D20201001-20201118" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzM4NDgyOTA3Mjk1MjE_36e34da3-9a28-4181-91a8-532c5b8a5194">1.9</ix:nonFraction> million in the fourth quarter of fiscal 2020 upon the settlement of the 2020 Notes and Gilead Note, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">h.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt">Lease termination</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a lease termination agreement for its lab space in Cambridge, Massachusetts.  The lease will terminate as of January 31, 2021 rather than continue through May 2021.  The cost for early termination is a payment of $<ix:nonFraction unitRef="usd" contextRef="i2ac6a536633140c584616f4aaff231e3_I20201118" decimals="-5" format="ixt:numdotdecimal" name="kron:LesseeOperatingLeaseEarlyTerminationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzM4NDgyOTA3MzAwNDM_7298d837-077d-4aaf-8a34-7d529fb91a44">0.1</ix:nonFraction> million.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_43"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND&#160;RESULTS&#160;OF&#160;OPERATIONS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with the our condensed financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and related notes as of and for the fiscal year ended December 31, 2019, and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation, both of which are included in our final prospectus dated October 8, 2020 filed with the Securities and Exchange Commission, or the SEC, pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended (&#8220;the Prospectus&#8221;) on October 9, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward Looking Statements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations, and intentions.  In some cases, you could identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or the negative of these terms or similar expressions. As a result of many factors, including those factors set forth under &#8220;Risk Factors&#8221; included in Item 1A of Part II of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, entospletinib (ENTO), is an orally administered, selective SYK inhibitor that has been tested in more than 200 AML patients. Based on clinical results in a biomarker-defined subset of patients and subject to discussions with regulatory agencies that we intend to have in the first half of 2021, we plan to initiate a registrational Phase 2/3 clinical trial in 2021 in newly-diagnosed AML patients with NPM1 mutations, with an anticipated data readout in 2023. We are also planning to initiate a Phase 1/2 clinical trial in patients with relapsed or refractory FLT3 mutated AML in 2021, with an anticipated data readout in 2022. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into an asset purchase agreement to acquire a portfolio of selective, orally bioavailable small molecule inhibitors of SYK from Gilead Sciences, Inc. Our expertise in TRN biology allowed us to recognize SYK as a critical node in the HOX/MEIS TRN, and this acquisition accelerated our pipeline to late clinical stage. The acquisition included two clinical-stage compounds entosplentinib (ENTO) and lanraplenib (LANRA).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are developing KB-0742 for the treatment of MYC-amplified solid tumors. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Subject to clearance of the IND for KB-0742, we plan to initiate a Phase 1/2 clinical trial in patients with advanced solid tumors in the first half of 2021. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also leveraging our product engine to drive multiple oncology discovery programs targeting dysregulated transcription factors and their associated TRNs. We have discovery initiatives focused on four cancer types where dysregulated transcription plays a central role: hematologic malignancies, prostate cancer, MYC-driven cancers, and small cell/neuroendocrine cancers. Our active discovery programs are focused on the specific TRNs MYC, MYB, ARv7, IRF4 and ASCL1. We anticipate submitting an IND for a drug candidate arising from one of these programs in 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current COVID-19 pandemic has presented substantial public health and economic challenges around the world. We cannot at this time predict the specific extent, duration or impact that COVID-19 will have on our financial condition and operations, including ongoing research activities, planned clinical trials and our financial results. While we are currently continuing to prepare to initiate clinical trials in 2021, COVID-19 precautions may directly or indirectly impact their timelines and interrupt clinical enrollment. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we had significant operating losses, primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. Our net loss was $39.7 million and $4.0 million for the three months ended September&#160;30, 2020 and 2019, respectively, and $55.3 million and $10.7 million for the nine months ended September&#160;30, 2020 and 2019, respectively. As of September&#160;30, 2020, we had an accumulated deficit of $78.7 million. As of September&#160;30, 2020, we had $211.3 million of cash, cash equivalents and short-term investments. In October 2020, we completed an initial public offering (IPO) of our common stock. As a result of the IPO, we received approximately $263.9 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures and, to a lesser extent, general and administrative expenditures. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gilead Asset Purchase Agreement </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into the Gilead Asset Purchase Agreement, pursuant to which we acquired certain assets from Gilead related to ENTO and LANRA, and patents and other intellectual property covering or related to the development, manufacture and commercialization of ENTO and LANRA.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for such assets, on the date of the Gilead Asset Purchase Agreement, we made a $3.0 million upfront cash payment and issued a $3.0 million principal amount convertible promissory note to Gilead (Gilead Note). We also made a $0.7 million payment to reimburse Gilead for certain liabilities we assumed pursuant to the Gilead Asset Purchase Agreement. In addition, we are required to make milestone payments upon successful achievement of certain regulatory and sales milestones for ENTO, LANRA and other SYK inhibitor compounds covered by the patent rights acquired pursuant to the Gilead Asset Purchase Agreement and developed by us as a back-up to ENTO or LANRA (Other Compounds). Upon initiation of our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC in AML patients with NPM1 mutations, we will be required to pay a milestone to Gilead of $29.0 million, and upon successful completion of certain other regulatory milestones in the United States, European Union and United Kingdom for ENTO, LANRA and any Other Compounds, across up to two distinct indications, we will be required to pay to Gilead an aggregate total of $51.3 million.  Upon achieving certain thresholds for the aggregate annual net sales of ENTO, LANRA and any Other Compounds combined, we would owe to Gilead potential milestone payments totaling $115.0 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead is also eligible to receive (i) tiered marginal royalties ranging from the very low-teens to high-teens on annual worldwide net sales of ENTO, (ii) tiered marginal royalties ranging from high-single digits to the mid-teens on annual worldwide net sales of LANRA and (iii) tiered marginal royalties ranging from the low single digits to mid-single digits on annual worldwide net sales of any Other Compounds. The royalties in the foregoing clauses are subject to reduction, on a country-by-country basis, for products not covered by certain claims within the assigned patents, for generic entry and, in the case of ENTO and LANRA, for any royalties paid for future licenses of third party intellectual property required to develop or commercialize ENTO or LANRA. Our royalty obligation with respect to a given product in a given country begins upon the first commercial sale of such product in such country and ends on the latest of (i) expiration of the last claim of a defined set of the assigned patent rights covering such product in such country; (ii) loss of exclusive data or marketing rights to such product in such country; or (iii) 10 years from the first commercial sale of such product in such country.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Gilead Asset Purchase Agreement, we are required to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize either ENTO or LANRA.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Harvard License Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into a license agreement with President and Fellows of Harvard College (Harvard), pursuant to which Harvard granted us a non-exclusive, worldwide, royalty-free license to certain intellectual property for the purpose of commercializing products relating to our SMM platform. We paid a one-time license fee in the amount of $10,000 on the date of the agreement and an annual license maintenance fee of $20,000 on each of the first two anniversaries. We are required to pay $25,000 on each subsequent anniversary until the last to expire of any valid claim included in the licensed patents.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses consisted of research and development expenses and general and administrative expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist primarily of direct and indirect costs incurred in connection with our therapeutic discovery efforts and the preclinical and clinical development of our product candidates, as well as the development of our product engine. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct costs include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations (CROs) and other vendors that conduct our clinical trials and preclinical activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of acquiring, developing, and manufacturing clinical trial materials and lab supplies; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments made under third-party strategic agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect costs include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel costs, which include salaries, benefits, and other employee related costs, including stock-based compensation, for personnel engaged in research and development functions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities costs, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as the services are performed or the goods are received. We recognize costs for certain development activities based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our internal management. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued research and development expenses. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are working on multiple research and development programs at any one time, we track our direct costs by the stage of program, clinical or preclinical. In the periods presented, we have not incurred clinical program research and development costs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods when clinical trial expenses are incurred, our direct costs will be broken out between our clinical programs and our preclinical programs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, our internal costs, employees and infrastructure are not directly tied to any one program and are deployed across multiple programs. As such, we do not track indirect costs on a specific program basis.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses may vary significantly based on a variety of factors, such as:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, rate of progress, expense and results of our preclinical development activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">per patient trial costs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of trials required for approval; the number of sites included in the trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients that participate in the trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the countries in which the trials are conducted;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates, particularly in light of the current COVID-19 pandemic environment;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional safety monitoring requested by regulatory agencies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration of patient participation in the trials and follow-up;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and non-U.S. regulators;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant and changing government regulation and regulatory guidance;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional trials requested by regulatory agencies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we establish additional strategic collaborations or other arrangements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work, particularly in light of the current COVID-19 pandemic environment;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to identify and develop additional product candidates and as more of our product candidates move into later stages of clinical development, which typically have higher development costs than those in earlier stages of clinical development due to the increased size and duration of later-stage clinical trials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors. We may never succeed in achieving regulatory approval for any of our product candidates. Further, a number of factors, including those outside of our control, could adversely impact the timing and duration of our product candidates&#8217; development, which could increase our research and development expenses. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel costs, which include salaries, benefits and other employee related costs, such as stock-based compensation, for personnel in our executive, finance, corporate and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; recruiting costs; travel expenses; and facilities-related costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will continue to increase substantially for the foreseeable future as we continue to increase our general and administrative personnel headcount to support personnel in research and development, and to support our operations generally as we increase our research and development activities and activities related to the potential commercialization of our product candidates. We also expect to incur increased expenses associated with operating as a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs, and investor and public relations costs.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Convertible Notes Payable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected on issuance to account for our convertible notes payable (2020 Notes and Gilead Note) at fair value until their settlement. In this reporting period, the change in fair value of our convertible notes payable was recognized through the statement of operations. The 2020 Notes and the Gilead Note settled on the closing of our IPO in October 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of debt issuance costs we incurred to issue the 2020 Notes. The debt issuance costs were expensed on issuance because we elected to record the 2020 Notes at fair value.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income, Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net primarily consists of interest earned on our cash, cash equivalents and investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Three Months Ended September&#160;30, 2020 and 2019</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,486&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,809)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,486)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,904)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,214)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net loss</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,713)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,013)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,700)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the three months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">Direct Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:104%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Indirect Costs:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Personnel</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Facilities, depreciation and other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Total research and development expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">In future periods when clinical trial expenses are incurred, direct costs will be broken out between our clinical programs and our preclinical programs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $16.8 million for the three months ended September&#160;30, 2020, compared to $3.5 million for the three months ended September&#160;30, 2019. The increase of $13.2 million was primarily due to $6.6 million in acquisition costs for our SYK portfolio related to the Gilead Asset Purchase Agreement (See Note 13), an increase of $2.7 million in outside and consulting research expenses, and an increase of $2.0 million in personnel costs primarily attributable to increased research and development personnel headcount, including an increase in stock-based compensation of $0.2 million. Also contributing to this increase in research and development expenses is an increase of $0.5 million in facilities, depreciation and other expenses primarily attributable to the commencement of the lease for our 301 Binney facility (as described below) in March 2020, and an increase of $0.3 million in lab supplies related to increased development activity in connection with our preclinical product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $4.1 million for the three months ended September&#160;30, 2020 compared to $0.8 million for the three months ended September&#160;30, 2019. The increase of $3.3 million was primarily due to $0.6 million in personnel costs, primarily attributable to increased general and administrative personnel headcount to support the growth of our research and development organization, $0.9 million in professional fees primarily attributable to legal and outside consultant costs, $0.9 million in other expenses primarily attributable to employee onboarding costs, and an increase in stock-based compensation of $1.0 million attributable to both the increases in personnel costs and outside consulting services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Convertible Notes Payable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of convertible notes payable of $15.2 million for the three months ended September&#160;30, 2020 was directly attributable to the Company&#8217;s progress towards completing an IPO from the issuance of the 2020 Notes and the Gilead Note through September&#160;30, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense of $3.9 million for the three months ended September&#160;30, 2020 and consists of debt issuance costs that were expensed on issuance of the 2020 Notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income, Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net primarily consists of interest earned on our cash, cash equivalents, and investments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Nine Months Ended September 30, 2020 and 2019</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Nine Months Ended September 30,</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,956&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,960&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,956)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,960)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,996)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,331)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,639)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net loss</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,287)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,652)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,635)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the nine months ended September 30, 2020 and 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Nine Months Ended September 30,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect Costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities, depreciation and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">In future periods when clinical trial expenses are incurred, direct costs will be broken out between our clinical programs and our preclinical programs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $30.1 million for the nine months ended September&#160;30, 2020 compared to $8.7 million for the nine months ended September&#160;30, 2019. The increase of $21.4 million was primarily due to $6.6 million in acquisition costs for our SYK portfolio the Gilead Asset Purchase Agreement (See Note 13), an increase of $5.8 million in outside and consulting research expenses, and an increase of $5.2 million in personnel costs primarily attributable to increased research and development personnel headcount, including an increase in stock-based compensation of $0.5 million.  Also contributing to this increase in research and development expenses is an increase of $1.6 million in facilities, depreciation and other expenses primarily attributable to the commencement of the lease for our 301 Binney facility (as described below) in March 2020, and an increase of $0.7 million in lab supplies related to increased development activity in connection with our preclinical product candidates.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $6.8 million for the nine months ended September&#160;30, 2020 compared to $2.3 million for the nine months ended September&#160;30, 2019. The increase of $4.6 million was primarily due to an increase of $0.7 million in personnel costs primarily attributable to increased general and administrative personnel headcount to support the growth of our research and development organization, an increase of $1.5 million in professional fees primarily attributable to legal and outside consultant costs, an increase of $1.4 million in in other expenses primarily attributable to employee onboarding costs, and an increase in stock-based compensation of $1.2 million attributable to both the increases in personnel costs and outside consulting services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Convertible Notes Payable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of convertible notes payable of $15.2 million for the nine months ended September&#160;30, 2020 was directly attributable to the Company&#8217;s progress towards completing an IPO from the issuance of the Series B Convertible Notes and 2020 Gilead Notes through September&#160;30, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense of $3.9 million for the nine months ended September&#160;30, 2020 consisted of debt issuance costs that were expensed on issuance of the 2020 Notes.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income, Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net primarily consists of interest earned on our cash, cash equivalents, and investments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity, Capital Resources and Plan of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have incurred significant operating losses and negative cash flows from operations. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for several years, if ever. Prior to our IPO, our operations were financed primarily by net proceeds from the sale and issuance of our convertible preferred stock and the 2020 Notes, totaling aggregate gross proceeds of $278.2 million. As of September&#160;30, 2020, we had cash, cash equivalents and short-term investments of $211.3 million, which includes the aggregate net proceeds of $151.3 million we received from the issuance and sale of the 2020 Notes in August 2020. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of our IPO on October 14, 2020, we sold an aggregate of 15,131,579 shares of our common stock including 1,973,684 shares of common stock sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares at a price of $19.00 per share and received approximately $263.9 million in net proceeds after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures related to ENTO, LANRA and KB-0742, and our other research efforts, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are still in the early stages of clinical and preclinical development, and the outcomes of these efforts are uncertain. Accordingly, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration agreements. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise capital when needed, we will need to delay, reduce or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for each of the periods presented: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Nine Months Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">September 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash used in operating activities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash used in investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,311)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net increase in cash and cash equivalents</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,652&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, cash used in operating activities was $22.3 million, which was primarily attributable to our net loss of $55.3 million, partially offset by non-cash charges of $27.1 million and cash provided by changes in our operating assets and liabilities of $5.9 million. Net cash provided by changes in our operating assets and liabilities of $5.9 million during the nine months ended September&#160;30, 2020 consisted of a net increase of $6.2 million in operating liabilities, offset by a $0.3 million increase in operating assets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2019, cash used in operating activities was $10.1 million, which was primarily attributable to our net loss of $10.7 million, as well as cash used in changes in our operating assets and liabilities of $0.1 million, and partially offset by non-cash charges of $0.5 million. Net cash used in changes in our operating assets and liabilities of $0.1 million during the nine months ended September&#160;30, 2019 consisted of an increase of $0.4 million in prepaid expenses and other assets as well as a decrease of $0.2 million in other liabilities, partially offset by a $0.7 million increase in accounts payable and accrued expenses. The increase in accounts payable and accrued expenses was largely due to an increase in external research and development costs. The increase in prepaid expenses and other current assets was due to prepaid rent.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, cash provided by investing activities was $1.5 million, consisting of $45.6 million in investment maturities, partially offset by $41.2 million of net investment purchases and $5.9 million for the purchase of property and equipment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2019, cash used in investing activities was $2.3 million, consisting of $2.3 million for the purchase of property and equipment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, net cash provided by financing activities was $149.4 million, consisting primarily of proceeds from the issuance of convertible notes (2020 Notes and Gilead Note) of $151.3 million and proceeds from the exercise of stock options of $0.4 million.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2019, net cash provided by financing activities was $105.0 million, consisting primarily of net proceeds of $104.9 million from our sales of shares of our Series A convertible preferred stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations and commitments as of December&#160;31, 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less than 1&#160;Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1-3 Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3-5 Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">More than 5&#160;Years</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Represents payments due for our lease of office space in San Mateo, California under an office lease agreement that expires in April 2025.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into additional lease agreements to expand our office and lab spaces.  In March 2020, we entered into an 11-year lease agreement to move our research and development operations to a 40,514 square-foot facility at 301 Binney Street, Cambridge, Massachusetts (301 Binney facility). The initial annual base rent is approximately $4.1 million and such amount will increase by 3% annually on each anniversary of the rent commencement date, which is October 2020.   </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we amended our agreement to extend the lease for our office space in San Mateo, California through April 2025. The initial annual base rent is approximately $0.3 million, and such amount will increase by 3.0% annually on each anniversary of the commencement date.  In July 2020, we expanded to an adjacent suite for an additional lease through April 2025 with similar economic terms.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Gilead Asset Purchase Agreement we entered into in July 2020, we are obligated to make milestone payments upon the achievement of specified regulatory and clinical milestones as well as royalty payments. We have not included future payments under this agreement in the table above since the payment obligations under this agreement are contingent upon future events, such as our achievement of specified milestones or generating product sales. We are currently unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. See the subsection titled &#8220;&#8212;Strategic Agreements&#8212;Gilead Asset Purchase Agreement&#8221; above.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the ordinary course of business with CROs for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are generally terminable by us upon prior notice and, as a result, are not included in the table of contractual obligations above.  Payments due upon termination generally  consist only of payments for services provided and expenses incurred up to the date of termination.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our unaudited condensed financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our unaudited condensed financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results could differ from our estimates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that there have been no significant changes in our critical accounting policies and estimates  from those described under the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in the Prospectus.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and we may remain an emerging growth company for up to five years following the completion of our IPO. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JOBS Act, emerging growth companies  can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued and Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is provided in Note 2 to our condensed financial statements included elsewhere in Item 1 of Part I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_617"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates of our investment portfolio of cash equivalents, short-term investments, and long-term investments. As of September&#160;30, 2020, our cash equivalents and short-term investments consisted of money market funds, certificates of deposit, corporate bonds, and U.S. Treasury securities. As of December&#160;31, 2019, our short-term investments consisted of investments in U.S. Treasury securities, commercial paper, and corporate bonds that have contractual maturities of less than one year. As of September&#160;30, 2020 and December&#160;31, 2019, our long-term investments consisted of investments in U.S. Treasury securities, U.S. agency securities, certificates of deposit, and corporate bonds that have contractual maturities of greater than one year. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates, including changes resulting from the impact of the COVID-19 pandemic. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. If a 100 basis point increase or decrease in interest rates were to have occurred on September 30, 2020, this change would not have had a material impact on our condensed financial statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had issued a $3.0 million promissory note (Gilead Note) with a fixed interest rate of 6%.  The fair value of this promissory note as of September&#160;30, 2020 was determined to be $5.5 million.  Our 2020 Notes do not accrue interest. As of December&#160;31, 2019, we had no debt outstanding.   As our debt securities are not impacted by changes in market interest rates, we are not exposed to interest rate risk with respect to debt.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our employees and our operations are currently located in the United States and our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for research and development services that permit us to satisfy our payment obligations in U.S. dollars (at prevailing exchange rates) but have underlying payment obligations denominated in foreign currencies, primarily including the Euro. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our financial statements, and we have not had a formal hedging program with respect to foreign currency. We believe a hypothetical 100 basis point increase or decrease in exchange rates at September 30, 2020 would not have had a material effect on our condensed financial statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We believe that inflation has not had a material effect on our condensed financial statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_612"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based, in part, upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) of the Exchange Act. An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_626"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_634"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings.  While the outcome of any such proceedings cannot be predicted with certainty, as of September 30, 2020, we were not a party to any litigation or legal proceedings that, in the opinion of our management, are probably to have a material effect on our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of material factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC before making investment decisions regarding our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">To date, we have incurred significant operating losses and negative cash flows from operations, and we will need substantial additional funding.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history and face significant challenges and will incur substantial expenses as we build our capabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We may not realize the benefits of our recent asset acquisition of product candidates from Gilead or any future acquisitions or strategic transactions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our discovery and development activities are focused on novel cancer therapeutics for patients with genetically-defined cancers and it is difficult to predict the time and cost of developing our product candidates and obtaining regulatory approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development involves a lengthy and expensive process with uncertain outcomes, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We may be required by the FDA or similar foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the potential approval and commercialization of our product candidates or of any future product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to successfully identify or develop companion diagnostic tests for our product candidates that require such tests, experience significant delays in doing so, or are unable to obtain any necessary approvals for such tests, we may not be able to obtain approval for our product candidates, may be delayed in doing so, or may not realize the full commercial potential of these product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic could adversely impact our business, including our planned clinical trials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and further improve upon our product engine to expand our pipeline of product candidates with commercial value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">If the market opportunities for our product candidates are smaller than we estimate or if any approval we obtain is based on a narrower definition of the patient population, our revenue potential and ability to achieve profitability will be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial success depends in part on our ability to protect our proprietary technologies and obtain, maintain and enforce our intellectual property, as well as our ability to operate without infringing the proprietary rights of others.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">We rely, and expect to rely in the future, on third parties, including independent clinical investigators and contract research organizations to conduct certain aspects of our preclinical studies and planned clinical trials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Our success is highly dependent on our ability to attract and retain highly-skilled executive officers and employees.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RISK FACTORS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have identified the following material factors that make an investment in our common stock speculative or risky. You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, including our condensed financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making investment decisions regarding our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. The risks described below are not the only ones we face.  Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have marked with an asterisk (*) those risk factors that reflect changes from the similarly titled risk factors included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the Prospectus.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Capital Requirements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant net losses since inception, and we expect to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future.* </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our ongoing operations. We have financed our operations primarily through private placements of our preferred stock and convertible notes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses in each period since we commenced operations in June 2017. For the three months ended September&#160;30, 2020 and 2019, we reported net losses of $39.7 million and $4.0 million, respectively. For the nine months ended September&#160;30, 2020 and 2019, we reported net losses of $55.3 million and $10.7 million, respectively. As of September&#160;30, 2020, we had an accumulated deficit of $78.7 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and as we: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct preclinical studies and clinical trials for our current and future product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our research and development efforts, submit INDs and clinically develop our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, negative or mixed clinical trial results, safety issues or other regulatory challenges, the risk of which in each case may be exacerbated by the ongoing COVID-19 pandemic; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure and establish manufacturing capabilities, whether alone or with third parties, to commercialize product candidates for which we may obtain regulatory approval, if any; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain, expand, maintain, enforce and protect our intellectual property portfolio; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, regulatory and scientific personnel; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate as a public company.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop, seek regulatory approval for and potentially market our product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability, if ever, to generate revenue from our product candidates. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not generated any revenue from our product candidates and may never be profitable.* </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from any of our product candidates. We do not expect to generate significant revenue unless or until we successfully complete clinical development and obtain regulatory approval of, and then successfully commercialize, our product candidates. ENTO and LANRA, which we only recently acquired from Gilead in July 2020, are our only product candidates in the clinical stage of development and KB-0742, our only other product candidate, has completed the preclinical stage of development but has not yet entered into clinical trials.  In addition, all of our product candidates will require additional clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. Our ability to generate revenue from our product candidates depends on a number of factors, including, but not limited to: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timely completion of our preclinical studies and planned clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete IND-enabling studies and successfully submit and receive authorizations to proceed under INDs or comparable applications; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are required by the FDA or similar foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the potential approval and commercialization of our product candidates or of any future product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, potency, purity, efficacy and acceptable risk-benefit profile of our product candidates or any future product candidates and such regulatory authorities&#8217; acceptance of our biomarker-driven development strategy (i.e., our pursuit of approval based on a biomarker rather than a specific cancer indication); </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates over or to use in combination with alternative or more established therapies, such as IC and HMAs, to treat AML and MYC-amplified solid tumors and other transcriptionally addicted cancers; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actual and perceived availability, cost, risk profile and side effects and efficacy of our product candidates, if approved, relative to existing and future alternative cancer therapies and competitive product candidates and technologies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices (cGMP); </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient demand for our product candidates and any future product candidates, if approved; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercializing any of our product candidates. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding. If we are unable to raise capital when needed, we would be compelled to delay, reduce or eliminate our product development programs or commercialization efforts.* </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we commence our planned clinical trials and any other future clinical trials, and continue our discovery and preclinical development activities to identify new product candidates, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to incur significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations, and we may need to raise additional funding sooner than expected if we choose to expand more rapidly than we presently anticipate. We cannot be certain that additional funding will be available on acceptable terms, or at all. Further, the duration and severity of the COVID-19 pandemic and its impact on the economy and financial markets in general could adversely affect our ability to raise additional capital. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate our discovery and preclinical development programs or any future commercialization efforts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents, and short-term investments of $211.3 million as of September&#160;30, 2020, which does not include approximately $263.9 million in net proceeds from our IPO completed in October 2020. We believe that, based upon our current operating plan, our existing capital resources will be sufficient to fund our anticipated operations into 2024, including through the completion of our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC in AML patients with NPM1 mutations and the completion of our planned Phase 1/2 clinical trial of KB-0742 for the treatment of advanced solid tumors. However, we have based this estimate on our current development plans and assumptions that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control, including as a result of the COVID-19 pandemic. In any event, our future capital requirements will depend on many factors, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC for the treatment of AML patients with NPM1 mutations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our planned Phase 1/2 clinical trial of KB-0742;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we pursue clinical development of LANRA;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of discovery, preclinical development and clinical trials for our other product candidates; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates and any required companion diagnostic; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we develop, in-license or acquire other pipeline product candidates or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with completing any post-marketing studies or trials required by the FDA or other regulatory authorities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, enforcing and protecting our intellectual property rights and defending intellectual property-related claims; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to the extent we pursue strategic collaborations, including collaborations to commercialize any of our product candidates or any companion diagnostic collaborations, our ability to establish and maintain collaborations on favorable terms, if at all. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require additional capital to complete our planned clinical development programs for our current product candidates to obtain regulatory approval. Any additional capital-raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future product candidates, if approved.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of our Product Candidates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history and face significant challenges and will incur substantial expenses as we build our capabilities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in June 2017 and acquired certain rights to ENTO and LANRA and other orally bioavailable small molecule SYK inhibitors from Gilead in July 2020. We have a limited operating history and are subject to the risks inherent in a growing company, including, among other things, risks that we may not be able to hire sufficient qualified personnel and establish operating controls and procedures. We currently do not have complete in-house resources to enable our operations. As we build our own capabilities, we expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties related to the evolving effects of the COVID-19 pandemic and those described herein. If we are unable to build our own capabilities, our operating and financial results could differ materially from our expectations, and our business could suffer.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although ENTO and LANRA have been evaluated in Phase 1 and 2 clinical trials by Gilead, as a company, we have not progressed any product candidates into the clinic. We cannot be certain that our planned clinical trials of our product candidates, including our planned Phase 1/2 clinical trial of KB-0742, our only internally generated product candidate, will begin or be completed when we currently expect, or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of our recent asset acquisition from Gilead or any future acquisitions or strategic transactions.* </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently completed the transfer from Gilead of a portfolio of selective, orally bioavailable small molecule SYK inhibitors, including ENTO and LANRA, that we acquired from Gilead in July 2020, and it is possible that we will encounter challenges with integrating the data and technology, along with the related regulatory materials,  related to these acquired product candidates into our business.  In such event, our clinical development plans related to the acquired SYK product candidates, including our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC in AML patients with NPM1 mutations, or the associated or subsequent regulatory filings, could be delayed or otherwise adversely affected. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our recent SYK portfolio acquisition from Gilead, and any future acquisitions or strategic transactions depends on the risks and uncertainties involved including, but not limited to, the following:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated liabilities related to acquired assets, companies or joint ventures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retention of key employees;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible write-offs or impairment charges relating to acquired assets, businesses or joint ventures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future acquisitions or dispositions could also result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our discovery and development activities are focused on novel cancer therapeutics for patients with genetically-defined cancers and it is difficult to predict the time and cost of product candidate development and obtaining regulatory approval. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discovery and development of novel cancer therapeutics by targeting dysregulated transcription using a biomarker-driven precision medicine strategy is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Although we believe, based on our preclinical work, and the data for ENTO and LANRA generated in clinical trials conducted by Gilead, the TRNs targeted by our programs drive oncogenic activity, future clinical results may not confirm this hypothesis or may only confirm it for certain mutations or certain tumor types. The patient populations for our product candidates are limited to those with cancers that exhibit specific target mutations that we believe serve as a genomic biomarker of transcription factor dysregulation, and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify those patients who have the targeted mutations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific genetic alterations respond to our product candidates and developing or otherwise obtaining access to satisfactory companion diagnostics to identify such genetic alterations. Furthermore, even if we are successful in identifying patients, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation type and commercialize our products and achieve profitability. In any event, we do not know if our approach of treating patients with genetically defined cancers will be successful, and if our approach is unsuccessful, our business will suffer and you may lose all or part of your investment.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are pursuing a biomarker-driven development strategy (i.e., pursuing regulatory approval based on efficacy of our product candidates in a biomarker-defined subset of patients with a specific cancer indication, rather than all such patients who suffer from a specific cancer indication). There is currently a limited number of approved biomarker-specific therapies. We may not receive approval for a biomarker-specific indication or may be delayed in receiving biomarker-specific approval. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of ENTO or our other product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict when or if our products candidates will prove effective or safe in humans or will obtain marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim or preliminary results of a clinical trial do not necessarily predict final results. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there can be no assurance that the encouraging safety and efficacy data observed in the Phase 1b/2 clinical trial of ENTO in 148 AML patients, which was conducted by Gilead, will be indicative of the safety or efficacy results that we will observe in our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC in AML patients with NPM1 mutations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to obtain marketing approval or commercialize our product candidates, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards (IRBs)/ethics committees (ECs) may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts with prospective trial sites;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials for our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials, delay clinical trials or abandon product development programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials for our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition for clinical trial participants from investigational and approved therapies may make it more difficult to enroll patients in our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or potential future third-party collaborators may fail to obtain the clearance or approval of any required companion diagnostic on a timely basis, or at all;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply with regulatory requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to suspend or terminate clinical trials for our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable or unexpected side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs/ECs to suspend or terminate the trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials for our product candidates may be greater than we anticipate;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials for our product candidates may be insufficient or inadequate and result in delays or suspension of our clinical trials; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or potential future third-party collaborators may fail to receive regulatory approval of a companion diagnostic for one or more of our product candidates, or for use with a marketed product.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our planned preclinical studies or clinical trials will begin on a timely basis or at all, will need to be restructured or will be completed on schedule, or at all. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any delays in the commencement or completion, or termination or suspension, of our planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can initiate clinical trials of a product candidate in any indication, we must submit the results of preclinical studies to the FDA along with other information, including information about the product candidate&#8217;s chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory submission</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under which we must receive authorization to proceed with clinical development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from the FDA of ENTO or of any other product candidate in any indication, we must conduct extensive clinical studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we expect to rely in part on preclinical, clinical and quality data generated by our CROs and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties&#8217; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. We have two clinical stage product candidates, ENTO and LANRA, which we only recently acquired from Gilead in July 2020 pursuant to the Gilead Asset Purchase Agreement. We are required to submit an IND to the FDA, which must become effective prior to initiating any clinical trials in the United States, for our other product candidates, including KB-0742.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may require us to conduct additional preclinical studies for any product candidate before it allows us to initiate clinical trials under any IND, which may lead to additional delays and increase the costs of our preclinical development programs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delays in the commencement or completion of our planned or future clinical trials could significantly affect our product development costs. We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to ENTO, the FDA or applicable European regulatory agencies disagreeing as to the proposed design or implementation of our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining FDA or foreign regulatory authority authorization to commence a clinical trial or reaching a consensus with the FDA or a foreign regulatory authority on clinical trial design;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failing to obtain regulatory clearance or approval of companion diagnostics we may use to identify patients for enrollment in our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining approval from one or more IRBs/ECs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IRBs/ECs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to clinical trial protocol;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failing to manufacture or obtain sufficient quantities of product candidate or, if applicable, combination therapies for use in clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up, including patients failing to remain in our trials due to movement restrictions, health reasons or otherwise resulting from the evolving effects of the COVID-19 pandemic;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients choosing an alternative treatment, or participating in competing clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients experiencing severe or unexpected drug-related adverse effects;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selecting or being required to use clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA or applicable foreign regulatory authorities to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions to operations of clinical sites, manufacturers, suppliers, or other vendors from a health epidemic or pandemic, such as the COVID-19 pandemic;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (GCP) or other regulatory requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">us, or our third-party contractors not performing data collection or analysis in a timely or accurate manner or improperly disclosing data prematurely or otherwise in violation of a clinical trial protocol;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; or</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by the COVID-19 pandemic, which may increase the likelihood that we encounter difficulties or delays in initiating, enrolling, conducting or completing our planned clinical trials.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our proposal for new or emerging biomarker focused endpoints may result in data that is not accepted by certain regulatory bodies or industry professionals, or if such endpoints are later found to be insufficient to establish clinical efficacy, may require us to change the design of our clinical trials. With respect to our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC for the treatment of newly diagnosed AML patients with NPM1 mutations, we plan to establish measurable residual disease (MRD) negative CR as the primary endpoint, in support of regulatory approval. MRD has only recently emerged as a surrogate endpoint for progression free survival in hematological malignancies, and while regulatory approvals on the basis of MRD status have been granted in acute lymphocytic leukemia and Chronic Lymphocytic Leukemia (CLL), to date there has not been any regulatory approval on the basis of MRD status in AML. Further, we have not yet discussed the proposed trial protocol with the FDA, including the proposal to use MRD negative CR as a biomarker-driven primary endpoint or the potential of this trial to serve as a registrational trial to support submission of a New Drug Application (NDA). Our proposed trial design for our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC for the treatment of AML patients with NPM1 mutations, including establishing MRD negative CR rate as the primary endpoint, may not enable an expeditious path to regulatory approval in newly diagnosed AML patients with NPM1 mutations and may not be accepted by the FDA or otherwise be sufficient to obtain regulatory approval, and we may be required to change the design of this trial, including with respect to the primary endpoint, in order to commence this clinical trial or potentially obtain regulatory approval for this indication, which could result in a longer time to potential commercialization of ENTO in the United States, if approved and commercialized at all, could increase the costs of development and could harm our competitive position in the marketplace.  In addition, even if regulatory agencies accept MRD negative CR as a primary endpoint and we are allowed to proceed with our planned Phase 2/3 clinical trial, failure of the industry to adopt MRD negative CR rate as a valid or meaningful endpoint for an AML therapeutic may result in our clinical trial results being discounted or disregarded by industry professionals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs/ECs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a pharmaceutical, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs/ECs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our current or future scientific advisors or consultants who receive compensation from us may become investigators for our future clinical trials. Under certain circumstances, we may be required to report some of these relationships to the FDA. Although we expect any such relationships to be within the FDA&#8217;s guidelines, the FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of ENTO or our other product candidates. If we experience delays in the completion of, or termination of, any clinical trial of ENTO or any other product candidate, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenues will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and generate revenues which may harm our business, financial condition, results of operations and prospects significantly.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in enrolling patients in our planned clinical trials, regulatory approval could be delayed or prevented.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue our planned clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA. In addition, some of our competitors may have ongoing clinical trials for product candidates that would treat the same or a similar patient population as we plan to treat with ENTO or our other product candidates in clinical trials, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the clearance of the IND for KB-0742, we plan to initiate a Phase 1/2 clinical trial of KB-0742 in cancer patients to evaluate its safety, PK and PD across multiple dose levels and dosing schedules. Following identification of a recommended Phase 2 clinical trial dose and schedule, we intend to enroll expansion cohorts in one or more biomarker-defined patient populations with transcriptionally addicted cancers, beginning with MYC-amplified solid tumors independent of histology. However, if the safety, PK or PD data from the first stage of the clinical trial suggest our initial doses are suboptimal, this would likely delay initiation of the expansion cohorts. We may also seek to enroll an additional cohort of soft tissue sarcoma patients with transcription factor fusions and patients with chordoma, an incurable solid tumor addicted to the brachyury transcription factor, in order to further demonstrate proof of concept for KB-0742.  While we believe it is feasible to enroll such patients at major academic centers, patients with these tumor types are relatively rare, and we may unable to enroll or maintain a sufficient number of these patients in any such additional cohort, which could adversely affect our development and registration strategy for KB-0742.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is also affected by other factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severity of the disease under investigation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit clinical trial investigators of appropriate competencies and experience;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the incidence and prevalence of our target indications;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; awareness of, and perceptions as to the potential advantages and risks of our product candidates in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invasive procedures required to enroll patients and to obtain evidence of the product candidate&#8217;s performance during the clinical trial;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability and efficacy of approved medications for the disease under investigation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eligibility criteria defined in the protocol for the trial in question;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are subject to a partial or full clinical hold on any of our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reluctance of physicians to encourage patient participation in clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patient consents; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical trial sites for prospective patients; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to timely activate clinical trial sites during the ongoing COVID-19 pandemic and other delays and complications resulting from the evolving effects of the COVID-19 pandemic. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll the required number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse side effects or other safety risks associated with ENTO or our other product candidates or future product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials or abandon further development, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with pharmaceuticals generally, side effects and adverse events (AEs) associated with ENTO have been observed. In ENTO&#8217;s first clinical trial in healthy volunteers and subjects with rheumatoid arthritis (RA), the most frequently reported AEs were headache, nausea and constipation without any clear relationship to dose level. Mildly increased liver enzymes were observed in some healthy subjects and patients with RA. In a clinical trial of ENTO in more than 700 patients with hematologic malignancies, predominantly with B cell malignancies such as CLL, the most frequently reported treatment-related AEs, with an incidence greater than 10% in CLL patients, were fatigue, nausea, diarrhea, headache, decreased appetite and fever. AEs of Grade 3 or greater in at least 5% of patients included neutropenia, elevated liver enzymes and electrolyte abnormalities. ENTO has also been tested in a Phase 1b/2 clinical trial in 148 AML patients. Early ENTO safety studies were conducted in relapsed patients as monotherapy and in combination with IC and in newly diagnosed elderly patients in combination with HMAs such as azacytidine or decitabine. Aside from the AEs typical of the disease and IC, such as cytopenias and fever, the main AEs attributable to ENTO included diarrhea, nausea, and febrile neutropenia. Results of our planned clinical trials, including those for ENTO and KB-0742, could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could result in the delay, suspension or termination of clinical trials by us or the FDA or foreign regulatory authorities for a number of reasons. Additionally, due to the high mortality rates of the cancers for which we are initially pursuing development of ENTO and KB-0742, a significant percentage of patients in these clinical trials may die during a trial, which could impact development of these product candidates. If we elect or are required to delay, suspend or terminate any clinical trial, the commercial prospects of our product candidates will be harmed and our ability to generate product revenues from this product candidate will be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of our product candidates. Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for our product candidates, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Many drugs that initially showed promise in early stage testing have later been found to cause side effects that prevented further development. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of our product candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantly.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if any of our product candidates receive marketing approval, and we or others later identify undesirable side effects caused by treatment with such drug, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw or limit their approval of the product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to recall a product or we may voluntarily remove it from the marketplace;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered to patients or conduct additional clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to implement a Risk Evaluation and Mitigation Strategy (REMS) or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing or promotion of the particular product or the manufacturing processes for the product or any component thereof;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the drug could become less competitive; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates, if approved, and could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time in the future, we may publicly disclose preliminary, interim or topline data from our planned clinical trials. These updates are typically based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we may report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, such data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim, topline, or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim, topline or preliminary data by us or by our competitors in the future could result in volatility in the price of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim, topline or preliminary data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, ENTO or any other product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop companion diagnostic tests for our product candidates that require such tests, experience significant delays in doing so, or are unable to obtain any necessary FDA approvals of such tests,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">we may not be able to obtain approval for our product candidates, may be delayed in doing so, or may not realize the full commercial potential of these product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In developing a product candidate for certain indications, we may decide to use a biomarker-based test to identify patients for enrollment and, or, monitor patients in clinical trials.  For example, we plan to use a biomarker-based test to identify patients for enrollment in our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC for the treatment of AML patients with NPM1 mutations.  If the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication.  The FDA generally requires contemporaneous approvals of a new companion diagnostic with the proposed therapeutic. To date, the FDA has required premarket approval of all companion diagnostics for cancer therapies.  As such, if a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to regulatory approval or clearance requirements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop, either by ourselves or with collaborators, companion diagnostic tests for our product candidates for certain indications, which may include ENTO for the treatment of AML patients with NPM1 mutations. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companion diagnostics are regulated as medical devices, and we</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have no prior experience with medical device or diagnostic test development. If we choose to or are required to develop and seek FDA approval for companion diagnostic tests on our own, we will require additional personnel. We may rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates that require such tests. If these parties are unable to successfully develop companion diagnostics for these product candidates, or experience delays in doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of these product candidates may be adversely affected, these product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these products that obtain marketing approval. In the event a satisfactory companion diagnostic is not commercially available for use with ENTO for the treatment of AML patients with NPM1 mutations, we plan to pursue co-development of a companion diagnostic with ENTO, and would plan to initially develop a prototype companion diagnostic for use as a clinical trial assay to confirm the presence of NPM1 mutations in AML patients in our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC. Any failure to successfully develop this companion diagnostic, if required, may cause or contribute to delayed enrollment of this trial, and may prevent us from initiating the registrational clinical trial of ENTO as well as ultimately seek approval for ENTO in AML patients with NPM1 mutations. As a result, our business, results of operations and financial condition could be materially harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic could adversely impact our business, including our planned clinical trials. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic in the United States and in other countries in which we have planned clinical trials and where our current or future third party manufacturers or supply chain vendors operate, could cause significant disruptions that could severely impact our business and our planned clinical trials, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in screening and enrolling patients in our planned clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability or unwillingness of subjects to travel to the clinical trial sites;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in data collection and analysis and other related activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased implementation of protocol-required clinical trial activities and quality of source data verification at clinical trial sites;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials and our other research and development activities, including because of sickness of employees or their families or mitigation measures such as lock-downs and social distancing;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, delays, or to discontinue the clinical trials altogether;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA or foreign regulatory authorities to accept data from clinical trials in affected geographies; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse impacts on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise additional capital when needed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such disruptions could impede, delay, limit or prevent completion of our preclinical studies or commencement or the continuation of planned or other future clinical trials and ultimately lead to the delay or denial of regulatory approval of our product candidates, which would seriously harm our operations and financial condition and increase our costs and expenses. In addition, we also experienced delays in our discovery and development activities as a result of the COVID-19 pandemic, primarily due to temporary and partial shutdowns at certain of our CROs that have since resumed normal operations, and due to the California and Massachusetts stay-at-home orders where our operations are located. Future or revised stay-at-home orders could result in additional delays or otherwise negatively impact our discovery and development activities. The COVID-19 pandemic could also affect the business of the FDA or other health authorities which could result in delays in meetings related to planned clinical trials and ultimately of reviews and approvals of our product candidates. Moreover, to the extent the evolving effects of the COVID-19 pandemic adversely affect our business and financial condition, they may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8220;Risk Factors&#8221; section.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to rapidly evolve. The extent to which the COVID-19 pandemic may impact our business, preclinical development activities and planned clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate duration and severity of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and further develop our product engine to expand our pipeline of product candidates with commercial value.* </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to use our product engine to further develop our pipeline of product candidates and progress these product candidates through clinical development and ultimately achieve approval for the treatment of various cancers by focusing on dysregulated transcription factors and the TRNs through which they drive oncogenic activity. The discovery and development activities that we are conducting may not be successful in developing product candidates that are useful in treating cancer or other diseases. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to an internally developed product candidates, our research and development efforts to date have resulted in our discovery and preclinical development of KB-0742 as well as four early-stage discovery programs. KB-0742 may not be safe or effective as a cancer treatment and, with respect to our early-stage discovery programs, we may not identify suitable product candidates for preclinical or clinical development. Our product engine may not be successful in further developing our pipeline of product candidates. For example, we may not be successful in identifying novel product candidates that can selectively modulate oncogenic TRNs. Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future, which likely would result in significant harm to our financial position and adversely affect our stock price.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a company, we have not conducted any clinical trials to date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our management team has extensive experience conducting clinical trials, we have not as a company conducted any clinical trials to date. We therefore cannot be certain that our planned clinical trials will begin or be completed on time, or at all. In addition, the ongoing COVID-19 pandemic may create additional challenges in conducting such clinical trials. Moreover, we currently do not have complete in-house resources to enable our operations, including our planned clinical trials, and we may not be able to hire sufficient qualified personnel to support our planned clinical trials. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, large-scale clinical trials require significant financial and management resources and reliance on third-party clinical investigators, CROs and consultants. Relying on third-party clinical investigators, CROs and consultants may force us to encounter delays that are outside of our control. We may be unable to identify and contract with sufficient investigators, CROs and consultants on a timely basis, or at all. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Since the number of patients that we plan to dose in our planned Phase 1/2 clinical trial of KB-0742 will likely be small relative to a later-stage clinical trial, the results from such clinical trial, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder our efforts to further develop and obtain regulatory approval for this product candidate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our planned Phase 1/2 clinical trial of KB-0742, we plan to evaluate the safety, PK and PD profile of KB-0742 in patients with advanced solid tumors, and define an optimal dose and schedule for expansion cohorts in cancer patients with MYC-amplified solid tumors and other transcriptionally addicted cancers. The number of patients we would expect to enroll in this clinical trial is likely to be significantly smaller than the number of patients that would need to be enrolled in a registrational or other late-stage clinical trial.  The results of clinical trials with smaller sample sizes, such as our planned Phase 1/2 clinical trial of KB-0742, can be disproportionately influenced by various biases associated with the conduct of small clinical trials, such as the potential failure of the smaller sample size to accurately depict the features of the broader patient population, which limits the ability to generalize the results across a broader community, thus making the clinical trial results less reliable than clinical trials with a larger number of patients. As a result, there may be less certainty that such product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials of KB-0742, we may not achieve a statistically significant result or the same level of statistical significance, if any, that we might have anticipated based on the results observed in our initial Phase 1/2 clinical trial. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Product Candidates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, it will adversely affect our revenue potential and ability to achieve profitability.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total addressable market opportunity for ENTO and our other product candidates will ultimately depend upon, among other things, the final label for each product candidate, acceptance by the medical community and patient access, drug and any related companion diagnostic pricing and reimbursement. The number of patients in our targeted commercial markets and elsewhere may turn out to be lower than expected, patients may not be amenable to treatment with our products, or new patients may become increasingly difficult to identify, all of which would adversely affect our results of operations and our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for certain of our product candidates may be relatively small as they be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer therapies are sometimes characterized as first line, second line, or third line, and the FDA often approves new therapies initially only for a particular line of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. Although we plan to initiate a registrational Phase 2/3 clinical trial of ENTO in combination with IC for the treatment of newly diagnosed AML patients with NPM1 mutations, in some instances we may initially seek approval of our product candidates as a second- or third-line therapy. Subsequently, for those product candidates that prove to be sufficiently safe and beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved as a second or third or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of both the number of people who have the cancers we are targeting, who may have their tumors genetically sequenced, as well as the subset of people with these cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of the cancers that we are targeting. Consequently, even if our product candidates are approved for a second or third line of therapy, the number of patients that may be eligible for treatment with our product candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each such tumor type.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates are approved, they may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments, as well as other perceived advantages;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval, availability, market acceptance, and reimbursement of any companion diagnostic;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of the product candidate as well as competitive products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which the product candidate is approved;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the use of our product candidates, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required of alternative treatments and competitor products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer the product candidate for sale at competitive prices;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by hospital pharmacy and therapeutics committees in the U.S., E.U., and other countries;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of the approved product candidate for use as a combination therapy;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable publicity relating to our products or product candidates or similar approved products or product candidates in development by third parties; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval of other new therapies for the same indications.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization and have no experience as a company in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing or distribution capabilities and have no experience as a company in marketing products. We currently intend to build a commercial infrastructure to support sales of our product candidates. We expect to manage sales, marketing and distribution through internal resources and third-party relationships. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. While we may commit significant financial and management resources to commercial activities, we will also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue arrangements with third-party sales, marketing, and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain such arrangements on favorable terms or if at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA, EMA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA, EMA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement policies, third-party reimbursement practices, or health care reform initiatives, which could harm our business.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be covered and reimbursed by third-party payors. If coverage is not available, or is available only to limited indications or strict coverage criteria, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new drugs will be covered and reimbursed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Centers for Medicare &amp; Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> responsible for administering the Medicare program, determines </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether and to what extent a new product will be covered and reimbursed under Medicare. One third-party payor&#8217;s determination to provide coverage for a drug product, however, does not assure that other payors will also provide coverage for the product. As a result, the coverage determination process is often time-consuming and costly. This process may require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of pharmaceutical products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product candidates. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a large number of pharmaceutical and biotechnology companies developing or marketing targeted treatments for cancer that would be competitive with the product candidates we are developing, if our product candidates are approved. Many of these companies are developing cancer therapeutics that are also kinase inhibitors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are successful in developing ENTO, our lead product candidate, it may compete against product candidates that are currently in clinical development to the extent any such candidates are approved, including: (i) HMPL-523, a SYK inhibitor being developed by Hutchison Medipharma Ltd. that is in Phase 1 evaluation in hematologic malignancies; (ii) product candidates in early clinical development that target the interaction between MLL and MENIN in MLL-r and AML patients with NPM1 mutations, which, if approved, could compete with ENTO, including (a) SNDX-5613, being developed by Syndax Pharmaceuticals, Inc. in a Phase 1 clinical trial as monotherapy in relapsed or refractory AML, and (b) KO-539, being developed by Kura Oncology, Inc. in a Phase 1 clinical trial as monotherapy in relapsed or refractory AML; and (iii) product candidates that may compete with ENTO by addressing the subset of AML patients with FLT3 mutations and are currently in development in combination with FLT3 inhibitors, including (a) venetoclax, a BCL-2 inhibitor being developed by Abbvie, (b) CPX-351, a liposomal formulation of daunorubicin and cytarabine being developed by Jazz Pharmaceuticals, and (c) CC-90009, a cereblon E3 ligase modulator being developed by Bristol-Myers Squibb.  If we choose to develop, and are successful in developing LANRA as a follow-on compound to ENTO, we expect that LANRA would face competition from the same sources.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are successful in developing KB-0742, it may compete against various multi-CDK inhibitors that are currently in early-stage clinical development, including: AZD4573, being developed by AstraZeneca; TP-1287 (Alvocidib), being developed by Tolero Pharmaceuticals; CYC-065, being developed by Cyclacel Pharmaceuticals; Zotiraciclib, being developed by the National Cancer Institute; Dinaciclib, being developed by Merck &amp; Co.; and Voruciclib, being developed by MEI Pharma. We also expect it to compete against VIP152, a PTEFb/CDK9 inhibitor in early-stage clinical development by Vincera Pharma, Inc., and PRT2527, a CDK9 inhibitor in preclinical development by Prelude Therapeutics.   </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that our product candidates, if approved, will compete with more established therapies, such as IC and HMAs to treat AML and other agents to treat MYC-amplified solid tumors and other transcriptionally addicted cancers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing and selling approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and sales and marketing personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are approved for broader indications or patient populations, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other marketing approval for their products more rapidly than any approval we may obtain for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. Generic products are currently on the market for some of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over any competitive generic products. The key competitive factors affecting the success of ENTO are likely to be its efficacy, safety, scope and limitations of marketing approval, and availability of reimbursement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek marketing approvals of our product candidates outside of the United States and, accordingly, we may be subject to additional risks related to operating in foreign countries if we obtain the necessary foreign marketing approvals, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements in foreign countries, for example, no country other than the United States has a pathway for accelerated drug approval and so obtaining regulatory approvals outside of the United States will take longer and be more costly than obtaining approval in the United States; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing pricing, payment and reimbursement regimes;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties staffing and managing foreign operations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the U.S. Foreign Corrupt Practices Act (FCPA) or comparable foreign regulations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company, we have not conducted any clinical trials of any product candidates, nor have we managed the regulatory approval process with the FDA or any other regulatory authority. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable, and requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can and often changes during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in FDA policy during the period of drug development, clinical trials and FDA regulatory review.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are developing and seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of approving a NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future conduct clinical trials for our product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future choose to conduct one or more clinical trials outside the United States, including in Europe. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the sole basis of foreign data unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence; and (iii) the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Otherwise, for studies that are conducted at sites outside of the United States and not subject to an IND and which are intended to support a marketing application, the FDA requires the clinical trial to have been conducted in accordance with good clinical practice (GCP) requirements and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following any regulatory approvals, our products will be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or the rejection of product approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the products, manufacturers or manufacturing process;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures, detentions or import bans;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, the current U.S. administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are required by the FDA to obtain approval of a companion diagnostic test in connection with approval of any of our product candidates, and we do not obtain or face delays in obtaining FDA approval of a diagnostic device, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safe and effective use of any of our product candidates depends on an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostic that is not otherwise commercially available, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates if at all. If a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to regulatory approval requirements. The process of obtaining or creating such diagnostic is time consuming and costly.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companion diagnostics are developed in conjunction with clinical programs for the associated therapeutic product candidate and are subject to regulation as medical devices by the FDA and comparable regulatory authorities, and, to date, the FDA has required premarket approval of all companion diagnostics for cancer therapies. The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority requires approval of a companion diagnostic for any of our product candidates, whether before or after it obtains marketing approval, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such product candidate. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval or continued marketing of such product candidate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidate, if approved, on a timely or profitable basis, if at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products through April 2020. On March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint, such as MRD negative CR, or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from changes to current regulations and future legislation.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. There remain judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have passed. On December 22, 2017, President Trump signed into law federal tax legislation commonly referred to as the Tax Cuts and Jobs Act (Tax Act), which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018 (BBA), among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare Part D drug plans. In December 2018, CMS published a new final rule permitting further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March 2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review the case, although it is unclear when a decision will be made or how the Supreme Court will rule. In addition, there may be other efforts to challenge, repeal or replace the ACA. We are continuing to monitor any changes to the ACA that, in turn, may potentially impact our business in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030 unless additional congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act (CARES Act), which was signed into law in March 2020 and is designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, at the federal level, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. On March 10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, the Trump administration&#8217;s budget proposal for the fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. Further, on July 24, 2020, the Trump administration announced four executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals, including a policy that would tie Medicare Part B drug prices to international drug prices; one that directs HHS to finalize the Canadian drug importation proposed rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada; one that directs HHS to finalize the rulemaking process on modifying the anti-kickback law safe harbors for discounts for plans, pharmacies, and pharmaceutical benefit managers; and one that reduces costs of insulin and epinephrine injections to patients of federally qualified health centers. Although a number of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able attain profitability or commercialize our product candidates. It is possible that additional governmental action is taken to address the COVID-19 pandemic. For example, on August 6, 2020, the Trump administration issued another executive order that instructs the federal government to develop a list of &#8220;essential&#8221; medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and government price reporting, which could expose us to, among other things, criminal sanctions, administrative and civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct our research as well as market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties laws, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, as defined by such law, and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and transfers of value provided during the previous year to certain other healthcare providers, such as physician assistants and nurse practitioners. The information reported is publicly available on a searchable website, with disclosure required annually; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">some state laws that require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; some state laws that require biotechnology companies to report information on the pricing of certain drug products; and certain state and local laws that require the registration of pharmaceutical sales representatives.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including, without limitation, our consulting agreements with certain physicians, who may be in a position to order and/or influence the purchase of our product candidates, if approved, and are compensated in the form of stock or stock options for services provided to us,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are or may become subject to a variety of stringent privacy and data security laws, regulations, policies and contractual obligations related to data privacy and security, and changes in such laws, regulations, policies and contractual obligations and our failure, or any failure by our third-party vendors, collaborators, contractors or consultants, to comply with them could harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain and process, and our third-party vendors, collaborators, contractors and consultants maintain and process on our behalf, a large quantity of sensitive information, including confidential business, personal and patient health information in connection with our preclinical studies and our employees, and are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. Failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations and the legislative landscape is constantly evolving. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. The HHS has the discretion to impose penalties without attempting to first resolve violations. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect. For example, in June 2018 the State of California enacted the California Consumer Privacy Act of 2018 (CCPA), which went into effect on January 1, 2020 and requires companies that process information on California residents to make new disclosures to consumers about their data collection, use and sharing practices, allow consumers to opt out of certain data sharing with third parties and provide a new cause of action for data breaches. Moreover, although the CCPA includes limited exceptions from its prescriptions, including exceptions for personal health information collected by covered entities or business associates subject to HIPAA, among others, the CCPA may regulate or impact our processing of personal information depending on the context. Moreover, certain exceptions built into the CCPA are set to sunset at the end of the 2020, in particular with regard to business contact and employee personal information. It remains unclear what, if any, modifications will be made to this legislation or how it will be interpreted. Additionally, a new ballot initiative, the California Privacy Rights Act or, the CPRA, passed in  November 2020 in California. The CPRA imposes additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, and opt outs for certain uses of sensitive data. It creates a new California data protection agency to enforce the law, and require certain businesses with higher risk privacy and security practices to submit annual audits to the agency on a regular basis. The CPRA may result in broader increased regulatory scrutiny of California for businesses&#8217; privacy and security practices, and could lead to a further rise in data protection litigation. The majority of CPRA provisions go into effect in January 2023, and require additional compliance investment and potential business process changes in the meantime.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S. Indeed, a number of state legislatures are considering privacy and/or data protection laws, which could increase our potential liability and adversely affect our business. The interplay of federal and state laws (e.g., in addition to California, Massachusetts and Nevada have adopted laws requiring the implementation of certain security measures to protect personal information, and all 50 states and the District of Columbia, Puerto Rico, the U.S. Virgin Islands and Guam have adopted breach notification laws) may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our customers and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy, security and data use issues in the U.S. continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to products and services could intensify.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in May 2018, the General Data Protection Regulation (GDPR), took effect in the European Economic Area (EEA). The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of European persons, replacing data protection laws issued by each European Union (EU) member state based on the Directive 95/46/EC (Directive). Unlike the Directive, which needed to be transposed at a national level, the GDPR text is directly applicable in each EU member state, resulting in a more uniform application of data privacy laws across the EU. Among other things, the GDPR imposes new requirements regarding the security of personal data and notification of data processing obligations to the competent national data processing authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws. For example, following a decision of the Court of Justice of the EU in October 2015, the transfer of personal data to U.S. companies that had certified as members of the U.S. Safe Harbor Scheme, was declared invalid. In July 2016, the European Commission adopted the EU-U.S. Privacy Shield Framework (the Privacy Shield Framework), which replaced the U.S. Safe Harbor Scheme. On July 16, 2020, the Court of Justice of the European Union issued a decision that declared the Privacy Shield Framework invalid, and will also result in additional compliance obligations for companies that implement standard contractual clauses to ensure a valid basis for the transfer of personal data outside of Europe. Additionally, other countries (e.g., Australia and Japan) have adopted certain legal requirements for cross-border transfers of personal information. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. The GDPR imposes substantial fines for breaches and violations (up to the greater of &#8364;20 million or 4% of our global turnover). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Further, while the United Kingdom enacted the Data Protection Act 2018 in May 2018 that supplements the GDPR and has publicly announced that it will continue to regulate the protection of personal data in the same way post-Brexit, Brexit has created uncertainty with regard to the future of regulation of data protection in the United Kingdom. Some countries also are considering or have passed legislation requiring local storage and processing of data, or similar requirements, which could increase the cost and complexity of delivering our products and services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. In addition to the possibility of fines, lawsuits, regulatory investigations, public censure, other claims and penalties, and significant costs for remediation and damage to our reputation, we could be materially and adversely affected if legislation or regulations are expanded to require changes in our data processing practices and policies or if governing jurisdictions interpret or implement their legislation or regulations in ways that negatively impact our business. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we or our third-party vendors, collaborators, contractors and consultants fail to comply with any such laws or regulations, we may face regulatory investigations, significant fines and penalties, reputational damage or be required to change our business practices, all of which could adversely affect our business, financial condition and results of operations. Any inability to adequately address data privacy or security-related concerns, even if unfounded, or to comply with applicable laws, regulations, standards and other obligations relating to data privacy and security, could result in additional cost and liability to us, harm our reputation and brand, damage our relationships with customers and have a material and adverse impact on our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The withdrawal of the United Kingdom from the European Union, commonly referred to as &#8220;Brexit,&#8221; may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union, result in restrictions or imposition of taxes and duties for importing our product candidates into the European Union, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the European Union.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the result of a referendum in 2016, the United Kingdom left the European Union on January 31, 2020, commonly referred to as &#8220;Brexit.&#8221; Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom will be subject to a transition period until December 31, 2020 (the Transition Period), during which EU rules will continue to apply. Negotiations between the United Kingdom and the European Union are expected to continue in relation to the customs and trading relationship between the United Kingdom and the European Union following the expiry of the Transition Period.  Under the formal withdrawal arrangements between the United Kingdom and the European Union, the parties had until June 30, 2020 to agree to extend the Transition Period if required.  No such extension was agreed prior to such date.  No agreement has yet been reached between the United Kingdom and the European Union and it may be the case that no formal customs and trading agreement will be reached prior to the expiry of the Transition Period on December 31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from EU directives and regulations, Brexit, following the Transition Period, could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the European Union. For example, as a result of the uncertainty surrounding Brexit, the EMA relocated to Amsterdam from London. Following the Transition Period, the United Kingdom will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA and, unless a specific agreement is entered into, a separate process for authorization of drug products, including our product candidates, will be required in the United Kingdom, the potential process for which is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the European Union, or we may incur expenses in establishing a manufacturing facility in the European Union in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the European Union for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA requirements, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, prospects, operating results and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our products and activities may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell access to our products would likely adversely affect our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses, as well as our ability to operate without infringing the proprietary rights of others. If we or our licensors are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims read on the technology. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents, if issued, will not be infringed, designed around, invalidated or rendered unenforceable by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and such protection may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have issued patents in the United States and foreign countries, we cannot be certain that the claims in our other pending U.S. patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the United States Patent and Trademark Office (USPTO), courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our licensors or any of our potential future collaborators will be successful in protecting our technologies and product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications may not result in any patents being issued;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors, many of which have substantially greater resources than we or our licensors have and many of which have made significant investments in competing technologies, may seek or may have already obtained patents that could or will limit, interfere with or block our ability to make, use and sell our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is also expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensors may not identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control, or are subject to certain obligations with respect to, the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license or acquire, including those from our licensors and from third parties. We also may require the cooperation of our licensors, whether current or future, in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.  Furthermore, the terms of the license agreements with some of our licensors may be non-exclusive, such that we would have no rights to enforce the licensed intellectual property against a competitor.   </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, licensors, and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license or otherwise acquire intellectual property rights from our licensors and third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business or our business may otherwise be materially harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we acquired a portfolio of selective, orally bioavailable small molecule SYK inhibitors from Gilead, including ENTO and LANRA, pursuant to the Gilead Asset Purchase Agreement. We also have a non-exclusive worldwide right to certain patents under a license agreement with Harvard University that provides us with rights to use the SMM screen, which is a key component of our product engine.  These agreements impose on us, and we expect that any future license or other agreements where we in-license or acquire intellectual property will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses or acquired intellectual property from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our product candidates in the absence of such a license or acquisition. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business, and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing and acquisitions of intellectual property involve complex legal, business and scientific issues. Disputes may arise between us and our existing or future licensors and other third parties regarding intellectual property subject to a license or purchase agreement, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license or purchase agreement and other interpretation-related issues;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technology and processes infringe intellectual property of the licensor or other third party that is not subject to the license or purchase agreement;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patents and other rights to third parties;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of the licensed or acquired technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of termination;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to transfer or assign the license or purchase agreement; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and their affiliates and sublicensees and by us and our partners and sublicensees.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property, or increase what we believe to be our financial or other obligations under the relevant agreement. And if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of the patent protection we have, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the existence, issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our product candidates or that effectively prevent others from commercializing competitive product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the scope of claims in a patent application can be significantly reduced before any claims in a patent issue, and claim scope can be reinterpreted after issuance. Even if patent applications we currently have issue as patents in the future, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any patents that we have may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner, which could materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may not cover our product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review (PGR), and inter partes review (IPR), or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity of our patents, for example, we cannot be certain that there is no invalidating prior art, of which we or third parties from whom we acquired our patents, their counsel, and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. There is also no assurance that there is not prior art of which we or third parties from whom we acquired patents and patent applications are aware, but which we or the third parties do not believe affects the validity or enforceability of a claim in our patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of patent rights, loss of exclusivity or patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates may be dependent on our licensors and third parties.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects as to form in the preparation or filing of our owned or in-licensed patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our current or future licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our owned or in-licensed patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a licensee of third parties, whether currently or in the future, we rely and may rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under in-license agreements. We have not had, do not have, and may not have in the future, primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, whether current or future, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents, and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fails to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. Furthermore, the terms of the license agreements with some of our licensors may be non-exclusive, such that we would have no rights to enforce the licensed intellectual property against a competitor.  In such cases, the licensors to our non-exclusive licenses may offer licenses to our competitors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to us assuming control over patent prosecution.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology acquired or licensed from various third parties, including our licensors, whether currently or in the future, may be subject to retained rights. Our licensors, whether current or future, may often retain certain rights under their agreements with us, including the right to use the underlying technology for use in fields other than the fields licensed to us or for use in noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidate.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop products that are similar to our product candidates but that are not within the scope of the claims of the patents that we own or license;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, third parties from whom we acquired intellectual property, or our licensors might not have been the first to make the inventions covered by the issued patents or patent application that we own or license;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, third parties from whom we acquired intellectual property, or our licensors might not have been the first to file patent applications directed to certain of our inventions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, inter partes review proceedings and post-grant review proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by development or commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. As such, we may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our product candidates.  We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in costly litigation that may cause negative publicity;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause development delays;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or unenforceable or not infringed in a court of law;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject us to significant liability to third parties; or</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although no third party has asserted a claim of patent infringement against us as of the date of this filing, others may hold proprietary rights that could prevent our product candidates from being marketed or could require us to pay significant royalties or other damages. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license, if available, to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits or administrative disputes to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors and other third parties may infringe, misappropriate or otherwise violate our patents, trademarks, copyrights, trade secrets or other intellectual property. To counter infringement, misappropriation or other violations, we may be required to file infringement, misappropriation or other violation claims, which can be expensive and time-consuming and divert the time and attention of our management and business and scientific personnel. In addition, many of our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or service. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their patents or their other intellectual property, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. Similarly, third parties may initiate legal proceedings against us seeking a declaration that certain of our intellectual property is not infringed, invalid or unenforceable. The outcome of any such proceeding is generally unpredictable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. If a defendant were to prevail on a legal assertion of invalidity or unenforceability of our patents covering one of our product candidates, we could lose at least a part, and perhaps all, of the patent protection covering such a product candidate. Competing drugs may also be sold in other countries in which our patent coverage might not exist or be as strong. If we lose a foreign patent lawsuit, alleging our infringement of a competitor&#8217;s patents, we could be prevented from marketing our drugs in one or more foreign countries. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, third parties may also raise invalidity or unenforceability claims before administrative bodies in the United States or foreign authorities, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation, cancellation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, enablement or written description. Grounds for an unenforceability assertion could be an allegation that someone connected with the prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution of the patent. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, third parties from whom we acquired patents and patent applications and their patent counsel, our licensors, our patent counsel, patent counsel for licensors or third parties, and the patent examiner were unaware during prosecution. Moreover, it is possible that prior art may exist that we, our licensors, or third parties from whom we acquired patents and patent applications are aware of but do not believe is relevant to our current or future patents, but that could nevertheless be determined to render our patents invalid. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Any such loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before the date of filing of our patents could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or the third parties from which we acquired our patents were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or licensors&#8217; patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on legislation and decisions made by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors&#8217; ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, Gilead, or our licensors, may be subject to claims by third parties asserting that our, Gilead&#8217;s, or our licensor&#8217;s, employees or consultants or we, Gilead, or our licensors, have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Some of our employees and consultants, or employees or consultants of Gilead or our licensors, are currently or have been previously employed at universities or at other biotechnology or pharmaceutical companies, or may have previously provided or may be currently providing consulting services to other biopharmaceutical companies, including our competitors or potential competitors. These employees and consultants may have executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such other current or previous employment. Although we, and likely Gilead and our licensors, try to ensure that our and their employees and consultants do not use the proprietary information or know-how of others in their work for us or them, we or they may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of third parties or former employers or former or current clients, or claims that we, Gilead, or our licensors have wrongfully hired an employee from a competitor. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property or personnel or sustain damages. Such intellectual property could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management. Any of the foregoing would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. Likewise, Gilead and our licensors may have been or may be unsuccessful in executing such an agreement with each party who conceived or developed intellectual property that we purchased or licensed, which may result in additional such claims by or against us. In addition, such agreements may not be self-executing such that the intellectual property subject to such agreements may not be assigned to us without additional assignments being executed, and we, Gilead, or our licensors may fail or may have failed to obtain such assignments. In addition, such agreements may be breached. Accordingly, we, Gilead, or our licensors may be forced to bring claims against third parties, or defend claims that they may bring against us, Gilead, or our licensors to determine the ownership of what we regard as our owned or licensed intellectual property. If we, Gilead, or our licensors fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, is limited. In addition, the term of a patent may be reduced if a terminal disclaimer is or was filed in that patent, limiting the term of the patent to that of one or more other patents referenced in the terminal disclaimer.  Even if patents directed to our product candidates are obtained, once the patent term has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents directed to our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our licensors do not obtain patent term extension for our product candidates, our business may be materially harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Amendments). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we or our licensors may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we or our licensors are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we own or have acquired or in-licensed issued patents and have pending patent applications in the United States and certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. Our patent rights protecting ENTO is limited to the United States, Europe, and Hong Kong.  In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our technology in all countries outside the United States or from selling or importing products made using our technology in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our or our licensors patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our or our licensors&#8217; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our or our licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could put our or our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our licensors&#8217; efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants, licensors and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary information will be effective. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we or our licensors do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to rely in the future, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies and planned clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to rely in the future upon third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our preclinical studies and planned clinical trials and to monitor and manage data for our ongoing preclinical and planned clinical programs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Gilead Asset Purchase Agreement, Gilead is responsible for certain ongoing clinical trials of ENTO and LANRA.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely or will rely on these parties for execution of our preclinical studies and planned clinical trials, and may not control, or will only control certain aspects of, their activities. Nevertheless, we are or will be responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. If we are unable to rely on clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have CROs located in China and India.  International tension or conflict with these countries could result in a material disruption in our contractual relationship with the CROs, which could delay or otherwise negatively impact progress in our preclinical programs.  Our CROs have the right to terminate their agreements with us in the event of an uncured material breach, upon clinical trial subject safety concerns, or upon our insolvency. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the COVID-19 pandemic and government measures taken in response have also had a significant impact on our CROs, and they have in the past faced disruptions and in the future may face further disruption which may affect our ability to initiate and complete our preclinical studies and planned clinical trials.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form or seek collaborations or strategic alliances or enter into additional strategic arrangements in the future, which involve risks, and we may not realize the benefits of such collaborations, alliances or strategic arrangements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional strategic arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency, purity and efficacy and obtain marketing approval. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense.  If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. If we are unable to obtain exclusive licenses to any such co-owner&#8217;s interest in such intellectual property, such co-owner may be able to license their rights to third parties, including our competitors, and our competitors could market competing products and technology.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, if we enter into collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to manufacture our clinical product supplies, and we may rely on third parties to produce and process our product candidates, if approved. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to continue to rely for the foreseeable future, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture of any products that we may commercialize. In this regard, while we have purchased initial inventory of active pharmaceutical ingredients (APIs) and product candidates for ENTO and LANRA from Gilead under the Gilead Asset Purchase Agreement, we will need to obtain further supplies of APIs and clinical drug supply for ENTO, KB-0742 and, if we choose to develop it, LANRA, from third-party manufacturers. We do not currently have arrangements in place for redundant supply for APIs or our clinical product candidates.  In addition, we only recently completed the transfer of the SYK technology we acquired from Gilead in July 2020, and we have not yet transferred the manufacturing technology for ENTO or LANRA to a third-party manufacturer. We will need to arrange for the manufacture of these product candidates for use in clinical trials, including our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC in AML patients with NPM1 mutations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to negotiate and maintain contractual arrangements with outside vendors for the supply of our product candidates and we may not be able to do so on favorable terms. In addition, these third-party manufacturing providers may not be able to provide adequate resources or capacity to meet our needs. We expect to initially obtain our supplies from manufacturers on a purchase order basis without long-term supply arrangements in place We have not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates. In the future, we may be unable to enter into agreements with third-party manufacturers for commercial supplies of any product candidate, or may be unable to do so on acceptable terms. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks, including reliance on single sources for product components and lack of qualified backup suppliers for those components purchased from a sole or single source supplier.  We cannot be sure that single source suppliers for our product components will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these components for our intended purpose.  In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier.  The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or other foreign regulatory authorities following inspections that will be conducted after we submit an application to the FDA or other foreign regulatory authorities. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with cGMPs and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, if any third-party manufacturers on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing our product candidates is complex and we may encounter difficulties in production. If we encounter such difficulties, our ability to provide supply of our product candidates for preclinical studies and clinical trials or for commercial purposes could be delayed or stopped. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our product candidates is complex and highly regulated. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to rely on third parties for the manufacture of our product candidates. These third-party manufacturers may incorporate their own proprietary processes into our product candidate manufacturing processes. We will have limited control and oversight of a third party&#8217;s proprietary process, and a third party may elect to modify its process without our consent or knowledge. These modifications could negatively impact our manufacturing, including product loss or failure that requires additional manufacturing runs or a change in manufacturer, both of which could significantly increase the cost of and significantly delay the manufacture of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our product candidates progress through preclinical studies and clinical trials towards approval and commercialization, it is expected that various aspects of the manufacturing process will be altered in an effort to optimize processes and results. Such changes may require amendments to be made to regulatory applications which may further delay the timeframes under which modified manufacturing processes can be used for any of our product candidates and additional bridging studies or trials may be required. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in order to conduct clinical trials of our product candidates, we will need to have them manufactured in potentially large quantities.  Our third-party manufacturers may be unable to successfully increase the manufacturing capacity for any of our clinical drug supplies (including key starting and intermediate materials) in a timely or cost-effective manner, or at all.  In addition, quality issues may arise during scale-up activities and at any other time.  If the third-party manufacturers are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Our Growth, Employee Matters and Other Risks</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have grown rapidly and will need to continue to grow the size of our organization and expand our capabilities, and we may experience difficulties in managing this growth.* </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 1, 2020, we had 61 full-time employees.  As of January 1, 2019, we had nine full-time employees and within the last 12 months, we have expanded our executive team with the additions of our Chief Medical Officer and Executive Vice President, Clinical Development, our Chief Scientific Officer, our Chief Operating Officer and General Counsel, and our Chief Financial Officer. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, clinical operations, manufacturing, regulatory affairs, and, if any of our product candidates receives marketing approval, sales, marketing and distribution. In addition, we do not yet have a self-sufficient accounting and finance group within our company, and have relied and continue to rely on a third-party accounting consulting firm to augment our internal accounting and finance function. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. We have built out our leased office and laboratory space in Cambridge, Massachusetts, which we anticipate occupying in early 2021, and it is possible that we will encounter delays or difficulties with our move to this new facility, including due to the ongoing COVID-19 pandemic, which could negatively impact our operating plans. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth and with building clinical development, manufacturing and internal accounting and finance infrastructure, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we currently rely, and for the foreseeable future will continue to rely, in substantial part on certain third-party contract organizations, advisors and consultants to provide certain services, including assuming substantial responsibilities for the conduct of our planned clinical trials and the manufacture of our current or future product candidates. We cannot assure you that the services of such third-party contract organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by our vendors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any of our product candidates or otherwise advance our business. We cannot assure you that we will be able to properly manage our existing vendors or consultants or find other competent outside vendors and consultants on economically reasonable terms, or at all.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively manage growth and expand our organization, we may not be able to successfully implement the tasks necessary to further develop and commercialize ENTO, KB-0742, our other pipeline product candidates or any future product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our information technology systems, or those used by our third-party CROs or other contractors or consultants, may fail, be disrupted or suffer security breaches, which could result in a material disruption of our discovery and development programs or otherwise materially and adversely affect our business.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our current and future CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, and telecommunication and electrical failures. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our discovery and development programs and our business operations. For example, the loss of data from completed or future preclinical studies and clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates and will rely on third parties to conduct our clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our CROs, contract manufacturing organizations (CMOs) and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, epidemics and pandemics such as the COVID-19 pandemic, and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.* </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Act, as modified by the CARES Act, federal net operating losses incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal net operating losses in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income and taxes may be limited. As a result of our private placements and other transactions that have occurred over the past three years, including our recently completed IPO, we may have experienced, an &#8220;ownership change.&#8221; We may also experience ownership changes in the future as a result of subsequent issuances of our common stock or other shifts in our stock ownership. We anticipate incurring significant additional net losses for the foreseeable future, and our ability to utilize net operating loss carryforwards associated with any such losses to offset future taxable income may be limited to the extent we incur future ownership changes. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California recently imposed limits on the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023. As a result, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could adve</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rsely affect our future cash flows.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As widely reported, global credit and financial markets have experienced extreme volatility and disruptions in the past several years, most recently due to the COVID-19 pandemic, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions, whether due to the evolving effects of the COVID-19 pandemic or otherwise, will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price may decline due in part to the volatility of the stock market and the general economic downturn. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology systems that we or our third-party vendors operate to process, transmit and store electronic information in our day-to-day operations. In addition, the COVID-19 pandemic has intensified our dependence on information technology systems as many of our critical business activities are currently being conducted remotely.  In connection with our discovery and development efforts, we may collect and use a variety of personal data, such as name, mailing address, email addresses, phone number and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Moreover, the prevalent use of mobile devices to access confidential information increases the risk of security breaches. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#8217; personal data could result in significant liability under state (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, state breach notification laws), federal (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HIPAA, as amended by HITECH), and international law (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the GDPR) and may cause a material adverse impact to our reputation, affect our ability to conduct our planned clinical trials and potentially disrupt our business.  In addition, failure to maintain effective internal accounting controls related to security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and subject us to regulatory scrutiny.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the information technology systems of various third parties on which we rely, including our CROs and other contractors, consultants and legal and accounting firms, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication and electrical failures. We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could significantly increase our costs and lead to a potential disruption to our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws, may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the authorized number of directors may be changed only by resolution of the board of directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then-outstanding common stock;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divide our board of directors into three classes;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that special meetings of our stockholders may be called only by the chair of our board of directors, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants; provided these provisions of our amended and restated certificate of incorporation and amended and restated bylaws will not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended (Exchange Act), or any other claim for which the federal courts have exclusive jurisdiction; and provided that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (Securities Act).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action or proceeding asserting a breach of fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or bylaws; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, an active trading market for our shares may not be sustained.  If an active market for our stock does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or to sell their shares at all.  An inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is likely to be volatile. The stock market in general and the market for smaller pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree of success of competitive products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commencement, enrollment or results of clinical trials and preclinical studies of our product candidates or those of our competitors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results from, delays in or termination of clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of, or failure to obtain, regulatory approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower than expected market acceptance of our product candidates following approval, if any, for commercialization;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to develop, acquire or in-license additional technologies or product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rumors or announcements regarding transactions involving our company or product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proposed changes to healthcare laws in the United States or foreign jurisdictions, or speculation regarding such changes;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions or trends in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the societal and economic impact of public health epidemics, such as the ongoing COVID-19 pandemic; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other events or factors, including those described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our officers, directors, and holders of substantially all of our capital stock, stock options and other securities convertible into, exercisable or exchangeable for our capital stock outstanding immediately prior to the closing of our IPO have agreed with the underwriters for our IPO, subject to certain exceptions, not to dispose of or hedge any of common stock or securities convertible into or exchangeable for shares of common stock for a period of 180 days following the date of the final prospectus for our IPO, except with the prior written consent of Goldman Sachs &amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC and Piper Sandler &amp; Co. on behalf of the underwriters. We refer to such period as the lock-up period. When the lock-up period expires, we and our securityholders subject to a lock-up agreement or market stand-off agreement will be able to sell our shares in the public market. In addition, Goldman Sachs &amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC and Piper Sandler &amp; Co. may, in their sole discretion, release all or some portion of the shares subject to lock-up agreements at any time and for any reason. Sales of a substantial number of such shares upon expiration of the lock-up and market stand-off agreements, the perception that such sales may occur, or early release of these agreements, could cause our market price to fall.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herent limitations in our control system, misstatements due to error or fraud may occur and not be detected. In addition, while we have only recently begun to design and implement a risk management program and processes or procedures for identifying and addressing risks to our business in other areas.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and may remain an emerging growth company for up to five full fiscal years following our IPO. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur substantial costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, and particularly after we are no longer an emerging growth company, we incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and will make some activities more time-consuming and costly. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.*</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements we may enter into may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to securities class action litigation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_832"></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is information regarding securities issued and options granted by us during the three months ended September 30, 2020 that were not registered under the Securities Act. Also included is the consideration, if any, received by us, for such securities and options and information relating to the Securities Act, or rule of the SEC, under which exemption from registration was claimed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">In July 2020, we entered into an asset purchase agreement with Gilead Sciences, Inc. (Gilead), pursuant to which we issued to Gilead a $3.0 million principal amount convertible promissory note as partial consideration under an Asset Purchase Agreement between us and Gilead. The Gilead Note accrued interest at a rate of 6% per year, compounded annually, and had a maturity date of July 14, 2022. The Gilead Note provided that, upon the completion of our initial public offering, the Gilead Note would be settled through our payment to Gilead of $6.0 million plus unpaid accrued interest thereon, unless Gilead notified us within a specified time of Gilead&#8217;s election to cause the Gilead Note (including unpaid accrued interest) to be converted into shares of our common stock upon the closing of our initial public offering, with the conversion price being equal to 85% of the initial public </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offering price. In October 2020, Gilead elected to cause the Gilead Note and unpaid accrued interest thereon to be converted into shares of our common stock upon the closing of our initial public offering. Accordingly, upon the closing of our IPO on October 14, 2020, the Gilead Note and accrued interest thereon was converted into 188,567 shares of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">In August 2020, we entered into a note purchase agreement with certain individual and accredited investors, pursuant to which we sold and issued $155.2 million aggregate principal amount of convertible promissory notes (2020 Notes) and received $151.3 million in net cash proceeds after deducting placement agent fees.  The 2020 Notes did not accrue interest and provided for their automatic conversion into shares of our common stock at a price equal to 85% of the initial public offering price upon the closing of our initial public offering. Accordingly, upon the closing our IPO on October 14, 2020, the 2020 Notes automatically converted into 9,610,713 shares of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">During the three months ended September 30, 2020, we granted options to purchase an aggregate of 1,981,549 shares of our common stock, at a weighted-average exercise price of $6.79 per share, and 274,341 shares pursuant to restricted stock awards.  In addition, during this period, we issued 858,386 shares upon the exercise of stock options for aggregate exercise proceeds of $3.6 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The offers, sales and issuances of the securities described in paragraphs (1) and (2) were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) in that the issuance of securities to the accredited investors did not involve a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor under Rule 501 of Regulation D. No underwriters were involved in these transactions.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The offers, sales and issuances of the securities described in paragraph (3) were deemed to be exempt from registration under the Securities Act in reliance on either Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701 or Section 4(a)(2) in that the issuance of securities to the accredited investors did not involve a public offering. The recipients of such securities were our employees, directors or bona fide consultants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions had adequate access, through employment, business or other relationships, to information about us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds from our Initial Public Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced our IPO pursuant to a registration statement on Form S-1 (File No. 333-248925) that was declared effective on October 8, 2020 and registered an aggregate of 15,131,579 shares of our common stock. On October 14, 2020, we completed the closing of our IPO in which we sold 15,131,579 shares of our common stock at a price to the public of $19.00 per share, including 1,973,684 shares sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, for gross proceeds of $287.5 million. Goldman Sachs &amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC and Piper Sandler &amp; Co. acted as joint book-running managers for our IPO.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriting discounts and commissions for the offering totaled approximately $20.1 million. We incurred additional costs of approximately $3.5 million in offering expenses, which when added to the underwriting discounts and commissions paid by us, amounts to total fees and costs of approximately $23.6 million. Thus, net offering proceeds to us, after deducting underwriting discounts and commissions and offering costs, were approximately $263.9 million. No offering costs were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents, primarily bank money market accounts. Through November 15, 2020, we have not used any of the net proceeds from our IPO. We are investing these funds in some combination of short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. We expect to use the net proceeds from our IPO as described under &#8220;Use of Proceeds&#8221; in the Prospectus. We cannot predict with certainty all of the particular uses for the net proceeds from our IPO, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including our ability to access additional financing, the relative success and cost of our research, preclinical and clinical development programs and whether we are able to enter into future licensing arrangements. As a result, our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from our IPO.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_172"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Exhibits. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed as part of this registration statement. </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.857%"><tr><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description Of Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020014473/exhibit31-closing8xkam.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020014473/exhibit31-closing8xkam.htm">Amended and Restated Certificate of Incorporation  (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K, filed with the SEC on October 14, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020014473/exhibit32-8xkxamendeda.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020014473/exhibit32-8xkxamendeda.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Current Report on Form 8-K, filed with the SEC on October 14, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020014248/exhibit41-sx1a1xformof.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020014248/exhibit41-sx1a1xformof.htm">Form of Common Stock Certificate of the registrant (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s Registration Statement on Form S-1 (File No. 333-248925), as amended, filed with the SEC on October 5, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020013757/exhibit42-sx1xamendeda.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020013757/exhibit42-sx1xamendeda.htm">Amended and Restated Investors&#8217; Rights Agreement, by and among the registrant and certain of its stockholders, dated July 1, 2019, as amended on August 20, 2020 (incorporated by reference to Exhibit 4.2 to the registrant&#8217;s Registration Statement on Form S-1 (File No. 333-248925), as amended, filed with the SEC on September 18, 2020).</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex101.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex101.htm">Letter of Agreement, by and between the registrant and Barbara Kosacz, dated July </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex101.htm">15,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex101.htm"> 2020</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020013757/exhibit108-sx1xemploym.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1741830/000162828020013757/exhibit108-sx1xemploym.htm">Letter Agreement, by and between the registrant and Yasir Al-Wakeel, dated August 16, 2020  (incorporated by reference to Exhibit 10.8 to the registrant&#8217;s Registration Statement on Form S-1 (File No. 333-248925), as amended, filed with the SEC on September 18, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="kronq3fy2020ex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex311.htm">Certifica</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex311.htm">tion of Principal Executi</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex311.htm">ve Officer pursuant to Rule 13a-14(a) or Rule 15</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex311.htm">d-14(a) of the Securities Exchange Act of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex311.htm">1934, as </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex311.htm">amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="kronq3fy2020ex312.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="kronq3fy2020ex312.htm">1.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="kronq3fy2020ex312.htm">Certification of Principal Fin</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="kronq3fy2020ex312.htm">ancial Officer pursuant to Rule 13</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="kronq3fy2020ex312.htm">a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="kronq3fy2020ex312.htm">amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kronq3fy2020ex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="id4bb4e4f9863422ab5c3f3e7868262d4_178"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-bottom:9pt;text-align:right"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KRONOS BIO, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 18, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Norbert Bischofberger</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norbert Bischofberger, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 18, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Yasir Al-Wakeel</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yasir Al-Wakeel, BM BCh</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Head of Corporate Development</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>kronq3fy2020ex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4bc65ef4da4941f0860a2d038ae9edb8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">July 15, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barbara A. Kosacz</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28140 Story Hill Lane</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Los Altos Hills, CA</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94022 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Re&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Employment Letter</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dear Ms. Kosacz&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kronos Bio, Inc. (the &#8220;Company&#8221;) is pleased to offer you the position of Chief Operating Officer and General Counsel of the Company, on the following terms and conditions (the &#8220;Agreement&#8221;)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Title&#59; Reporting&#59; Duties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">As Chief Operating Officer and General Counsel, you will perform such duties as are customarily provided by a Chief Operating Officer and General Counsel of a similarly situated company in the United States and shall have such other responsibilities and duties as may be from time to time directed by the Company.  You shall report directly to the Company&#8217;s Chief Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">You shall devote substantially all of your business time, attention and energies to the business and affairs of the Company and shall not during the term of your employment be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage, that will interfere with the performance of your duties or your availability to perform such duties or that will adversely affect, or negatively reflect upon, the Company.  Any such outside business activities that you may wish to pursue during the term of your employment with the Company shall require the prior written consent of the Company&#8217;s Chief Executive Officer. Notwithstanding the foregoing, you may continue to provide the services set forth on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, attached hereto and made a part hereof, in the capacity set forth thereon.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Your duties shall be performed primarily at 1300 S. El Camino Real, Suite 300, San Mateo, CA 94402 or such other place as the parties may agree.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Start Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Your employment shall commence on July 15, 2020, or such other date as may be agreed to by you and the Company (the &#8220;Start Date&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You shall receive an annual base salary equal to Three Hundred Fifty Thousand Dollars (US$350,000), which shall be payable in accordance with the Company&#8217;s payroll practices. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  You shall be eligible to receive an annual performance bonus payable in cash at a target amount equal to 35% of your Base Salary, subject to the successful achievement of agreed upon individual and corporate performance goals, payable at the same time as such bonuses are generally paid to the Company&#8217;s executive officers. Any Performance Bonus paid to you for the calendar year 2020 shall be pro-rated.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as expressly stated otherwise, the Company shall withhold all applicable federal, state and local taxes and social security and such other amounts as may be required by law from all amounts payable under this Section&#160;3.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Equity Awards.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt;text-decoration:underline">Restricted Stock Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Subject to the approval of the Board of Directors of the Company (the &#8220;Board&#8221;), or an authorized committee thereof, you shall be granted a Restricted Stock Award of 260,039 shares of common stock of the Company, par value $0,001 per share (the &#8220;Common Stock&#8221;) pursuant to the Company&#8217;s 2017 Equity Incentive Plan (the &#8220;Plan&#8221;).  Such grant shall be evidenced by a Restrictive Stock Agreement to be entered into by and between you and the Company.  In the event of a conflict between this Agreement and the Restricted Stock Agreement, the terms of the Restricted Stock Agreement shall control.  The shares subject to the Restricted Stock Award (the &#8220;Restricted Shares&#8221;) shall vest as follows&#58; (i) 130,020 Restricted Shares shall be fully vested on the date the Restricted Stock Award is granted (the &#8220;RSA Grant Date&#8221;)&#59; (ii) 32,505 Restricted Shares shall vest upon the first anniversary of your Start Date&#59; and thereafter, (iii) 97,514 Restricted Shares shall vest in 36 substantially equal monthly installments on the last business day of each calendar month.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt;text-decoration:underline">Employment Options</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the approval of the Board or an authorized committee thereof, you shall be granted a stock option (the &#8220;Employment Option&#8221;) to purchase 317,544 shares of Common Stock (the &#8220;Employment Option Shares&#8221;) pursuant to the Plan.  Such grant shall be evidenced by an option agreement (the &#8220;Option Agreement&#8221;) to be entered into by and between you and the Company.  In the event of a conflict between this Agreement and the Option Agreement, the terms of the Option Agreement shall control. The exercise price per Employment Option Share will be equal to the fair market value per share of the Company&#8217;s Common Stock as of the date that such Employment Option is granted. &#160;The Employment Option shall have a 10-year term and shall vest and become exercisable as follows&#58; (i) 73,136 Employment Options shall vest upon the first anniversary of your Start Date (the &#8220;Initial Vesting Date&#8221;)&#59; and thereafter (ii) the remaining unvested Employment Options Shares shall vest in 36 substantially equal monthly installments as of the last calendar day of each month following the Initial Vesting Date.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;text-decoration:underline">Early Exercise</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  All Employment Options shall be immediately exercisable with respect to one hundred percent (100%) of the Employment Option Shares in exchange for restricted shares of Common Stock of the Company (the &#8220;Restricted Option Shares&#8221;)&#59; provided, however, that the Restricted Option Shares will be subject to a repurchase right (the &#8220;Repurchase Right&#8221;) in favor of the Company that lapses in accordance with the schedule described above.  Upon termination of your employment, the Company may exercise its Repurchase Right with respect to any or all Restricted Option Shares for which the Repurchase Right has not lapsed at a price equal to the exercise price per Employment Option.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt;text-decoration:underline">Accelerated Vesting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">All unvested Equity Awards described in this Section 4 (collectively, the &#8220;Equity Awards&#8221;) shall become one hundred percent (100%) vested upon the consummation of a Change of Control (as defined in the Plan) that occurs at any time prior to the date that the Company becomes a publicly reporting company.  </font></div><div style="padding-left:85.5pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">After such time as the Company becomes a publicly reporting company,  in the event that your employment is terminated without Cause (as defined in the Plan) or you terminate your employment for Good Reason (as defined in Section 11(c)), in either </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">case at any time beginning on the date that is 90 days prior to the effective date of a Change of Control (as defined in the Plan) and ending on the date that is 12 months following the Change of Control (or any time after the Outside Date, if for Good Reason), then (A) all unvested Equity Awards shall immediately vest in full, and (B) all Employment Options will remain exercisable for a period of 90 calendar days following the date of such termination, after which time any unexercised Employment Options shall expire&#59; provided, however, that no such Employment Option shall be exercisable after the expiration of its maximum term.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">In order to give effect to Sections 4(d)(i) and (ii) above, notwithstanding anything to the contrary set forth in any agreement or any equity plan governing an equity award regarding immediate forfeiture of unvested shares upon termination of service or the duration of post-termination of service exercise periods, following any termination of your employment, none of your equity incentive awards shall terminate with respect to any vested or unvested portion subject to such equity award before 90 days following such termination.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company will reimburse you for all normal, usual and necessary expenses incurred in furtherance of the business and affairs of the Company upon timely receipt by the Company of appropriate vouchers or other proof of your expenditures and otherwise in accordance with any expense reimbursement and approval policy as may from time to time be adopted by the Company.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As a regular full-time employee, you shall be entitled to participate in the employee benefits made available to senior executives of the Company, in accordance with the terms of such benefits plans and programs.  Details on each plan and program will be provided at the time of hire.  The Company, in its sole discretion, has the right to amend or terminate any benefit plan or program at any time and without prior notice.  Your health benefits will be effective on the effective date of your hire if you timely enroll when you commence employment with Kronos. </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Paid Time Off</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Consistent with the Company&#8217;s Time Off Policy, during each year of your employment you shall not accrue vacation benefits but are entitled to an indeterminate amount of personal time off subject to approval from your supervisor and as operational conditions permit. Under the Company&#8217;s policy, you will still be responsible for meeting the expectations and requirements of your position including timely and satisfactorily completing all work assignments while taking time off.  This may include being required to respond to emails, telephone calls, mobile messages and other forms of communication. For purposes of the Company&#8217;s policy, this personal time off is in addition to company recognized holidays or sick leave. You will accrue sick leave consistent with applicable law. Sick leave may be used for yourself or a family member for the diagnosis, care or treatment of an existing health condition or preventive care, or specified purposes set forth in the Company&#8217;s policy if you are a victim of domestic violence, sexual assault, or stalking. Notwithstanding the foregoing, you shall not be entitled to take more than two consecutive weeks of time off without the prior written consent of the Company.   </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  You hereby represent and warrant as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-22.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">By accepting the Company&#8217;s offer of employment, you represent that you have no agreements, relationships, or commitments with any other person or entity that conflict with your obligations to the Company. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-25.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">You have the full right, power and legal capacity to enter and deliver this Agreement and to perform your duties and other obligations hereunder.  This Agreement constitutes the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legal, valid and binding obligation of the parties, enforceable against each in accordance with its terms.  No approvals or consents of any persons or entities are required for you to execute and deliver this Agreement or perform your duties and other obligations hereunder.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-27.43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">You represent and warrant to the Company that you have not brought and shall not bring with you to the Company, or use in the performance of your duties, any materials or documents of any former employer that are not generally available to the public, unless you have obtained written authorization from the former employer for their possession and use and provided the Company with a copy thereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Conditions to Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This offer of employment is contingent upon, and your employment shall be subject to&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">execution of the Company&#8217;s form of Proprietary Information and Invention Assignment Agreement attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which prohibits unauthorized use or disclosure of the Company&#8217;s proprietary information&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">completion of a background examination to the reasonable satisfaction of the Company&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">satisfying the requirements of the Immigration Control and Reform Act, which may be accomplished by showing your proof of right to work in the U.S. within three days of commencing employment (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">http&#58;&#47;&#47;www.uscis.gov&#47;i-9 for a list of acceptable proof, such as (i) an original driver&#8217;s license and social security card, or (ii) a passport).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Notwithstanding the foregoing, this offer may be withdrawn by the Company at any time prior to its execution by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.11pt;text-decoration:underline">Employment-at-will and Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Your employment shall be at-will.  Accordingly, you may terminate your employment with the Company at any time and for any reason whatsoever, without or without advance notice, simply by notifying the Company in writing.  Similarly, the Company may terminate your employment at any time and for any reason whatsoever, with or without cause or advance notice.  This at-will relationship cannot be changed except in a writing signed by a duly authorized office of the Company and you. The employment terms contained in this Agreement supersede any other agreements and promises made to you by the Company or any representative on its behalf, whether oral, written or implied.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.11pt;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.38pt">In the event that at any time your employment is terminated by the Company without Cause (as defined in the Plan), or by you for Good Reason (as defined below), then&#58; </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.12pt">the Company shall pay your accrued but unpaid Base Salary through the date of termination, at the rate in effect at the time of termination, accrued but unused vacation, and reimburse you for any unreimbursed business expenses incurred prior to the date of termination&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">the Company shall continue to pay your Base Salary at the rate in effect at the time of termination (without regard to any reduction in Base Salary that served as the basis for a resignation for Good Reason) for a period of 180 days following the date of termination in accordance with the Company&#8217;s ordinary payroll practice&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">to the extent permitted by applicable healthcare laws and provided that you make a timely election to continue coverage, the Company shall pay directly to the insurance provider the premium for COBRA continuation coverage for the you and the your dependents, less the amount payable by an active employee for such coverage, for a period of 180 days or until you obtain new employment, whichever comes first (the benefits provided in this Section 11(a)(iii) shall be referred to as the &#8220;Continued Benefits&#8221;). Notwithstanding the foregoing, in the event that applicable healthcare laws do not permit continuation of coverage, then the Company shall reimburse you for the costs of obtaining coverage in an amount not to exceed the coverage amounts paid or payable by you immediately prior to the date of termination&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">(A) all unvested Equity Awards and any other Company equity compensation awards you then hold shall immediately vest in full, and (B) all Equity Awards will remain exercisable for a period of 90 calendar days following the date of such termination, after which time the Equity Awards shall expire&#59; provided, however, that no such Equity Award shall be exercisable after the expiration of its maximum term. In order to give effect to the foregoing provision, notwithstanding anything to the contrary set forth in any agreement governing an equity award regarding immediate forfeiture of unvested shares upon termination of service or the duration of post-termination of service exercise periods, following any termination of your employment, none of your equity incentive awards shall terminate with respect to any vested or unvested portion subject to such equity award before 90 days following such termination.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.38pt">In the event that your employment is terminated by the Company for Cause, or by you other than for Good Reason, then&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.12pt">the Company shall pay your accrued but unpaid Base Salary through the date of termination, at the rate in effect at the time of termination, accrued but unused vacation, and reimburse you for any unreimbursed business expenses incurred prior to the date of termination&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">you shall not be entitled to receive any payments and Continued Benefits described in this Section 11&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">the vesting applicable to all Equity Awards granted to you by the Company shall cease immediately and you shall have a period of 90 days to exercise any and all vested Equity Awards, after which time all Equity Awards shall expire&#59; provided, however, that no such Equity Award shall be exercisable after the expiration of its maximum term pursuant to the terms thereof.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt">For purposes of this Agreement&#58; &#8220;Good Reason&#8221; shall mean your resignation after one of the following conditions has come into existence (i) any material diminution by the Company of your title, duties, authority or Base Salary (including without limitation any requirement that you report to any person(s) other than the Board of the Company)&#59; (ii) a material breach by the Company of any of the provisions contained in this Agreement, which, if capable of being cured, is not cured by the Company within 30 days after written notice thereof by you to the Company&#59; (iii) the relocation of the Company&#8217;s principal place of business more than 50 miles from its current location without your consent&#59; or (iv) the occurrence of any date  following the first anniversary of the effective date of a Change of Control (the &#8220;Outside Date&#8221;) if none of the conditions described in Sections 11(c)(i), (ii) or (iii) above has occurred prior to the Outside Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.38pt">This Section 11 sets forth the only obligations of the Company with respect to the termination of your employment with the Company, and you acknowledges that, upon the termination of your employment, you shall not be entitled to any payments or benefits which are not explicitly provided in this Section 11.  Further, notwithstanding anything to the contrary contained herein, the Company shall have no obligation to pay, and you shall have no right to receive, any compensation, benefits or other consideration provided for in this Section 11 (other than any accrued but unpaid Base Salary through the date of termination and any reimbursement of unreimbursed expenses incurred prior to the date of termination) (the &#8220;Payments&#8221;) unless you execute a release agreement substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Company (the &#8220;Release Agreement&#8221;) releasing the Company from any and all liability in connection with your employment or the termination thereof that becomes effective no later than 60 days following your termination (the &#8220;Release Deadline&#8221;).  Except as required by Section 13, the Payments will commence on the first payroll period following the Release Agreement becoming effective&#59; provided, that (i) if the Payments (or any portion thereof) constitute &#8220;deferred compensation&#8221; within the meaning of Section 409A (as defined in Section 13) and (ii) the period commencing on the date of termination and ending on the Release Deadline spans two calendar years, then the Payments (or such portion thereof that constitute &#8220;deferred compensation&#8221;) will commence on the later of the Release Agreement becoming effective and the first payroll date of the Company in the second calendar year.  Any portion of the Payments that is delayed due to the application of the preceding sentence shall be made on the date that the Payments commence.    </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.38pt">The Company shall withhold all applicable federal, state and local taxes and social security and such other amounts as may be required by law from all amounts payable to the you under this Section 11. The provisions of this Section 11 shall survive any termination of this Agreement.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.11pt;text-decoration:underline">No Reliance by You on Promise or Representation Not in this Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In accepting employment with the Company and signing this Agreement, you agree that you are not relying on any representation, promise or inducement that has been made by the Company or any representative on its behalf that is not explicitly stated in this Agreement.  the Company is not bound by and will not be liable for any representation, promise or inducement that is not explicitly stated forth in this Agreement.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.11pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this offer letter that constitute &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the regulations and other guidance thereunder and any state law of similar effect (collectively, &#8220;Section 409A&#8221;) and that are payable in connection with your termination of employment shall not commence unless and until you have also incurred a &#8220;separation from service&#8221; within the meaning of Section 409A, unless the Company reasonably determines that such amounts may be provided to you without causing you to incur the additional 20% tax under Section 409A. If you are, upon a separation from service, a &#8220;specified employee&#8221; within the meaning of Section 409A, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the payment of any deferred compensation shall not commence until the earlier to occur of&#58; (i) the date that is six months and one day after your separation from service, or (ii) the date of your death. Any payments that are delayed due to the application of the preceding sentence shall be made on the date that payments commence. For purposes of Section 409A, the right to a series of installment payments under this offer letter shall be treated as a right to a series of separate payments.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.11pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The terms of this offer letter shall be governed by, and construed and interpreted in accordance with, the laws of the State of California without regard to such State&#8217;s principles of conflict of laws, except as provided in Section 1.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.11pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  To the maximum extent permitted by law, any dispute between the parties, including but not limited to those arising out of, or relating to, this Agreement, shall be exclusively decided by binding arbitration in accordance with the terms of the Mutual Agreement to Arbitrate Claims, which is attached as&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and incorporated into this Agreement. The Federal Arbitration Act shall govern the interpretation, enforcement and all proceedings pursuant to the Arbitration Agreement. To the extent that the Federal Arbitration Act is inapplicable, the terms of the Arbitration Agreement shall be construed in accordance with California law. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.11pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">This agreement, and your rights and obligations hereunder, may not be assigned.  The Company may assign its rights, together with its obligations, hereunder in connection with any sale, transfer or other disposition of all or substantially all of its business or assets provided the assignee entity which succeeds to the Company expressly assumes the Company&#8217;s obligations hereunder and complies with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">This agreement cannot be amended orally, or by any course of conduct or dealing, but only by a written agreement signed by the parties hereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The failure of either party to insist upon the strict performance of any of the terms, conditions and provisions of this agreement shall not be construed as a waiver or relinquishment of future compliance therewith, and such terms, conditions and provisions shall remain in full force and effect.  No waiver of any term or condition of this agreement on the part of either party shall be effective for any purpose whatsoever unless such waiver is in writing and signed by such party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">This agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof.  No representation, promise or inducement has been made by either party that is not embodied in this agreement, and neither party shall be bound by or liable for any alleged representation, promise or inducement not so set forth.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A portable document format (&#8220;.pdf&#8221;) copy of this Agreement, including the signature pages, will be deemed an original.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you wish to accept employment at Kronos Bio, Inc., under the terms described above, please sign and date this letter, and return it to me.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We look forward to your favorable reply and to a productive and enjoyable working relationship.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Very truly yours, </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kronos Bio, Inc.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreed and Accepted&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Norbert Bischofberger</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Barbara A. Kosacz</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norbert Bischofberger, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barbara A. Kosacz</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 15, 2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 15, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>kronq3fy2020ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i961ec05befc944e7afe9c0b6b73a2af1_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO EXCHANGE ACT RULES 13a-14(a)&#160;AND 15d-14(a) AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302&#160;OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Norbert Bischofberger, Ph.D., certify that&#58; </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Kronos Bio, Inc.&#59;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:43.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.329%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 18, 2020</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Norbert Bischofberger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norbert Bischofberger, Ph.D.<br></font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>kronq3fy2020ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i57731e2a470d4dab92811fbfbd7bed6d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO EXCHANGE ACT RULES 13a-14(a)&#160;AND 15d-14(a)&#160;AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Yasir Al-Wakeel, BM BCh, certify that&#58; </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Kronos Bio, Inc.&#59;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:43.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 18, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Yasir Al-Wakeel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yasir Al-Wakeel, BM BCh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Head of Corporate Development</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>kronq3fy2020ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iac2120497bfa4988bd59534073d098a4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Kronos Bio, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Norbert Bischofberger, Ph.D., the Chief Executive Officer of the Company, and I, Yasir Al-Wakeel, BM BCh, Chief Financial Office of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended (the &#34;Exchange Act&#34;)&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:43.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.329%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 18, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Norbert Bischofberger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Norbert Bischofberger, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 18, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Yasir Al-Wakeel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yasir Al-Wakeel, BM BCh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Head of Corporate Development</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>kron-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:24f323b6-3e05-4299-b60b-ed7d0f94eb5e,g:b8dc781a-ce5b-4a7b-a930-702eddd4413f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kron="http://www.kronosbio.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.kronosbio.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kron-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kron-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kron-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kron-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.kronosbio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsUnaudited" roleURI="http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Condensed Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsUnauditedParenthetical" roleURI="http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited" roleURI="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited">
        <link:definition>1004005 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals" roleURI="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals">
        <link:definition>1005006 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlowsunaudited" roleURI="http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited">
        <link:definition>1006007 - Statement - Condensed Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsandBasisofPresentation" roleURI="http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Nature of Operations and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsDetails" roleURI="http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails">
        <link:definition>2402401 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesEstimatesandJudgments" roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies, Estimates and Judgments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesEstimatesandJudgmentsPolicies" roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies, Estimates and Judgments (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesEstimatesandJudgmentsTables" roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables">
        <link:definition>2305301 - Disclosure - Significant Accounting Policies, Estimates and Judgments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails" roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails">
        <link:definition>2406402 - Disclosure - Significant Accounting Policies, Estimates and Judgments - R&amp;D Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails" roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails">
        <link:definition>2407403 - Disclosure - Significant Accounting Policies, Estimates and Judgments - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails" roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails">
        <link:definition>2408404 - Disclosure - Significant Accounting Policies, Estimates and Judgments - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails" roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails">
        <link:definition>2409405 - Disclosure - Significant Accounting Policies, Estimates and Judgments - Schedule of Cash, Cash Equivalents, and Restricted Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.kronosbio.com/role/FairValueMeasurements">
        <link:definition>2110103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.kronosbio.com/role/FairValueMeasurementsTables">
        <link:definition>2311302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.kronosbio.com/role/FairValueMeasurementsDetails">
        <link:definition>2412406 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.kronosbio.com/role/Investments">
        <link:definition>2113104 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.kronosbio.com/role/InvestmentsTables">
        <link:definition>2314303 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValueandAmortizedCostDetails" roleURI="http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails">
        <link:definition>2415407 - Disclosure - Investments - Fair Value and Amortized Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsBalanceSheetDetails" roleURI="http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails">
        <link:definition>2416408 - Disclosure - Investments - Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsContractualMaturityDetails" roleURI="http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails">
        <link:definition>2417409 - Disclosure - Investments - Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets">
        <link:definition>2118105 - Disclosure - Prepaid Expenses And Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>2319304 - Disclosure - Prepaid Expenses And Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>2420410 - Disclosure - Prepaid Expenses And Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.kronosbio.com/role/PropertyandEquipmentNet">
        <link:definition>2121106 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.kronosbio.com/role/PropertyPlantandEquipmentTables">
        <link:definition>2322305 - Disclosure - Property, Plant, and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>2423411 - Disclosure - Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandCurrentPortionofOtherLiabilities" roleURI="http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities">
        <link:definition>2124107 - Disclosure - Accrued Expenses and Current Portion of Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables" roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables">
        <link:definition>2325306 - Disclosure - Accrued Expenses And Current Portion Of Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails" roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails">
        <link:definition>2426412 - Disclosure - Accrued Expenses And Current Portion Of Other Liabilities - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails" roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails">
        <link:definition>2427413 - Disclosure - Accrued Expenses And Current Portion Of Other Liabilities - Current Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStock" roleURI="http://www.kronosbio.com/role/PreferredStock">
        <link:definition>2128108 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStockTables" roleURI="http://www.kronosbio.com/role/PreferredStockTables">
        <link:definition>2329307 - Disclosure - Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStockNarrativeDetails" roleURI="http://www.kronosbio.com/role/PreferredStockNarrativeDetails">
        <link:definition>2430414 - Disclosure - Preferred Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredStockDetails" roleURI="http://www.kronosbio.com/role/PreferredStockDetails">
        <link:definition>2431415 - Disclosure - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://www.kronosbio.com/role/CommonStock">
        <link:definition>2132109 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://www.kronosbio.com/role/CommonStockDetails">
        <link:definition>2433416 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.kronosbio.com/role/StockBasedCompensation">
        <link:definition>2134110 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.kronosbio.com/role/StockBasedCompensationTables">
        <link:definition>2335308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2436417 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionpricingModelAssumptionsDetails" roleURI="http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails">
        <link:definition>2437418 - Disclosure - Stock-Based Compensation - Option-pricing Model Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2438419 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationClassifiedinStatementsofOperationsDetails" roleURI="http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails">
        <link:definition>2439420 - Disclosure - Stock-Based Compensation - Classified in Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockDetails" roleURI="http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails">
        <link:definition>2440421 - Disclosure - Stock-Based Compensation - Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.kronosbio.com/role/IncomeTaxes">
        <link:definition>2141111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.kronosbio.com/role/IncomeTaxesDetails">
        <link:definition>2442422 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.kronosbio.com/role/NetLossPerShare">
        <link:definition>2143112 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.kronosbio.com/role/NetLossPerShareTables">
        <link:definition>2344309 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://www.kronosbio.com/role/NetLossPerShareDetails">
        <link:definition>2445423 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>2446424 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.kronosbio.com/role/CommitmentandContingencies">
        <link:definition>2147113 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesTables">
        <link:definition>2348310 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>2449425 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesKeyValuationAssumptionsDetails" roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails">
        <link:definition>2450426 - Disclosure - Commitment and Contingencies - Key Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.kronosbio.com/role/Leases">
        <link:definition>2151114 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.kronosbio.com/role/LeasesTables">
        <link:definition>2352311 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.kronosbio.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2453427 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofLeaseCostsDetails" roleURI="http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails">
        <link:definition>2454428 - Disclosure - Leases - Summary of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails" roleURI="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails">
        <link:definition>2455429 - Disclosure - Leases - Supplemental Balance Sheet Information - Finance Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails" roleURI="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails">
        <link:definition>2456430 - Disclosure - Leases - Supplemental Balance Sheet Information - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails" roleURI="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails">
        <link:definition>2457431 - Disclosure - Leases - Schedule of Maturities on Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1" roleURI="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1">
        <link:definition>2457431 - Disclosure - Leases - Schedule of Maturities on Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A2020Notes" roleURI="http://www.kronosbio.com/role/A2020Notes">
        <link:definition>2158115 - Disclosure - 2020 Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A2020NotesTables" roleURI="http://www.kronosbio.com/role/A2020NotesTables">
        <link:definition>2359312 - Disclosure - 2020 Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A2020NotesNarrativeDetails" roleURI="http://www.kronosbio.com/role/A2020NotesNarrativeDetails">
        <link:definition>2460432 - Disclosure - 2020 Notes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A2020NotesKeyValueAssumptionsDetails" roleURI="http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails">
        <link:definition>2461433 - Disclosure - 2020 Notes - Key Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.kronosbio.com/role/RelatedParties">
        <link:definition>2162116 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresDetails" roleURI="http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails">
        <link:definition>2463434 - Disclosure - Related Party Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.kronosbio.com/role/SubsequentEvents">
        <link:definition>2164117 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.kronosbio.com/role/SubsequentEventsDetails">
        <link:definition>2465435 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="kron_DeferredOfferingCostsIncurredButNotYetPaid" abstract="false" name="DeferredOfferingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_GileadAssetPurchaseMember" abstract="true" name="GileadAssetPurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_LeaseExpenseNoncash" abstract="false" name="LeaseExpenseNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_RDEquipmentMember" abstract="true" name="RDEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_OperatingLeaseAssetsAbstract" abstract="true" name="OperatingLeaseAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kron_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_PrepaidExternalResearchAndDevelopment" abstract="false" name="PrepaidExternalResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_AssetAcquisitionAxis" abstract="true" name="AssetAcquisitionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="kron_LesseeOperatingLeaseInitialAnnualBaseRent" abstract="false" name="LesseeOperatingLeaseInitialAnnualBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_EquityIncentivePlan2017Member" abstract="true" name="EquityIncentivePlan2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_SeriesSeedPreferredStockMember" abstract="true" name="SeriesSeedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_SharePriceFairValueDisclosure" abstract="false" name="SharePriceFairValueDisclosure" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="kron_LiquidationConversionScenarioMember" abstract="true" name="LiquidationConversionScenarioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_LesseeOperatingLeaseEarlyTerminationCost" abstract="false" name="LesseeOperatingLeaseEarlyTerminationCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" abstract="false" name="IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_A2020GileadNotesMember" abstract="true" name="A2020GileadNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_AssetAcquisitionDomain" abstract="true" name="AssetAcquisitionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_LiquidationCashPayoutScenarioMember" abstract="true" name="LiquidationCashPayoutScenarioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="kron_PaymentsOfOfferingCosts" abstract="false" name="PaymentsOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_LesseeOperatingLeaseMonthlyBaseRent" abstract="false" name="LesseeOperatingLeaseMonthlyBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_IPOCashPayoutScenarioMember" abstract="true" name="IPOCashPayoutScenarioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_SaleOfStockPurchasePriceOfCommonStockPercent" abstract="false" name="SaleOfStockPurchasePriceOfCommonStockPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="kron_SanMateoCaliforniaMember" abstract="true" name="SanMateoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid" abstract="false" name="TemporaryEquityIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_ScheduleOfAssetAcquisitionTable" abstract="true" name="ScheduleOfAssetAcquisitionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="kron_ServicesAgreementTerm" abstract="false" name="ServicesAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kron_LesseeOperatingLeaseIncrementalBorrowingRate" abstract="false" name="LesseeOperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="kron_GainLossOnChangeInFairValueOfDebtInstrument" abstract="false" name="GainLossOnChangeInFairValueOfDebtInstrument" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" abstract="false" name="CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_TwoRiverConsultingLLCMember" abstract="true" name="TwoRiverConsultingLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_A2020StockOptionAndIncentivePlanMember" abstract="true" name="A2020StockOptionAndIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_AccruedExternalResearchAndDevelopmentCurrent" abstract="false" name="AccruedExternalResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_MeasurementInputWeightingMember" abstract="true" name="MeasurementInputWeightingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_FinanceLeasesAssetsAbstract" abstract="true" name="FinanceLeasesAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kron_SeriesBScenarioMember" abstract="true" name="SeriesBScenarioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_AccruedOfferingCostsCurrent" abstract="false" name="AccruedOfferingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_A21ErieStreetCambridgeMassachusettsMember" abstract="true" name="A21ErieStreetCambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_StockOptionsEarlyExerciseMember" abstract="true" name="StockOptionsEarlyExerciseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity" abstract="false" name="DebtSecuritiesAvailableForSaleRemainingContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kron_PrepaidEquipmentServiceContracts" abstract="false" name="PrepaidEquipmentServiceContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty" abstract="false" name="RelatedPartyTransactionsReimbursableExpensesToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_BellcoCapitalLLCMember" abstract="true" name="BellcoCapitalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_DebtSecuritiesAvailableForSaleAccruedInterest" abstract="false" name="DebtSecuritiesAvailableForSaleAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_NotesPayableFairValueGainLoss" abstract="false" name="NotesPayableFairValueGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_SettlementPlanAxis" abstract="true" name="SettlementPlanAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="kron_FinancingScenarioMember" abstract="true" name="FinancingScenarioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_IPOScenarioMember" abstract="true" name="IPOScenarioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_A2020ConvertibleNotesMember" abstract="true" name="A2020ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_RepaymentOfDebtPaymentToBeMade" abstract="false" name="RepaymentOfDebtPaymentToBeMade" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kron_IPOConversionScenarioMember" abstract="true" name="IPOConversionScenarioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_OperatingLeaseFacilitySize" abstract="false" name="OperatingLeaseFacilitySize" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="kron_TemporaryEquityTextBlock" abstract="false" name="TemporaryEquityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="kron_SettlementPlanDomain" abstract="true" name="SettlementPlanDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_LesseeOperatingLeaseTenantImprovementAllowances" abstract="false" name="LesseeOperatingLeaseTenantImprovementAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_CambridgeMassachusettsMember" abstract="true" name="CambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" abstract="false" name="AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_ConvertibleNotesPayable2020NotesMember" abstract="true" name="ConvertibleNotesPayable2020NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_PrepaidSoftware" abstract="false" name="PrepaidSoftware" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_SanMateoCaliforniaAdjacentSpaceMember" abstract="true" name="SanMateoCaliforniaAdjacentSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" abstract="false" name="CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent" abstract="false" name="LesseeOperatingLeaseEscalatingRentPaymentsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="kron_ExecutiveEmployeeMember" abstract="true" name="ExecutiveEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_PaymentsForAssetAcquisitionsReimbursements" abstract="false" name="PaymentsForAssetAcquisitionsReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_ScheduleOfAssetAcquisitionLineItems" abstract="true" name="ScheduleOfAssetAcquisitionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_FundraiseScenarioMember" abstract="true" name="FundraiseScenarioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_A301BinneyStreetCambridgeMassachusettsMember" abstract="true" name="A301BinneyStreetCambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_DebtConversionValuationOfCompany" abstract="false" name="DebtConversionValuationOfCompany" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_PaymentsOfUnderwritingDiscountsAndCommissions" abstract="false" name="PaymentsOfUnderwritingDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kron_PaymentsForLegalCosts" abstract="false" name="PaymentsForLegalCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kron_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>kron-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:24f323b6-3e05-4299-b60b-ed7d0f94eb5e,g:b8dc781a-ce5b-4a7b-a930-702eddd4413f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.kronosbio.com/role/CoverPage" xlink:type="simple" xlink:href="kron-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dc84bdbb-59bf-479a-a68e-cc37c77ceda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d077e799-b6a8-478e-a32c-707a694d9942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dc84bdbb-59bf-479a-a68e-cc37c77ceda3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d077e799-b6a8-478e-a32c-707a694d9942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_83ebdf31-191c-41df-a7bb-b1fd3f43c114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dc84bdbb-59bf-479a-a68e-cc37c77ceda3" xlink:to="loc_us-gaap_LiabilitiesCurrent_83ebdf31-191c-41df-a7bb-b1fd3f43c114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d0c635aa-3c70-490c-ab3b-a1f78b3c548f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_dc84bdbb-59bf-479a-a68e-cc37c77ceda3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d0c635aa-3c70-490c-ab3b-a1f78b3c548f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c879aa73-41b0-4d85-ba5c-820213cdd55f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68f55164-c87a-4012-94be-a9a03bf9445c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c879aa73-41b0-4d85-ba5c-820213cdd55f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68f55164-c87a-4012-94be-a9a03bf9445c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a5c6bc2f-32ae-4012-a66e-fe998f1a3dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c879aa73-41b0-4d85-ba5c-820213cdd55f" xlink:to="loc_us-gaap_ShortTermInvestments_a5c6bc2f-32ae-4012-a66e-fe998f1a3dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_400e8f8f-a00a-470e-bf32-6354b39f2199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c879aa73-41b0-4d85-ba5c-820213cdd55f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_400e8f8f-a00a-470e-bf32-6354b39f2199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_037cbf24-69ba-4c8b-9612-4ddcb7887b73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5d1d3bb5-1c8e-4ebf-ab94-9017fcf5be74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_037cbf24-69ba-4c8b-9612-4ddcb7887b73" xlink:to="loc_us-gaap_CommonStockValue_5d1d3bb5-1c8e-4ebf-ab94-9017fcf5be74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_eb3c6a42-0a18-4332-ad05-471c4c927ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_037cbf24-69ba-4c8b-9612-4ddcb7887b73" xlink:to="loc_us-gaap_AdditionalPaidInCapital_eb3c6a42-0a18-4332-ad05-471c4c927ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7799605b-d049-4c9d-8582-c2963a4e8ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_037cbf24-69ba-4c8b-9612-4ddcb7887b73" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7799605b-d049-4c9d-8582-c2963a4e8ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4224baf1-9712-4513-8cd1-8e51b2724092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_037cbf24-69ba-4c8b-9612-4ddcb7887b73" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4224baf1-9712-4513-8cd1-8e51b2724092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7905483b-d6dc-4005-9f34-5c83539b6114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5a60323e-bc80-4cac-bf45-4694dba2cdb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7905483b-d6dc-4005-9f34-5c83539b6114" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5a60323e-bc80-4cac-bf45-4694dba2cdb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_be5b0d6c-194b-4065-bcd4-6483781bab20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7905483b-d6dc-4005-9f34-5c83539b6114" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_be5b0d6c-194b-4065-bcd4-6483781bab20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4e602f68-8ee7-4f6d-8a59-38bbdd6041dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7905483b-d6dc-4005-9f34-5c83539b6114" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4e602f68-8ee7-4f6d-8a59-38bbdd6041dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8623c707-6228-42d3-8403-93932d6a8e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7905483b-d6dc-4005-9f34-5c83539b6114" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8623c707-6228-42d3-8403-93932d6a8e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_e4f1f8d9-6b51-4cbf-a5e4-413c5ef956ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7905483b-d6dc-4005-9f34-5c83539b6114" xlink:to="loc_us-gaap_LongTermInvestments_e4f1f8d9-6b51-4cbf-a5e4-413c5ef956ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_46c55687-5826-4059-bfe5-c75eb1252f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7905483b-d6dc-4005-9f34-5c83539b6114" xlink:to="loc_us-gaap_AssetsCurrent_46c55687-5826-4059-bfe5-c75eb1252f8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f651dc07-8488-4f94-85c8-55d1b108e39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e35553ed-6112-4bb9-8a26-08c7915d81e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f651dc07-8488-4f94-85c8-55d1b108e39a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e35553ed-6112-4bb9-8a26-08c7915d81e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ad21825a-9351-43dd-afa4-dfe5b3dca74b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f651dc07-8488-4f94-85c8-55d1b108e39a" xlink:to="loc_us-gaap_AccountsPayableCurrent_ad21825a-9351-43dd-afa4-dfe5b3dca74b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a5582676-b404-455f-a667-98aa9b1295ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f651dc07-8488-4f94-85c8-55d1b108e39a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a5582676-b404-455f-a667-98aa9b1295ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_259fde0f-3237-4273-b12b-826aef5ddc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f651dc07-8488-4f94-85c8-55d1b108e39a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_259fde0f-3237-4273-b12b-826aef5ddc4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_f4e062d0-2454-4a48-89c6-27f14ed7f51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f651dc07-8488-4f94-85c8-55d1b108e39a" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_f4e062d0-2454-4a48-89c6-27f14ed7f51c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2684cb3-2ec0-4c2b-8dbc-541d0a5afef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f3794aee-79d4-46d3-a7a4-27a10a2103ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2684cb3-2ec0-4c2b-8dbc-541d0a5afef1" xlink:to="loc_us-gaap_Liabilities_f3794aee-79d4-46d3-a7a4-27a10a2103ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bd2446fd-c71a-452b-80ac-76750878a115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2684cb3-2ec0-4c2b-8dbc-541d0a5afef1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bd2446fd-c71a-452b-80ac-76750878a115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ef5eac92-d82b-4d16-ac66-6245f3c1092e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2684cb3-2ec0-4c2b-8dbc-541d0a5afef1" xlink:to="loc_us-gaap_StockholdersEquity_ef5eac92-d82b-4d16-ac66-6245f3c1092e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_13feb0ab-01f6-4604-a98e-a4c4e8988256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2684cb3-2ec0-4c2b-8dbc-541d0a5afef1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_13feb0ab-01f6-4604-a98e-a4c4e8988256" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_55e2a186-7e0a-4649-a7c1-bafca5589739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_eb285e2d-d09a-4340-9aa4-3dff22be9548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_55e2a186-7e0a-4649-a7c1-bafca5589739" xlink:to="loc_us-gaap_InterestExpense_eb285e2d-d09a-4340-9aa4-3dff22be9548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_10c96d39-c055-43e9-b1e3-5297f9cc4f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_55e2a186-7e0a-4649-a7c1-bafca5589739" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_10c96d39-c055-43e9-b1e3-5297f9cc4f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_NotesPayableFairValueGainLoss_d14bc4ef-1d6c-43bd-b00b-e682a4ea5c37" xlink:href="kron-20200930.xsd#kron_NotesPayableFairValueGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_55e2a186-7e0a-4649-a7c1-bafca5589739" xlink:to="loc_kron_NotesPayableFairValueGainLoss_d14bc4ef-1d6c-43bd-b00b-e682a4ea5c37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_24871b2b-40e8-4a48-af75-41a0f507c676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ab9121c1-5e80-43a4-9e2e-d6180673f633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_24871b2b-40e8-4a48-af75-41a0f507c676" xlink:to="loc_us-gaap_OperatingIncomeLoss_ab9121c1-5e80-43a4-9e2e-d6180673f633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_65d3cd54-c4d5-43cf-874b-40e25b4db24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_24871b2b-40e8-4a48-af75-41a0f507c676" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_65d3cd54-c4d5-43cf-874b-40e25b4db24a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_425933bd-983c-4ca0-a8e0-58540b7e210d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b00ed623-07ae-4d6d-9be6-39fd1d43e90f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_425933bd-983c-4ca0-a8e0-58540b7e210d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b00ed623-07ae-4d6d-9be6-39fd1d43e90f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a0bc1957-156f-4f62-a1b6-a9a01af7a46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_425933bd-983c-4ca0-a8e0-58540b7e210d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a0bc1957-156f-4f62-a1b6-a9a01af7a46c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b4b9362e-8027-4e45-8887-b2426915b475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6a4325f8-f04c-431f-bdb0-8053513c6df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b4b9362e-8027-4e45-8887-b2426915b475" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6a4325f8-f04c-431f-bdb0-8053513c6df4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34f2c8ad-e467-4b20-8f43-f721358d32dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b4b9362e-8027-4e45-8887-b2426915b475" xlink:to="loc_us-gaap_NetIncomeLoss_34f2c8ad-e467-4b20-8f43-f721358d32dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5dde7c9c-ce9f-466b-9984-a7c3cc3f25ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2b804826-7dca-4184-bd31-e7d49487a53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5dde7c9c-ce9f-466b-9984-a7c3cc3f25ab" xlink:to="loc_us-gaap_OperatingExpenses_2b804826-7dca-4184-bd31-e7d49487a53c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2a6b2f1-6bc8-49cc-b0ec-228aea1d810b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_8ca71a58-922d-42d1-9bfe-3d665bf46481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2a6b2f1-6bc8-49cc-b0ec-228aea1d810b" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_8ca71a58-922d-42d1-9bfe-3d665bf46481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_faf1d971-6d40-49ab-b33b-c949d847849a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2a6b2f1-6bc8-49cc-b0ec-228aea1d810b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_faf1d971-6d40-49ab-b33b-c949d847849a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_10ad2e06-5454-477c-80b0-0a2d070dd8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2a6b2f1-6bc8-49cc-b0ec-228aea1d810b" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_10ad2e06-5454-477c-80b0-0a2d070dd8a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_f7b04271-8e4c-43e1-b73f-14cc1386d8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2a6b2f1-6bc8-49cc-b0ec-228aea1d810b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_f7b04271-8e4c-43e1-b73f-14cc1386d8f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c0e0fbe9-d622-4df1-8f70-73052d667d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2a6b2f1-6bc8-49cc-b0ec-228aea1d810b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c0e0fbe9-d622-4df1-8f70-73052d667d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69bffaf6-5111-4c00-80c1-2a8b0dbc3e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_388db0e4-86ae-4b73-86ed-1a1be6423922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69bffaf6-5111-4c00-80c1-2a8b0dbc3e44" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_388db0e4-86ae-4b73-86ed-1a1be6423922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30170aa0-ea07-4896-b27c-fa0f60884933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69bffaf6-5111-4c00-80c1-2a8b0dbc3e44" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30170aa0-ea07-4896-b27c-fa0f60884933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_256d5e6f-0c9b-4c5b-ae29-f4b4a0fa289f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69bffaf6-5111-4c00-80c1-2a8b0dbc3e44" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_256d5e6f-0c9b-4c5b-ae29-f4b4a0fa289f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2ab1a02e-c403-4ef4-8894-e76053eb0df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2ab1a02e-c403-4ef4-8894-e76053eb0df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d044c6cb-39bf-43ca-889a-f08c96b93466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d044c6cb-39bf-43ca-889a-f08c96b93466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5b74e940-1141-4295-920a-bea2ff7dcaf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5b74e940-1141-4295-920a-bea2ff7dcaf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_cffd5eaf-2ae8-41cb-aa63-4364c248602a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_cffd5eaf-2ae8-41cb-aa63-4364c248602a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet_520415df-d44a-4377-b668-a807815d420b" xlink:href="kron-20200930.xsd#kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet_520415df-d44a-4377-b668-a807815d420b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_734d1f40-7170-4532-a4e4-c89b75ab92b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_734d1f40-7170-4532-a4e4-c89b75ab92b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_92155768-1803-40e4-9389-a5aab0e46baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_92155768-1803-40e4-9389-a5aab0e46baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e97deed0-63d0-4064-993f-c497363e8ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e97deed0-63d0-4064-993f-c497363e8ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_455c946e-1250-407f-812a-351e5bf183f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_455c946e-1250-407f-812a-351e5bf183f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_32dbc8b2-ce67-4c87-9f23-ccaee15a7911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_32dbc8b2-ce67-4c87-9f23-ccaee15a7911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_a72c25a0-80cb-45dd-9dfa-243f1c25984d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_a72c25a0-80cb-45dd-9dfa-243f1c25984d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9063cb55-6679-40a0-a602-8d169504b23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_ShareBasedCompensation_9063cb55-6679-40a0-a602-8d169504b23d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e5d10624-7242-4a88-ab4d-6c05b1c0f64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e5d10624-7242-4a88-ab4d-6c05b1c0f64f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fca8552a-86aa-4c09-81e1-be7e546eeb8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_us-gaap_NetIncomeLoss_fca8552a-86aa-4c09-81e1-be7e546eeb8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LeaseExpenseNoncash_4056de8d-846f-4f37-a98a-e157d2be1e38" xlink:href="kron-20200930.xsd#kron_LeaseExpenseNoncash"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ab72f85-cbcb-4336-a40e-f10c7a1d29c5" xlink:to="loc_kron_LeaseExpenseNoncash_4056de8d-846f-4f37-a98a-e157d2be1e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72efe43e-5fca-4b0b-90a5-27bd34adfed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0094de3-0f9c-4e20-8be4-9e1b4a2dc2cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72efe43e-5fca-4b0b-90a5-27bd34adfed4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0094de3-0f9c-4e20-8be4-9e1b4a2dc2cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b83f45a0-fe7b-4c47-80cd-9f3151550765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72efe43e-5fca-4b0b-90a5-27bd34adfed4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b83f45a0-fe7b-4c47-80cd-9f3151550765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f7898d7-caec-4d40-b76a-86b7d8ccb60b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72efe43e-5fca-4b0b-90a5-27bd34adfed4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f7898d7-caec-4d40-b76a-86b7d8ccb60b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation" xlink:type="simple" xlink:href="kron-20200930.xsd#NatureofOperationsandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgments"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_360464f9-affa-489f-b18e-00aefdce2fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4190c09c-be09-472e-b510-67f759bd685a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_360464f9-affa-489f-b18e-00aefdce2fd9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4190c09c-be09-472e-b510-67f759bd685a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c8f51fef-3971-4896-8f1d-cb15776aa579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_360464f9-affa-489f-b18e-00aefdce2fd9" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c8f51fef-3971-4896-8f1d-cb15776aa579" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="kron-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1a4b006d-aaaa-4745-bb45-d7a0ea15335e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b4ecc934-c463-4213-a815-4d69e234b6d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1a4b006d-aaaa-4745-bb45-d7a0ea15335e" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b4ecc934-c463-4213-a815-4d69e234b6d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_dc4198fb-73c4-408c-b6a6-2aabdfe5e667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1a4b006d-aaaa-4745-bb45-d7a0ea15335e" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_dc4198fb-73c4-408c-b6a6-2aabdfe5e667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_16c24b29-c681-4817-bd71-43b0a5fcd42e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_22ddb51e-423f-4ffe-ad4b-beb9246bb251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_16c24b29-c681-4817-bd71-43b0a5fcd42e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_22ddb51e-423f-4ffe-ad4b-beb9246bb251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9192eecd-aa0c-41e4-8273-433ff906730f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_16c24b29-c681-4817-bd71-43b0a5fcd42e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9192eecd-aa0c-41e4-8273-433ff906730f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/Investments" xlink:type="simple" xlink:href="kron-20200930.xsd#Investments"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/Investments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/InvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsFairValueandAmortizedCostDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_1a6367ba-557a-4b17-806c-2a15f268d1a0" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax_a0aa336c-319b-496b-b6cd-d8b343ddccaf" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_1a6367ba-557a-4b17-806c-2a15f268d1a0" xlink:to="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax_a0aa336c-319b-496b-b6cd-d8b343ddccaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_27f59519-5246-4a8b-863c-503d4941b6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_1a6367ba-557a-4b17-806c-2a15f268d1a0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_27f59519-5246-4a8b-863c-503d4941b6b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax_479ab7c0-0857-4ad5-aa3b-b0cc4b686824" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_1a6367ba-557a-4b17-806c-2a15f268d1a0" xlink:to="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax_479ab7c0-0857-4ad5-aa3b-b0cc4b686824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9a9d5106-49c9-4524-926a-60c1b3a06512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d41c40a7-6150-46f6-8b92-fe4ccc95f4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9a9d5106-49c9-4524-926a-60c1b3a06512" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d41c40a7-6150-46f6-8b92-fe4ccc95f4ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7237b91d-39a9-4c90-8252-0057b34bd0d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9a9d5106-49c9-4524-926a-60c1b3a06512" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7237b91d-39a9-4c90-8252-0057b34bd0d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e21b2e8d-a681-4888-b3ef-74d7e5a97875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9a9d5106-49c9-4524-926a-60c1b3a06512" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e21b2e8d-a681-4888-b3ef-74d7e5a97875" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_eb896b51-520f-40d0-8465-c1ba12776c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_d43dd03b-6309-4b9e-b748-1f53c7e80b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_eb896b51-520f-40d0-8465-c1ba12776c6d" xlink:to="loc_us-gaap_ShortTermInvestments_d43dd03b-6309-4b9e-b748-1f53c7e80b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_ddb96e98-ee6c-46ea-83a0-cbbfc90582d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_eb896b51-520f-40d0-8465-c1ba12776c6d" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_ddb96e98-ee6c-46ea-83a0-cbbfc90582d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_d14fba14-7c3d-4865-8636-73ce4806ac90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_eb896b51-520f-40d0-8465-c1ba12776c6d" xlink:to="loc_us-gaap_LongTermInvestments_d14fba14-7c3d-4865-8636-73ce4806ac90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_11f7dc0e-31e1-43e4-94a2-37a75d3aaf17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_7de085b3-732f-481a-9500-39ff5a206180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_11f7dc0e-31e1-43e4-94a2-37a75d3aaf17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_7de085b3-732f-481a-9500-39ff5a206180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_d0067867-a720-4dc4-be00-0b2686f785cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_11f7dc0e-31e1-43e4-94a2-37a75d3aaf17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_d0067867-a720-4dc4-be00-0b2686f785cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_19fd7c93-ef3c-42b3-91b0-c2583650e65a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_11f7dc0e-31e1-43e4-94a2-37a75d3aaf17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_19fd7c93-ef3c-42b3-91b0-c2583650e65a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" xlink:href="kron-20200930.xsd#PrepaidExpensesAndOtherCurrentAssets"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#PrepaidExpensesAndOtherCurrentAssetsTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8712817d-9d12-402e-b09f-6ce07255cc54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PrepaidEquipmentServiceContracts_522627b0-e364-4482-b8aa-d934c0d367e2" xlink:href="kron-20200930.xsd#kron_PrepaidEquipmentServiceContracts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8712817d-9d12-402e-b09f-6ce07255cc54" xlink:to="loc_kron_PrepaidEquipmentServiceContracts_522627b0-e364-4482-b8aa-d934c0d367e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DebtSecuritiesAvailableForSaleAccruedInterest_17646823-f743-4aaa-a514-b865e0e90fed" xlink:href="kron-20200930.xsd#kron_DebtSecuritiesAvailableForSaleAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8712817d-9d12-402e-b09f-6ce07255cc54" xlink:to="loc_kron_DebtSecuritiesAvailableForSaleAccruedInterest_17646823-f743-4aaa-a514-b865e0e90fed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PrepaidExternalResearchAndDevelopment_cd419bf9-3c6e-421d-97ca-234f70506b6c" xlink:href="kron-20200930.xsd#kron_PrepaidExternalResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8712817d-9d12-402e-b09f-6ce07255cc54" xlink:to="loc_kron_PrepaidExternalResearchAndDevelopment_cd419bf9-3c6e-421d-97ca-234f70506b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_45af1080-dc3a-40e3-874a-62171011eed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8712817d-9d12-402e-b09f-6ce07255cc54" xlink:to="loc_us-gaap_PrepaidRent_45af1080-dc3a-40e3-874a-62171011eed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_2dfd6a96-f0b9-443c-8fe9-04c114a42f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8712817d-9d12-402e-b09f-6ce07255cc54" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_2dfd6a96-f0b9-443c-8fe9-04c114a42f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_e055bd4a-67c0-4f0a-8fca-91ac9c44a17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8712817d-9d12-402e-b09f-6ce07255cc54" xlink:to="loc_us-gaap_PrepaidInsurance_e055bd4a-67c0-4f0a-8fca-91ac9c44a17d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PrepaidSoftware_1d40c8c6-1bfb-4de3-875b-db5b8bb59e46" xlink:href="kron-20200930.xsd#kron_PrepaidSoftware"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8712817d-9d12-402e-b09f-6ce07255cc54" xlink:to="loc_kron_PrepaidSoftware_1d40c8c6-1bfb-4de3-875b-db5b8bb59e46" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="kron-20200930.xsd#PropertyandEquipmentNet"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PropertyandEquipmentNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="kron-20200930.xsd#PropertyPlantandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PropertyPlantandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9ff85c9d-5cee-4747-afd6-3c7aeafa2272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_aad4851e-91d3-426c-9846-416ba74721d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9ff85c9d-5cee-4747-afd6-3c7aeafa2272" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_aad4851e-91d3-426c-9846-416ba74721d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_b380c11b-d175-4f8b-87c9-8b1cc38a8d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9ff85c9d-5cee-4747-afd6-3c7aeafa2272" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_b380c11b-d175-4f8b-87c9-8b1cc38a8d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_876b65f8-29a9-4090-a573-63926e6d5bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a57d6c98-99a8-45e5-a9d9-233ec3559720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_876b65f8-29a9-4090-a573-63926e6d5bcc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a57d6c98-99a8-45e5-a9d9-233ec3559720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6398cb97-ead7-408a-8b2d-68baa5943ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_876b65f8-29a9-4090-a573-63926e6d5bcc" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6398cb97-ead7-408a-8b2d-68baa5943ef0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesandCurrentPortionofOtherLiabilities"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ed59864b-a467-4cf2-b30c-02c018824920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a0626f0c-2230-4b63-b90f-c1a8f17a6e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ed59864b-a467-4cf2-b30c-02c018824920" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a0626f0c-2230-4b63-b90f-c1a8f17a6e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_3f57d48f-4c68-4208-a31d-c90a977786f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ed59864b-a467-4cf2-b30c-02c018824920" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_3f57d48f-4c68-4208-a31d-c90a977786f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e1d86972-3c80-4a33-94c3-4262e7d288c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ed59864b-a467-4cf2-b30c-02c018824920" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e1d86972-3c80-4a33-94c3-4262e7d288c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AccruedExternalResearchAndDevelopmentCurrent_3e7829bc-e335-4e11-b997-9e9f0e8c628f" xlink:href="kron-20200930.xsd#kron_AccruedExternalResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ed59864b-a467-4cf2-b30c-02c018824920" xlink:to="loc_kron_AccruedExternalResearchAndDevelopmentCurrent_3e7829bc-e335-4e11-b997-9e9f0e8c628f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AccruedOfferingCostsCurrent_df43d879-725c-484d-acba-a52add38a1d6" xlink:href="kron-20200930.xsd#kron_AccruedOfferingCostsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ed59864b-a467-4cf2-b30c-02c018824920" xlink:to="loc_kron_AccruedOfferingCostsCurrent_df43d879-725c-484d-acba-a52add38a1d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_535d1e94-5f20-49b5-867c-4d9317a88b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_77f9fe06-e47c-4434-9975-9fce55327f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_535d1e94-5f20-49b5-867c-4d9317a88b52" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_77f9fe06-e47c-4434-9975-9fce55327f8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_368443dc-2bcd-44b7-8877-7931e78e653e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_535d1e94-5f20-49b5-867c-4d9317a88b52" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_368443dc-2bcd-44b7-8877-7931e78e653e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStock" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStock"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PreferredStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStockTables" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStockTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PreferredStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStockNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PreferredStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStockDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/PreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommonStock" xlink:type="simple" xlink:href="kron-20200930.xsd#CommonStock"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommonStockDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#CommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationOptionpricingModelAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationClassifiedinStatementsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationRestrictedStockDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="kron-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/NetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingencies"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingenciesKeyValuationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/Leases" xlink:type="simple" xlink:href="kron-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/LeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesSummaryofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_14d22e9b-4a91-45df-9369-25ba27eaefb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_37ec0a7e-30a3-438a-b3cb-0976b19880fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_14d22e9b-4a91-45df-9369-25ba27eaefb5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_37ec0a7e-30a3-438a-b3cb-0976b19880fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d79acd92-99f6-4d4d-9aab-843409f1f5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_14d22e9b-4a91-45df-9369-25ba27eaefb5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d79acd92-99f6-4d4d-9aab-843409f1f5d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fd77ff7f-ad5c-4572-b1dd-2c76478e9024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9537b0a8-20ed-4ce9-bc15-e66c52a4185d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_fd77ff7f-ad5c-4572-b1dd-2c76478e9024" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9537b0a8-20ed-4ce9-bc15-e66c52a4185d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f7687a79-b8aa-4803-8857-af4f9aaaf802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_fd77ff7f-ad5c-4572-b1dd-2c76478e9024" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f7687a79-b8aa-4803-8857-af4f9aaaf802" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b412c7ef-e34b-44fb-be83-4bd88119af4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_58371c2f-35dc-4cc1-a3de-9a6e291be4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b412c7ef-e34b-44fb-be83-4bd88119af4a" xlink:to="loc_us-gaap_OperatingLeaseLiability_58371c2f-35dc-4cc1-a3de-9a6e291be4c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_4bd46382-b9f8-4e65-be88-1cd96707ffba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b412c7ef-e34b-44fb-be83-4bd88119af4a" xlink:to="loc_us-gaap_TenantImprovements_4bd46382-b9f8-4e65-be88-1cd96707ffba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a51f00e1-59b9-4299-80ff-26034869364e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b412c7ef-e34b-44fb-be83-4bd88119af4a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a51f00e1-59b9-4299-80ff-26034869364e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67415016-3bf8-4dc2-80ac-24f4528ad0a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b7c87a07-612d-48eb-86b4-0f60bf35bbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67415016-3bf8-4dc2-80ac-24f4528ad0a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b7c87a07-612d-48eb-86b4-0f60bf35bbee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8405a209-514e-430c-9022-8cc371db1f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67415016-3bf8-4dc2-80ac-24f4528ad0a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8405a209-514e-430c-9022-8cc371db1f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2571094a-5148-4f87-8312-e4438b60c380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67415016-3bf8-4dc2-80ac-24f4528ad0a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2571094a-5148-4f87-8312-e4438b60c380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_c6964f89-8b31-4012-b7c7-469d1f8beff9" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67415016-3bf8-4dc2-80ac-24f4528ad0a2" xlink:to="loc_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_c6964f89-8b31-4012-b7c7-469d1f8beff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_808c5ca3-2244-4a2d-a89b-bcc92e9d9523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67415016-3bf8-4dc2-80ac-24f4528ad0a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_808c5ca3-2244-4a2d-a89b-bcc92e9d9523" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020Notes" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020Notes"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/A2020Notes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020NotesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020NotesTables"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/A2020NotesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020NotesNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020NotesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/A2020NotesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020NotesKeyValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/RelatedParties" xlink:type="simple" xlink:href="kron-20200930.xsd#RelatedParties"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/RelatedParties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#RelatedPartyDisclosuresDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="kron-20200930.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.kronosbio.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>kron-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:24f323b6-3e05-4299-b60b-ed7d0f94eb5e,g:b8dc781a-ce5b-4a7b-a930-702eddd4413f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CoverPage" xlink:type="simple" xlink:href="kron-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CoverPage" xlink:type="extended" id="i2fc10901f41f47a2aff6ea6f4abf8a03_CoverPage"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited" xlink:type="extended" id="if4f6bc5a81c04b8c9dd4bef0a7f80ef6_CondensedBalanceSheetsUnaudited"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="ifb4632225575425e9d4b2e8082641403_CondensedBalanceSheetsUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended" id="i2825e76c16d84056a41abb7a4501f446_CondensedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited" xlink:type="extended" id="i472e46128910491d9eb7153b8184684c_CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f17c9fac-4abb-483a-b04d-f38d5ed04cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f17c9fac-4abb-483a-b04d-f38d5ed04cd7" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_37df4eee-0f87-4ff0-853f-a08d0faf9a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_37df4eee-0f87-4ff0-853f-a08d0faf9a2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fd7a5af5-a1fe-4af7-80ee-cd9bedd62b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fd7a5af5-a1fe-4af7-80ee-cd9bedd62b89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_972db71c-9071-4296-8436-d9f5d35d1b30" xlink:href="kron-20200930.xsd#kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_972db71c-9071-4296-8436-d9f5d35d1b30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5fe2ab5b-0bbb-4beb-8b5d-a82a74de9fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5fe2ab5b-0bbb-4beb-8b5d-a82a74de9fb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_913226d9-cf5f-4400-8b28-127da0dabbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9adf3fa1-43cc-42f5-8c45-d390e01fbc57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f17c9fac-4abb-483a-b04d-f38d5ed04cd7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1260bcd7-b0c4-4558-bfb6-34ebd37898ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_SharesOutstanding_1260bcd7-b0c4-4558-bfb6-34ebd37898ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b5cd1326-dce0-4f2a-9af2-cbe92bde98ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_StockholdersEquity_b5cd1326-dce0-4f2a-9af2-cbe92bde98ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_18f9c4d0-df81-44f7-8442-76cf767b8b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_18f9c4d0-df81-44f7-8442-76cf767b8b5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cbcab457-e435-40c8-982e-1983402f403b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cbcab457-e435-40c8-982e-1983402f403b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f10f6b7-bc87-4255-8c76-14837d240f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f10f6b7-bc87-4255-8c76-14837d240f1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c84f81c9-bee9-4dad-8eff-e5a5394fe1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c84f81c9-bee9-4dad-8eff-e5a5394fe1e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_72c66cc6-c22d-44f2-b36b-c279ceaf6e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_NetIncomeLoss_72c66cc6-c22d-44f2-b36b-c279ceaf6e7e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4b9b8648-99ce-4d3c-8906-ac531c5cbb02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f452925a-5a5c-41ad-8c51-7cc33d474cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3339b02c-011c-4629-9aa0-e898651963ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f17c9fac-4abb-483a-b04d-f38d5ed04cd7" xlink:to="loc_us-gaap_StatementTable_3339b02c-011c-4629-9aa0-e898651963ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_325d0e5c-0775-4d0c-99c9-15da9a4b1527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3339b02c-011c-4629-9aa0-e898651963ad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_325d0e5c-0775-4d0c-99c9-15da9a4b1527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_325d0e5c-0775-4d0c-99c9-15da9a4b1527_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_325d0e5c-0775-4d0c-99c9-15da9a4b1527" xlink:to="loc_us-gaap_EquityComponentDomain_325d0e5c-0775-4d0c-99c9-15da9a4b1527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_325d0e5c-0775-4d0c-99c9-15da9a4b1527" xlink:to="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_062697a2-7c02-48df-97cd-d77f1d925d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:to="loc_us-gaap_CommonStockMember_062697a2-7c02-48df-97cd-d77f1d925d33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2312d0bd-0851-4a64-af28-d6836b034770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2312d0bd-0851-4a64-af28-d6836b034770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6cb9ce1-d7df-48f8-bc08-279de05cdee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6cb9ce1-d7df-48f8-bc08-279de05cdee6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2ed72090-dbb2-47f6-a951-7a3bbdd1e8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:to="loc_us-gaap_RetainedEarningsMember_2ed72090-dbb2-47f6-a951-7a3bbdd1e8e3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals" xlink:type="extended" id="ic4c47e40b283453aacf2bcfbe54f023d_CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9e28dcc2-b1f9-4678-b6c8-d74ddd7d33f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_b5c85700-384f-44b2-bbba-026ddadc47f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9e28dcc2-b1f9-4678-b6c8-d74ddd7d33f1" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_b5c85700-384f-44b2-bbba-026ddadc47f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d9a4fdbb-86de-4cd9-9dad-b589e75548c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9e28dcc2-b1f9-4678-b6c8-d74ddd7d33f1" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d9a4fdbb-86de-4cd9-9dad-b589e75548c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c704506c-fe05-4317-b0c1-aab91a07513d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9e28dcc2-b1f9-4678-b6c8-d74ddd7d33f1" xlink:to="loc_us-gaap_StatementTable_c704506c-fe05-4317-b0c1-aab91a07513d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2ce14438-a80c-44ce-bfb0-26c2818d2667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c704506c-fe05-4317-b0c1-aab91a07513d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2ce14438-a80c-44ce-bfb0-26c2818d2667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ce14438-a80c-44ce-bfb0-26c2818d2667_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ce14438-a80c-44ce-bfb0-26c2818d2667" xlink:to="loc_us-gaap_EquityComponentDomain_2ce14438-a80c-44ce-bfb0-26c2818d2667_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e8aa9f4-60b4-440e-abcc-937d82897b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ce14438-a80c-44ce-bfb0-26c2818d2667" xlink:to="loc_us-gaap_EquityComponentDomain_5e8aa9f4-60b4-440e-abcc-937d82897b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_cf0e9bc4-303b-4fbf-b745-afca92810ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e8aa9f4-60b4-440e-abcc-937d82897b4c" xlink:to="loc_us-gaap_PreferredStockMember_cf0e9bc4-303b-4fbf-b745-afca92810ba2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofCashFlowsunaudited"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="extended" id="id79a23b65fb8416b94ad7bf4f58e4812_CondensedStatementsofCashFlowsunaudited"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation" xlink:type="simple" xlink:href="kron-20200930.xsd#NatureofOperationsandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation" xlink:type="extended" id="i54ebc9573b7646558454c787edae9f73_NatureofOperationsandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended" id="ia0d4a070ceb6452882d39d5870b34102_OrganizationConsolidationandPresentationofFinancialStatementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_173ab2a9-34b0-4637-bf1f-47320cb64a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_173ab2a9-34b0-4637-bf1f-47320cb64a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6b8748ce-cb73-4b5a-90b3-0c25f3c3782e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6b8748ce-cb73-4b5a-90b3-0c25f3c3782e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_faef966f-7922-4202-9df0-fd7e33c416ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_faef966f-7922-4202-9df0-fd7e33c416ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0c62a3b8-d373-40ba-bca8-dc84a4c69f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0c62a3b8-d373-40ba-bca8-dc84a4c69f57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsOfUnderwritingDiscountsAndCommissions_eda408d5-e94f-4fdd-ac52-05b55c80392d" xlink:href="kron-20200930.xsd#kron_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_kron_PaymentsOfUnderwritingDiscountsAndCommissions_eda408d5-e94f-4fdd-ac52-05b55c80392d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsOfOfferingCosts_459ac87c-23d5-483f-9617-e8a7b519219a" xlink:href="kron-20200930.xsd#kron_PaymentsOfOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_kron_PaymentsOfOfferingCosts_459ac87c-23d5-483f-9617-e8a7b519219a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_323e4c45-6960-4f89-a5fd-9099f9e5b82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_323e4c45-6960-4f89-a5fd-9099f9e5b82e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_cc239b8b-3ed5-48ae-95a9-b6d7fcedbabc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_cc239b8b-3ed5-48ae-95a9-b6d7fcedbabc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ebbec6f1-825e-494c-88e5-047cbc5958ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ebbec6f1-825e-494c-88e5-047cbc5958ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_b11f8d81-1d97-49de-bdd5-c734b3dc773c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_DeferredOfferingCosts_b11f8d81-1d97-49de-bdd5-c734b3dc773c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3b0b83b0-1582-430c-9c28-538b3d8d7db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3b0b83b0-1582-430c-9c28-538b3d8d7db9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d8ce1edd-ee31-4d0f-a4dd-69853e9545a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_NetIncomeLoss_d8ce1edd-ee31-4d0f-a4dd-69853e9545a7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1b197df6-7126-437e-bfdf-7b53000859da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1b197df6-7126-437e-bfdf-7b53000859da" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9e46af76-64d0-496c-8e40-d54910c5f3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9e46af76-64d0-496c-8e40-d54910c5f3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e46af76-64d0-496c-8e40-d54910c5f3ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9e46af76-64d0-496c-8e40-d54910c5f3ec" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e46af76-64d0-496c-8e40-d54910c5f3ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca261fc1-4ccc-4962-a12a-d6ed7d64aa4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9e46af76-64d0-496c-8e40-d54910c5f3ec" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca261fc1-4ccc-4962-a12a-d6ed7d64aa4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_725adf62-79e3-43d0-9a15-37732274a461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca261fc1-4ccc-4962-a12a-d6ed7d64aa4c" xlink:to="loc_us-gaap_IPOMember_725adf62-79e3-43d0-9a15-37732274a461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_10ada2df-47ea-4fc5-a84c-8bea9509d0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca261fc1-4ccc-4962-a12a-d6ed7d64aa4c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_10ada2df-47ea-4fc5-a84c-8bea9509d0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8271824a-36c0-4bab-920b-ce7df4ba5f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8271824a-36c0-4bab-920b-ce7df4ba5f35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8271824a-36c0-4bab-920b-ce7df4ba5f35_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8271824a-36c0-4bab-920b-ce7df4ba5f35" xlink:to="loc_us-gaap_EquityComponentDomain_8271824a-36c0-4bab-920b-ce7df4ba5f35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d0d34242-9b03-4bfd-a44c-a3819932f6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8271824a-36c0-4bab-920b-ce7df4ba5f35" xlink:to="loc_us-gaap_EquityComponentDomain_d0d34242-9b03-4bfd-a44c-a3819932f6b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_819f038c-a142-4a6a-969d-914386c2323b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d0d34242-9b03-4bfd-a44c-a3819932f6b1" xlink:to="loc_us-gaap_CommonStockMember_819f038c-a142-4a6a-969d-914386c2323b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8b0ddad2-8c46-4dc6-9032-ae2772e47b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8b0ddad2-8c46-4dc6-9032-ae2772e47b7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8b0ddad2-8c46-4dc6-9032-ae2772e47b7d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8b0ddad2-8c46-4dc6-9032-ae2772e47b7d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8b0ddad2-8c46-4dc6-9032-ae2772e47b7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_aab5d596-d166-4209-9cf1-9bc911bfde29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8b0ddad2-8c46-4dc6-9032-ae2772e47b7d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_aab5d596-d166-4209-9cf1-9bc911bfde29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8450869c-84d0-4fb4-a16d-48bb562ca54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_aab5d596-d166-4209-9cf1-9bc911bfde29" xlink:to="loc_us-gaap_SubsequentEventMember_8450869c-84d0-4fb4-a16d-48bb562ca54f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5eeb67f-b273-4a98-b00f-80c7bd8048df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5eeb67f-b273-4a98-b00f-80c7bd8048df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b5eeb67f-b273-4a98-b00f-80c7bd8048df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5eeb67f-b273-4a98-b00f-80c7bd8048df" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b5eeb67f-b273-4a98-b00f-80c7bd8048df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1eb71194-eb9a-4659-89ad-0fbb4b1b4148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5eeb67f-b273-4a98-b00f-80c7bd8048df" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1eb71194-eb9a-4659-89ad-0fbb4b1b4148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020ConvertibleNotesMember_162aa298-66f3-4b48-b1ac-0d82db95349a" xlink:href="kron-20200930.xsd#kron_A2020ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1eb71194-eb9a-4659-89ad-0fbb4b1b4148" xlink:to="loc_kron_A2020ConvertibleNotesMember_162aa298-66f3-4b48-b1ac-0d82db95349a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020GileadNotesMember_b294f29e-1bbe-44c6-a798-d629aedf2e47" xlink:href="kron-20200930.xsd#kron_A2020GileadNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1eb71194-eb9a-4659-89ad-0fbb4b1b4148" xlink:to="loc_kron_A2020GileadNotesMember_b294f29e-1bbe-44c6-a798-d629aedf2e47" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgments"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments" xlink:type="extended" id="i3522a6cb96844228bafa5ef09442fb72_SignificantAccountingPoliciesEstimatesandJudgments"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies" xlink:type="extended" id="ibb9bcb9216a840dda435adde52148494_SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables" xlink:type="extended" id="id2482d46dd9a416881286688c5b39eaa_SignificantAccountingPoliciesEstimatesandJudgmentsTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails" xlink:type="extended" id="i0af12259c1724787975a5f44c63050ea_SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionLineItems_1c60bdfb-4b36-4ba5-909d-44eb94d50fc7" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25691d3e-1b57-48b7-b8d0-107df0b53362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_1c60bdfb-4b36-4ba5-909d-44eb94d50fc7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25691d3e-1b57-48b7-b8d0-107df0b53362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionTable_93d7d145-0bd7-4933-b11e-ce56ae5dc019" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_1c60bdfb-4b36-4ba5-909d-44eb94d50fc7" xlink:to="loc_kron_ScheduleOfAssetAcquisitionTable_93d7d145-0bd7-4933-b11e-ce56ae5dc019" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionAxis_a4234fcd-49d0-41e3-8b31-ed4267ebeb4b" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_93d7d145-0bd7-4933-b11e-ce56ae5dc019" xlink:to="loc_kron_AssetAcquisitionAxis_a4234fcd-49d0-41e3-8b31-ed4267ebeb4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionDomain_a4234fcd-49d0-41e3-8b31-ed4267ebeb4b_default" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kron_AssetAcquisitionAxis_a4234fcd-49d0-41e3-8b31-ed4267ebeb4b" xlink:to="loc_kron_AssetAcquisitionDomain_a4234fcd-49d0-41e3-8b31-ed4267ebeb4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionDomain_2deaf703-818a-4466-b907-e62ded1ab071" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kron_AssetAcquisitionAxis_a4234fcd-49d0-41e3-8b31-ed4267ebeb4b" xlink:to="loc_kron_AssetAcquisitionDomain_2deaf703-818a-4466-b907-e62ded1ab071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GileadAssetPurchaseMember_44dced18-a267-437f-a209-3ce2984ed0e0" xlink:href="kron-20200930.xsd#kron_GileadAssetPurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_AssetAcquisitionDomain_2deaf703-818a-4466-b907-e62ded1ab071" xlink:to="loc_kron_GileadAssetPurchaseMember_44dced18-a267-437f-a209-3ce2984ed0e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails" xlink:type="extended" id="iae8d475b75054319a9a6604c9c4c00ec_SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails" xlink:type="extended" id="i5fb7a84a84ec4b06a81f59518321bcd3_SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b135597-5e52-4b28-b105-10710f9c0541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a82969f8-b7e5-4d9c-897b-52b234eda14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b135597-5e52-4b28-b105-10710f9c0541" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a82969f8-b7e5-4d9c-897b-52b234eda14a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5a10a81e-3c01-4307-b3b2-216b68afbb97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b135597-5e52-4b28-b105-10710f9c0541" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5a10a81e-3c01-4307-b3b2-216b68afbb97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97722a11-1f18-4469-adca-385476ce6d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5a10a81e-3c01-4307-b3b2-216b68afbb97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97722a11-1f18-4469-adca-385476ce6d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97722a11-1f18-4469-adca-385476ce6d6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97722a11-1f18-4469-adca-385476ce6d6e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97722a11-1f18-4469-adca-385476ce6d6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b77a62f7-07b9-4c95-af1f-f260f7a7e23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97722a11-1f18-4469-adca-385476ce6d6e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b77a62f7-07b9-4c95-af1f-f260f7a7e23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LabEquipmentMember_818d34e1-e52a-4e14-b438-19f18b6bedf9" xlink:href="kron-20200930.xsd#kron_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b77a62f7-07b9-4c95-af1f-f260f7a7e23d" xlink:to="loc_kron_LabEquipmentMember_818d34e1-e52a-4e14-b438-19f18b6bedf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_378a2044-5e08-4999-95c0-af5d43d1f008" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5a10a81e-3c01-4307-b3b2-216b68afbb97" xlink:to="loc_srt_RangeAxis_378a2044-5e08-4999-95c0-af5d43d1f008" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_378a2044-5e08-4999-95c0-af5d43d1f008_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_378a2044-5e08-4999-95c0-af5d43d1f008" xlink:to="loc_srt_RangeMember_378a2044-5e08-4999-95c0-af5d43d1f008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86d3bb87-83ef-41d8-a5a2-0b95483f95ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_378a2044-5e08-4999-95c0-af5d43d1f008" xlink:to="loc_srt_RangeMember_86d3bb87-83ef-41d8-a5a2-0b95483f95ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b1d84cc4-844f-4a50-8e02-f79008a3de5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86d3bb87-83ef-41d8-a5a2-0b95483f95ee" xlink:to="loc_srt_MinimumMember_b1d84cc4-844f-4a50-8e02-f79008a3de5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d164ab6c-40b4-40e9-913c-311e6fbfda8a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86d3bb87-83ef-41d8-a5a2-0b95483f95ee" xlink:to="loc_srt_MaximumMember_d164ab6c-40b4-40e9-913c-311e6fbfda8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails" xlink:type="extended" id="iec71ad55b1d441e88c6e18cb4fcf6bea_SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="kron-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/FairValueMeasurements" xlink:type="extended" id="i2be4c27a4c854960994498a414ab84c7_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/FairValueMeasurementsTables" xlink:type="extended" id="id2aedf88c8c14a87a95738ea21d0bace_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ida0998ad0409403fbaf623533964e8c0_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1778247b-6e13-435c-8a1e-b9dfdd943952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1778247b-6e13-435c-8a1e-b9dfdd943952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6711ea19-a890-4b8e-97bb-581fada6fa73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6711ea19-a890-4b8e-97bb-581fada6fa73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a27a0624-f181-404d-aecc-c6cfffe632e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a27a0624-f181-404d-aecc-c6cfffe632e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b8a57cbd-efed-4550-8247-d282ebd146b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b8a57cbd-efed-4550-8247-d282ebd146b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_708c7f4b-21d0-4a3a-822e-e30f89d984e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_708c7f4b-21d0-4a3a-822e-e30f89d984e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_624e9c50-f8c1-4d78-8e6d-cff162556074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_624e9c50-f8c1-4d78-8e6d-cff162556074" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3c939e3-a385-49ef-856b-3c227a8e5704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3c939e3-a385-49ef-856b-3c227a8e5704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3c939e3-a385-49ef-856b-3c227a8e5704_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3c939e3-a385-49ef-856b-3c227a8e5704" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3c939e3-a385-49ef-856b-3c227a8e5704_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5be3afcd-45d2-4eb3-8b42-3e9634793f15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3c939e3-a385-49ef-856b-3c227a8e5704" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5be3afcd-45d2-4eb3-8b42-3e9634793f15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2141fd52-6937-4058-8ed8-cfccae043510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5be3afcd-45d2-4eb3-8b42-3e9634793f15" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2141fd52-6937-4058-8ed8-cfccae043510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6e26616-5517-4aa3-a69f-b03e93cfffb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6e26616-5517-4aa3-a69f-b03e93cfffb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6e26616-5517-4aa3-a69f-b03e93cfffb7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6e26616-5517-4aa3-a69f-b03e93cfffb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6e26616-5517-4aa3-a69f-b03e93cfffb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6e26616-5517-4aa3-a69f-b03e93cfffb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_faefd44d-056f-44c1-b35b-556a2883f0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_faefd44d-056f-44c1-b35b-556a2883f0d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_41fcd8bc-8b3c-4162-9e53-f4c936f6802a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_41fcd8bc-8b3c-4162-9e53-f4c936f6802a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7922bc2c-e82e-495c-839d-a16258b03be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7922bc2c-e82e-495c-839d-a16258b03be3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_def132d8-8c19-4679-8670-e249cc33d537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:to="loc_us-gaap_FinancialInstrumentAxis_def132d8-8c19-4679-8670-e249cc33d537" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_def132d8-8c19-4679-8670-e249cc33d537_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_def132d8-8c19-4679-8670-e249cc33d537" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_def132d8-8c19-4679-8670-e249cc33d537_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_def132d8-8c19-4679-8670-e249cc33d537" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_67fc1890-6083-4607-80bf-ba4c257d54dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_MoneyMarketFundsMember_67fc1890-6083-4607-80bf-ba4c257d54dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7bbef899-7985-4911-8106-d9c0daa6b663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7bbef899-7985-4911-8106-d9c0daa6b663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6f03fb2e-5e00-4bbf-a009-89b236a5d7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_CommercialPaperMember_6f03fb2e-5e00-4bbf-a009-89b236a5d7b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_74ada84a-e579-42a9-97b9-0d02c646fe54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_74ada84a-e579-42a9-97b9-0d02c646fe54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7e3cb8ec-8540-4f3c-b1bf-ed62350d9a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7e3cb8ec-8540-4f3c-b1bf-ed62350d9a43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d51de259-2956-459e-8628-2f9be485316c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d51de259-2956-459e-8628-2f9be485316c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_5ef96607-86f0-4b08-b678-bfd6a777bc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_5ef96607-86f0-4b08-b678-bfd6a777bc7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f075ba1d-8811-4b7d-a507-9416371ad360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f075ba1d-8811-4b7d-a507-9416371ad360" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2ecfe990-e0cb-4d8a-9bc2-6c52241eb785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2ecfe990-e0cb-4d8a-9bc2-6c52241eb785" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2ecfe990-e0cb-4d8a-9bc2-6c52241eb785_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2ecfe990-e0cb-4d8a-9bc2-6c52241eb785" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2ecfe990-e0cb-4d8a-9bc2-6c52241eb785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4018b52-f597-4ca6-8eab-42e37bf1d68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2ecfe990-e0cb-4d8a-9bc2-6c52241eb785" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4018b52-f597-4ca6-8eab-42e37bf1d68a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3af12346-e414-470f-b437-185aa5bf827b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4018b52-f597-4ca6-8eab-42e37bf1d68a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3af12346-e414-470f-b437-185aa5bf827b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/Investments" xlink:type="simple" xlink:href="kron-20200930.xsd#Investments"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/Investments" xlink:type="extended" id="i2a29dcce87874741a5277fd19b8ffd57_Investments"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/InvestmentsTables" xlink:type="extended" id="ib40fcbc6cfd349b6a00364975628edee_InvestmentsTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsFairValueandAmortizedCostDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails" xlink:type="extended" id="i09c15a16c01d41ca8e24b6e26b5cc1bf_InvestmentsFairValueandAmortizedCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_fb9454eb-18ce-4edd-a354-8d12048f0019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_fb9454eb-18ce-4edd-a354-8d12048f0019" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bbfc0e05-b663-4959-9c03-8cd5f018bdee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bbfc0e05-b663-4959-9c03-8cd5f018bdee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a4d8d787-503f-49a4-af16-44e9bcc61d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a4d8d787-503f-49a4-af16-44e9bcc61d52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3a9fdcb9-02de-4058-8fff-b785ae9fd98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3a9fdcb9-02de-4058-8fff-b785ae9fd98e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_551a4216-5fd5-4715-a161-c26b40e7bf52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_551a4216-5fd5-4715-a161-c26b40e7bf52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_507a314c-a2b1-462c-80c7-f6c746149916" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_507a314c-a2b1-462c-80c7-f6c746149916" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax_efac8160-f81d-4ecb-ad2b-1d95133a3be5" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax_efac8160-f81d-4ecb-ad2b-1d95133a3be5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax_06438c9e-416e-4c02-b7eb-b5d20b532460" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax_06438c9e-416e-4c02-b7eb-b5d20b532460" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d4b40251-fbe9-4e56-b42a-3710bafcef5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d4b40251-fbe9-4e56-b42a-3710bafcef5b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_919c1ba1-da88-4035-acef-7d563c1bc714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_919c1ba1-da88-4035-acef-7d563c1bc714" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_69be36b3-ccf0-4ca9-a595-818671e40666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_919c1ba1-da88-4035-acef-7d563c1bc714" xlink:to="loc_us-gaap_FinancialInstrumentAxis_69be36b3-ccf0-4ca9-a595-818671e40666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69be36b3-ccf0-4ca9-a595-818671e40666_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69be36b3-ccf0-4ca9-a595-818671e40666" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69be36b3-ccf0-4ca9-a595-818671e40666_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69be36b3-ccf0-4ca9-a595-818671e40666" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_24f27332-27bd-45eb-86a2-92eeb96bef7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_CertificatesOfDepositMember_24f27332-27bd-45eb-86a2-92eeb96bef7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_771f643e-217d-4e19-96c8-38a930477218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_CommercialPaperMember_771f643e-217d-4e19-96c8-38a930477218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_77170577-961a-4560-97ef-d68c1fe3dccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_77170577-961a-4560-97ef-d68c1fe3dccf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7af1a4b9-8716-4856-ae8f-dd176e6336ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7af1a4b9-8716-4856-ae8f-dd176e6336ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7edc3486-18cf-47f5-a124-3d897faa8812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7edc3486-18cf-47f5-a124-3d897faa8812" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4e9f10ac-a815-409d-8632-d643d2489364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_919c1ba1-da88-4035-acef-7d563c1bc714" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4e9f10ac-a815-409d-8632-d643d2489364" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e9f10ac-a815-409d-8632-d643d2489364_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4e9f10ac-a815-409d-8632-d643d2489364" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e9f10ac-a815-409d-8632-d643d2489364_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_73b545da-eaee-422c-a0d4-4c22094090ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4e9f10ac-a815-409d-8632-d643d2489364" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_73b545da-eaee-422c-a0d4-4c22094090ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_40652032-e0b3-4784-8f9d-7b7fc10051ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_73b545da-eaee-422c-a0d4-4c22094090ba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_40652032-e0b3-4784-8f9d-7b7fc10051ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails" xlink:type="extended" id="i9b1f4ffb0fb74501926ff66d5be58d0e_InvestmentsBalanceSheetDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails" xlink:type="extended" id="ie6e16c9aac3c4746a0d521d01d8ca45f_InvestmentsContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" xlink:href="kron-20200930.xsd#PrepaidExpensesAndOtherCurrentAssets"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" id="i811df501c0284ccabc63c701c8aa8e8a_PrepaidExpensesAndOtherCurrentAssets"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#PrepaidExpensesAndOtherCurrentAssetsTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" id="i4e836b1815ed4d5e95df98d167e0842c_PrepaidExpensesAndOtherCurrentAssetsTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" id="i14adc6e690f44b61b9c941bc13003f6a_PrepaidExpensesAndOtherCurrentAssetsDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="kron-20200930.xsd#PropertyandEquipmentNet"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PropertyandEquipmentNet" xlink:type="extended" id="i46dd27a58d0f41a5a7156fa39289ba03_PropertyandEquipmentNet"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="kron-20200930.xsd#PropertyPlantandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PropertyPlantandEquipmentTables" xlink:type="extended" id="i8f64b544ac5849b4b65157861a857d63_PropertyPlantandEquipmentTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended" id="i46a77380e0dd41fe937954f75a4347a7_PropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b1665943-ca62-4339-b46e-a00abe422e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b1665943-ca62-4339-b46e-a00abe422e05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b46aa46a-ec9d-4b42-bb50-651703cf4dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b46aa46a-ec9d-4b42-bb50-651703cf4dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3211215a-64c8-4802-973c-0644414d8e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3211215a-64c8-4802-973c-0644414d8e17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_d4c43b8f-d139-4d68-a4a0-1b526a51eb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_d4c43b8f-d139-4d68-a4a0-1b526a51eb9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fb500440-90e6-438d-906f-037cf35fad23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fb500440-90e6-438d-906f-037cf35fad23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f780ea45-a88a-4600-bd40-c6e88b368dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f780ea45-a88a-4600-bd40-c6e88b368dd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb9bb945-1f36-4567-ba29-4e36e38489ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f780ea45-a88a-4600-bd40-c6e88b368dd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb9bb945-1f36-4567-ba29-4e36e38489ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb9bb945-1f36-4567-ba29-4e36e38489ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb9bb945-1f36-4567-ba29-4e36e38489ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb9bb945-1f36-4567-ba29-4e36e38489ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_817f2bd7-4b0c-4f61-92d5-cc2e26082fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb9bb945-1f36-4567-ba29-4e36e38489ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_817f2bd7-4b0c-4f61-92d5-cc2e26082fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LabEquipmentMember_27a6e844-10fb-45d8-a672-6698337219fc" xlink:href="kron-20200930.xsd#kron_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_817f2bd7-4b0c-4f61-92d5-cc2e26082fd5" xlink:to="loc_kron_LabEquipmentMember_27a6e844-10fb-45d8-a672-6698337219fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_5e569eeb-6605-49a4-8810-93bfe8581258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_817f2bd7-4b0c-4f61-92d5-cc2e26082fd5" xlink:to="loc_us-gaap_ConstructionInProgressMember_5e569eeb-6605-49a4-8810-93bfe8581258" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesandCurrentPortionofOtherLiabilities"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities" xlink:type="extended" id="i612b3d25ec0a4728907cc84426925e65_AccruedExpensesandCurrentPortionofOtherLiabilities"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables" xlink:type="extended" id="i1a5865e7638c40838c322470a7c96595_AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails" xlink:type="extended" id="i006e02ee17a0444aa7b81bb63e56be31_AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails" xlink:type="extended" id="ief66f5c22ed84639b5399e0acd47944a_AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStock" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStock"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PreferredStock" xlink:type="extended" id="i5262cbec42074da59f36f797341f7e60_PreferredStock"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStockTables" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStockTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PreferredStockTables" xlink:type="extended" id="i4511305a07084e5f870e8d13708a2213_PreferredStockTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStockNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PreferredStockNarrativeDetails" xlink:type="extended" id="i6052a954d5bb4813b87dce405226b378_PreferredStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68a89bea-b81b-4409-b490-579d6025acb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68a89bea-b81b-4409-b490-579d6025acb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_bfcd5fb2-5e7c-4e2c-a92e-7e310d80efa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_bfcd5fb2-5e7c-4e2c-a92e-7e310d80efa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_75f40454-c739-4b37-97d7-d9ca47ed84a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_75f40454-c739-4b37-97d7-d9ca47ed84a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_abd12cdf-12dc-466d-b972-35cc8d286b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_abd12cdf-12dc-466d-b972-35cc8d286b2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60227ce2-9615-4895-8aad-3a2e8c9301fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60227ce2-9615-4895-8aad-3a2e8c9301fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7ec27a4c-11ad-48ac-aa5f-bb1c0b583922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7ec27a4c-11ad-48ac-aa5f-bb1c0b583922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ec27a4c-11ad-48ac-aa5f-bb1c0b583922_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ec27a4c-11ad-48ac-aa5f-bb1c0b583922" xlink:to="loc_us-gaap_ClassOfStockDomain_7ec27a4c-11ad-48ac-aa5f-bb1c0b583922_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1b467fa5-e3b3-4147-a036-f7960f58c838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ec27a4c-11ad-48ac-aa5f-bb1c0b583922" xlink:to="loc_us-gaap_ClassOfStockDomain_1b467fa5-e3b3-4147-a036-f7960f58c838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SeriesSeedPreferredStockMember_bb096548-bd9f-4882-ae1e-4c89b5e5915f" xlink:href="kron-20200930.xsd#kron_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1b467fa5-e3b3-4147-a036-f7960f58c838" xlink:to="loc_kron_SeriesSeedPreferredStockMember_bb096548-bd9f-4882-ae1e-4c89b5e5915f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0b6ab33f-5686-4ec6-8e7e-52c7ef5309cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1b467fa5-e3b3-4147-a036-f7960f58c838" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0b6ab33f-5686-4ec6-8e7e-52c7ef5309cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1f3a44a6-1b50-4fe1-a897-acbd23727461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1f3a44a6-1b50-4fe1-a897-acbd23727461" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1f3a44a6-1b50-4fe1-a897-acbd23727461_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1f3a44a6-1b50-4fe1-a897-acbd23727461" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1f3a44a6-1b50-4fe1-a897-acbd23727461_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ee74108-8d24-498e-af44-f1083476f218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1f3a44a6-1b50-4fe1-a897-acbd23727461" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ee74108-8d24-498e-af44-f1083476f218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_94c20303-d7ef-4ece-a1a0-bb00907f6d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ee74108-8d24-498e-af44-f1083476f218" xlink:to="loc_us-gaap_PrivatePlacementMember_94c20303-d7ef-4ece-a1a0-bb00907f6d69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_351f44a5-588c-48ba-b010-7e5981e57945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_351f44a5-588c-48ba-b010-7e5981e57945" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_351f44a5-588c-48ba-b010-7e5981e57945_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_351f44a5-588c-48ba-b010-7e5981e57945" xlink:to="loc_us-gaap_DebtConversionNameDomain_351f44a5-588c-48ba-b010-7e5981e57945_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_0bffdee7-b54f-445a-b9b5-27b4451b8913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_351f44a5-588c-48ba-b010-7e5981e57945" xlink:to="loc_us-gaap_DebtConversionNameDomain_0bffdee7-b54f-445a-b9b5-27b4451b8913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1a91d469-c98d-4f26-be5d-ddf63eff951e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_0bffdee7-b54f-445a-b9b5-27b4451b8913" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1a91d469-c98d-4f26-be5d-ddf63eff951e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ca79b0d9-3a1b-400c-92c7-57e3421416cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ca79b0d9-3a1b-400c-92c7-57e3421416cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ca79b0d9-3a1b-400c-92c7-57e3421416cd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ca79b0d9-3a1b-400c-92c7-57e3421416cd" xlink:to="loc_us-gaap_EquityComponentDomain_ca79b0d9-3a1b-400c-92c7-57e3421416cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87f94a3d-e399-442b-91e5-d436b71da083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ca79b0d9-3a1b-400c-92c7-57e3421416cd" xlink:to="loc_us-gaap_EquityComponentDomain_87f94a3d-e399-442b-91e5-d436b71da083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6e9b7367-d6cc-4251-a189-ac654efd7ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87f94a3d-e399-442b-91e5-d436b71da083" xlink:to="loc_us-gaap_CommonStockMember_6e9b7367-d6cc-4251-a189-ac654efd7ec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b50f2bb8-f981-4997-96a7-63c965203538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b50f2bb8-f981-4997-96a7-63c965203538" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b50f2bb8-f981-4997-96a7-63c965203538_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b50f2bb8-f981-4997-96a7-63c965203538" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b50f2bb8-f981-4997-96a7-63c965203538_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5d7b561e-a762-4d52-b1d1-c9bfbb5e359f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b50f2bb8-f981-4997-96a7-63c965203538" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5d7b561e-a762-4d52-b1d1-c9bfbb5e359f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4dc4d4f1-cb91-41e0-bf75-532fdd3a7e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5d7b561e-a762-4d52-b1d1-c9bfbb5e359f" xlink:to="loc_us-gaap_SubsequentEventMember_4dc4d4f1-cb91-41e0-bf75-532fdd3a7e83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStockDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/PreferredStockDetails" xlink:type="extended" id="i87651f9eb5264a30b6315388cd8616a8_PreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_368be96e-f601-4f7e-acee-b83f976009c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_368be96e-f601-4f7e-acee-b83f976009c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_42d4fffc-5841-45cf-97ff-d0545c26a535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_42d4fffc-5841-45cf-97ff-d0545c26a535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_647fa358-3380-4f5c-8597-7cbdb2dc66d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_647fa358-3380-4f5c-8597-7cbdb2dc66d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fee60de6-81a0-4d20-ae0e-28bb4851f38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fee60de6-81a0-4d20-ae0e-28bb4851f38d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_3a98254d-226c-4fe0-9238-218ad48e16b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_3a98254d-226c-4fe0-9238-218ad48e16b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1a11fe2c-e278-427e-b6ec-a6bfd4b567bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1a11fe2c-e278-427e-b6ec-a6bfd4b567bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_5b0d922c-3429-4e35-8bd1-48b20e50c78d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_5b0d922c-3429-4e35-8bd1-48b20e50c78d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c246d093-7955-4d4e-b58d-1199be33f39f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5b0d922c-3429-4e35-8bd1-48b20e50c78d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c246d093-7955-4d4e-b58d-1199be33f39f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c246d093-7955-4d4e-b58d-1199be33f39f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c246d093-7955-4d4e-b58d-1199be33f39f" xlink:to="loc_us-gaap_ClassOfStockDomain_c246d093-7955-4d4e-b58d-1199be33f39f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f49b039c-302b-4d10-9072-b5ed92101d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c246d093-7955-4d4e-b58d-1199be33f39f" xlink:to="loc_us-gaap_ClassOfStockDomain_f49b039c-302b-4d10-9072-b5ed92101d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SeriesSeedPreferredStockMember_1364f816-18b2-4991-9272-3c63638b8b3a" xlink:href="kron-20200930.xsd#kron_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f49b039c-302b-4d10-9072-b5ed92101d75" xlink:to="loc_kron_SeriesSeedPreferredStockMember_1364f816-18b2-4991-9272-3c63638b8b3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9f64c363-df05-4701-b820-e453ac1300ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f49b039c-302b-4d10-9072-b5ed92101d75" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9f64c363-df05-4701-b820-e453ac1300ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommonStock" xlink:type="simple" xlink:href="kron-20200930.xsd#CommonStock"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CommonStock" xlink:type="extended" id="i409dc5f87ac4410091fca77e8e7406a8_CommonStock"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommonStockDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CommonStockDetails" xlink:type="extended" id="i5a3eeb6204794fa98663aebad2e70689_CommonStockDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensation" xlink:type="extended" id="i6e29ef549ca044cfb618483e16f8dc53_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationTables" xlink:type="extended" id="i2479a9e0620c4e79a94ba4aa95ec8051_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i322d23918ca246389f91cbed06fc77ea_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7ff4f477-f4de-416f-b1bd-11517b2c73d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7ff4f477-f4de-416f-b1bd-11517b2c73d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_deb9332a-7ed8-4884-96be-08292ce1d7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_deb9332a-7ed8-4884-96be-08292ce1d7b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_517e3498-5bd6-420c-8572-6df0ca296f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_517e3498-5bd6-420c-8572-6df0ca296f84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce9177e1-020a-4762-9bca-0bd9393e9fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce9177e1-020a-4762-9bca-0bd9393e9fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6ee1137e-95c2-4965-830a-732ea37a815c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6ee1137e-95c2-4965-830a-732ea37a815c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_05f692ca-bb2c-40b7-82fe-7a89f4aa73e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_05f692ca-bb2c-40b7-82fe-7a89f4aa73e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_738c3c65-b4da-4f2a-b9fe-1d94cf29093c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_738c3c65-b4da-4f2a-b9fe-1d94cf29093c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cea19a61-d3b9-49b0-93c7-a3f8fa05fd37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cea19a61-d3b9-49b0-93c7-a3f8fa05fd37" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53455406-8337-4de9-ab47-4f882fa705d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53455406-8337-4de9-ab47-4f882fa705d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares_4cae8ad4-1946-4a80-ba90-7cc7b7cc38a4" xlink:href="kron-20200930.xsd#kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares_4cae8ad4-1946-4a80-ba90-7cc7b7cc38a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_7dc45908-99ff-4eca-8194-97d5c87136a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_7dc45908-99ff-4eca-8194-97d5c87136a6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_e5c86153-7ae5-4373-ab99-3a0c5d5e4e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_e5c86153-7ae5-4373-ab99-3a0c5d5e4e1b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_29a806e0-ef85-4820-bcb8-18383b39fdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:to="loc_us-gaap_AwardTypeAxis_29a806e0-ef85-4820-bcb8-18383b39fdbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29a806e0-ef85-4820-bcb8-18383b39fdbc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_29a806e0-ef85-4820-bcb8-18383b39fdbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29a806e0-ef85-4820-bcb8-18383b39fdbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e21a7e5b-4262-43b1-9bbe-0638a515d668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_29a806e0-ef85-4820-bcb8-18383b39fdbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e21a7e5b-4262-43b1-9bbe-0638a515d668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a7127b5-1d74-4de4-89ef-8f25a3ef14e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e21a7e5b-4262-43b1-9bbe-0638a515d668" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a7127b5-1d74-4de4-89ef-8f25a3ef14e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7e562729-2617-4ed3-adc6-754f125f088b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:to="loc_us-gaap_PlanNameAxis_7e562729-2617-4ed3-adc6-754f125f088b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7e562729-2617-4ed3-adc6-754f125f088b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7e562729-2617-4ed3-adc6-754f125f088b" xlink:to="loc_us-gaap_PlanNameDomain_7e562729-2617-4ed3-adc6-754f125f088b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a189dbc6-1163-4bd4-9c38-88fed02c4cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7e562729-2617-4ed3-adc6-754f125f088b" xlink:to="loc_us-gaap_PlanNameDomain_a189dbc6-1163-4bd4-9c38-88fed02c4cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_EquityIncentivePlan2017Member_5eec4573-3f85-45dc-9692-22ac38936266" xlink:href="kron-20200930.xsd#kron_EquityIncentivePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a189dbc6-1163-4bd4-9c38-88fed02c4cf6" xlink:to="loc_kron_EquityIncentivePlan2017Member_5eec4573-3f85-45dc-9692-22ac38936266" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_139f22a4-e4ae-413e-8e92-6bda9335035a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_139f22a4-e4ae-413e-8e92-6bda9335035a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_139f22a4-e4ae-413e-8e92-6bda9335035a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_139f22a4-e4ae-413e-8e92-6bda9335035a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_139f22a4-e4ae-413e-8e92-6bda9335035a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a83114b5-92b6-41bc-b6a0-7863cb9b099b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_139f22a4-e4ae-413e-8e92-6bda9335035a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a83114b5-92b6-41bc-b6a0-7863cb9b099b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7b0134c3-b2d2-40f1-9096-db8d1a1aa2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a83114b5-92b6-41bc-b6a0-7863cb9b099b" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7b0134c3-b2d2-40f1-9096-db8d1a1aa2ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_73e90e77-61b6-4622-b8db-fdd9223f4e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a83114b5-92b6-41bc-b6a0-7863cb9b099b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_73e90e77-61b6-4622-b8db-fdd9223f4e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_68402f4a-0f8b-4a22-a6eb-9a7e028a9b85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:to="loc_srt_RangeAxis_68402f4a-0f8b-4a22-a6eb-9a7e028a9b85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68402f4a-0f8b-4a22-a6eb-9a7e028a9b85_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_68402f4a-0f8b-4a22-a6eb-9a7e028a9b85" xlink:to="loc_srt_RangeMember_68402f4a-0f8b-4a22-a6eb-9a7e028a9b85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8652593e-c548-43df-8369-4c83c72300f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_68402f4a-0f8b-4a22-a6eb-9a7e028a9b85" xlink:to="loc_srt_RangeMember_8652593e-c548-43df-8369-4c83c72300f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63e48881-2573-4eaa-918b-da6c4d3ce920" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8652593e-c548-43df-8369-4c83c72300f5" xlink:to="loc_srt_MinimumMember_63e48881-2573-4eaa-918b-da6c4d3ce920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_822e49e8-f793-492c-b0e7-1774545e2283" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8652593e-c548-43df-8369-4c83c72300f5" xlink:to="loc_srt_MaximumMember_822e49e8-f793-492c-b0e7-1774545e2283" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationOptionpricingModelAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails" xlink:type="extended" id="i506ba9fafe1640468e4cb15c177c13ba_StockBasedCompensationOptionpricingModelAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SharePriceFairValueDisclosure_c0d43803-bb32-48aa-859a-f023cc9f5d89" xlink:href="kron-20200930.xsd#kron_SharePriceFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_kron_SharePriceFairValueDisclosure_c0d43803-bb32-48aa-859a-f023cc9f5d89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_51f84c5c-e46b-43ae-b7b5-13a839c48f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_51f84c5c-e46b-43ae-b7b5-13a839c48f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3e0a293e-d5f8-4f0d-9892-8994306caa6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3e0a293e-d5f8-4f0d-9892-8994306caa6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bb13fb9c-37b6-454d-8151-431ef458d165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bb13fb9c-37b6-454d-8151-431ef458d165" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_72a23f68-6c86-4353-82ac-4d3ec479d151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_72a23f68-6c86-4353-82ac-4d3ec479d151" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5276e5c-1a17-4ab3-b875-622be126d907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5276e5c-1a17-4ab3-b875-622be126d907" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86eb49f1-f998-4bf7-a212-af77c662f5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5276e5c-1a17-4ab3-b875-622be126d907" xlink:to="loc_us-gaap_AwardTypeAxis_86eb49f1-f998-4bf7-a212-af77c662f5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86eb49f1-f998-4bf7-a212-af77c662f5ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_86eb49f1-f998-4bf7-a212-af77c662f5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86eb49f1-f998-4bf7-a212-af77c662f5ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_802d45f6-dcd8-473c-bbf3-01b3a8d76f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_86eb49f1-f998-4bf7-a212-af77c662f5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_802d45f6-dcd8-473c-bbf3-01b3a8d76f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ecb82bdd-15f7-4e73-8ea3-cdaef922cd7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_802d45f6-dcd8-473c-bbf3-01b3a8d76f9b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ecb82bdd-15f7-4e73-8ea3-cdaef922cd7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="id19b6aad92d84428932f96a5764dd796_StockBasedCompensationStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationClassifiedinStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails" xlink:type="extended" id="i65b7cbd8e04e47b7a47db0bcc6ed03ed_StockBasedCompensationClassifiedinStatementsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d93e60e2-b83f-49ed-b042-ee0a510d2238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2d7d05ab-67e2-4963-a836-7bb00948e614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d93e60e2-b83f-49ed-b042-ee0a510d2238" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2d7d05ab-67e2-4963-a836-7bb00948e614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5e1a8223-6351-4b46-935b-7fc0da73940a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d93e60e2-b83f-49ed-b042-ee0a510d2238" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5e1a8223-6351-4b46-935b-7fc0da73940a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_665cd82c-a0ff-49e8-ad42-a99fefc8aeb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5e1a8223-6351-4b46-935b-7fc0da73940a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_665cd82c-a0ff-49e8-ad42-a99fefc8aeb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_665cd82c-a0ff-49e8-ad42-a99fefc8aeb5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_665cd82c-a0ff-49e8-ad42-a99fefc8aeb5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_665cd82c-a0ff-49e8-ad42-a99fefc8aeb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1f600607-a77a-4df0-909b-2d4f9694cba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_665cd82c-a0ff-49e8-ad42-a99fefc8aeb5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1f600607-a77a-4df0-909b-2d4f9694cba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_04a96462-3b91-4ece-9e8a-e6151e807586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f600607-a77a-4df0-909b-2d4f9694cba5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_04a96462-3b91-4ece-9e8a-e6151e807586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c8bac9bf-6ada-4857-ae12-f5c453a94d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f600607-a77a-4df0-909b-2d4f9694cba5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c8bac9bf-6ada-4857-ae12-f5c453a94d85" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails" xlink:type="extended" id="ic342c0b76c594a229ff138567ed13185_StockBasedCompensationRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75de4fde-df4d-4186-aee7-ceaa8c2af0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75de4fde-df4d-4186-aee7-ceaa8c2af0a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_203a707f-acb8-4556-aa64-f3788493a275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_203a707f-acb8-4556-aa64-f3788493a275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0fdedae2-4c85-42f5-b814-b3acd3a75a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0fdedae2-4c85-42f5-b814-b3acd3a75a8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b9022fe0-6cce-4a7a-b3bc-1c1aa6cf2484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b9022fe0-6cce-4a7a-b3bc-1c1aa6cf2484" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae2aefb6-b3d7-4a37-a227-5cd1de62fe70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae2aefb6-b3d7-4a37-a227-5cd1de62fe70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3b3eec69-3805-4b49-8593-3a79869dcaab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae2aefb6-b3d7-4a37-a227-5cd1de62fe70" xlink:to="loc_us-gaap_AwardTypeAxis_3b3eec69-3805-4b49-8593-3a79869dcaab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b3eec69-3805-4b49-8593-3a79869dcaab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3b3eec69-3805-4b49-8593-3a79869dcaab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b3eec69-3805-4b49-8593-3a79869dcaab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45af72c1-06f4-4ec1-bcc4-a41f6a5c787b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3b3eec69-3805-4b49-8593-3a79869dcaab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45af72c1-06f4-4ec1-bcc4-a41f6a5c787b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_08594b74-cddd-47c1-a72d-b3a296335b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45af72c1-06f4-4ec1-bcc4-a41f6a5c787b" xlink:to="loc_us-gaap_RestrictedStockMember_08594b74-cddd-47c1-a72d-b3a296335b8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_10afcaf3-894f-4a9e-b6e0-2bc4c1cde3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae2aefb6-b3d7-4a37-a227-5cd1de62fe70" xlink:to="loc_us-gaap_GranteeStatusAxis_10afcaf3-894f-4a9e-b6e0-2bc4c1cde3f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_10afcaf3-894f-4a9e-b6e0-2bc4c1cde3f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_10afcaf3-894f-4a9e-b6e0-2bc4c1cde3f4" xlink:to="loc_us-gaap_GranteeStatusDomain_10afcaf3-894f-4a9e-b6e0-2bc4c1cde3f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_55ca58cc-0a4c-4aaa-989d-82605a1cbf04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_10afcaf3-894f-4a9e-b6e0-2bc4c1cde3f4" xlink:to="loc_us-gaap_GranteeStatusDomain_55ca58cc-0a4c-4aaa-989d-82605a1cbf04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_NonEmployeeMember_1c0affd1-f633-4f86-8738-e93ae810cf06" xlink:href="kron-20200930.xsd#kron_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_55ca58cc-0a4c-4aaa-989d-82605a1cbf04" xlink:to="loc_kron_NonEmployeeMember_1c0affd1-f633-4f86-8738-e93ae810cf06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ExecutiveEmployeeMember_e8be8c42-f4c9-465a-87fb-c2441ea0402d" xlink:href="kron-20200930.xsd#kron_ExecutiveEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_55ca58cc-0a4c-4aaa-989d-82605a1cbf04" xlink:to="loc_kron_ExecutiveEmployeeMember_e8be8c42-f4c9-465a-87fb-c2441ea0402d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="kron-20200930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/IncomeTaxes" xlink:type="extended" id="iab565b49daac42019f57b362eb27eaa2_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/IncomeTaxesDetails" xlink:type="extended" id="i01c71f558798420db53b801cca70376a_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/NetLossPerShare" xlink:type="extended" id="i1a7446ff844d4cfdac97feaf0e845b59_NetLossPerShare"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/NetLossPerShareTables" xlink:type="extended" id="iddd4ae91bce64ba3a3d4525192a81d3e_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/NetLossPerShareDetails" xlink:type="extended" id="i51d02c3a319c40dfb6637e6914531bbf_NetLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i06e730f872a645b2985022cca1e88e13_NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d151a54-bbc1-42be-a40f-59184e11a1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c633f286-a78f-4df3-99de-8b6a524d081b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d151a54-bbc1-42be-a40f-59184e11a1dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c633f286-a78f-4df3-99de-8b6a524d081b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_11be80d2-d75b-40bb-be90-2f2f27b44894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d151a54-bbc1-42be-a40f-59184e11a1dd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_11be80d2-d75b-40bb-be90-2f2f27b44894" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22f28526-fb28-4a77-9f3a-ed63d7eefa79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_11be80d2-d75b-40bb-be90-2f2f27b44894" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22f28526-fb28-4a77-9f3a-ed63d7eefa79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22f28526-fb28-4a77-9f3a-ed63d7eefa79_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22f28526-fb28-4a77-9f3a-ed63d7eefa79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22f28526-fb28-4a77-9f3a-ed63d7eefa79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22f28526-fb28-4a77-9f3a-ed63d7eefa79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_654b31e6-9c7c-488e-b57c-eafce85fe8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_654b31e6-9c7c-488e-b57c-eafce85fe8f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_42c3a200-50d1-4fca-8d7b-529824a2f8aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_42c3a200-50d1-4fca-8d7b-529824a2f8aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f528cf3e-4956-47f1-afcb-6d1f1e3bfa99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_us-gaap_EmployeeStockMember_f528cf3e-4956-47f1-afcb-6d1f1e3bfa99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_StockOptionsEarlyExerciseMember_fad83a20-2409-41b0-939a-c4979a79c13e" xlink:href="kron-20200930.xsd#kron_StockOptionsEarlyExerciseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_kron_StockOptionsEarlyExerciseMember_fad83a20-2409-41b0-939a-c4979a79c13e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_79699533-c319-4225-b0c6-66a2adf78534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_us-gaap_RestrictedStockMember_79699533-c319-4225-b0c6-66a2adf78534" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e0d3e2f0-fc2c-4a53-ae4a-c0899469efa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_11be80d2-d75b-40bb-be90-2f2f27b44894" xlink:to="loc_us-gaap_DebtInstrumentAxis_e0d3e2f0-fc2c-4a53-ae4a-c0899469efa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e0d3e2f0-fc2c-4a53-ae4a-c0899469efa8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e0d3e2f0-fc2c-4a53-ae4a-c0899469efa8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e0d3e2f0-fc2c-4a53-ae4a-c0899469efa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_059eac48-ec9c-4636-8063-b7945c180fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e0d3e2f0-fc2c-4a53-ae4a-c0899469efa8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_059eac48-ec9c-4636-8063-b7945c180fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020ConvertibleNotesMember_c847898a-a9bf-4861-b52f-ccf573d497d9" xlink:href="kron-20200930.xsd#kron_A2020ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_059eac48-ec9c-4636-8063-b7945c180fa9" xlink:to="loc_kron_A2020ConvertibleNotesMember_c847898a-a9bf-4861-b52f-ccf573d497d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020GileadNotesMember_2a96494b-800f-4669-9f9c-88cc20b4c9c6" xlink:href="kron-20200930.xsd#kron_A2020GileadNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_059eac48-ec9c-4636-8063-b7945c180fa9" xlink:to="loc_kron_A2020GileadNotesMember_2a96494b-800f-4669-9f9c-88cc20b4c9c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingencies"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingencies" xlink:type="extended" id="id90beb8daa174ef0ae101a58a73a19e1_CommitmentandContingencies"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingenciesTables" xlink:type="extended" id="ica87c1d17eb94966bb7a2ad8c6036a22_CommitmentandContingenciesTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended" id="i65e53e8b7e834065be4c2649e695b2d3_CommitmentandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsForAssetAcquisitions_9eabbd18-927c-4efb-8335-1c1e45904660" xlink:href="kron-20200930.xsd#kron_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_PaymentsForAssetAcquisitions_9eabbd18-927c-4efb-8335-1c1e45904660" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_f6f0210f-be1b-4119-b6ab-925b226a3501" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_f6f0210f-be1b-4119-b6ab-925b226a3501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsForAssetAcquisitionsReimbursements_aa067381-e615-4825-9f8a-9397e257b901" xlink:href="kron-20200930.xsd#kron_PaymentsForAssetAcquisitionsReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_PaymentsForAssetAcquisitionsReimbursements_aa067381-e615-4825-9f8a-9397e257b901" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment_d6a4ca30-1e08-4df1-a9ed-8ca7b988377c" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment_d6a4ca30-1e08-4df1-a9ed-8ca7b988377c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment_c4ef8d22-e292-43ad-aeb3-6bf7ff2b0a24" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment_c4ef8d22-e292-43ad-aeb3-6bf7ff2b0a24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment_5f564af8-3ba5-449a-9427-dbd4d4b63459" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment_5f564af8-3ba5-449a-9427-dbd4d4b63459" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ead05323-6a33-4eba-b3af-16dc8b9dbde2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ead05323-6a33-4eba-b3af-16dc8b9dbde2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_RepaymentOfDebtPaymentToBeMade_2381de16-979a-4a50-85de-45e124f69867" xlink:href="kron-20200930.xsd#kron_RepaymentOfDebtPaymentToBeMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_RepaymentOfDebtPaymentToBeMade_2381de16-979a-4a50-85de-45e124f69867" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_7f2f100f-427b-49b7-a9fc-526f49a08320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_7f2f100f-427b-49b7-a9fc-526f49a08320" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument_357d72bc-518b-4d46-9023-51cb8ba1891a" xlink:href="kron-20200930.xsd#kron_GainLossOnChangeInFairValueOfDebtInstrument"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument_357d72bc-518b-4d46-9023-51cb8ba1891a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionAxis_a75bd848-5170-443c-8c6a-bdfecfc9410e" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:to="loc_kron_AssetAcquisitionAxis_a75bd848-5170-443c-8c6a-bdfecfc9410e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionDomain_a75bd848-5170-443c-8c6a-bdfecfc9410e_default" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kron_AssetAcquisitionAxis_a75bd848-5170-443c-8c6a-bdfecfc9410e" xlink:to="loc_kron_AssetAcquisitionDomain_a75bd848-5170-443c-8c6a-bdfecfc9410e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionDomain_1fecc2b2-c1eb-4392-a0e3-f912f3dc6fef" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kron_AssetAcquisitionAxis_a75bd848-5170-443c-8c6a-bdfecfc9410e" xlink:to="loc_kron_AssetAcquisitionDomain_1fecc2b2-c1eb-4392-a0e3-f912f3dc6fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GileadAssetPurchaseMember_31b2651f-5a7e-48d5-9ae9-ba07e89a1d3c" xlink:href="kron-20200930.xsd#kron_GileadAssetPurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_AssetAcquisitionDomain_1fecc2b2-c1eb-4392-a0e3-f912f3dc6fef" xlink:to="loc_kron_GileadAssetPurchaseMember_31b2651f-5a7e-48d5-9ae9-ba07e89a1d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_176175b7-a0ff-4d0e-8d93-dd1944d58c89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_176175b7-a0ff-4d0e-8d93-dd1944d58c89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_176175b7-a0ff-4d0e-8d93-dd1944d58c89_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_176175b7-a0ff-4d0e-8d93-dd1944d58c89" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_176175b7-a0ff-4d0e-8d93-dd1944d58c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ce3e994f-1824-4b20-a0d1-b90323f9fd77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_176175b7-a0ff-4d0e-8d93-dd1944d58c89" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ce3e994f-1824-4b20-a0d1-b90323f9fd77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseProvisionTermsMember_452764e7-dbd9-4005-9685-4914bfafe4f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseProvisionTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ce3e994f-1824-4b20-a0d1-b90323f9fd77" xlink:to="loc_us-gaap_PurchaseProvisionTermsMember_452764e7-dbd9-4005-9685-4914bfafe4f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e783c119-2b51-4a4a-b0f8-7d7cf01d151b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:to="loc_us-gaap_DebtInstrumentAxis_e783c119-2b51-4a4a-b0f8-7d7cf01d151b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e783c119-2b51-4a4a-b0f8-7d7cf01d151b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e783c119-2b51-4a4a-b0f8-7d7cf01d151b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e783c119-2b51-4a4a-b0f8-7d7cf01d151b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c57f9add-cc26-478a-93cb-e7af36747069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e783c119-2b51-4a4a-b0f8-7d7cf01d151b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c57f9add-cc26-478a-93cb-e7af36747069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020GileadNotesMember_801963bf-32f5-4ff9-b50d-18759313950f" xlink:href="kron-20200930.xsd#kron_A2020GileadNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57f9add-cc26-478a-93cb-e7af36747069" xlink:to="loc_kron_A2020GileadNotesMember_801963bf-32f5-4ff9-b50d-18759313950f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_376c8b87-e4a4-4b36-9d46-74e282a344dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_376c8b87-e4a4-4b36-9d46-74e282a344dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_376c8b87-e4a4-4b36-9d46-74e282a344dd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_376c8b87-e4a4-4b36-9d46-74e282a344dd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_376c8b87-e4a4-4b36-9d46-74e282a344dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9f04021e-262a-4c46-b845-cd69e09b5684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_376c8b87-e4a4-4b36-9d46-74e282a344dd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9f04021e-262a-4c46-b845-cd69e09b5684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_18ff1a50-5229-4627-976b-e968b717fd6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9f04021e-262a-4c46-b845-cd69e09b5684" xlink:to="loc_us-gaap_ConvertibleDebtMember_18ff1a50-5229-4627-976b-e968b717fd6c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingenciesKeyValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails" xlink:type="extended" id="i403f287cf50d4cd08e59401a20822c9d_CommitmentandContingenciesKeyValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2c361237-8c87-494b-806e-bfe3b2274f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_b0b9a15b-731c-4e83-b988-fa4edacc4b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2c361237-8c87-494b-806e-bfe3b2274f5f" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_b0b9a15b-731c-4e83-b988-fa4edacc4b3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6e6cd03c-348f-4aab-83bc-bf214d4bfbcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2c361237-8c87-494b-806e-bfe3b2274f5f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6e6cd03c-348f-4aab-83bc-bf214d4bfbcb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_302c1011-5ad0-4757-a2a7-4e75601273a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6e6cd03c-348f-4aab-83bc-bf214d4bfbcb" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_302c1011-5ad0-4757-a2a7-4e75601273a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_302c1011-5ad0-4757-a2a7-4e75601273a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_302c1011-5ad0-4757-a2a7-4e75601273a3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_302c1011-5ad0-4757-a2a7-4e75601273a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_302c1011-5ad0-4757-a2a7-4e75601273a3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_c729fcb3-4a82-49be-bfb5-ad61da21cc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_c729fcb3-4a82-49be-bfb5-ad61da21cc15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d8f63ff7-e44b-4bb5-ba2c-bbab27c43bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d8f63ff7-e44b-4bb5-ba2c-bbab27c43bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_MeasurementInputWeightingMember_9815c2d7-19ad-43d8-b9e0-be9cdfbcc220" xlink:href="kron-20200930.xsd#kron_MeasurementInputWeightingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:to="loc_kron_MeasurementInputWeightingMember_9815c2d7-19ad-43d8-b9e0-be9cdfbcc220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanAxis_861d8eb5-a1cb-489f-8c8b-17169c766a6d" xlink:href="kron-20200930.xsd#kron_SettlementPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6e6cd03c-348f-4aab-83bc-bf214d4bfbcb" xlink:to="loc_kron_SettlementPlanAxis_861d8eb5-a1cb-489f-8c8b-17169c766a6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanDomain_861d8eb5-a1cb-489f-8c8b-17169c766a6d_default" xlink:href="kron-20200930.xsd#kron_SettlementPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kron_SettlementPlanAxis_861d8eb5-a1cb-489f-8c8b-17169c766a6d" xlink:to="loc_kron_SettlementPlanDomain_861d8eb5-a1cb-489f-8c8b-17169c766a6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:href="kron-20200930.xsd#kron_SettlementPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kron_SettlementPlanAxis_861d8eb5-a1cb-489f-8c8b-17169c766a6d" xlink:to="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_FundraiseScenarioMember_d3648d6d-ebcd-4288-9f03-56d5549fee8d" xlink:href="kron-20200930.xsd#kron_FundraiseScenarioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_FundraiseScenarioMember_d3648d6d-ebcd-4288-9f03-56d5549fee8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IPOCashPayoutScenarioMember_5354c032-ac30-403e-8420-d9dc3cee8fd6" xlink:href="kron-20200930.xsd#kron_IPOCashPayoutScenarioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_IPOCashPayoutScenarioMember_5354c032-ac30-403e-8420-d9dc3cee8fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IPOConversionScenarioMember_8e5ddd42-91f5-4f02-b21f-9c3041132e03" xlink:href="kron-20200930.xsd#kron_IPOConversionScenarioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_IPOConversionScenarioMember_8e5ddd42-91f5-4f02-b21f-9c3041132e03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LiquidationCashPayoutScenarioMember_e2837d66-ba77-44a2-b978-aab73ebda2de" xlink:href="kron-20200930.xsd#kron_LiquidationCashPayoutScenarioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_LiquidationCashPayoutScenarioMember_e2837d66-ba77-44a2-b978-aab73ebda2de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LiquidationConversionScenarioMember_bf2fd775-85b2-4fad-a04a-89612179bfb7" xlink:href="kron-20200930.xsd#kron_LiquidationConversionScenarioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_LiquidationConversionScenarioMember_bf2fd775-85b2-4fad-a04a-89612179bfb7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/Leases" xlink:type="simple" xlink:href="kron-20200930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/Leases" xlink:type="extended" id="i384befce1eb44df6a804cac240b4a3d8_Leases"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/LeasesTables" xlink:type="extended" id="id13f73745de54257b592f42614c24406_LeasesTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="i5139675b51204aa49f8f2bc949afc52f_LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b751a2f3-65c1-471f-9797-d0e041a345c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b751a2f3-65c1-471f-9797-d0e041a345c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f2f6c252-09d5-4c90-9874-05d756242650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_OperatingLeaseLiability_f2f6c252-09d5-4c90-9874-05d756242650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_251cb65b-ba8a-4e51-8fb3-04ba07005343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_251cb65b-ba8a-4e51-8fb3-04ba07005343" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseIncrementalBorrowingRate_2b146136-c558-434c-bffe-c459cbf7a333" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseIncrementalBorrowingRate_2b146136-c558-434c-bffe-c459cbf7a333" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d77513e1-7272-4a80-a4db-b556818cb8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d77513e1-7272-4a80-a4db-b556818cb8f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_OperatingLeaseFacilitySize_97849802-5b35-4080-8268-30278cccbfc0" xlink:href="kron-20200930.xsd#kron_OperatingLeaseFacilitySize"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_OperatingLeaseFacilitySize_97849802-5b35-4080-8268-30278cccbfc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseMonthlyBaseRent_db90afe9-f144-4425-9e98-42d3cc5ad359" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseMonthlyBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseMonthlyBaseRent_db90afe9-f144-4425-9e98-42d3cc5ad359" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent_ec4d6854-234f-4ed3-9e7e-fb80d7ca184c" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent_ec4d6854-234f-4ed3-9e7e-fb80d7ca184c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_7d18e1df-ba94-41cc-be51-af49635b715c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_7d18e1df-ba94-41cc-be51-af49635b715c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseTenantImprovementAllowances_fec12160-0241-4ff6-8d61-55b862df6ade" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseTenantImprovementAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseTenantImprovementAllowances_fec12160-0241-4ff6-8d61-55b862df6ade" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_93e54de5-94a6-44f5-a478-21e4760a4d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_SecurityDeposit_93e54de5-94a6-44f5-a478-21e4760a4d13" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseInitialAnnualBaseRent_fbda1126-8e53-424a-8675-a601b4a168fc" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseInitialAnnualBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseInitialAnnualBaseRent_fbda1126-8e53-424a-8675-a601b4a168fc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_139f0351-b9ba-46ff-b4df-2f0ee44828a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_OperatingLeasePayments_139f0351-b9ba-46ff-b4df-2f0ee44828a3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_14705d63-ec2a-45e7-82d9-9db14e351d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_14705d63-ec2a-45e7-82d9-9db14e351d87" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_35782c7f-a7ea-46c5-9de9-c90aec276c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_35782c7f-a7ea-46c5-9de9-c90aec276c7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_09b637fc-995f-4026-8b57-a9b7a8dda39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_35782c7f-a7ea-46c5-9de9-c90aec276c7f" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_09b637fc-995f-4026-8b57-a9b7a8dda39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_09b637fc-995f-4026-8b57-a9b7a8dda39e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_09b637fc-995f-4026-8b57-a9b7a8dda39e" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_09b637fc-995f-4026-8b57-a9b7a8dda39e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_09b637fc-995f-4026-8b57-a9b7a8dda39e" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A21ErieStreetCambridgeMassachusettsMember_6de482c2-ca57-4d9b-8f54-93b0dac38b12" xlink:href="kron-20200930.xsd#kron_A21ErieStreetCambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:to="loc_kron_A21ErieStreetCambridgeMassachusettsMember_6de482c2-ca57-4d9b-8f54-93b0dac38b12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A301BinneyStreetCambridgeMassachusettsMember_00d1e001-9555-4754-ae19-a73a03d5df3c" xlink:href="kron-20200930.xsd#kron_A301BinneyStreetCambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:to="loc_kron_A301BinneyStreetCambridgeMassachusettsMember_00d1e001-9555-4754-ae19-a73a03d5df3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SanMateoCaliforniaMember_200431a3-6816-49ed-b30b-dcf60218a4be" xlink:href="kron-20200930.xsd#kron_SanMateoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:to="loc_kron_SanMateoCaliforniaMember_200431a3-6816-49ed-b30b-dcf60218a4be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SanMateoCaliforniaAdjacentSpaceMember_129cca3f-8710-4cfb-a530-e0d92eea175d" xlink:href="kron-20200930.xsd#kron_SanMateoCaliforniaAdjacentSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:to="loc_kron_SanMateoCaliforniaAdjacentSpaceMember_129cca3f-8710-4cfb-a530-e0d92eea175d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1cc3d8ed-3482-4a4a-9370-e610556dee0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_35782c7f-a7ea-46c5-9de9-c90aec276c7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1cc3d8ed-3482-4a4a-9370-e610556dee0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1cc3d8ed-3482-4a4a-9370-e610556dee0b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1cc3d8ed-3482-4a4a-9370-e610556dee0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1cc3d8ed-3482-4a4a-9370-e610556dee0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec69599-c69d-49b9-a3c9-75e593b2f1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1cc3d8ed-3482-4a4a-9370-e610556dee0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec69599-c69d-49b9-a3c9-75e593b2f1d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_RDEquipmentMember_c78240a8-c3a7-42b4-a4d8-479ea54d10c2" xlink:href="kron-20200930.xsd#kron_RDEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec69599-c69d-49b9-a3c9-75e593b2f1d0" xlink:to="loc_kron_RDEquipmentMember_c78240a8-c3a7-42b4-a4d8-479ea54d10c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesSummaryofLeaseCostsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="extended" id="i9e6b09a04dff45c7b350f2fd4bb086b5_LeasesSummaryofLeaseCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_82d2bdf9-db1b-4814-9a74-9d05e784135d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_82d2bdf9-db1b-4814-9a74-9d05e784135d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_bfd3f9d5-344f-450c-9d49-d6b16bf12922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_bfd3f9d5-344f-450c-9d49-d6b16bf12922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_477d7ab3-ef68-41b8-9f6f-b522376319f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:to="loc_us-gaap_OperatingLeaseCost_477d7ab3-ef68-41b8-9f6f-b522376319f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5235bd06-9aa4-42a1-ba66-d4596068b496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5235bd06-9aa4-42a1-ba66-d4596068b496" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_edfbc866-8ff6-4143-96a4-7bb86d381a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5235bd06-9aa4-42a1-ba66-d4596068b496" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_edfbc866-8ff6-4143-96a4-7bb86d381a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_edfbc866-8ff6-4143-96a4-7bb86d381a78_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_edfbc866-8ff6-4143-96a4-7bb86d381a78" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_edfbc866-8ff6-4143-96a4-7bb86d381a78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94fb4ff0-5678-4938-bac6-e416af0de5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_edfbc866-8ff6-4143-96a4-7bb86d381a78" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94fb4ff0-5678-4938-bac6-e416af0de5f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentMember_d2485d18-2c56-4489-8dd5-00ac20c71c96" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_94fb4ff0-5678-4938-bac6-e416af0de5f4" xlink:to="loc_kron_ResearchAndDevelopmentMember_d2485d18-2c56-4489-8dd5-00ac20c71c96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_554d4b58-0b3f-4c08-8f0d-f67140e00d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_94fb4ff0-5678-4938-bac6-e416af0de5f4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_554d4b58-0b3f-4c08-8f0d-f67140e00d0e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails" xlink:type="extended" id="i7fde1806b9ff42bda93acab3c390b957_LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails" xlink:type="extended" id="i48b2ed5940024515b7d0535dca152e31_LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails" xlink:type="extended" id="ib9955d5215f14d4299fa651686357f39_LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020Notes" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020Notes"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/A2020Notes" xlink:type="extended" id="i870e290a92344ccd8c2fc445e2a10ba1_A2020Notes"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020NotesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020NotesTables"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/A2020NotesTables" xlink:type="extended" id="i3986713cd9194bb08c10e731dbadf382_A2020NotesTables"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020NotesNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020NotesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/A2020NotesNarrativeDetails" xlink:type="extended" id="i4a4186b9fc6d4f6e842600b96bd22306_A2020NotesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_be0dc4ad-493b-4129-a1b6-c733ad68bceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_be0dc4ad-493b-4129-a1b6-c733ad68bceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_49a31485-f059-4a9f-8489-e39ca62e06ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_49a31485-f059-4a9f-8489-e39ca62e06ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f3af09cb-0a26-49ce-abe6-f9014b1509ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f3af09cb-0a26-49ce-abe6-f9014b1509ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SaleOfStockPurchasePriceOfCommonStockPercent_b6eb32c9-8340-420f-8ad9-a6fab059dfc8" xlink:href="kron-20200930.xsd#kron_SaleOfStockPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_kron_SaleOfStockPurchasePriceOfCommonStockPercent_b6eb32c9-8340-420f-8ad9-a6fab059dfc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DebtConversionValuationOfCompany_6ea67268-f5fe-422a-b9e2-f3f16d2b0ae8" xlink:href="kron-20200930.xsd#kron_DebtConversionValuationOfCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_kron_DebtConversionValuationOfCompany_6ea67268-f5fe-422a-b9e2-f3f16d2b0ae8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_eaa94cdb-fe14-458b-961c-d01f3fba6332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_eaa94cdb-fe14-458b-961c-d01f3fba6332" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument_1acbf121-ec1c-46eb-9ca8-19295eef620e" xlink:href="kron-20200930.xsd#kron_GainLossOnChangeInFairValueOfDebtInstrument"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument_1acbf121-ec1c-46eb-9ca8-19295eef620e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_57f28774-fd82-4543-9aa6-593d66dcdd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_57f28774-fd82-4543-9aa6-593d66dcdd8e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsForLegalCosts_a80a8fd1-af32-476b-9100-3cbe56c3d520" xlink:href="kron-20200930.xsd#kron_PaymentsForLegalCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_kron_PaymentsForLegalCosts_a80a8fd1-af32-476b-9100-3cbe56c3d520" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_efe7164c-41d1-4623-89d7-346b7b1ec20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_efe7164c-41d1-4623-89d7-346b7b1ec20d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_efe7164c-41d1-4623-89d7-346b7b1ec20d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_efe7164c-41d1-4623-89d7-346b7b1ec20d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_efe7164c-41d1-4623-89d7-346b7b1ec20d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb1998c0-7f13-422e-971a-e771911b7e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_efe7164c-41d1-4623-89d7-346b7b1ec20d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb1998c0-7f13-422e-971a-e771911b7e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_783ee1ef-f380-43ad-88b3-10284babe224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb1998c0-7f13-422e-971a-e771911b7e7f" xlink:to="loc_us-gaap_ConvertibleDebtMember_783ee1ef-f380-43ad-88b3-10284babe224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1fcf97b3-b891-4ecd-b3ff-7741189871c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_DebtInstrumentAxis_1fcf97b3-b891-4ecd-b3ff-7741189871c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1fcf97b3-b891-4ecd-b3ff-7741189871c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1fcf97b3-b891-4ecd-b3ff-7741189871c4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1fcf97b3-b891-4ecd-b3ff-7741189871c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_db100b84-9878-4f25-bad2-0b8c45d1fda5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1fcf97b3-b891-4ecd-b3ff-7741189871c4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_db100b84-9878-4f25-bad2-0b8c45d1fda5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ConvertibleNotesPayable2020NotesMember_1ff5d695-9d2f-493e-ad02-658595507a9e" xlink:href="kron-20200930.xsd#kron_ConvertibleNotesPayable2020NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_db100b84-9878-4f25-bad2-0b8c45d1fda5" xlink:to="loc_kron_ConvertibleNotesPayable2020NotesMember_1ff5d695-9d2f-493e-ad02-658595507a9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020ConvertibleNotesMember_8da9f11f-afa0-44f9-9eaa-f9e88e80acd1" xlink:href="kron-20200930.xsd#kron_A2020ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_db100b84-9878-4f25-bad2-0b8c45d1fda5" xlink:to="loc_kron_A2020ConvertibleNotesMember_8da9f11f-afa0-44f9-9eaa-f9e88e80acd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dc3c9f34-324b-4657-b08d-17f951ed7631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dc3c9f34-324b-4657-b08d-17f951ed7631" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc3c9f34-324b-4657-b08d-17f951ed7631_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dc3c9f34-324b-4657-b08d-17f951ed7631" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc3c9f34-324b-4657-b08d-17f951ed7631_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3817cac4-59d9-4381-b64c-34951c3995cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dc3c9f34-324b-4657-b08d-17f951ed7631" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3817cac4-59d9-4381-b64c-34951c3995cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_993e2539-b96b-4a7f-8795-836426c3a0b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3817cac4-59d9-4381-b64c-34951c3995cd" xlink:to="loc_us-gaap_IPOMember_993e2539-b96b-4a7f-8795-836426c3a0b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30f45884-8b4b-4531-9d4c-1f4328807e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30f45884-8b4b-4531-9d4c-1f4328807e48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30f45884-8b4b-4531-9d4c-1f4328807e48_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30f45884-8b4b-4531-9d4c-1f4328807e48" xlink:to="loc_us-gaap_EquityComponentDomain_30f45884-8b4b-4531-9d4c-1f4328807e48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1386420e-d2c6-47ae-a4a4-5567f5678d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30f45884-8b4b-4531-9d4c-1f4328807e48" xlink:to="loc_us-gaap_EquityComponentDomain_1386420e-d2c6-47ae-a4a4-5567f5678d38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2be67ae7-2586-4d31-849e-fdc1db5f4217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1386420e-d2c6-47ae-a4a4-5567f5678d38" xlink:to="loc_us-gaap_CommonStockMember_2be67ae7-2586-4d31-849e-fdc1db5f4217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_71d94528-361b-4602-a6f0-b7caebc77376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_71d94528-361b-4602-a6f0-b7caebc77376" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_71d94528-361b-4602-a6f0-b7caebc77376_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_71d94528-361b-4602-a6f0-b7caebc77376" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_71d94528-361b-4602-a6f0-b7caebc77376_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d82fadcf-7d7c-4d5c-885e-d2d90b7b0979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_71d94528-361b-4602-a6f0-b7caebc77376" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d82fadcf-7d7c-4d5c-885e-d2d90b7b0979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d7d55886-c76a-4148-aab2-0b38fb061ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d82fadcf-7d7c-4d5c-885e-d2d90b7b0979" xlink:to="loc_us-gaap_SubsequentEventMember_d7d55886-c76a-4148-aab2-0b38fb061ef6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020NotesKeyValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails" xlink:type="extended" id="i2b2865a7f6fd478593f3decc9b290f79_A2020NotesKeyValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_12cf69f8-ceeb-4742-9587-a1a47f0f3efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_b94654bf-0990-4db7-b0fb-e37c74d2a8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_12cf69f8-ceeb-4742-9587-a1a47f0f3efc" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_b94654bf-0990-4db7-b0fb-e37c74d2a8e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d116c2cb-4a49-49af-a761-c79bf8007ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_12cf69f8-ceeb-4742-9587-a1a47f0f3efc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d116c2cb-4a49-49af-a761-c79bf8007ac3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_927105c0-17b0-4c3f-9f7e-7ec0c7872571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d116c2cb-4a49-49af-a761-c79bf8007ac3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_927105c0-17b0-4c3f-9f7e-7ec0c7872571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_927105c0-17b0-4c3f-9f7e-7ec0c7872571_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_927105c0-17b0-4c3f-9f7e-7ec0c7872571" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_927105c0-17b0-4c3f-9f7e-7ec0c7872571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_927105c0-17b0-4c3f-9f7e-7ec0c7872571" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_20b03586-32de-4759-a744-3ba61c02b2dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_20b03586-32de-4759-a744-3ba61c02b2dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_73e3ddfe-e851-4866-b4ea-0f73b23ee2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_73e3ddfe-e851-4866-b4ea-0f73b23ee2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_MeasurementInputWeightingMember_fc478996-fca1-4ae7-a941-b810ec7ae0f0" xlink:href="kron-20200930.xsd#kron_MeasurementInputWeightingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:to="loc_kron_MeasurementInputWeightingMember_fc478996-fca1-4ae7-a941-b810ec7ae0f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanAxis_fb7f4ffa-2cc9-4892-9fda-8c3db28ca178" xlink:href="kron-20200930.xsd#kron_SettlementPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d116c2cb-4a49-49af-a761-c79bf8007ac3" xlink:to="loc_kron_SettlementPlanAxis_fb7f4ffa-2cc9-4892-9fda-8c3db28ca178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanDomain_fb7f4ffa-2cc9-4892-9fda-8c3db28ca178_default" xlink:href="kron-20200930.xsd#kron_SettlementPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kron_SettlementPlanAxis_fb7f4ffa-2cc9-4892-9fda-8c3db28ca178" xlink:to="loc_kron_SettlementPlanDomain_fb7f4ffa-2cc9-4892-9fda-8c3db28ca178_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:href="kron-20200930.xsd#kron_SettlementPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kron_SettlementPlanAxis_fb7f4ffa-2cc9-4892-9fda-8c3db28ca178" xlink:to="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IPOScenarioMember_07909f73-edab-46b6-836f-4ca7b605a35a" xlink:href="kron-20200930.xsd#kron_IPOScenarioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:to="loc_kron_IPOScenarioMember_07909f73-edab-46b6-836f-4ca7b605a35a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SeriesBScenarioMember_18d0551d-1ae2-48ee-9931-dbc0236e9a0c" xlink:href="kron-20200930.xsd#kron_SeriesBScenarioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:to="loc_kron_SeriesBScenarioMember_18d0551d-1ae2-48ee-9931-dbc0236e9a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_FinancingScenarioMember_12adc39f-4744-4e50-9b4d-03230d6f3795" xlink:href="kron-20200930.xsd#kron_FinancingScenarioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:to="loc_kron_FinancingScenarioMember_12adc39f-4744-4e50-9b4d-03230d6f3795" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/RelatedParties" xlink:type="simple" xlink:href="kron-20200930.xsd#RelatedParties"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/RelatedParties" xlink:type="extended" id="i49404dfb7efe48ae867573104a3cdf47_RelatedParties"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#RelatedPartyDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended" id="i3f6b1e65f60e4362a2813c27cf0daa2c_RelatedPartyDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ServicesAgreementTerm_5b0cd39a-b08e-45df-9696-6c522fcf6bea" xlink:href="kron-20200930.xsd#kron_ServicesAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:to="loc_kron_ServicesAgreementTerm_5b0cd39a-b08e-45df-9696-6c522fcf6bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_a25cfe56-ff09-4d99-b11b-2c83432734b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_a25cfe56-ff09-4d99-b11b-2c83432734b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty_e83d19d0-0d2a-459c-9ef1-2c860fe76dbb" xlink:href="kron-20200930.xsd#kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:to="loc_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty_e83d19d0-0d2a-459c-9ef1-2c860fe76dbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_ca0e0271-755d-4e36-91a3-d97ae9ab4885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_ca0e0271-755d-4e36-91a3-d97ae9ab4885" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e3d075b-1080-4dcc-b364-7b7ddcf42a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e3d075b-1080-4dcc-b364-7b7ddcf42a2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66969449-e39d-427c-a923-93291658412f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e3d075b-1080-4dcc-b364-7b7ddcf42a2b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66969449-e39d-427c-a923-93291658412f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_66969449-e39d-427c-a923-93291658412f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66969449-e39d-427c-a923-93291658412f" xlink:to="loc_us-gaap_RelatedPartyDomain_66969449-e39d-427c-a923-93291658412f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_959fe112-c5d2-4886-876a-0b209b30dc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66969449-e39d-427c-a923-93291658412f" xlink:to="loc_us-gaap_RelatedPartyDomain_959fe112-c5d2-4886-876a-0b209b30dc3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_d39a3a05-cead-4780-ba3b-b7b6b47d6de4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_959fe112-c5d2-4886-876a-0b209b30dc3e" xlink:to="loc_srt_AffiliatedEntityMember_d39a3a05-cead-4780-ba3b-b7b6b47d6de4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_9df485ab-a02f-4ade-ac4a-4888885aeef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e3d075b-1080-4dcc-b364-7b7ddcf42a2b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_9df485ab-a02f-4ade-ac4a-4888885aeef2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9df485ab-a02f-4ade-ac4a-4888885aeef2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9df485ab-a02f-4ade-ac4a-4888885aeef2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9df485ab-a02f-4ade-ac4a-4888885aeef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d036860c-f32c-40bc-98fb-41af06a00afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9df485ab-a02f-4ade-ac4a-4888885aeef2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d036860c-f32c-40bc-98fb-41af06a00afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TwoRiverConsultingLLCMember_9713edea-0d85-44b9-bf4b-8787b2cfa90b" xlink:href="kron-20200930.xsd#kron_TwoRiverConsultingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d036860c-f32c-40bc-98fb-41af06a00afd" xlink:to="loc_kron_TwoRiverConsultingLLCMember_9713edea-0d85-44b9-bf4b-8787b2cfa90b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_BellcoCapitalLLCMember_3cf5570a-e758-4ab4-8a48-82a14a0c0576" xlink:href="kron-20200930.xsd#kron_BellcoCapitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d036860c-f32c-40bc-98fb-41af06a00afd" xlink:to="loc_kron_BellcoCapitalLLCMember_3cf5570a-e758-4ab4-8a48-82a14a0c0576" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="kron-20200930.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/SubsequentEvents" xlink:type="extended" id="i4d2cb3734621453a93cf649e173151db_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.kronosbio.com/role/SubsequentEventsDetails" xlink:type="extended" id="i1d43506c636841b09598a07e2e62028e_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9b4c1daa-a576-4b1b-9c6d-33860730f69f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9b4c1daa-a576-4b1b-9c6d-33860730f69f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_00bc206d-37de-45de-883f-630381cb97da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_00bc206d-37de-45de-883f-630381cb97da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e2d3abeb-a4a2-464d-8874-66302d74f456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e2d3abeb-a4a2-464d-8874-66302d74f456" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1835e0a6-6a4e-4697-b2d7-16b31ad4fe4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1835e0a6-6a4e-4697-b2d7-16b31ad4fe4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_da319491-3539-499f-a12e-55b657fb29ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_da319491-3539-499f-a12e-55b657fb29ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_54eb23ad-cb85-4cfc-b955-f17fc7cec24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_54eb23ad-cb85-4cfc-b955-f17fc7cec24f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseEarlyTerminationCost_3388ac11-98e6-4ff5-87ce-e1b7b7d7a0b4" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseEarlyTerminationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_kron_LesseeOperatingLeaseEarlyTerminationCost_3388ac11-98e6-4ff5-87ce-e1b7b7d7a0b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f2239b10-c06c-45e3-8851-057d0dc28223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f2239b10-c06c-45e3-8851-057d0dc28223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f2239b10-c06c-45e3-8851-057d0dc28223_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f2239b10-c06c-45e3-8851-057d0dc28223" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f2239b10-c06c-45e3-8851-057d0dc28223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7434c658-a6f5-4a8d-8e01-bae62c7d1413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f2239b10-c06c-45e3-8851-057d0dc28223" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7434c658-a6f5-4a8d-8e01-bae62c7d1413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a893e98a-705a-447a-8345-fc88f7cee4be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7434c658-a6f5-4a8d-8e01-bae62c7d1413" xlink:to="loc_us-gaap_SubsequentEventMember_a893e98a-705a-447a-8345-fc88f7cee4be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d0cc9df1-e8f0-4748-8e14-1041ff1a08d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_PlanNameAxis_d0cc9df1-e8f0-4748-8e14-1041ff1a08d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d0cc9df1-e8f0-4748-8e14-1041ff1a08d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d0cc9df1-e8f0-4748-8e14-1041ff1a08d0" xlink:to="loc_us-gaap_PlanNameDomain_d0cc9df1-e8f0-4748-8e14-1041ff1a08d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3b5b070d-4693-442b-8c77-701fd7195537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d0cc9df1-e8f0-4748-8e14-1041ff1a08d0" xlink:to="loc_us-gaap_PlanNameDomain_3b5b070d-4693-442b-8c77-701fd7195537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020StockOptionAndIncentivePlanMember_9bc8a402-9ccc-438c-bc5e-cc9a2de4d592" xlink:href="kron-20200930.xsd#kron_A2020StockOptionAndIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3b5b070d-4693-442b-8c77-701fd7195537" xlink:to="loc_kron_A2020StockOptionAndIncentivePlanMember_9bc8a402-9ccc-438c-bc5e-cc9a2de4d592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020EmployeeStockPurchasePlanMember_caef6cd1-f541-4d84-affa-b8d88eb39d8f" xlink:href="kron-20200930.xsd#kron_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3b5b070d-4693-442b-8c77-701fd7195537" xlink:to="loc_kron_A2020EmployeeStockPurchasePlanMember_caef6cd1-f541-4d84-affa-b8d88eb39d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6c229079-5cf6-47c2-bdd7-2f4bf11b4705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_AwardTypeAxis_6c229079-5cf6-47c2-bdd7-2f4bf11b4705" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c229079-5cf6-47c2-bdd7-2f4bf11b4705_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6c229079-5cf6-47c2-bdd7-2f4bf11b4705" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c229079-5cf6-47c2-bdd7-2f4bf11b4705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5178c10c-6777-445c-a864-3400a3b9fc9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6c229079-5cf6-47c2-bdd7-2f4bf11b4705" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5178c10c-6777-445c-a864-3400a3b9fc9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c5bbccca-60d0-4f2f-9995-72fda20e99e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5178c10c-6777-445c-a864-3400a3b9fc9c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c5bbccca-60d0-4f2f-9995-72fda20e99e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2e82b143-b6a7-4d6d-9e16-471e87a45a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5178c10c-6777-445c-a864-3400a3b9fc9c" xlink:to="loc_us-gaap_EmployeeStockMember_2e82b143-b6a7-4d6d-9e16-471e87a45a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_290efea0-96fb-4889-ac02-e627ab38347f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_290efea0-96fb-4889-ac02-e627ab38347f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_290efea0-96fb-4889-ac02-e627ab38347f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_290efea0-96fb-4889-ac02-e627ab38347f" xlink:to="loc_us-gaap_EquityComponentDomain_290efea0-96fb-4889-ac02-e627ab38347f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_69959e86-0f23-4f56-9473-2905b8a920ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_290efea0-96fb-4889-ac02-e627ab38347f" xlink:to="loc_us-gaap_EquityComponentDomain_69959e86-0f23-4f56-9473-2905b8a920ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_268f89d2-8757-4253-974d-095feccc803b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_69959e86-0f23-4f56-9473-2905b8a920ce" xlink:to="loc_us-gaap_CommonStockMember_268f89d2-8757-4253-974d-095feccc803b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cece934d-ab53-4fd5-b788-704383bf0044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cece934d-ab53-4fd5-b788-704383bf0044" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cece934d-ab53-4fd5-b788-704383bf0044_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cece934d-ab53-4fd5-b788-704383bf0044" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cece934d-ab53-4fd5-b788-704383bf0044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64395970-b985-4383-b0d9-28c4e84e86f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cece934d-ab53-4fd5-b788-704383bf0044" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64395970-b985-4383-b0d9-28c4e84e86f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_b9cad982-243c-4f6d-a803-b2cf4f884b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64395970-b985-4383-b0d9-28c4e84e86f0" xlink:to="loc_us-gaap_ConvertibleDebtMember_b9cad982-243c-4f6d-a803-b2cf4f884b1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dbd96570-4edb-470f-a72a-2e9870e0fa9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_DebtInstrumentAxis_dbd96570-4edb-470f-a72a-2e9870e0fa9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dbd96570-4edb-470f-a72a-2e9870e0fa9b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_dbd96570-4edb-470f-a72a-2e9870e0fa9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dbd96570-4edb-470f-a72a-2e9870e0fa9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_71f65a65-c120-4cfb-9e2b-70185f3fc865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_dbd96570-4edb-470f-a72a-2e9870e0fa9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_71f65a65-c120-4cfb-9e2b-70185f3fc865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020ConvertibleNotesMember_2160ddf0-bb68-4e50-af8c-7133a31c2145" xlink:href="kron-20200930.xsd#kron_A2020ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_71f65a65-c120-4cfb-9e2b-70185f3fc865" xlink:to="loc_kron_A2020ConvertibleNotesMember_2160ddf0-bb68-4e50-af8c-7133a31c2145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020GileadNotesMember_9672dfb1-c719-438c-b07a-548aded91074" xlink:href="kron-20200930.xsd#kron_A2020GileadNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_71f65a65-c120-4cfb-9e2b-70185f3fc865" xlink:to="loc_kron_A2020GileadNotesMember_9672dfb1-c719-438c-b07a-548aded91074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_15fec7b7-3c54-4d5b-8115-ed0a032321ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_srt_StatementGeographicalAxis_15fec7b7-3c54-4d5b-8115-ed0a032321ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_15fec7b7-3c54-4d5b-8115-ed0a032321ae_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_15fec7b7-3c54-4d5b-8115-ed0a032321ae" xlink:to="loc_srt_SegmentGeographicalDomain_15fec7b7-3c54-4d5b-8115-ed0a032321ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6f1cfb60-7f70-4464-8b3d-1ddf5f590c44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_15fec7b7-3c54-4d5b-8115-ed0a032321ae" xlink:to="loc_srt_SegmentGeographicalDomain_6f1cfb60-7f70-4464-8b3d-1ddf5f590c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CambridgeMassachusettsMember_e6da1daf-52a2-4e59-8d16-d0d09f09e54b" xlink:href="kron-20200930.xsd#kron_CambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6f1cfb60-7f70-4464-8b3d-1ddf5f590c44" xlink:to="loc_kron_CambridgeMassachusettsMember_e6da1daf-52a2-4e59-8d16-d0d09f09e54b" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>kron-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:24f323b6-3e05-4299-b60b-ed7d0f94eb5e,g:b8dc781a-ce5b-4a7b-a930-702eddd4413f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7f4ee391-a328-4d0e-ae19-700baa7f7581_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7a6bb27b-9450-4bdc-a290-7770fe4433d8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4a2028f6-464e-4e91-9f33-a78d79cdf037_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b0bdec52-a74f-4d07-b7e4-c4ba7a85582e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6b13140c-7de1-4a13-9139-7b5de89170e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0f32b665-acc1-4dda-a732-262ff3f6f9a7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_57162a63-4ba3-407e-8fa9-5aa415c979b0_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_a0922ffe-7a32-475a-850a-22493f3795ea_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_b45c91dd-4378-4cc2-b548-6a43e811d6a2_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LesseeOperatingLeaseInitialAnnualBaseRent_13a88085-8f5a-4ed9-84a7-c71d1c28bfa6_terseLabel_en-US" xlink:label="lab_kron_LesseeOperatingLeaseInitialAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial annual base rent</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseInitialAnnualBaseRent_label_en-US" xlink:label="lab_kron_LesseeOperatingLeaseInitialAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Initial Annual Base Rent</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseInitialAnnualBaseRent_documentation_en-US" xlink:label="lab_kron_LesseeOperatingLeaseInitialAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Initial Annual Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseInitialAnnualBaseRent" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseInitialAnnualBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LesseeOperatingLeaseInitialAnnualBaseRent" xlink:to="lab_kron_LesseeOperatingLeaseInitialAnnualBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_244d0b80-c688-41e1-bb5a-9eea62759e81_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_c9d7b512-bcbf-4266-b555-5761c3771568_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_00b36607-2c61-4587-84d8-3d388c4d75a6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses from transaction with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_GainLossOnChangeInFairValueOfDebtInstrument_4c00a5ce-fc20-44bb-aeaa-1965e4077489_verboseLabel_en-US" xlink:label="lab_kron_GainLossOnChangeInFairValueOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) in fair value</link:label>
    <link:label id="lab_kron_GainLossOnChangeInFairValueOfDebtInstrument_becd94b0-5fa0-42b3-8659-e5a2bdb1acce_negatedLabel_en-US" xlink:label="lab_kron_GainLossOnChangeInFairValueOfDebtInstrument" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of 2020 Notes</link:label>
    <link:label id="lab_kron_GainLossOnChangeInFairValueOfDebtInstrument_label_en-US" xlink:label="lab_kron_GainLossOnChangeInFairValueOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Change In Fair Value Of Debt Instrument</link:label>
    <link:label id="lab_kron_GainLossOnChangeInFairValueOfDebtInstrument_documentation_en-US" xlink:label="lab_kron_GainLossOnChangeInFairValueOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Change In Fair Value Of Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument" xlink:href="kron-20200930.xsd#kron_GainLossOnChangeInFairValueOfDebtInstrument"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument" xlink:to="lab_kron_GainLossOnChangeInFairValueOfDebtInstrument" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_98c915a0-bbaa-4e0c-8601-e30039ca16b0_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bbb33a39-46bf-4e0d-800d-efbb61d6e2fd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, convertible preferred stock and stockholders' deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent_5a8f6fb7-eb49-4ca4-a08a-1371e66829fa_terseLabel_en-US" xlink:label="lab_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escalating rent payments, percent</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent_label_en-US" xlink:label="lab_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Escalating Rent Payments, Percent</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent_documentation_en-US" xlink:label="lab_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Escalating Rent Payments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent" xlink:to="lab_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607b112f-569e-472d-9fab-7ff50443ea46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_24dfbd0f-4eb0-49db-a370-387d91bc54ff_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_25b92f8e-3717-48ee-bca9-a1ec72a37f29_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_25b9b443-fe28-413a-b6c5-fa95eaa13e12_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_001af038-08f3-4363-8c52-379126ca791c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LiquidationConversionScenarioMember_d300a1e5-b89c-49f5-a3ac-3cca38026a1e_terseLabel_en-US" xlink:label="lab_kron_LiquidationConversionScenarioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation conversion scenario</link:label>
    <link:label id="lab_kron_LiquidationConversionScenarioMember_label_en-US" xlink:label="lab_kron_LiquidationConversionScenarioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Conversion Scenario [Member]</link:label>
    <link:label id="lab_kron_LiquidationConversionScenarioMember_documentation_en-US" xlink:label="lab_kron_LiquidationConversionScenarioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Conversion Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LiquidationConversionScenarioMember" xlink:href="kron-20200930.xsd#kron_LiquidationConversionScenarioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LiquidationConversionScenarioMember" xlink:to="lab_kron_LiquidationConversionScenarioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_cf5d6e91-1673-4eb8-8be4-5dbc5cede027_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments not due at a single maturity date</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_df78efb2-35e7-469e-8f77-12afdcca7a36_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_7ae696eb-5ddf-4b1d-a28d-782a1e8aca0f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6eeb752a-183b-4389-82d6-157ae8795ded_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease on R&amp;D equipment</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c00fa252-dfc3-43b1-bc10-91a4af78de3e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ee39fa5e-76f6-4880-8a23-aa7deae53539_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_721308a5-27d7-4b98-be3a-cb44f3ce40b8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ab19fba6-7d1e-4a5a-89fc-02a919e88fd8_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_SanMateoCaliforniaAdjacentSpaceMember_402d5739-162b-4f8a-b292-aa8381b12451_terseLabel_en-US" xlink:label="lab_kron_SanMateoCaliforniaAdjacentSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Mateo, California, Adjacent Space</link:label>
    <link:label id="lab_kron_SanMateoCaliforniaAdjacentSpaceMember_label_en-US" xlink:label="lab_kron_SanMateoCaliforniaAdjacentSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Mateo, California, Adjacent Space [Member]</link:label>
    <link:label id="lab_kron_SanMateoCaliforniaAdjacentSpaceMember_documentation_en-US" xlink:label="lab_kron_SanMateoCaliforniaAdjacentSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Mateo, California, Adjacent Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SanMateoCaliforniaAdjacentSpaceMember" xlink:href="kron-20200930.xsd#kron_SanMateoCaliforniaAdjacentSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_SanMateoCaliforniaAdjacentSpaceMember" xlink:to="lab_kron_SanMateoCaliforniaAdjacentSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a3afbcbd-ee05-4b66-a694-e2a718048eed_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_92282a14-e2e0-4e75-b262-e40ad8970a45_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ca02fee2-5c25-44bd-b82f-0cd932f8a393_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_A21ErieStreetCambridgeMassachusettsMember_aacb8ee4-a076-4219-b1a4-73e515476468_terseLabel_en-US" xlink:label="lab_kron_A21ErieStreetCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">21 Erie Street, Cambridge, Massachusetts</link:label>
    <link:label id="lab_kron_A21ErieStreetCambridgeMassachusettsMember_label_en-US" xlink:label="lab_kron_A21ErieStreetCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">21 Erie Street, Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_kron_A21ErieStreetCambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_kron_A21ErieStreetCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">21 Erie Street, Cambridge, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A21ErieStreetCambridgeMassachusettsMember" xlink:href="kron-20200930.xsd#kron_A21ErieStreetCambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_A21ErieStreetCambridgeMassachusettsMember" xlink:to="lab_kron_A21ErieStreetCambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseProvisionTermsMember_fcc65e9d-6bc0-4416-abda-48b99e88aab3_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseProvisionTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_us-gaap_PurchaseProvisionTermsMember_label_en-US" xlink:label="lab_us-gaap_PurchaseProvisionTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Provision Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseProvisionTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseProvisionTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseProvisionTermsMember" xlink:to="lab_us-gaap_PurchaseProvisionTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bac41e62-0b70-4df4-a282-c86cd082fe82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax_d4770322-d3d2-4da6-9df4-253c6ac2c5d7_negatedTerseLabel_en-US" xlink:label="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, unrealized losses</link:label>
    <link:label id="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" xlink:to="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2558c362-3b18-4f3e-918b-ddec21230193_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0cc42b06-68c4-4413-9907-bf37be790900_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_679d338b-47f2-4352-93f7-9ecb75769757_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment_fec00164-5a6b-45c9-a1fd-450ff24335b0_terseLabel_en-US" xlink:label="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone payment</link:label>
    <link:label id="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment_label_en-US" xlink:label="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Regulatory Milestone Payment</link:label>
    <link:label id="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment" xlink:to="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d7fd0ac5-6330-4900-9f58-b323ff29b3ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_eab4a844-28fb-4219-bbb2-d55f347d3cbf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_a3bb4ed8-6e95-4da3-9560-27507cbd9e47_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_e137df97-1818-40ea-90cf-5b5eac16b980_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_FundraiseScenarioMember_18f0ef5b-bd16-4fe4-83a9-2592bc18336b_terseLabel_en-US" xlink:label="lab_kron_FundraiseScenarioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fundraise scenario</link:label>
    <link:label id="lab_kron_FundraiseScenarioMember_label_en-US" xlink:label="lab_kron_FundraiseScenarioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fundraise Scenario [Member]</link:label>
    <link:label id="lab_kron_FundraiseScenarioMember_documentation_en-US" xlink:label="lab_kron_FundraiseScenarioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fundraise Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_FundraiseScenarioMember" xlink:href="kron-20200930.xsd#kron_FundraiseScenarioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_FundraiseScenarioMember" xlink:to="lab_kron_FundraiseScenarioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_1f59e597-8fa5-4a52-ad53-f65c117a1da5_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_8b70038b-d2fb-4820-ad81-d413d4e94457_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Issued</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_36c4e4a5-03a6-40c6-8c1a-9a57d80f4645_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_164a38aa-efbc-42a7-965c-c888fecc397a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6c7e18bc-d008-4f9e-a234-777d3c3a3361_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3929ad00-294c-4c5c-8d71-d979895208c4_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on settlement of convertible notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9b94c466-9b98-48ff-adfd-f0b71af178e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d77893c7-b74b-40fd-a043-21fee89a0b94_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_66121596-fe36-439a-878d-a7aa86a2bc53_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at September 30, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f5420873-bfa2-422e-b111-042246061f71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e76af417-9b36-4a37-87c1-ed7a3863baa2_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d5d897f0-25ad-4790-be1a-832f01829763_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e4e847d2-71d4-4fdf-930b-20dd69a2f953_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_PaymentsForLegalCosts_ab5aa244-ac98-49e7-afd6-1a9a5f323417_terseLabel_en-US" xlink:label="lab_kron_PaymentsForLegalCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement for legal costs</link:label>
    <link:label id="lab_kron_PaymentsForLegalCosts_label_en-US" xlink:label="lab_kron_PaymentsForLegalCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Legal Costs</link:label>
    <link:label id="lab_kron_PaymentsForLegalCosts_documentation_en-US" xlink:label="lab_kron_PaymentsForLegalCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Legal Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsForLegalCosts" xlink:href="kron-20200930.xsd#kron_PaymentsForLegalCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_PaymentsForLegalCosts" xlink:to="lab_kron_PaymentsForLegalCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_14fecab4-aeb6-4ffa-9bbd-a34179b4f209_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_00f94c03-3473-40f9-9dde-d8ef107df081_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_677aaa23-4852-4f88-abb7-c8706dd4084b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at September 30, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ba1a5140-7bfe-46d9-bd52-e447e6df8031_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4a7cfd12-0f83-4176-aefe-a869d5c3c562_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_ddb6992b-7c59-4251-9128-4895bf9e9df9_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_2576a9e3-241a-4ec0-8508-14195f64d8db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c3860f3a-991f-4e7a-b202-8b8199bee19a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty_7cee4cbf-37eb-46c2-8a81-36b6722cc9ad_terseLabel_en-US" xlink:label="lab_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursable expenses to related parties</link:label>
    <link:label id="lab_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty_label_en-US" xlink:label="lab_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions, Reimbursable Expenses To Related Party</link:label>
    <link:label id="lab_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty_documentation_en-US" xlink:label="lab_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions, Reimbursable Expenses To Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty" xlink:href="kron-20200930.xsd#kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty" xlink:to="lab_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_28b65f72-810c-48fb-bb4b-4b636b183b04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_f13f40d9-94a0-43ec-88f3-6b78d0494ffb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_ca5475f4-4147-4e57-b126-5a9c62e60ef1_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, liquidation preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_47deacae-86b2-4142-9b82-1e6700e8e548_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_4b6e7c67-1991-4afa-9770-5b7a65c7e234_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_857edac3-e159-40ae-a623-d00d2036666a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e2dddd7d-0b24-4f38-816d-a1e2e71303e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1eb76912-17be-4e1f-b7e1-4a2713bc88d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b810df72-bdaf-41b2-a590-46385bef16e5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_41e54080-049c-41e9-afb1-a89a2d36d5ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in accrued interest on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_912837e4-921c-4925-b08a-fb4cb00b147e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_NonEmployeeMember_75843225-dbba-4f75-90cf-801e25483e2a_terseLabel_en-US" xlink:label="lab_kron_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee</link:label>
    <link:label id="lab_kron_NonEmployeeMember_label_en-US" xlink:label="lab_kron_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee [Member]</link:label>
    <link:label id="lab_kron_NonEmployeeMember_documentation_en-US" xlink:label="lab_kron_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_NonEmployeeMember" xlink:href="kron-20200930.xsd#kron_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_NonEmployeeMember" xlink:to="lab_kron_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a7fa06ff-f230-447c-8026-5a965dc083ee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3355f732-f196-4b30-a5be-80fd261e5480_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_34f0b5f9-87d1-4786-9423-9ba3c2c421c7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a73a7f22-25b5-474a-9283-1078a0ebd6b0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_24a0f50f-bc2d-404f-8ac5-e775eb009c48_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a7dd2837-764b-46da-b55d-efe75b0aed74_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_56861eeb-3ffa-44e5-b583-543f5719c2c0_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_AccruedOfferingCostsCurrent_60c14f8e-e7e6-4743-b07d-cd985679792f_terseLabel_en-US" xlink:label="lab_kron_AccruedOfferingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued offering costs</link:label>
    <link:label id="lab_kron_AccruedOfferingCostsCurrent_label_en-US" xlink:label="lab_kron_AccruedOfferingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Offering Costs, Current</link:label>
    <link:label id="lab_kron_AccruedOfferingCostsCurrent_documentation_en-US" xlink:label="lab_kron_AccruedOfferingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Offering Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AccruedOfferingCostsCurrent" xlink:href="kron-20200930.xsd#kron_AccruedOfferingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_AccruedOfferingCostsCurrent" xlink:to="lab_kron_AccruedOfferingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LesseeOperatingLeaseMonthlyBaseRent_2996b192-93a3-4fbb-aa34-7de5d233c145_terseLabel_en-US" xlink:label="lab_kron_LesseeOperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base rent</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseMonthlyBaseRent_label_en-US" xlink:label="lab_kron_LesseeOperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Rent</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseMonthlyBaseRent_documentation_en-US" xlink:label="lab_kron_LesseeOperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseMonthlyBaseRent" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseMonthlyBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LesseeOperatingLeaseMonthlyBaseRent" xlink:to="lab_kron_LesseeOperatingLeaseMonthlyBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_55001c3d-bfcb-4210-a6fb-2bf43cd86a1c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f3d33f75-dbc6-450e-a213-1a9a6082ba15_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e98613e0-230a-4edf-80ef-767bf36933f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91617b5c-f7a6-42a1-af35-ade73f795ebf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in private placement (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_caade14d-9481-449d-a92b-b344222c15eb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4763bc63-11d0-4df9-b277-a298e5e1140e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90e96b14-76d9-46c1-a1df-e3bc1d69c5d3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c8c9cb48-94a5-4957-8be1-f96fb48835dc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_BellcoCapitalLLCMember_b4a18bcd-eabc-4ff4-98b7-fd89da541094_terseLabel_en-US" xlink:label="lab_kron_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital, LLC</link:label>
    <link:label id="lab_kron_BellcoCapitalLLCMember_label_en-US" xlink:label="lab_kron_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital, LLC [Member]</link:label>
    <link:label id="lab_kron_BellcoCapitalLLCMember_documentation_en-US" xlink:label="lab_kron_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_BellcoCapitalLLCMember" xlink:href="kron-20200930.xsd#kron_BellcoCapitalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_BellcoCapitalLLCMember" xlink:to="lab_kron_BellcoCapitalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_PaymentsForAssetAcquisitionsReimbursements_355c0d67-d74c-492f-bdeb-8bc2e955c208_terseLabel_en-US" xlink:label="lab_kron_PaymentsForAssetAcquisitionsReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for reimbursements</link:label>
    <link:label id="lab_kron_PaymentsForAssetAcquisitionsReimbursements_label_en-US" xlink:label="lab_kron_PaymentsForAssetAcquisitionsReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions, Reimbursements</link:label>
    <link:label id="lab_kron_PaymentsForAssetAcquisitionsReimbursements_documentation_en-US" xlink:label="lab_kron_PaymentsForAssetAcquisitionsReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions, Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsForAssetAcquisitionsReimbursements" xlink:href="kron-20200930.xsd#kron_PaymentsForAssetAcquisitionsReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_PaymentsForAssetAcquisitionsReimbursements" xlink:to="lab_kron_PaymentsForAssetAcquisitionsReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fe1a7b4e-1654-49dc-b9e1-df6a4bb3fa7b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e4d10ea1-611a-466d-a89d-d927e986b7d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRent_5436c5ff-f7f9-47d2-8040-764c7f28ba55_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid rent</link:label>
    <link:label id="lab_us-gaap_PrepaidRent_label_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRent" xlink:to="lab_us-gaap_PrepaidRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_968e7f72-3b16-40a9-84c1-c40c1b8cf640_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d6fabcad-a96a-4032-a4ce-e3b18dc084fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares that may have been issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_57ec0b49-a0ae-4998-a01d-a9a5602c66b9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a8fcbc33-3c06-47a8-ac76-db407380e189_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_f896e537-0316-4842-9d26-0641c450b3eb_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable, at fair value</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7ff8a01b-409b-4076-82c0-07f435eb73ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LesseeOperatingLeaseEarlyTerminationCost_64a74d03-5766-4d1e-8725-847bd365d93e_terseLabel_en-US" xlink:label="lab_kron_LesseeOperatingLeaseEarlyTerminationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost for early lease termination</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseEarlyTerminationCost_label_en-US" xlink:label="lab_kron_LesseeOperatingLeaseEarlyTerminationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Early Termination Cost</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseEarlyTerminationCost_documentation_en-US" xlink:label="lab_kron_LesseeOperatingLeaseEarlyTerminationCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Early Termination Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseEarlyTerminationCost" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseEarlyTerminationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LesseeOperatingLeaseEarlyTerminationCost" xlink:to="lab_kron_LesseeOperatingLeaseEarlyTerminationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e6d6f8a-ffe9-4f79-b435-5a3155da51b0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_50cc2030-4a51-4d13-b344-b7f860383a9d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_d6fb8714-56a1-467b-89d8-55039187d02e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4679fd94-fbae-46d5-a1e1-c64ce067a8e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_d1f69a89-aa2a-4302-bf01-905df673d160_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cc9ef040-5215-43d5-8c4b-7e02f81c1db6_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9cb4a987-8f07-4436-bba6-67c9e8e9a5ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LesseeOperatingLeaseTenantImprovementAllowances_b19a31d7-4c4f-44b4-a2d2-a3ad66ba4cb5_terseLabel_en-US" xlink:label="lab_kron_LesseeOperatingLeaseTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowances</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseTenantImprovementAllowances_label_en-US" xlink:label="lab_kron_LesseeOperatingLeaseTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Tenant Improvement Allowances</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseTenantImprovementAllowances_documentation_en-US" xlink:label="lab_kron_LesseeOperatingLeaseTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Tenant Improvement Allowances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseTenantImprovementAllowances" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LesseeOperatingLeaseTenantImprovementAllowances" xlink:to="lab_kron_LesseeOperatingLeaseTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_9eb219ce-2f43-46fb-a355-3f6f64e0d9dd_netLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, amortized cost</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_0dbb77d4-f3e4-4eea-a188-572463c2f5fc_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_d185349c-6418-4584-805c-52436ac001e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, term</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_e5a0355d-e148-4cfc-8588-68f4a66259b9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_57894b08-3e6a-48e1-866d-72f3925374c0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment additions included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_5525e313-ca4d-4d4d-89a6-ed13da9583d8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_072a51b6-a2d4-4c16-bb87-504ed181affb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_RDEquipmentMember_deaf9b74-0ba8-4513-9ded-f35e89edfe4d_terseLabel_en-US" xlink:label="lab_kron_RDEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Equipment</link:label>
    <link:label id="lab_kron_RDEquipmentMember_label_en-US" xlink:label="lab_kron_RDEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Equipment [Member]</link:label>
    <link:label id="lab_kron_RDEquipmentMember_documentation_en-US" xlink:label="lab_kron_RDEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_RDEquipmentMember" xlink:href="kron-20200930.xsd#kron_RDEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_RDEquipmentMember" xlink:to="lab_kron_RDEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_11064866-f125-4d3d-86c1-281489ef1117_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_aeef3032-200d-44b6-a728-72eaa143aee3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unrecognized cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bc6d4e14-679f-423e-894d-578645972bc1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_c859f714-9396-4c8a-905b-a5e459a826f0_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9dc3d5c3-5c8b-4425-b0b7-43b4a9566e8e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_6376dbec-dcfc-432d-b4f1-f11691ba1a1f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3f2c585f-87ed-4869-bf42-b527a73b0496_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_554ae463-9e7c-4ea5-b896-fed93a8a4c4f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7b6c32bd-c4c8-4315-8151-22926c1e3cab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fb2673c0-050f-48c6-a3ef-bb35cfd349ca_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_210bd0a2-2f68-4463-ad44-18c357baad69_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_588768fa-8d84-432f-8d41-c04f63b5bfb4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_3381085b-b79e-4fc8-bf95-5389e65f96b5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment_e435512b-71d9-4f00-b99b-ded0e60e80a2_terseLabel_en-US" xlink:label="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate sales milestone payment</link:label>
    <link:label id="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment_label_en-US" xlink:label="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Aggregate Net Sales Milestone Payment</link:label>
    <link:label id="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment_documentation_en-US" xlink:label="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Aggregate Net Sales Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment" xlink:to="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_af9968e4-23de-415c-9746-7aa5e1fcd6e3_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2d5a35b3-a4ca-4556-b10b-b8dc482b9c30_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f9babba5-759d-48ec-bbb5-cf2324941921_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_c7e75011-dd56-4a75-b091-127f8a118278_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_170275f0-3eb8-47a9-8904-8cb56710e46f_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Authorized</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_26d731a8-08df-447d-8d42-ab466f702bb1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_113e237b-c779-49ac-b3c1-30387459b8ea_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_25a5456f-fad5-4be7-a86a-ccf4aac3fe90_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_61676f1e-284c-402b-805d-7a0acc01055b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_04ad09ab-4470-4416-98c7-0e14fe89e32e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a0abc92d-c627-48e6-ad94-41fbac3faa07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value, options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ScheduleOfAssetAcquisitionTable_790be34a-34ca-499d-af46-8246f59dfbde_terseLabel_en-US" xlink:label="lab_kron_ScheduleOfAssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Asset Acquisition [Table]</link:label>
    <link:label id="lab_kron_ScheduleOfAssetAcquisitionTable_label_en-US" xlink:label="lab_kron_ScheduleOfAssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Asset Acquisition [Table]</link:label>
    <link:label id="lab_kron_ScheduleOfAssetAcquisitionTable_documentation_en-US" xlink:label="lab_kron_ScheduleOfAssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionTable" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable" xlink:to="lab_kron_ScheduleOfAssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_567f9c73-9a85-4bd5-b8d4-a2af8631c501_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4532f5e4-b35a-430c-8637-f996461c23c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c65bdc4b-0ca6-46f6-b575-897be8c075dd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_ded5b51c-d467-439b-8511-e21f3867bc98_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_SettlementPlanAxis_d23c9a07-3d2e-45bd-81cd-5c1fc8e4a8d2_terseLabel_en-US" xlink:label="lab_kron_SettlementPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Plan [Axis]</link:label>
    <link:label id="lab_kron_SettlementPlanAxis_label_en-US" xlink:label="lab_kron_SettlementPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Plan [Axis]</link:label>
    <link:label id="lab_kron_SettlementPlanAxis_documentation_en-US" xlink:label="lab_kron_SettlementPlanAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanAxis" xlink:href="kron-20200930.xsd#kron_SettlementPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_SettlementPlanAxis" xlink:to="lab_kron_SettlementPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_25b2b488-3375-4eb0-a213-22e9b138b00f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ad770d9f-2efa-4ceb-a6a3-3fe655ac5f67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3d73ece3-da3c-4093-b394-9ccda4c7e24a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9569c96a-497a-4200-ab0f-b879357c7882_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_861aa60d-44b7-4d0d-a3a9-4a5fb24d9030_terseLabel_en-US" xlink:label="lab_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="kron-20200930.xsd#kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LesseeOperatingLeaseIncrementalBorrowingRate_83a663e4-274a-4b68-8875-961135eb5cdd_terseLabel_en-US" xlink:label="lab_kron_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_kron_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Incremental Borrowing Rate</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_kron_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:to="lab_kron_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_39eae50c-9ade-46a5-8f11-d6d811c806d2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LeaseExpenseNoncash_85db6906-f526-47ad-93d6-f51e99e324f3_terseLabel_en-US" xlink:label="lab_kron_LeaseExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash lease expense</link:label>
    <link:label id="lab_kron_LeaseExpenseNoncash_label_en-US" xlink:label="lab_kron_LeaseExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expense, Noncash</link:label>
    <link:label id="lab_kron_LeaseExpenseNoncash_documentation_en-US" xlink:label="lab_kron_LeaseExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expense, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LeaseExpenseNoncash" xlink:href="kron-20200930.xsd#kron_LeaseExpenseNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LeaseExpenseNoncash" xlink:to="lab_kron_LeaseExpenseNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_39564a37-2e05-40e7-b5a0-406979a0f0ba_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options recognized, weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_cd85f223-79e3-45db-8033-e656ac0f710e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_966779cd-c431-4d9f-8d02-dea8885fa241_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_adf12d00-7e20-4c9e-9246-dd5a9ca5428a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f5b89538-0b39-4bff-92a0-9986972427f4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and expected to vest, Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31e74e31-7c0e-403d-bdc4-9610536aa908_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_DebtConversionValuationOfCompany_b07d3116-fe4c-478a-8d9a-9a123915820d_terseLabel_en-US" xlink:label="lab_kron_DebtConversionValuationOfCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of company</link:label>
    <link:label id="lab_kron_DebtConversionValuationOfCompany_label_en-US" xlink:label="lab_kron_DebtConversionValuationOfCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Valuation Of Company</link:label>
    <link:label id="lab_kron_DebtConversionValuationOfCompany_documentation_en-US" xlink:label="lab_kron_DebtConversionValuationOfCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Valuation Of Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DebtConversionValuationOfCompany" xlink:href="kron-20200930.xsd#kron_DebtConversionValuationOfCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_DebtConversionValuationOfCompany" xlink:to="lab_kron_DebtConversionValuationOfCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c71a27f5-53e4-44ba-b911-b723a95b4265_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_144cbc34-f01c-4159-a131-87aaa7f565b5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b488980d-fd15-4a64-bd08-b41a1e4f2591_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ac230ec6-6c12-4b31-a8ea-5a31bf6b06de_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_57ef1242-46f5-4ee9-820e-8582895167a9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value, options vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_10b8190b-60c7-4f17-9e1b-dc102ada15a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7fbd9bae-5fb1-479b-8ae1-fac77ebf4280_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_A2020StockOptionAndIncentivePlanMember_cd7261fd-ba44-4161-944a-4e5216dcb8e2_terseLabel_en-US" xlink:label="lab_kron_A2020StockOptionAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2020 Plan</link:label>
    <link:label id="lab_kron_A2020StockOptionAndIncentivePlanMember_label_en-US" xlink:label="lab_kron_A2020StockOptionAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Option And Incentive Plan [Member]</link:label>
    <link:label id="lab_kron_A2020StockOptionAndIncentivePlanMember_documentation_en-US" xlink:label="lab_kron_A2020StockOptionAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Option And Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020StockOptionAndIncentivePlanMember" xlink:href="kron-20200930.xsd#kron_A2020StockOptionAndIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_A2020StockOptionAndIncentivePlanMember" xlink:to="lab_kron_A2020StockOptionAndIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_a8f87a8f-1b83-4154-95c0-65a5c0b867b6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining term (years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_54d8e6ad-5518-4d0e-b077-80cf439432b9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity_0c8c3a72-bef4-48d0-80de-536b9dd32a42_terseLabel_en-US" xlink:label="lab_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, remaining contractual maturity</link:label>
    <link:label id="lab_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity_label_en-US" xlink:label="lab_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Remaining Contractual Maturity</link:label>
    <link:label id="lab_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity_documentation_en-US" xlink:label="lab_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Remaining Contractual Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity" xlink:href="kron-20200930.xsd#kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity" xlink:to="lab_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_52b535d0-1951-46d9-bd5c-fde00c538bb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_92ba311a-ab22-41fa-9b1b-b65ad78ed3db_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_SharePriceFairValueDisclosure_67e50146-2ec2-4bf6-97a9-04b04f4afbad_terseLabel_en-US" xlink:label="lab_kron_SharePriceFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock per share (dollars per share)</link:label>
    <link:label id="lab_kron_SharePriceFairValueDisclosure_label_en-US" xlink:label="lab_kron_SharePriceFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price, Fair Value Disclosure</link:label>
    <link:label id="lab_kron_SharePriceFairValueDisclosure_documentation_en-US" xlink:label="lab_kron_SharePriceFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SharePriceFairValueDisclosure" xlink:href="kron-20200930.xsd#kron_SharePriceFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_SharePriceFairValueDisclosure" xlink:to="lab_kron_SharePriceFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87266b3b-475a-4238-8d2e-88684e06fe36_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_3215baaa-93f5-487d-9273-ff8620660d08_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4d73189a-2cc0-432f-b728-4fd79fe28142_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_6706863c-8856-402a-a8e8-fc45067c40c0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_2b933944-a2cc-4128-865e-b1da14037709_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7c3443fc-5d43-492c-9e7b-7c13c3359870_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_b293bc26-e740-412f-b322-750787851256_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e26f8642-3fad-4c1e-a832-52e4f54808ea_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9c474cfa-e8be-4c0c-a8cd-cb9d759840e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019 (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ccd61ac4-590b-47d2-b4b3-6a7046d9db56_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at September 30, 2020 (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_ef28d060-3fac-4588-866a-d64d065809fc_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_1d857e14-a788-446c-8830-9a919469e4b4_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_af50352d-e28f-4999-9221-b63fe04c258a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_9ac6784a-c758-49fe-b1b2-d06e8823709a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_SeriesBScenarioMember_828e221a-b5bb-4600-8304-c50268c0fcee_terseLabel_en-US" xlink:label="lab_kron_SeriesBScenarioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Scenario</link:label>
    <link:label id="lab_kron_SeriesBScenarioMember_label_en-US" xlink:label="lab_kron_SeriesBScenarioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Scenario [Member]</link:label>
    <link:label id="lab_kron_SeriesBScenarioMember_documentation_en-US" xlink:label="lab_kron_SeriesBScenarioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SeriesBScenarioMember" xlink:href="kron-20200930.xsd#kron_SeriesBScenarioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_SeriesBScenarioMember" xlink:to="lab_kron_SeriesBScenarioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_SanMateoCaliforniaMember_de430246-f913-487b-b14c-ced35bc9e971_terseLabel_en-US" xlink:label="lab_kron_SanMateoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Mateo, California</link:label>
    <link:label id="lab_kron_SanMateoCaliforniaMember_label_en-US" xlink:label="lab_kron_SanMateoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Mateo, California [Member]</link:label>
    <link:label id="lab_kron_SanMateoCaliforniaMember_documentation_en-US" xlink:label="lab_kron_SanMateoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Mateo, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SanMateoCaliforniaMember" xlink:href="kron-20200930.xsd#kron_SanMateoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_SanMateoCaliforniaMember" xlink:to="lab_kron_SanMateoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LiquidationCashPayoutScenarioMember_d064b324-8530-48fd-9870-bf2950a5eafa_terseLabel_en-US" xlink:label="lab_kron_LiquidationCashPayoutScenarioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation cash payout scenario</link:label>
    <link:label id="lab_kron_LiquidationCashPayoutScenarioMember_label_en-US" xlink:label="lab_kron_LiquidationCashPayoutScenarioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Cash Payout Scenario [Member]</link:label>
    <link:label id="lab_kron_LiquidationCashPayoutScenarioMember_documentation_en-US" xlink:label="lab_kron_LiquidationCashPayoutScenarioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Cash Payout Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LiquidationCashPayoutScenarioMember" xlink:href="kron-20200930.xsd#kron_LiquidationCashPayoutScenarioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LiquidationCashPayoutScenarioMember" xlink:to="lab_kron_LiquidationCashPayoutScenarioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_OperatingLeaseAssetsAbstract_3a639666-dfde-49bb-9305-daa6973db081_verboseLabel_en-US" xlink:label="lab_kron_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_kron_OperatingLeaseAssetsAbstract_label_en-US" xlink:label="lab_kron_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_OperatingLeaseAssetsAbstract" xlink:href="kron-20200930.xsd#kron_OperatingLeaseAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_OperatingLeaseAssetsAbstract" xlink:to="lab_kron_OperatingLeaseAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0beb23e1-08d7-4afa-acfd-b78f59f05422_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_68ea9418-d2ef-4a33-96a5-f90e9211bf5a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c394e67d-61cb-4e34-b784-101b1a61e79e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_37d11d34-d8db-4667-893a-4160dbb3ae39_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_7d6c762a-00a8-43ed-af21-30a1d3aefa55_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_279c7939-a0ec-4a20-a60f-22ac02ac2d61_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4a64bc30-c5ee-45d4-9bd7-7a4107373c61_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_2f08673a-325c-4ae0-a724-cb50670aeacd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="lab_us-gaap_DebtConversionNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_db78d7cb-70f4-4ca9-b8d9-c087851e7ae6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f0c21bea-d3f4-4267-bd8d-27077fe9dfab_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6ef3c134-02a6-4152-bd08-7550834dd235_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23b1cfd1-3765-4aa5-898c-87fa454f0b9d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f1a04269-4199-49cd-bfb4-b102399c6749_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f4ce7522-bcb0-4df3-a89e-f9502434f948_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LabEquipmentMember_7a357adc-9495-4529-8c4c-0499a042a792_terseLabel_en-US" xlink:label="lab_kron_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_kron_LabEquipmentMember_label_en-US" xlink:label="lab_kron_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_kron_LabEquipmentMember_documentation_en-US" xlink:label="lab_kron_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LabEquipmentMember" xlink:href="kron-20200930.xsd#kron_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LabEquipmentMember" xlink:to="lab_kron_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_366acaac-1295-449c-b796-9f803ef0b043_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_A301BinneyStreetCambridgeMassachusettsMember_02155718-5c1b-40b6-8145-5bd67762950f_terseLabel_en-US" xlink:label="lab_kron_A301BinneyStreetCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">301 Binney Street, Cambridge, Massachusetts</link:label>
    <link:label id="lab_kron_A301BinneyStreetCambridgeMassachusettsMember_label_en-US" xlink:label="lab_kron_A301BinneyStreetCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">301 Binney Street, Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_kron_A301BinneyStreetCambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_kron_A301BinneyStreetCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">301 Binney Street, Cambridge, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A301BinneyStreetCambridgeMassachusettsMember" xlink:href="kron-20200930.xsd#kron_A301BinneyStreetCambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_A301BinneyStreetCambridgeMassachusettsMember" xlink:to="lab_kron_A301BinneyStreetCambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_e5403159-4b56-429e-aad8-61fae7c39918_totalLabel_en-US" xlink:label="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, amortized cost</link:label>
    <link:label id="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost</link:label>
    <link:label id="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f2074a76-0bb8-4003-9b3e-0075315ce7f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_9690724e-3630-4dc8-9211-75c49812ce6d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuable Upon Conversion</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_c8045e17-49cd-40c1-8b5a-08a9867e5470_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d9627dfc-50ad-4ff2-a5e3-e4333f31fc31_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_c2f4c065-3c97-4ae4-95ec-ef6ba1373958_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_87d66121-8106-47fb-8013-17bdfb6ef18e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Held-to-maturity Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Held-to-maturity Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_SaleOfStockPurchasePriceOfCommonStockPercent_b8f466f3-9b26-4cce-be5a-c6d17b7a98f6_terseLabel_en-US" xlink:label="lab_kron_SaleOfStockPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement price, percentage</link:label>
    <link:label id="lab_kron_SaleOfStockPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_kron_SaleOfStockPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Purchase Price Of Common Stock, Percent</link:label>
    <link:label id="lab_kron_SaleOfStockPurchasePriceOfCommonStockPercent_documentation_en-US" xlink:label="lab_kron_SaleOfStockPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Purchase Price Of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SaleOfStockPurchasePriceOfCommonStockPercent" xlink:href="kron-20200930.xsd#kron_SaleOfStockPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_SaleOfStockPurchasePriceOfCommonStockPercent" xlink:to="lab_kron_SaleOfStockPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_80679504-b859-4423-9628-209601806715_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Note</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_PaymentsOfUnderwritingDiscountsAndCommissions_72e5dbef-35b1-403d-afc4-f2732b1d5c06_negatedTerseLabel_en-US" xlink:label="lab_kron_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of underwriting discounts and commissions</link:label>
    <link:label id="lab_kron_PaymentsOfUnderwritingDiscountsAndCommissions_label_en-US" xlink:label="lab_kron_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Underwriting Discounts And Commissions</link:label>
    <link:label id="lab_kron_PaymentsOfUnderwritingDiscountsAndCommissions_documentation_en-US" xlink:label="lab_kron_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Underwriting Discounts And Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:href="kron-20200930.xsd#kron_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:to="lab_kron_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d1cefa83-4759-4d74-8320-4fb02423ffc2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8c5c044d-15e6-4b63-8e98-a8cf398952f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_9bdffc69-10b4-45a5-b387-f241b02224a6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_d660c56f-fc75-4763-bf8c-9ab1159874f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_751e759f-cc9b-4110-9395-be80ff840a98_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_4b49afc2-911a-4533-8539-e0731dc62fd2_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_248e177c-a9a9-4c16-85cb-38d9959227a6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities related to shares that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_f6614d16-7f79-42d9-8338-d8bdedd002a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Tenant improvement allowance</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_b732daa4-26c1-40b8-b9b2-62e0534602c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_36eabf3f-3c3e-46e9-aa4c-0a95092bd04e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b843f6c8-4fc4-46a9-8eda-7048588663cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization/accretion on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0625a07d-d5db-462d-89bf-ecf494e9cfd1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5f53f85a-79ec-4a27-ab38-d95d819d523f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ServicesAgreementTerm_772341e6-754c-4e77-85dd-0cc96e271003_terseLabel_en-US" xlink:label="lab_kron_ServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services agreement term</link:label>
    <link:label id="lab_kron_ServicesAgreementTerm_label_en-US" xlink:label="lab_kron_ServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreement Term</link:label>
    <link:label id="lab_kron_ServicesAgreementTerm_documentation_en-US" xlink:label="lab_kron_ServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ServicesAgreementTerm" xlink:href="kron-20200930.xsd#kron_ServicesAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ServicesAgreementTerm" xlink:to="lab_kron_ServicesAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_63f432dd-23cd-4cea-9795-c42d23f0e0a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fa42a8c2-1c95-49f9-b5d1-21a09ae7e43b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_c2eb625f-18bf-46c5-b8b3-3d383f797c60_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_8c8ff7cf-3f43-45b1-8fa6-270b9c334148_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_0375a407-54f9-4145-888b-e3d8190da3ca_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds received in private placement</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_AssetAcquisitionDomain_40ec3cae-99b7-41ff-9d35-507f3e086c45_terseLabel_en-US" xlink:label="lab_kron_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_kron_AssetAcquisitionDomain_label_en-US" xlink:label="lab_kron_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_kron_AssetAcquisitionDomain_documentation_en-US" xlink:label="lab_kron_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionDomain" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_AssetAcquisitionDomain" xlink:to="lab_kron_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_41b6689d-b887-460e-9db9-959ca4f9145f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_66c6dfb6-ae49-45ae-9769-fe88212a3739_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6120a8e1-4ba8-4cab-be4f-edbd873a99b6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7a424410-104a-4119-9f75-35d33105b44a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_31fa0984-1d61-4878-a5a1-19301b88049d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_16bb641d-315a-41bc-9c23-84e947fe5a4f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock_035d46d8-195d-45cb-811c-36075486eb3e_terseLabel_en-US" xlink:label="lab_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Operating Leases, Lessee</link:label>
    <link:label id="lab_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock_label_en-US" xlink:label="lab_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Operating Leases, Lessee [Table Text Block]</link:label>
    <link:label id="lab_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Operating Leases, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock" xlink:href="kron-20200930.xsd#kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock" xlink:to="lab_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_be084228-6456-4696-9742-4ba91b3f70b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_53814ce1-a57a-4c5b-83bf-e765498d3221_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option-pricing Model Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_PaymentsForAssetAcquisitions_856f119c-1243-4fca-ba15-8779c2083bba_terseLabel_en-US" xlink:label="lab_kron_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_kron_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_kron_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions</link:label>
    <link:label id="lab_kron_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_kron_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsForAssetAcquisitions" xlink:href="kron-20200930.xsd#kron_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_PaymentsForAssetAcquisitions" xlink:to="lab_kron_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b1ae75e3-50a0-44f1-8d34-95ffe0b170d8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_17e5a096-3faa-4a0f-bef5-6a33a1376c5f_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_3102f45e-4802-4490-8c19-bb49ee7365c0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_09b9327f-e557-4d34-a0ff-78bd1bdd22ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_550c7f4f-15c5-403e-95fe-84410084d778_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb858d5c-a9d0-40ac-bea5-f511ca6eb88b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bb6ec058-dc27-4a92-99af-b341d12373da_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1fe9c495-0f51-45e3-a7d5-e7643d5b5f05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_a66f7df6-7300-471b-a092-b8f01d3c88a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f5299f89-c747-49bf-b6bf-62b23f48bed6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_RepaymentOfDebtPaymentToBeMade_ac0d04fd-85ab-4c9e-be1e-5829612bbf15_terseLabel_en-US" xlink:label="lab_kron_RepaymentOfDebtPaymentToBeMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt, payments to be made</link:label>
    <link:label id="lab_kron_RepaymentOfDebtPaymentToBeMade_label_en-US" xlink:label="lab_kron_RepaymentOfDebtPaymentToBeMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Debt, Payment To Be Made</link:label>
    <link:label id="lab_kron_RepaymentOfDebtPaymentToBeMade_documentation_en-US" xlink:label="lab_kron_RepaymentOfDebtPaymentToBeMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Debt, Payment To Be Made</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_RepaymentOfDebtPaymentToBeMade" xlink:href="kron-20200930.xsd#kron_RepaymentOfDebtPaymentToBeMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_RepaymentOfDebtPaymentToBeMade" xlink:to="lab_kron_RepaymentOfDebtPaymentToBeMade" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ExecutiveEmployeeMember_9755c050-3f4d-457a-b87a-06e64bafe20f_terseLabel_en-US" xlink:label="lab_kron_ExecutiveEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Employee</link:label>
    <link:label id="lab_kron_ExecutiveEmployeeMember_label_en-US" xlink:label="lab_kron_ExecutiveEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Employee [Member]</link:label>
    <link:label id="lab_kron_ExecutiveEmployeeMember_documentation_en-US" xlink:label="lab_kron_ExecutiveEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ExecutiveEmployeeMember" xlink:href="kron-20200930.xsd#kron_ExecutiveEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ExecutiveEmployeeMember" xlink:to="lab_kron_ExecutiveEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_StockOptionsEarlyExerciseMember_4d855896-9c29-424a-8002-35eca6dd80eb_terseLabel_en-US" xlink:label="lab_kron_StockOptionsEarlyExerciseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised stock options subject to future vesting</link:label>
    <link:label id="lab_kron_StockOptionsEarlyExerciseMember_label_en-US" xlink:label="lab_kron_StockOptionsEarlyExerciseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Early Exercise [Member]</link:label>
    <link:label id="lab_kron_StockOptionsEarlyExerciseMember_documentation_en-US" xlink:label="lab_kron_StockOptionsEarlyExerciseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Early Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_StockOptionsEarlyExerciseMember" xlink:href="kron-20200930.xsd#kron_StockOptionsEarlyExerciseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_StockOptionsEarlyExerciseMember" xlink:to="lab_kron_StockOptionsEarlyExerciseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fdba93b4-dcda-4398-b801-7bed54bf3134_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_IPOConversionScenarioMember_19659720-1828-43dd-9b9b-a12a8107cdc0_terseLabel_en-US" xlink:label="lab_kron_IPOConversionScenarioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO conversion scenario</link:label>
    <link:label id="lab_kron_IPOConversionScenarioMember_label_en-US" xlink:label="lab_kron_IPOConversionScenarioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Conversion Scenario [Member]</link:label>
    <link:label id="lab_kron_IPOConversionScenarioMember_documentation_en-US" xlink:label="lab_kron_IPOConversionScenarioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Conversion Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IPOConversionScenarioMember" xlink:href="kron-20200930.xsd#kron_IPOConversionScenarioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_IPOConversionScenarioMember" xlink:to="lab_kron_IPOConversionScenarioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_d2bbedac-749c-4c78-9666-3cc9a32009dd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b8666c77-bb9c-477f-85c9-2902d3e30682_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_76256ee3-9ae8-4b64-9fff-c7a723b26f39_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3e26483b-3e82-42d7-b6bb-45594a45cc6a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0723fd4c-925b-43bf-88a0-2ef91466f604_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a28792ce-7a60-47f9-a4a7-5238fd123efc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_69b53ded-a99b-4a66-92bf-fc43de680489_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents, and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_01d863e0-d37b-43cb-8f2b-a4260c7c53c6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_909efdd5-f125-4a1e-b874-433ad84b07f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5cf10160-853b-422f-8d24-11f9c3eb9cdc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_ce56935f-514e-45cc-8ad3-fc014a9a2af4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_04a8678d-1abc-4bfa-920c-7cce9e94add1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e5b48b3b-8e90-4cb6-a6d4-74000c7a0630_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares of common stock, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_776ca42a-9be7-4ebc-a6e1-52a0a221e7e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2304a4d0-c2b2-4b86-8550-624355267220_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Current Portion of Other Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e36d7e04-d299-438e-a228-9a79d47dab2d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bd1b54b3-78ae-4be8-b4ea-27eacc6466d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock_a7eaf304-6621-413f-96c6-82220dc31e19_terseLabel_en-US" xlink:label="lab_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Finance Leases, Lessee</link:label>
    <link:label id="lab_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock_label_en-US" xlink:label="lab_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Finance Leases, Lessee [Table Text Block]</link:label>
    <link:label id="lab_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Finance Leases, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock" xlink:href="kron-20200930.xsd#kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock" xlink:to="lab_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0aea5ae9-781c-4f20-88fc-1bc3ebb4670c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00eb6647-fcd6-4fd1-80f5-80f69eb8a90f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_33d5d5e8-3c74-471e-97ca-e0bbad941d53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a12c4374-8311-4c44-bb35-c0f6d4ce7f9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d4f41809-4731-4c1b-9f97-d2dd7e6b5061_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9de0f72b-13b7-41c5-9b6f-e0942a67bf48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_afb41ed2-07d6-40b5-92d0-a4bb57799c71_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ef4dd667-d907-4817-9ef3-4ffb7b233609_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_65b3bc81-0230-406e-9f1f-6bbec3577e46_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_de836ab2-7e36-4a11-bca7-182978a0f027_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_FinanceLeasesAssetsAbstract_16649ba3-1c71-4a36-9bad-1a2ae9dfc043_terseLabel_en-US" xlink:label="lab_kron_FinanceLeasesAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_kron_FinanceLeasesAssetsAbstract_label_en-US" xlink:label="lab_kron_FinanceLeasesAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases Assets [Abstract]</link:label>
    <link:label id="lab_kron_FinanceLeasesAssetsAbstract_documentation_en-US" xlink:label="lab_kron_FinanceLeasesAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_FinanceLeasesAssetsAbstract" xlink:href="kron-20200930.xsd#kron_FinanceLeasesAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_FinanceLeasesAssetsAbstract" xlink:to="lab_kron_FinanceLeasesAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bf7c8eb7-63fb-4a3b-ad4f-a196a8d3dc5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_DebtSecuritiesAvailableForSaleAccruedInterest_85f70abd-3943-46e4-a966-5bcf0a59a55a_terseLabel_en-US" xlink:label="lab_kron_DebtSecuritiesAvailableForSaleAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest on short-term available-for-sale securities</link:label>
    <link:label id="lab_kron_DebtSecuritiesAvailableForSaleAccruedInterest_label_en-US" xlink:label="lab_kron_DebtSecuritiesAvailableForSaleAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest</link:label>
    <link:label id="lab_kron_DebtSecuritiesAvailableForSaleAccruedInterest_documentation_en-US" xlink:label="lab_kron_DebtSecuritiesAvailableForSaleAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DebtSecuritiesAvailableForSaleAccruedInterest" xlink:href="kron-20200930.xsd#kron_DebtSecuritiesAvailableForSaleAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_DebtSecuritiesAvailableForSaleAccruedInterest" xlink:to="lab_kron_DebtSecuritiesAvailableForSaleAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_bccda87b-ea5f-472d-8fca-2bfbaea61f9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_TemporaryEquityTextBlock_15f42c40-d8ed-4782-8a57-22104a239537_terseLabel_en-US" xlink:label="lab_kron_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_kron_TemporaryEquityTextBlock_label_en-US" xlink:label="lab_kron_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Text Block]</link:label>
    <link:label id="lab_kron_TemporaryEquityTextBlock_documentation_en-US" xlink:label="lab_kron_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TemporaryEquityTextBlock" xlink:href="kron-20200930.xsd#kron_TemporaryEquityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_TemporaryEquityTextBlock" xlink:to="lab_kron_TemporaryEquityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_df62615b-76b7-49fc-ba5f-ec78cb5c8011_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_PrepaidExternalResearchAndDevelopment_9c0bf7e2-12b7-49d0-9767-5f409ae0a35f_terseLabel_en-US" xlink:label="lab_kron_PrepaidExternalResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid external research and development</link:label>
    <link:label id="lab_kron_PrepaidExternalResearchAndDevelopment_label_en-US" xlink:label="lab_kron_PrepaidExternalResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid External Research and Development</link:label>
    <link:label id="lab_kron_PrepaidExternalResearchAndDevelopment_documentation_en-US" xlink:label="lab_kron_PrepaidExternalResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid External Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PrepaidExternalResearchAndDevelopment" xlink:href="kron-20200930.xsd#kron_PrepaidExternalResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_PrepaidExternalResearchAndDevelopment" xlink:to="lab_kron_PrepaidExternalResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d44783d0-209b-4ec0-8a64-65e4ab48458d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ed2ea45b-2337-421d-906c-439fc86aff53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and expected to vest at September 30, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_AssetAcquisitionAxis_c341d84e-0f7d-43ed-afb2-0e95224e7722_terseLabel_en-US" xlink:label="lab_kron_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_kron_AssetAcquisitionAxis_label_en-US" xlink:label="lab_kron_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_kron_AssetAcquisitionAxis_documentation_en-US" xlink:label="lab_kron_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionAxis" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_AssetAcquisitionAxis" xlink:to="lab_kron_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_4b52ca52-fc60-42dc-8648-959860677107_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 1 to 2 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_7e6654aa-21bc-4a14-bb45-8631b9ae3fe1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d48cf373-0523-42ff-b0d1-5058e8bcc90b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_SeriesSeedPreferredStockMember_27f2efe4-8791-4067-9eec-001ae3c3f86c_terseLabel_en-US" xlink:label="lab_kron_SeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Preferred Stock</link:label>
    <link:label id="lab_kron_SeriesSeedPreferredStockMember_label_en-US" xlink:label="lab_kron_SeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed, Preferred Stock [Member]</link:label>
    <link:label id="lab_kron_SeriesSeedPreferredStockMember_documentation_en-US" xlink:label="lab_kron_SeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed, Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SeriesSeedPreferredStockMember" xlink:href="kron-20200930.xsd#kron_SeriesSeedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_SeriesSeedPreferredStockMember" xlink:to="lab_kron_SeriesSeedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_863fc8de-1eb1-4ce9-8feb-11c470f262cb_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_047a5b67-8848-4ac6-a7a8-7f13cc86d95f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_f9734d4b-0f4f-4e5d-a9df-9f7fa14d4b50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_e8d9648e-40c8-4159-9c61-15e20adafcf6_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued franchise tax</link:label>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_379779a0-8f7d-49d4-988e-794fb76a1566_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7eeb915c-2bbe-4e93-8c9a-62fad45caa38_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_bc3a53ef-e040-4008-9a0d-25e3da552d82_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_40374cbe-86f7-42c8-b336-dafa70f14885_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 40,000,000 and 40,000,000 shares authorized as of September 30, 2020 and December 31, 2019 respectively; 6,284,326 and 5,660,391 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_1a3396d3-08da-455a-ab30-3e324e472a25_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7bf8a825-7903-4911-95dd-7d2544c25751_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_4ad0d59c-4e17-42b1-8538-b4383c99d31b_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f55dc545-c789-4e94-953a-0ed0a0e42317_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_e7c2a7e5-e751-4c27-b082-22b04c659483_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5367b20a-2d3a-463b-886a-096bfddc8000_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_1cab64d6-81ff-4d17-b2a0-2357295bb406_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in private placement, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment_74484010-dd2f-4ed4-a1c8-8a41d3df8391_terseLabel_en-US" xlink:label="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payment</link:label>
    <link:label id="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment_label_en-US" xlink:label="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Sales Milestone Payment</link:label>
    <link:label id="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment_documentation_en-US" xlink:label="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Sales Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment" xlink:to="lab_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_53b5a9f1-d62c-4808-93b6-13ae6ed741a3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_d30939a4-bffe-4935-9b5d-44cff277a931_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_37be4f5e-ec91-4481-9fa3-7ad1cced9b7f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_172d8c4c-23cf-4b6f-9cf3-dd37b2e01110_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cba458f4-c6f6-48d2-8abc-67351556da61_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_eea26b2c-0650-43e6-8d35-09688aefce3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_874b3561-0b69-47cd-bbe6-3cee93d53938_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_A2020EmployeeStockPurchasePlanMember_8c0b8f8b-0e48-49c5-8d27-6a65254e0699_terseLabel_en-US" xlink:label="lab_kron_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The ESPP</link:label>
    <link:label id="lab_kron_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_kron_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_kron_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_kron_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020EmployeeStockPurchasePlanMember" xlink:href="kron-20200930.xsd#kron_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_kron_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dde29637-fdbf-4559-9203-725337e7bac6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d61fed4a-e8ef-489e-b151-5fbd2fe5a05f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd389137-12b1-4518-a84e-b04668f81096_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_a3dcce13-ea8b-459d-af86-eee94ee17aab_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 1 year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_NotesPayableFairValueGainLoss_a808276c-6d28-44d4-b456-4c492b32387e_terseLabel_en-US" xlink:label="lab_kron_NotesPayableFairValueGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible notes payable</link:label>
    <link:label id="lab_kron_NotesPayableFairValueGainLoss_label_en-US" xlink:label="lab_kron_NotesPayableFairValueGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Gain (Loss)</link:label>
    <link:label id="lab_kron_NotesPayableFairValueGainLoss_documentation_en-US" xlink:label="lab_kron_NotesPayableFairValueGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_NotesPayableFairValueGainLoss" xlink:href="kron-20200930.xsd#kron_NotesPayableFairValueGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_NotesPayableFairValueGainLoss" xlink:to="lab_kron_NotesPayableFairValueGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d6e3c0ca-5bd3-4ecd-994b-5858c8a29d10_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_30b7d683-53dc-4605-b0de-47ad5673721b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_58ed0761-f556-4656-b8c0-9ff4786be7c9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9cc7eecd-96d0-410d-b4ad-fedebe2690d6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_01483d09-3c78-4b2b-b849-5bbf9fc20d03_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_96d5ca5f-8aec-4624-a170-412666622dd6_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, $0.001 par value; 21,506,977 and 21,506,977 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 21,504,893 and 21,504,893 share issued and outstanding as of September, 2020 and December 31, 2019, respectively; $123,016 and $123,016 liquidation preference as of September 30, 2020 and December 31, 2019, respectively.</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_49e5e341-e991-4d3d-93b1-0e53f8b1d79f_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_181e777c-b10e-4981-b94e-50cb65d16e99_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_ca39bbca-c66a-42c6-90db-596795ce906a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a953fe63-bafd-4ef0-bb8b-0f3028dc34cd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_16a6f035-f6cc-41ac-b773-8da6dc04189e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6d84c556-1f25-43e9-a5fd-6703bdfccf79_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_71642ce1-e3dd-41f6-a262-476e6e411733_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_8b94f6f6-98ab-4d3d-a15f-5be77a37a87c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_41ba4d90-9173-466b-ad5f-c80784140758_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2d4ea69e-6565-469f-a129-80cb8aecc881_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_f954804f-3a6a-4a4a-8e30-48949b42c873_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible notes payable</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ScheduleOfAssetAcquisitionLineItems_90506287-ef19-4f1c-be21-50a9dd53a2f1_terseLabel_en-US" xlink:label="lab_kron_ScheduleOfAssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_kron_ScheduleOfAssetAcquisitionLineItems_label_en-US" xlink:label="lab_kron_ScheduleOfAssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_kron_ScheduleOfAssetAcquisitionLineItems_documentation_en-US" xlink:label="lab_kron_ScheduleOfAssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionLineItems" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems" xlink:to="lab_kron_ScheduleOfAssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_01113db0-0dbb-4ddd-a711-65cff9f55fb5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9210d184-b7a8-4dc8-b5af-821592df14f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8e7b51c8-bf21-40b9-a011-b0678d8b194f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_11429e0a-840d-42c2-8af8-522642e3be2f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_36a31111-e8e4-4619-a025-0086241fc1f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c1336497-35a2-4442-a0a9-f5b858248ed1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d89a2bda-ae97-4930-9189-9e2eca6869d1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_53ae7d06-1f18-4d5a-bc34-d7fe2bf4dd93_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_ade59875-bf6d-4b30-9ef5-25c24a8c68d0_terseLabel_en-US" xlink:label="lab_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_label_en-US" xlink:label="lab_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter</link:label>
    <link:label id="lab_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_documentation_en-US" xlink:label="lab_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="lab_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d17dc1f8-d520-4b03-a8b6-46116c348b51_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_3c300066-d5ca-4520-a876-4c13e5b34fec_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ResearchAndDevelopmentMember_13b86d3a-b686-42dc-8318-7275ab86922b_terseLabel_en-US" xlink:label="lab_kron_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_kron_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_kron_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_kron_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_kron_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentMember" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ResearchAndDevelopmentMember" xlink:to="lab_kron_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid_912cdf63-b085-493f-b92c-20cad68445a2_terseLabel_en-US" xlink:label="lab_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issuance costs in accounts payable and accrued expenses</link:label>
    <link:label id="lab_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid" xlink:href="kron-20200930.xsd#kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3ef8f95b-8702-41dc-aff0-e8c0c56fd329_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_PrepaidEquipmentServiceContracts_c85b0ba9-7259-43f4-b4f4-9a225212b8ca_terseLabel_en-US" xlink:label="lab_kron_PrepaidEquipmentServiceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid equipment service contracts</link:label>
    <link:label id="lab_kron_PrepaidEquipmentServiceContracts_label_en-US" xlink:label="lab_kron_PrepaidEquipmentServiceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Equipment Service Contracts</link:label>
    <link:label id="lab_kron_PrepaidEquipmentServiceContracts_documentation_en-US" xlink:label="lab_kron_PrepaidEquipmentServiceContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Equipment Service Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PrepaidEquipmentServiceContracts" xlink:href="kron-20200930.xsd#kron_PrepaidEquipmentServiceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_PrepaidEquipmentServiceContracts" xlink:to="lab_kron_PrepaidEquipmentServiceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_55d1be4a-1444-4c1b-9197-f84c163c947c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_ffc7369e-550e-4aae-8079-f6f8337dc156_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, fair value</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_da85489f-5833-45f7-b99b-01f5a31e48d9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_53e3c60b-55e4-4942-b14d-f259755a73c6_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2772d83e-0de4-4be6-8dd2-d3a8ee08ad45_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet_4d564e09-c7bb-42f2-a942-e36289fafd7e_negatedTerseLabel_en-US" xlink:label="lab_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating assets and liabilities, net</link:label>
    <link:label id="lab_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Right Of Use Operating Assets And Liabilities, Net</link:label>
    <link:label id="lab_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Right Of Use Operating Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" xlink:href="kron-20200930.xsd#kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" xlink:to="lab_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_d47babe2-541c-449a-8f8a-7adf14e3a6fc_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_A2020ConvertibleNotesMember_6f6d5cf0-170f-4da0-a552-7c22b6d4f735_terseLabel_en-US" xlink:label="lab_kron_A2020ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible Notes</link:label>
    <link:label id="lab_kron_A2020ConvertibleNotesMember_label_en-US" xlink:label="lab_kron_A2020ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible Notes [Member]</link:label>
    <link:label id="lab_kron_A2020ConvertibleNotesMember_documentation_en-US" xlink:label="lab_kron_A2020ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020ConvertibleNotesMember" xlink:href="kron-20200930.xsd#kron_A2020ConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_A2020ConvertibleNotesMember" xlink:to="lab_kron_A2020ConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e5c2ce27-189b-4e92-be78-ae7274bf9cde_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_f6ad05a6-40b9-49e5-b9c5-f79313d5b4d2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_313f4a61-1473-44de-a460-e2ebde547191_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0dbee2ec-c30c-488e-91c8-76fb171c1ac1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8b4a8655-8df9-49b9-8696-34a4d01a8404_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4c92d7c5-8984-4c9d-a8dc-8bff3bdad66f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9310d80b-2115-40af-b50f-4067d5885864_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_3607038f-9f08-4a0f-8f98-57d08f846213_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_92ae40de-256c-4d83-b48b-170117a0788c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9ec89628-dc3e-4347-90a7-e41095426cd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4ed80abf-da74-4c95-9b79-0310abd10735_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current portion of other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fcd1d10a-04d2-4575-8d67-fb5a5b8f7710_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining three months of 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_GileadAssetPurchaseMember_150bf8f0-f0d6-42b0-865e-6f89b9c76ae5_terseLabel_en-US" xlink:label="lab_kron_GileadAssetPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Asset Purchase</link:label>
    <link:label id="lab_kron_GileadAssetPurchaseMember_label_en-US" xlink:label="lab_kron_GileadAssetPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Asset Purchase [Member]</link:label>
    <link:label id="lab_kron_GileadAssetPurchaseMember_documentation_en-US" xlink:label="lab_kron_GileadAssetPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Asset Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GileadAssetPurchaseMember" xlink:href="kron-20200930.xsd#kron_GileadAssetPurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_GileadAssetPurchaseMember" xlink:to="lab_kron_GileadAssetPurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_3976efc1-3769-4ac1-bb01-d9ee63dccfe9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a90997d4-96e6-4b37-baa6-e26e8f7bb6e7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_806f2425-d501-4a27-89e9-973e9034ad4b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a0c6aefa-3bd5-4c60-be20-9d3258d7076b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_54cc8f84-61c6-48c4-8568-288a048f7001_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a409de7d-6eec-4b89-8e8c-8ea64feebe5d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_EquityIncentivePlan2017Member_ad12d531-d788-4532-8f9c-6d2a1119f5b8_terseLabel_en-US" xlink:label="lab_kron_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_kron_EquityIncentivePlan2017Member_label_en-US" xlink:label="lab_kron_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan, 2017 [Member]</link:label>
    <link:label id="lab_kron_EquityIncentivePlan2017Member_documentation_en-US" xlink:label="lab_kron_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan, 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_EquityIncentivePlan2017Member" xlink:href="kron-20200930.xsd#kron_EquityIncentivePlan2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_EquityIncentivePlan2017Member" xlink:to="lab_kron_EquityIncentivePlan2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2dedb801-cf02-4343-91ef-c5851a1424f2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_94868df5-031d-4143-8e65-ca27c9230c48_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholder's equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_986ead7c-5643-437c-8e30-92f5cdb7d868_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity Under the 2017 Plan [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_51b867c5-dfe1-4e47-b037-c89039f9a32c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_e5549691-ad7d-4f56-87b7-d99c42b842f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_f618dd3f-07b1-4a3b-bab9-c7366fa78832_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_2bf3d573-b586-45a7-a082-2d2bc4dbfd8a_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_8393d34c-f6ad-4642-aa55-3c756a342ec5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_42fdb211-8c12-4394-a6a2-e263d449c82c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cc113c1c-2e5d-4d63-8521-f5a2fb9ab10d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation, Classified in Statements of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6f34cd78-692c-43dd-bfa9-44de3b967413_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e231db81-2b33-4f21-8507-935fbd3bd7b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_77626d16-1d4c-4fed-aa3e-b2d8586c5b2e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_14409feb-0d7d-4f6d-9d6f-9f04dcf79faf_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_e2a47922-e638-406e-b0a3-9a15a718407c_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_304b60ab-3f17-4c10-9e2f-c189d63987bd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0e5e9edf-3a62-4d49-9ab7-b8ba1dfd2c97_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_37419a99-16ff-4a14-baf9-199f158d3274_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key valuation assumptions</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_d3641f63-0b2f-4d85-8443-0300ee801833_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_1effdc96-ad5b-4261-9771-f56712e4fc9f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_A2020GileadNotesMember_c3612c06-3297-4d62-8929-b348b558cd17_terseLabel_en-US" xlink:label="lab_kron_A2020GileadNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Gilead Notes</link:label>
    <link:label id="lab_kron_A2020GileadNotesMember_label_en-US" xlink:label="lab_kron_A2020GileadNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Gilead Notes [Member]</link:label>
    <link:label id="lab_kron_A2020GileadNotesMember_documentation_en-US" xlink:label="lab_kron_A2020GileadNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Gilead Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020GileadNotesMember" xlink:href="kron-20200930.xsd#kron_A2020GileadNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_A2020GileadNotesMember" xlink:to="lab_kron_A2020GileadNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b94df44e-e183-4550-9acf-491d07737fa3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_aa45eb6b-87d5-4f89-af7a-d7d06de25d57_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of unvested early exercised share liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_ebaf095f-63ad-4354-ac6f-1008ebe5377b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities related to shares that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ac69ad3d-232a-4788-a699-f6d2af448483_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion of convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_IPOCashPayoutScenarioMember_398e0bad-90fe-4ad6-9522-88fb42ed5307_terseLabel_en-US" xlink:label="lab_kron_IPOCashPayoutScenarioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO cash payout scenario</link:label>
    <link:label id="lab_kron_IPOCashPayoutScenarioMember_label_en-US" xlink:label="lab_kron_IPOCashPayoutScenarioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Cash Payout Scenario [Member]</link:label>
    <link:label id="lab_kron_IPOCashPayoutScenarioMember_documentation_en-US" xlink:label="lab_kron_IPOCashPayoutScenarioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Cash Payout Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IPOCashPayoutScenarioMember" xlink:href="kron-20200930.xsd#kron_IPOCashPayoutScenarioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_IPOCashPayoutScenarioMember" xlink:to="lab_kron_IPOCashPayoutScenarioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_fbe376e9-b1bb-46aa-96e8-b373b4a7365d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_310fad05-2a86-4daa-892c-f1e39d3da475_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_72b55ca5-692c-47e4-babd-f243d01686ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4193e2d4-1df9-42b7-bb02-7f44674726f2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_23bd1b51-85e2-484b-bce3-e465851b8fbc_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_fa653af9-7e33-4b24-9b67-9b2d767285bc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_322bda19-b730-4095-86fb-3f78d4395689_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities on Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_629e573e-92db-4e09-a987-d9c08a540b07_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_27dcc25f-4d4c-4254-a5b3-690957ffcb0a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_DeferredOfferingCostsIncurredButNotYetPaid_a014bbc0-7749-404f-81c5-ccea223ce659_terseLabel_en-US" xlink:label="lab_kron_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_kron_DeferredOfferingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_kron_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_kron_DeferredOfferingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_kron_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DeferredOfferingCostsIncurredButNotYetPaid" xlink:href="kron-20200930.xsd#kron_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_DeferredOfferingCostsIncurredButNotYetPaid" xlink:to="lab_kron_DeferredOfferingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e3be9cd6-a3fa-4a27-b90d-a22c3384540e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_8e2fe0db-8e0a-4d42-aa4d-3be8ca512c01_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_73a99962-4a61-4f48-963d-77ffaf452e30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_c4df7602-e255-4674-91c7-885b7ca7411f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_SettlementPlanDomain_e2500484-03d3-49f6-b43e-98613b1f1cfd_terseLabel_en-US" xlink:label="lab_kron_SettlementPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Plan [Domain]</link:label>
    <link:label id="lab_kron_SettlementPlanDomain_label_en-US" xlink:label="lab_kron_SettlementPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Plan [Domain]</link:label>
    <link:label id="lab_kron_SettlementPlanDomain_documentation_en-US" xlink:label="lab_kron_SettlementPlanDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanDomain" xlink:href="kron-20200930.xsd#kron_SettlementPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_SettlementPlanDomain" xlink:to="lab_kron_SettlementPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7f92306b-2cc1-4ee9-b56b-9c1c7fc8c594_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5a0db1de-7dc7-4917-91f2-3dc80f85c8c6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_FinancingScenarioMember_1de10baa-3161-47aa-8f91-054e9274dd43_terseLabel_en-US" xlink:label="lab_kron_FinancingScenarioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Scenario</link:label>
    <link:label id="lab_kron_FinancingScenarioMember_label_en-US" xlink:label="lab_kron_FinancingScenarioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Scenario [Member]</link:label>
    <link:label id="lab_kron_FinancingScenarioMember_documentation_en-US" xlink:label="lab_kron_FinancingScenarioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_FinancingScenarioMember" xlink:href="kron-20200930.xsd#kron_FinancingScenarioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_FinancingScenarioMember" xlink:to="lab_kron_FinancingScenarioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_MeasurementInputWeightingMember_8d070960-2a62-4195-b8fe-d922efbee6ab_terseLabel_en-US" xlink:label="lab_kron_MeasurementInputWeightingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighting</link:label>
    <link:label id="lab_kron_MeasurementInputWeightingMember_label_en-US" xlink:label="lab_kron_MeasurementInputWeightingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighting [Member]</link:label>
    <link:label id="lab_kron_MeasurementInputWeightingMember_documentation_en-US" xlink:label="lab_kron_MeasurementInputWeightingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_MeasurementInputWeightingMember" xlink:href="kron-20200930.xsd#kron_MeasurementInputWeightingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_MeasurementInputWeightingMember" xlink:to="lab_kron_MeasurementInputWeightingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_927fa4a9-fad1-47bd-bc3e-8b63669529f8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_b721f28e-67da-4494-9414-dc59074f2503_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_4b21ee4c-ee29-494e-95ef-765ddc837c83_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3483740e-97e6-4dc1-8b34-9a8bc4f99624_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5b5178f-8458-4b7a-bc2e-5ab728d494fd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d73db0d4-f8f7-4c91-a5b5-9fb67b7ce958_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ccd039ba-7c58-4fc7-ae13-521ac9992ad3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash as shown on the statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d88ab720-42e7-4f1c-81eb-30d65a7b3905_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_76e7524b-0c09-4e89-81f3-acc868bd127e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6140ce97-07bd-4d82-8964-9f2b0a12dc94_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_f68cb673-5ee4-4ba8-9ab4-3eb0bf8e40b9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_cbbb6080-06d0-40e1-9592-c3da98510a5d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6d73bc6c-0762-4a7d-8727-f2fbbeb1b7ca_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_f1c47022-c9b5-4fc2-bfe9-fa43d44717c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of preferred stock, net of financing fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_TwoRiverConsultingLLCMember_56335023-55ce-41b6-938e-623399b4d581_terseLabel_en-US" xlink:label="lab_kron_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting, LLC</link:label>
    <link:label id="lab_kron_TwoRiverConsultingLLCMember_label_en-US" xlink:label="lab_kron_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting, LLC [Member]</link:label>
    <link:label id="lab_kron_TwoRiverConsultingLLCMember_documentation_en-US" xlink:label="lab_kron_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TwoRiverConsultingLLCMember" xlink:href="kron-20200930.xsd#kron_TwoRiverConsultingLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_TwoRiverConsultingLLCMember" xlink:to="lab_kron_TwoRiverConsultingLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_3b59638c-f418-4833-8f8d-5220894c2ea6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_19f089c9-7d63-4469-9b39-e573454bb521_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_2a161b03-5d2e-485b-8e82-3df6042d69e1_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_ebc27fb4-d7b0-44c0-a18a-b1125982bb54_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_e684a458-9766-4595-a397-d17aa4d47438_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_c7211f9b-8b19-4dcd-a216-68589790d4ba_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Outstanding</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c4951b00-760f-4015-8950-e47224460776_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_OperatingLeaseFacilitySize_74adaceb-e4f8-4eb3-a5b9-3251c5963459_terseLabel_en-US" xlink:label="lab_kron_OperatingLeaseFacilitySize" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility size</link:label>
    <link:label id="lab_kron_OperatingLeaseFacilitySize_label_en-US" xlink:label="lab_kron_OperatingLeaseFacilitySize" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Facility Size</link:label>
    <link:label id="lab_kron_OperatingLeaseFacilitySize_documentation_en-US" xlink:label="lab_kron_OperatingLeaseFacilitySize" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Facility Size</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_OperatingLeaseFacilitySize" xlink:href="kron-20200930.xsd#kron_OperatingLeaseFacilitySize"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_OperatingLeaseFacilitySize" xlink:to="lab_kron_OperatingLeaseFacilitySize" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax_2f3ac257-b62b-4b57-b365-8a8a9043929b_terseLabel_en-US" xlink:label="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, unrealized gains</link:label>
    <link:label id="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" xlink:to="lab_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c8f9b182-d5fa-4f47-b1c8-9a59adc9eff1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9881eb12-a9ea-4eb2-8cc6-3fe16ee2a92d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_4624936f-2df1-4ff4-a6ce-3813f36892b1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e8024418-d37b-4885-ac38-8d5f493aa43b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_b6ff369c-0571-40bd-af56-a3153ab1141b_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ConvertibleNotesPayable2020NotesMember_a136f6a8-4d90-409b-be80-53660562c8e4_terseLabel_en-US" xlink:label="lab_kron_ConvertibleNotesPayable2020NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable (2020 Notes)</link:label>
    <link:label id="lab_kron_ConvertibleNotesPayable2020NotesMember_label_en-US" xlink:label="lab_kron_ConvertibleNotesPayable2020NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable (2020 Notes) [Member]</link:label>
    <link:label id="lab_kron_ConvertibleNotesPayable2020NotesMember_documentation_en-US" xlink:label="lab_kron_ConvertibleNotesPayable2020NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable (2020 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ConvertibleNotesPayable2020NotesMember" xlink:href="kron-20200930.xsd#kron_ConvertibleNotesPayable2020NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ConvertibleNotesPayable2020NotesMember" xlink:to="lab_kron_ConvertibleNotesPayable2020NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_AccruedExternalResearchAndDevelopmentCurrent_6b3c67f3-415b-4b30-9610-e0af11b91ac0_terseLabel_en-US" xlink:label="lab_kron_AccruedExternalResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External research and development</link:label>
    <link:label id="lab_kron_AccruedExternalResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_kron_AccruedExternalResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued External Research And Development, Current</link:label>
    <link:label id="lab_kron_AccruedExternalResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_kron_AccruedExternalResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued External Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AccruedExternalResearchAndDevelopmentCurrent" xlink:href="kron-20200930.xsd#kron_AccruedExternalResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_AccruedExternalResearchAndDevelopmentCurrent" xlink:to="lab_kron_AccruedExternalResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8dc2aa93-75c3-4f41-a814-8d46054af085_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e7874e27-7fe9-493d-bd4c-65e04b7f6b08_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_2d09e9c8-9fd6-4387-a525-e57671c359fa_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs on convertible notes payable</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_c1a9a0f4-3fe8-465a-926c-be3a9e2c58bc_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt issuance costs expensed and recognized</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_270cc763-ea87-4210-b4e3-1b350fae5558_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_CambridgeMassachusettsMember_49c958dd-0c65-427d-9132-c0eead96af4c_terseLabel_en-US" xlink:label="lab_kron_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts</link:label>
    <link:label id="lab_kron_CambridgeMassachusettsMember_label_en-US" xlink:label="lab_kron_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_kron_CambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_kron_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CambridgeMassachusettsMember" xlink:href="kron-20200930.xsd#kron_CambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_CambridgeMassachusettsMember" xlink:to="lab_kron_CambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_391cfaea-a1f8-441c-8185-453f99d52fbc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_646ed0a6-bab0-46c7-8f36-19fc2a2260b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d0fb2d01-c039-4613-a202-5a705ce7ac2e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies, Estimates and Judgments</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8def6a4-4ed0-4fdf-8b73-8a4fa474188c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e280b87b-a80f-4b06-a4ae-3dce8dd6dcf0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5e4bb632-5781-4a84-8b5b-a1cf62da4cac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e38e3f16-7fc3-4ec9-8cdd-c796798d46a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ce30a54-a521-4ae3-9fc5-697cf7fba715_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_bd446ba8-6cb9-4c06-b408-47235d41e862_terseLabel_en-US" xlink:label="lab_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible promissory note issued</link:label>
    <link:label id="lab_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Liabilities Incurred</link:label>
    <link:label id="lab_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_documentation_en-US" xlink:label="lab_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9a004b1f-f059-4ec9-b6d7-1050f2e9a32f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_PrepaidSoftware_0353d074-8108-4e41-b515-7c694813da99_terseLabel_en-US" xlink:label="lab_kron_PrepaidSoftware" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid software</link:label>
    <link:label id="lab_kron_PrepaidSoftware_label_en-US" xlink:label="lab_kron_PrepaidSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software</link:label>
    <link:label id="lab_kron_PrepaidSoftware_documentation_en-US" xlink:label="lab_kron_PrepaidSoftware" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PrepaidSoftware" xlink:href="kron-20200930.xsd#kron_PrepaidSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_PrepaidSoftware" xlink:to="lab_kron_PrepaidSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_IPOScenarioMember_624219b5-287e-4ff7-b992-89079597a6bc_terseLabel_en-US" xlink:label="lab_kron_IPOScenarioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Scenario</link:label>
    <link:label id="lab_kron_IPOScenarioMember_label_en-US" xlink:label="lab_kron_IPOScenarioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Scenario [Member]</link:label>
    <link:label id="lab_kron_IPOScenarioMember_documentation_en-US" xlink:label="lab_kron_IPOScenarioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IPOScenarioMember" xlink:href="kron-20200930.xsd#kron_IPOScenarioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_IPOScenarioMember" xlink:to="lab_kron_IPOScenarioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0cd58c52-ddb5-4be5-8dbd-96cb0bfc8e26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3f7fd9a5-3f5c-45a3-9fee-044e1ad32702_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_7e9ec14c-37f6-4a87-bd14-9b97ba28dbce_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_73775358-ea13-45eb-885e-ea3645213b6e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_6edbd0fb-e8b9-4e79-82d1-ac0581601187_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Note</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_fd2fb4ef-c8e2-4cc8-aadc-a21b3ca83996_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b5e18496-1189-4002-a13b-48b290b939db_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f1b30449-73a3-4fc7-8a57-f45c44da44b3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares_d5baf5cf-8553-4d98-9ebf-78b72eaed2e1_terseLabel_en-US" xlink:label="lab_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised stock options, shares</link:label>
    <link:label id="lab_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares_label_en-US" xlink:label="lab_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Shares</link:label>
    <link:label id="lab_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares_documentation_en-US" xlink:label="lab_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" xlink:href="kron-20200930.xsd#kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" xlink:to="lab_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9d779c91-16db-482f-9547-dec8bea20785_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_428a09d5-1662-48d8-a115-217eca91b6ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d702a5e6-e35f-4f59-bcea-68a9a0b7258d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a1346eed-722f-4718-afa0-b1356d350a3b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_c1c3fc62-cf6e-437c-b1b6-f6e1c5e7e98d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kron_PaymentsOfOfferingCosts_02d3df01-6668-46ee-aaef-2dd24281b0c1_terseLabel_en-US" xlink:label="lab_kron_PaymentsOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of offering costs</link:label>
    <link:label id="lab_kron_PaymentsOfOfferingCosts_label_en-US" xlink:label="lab_kron_PaymentsOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Offering Costs</link:label>
    <link:label id="lab_kron_PaymentsOfOfferingCosts_documentation_en-US" xlink:label="lab_kron_PaymentsOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsOfOfferingCosts" xlink:href="kron-20200930.xsd#kron_PaymentsOfOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kron_PaymentsOfOfferingCosts" xlink:to="lab_kron_PaymentsOfOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_cac45c7d-1a7e-49e9-8ed4-f2f992d65c9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>kron-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:24f323b6-3e05-4299-b60b-ed7d0f94eb5e,g:b8dc781a-ce5b-4a7b-a930-702eddd4413f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.kronosbio.com/role/CoverPage" xlink:type="simple" xlink:href="kron-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_534cd633-0be7-455d-9242-46330368a54a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_DocumentType_534cd633-0be7-455d-9242-46330368a54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c913184d-df02-4ca4-8059-faf435012842" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_DocumentQuarterlyReport_c913184d-df02-4ca4-8059-faf435012842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b18b74a7-555a-434e-ae62-701bf8ef7131" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_DocumentPeriodEndDate_b18b74a7-555a-434e-ae62-701bf8ef7131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a60c065a-4bbc-438b-897d-7354a37cf2aa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_DocumentTransitionReport_a60c065a-4bbc-438b-897d-7354a37cf2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_288408ba-fc9d-41fd-bac2-d4d064651be8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityFileNumber_288408ba-fc9d-41fd-bac2-d4d064651be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6dca08a4-544a-408d-867e-b31ef4e523a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityRegistrantName_6dca08a4-544a-408d-867e-b31ef4e523a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0f86cf29-e024-421c-937c-bafb1d9beaa0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0f86cf29-e024-421c-937c-bafb1d9beaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e966a741-c1c5-457c-a142-3494338211b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityTaxIdentificationNumber_e966a741-c1c5-457c-a142-3494338211b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7680b4c9-bd29-4e20-a992-0cb23f3a8bac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityAddressAddressLine1_7680b4c9-bd29-4e20-a992-0cb23f3a8bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_159c3f7e-52a1-465a-851c-3ec47886985a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityAddressAddressLine2_159c3f7e-52a1-465a-851c-3ec47886985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4a5e762c-ec33-4fa1-b675-22b679efae18" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityAddressCityOrTown_4a5e762c-ec33-4fa1-b675-22b679efae18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d64bbad8-d43b-4376-9205-e8d8084cbea7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityAddressStateOrProvince_d64bbad8-d43b-4376-9205-e8d8084cbea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7f994095-f7f8-41db-bd28-9d3c2bebbc1e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityAddressPostalZipCode_7f994095-f7f8-41db-bd28-9d3c2bebbc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d465cdc1-49bf-448e-9f8c-3780d8adf136" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_CityAreaCode_d465cdc1-49bf-448e-9f8c-3780d8adf136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ae768103-adee-41f4-a157-2722ac89bead" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_LocalPhoneNumber_ae768103-adee-41f4-a157-2722ac89bead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_38507ba9-5e1c-4745-b3e2-628ad6d81f41" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_Security12bTitle_38507ba9-5e1c-4745-b3e2-628ad6d81f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4b445587-a99c-4511-a9ac-7cc23f983e08" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_TradingSymbol_4b445587-a99c-4511-a9ac-7cc23f983e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b9a21f58-7b12-4d69-9c18-f002e21a4c31" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_SecurityExchangeName_b9a21f58-7b12-4d69-9c18-f002e21a4c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_89e1fed8-c1c6-4509-9b5c-f55ccc263e9b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityCurrentReportingStatus_89e1fed8-c1c6-4509-9b5c-f55ccc263e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8715badb-8a74-4649-8a63-9a3ed7954ade" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityInteractiveDataCurrent_8715badb-8a74-4649-8a63-9a3ed7954ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2409d73c-5f30-4aa6-8b0a-e3d3a5e80537" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityFilerCategory_2409d73c-5f30-4aa6-8b0a-e3d3a5e80537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f5fa2818-d938-40e2-a861-31ff6ebd5d4a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntitySmallBusiness_f5fa2818-d938-40e2-a861-31ff6ebd5d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_33eb2882-d1d4-442d-82e8-4102f780def7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityEmergingGrowthCompany_33eb2882-d1d4-442d-82e8-4102f780def7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_c82ad04a-d36b-4864-a56b-bb9b45e3f04a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityExTransitionPeriod_c82ad04a-d36b-4864-a56b-bb9b45e3f04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ac2019d1-94b5-4382-8f33-af52f488714e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityShellCompany_ac2019d1-94b5-4382-8f33-af52f488714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6c76d072-7ae6-42fa-a33f-b4eab57d6604" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6c76d072-7ae6-42fa-a33f-b4eab57d6604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_649fc641-8552-45cf-bec5-1e0ce1ee096b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_EntityCentralIndexKey_649fc641-8552-45cf-bec5-1e0ce1ee096b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_76a08a2c-ad02-4514-97c6-d32737d05232" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_CurrentFiscalYearEndDate_76a08a2c-ad02-4514-97c6-d32737d05232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_86ece440-506d-4536-857a-a88886b1145f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_DocumentFiscalYearFocus_86ece440-506d-4536-857a-a88886b1145f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bf286bc7-8d03-429f-884a-ad97fa359976" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bf286bc7-8d03-429f-884a-ad97fa359976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_035b1de5-957e-4547-9191-0c6ae9eaaf10" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ff9d595a-1817-4d69-bae0-245c9e4c2e81" xlink:to="loc_dei_AmendmentFlag_035b1de5-957e-4547-9191-0c6ae9eaaf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f5a2a746-b466-43ff-9597-e5bc1ac9e3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a300d2a1-3582-4ddd-9ec6-2cbc7c62f670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f5a2a746-b466-43ff-9597-e5bc1ac9e3e9" xlink:to="loc_us-gaap_AssetsAbstract_a300d2a1-3582-4ddd-9ec6-2cbc7c62f670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_63b25c96-89e2-44d8-b771-7792b7139093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a300d2a1-3582-4ddd-9ec6-2cbc7c62f670" xlink:to="loc_us-gaap_AssetsCurrentAbstract_63b25c96-89e2-44d8-b771-7792b7139093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d732d552-c73d-4178-81ae-d75ee0226e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_63b25c96-89e2-44d8-b771-7792b7139093" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d732d552-c73d-4178-81ae-d75ee0226e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ecdcbc2d-83a5-4f8d-ac69-d0efe89d5db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_63b25c96-89e2-44d8-b771-7792b7139093" xlink:to="loc_us-gaap_ShortTermInvestments_ecdcbc2d-83a5-4f8d-ac69-d0efe89d5db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_512ee8d6-ea02-4c24-816f-a902979b5783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_63b25c96-89e2-44d8-b771-7792b7139093" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_512ee8d6-ea02-4c24-816f-a902979b5783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f20777ab-8525-4f16-878a-335254698901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_63b25c96-89e2-44d8-b771-7792b7139093" xlink:to="loc_us-gaap_AssetsCurrent_f20777ab-8525-4f16-878a-335254698901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_82431f36-ca93-4391-aca9-851e13a29fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a300d2a1-3582-4ddd-9ec6-2cbc7c62f670" xlink:to="loc_us-gaap_LongTermInvestments_82431f36-ca93-4391-aca9-851e13a29fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_866cd12b-01bc-4488-865c-16a2b13afe91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a300d2a1-3582-4ddd-9ec6-2cbc7c62f670" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_866cd12b-01bc-4488-865c-16a2b13afe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_05705fa5-6566-4941-b074-4532ca331193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a300d2a1-3582-4ddd-9ec6-2cbc7c62f670" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_05705fa5-6566-4941-b074-4532ca331193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ed81ff41-d538-4290-9a94-5b22ad2dc59e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a300d2a1-3582-4ddd-9ec6-2cbc7c62f670" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ed81ff41-d538-4290-9a94-5b22ad2dc59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9d1de0d8-22ab-4b6e-9347-8af0620d42dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a300d2a1-3582-4ddd-9ec6-2cbc7c62f670" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9d1de0d8-22ab-4b6e-9347-8af0620d42dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2062aef6-66f6-4ae9-ba0d-fb09db906c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a300d2a1-3582-4ddd-9ec6-2cbc7c62f670" xlink:to="loc_us-gaap_Assets_2062aef6-66f6-4ae9-ba0d-fb09db906c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f5a2a746-b466-43ff-9597-e5bc1ac9e3e9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_076121c3-8b09-48d2-9aae-a972d78c13ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_076121c3-8b09-48d2-9aae-a972d78c13ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_474d3604-02cc-495b-bcc7-4073840651c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076121c3-8b09-48d2-9aae-a972d78c13ef" xlink:to="loc_us-gaap_AccountsPayableCurrent_474d3604-02cc-495b-bcc7-4073840651c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b8857e63-eb40-4fd6-a6d3-cc815c3e60f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076121c3-8b09-48d2-9aae-a972d78c13ef" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b8857e63-eb40-4fd6-a6d3-cc815c3e60f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_21d81012-6223-4345-a28e-da2179e0e7f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076121c3-8b09-48d2-9aae-a972d78c13ef" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_21d81012-6223-4345-a28e-da2179e0e7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c2ccd273-ecb5-4bc3-ae2c-0ff3b639c970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076121c3-8b09-48d2-9aae-a972d78c13ef" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c2ccd273-ecb5-4bc3-ae2c-0ff3b639c970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a6bb9829-933c-4eb7-9a3f-0c4c2c4a4916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076121c3-8b09-48d2-9aae-a972d78c13ef" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a6bb9829-933c-4eb7-9a3f-0c4c2c4a4916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a64723e1-48b1-4798-9c2a-cd00b6207bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076121c3-8b09-48d2-9aae-a972d78c13ef" xlink:to="loc_us-gaap_LiabilitiesCurrent_a64723e1-48b1-4798-9c2a-cd00b6207bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1e8b082c-17b6-4bf3-a249-ca68f474c7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1e8b082c-17b6-4bf3-a249-ca68f474c7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_996fa4a7-42c5-4a80-bf3b-786e9c046a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_996fa4a7-42c5-4a80-bf3b-786e9c046a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7ee9d976-0538-4cc8-94ac-c6d65f2b81e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:to="loc_us-gaap_Liabilities_7ee9d976-0538-4cc8-94ac-c6d65f2b81e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_335930e0-c8d5-4147-aae4-9371d7bb82c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:to="loc_us-gaap_CommitmentsAndContingencies_335930e0-c8d5-4147-aae4-9371d7bb82c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2ece1f4b-57e3-4168-ade0-c54c32e8d6c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2ece1f4b-57e3-4168-ade0-c54c32e8d6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7310b08e-85d6-443e-af5d-42a0adf127df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7310b08e-85d6-443e-af5d-42a0adf127df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7bd2cecf-81f0-4d23-90db-ca8b47ec1938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7310b08e-85d6-443e-af5d-42a0adf127df" xlink:to="loc_us-gaap_CommonStockValue_7bd2cecf-81f0-4d23-90db-ca8b47ec1938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2f9c9c70-8247-4894-8e45-f49e78e4956d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7310b08e-85d6-443e-af5d-42a0adf127df" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2f9c9c70-8247-4894-8e45-f49e78e4956d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fcc8fbdc-9718-46a4-a072-10da8168a6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7310b08e-85d6-443e-af5d-42a0adf127df" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fcc8fbdc-9718-46a4-a072-10da8168a6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc1d6487-2d2f-4d9e-b21a-4f985a05b8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7310b08e-85d6-443e-af5d-42a0adf127df" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc1d6487-2d2f-4d9e-b21a-4f985a05b8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_38421020-664d-4071-a92c-264dc3709664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7310b08e-85d6-443e-af5d-42a0adf127df" xlink:to="loc_us-gaap_StockholdersEquity_38421020-664d-4071-a92c-264dc3709664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_58cb890b-75f2-4959-8729-b744af2ca27f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b29365a6-46dd-4462-95fc-443e707aa4ab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_58cb890b-75f2-4959-8729-b744af2ca27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8a81149b-b58b-40cb-973b-697a98d45915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8a81149b-b58b-40cb-973b-697a98d45915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_6534c069-bd94-4aa0-ab0a-21e6e3280aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_6534c069-bd94-4aa0-ab0a-21e6e3280aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_a028643d-68c4-48c2-b3bc-39abb81ac19b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_a028643d-68c4-48c2-b3bc-39abb81ac19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_f1e100c1-cc3f-46cb-9ad4-e8bd733e1d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_f1e100c1-cc3f-46cb-9ad4-e8bd733e1d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_cc97233a-12df-44b5-869c-284961807639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_cc97233a-12df-44b5-869c-284961807639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_5222c9a4-776b-496e-86b7-9227ef6f592d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_5222c9a4-776b-496e-86b7-9227ef6f592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e9173ca0-fef7-423f-bea7-6306c0fae119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e9173ca0-fef7-423f-bea7-6306c0fae119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_669978a1-cf26-40a3-acaa-bb27a36ed17f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_669978a1-cf26-40a3-acaa-bb27a36ed17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6fef3ec5-f797-4091-9af7-3ef5627f4d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_CommonStockSharesIssued_6fef3ec5-f797-4091-9af7-3ef5627f4d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7695e45f-f40b-4122-b765-e549adbe1335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89ab1c9a-7d43-4ea5-bcd9-b240d5f04746" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7695e45f-f40b-4122-b765-e549adbe1335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0eb867e6-fd6e-4cd4-9cfe-e4e657587ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f4002530-564f-40ff-9ac5-2e3c2fc1c4ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0eb867e6-fd6e-4cd4-9cfe-e4e657587ec8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f4002530-564f-40ff-9ac5-2e3c2fc1c4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_958643f9-e1bf-4cca-ab8e-ed2306f3db62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f4002530-564f-40ff-9ac5-2e3c2fc1c4ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_958643f9-e1bf-4cca-ab8e-ed2306f3db62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3eb3f8ae-dbbc-4327-936d-5ce0d02e7f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f4002530-564f-40ff-9ac5-2e3c2fc1c4ee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3eb3f8ae-dbbc-4327-936d-5ce0d02e7f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5377716d-3c65-479a-868a-48a911e7aa48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f4002530-564f-40ff-9ac5-2e3c2fc1c4ee" xlink:to="loc_us-gaap_OperatingExpenses_5377716d-3c65-479a-868a-48a911e7aa48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5de2cc87-3d11-4799-a1b3-20774696a570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0eb867e6-fd6e-4cd4-9cfe-e4e657587ec8" xlink:to="loc_us-gaap_OperatingIncomeLoss_5de2cc87-3d11-4799-a1b3-20774696a570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_eb0d46c5-e071-4cfd-80c7-28162c12d617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0eb867e6-fd6e-4cd4-9cfe-e4e657587ec8" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_eb0d46c5-e071-4cfd-80c7-28162c12d617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_NotesPayableFairValueGainLoss_2735eb96-e1a5-4221-8388-734365f8e11c" xlink:href="kron-20200930.xsd#kron_NotesPayableFairValueGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_eb0d46c5-e071-4cfd-80c7-28162c12d617" xlink:to="loc_kron_NotesPayableFairValueGainLoss_2735eb96-e1a5-4221-8388-734365f8e11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c866b4c2-b945-4e13-9858-2e1515ae5dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_eb0d46c5-e071-4cfd-80c7-28162c12d617" xlink:to="loc_us-gaap_InterestExpense_c866b4c2-b945-4e13-9858-2e1515ae5dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_9e5ef088-1511-4c03-8f5e-30aa9c258e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_eb0d46c5-e071-4cfd-80c7-28162c12d617" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_9e5ef088-1511-4c03-8f5e-30aa9c258e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cb10483f-5c91-4c77-8c52-658429809d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_eb0d46c5-e071-4cfd-80c7-28162c12d617" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cb10483f-5c91-4c77-8c52-658429809d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_29cec0c4-06af-4bc2-9b5d-a009405c220e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0eb867e6-fd6e-4cd4-9cfe-e4e657587ec8" xlink:to="loc_us-gaap_NetIncomeLoss_29cec0c4-06af-4bc2-9b5d-a009405c220e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_96d31b48-2a99-4c0c-8f62-44a78dc52c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0eb867e6-fd6e-4cd4-9cfe-e4e657587ec8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_96d31b48-2a99-4c0c-8f62-44a78dc52c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7b676c59-1c19-48ee-a572-3ad6bbc48168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_96d31b48-2a99-4c0c-8f62-44a78dc52c25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7b676c59-1c19-48ee-a572-3ad6bbc48168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f27bdcd6-f439-46b6-a7e4-a47d406d5bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_96d31b48-2a99-4c0c-8f62-44a78dc52c25" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f27bdcd6-f439-46b6-a7e4-a47d406d5bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_b5f9b6cf-735c-4c5d-b234-7f9cab65f9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0eb867e6-fd6e-4cd4-9cfe-e4e657587ec8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_b5f9b6cf-735c-4c5d-b234-7f9cab65f9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_10588f29-7e85-4649-8bd6-b5d067150dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0eb867e6-fd6e-4cd4-9cfe-e4e657587ec8" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_10588f29-7e85-4649-8bd6-b5d067150dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ed32f215-28a0-47c1-a852-05650e4d9a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3339b02c-011c-4629-9aa0-e898651963ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ed32f215-28a0-47c1-a852-05650e4d9a0d" xlink:to="loc_us-gaap_StatementTable_3339b02c-011c-4629-9aa0-e898651963ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_325d0e5c-0775-4d0c-99c9-15da9a4b1527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3339b02c-011c-4629-9aa0-e898651963ad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_325d0e5c-0775-4d0c-99c9-15da9a4b1527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_325d0e5c-0775-4d0c-99c9-15da9a4b1527" xlink:to="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_062697a2-7c02-48df-97cd-d77f1d925d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:to="loc_us-gaap_CommonStockMember_062697a2-7c02-48df-97cd-d77f1d925d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2312d0bd-0851-4a64-af28-d6836b034770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2312d0bd-0851-4a64-af28-d6836b034770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6cb9ce1-d7df-48f8-bc08-279de05cdee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6cb9ce1-d7df-48f8-bc08-279de05cdee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2ed72090-dbb2-47f6-a951-7a3bbdd1e8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94f2131f-3095-4906-b117-0cd996e1084f" xlink:to="loc_us-gaap_RetainedEarningsMember_2ed72090-dbb2-47f6-a951-7a3bbdd1e8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f17c9fac-4abb-483a-b04d-f38d5ed04cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3339b02c-011c-4629-9aa0-e898651963ad" xlink:to="loc_us-gaap_StatementLineItems_f17c9fac-4abb-483a-b04d-f38d5ed04cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f17c9fac-4abb-483a-b04d-f38d5ed04cd7" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_37df4eee-0f87-4ff0-853f-a08d0faf9a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_37df4eee-0f87-4ff0-853f-a08d0faf9a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fd7a5af5-a1fe-4af7-80ee-cd9bedd62b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fd7a5af5-a1fe-4af7-80ee-cd9bedd62b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_972db71c-9071-4296-8436-d9f5d35d1b30" xlink:href="kron-20200930.xsd#kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_972db71c-9071-4296-8436-d9f5d35d1b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5fe2ab5b-0bbb-4beb-8b5d-a82a74de9fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5fe2ab5b-0bbb-4beb-8b5d-a82a74de9fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_913226d9-cf5f-4400-8b28-127da0dabbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_913226d9-cf5f-4400-8b28-127da0dabbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9adf3fa1-43cc-42f5-8c45-d390e01fbc57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bca834ca-a14a-42e3-81b5-91cb2e44a6cb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9adf3fa1-43cc-42f5-8c45-d390e01fbc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f17c9fac-4abb-483a-b04d-f38d5ed04cd7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1260bcd7-b0c4-4558-bfb6-34ebd37898ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_SharesOutstanding_1260bcd7-b0c4-4558-bfb6-34ebd37898ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b5cd1326-dce0-4f2a-9af2-cbe92bde98ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_StockholdersEquity_b5cd1326-dce0-4f2a-9af2-cbe92bde98ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_18f9c4d0-df81-44f7-8442-76cf767b8b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_18f9c4d0-df81-44f7-8442-76cf767b8b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cbcab457-e435-40c8-982e-1983402f403b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cbcab457-e435-40c8-982e-1983402f403b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f10f6b7-bc87-4255-8c76-14837d240f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f10f6b7-bc87-4255-8c76-14837d240f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c84f81c9-bee9-4dad-8eff-e5a5394fe1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c84f81c9-bee9-4dad-8eff-e5a5394fe1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_72c66cc6-c22d-44f2-b36b-c279ceaf6e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_NetIncomeLoss_72c66cc6-c22d-44f2-b36b-c279ceaf6e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4b9b8648-99ce-4d3c-8906-ac531c5cbb02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_SharesOutstanding_4b9b8648-99ce-4d3c-8906-ac531c5cbb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f452925a-5a5c-41ad-8c51-7cc33d474cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45777706-84b8-4154-a93a-3146539c58c3" xlink:to="loc_us-gaap_StockholdersEquity_f452925a-5a5c-41ad-8c51-7cc33d474cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0cf4eb19-914e-4870-94c5-fa9f1fbac4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c704506c-fe05-4317-b0c1-aab91a07513d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0cf4eb19-914e-4870-94c5-fa9f1fbac4b8" xlink:to="loc_us-gaap_StatementTable_c704506c-fe05-4317-b0c1-aab91a07513d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2ce14438-a80c-44ce-bfb0-26c2818d2667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c704506c-fe05-4317-b0c1-aab91a07513d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2ce14438-a80c-44ce-bfb0-26c2818d2667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e8aa9f4-60b4-440e-abcc-937d82897b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2ce14438-a80c-44ce-bfb0-26c2818d2667" xlink:to="loc_us-gaap_EquityComponentDomain_5e8aa9f4-60b4-440e-abcc-937d82897b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_cf0e9bc4-303b-4fbf-b745-afca92810ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e8aa9f4-60b4-440e-abcc-937d82897b4c" xlink:to="loc_us-gaap_PreferredStockMember_cf0e9bc4-303b-4fbf-b745-afca92810ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9e28dcc2-b1f9-4678-b6c8-d74ddd7d33f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c704506c-fe05-4317-b0c1-aab91a07513d" xlink:to="loc_us-gaap_StatementLineItems_9e28dcc2-b1f9-4678-b6c8-d74ddd7d33f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_b5c85700-384f-44b2-bbba-026ddadc47f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9e28dcc2-b1f9-4678-b6c8-d74ddd7d33f1" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_b5c85700-384f-44b2-bbba-026ddadc47f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d9a4fdbb-86de-4cd9-9dad-b589e75548c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9e28dcc2-b1f9-4678-b6c8-d74ddd7d33f1" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d9a4fdbb-86de-4cd9-9dad-b589e75548c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="kron-20200930.xsd#CondensedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7194bcc7-8337-430e-ae67-5c9543ecf26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a10892ab-507e-442d-b91a-b79569968998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7194bcc7-8337-430e-ae67-5c9543ecf26c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a10892ab-507e-442d-b91a-b79569968998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a04bb46-d52b-44a4-87ee-a0eca70ba54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a10892ab-507e-442d-b91a-b79569968998" xlink:to="loc_us-gaap_NetIncomeLoss_0a04bb46-d52b-44a4-87ee-a0eca70ba54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a10892ab-507e-442d-b91a-b79569968998" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b92ba37a-db80-411b-95ec-75156e968643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b92ba37a-db80-411b-95ec-75156e968643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0d8dd4a7-34fd-4299-90f2-49fefd3e0795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0d8dd4a7-34fd-4299-90f2-49fefd3e0795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b791bc6f-c2ed-4fe3-85c1-8214c6d74a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b791bc6f-c2ed-4fe3-85c1-8214c6d74a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d2ed436f-e482-4fa2-adb3-3daeb7e9c9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:to="loc_us-gaap_ShareBasedCompensation_d2ed436f-e482-4fa2-adb3-3daeb7e9c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LeaseExpenseNoncash_ba5c3459-b413-4ecb-8881-1dab9c6bddb9" xlink:href="kron-20200930.xsd#kron_LeaseExpenseNoncash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:to="loc_kron_LeaseExpenseNoncash_ba5c3459-b413-4ecb-8881-1dab9c6bddb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_f2066ad9-49bb-4ce0-a311-028d490e6b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_f2066ad9-49bb-4ce0-a311-028d490e6b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_e53ad242-ff8f-40f7-bcac-3f2e6cd035bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_e53ad242-ff8f-40f7-bcac-3f2e6cd035bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_b2af6aa7-a824-4a7b-a470-f3b221334b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_b2af6aa7-a824-4a7b-a470-f3b221334b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6870d21-4989-442a-9009-52e0d70f854d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f41c6b57-9fa4-4de6-8455-2de80bcdaa53" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6870d21-4989-442a-9009-52e0d70f854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d7200159-4746-44eb-bf2a-925fba22b783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6870d21-4989-442a-9009-52e0d70f854d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d7200159-4746-44eb-bf2a-925fba22b783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_dfefa3e5-a48d-478f-9a57-f31d071eeb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6870d21-4989-442a-9009-52e0d70f854d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_dfefa3e5-a48d-478f-9a57-f31d071eeb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_75462717-ac17-49dd-a41f-dba276fd2ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6870d21-4989-442a-9009-52e0d70f854d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_75462717-ac17-49dd-a41f-dba276fd2ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ccaded9-9423-40fd-be60-b5826f133fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6870d21-4989-442a-9009-52e0d70f854d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ccaded9-9423-40fd-be60-b5826f133fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet_d98da6e9-83d6-403e-bec0-d95230d3a5b5" xlink:href="kron-20200930.xsd#kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6870d21-4989-442a-9009-52e0d70f854d" xlink:to="loc_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet_d98da6e9-83d6-403e-bec0-d95230d3a5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5440e169-ff9b-4f45-b9d7-30faca428562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6870d21-4989-442a-9009-52e0d70f854d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5440e169-ff9b-4f45-b9d7-30faca428562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe06ff3b-0026-4275-982b-6e1422064c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a10892ab-507e-442d-b91a-b79569968998" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe06ff3b-0026-4275-982b-6e1422064c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cecd2d19-8736-4565-923b-6329b321f0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7194bcc7-8337-430e-ae67-5c9543ecf26c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cecd2d19-8736-4565-923b-6329b321f0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c3b13361-7a5c-4098-aac1-7eb23a98a536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cecd2d19-8736-4565-923b-6329b321f0fd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c3b13361-7a5c-4098-aac1-7eb23a98a536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f535aea7-dbbb-4b7b-84e3-0316791ce768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cecd2d19-8736-4565-923b-6329b321f0fd" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f535aea7-dbbb-4b7b-84e3-0316791ce768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_10340d56-9f76-4ec4-9f2f-2c53f59b5ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cecd2d19-8736-4565-923b-6329b321f0fd" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_10340d56-9f76-4ec4-9f2f-2c53f59b5ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_19542e9f-cdde-4508-97ee-f2a0a851fef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cecd2d19-8736-4565-923b-6329b321f0fd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_19542e9f-cdde-4508-97ee-f2a0a851fef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86c83e50-21e6-4364-bf53-7eaab8421869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7194bcc7-8337-430e-ae67-5c9543ecf26c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86c83e50-21e6-4364-bf53-7eaab8421869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_a9d51dcd-b4d9-446b-8ce1-7ceab76ba424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86c83e50-21e6-4364-bf53-7eaab8421869" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_a9d51dcd-b4d9-446b-8ce1-7ceab76ba424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_da1a5767-13c7-468d-a0c5-ae86cde32eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86c83e50-21e6-4364-bf53-7eaab8421869" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_da1a5767-13c7-468d-a0c5-ae86cde32eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_922a3044-fe4d-4e43-af6f-1b6756eca77e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86c83e50-21e6-4364-bf53-7eaab8421869" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_922a3044-fe4d-4e43-af6f-1b6756eca77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_77778358-913f-4a19-8455-7a3f8e16a1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86c83e50-21e6-4364-bf53-7eaab8421869" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_77778358-913f-4a19-8455-7a3f8e16a1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_7ffa7cac-295f-497d-a07e-00e507dba98f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86c83e50-21e6-4364-bf53-7eaab8421869" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_7ffa7cac-295f-497d-a07e-00e507dba98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a4002a9f-51a9-4809-b10d-161dc8e4ba50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86c83e50-21e6-4364-bf53-7eaab8421869" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a4002a9f-51a9-4809-b10d-161dc8e4ba50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d8b1ae95-d47e-4fa9-904b-fbde03e35e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7194bcc7-8337-430e-ae67-5c9543ecf26c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d8b1ae95-d47e-4fa9-904b-fbde03e35e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e0211a3-7e15-4d39-beb5-f17d50af0695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7194bcc7-8337-430e-ae67-5c9543ecf26c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e0211a3-7e15-4d39-beb5-f17d50af0695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_915432ff-54da-411b-85ec-04f246a63dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7194bcc7-8337-430e-ae67-5c9543ecf26c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_915432ff-54da-411b-85ec-04f246a63dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c8acf4de-9812-4d9b-bdc0-7ba3510b1c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7194bcc7-8337-430e-ae67-5c9543ecf26c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c8acf4de-9812-4d9b-bdc0-7ba3510b1c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_90992fa9-a1f5-4a86-ac30-a08fc3585c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c8acf4de-9812-4d9b-bdc0-7ba3510b1c11" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_90992fa9-a1f5-4a86-ac30-a08fc3585c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e83e60e2-bec2-4340-ab47-d0ea83bd576a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c8acf4de-9812-4d9b-bdc0-7ba3510b1c11" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e83e60e2-bec2-4340-ab47-d0ea83bd576a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DeferredOfferingCostsIncurredButNotYetPaid_7185063d-7ad7-4021-8c33-46c6aad3163c" xlink:href="kron-20200930.xsd#kron_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c8acf4de-9812-4d9b-bdc0-7ba3510b1c11" xlink:to="loc_kron_DeferredOfferingCostsIncurredButNotYetPaid_7185063d-7ad7-4021-8c33-46c6aad3163c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid_a7f509f9-8896-4122-840b-55db53342f1c" xlink:href="kron-20200930.xsd#kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c8acf4de-9812-4d9b-bdc0-7ba3510b1c11" xlink:to="loc_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid_a7f509f9-8896-4122-840b-55db53342f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation" xlink:type="simple" xlink:href="kron-20200930.xsd#NatureofOperationsandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b023210c-ed5e-43e5-b433-ad570828f084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_131372a9-aa5c-415a-b616-36e960a30f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b023210c-ed5e-43e5-b433-ad570828f084" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_131372a9-aa5c-415a-b616-36e960a30f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_187cbffb-60a9-4467-bea8-aef51acaf6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_187cbffb-60a9-4467-bea8-aef51acaf6a6" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9e46af76-64d0-496c-8e40-d54910c5f3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9e46af76-64d0-496c-8e40-d54910c5f3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca261fc1-4ccc-4962-a12a-d6ed7d64aa4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9e46af76-64d0-496c-8e40-d54910c5f3ec" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca261fc1-4ccc-4962-a12a-d6ed7d64aa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_725adf62-79e3-43d0-9a15-37732274a461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca261fc1-4ccc-4962-a12a-d6ed7d64aa4c" xlink:to="loc_us-gaap_IPOMember_725adf62-79e3-43d0-9a15-37732274a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_10ada2df-47ea-4fc5-a84c-8bea9509d0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca261fc1-4ccc-4962-a12a-d6ed7d64aa4c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_10ada2df-47ea-4fc5-a84c-8bea9509d0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8271824a-36c0-4bab-920b-ce7df4ba5f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8271824a-36c0-4bab-920b-ce7df4ba5f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d0d34242-9b03-4bfd-a44c-a3819932f6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8271824a-36c0-4bab-920b-ce7df4ba5f35" xlink:to="loc_us-gaap_EquityComponentDomain_d0d34242-9b03-4bfd-a44c-a3819932f6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_819f038c-a142-4a6a-969d-914386c2323b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d0d34242-9b03-4bfd-a44c-a3819932f6b1" xlink:to="loc_us-gaap_CommonStockMember_819f038c-a142-4a6a-969d-914386c2323b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8b0ddad2-8c46-4dc6-9032-ae2772e47b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8b0ddad2-8c46-4dc6-9032-ae2772e47b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_aab5d596-d166-4209-9cf1-9bc911bfde29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8b0ddad2-8c46-4dc6-9032-ae2772e47b7d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_aab5d596-d166-4209-9cf1-9bc911bfde29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8450869c-84d0-4fb4-a16d-48bb562ca54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_aab5d596-d166-4209-9cf1-9bc911bfde29" xlink:to="loc_us-gaap_SubsequentEventMember_8450869c-84d0-4fb4-a16d-48bb562ca54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5eeb67f-b273-4a98-b00f-80c7bd8048df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5eeb67f-b273-4a98-b00f-80c7bd8048df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1eb71194-eb9a-4659-89ad-0fbb4b1b4148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5eeb67f-b273-4a98-b00f-80c7bd8048df" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1eb71194-eb9a-4659-89ad-0fbb4b1b4148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020ConvertibleNotesMember_162aa298-66f3-4b48-b1ac-0d82db95349a" xlink:href="kron-20200930.xsd#kron_A2020ConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1eb71194-eb9a-4659-89ad-0fbb4b1b4148" xlink:to="loc_kron_A2020ConvertibleNotesMember_162aa298-66f3-4b48-b1ac-0d82db95349a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020GileadNotesMember_b294f29e-1bbe-44c6-a798-d629aedf2e47" xlink:href="kron-20200930.xsd#kron_A2020GileadNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1eb71194-eb9a-4659-89ad-0fbb4b1b4148" xlink:to="loc_kron_A2020GileadNotesMember_b294f29e-1bbe-44c6-a798-d629aedf2e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_fba918ff-c192-4a24-abdc-6a6b2d3ff118" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_173ab2a9-34b0-4637-bf1f-47320cb64a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_173ab2a9-34b0-4637-bf1f-47320cb64a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6b8748ce-cb73-4b5a-90b3-0c25f3c3782e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6b8748ce-cb73-4b5a-90b3-0c25f3c3782e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_faef966f-7922-4202-9df0-fd7e33c416ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_faef966f-7922-4202-9df0-fd7e33c416ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0c62a3b8-d373-40ba-bca8-dc84a4c69f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0c62a3b8-d373-40ba-bca8-dc84a4c69f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsOfUnderwritingDiscountsAndCommissions_eda408d5-e94f-4fdd-ac52-05b55c80392d" xlink:href="kron-20200930.xsd#kron_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_kron_PaymentsOfUnderwritingDiscountsAndCommissions_eda408d5-e94f-4fdd-ac52-05b55c80392d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsOfOfferingCosts_459ac87c-23d5-483f-9617-e8a7b519219a" xlink:href="kron-20200930.xsd#kron_PaymentsOfOfferingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_kron_PaymentsOfOfferingCosts_459ac87c-23d5-483f-9617-e8a7b519219a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_323e4c45-6960-4f89-a5fd-9099f9e5b82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_323e4c45-6960-4f89-a5fd-9099f9e5b82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_cc239b8b-3ed5-48ae-95a9-b6d7fcedbabc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_cc239b8b-3ed5-48ae-95a9-b6d7fcedbabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ebbec6f1-825e-494c-88e5-047cbc5958ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ebbec6f1-825e-494c-88e5-047cbc5958ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_b11f8d81-1d97-49de-bdd5-c734b3dc773c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_DeferredOfferingCosts_b11f8d81-1d97-49de-bdd5-c734b3dc773c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3b0b83b0-1582-430c-9c28-538b3d8d7db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3b0b83b0-1582-430c-9c28-538b3d8d7db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d8ce1edd-ee31-4d0f-a4dd-69853e9545a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_NetIncomeLoss_d8ce1edd-ee31-4d0f-a4dd-69853e9545a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1b197df6-7126-437e-bfdf-7b53000859da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7300fe4a-30f9-4813-bed6-12d328fcf8b7" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1b197df6-7126-437e-bfdf-7b53000859da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgments"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7583ae23-d37e-4078-8159-e2d4847b5413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d66563e7-f336-4a26-b08b-97fa71d68a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7583ae23-d37e-4078-8159-e2d4847b5413" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d66563e7-f336-4a26-b08b-97fa71d68a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0e9547d7-33af-4b43-8354-185cd136e4f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0e9547d7-33af-4b43-8354-185cd136e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_edb2f8c2-176a-4ea0-9b39-98693b200050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_UseOfEstimates_edb2f8c2-176a-4ea0-9b39-98693b200050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_01127381-70f7-4ef2-8ced-3db563253ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_01127381-70f7-4ef2-8ced-3db563253ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f5815dc2-26ab-4e04-bc41-f98b12c1af32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f5815dc2-26ab-4e04-bc41-f98b12c1af32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_534e9138-75eb-4c4b-ac04-158854008a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_534e9138-75eb-4c4b-ac04-158854008a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_8ddfd18f-e5e4-4ed6-a782-631266fc4d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_8ddfd18f-e5e4-4ed6-a782-631266fc4d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_857552c3-7a4e-4328-ad2f-6db3e4a6a524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_857552c3-7a4e-4328-ad2f-6db3e4a6a524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_660bdf10-817f-4e3f-8535-33cb622cd503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_660bdf10-817f-4e3f-8535-33cb622cd503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_3c3f3d6e-3ae4-4819-817c-abca8df45f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_3c3f3d6e-3ae4-4819-817c-abca8df45f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1192fbe2-305c-4ce0-b1bf-0eb22dab0bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1192fbe2-305c-4ce0-b1bf-0eb22dab0bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a93a7a1b-cab6-48c6-9d7c-f766dcf22895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a93a7a1b-cab6-48c6-9d7c-f766dcf22895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0789ab80-4c4d-4173-b0d2-25ff4ffd65df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0789ab80-4c4d-4173-b0d2-25ff4ffd65df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_da30fdbf-1e6a-4d62-83a6-62dc879479c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_da30fdbf-1e6a-4d62-83a6-62dc879479c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_47fe0d5c-6c21-4fbe-9c16-4b44b506e0f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_47fe0d5c-6c21-4fbe-9c16-4b44b506e0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_99eb0837-7acf-44da-bb99-dc6bc2ae471b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_99eb0837-7acf-44da-bb99-dc6bc2ae471b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e3499708-805b-48cf-ac43-fbeedf7710ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76982b87-353a-40af-9ab5-31aa7c9e0c44" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e3499708-805b-48cf-ac43-fbeedf7710ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5c1e5915-db28-4d63-a117-a30c002cf95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6b14a764-77f2-40e8-b646-7758af77265a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c1e5915-db28-4d63-a117-a30c002cf95a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6b14a764-77f2-40e8-b646-7758af77265a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_01eb3617-c1d6-4e66-b70b-8c428a712abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c1e5915-db28-4d63-a117-a30c002cf95a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_01eb3617-c1d6-4e66-b70b-8c428a712abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4f4fff65-ad9a-4134-97ae-800ed35b63e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionTable_93d7d145-0bd7-4933-b11e-ce56ae5dc019" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f4fff65-ad9a-4134-97ae-800ed35b63e4" xlink:to="loc_kron_ScheduleOfAssetAcquisitionTable_93d7d145-0bd7-4933-b11e-ce56ae5dc019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionAxis_a4234fcd-49d0-41e3-8b31-ed4267ebeb4b" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_93d7d145-0bd7-4933-b11e-ce56ae5dc019" xlink:to="loc_kron_AssetAcquisitionAxis_a4234fcd-49d0-41e3-8b31-ed4267ebeb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionDomain_2deaf703-818a-4466-b907-e62ded1ab071" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_AssetAcquisitionAxis_a4234fcd-49d0-41e3-8b31-ed4267ebeb4b" xlink:to="loc_kron_AssetAcquisitionDomain_2deaf703-818a-4466-b907-e62ded1ab071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GileadAssetPurchaseMember_44dced18-a267-437f-a209-3ce2984ed0e0" xlink:href="kron-20200930.xsd#kron_GileadAssetPurchaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_AssetAcquisitionDomain_2deaf703-818a-4466-b907-e62ded1ab071" xlink:to="loc_kron_GileadAssetPurchaseMember_44dced18-a267-437f-a209-3ce2984ed0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionLineItems_1c60bdfb-4b36-4ba5-909d-44eb94d50fc7" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_93d7d145-0bd7-4933-b11e-ce56ae5dc019" xlink:to="loc_kron_ScheduleOfAssetAcquisitionLineItems_1c60bdfb-4b36-4ba5-909d-44eb94d50fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25691d3e-1b57-48b7-b8d0-107df0b53362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_1c60bdfb-4b36-4ba5-909d-44eb94d50fc7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25691d3e-1b57-48b7-b8d0-107df0b53362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5a2da8e5-c60a-437f-ad8c-9b33a2f53ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_61d6fb7e-16df-44f7-9cfb-cfd5884b161d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a2da8e5-c60a-437f-ad8c-9b33a2f53ad9" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_61d6fb7e-16df-44f7-9cfb-cfd5884b161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d9e1029b-08c1-4d77-b0d8-de56b29dd356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5a10a81e-3c01-4307-b3b2-216b68afbb97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9e1029b-08c1-4d77-b0d8-de56b29dd356" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5a10a81e-3c01-4307-b3b2-216b68afbb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97722a11-1f18-4469-adca-385476ce6d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5a10a81e-3c01-4307-b3b2-216b68afbb97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97722a11-1f18-4469-adca-385476ce6d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b77a62f7-07b9-4c95-af1f-f260f7a7e23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_97722a11-1f18-4469-adca-385476ce6d6e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b77a62f7-07b9-4c95-af1f-f260f7a7e23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LabEquipmentMember_818d34e1-e52a-4e14-b438-19f18b6bedf9" xlink:href="kron-20200930.xsd#kron_LabEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b77a62f7-07b9-4c95-af1f-f260f7a7e23d" xlink:to="loc_kron_LabEquipmentMember_818d34e1-e52a-4e14-b438-19f18b6bedf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_378a2044-5e08-4999-95c0-af5d43d1f008" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5a10a81e-3c01-4307-b3b2-216b68afbb97" xlink:to="loc_srt_RangeAxis_378a2044-5e08-4999-95c0-af5d43d1f008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86d3bb87-83ef-41d8-a5a2-0b95483f95ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_378a2044-5e08-4999-95c0-af5d43d1f008" xlink:to="loc_srt_RangeMember_86d3bb87-83ef-41d8-a5a2-0b95483f95ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b1d84cc4-844f-4a50-8e02-f79008a3de5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86d3bb87-83ef-41d8-a5a2-0b95483f95ee" xlink:to="loc_srt_MinimumMember_b1d84cc4-844f-4a50-8e02-f79008a3de5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d164ab6c-40b4-40e9-913c-311e6fbfda8a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86d3bb87-83ef-41d8-a5a2-0b95483f95ee" xlink:to="loc_srt_MaximumMember_d164ab6c-40b4-40e9-913c-311e6fbfda8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b135597-5e52-4b28-b105-10710f9c0541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5a10a81e-3c01-4307-b3b2-216b68afbb97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b135597-5e52-4b28-b105-10710f9c0541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a82969f8-b7e5-4d9c-897b-52b234eda14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5b135597-5e52-4b28-b105-10710f9c0541" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a82969f8-b7e5-4d9c-897b-52b234eda14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f861de4d-ed46-40de-a9ad-725463bff858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d6c88a3-8b16-4d52-88c7-626dcb8830c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f861de4d-ed46-40de-a9ad-725463bff858" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d6c88a3-8b16-4d52-88c7-626dcb8830c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9a4977ec-e30d-4c5e-8289-ad5ddfaa083c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f861de4d-ed46-40de-a9ad-725463bff858" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9a4977ec-e30d-4c5e-8289-ad5ddfaa083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d9a701c-8823-441b-b5bb-60d54ba2f5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f861de4d-ed46-40de-a9ad-725463bff858" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d9a701c-8823-441b-b5bb-60d54ba2f5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="kron-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6e7fca34-50cd-4b45-8669-f1f9b3c3088f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_9a8ea4b0-a331-49ea-b882-489250271ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6e7fca34-50cd-4b45-8669-f1f9b3c3088f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_9a8ea4b0-a331-49ea-b882-489250271ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d420a809-47d0-4dbf-87ed-24eb0dbcb56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_11caf438-1702-4544-8ad9-185ddfdc6c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d420a809-47d0-4dbf-87ed-24eb0dbcb56f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_11caf438-1702-4544-8ad9-185ddfdc6c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_55789806-d15c-49d0-8ed2-3af091d208ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_55789806-d15c-49d0-8ed2-3af091d208ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3c939e3-a385-49ef-856b-3c227a8e5704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3c939e3-a385-49ef-856b-3c227a8e5704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5be3afcd-45d2-4eb3-8b42-3e9634793f15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3c939e3-a385-49ef-856b-3c227a8e5704" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5be3afcd-45d2-4eb3-8b42-3e9634793f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2141fd52-6937-4058-8ed8-cfccae043510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5be3afcd-45d2-4eb3-8b42-3e9634793f15" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2141fd52-6937-4058-8ed8-cfccae043510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6e26616-5517-4aa3-a69f-b03e93cfffb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6e26616-5517-4aa3-a69f-b03e93cfffb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6e26616-5517-4aa3-a69f-b03e93cfffb7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_faefd44d-056f-44c1-b35b-556a2883f0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_faefd44d-056f-44c1-b35b-556a2883f0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_41fcd8bc-8b3c-4162-9e53-f4c936f6802a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_41fcd8bc-8b3c-4162-9e53-f4c936f6802a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7922bc2c-e82e-495c-839d-a16258b03be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8163639-f918-4f7c-ac76-c1433fc629e7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7922bc2c-e82e-495c-839d-a16258b03be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_def132d8-8c19-4679-8670-e249cc33d537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:to="loc_us-gaap_FinancialInstrumentAxis_def132d8-8c19-4679-8670-e249cc33d537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_def132d8-8c19-4679-8670-e249cc33d537" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_67fc1890-6083-4607-80bf-ba4c257d54dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_MoneyMarketFundsMember_67fc1890-6083-4607-80bf-ba4c257d54dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7bbef899-7985-4911-8106-d9c0daa6b663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7bbef899-7985-4911-8106-d9c0daa6b663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6f03fb2e-5e00-4bbf-a009-89b236a5d7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_CommercialPaperMember_6f03fb2e-5e00-4bbf-a009-89b236a5d7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_74ada84a-e579-42a9-97b9-0d02c646fe54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_74ada84a-e579-42a9-97b9-0d02c646fe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7e3cb8ec-8540-4f3c-b1bf-ed62350d9a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7e3cb8ec-8540-4f3c-b1bf-ed62350d9a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d51de259-2956-459e-8628-2f9be485316c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d51de259-2956-459e-8628-2f9be485316c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_5ef96607-86f0-4b08-b678-bfd6a777bc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_5ef96607-86f0-4b08-b678-bfd6a777bc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f075ba1d-8811-4b7d-a507-9416371ad360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_adf95cc0-f97c-47a1-b26a-b680f9f0ddde" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f075ba1d-8811-4b7d-a507-9416371ad360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2ecfe990-e0cb-4d8a-9bc2-6c52241eb785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2ecfe990-e0cb-4d8a-9bc2-6c52241eb785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4018b52-f597-4ca6-8eab-42e37bf1d68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2ecfe990-e0cb-4d8a-9bc2-6c52241eb785" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4018b52-f597-4ca6-8eab-42e37bf1d68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3af12346-e414-470f-b437-185aa5bf827b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e4018b52-f597-4ca6-8eab-42e37bf1d68a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3af12346-e414-470f-b437-185aa5bf827b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3f9d7f0-40e3-4499-be2c-378c0a5bce26" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1778247b-6e13-435c-8a1e-b9dfdd943952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1778247b-6e13-435c-8a1e-b9dfdd943952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6711ea19-a890-4b8e-97bb-581fada6fa73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6711ea19-a890-4b8e-97bb-581fada6fa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a27a0624-f181-404d-aecc-c6cfffe632e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a27a0624-f181-404d-aecc-c6cfffe632e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b8a57cbd-efed-4550-8247-d282ebd146b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b8a57cbd-efed-4550-8247-d282ebd146b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_708c7f4b-21d0-4a3a-822e-e30f89d984e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_708c7f4b-21d0-4a3a-822e-e30f89d984e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_624e9c50-f8c1-4d78-8e6d-cff162556074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47079425-a4cd-40c8-8161-85999ab0eb1a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_624e9c50-f8c1-4d78-8e6d-cff162556074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/Investments" xlink:type="simple" xlink:href="kron-20200930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_237b9683-19fe-4c57-a05a-e16eedbcf362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_677f8edf-8a5e-4cab-837c-8da5e83b3961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_237b9683-19fe-4c57-a05a-e16eedbcf362" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_677f8edf-8a5e-4cab-837c-8da5e83b3961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_69a7d55b-89bf-4250-97e3-d642c910a02e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_401a4e7e-55b8-472d-86b6-46b9da02366e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_69a7d55b-89bf-4250-97e3-d642c910a02e" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_401a4e7e-55b8-472d-86b6-46b9da02366e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsFairValueandAmortizedCostDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5248b441-1c92-4ab7-8158-d9f4cf19aea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_919c1ba1-da88-4035-acef-7d563c1bc714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5248b441-1c92-4ab7-8158-d9f4cf19aea4" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_919c1ba1-da88-4035-acef-7d563c1bc714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_69be36b3-ccf0-4ca9-a595-818671e40666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_919c1ba1-da88-4035-acef-7d563c1bc714" xlink:to="loc_us-gaap_FinancialInstrumentAxis_69be36b3-ccf0-4ca9-a595-818671e40666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69be36b3-ccf0-4ca9-a595-818671e40666" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_24f27332-27bd-45eb-86a2-92eeb96bef7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_CertificatesOfDepositMember_24f27332-27bd-45eb-86a2-92eeb96bef7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_771f643e-217d-4e19-96c8-38a930477218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_CommercialPaperMember_771f643e-217d-4e19-96c8-38a930477218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_77170577-961a-4560-97ef-d68c1fe3dccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_77170577-961a-4560-97ef-d68c1fe3dccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7af1a4b9-8716-4856-ae8f-dd176e6336ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7af1a4b9-8716-4856-ae8f-dd176e6336ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7edc3486-18cf-47f5-a124-3d897faa8812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b32656ca-af28-4353-b786-42b9f79a24cf" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7edc3486-18cf-47f5-a124-3d897faa8812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4e9f10ac-a815-409d-8632-d643d2489364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_919c1ba1-da88-4035-acef-7d563c1bc714" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4e9f10ac-a815-409d-8632-d643d2489364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_73b545da-eaee-422c-a0d4-4c22094090ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4e9f10ac-a815-409d-8632-d643d2489364" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_73b545da-eaee-422c-a0d4-4c22094090ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_40652032-e0b3-4784-8f9d-7b7fc10051ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_73b545da-eaee-422c-a0d4-4c22094090ba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_40652032-e0b3-4784-8f9d-7b7fc10051ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_919c1ba1-da88-4035-acef-7d563c1bc714" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_fb9454eb-18ce-4edd-a354-8d12048f0019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_fb9454eb-18ce-4edd-a354-8d12048f0019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bbfc0e05-b663-4959-9c03-8cd5f018bdee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bbfc0e05-b663-4959-9c03-8cd5f018bdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a4d8d787-503f-49a4-af16-44e9bcc61d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a4d8d787-503f-49a4-af16-44e9bcc61d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3a9fdcb9-02de-4058-8fff-b785ae9fd98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3a9fdcb9-02de-4058-8fff-b785ae9fd98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_551a4216-5fd5-4715-a161-c26b40e7bf52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_551a4216-5fd5-4715-a161-c26b40e7bf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_507a314c-a2b1-462c-80c7-f6c746149916" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost_507a314c-a2b1-462c-80c7-f6c746149916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax_efac8160-f81d-4ecb-ad2b-1d95133a3be5" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax_efac8160-f81d-4ecb-ad2b-1d95133a3be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax_06438c9e-416e-4c02-b7eb-b5d20b532460" xlink:href="kron-20200930.xsd#kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax_06438c9e-416e-4c02-b7eb-b5d20b532460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d4b40251-fbe9-4e56-b42a-3710bafcef5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_56201658-f3c3-4132-b1c1-77a4e357436b" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d4b40251-fbe9-4e56-b42a-3710bafcef5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27da7fd0-df36-4e70-afb3-c2f050ba7098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_a7fb9713-89cd-402d-9565-90dd868921a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27da7fd0-df36-4e70-afb3-c2f050ba7098" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_a7fb9713-89cd-402d-9565-90dd868921a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_98fa0356-3164-4379-b222-eea26e0f9872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27da7fd0-df36-4e70-afb3-c2f050ba7098" xlink:to="loc_us-gaap_ShortTermInvestments_98fa0356-3164-4379-b222-eea26e0f9872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_2aa665a0-175e-4c27-9d7a-1e248331432d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27da7fd0-df36-4e70-afb3-c2f050ba7098" xlink:to="loc_us-gaap_LongTermInvestments_2aa665a0-175e-4c27-9d7a-1e248331432d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_559db8a9-be7a-4752-ad24-a76f4a4f6310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27da7fd0-df36-4e70-afb3-c2f050ba7098" xlink:to="loc_us-gaap_InvestmentsAndCash_559db8a9-be7a-4752-ad24-a76f4a4f6310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#InvestmentsContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa48ee00-50df-450b-9541-49203beb16e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_2b07230a-b43d-4e3c-a584-283250bf4e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa48ee00-50df-450b-9541-49203beb16e8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_2b07230a-b43d-4e3c-a584-283250bf4e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_0e59a8e3-1fee-491a-a8b4-6990e6ebf4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa48ee00-50df-450b-9541-49203beb16e8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_0e59a8e3-1fee-491a-a8b4-6990e6ebf4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_9fee84c0-32c4-4b41-90fa-721bbba1d06a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa48ee00-50df-450b-9541-49203beb16e8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_9fee84c0-32c4-4b41-90fa-721bbba1d06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_3e30d977-48cb-45db-8f44-5306aca8c324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa48ee00-50df-450b-9541-49203beb16e8" xlink:to="loc_us-gaap_InvestmentsAndCash_3e30d977-48cb-45db-8f44-5306aca8c324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity_4027a7b8-ff60-425a-9002-9d0966db7906" xlink:href="kron-20200930.xsd#kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa48ee00-50df-450b-9541-49203beb16e8" xlink:to="loc_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity_4027a7b8-ff60-425a-9002-9d0966db7906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" xlink:href="kron-20200930.xsd#PrepaidExpensesAndOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b325327d-13ac-44c3-a663-bde9a8ab5498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_5624e804-b27d-4025-84a2-62ae2ff03549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b325327d-13ac-44c3-a663-bde9a8ab5498" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_5624e804-b27d-4025-84a2-62ae2ff03549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" xlink:href="kron-20200930.xsd#PrepaidExpensesAndOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_859a618c-6379-4f5a-bd4f-c52ac5d73c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_f4fb0186-e184-410c-82dc-93e7fb0f3f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_859a618c-6379-4f5a-bd4f-c52ac5d73c3c" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_f4fb0186-e184-410c-82dc-93e7fb0f3f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9160885b-44c0-4bf2-b33e-6d4d15c5f32e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DebtSecuritiesAvailableForSaleAccruedInterest_3a203ac6-28a6-4710-a286-4c255c3e5de2" xlink:href="kron-20200930.xsd#kron_DebtSecuritiesAvailableForSaleAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9160885b-44c0-4bf2-b33e-6d4d15c5f32e" xlink:to="loc_kron_DebtSecuritiesAvailableForSaleAccruedInterest_3a203ac6-28a6-4710-a286-4c255c3e5de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PrepaidEquipmentServiceContracts_b60fba36-fbb4-4aa9-8e60-c134e0c340a1" xlink:href="kron-20200930.xsd#kron_PrepaidEquipmentServiceContracts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9160885b-44c0-4bf2-b33e-6d4d15c5f32e" xlink:to="loc_kron_PrepaidEquipmentServiceContracts_b60fba36-fbb4-4aa9-8e60-c134e0c340a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PrepaidExternalResearchAndDevelopment_6b3efadd-bb39-45b6-8dde-61eebbadf971" xlink:href="kron-20200930.xsd#kron_PrepaidExternalResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9160885b-44c0-4bf2-b33e-6d4d15c5f32e" xlink:to="loc_kron_PrepaidExternalResearchAndDevelopment_6b3efadd-bb39-45b6-8dde-61eebbadf971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PrepaidSoftware_5e427d18-6d4d-4a28-96e4-0a4150b4567b" xlink:href="kron-20200930.xsd#kron_PrepaidSoftware"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9160885b-44c0-4bf2-b33e-6d4d15c5f32e" xlink:to="loc_kron_PrepaidSoftware_5e427d18-6d4d-4a28-96e4-0a4150b4567b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_1536cf99-cbf6-47c2-9fb8-fa17f534daac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9160885b-44c0-4bf2-b33e-6d4d15c5f32e" xlink:to="loc_us-gaap_PrepaidInsurance_1536cf99-cbf6-47c2-9fb8-fa17f534daac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_328b6c4a-a0bb-493d-9eb9-979229033947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9160885b-44c0-4bf2-b33e-6d4d15c5f32e" xlink:to="loc_us-gaap_PrepaidRent_328b6c4a-a0bb-493d-9eb9-979229033947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_440f5b2e-31c5-4bc3-a89f-d925cf7c4ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9160885b-44c0-4bf2-b33e-6d4d15c5f32e" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_440f5b2e-31c5-4bc3-a89f-d925cf7c4ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa3b30be-ee78-42b3-bd54-11d35ddbd4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9160885b-44c0-4bf2-b33e-6d4d15c5f32e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa3b30be-ee78-42b3-bd54-11d35ddbd4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="kron-20200930.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b4ac23ee-b244-4285-a0d4-d3b7ca9d52f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f66e9d14-2075-4a0c-9724-84446798489b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b4ac23ee-b244-4285-a0d4-d3b7ca9d52f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f66e9d14-2075-4a0c-9724-84446798489b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="kron-20200930.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d318ba0e-9015-44a0-be4f-ad4f12fdd4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_db404256-ac27-4187-a8c0-24eb1f16419b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d318ba0e-9015-44a0-be4f-ad4f12fdd4a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_db404256-ac27-4187-a8c0-24eb1f16419b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eb6219b2-4306-4093-a525-e4c3a528e378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f780ea45-a88a-4600-bd40-c6e88b368dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eb6219b2-4306-4093-a525-e4c3a528e378" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f780ea45-a88a-4600-bd40-c6e88b368dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb9bb945-1f36-4567-ba29-4e36e38489ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f780ea45-a88a-4600-bd40-c6e88b368dd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb9bb945-1f36-4567-ba29-4e36e38489ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_817f2bd7-4b0c-4f61-92d5-cc2e26082fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb9bb945-1f36-4567-ba29-4e36e38489ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_817f2bd7-4b0c-4f61-92d5-cc2e26082fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LabEquipmentMember_27a6e844-10fb-45d8-a672-6698337219fc" xlink:href="kron-20200930.xsd#kron_LabEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_817f2bd7-4b0c-4f61-92d5-cc2e26082fd5" xlink:to="loc_kron_LabEquipmentMember_27a6e844-10fb-45d8-a672-6698337219fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_5e569eeb-6605-49a4-8810-93bfe8581258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_817f2bd7-4b0c-4f61-92d5-cc2e26082fd5" xlink:to="loc_us-gaap_ConstructionInProgressMember_5e569eeb-6605-49a4-8810-93bfe8581258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f780ea45-a88a-4600-bd40-c6e88b368dd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b1665943-ca62-4339-b46e-a00abe422e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b1665943-ca62-4339-b46e-a00abe422e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b46aa46a-ec9d-4b42-bb50-651703cf4dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_b46aa46a-ec9d-4b42-bb50-651703cf4dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3211215a-64c8-4802-973c-0644414d8e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3211215a-64c8-4802-973c-0644414d8e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_d4c43b8f-d139-4d68-a4a0-1b526a51eb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_d4c43b8f-d139-4d68-a4a0-1b526a51eb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fb500440-90e6-438d-906f-037cf35fad23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_818348d4-4ed0-46d7-ad75-fc791404866f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fb500440-90e6-438d-906f-037cf35fad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ffe8a079-967a-4002-8d55-64eb9677d9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eb6219b2-4306-4093-a525-e4c3a528e378" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ffe8a079-967a-4002-8d55-64eb9677d9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesandCurrentPortionofOtherLiabilities"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e97ca944-085b-4f1f-b317-b6564f923b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_5b83f5ca-9722-46a8-904d-6ffbe14b5259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e97ca944-085b-4f1f-b317-b6564f923b6a" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_5b83f5ca-9722-46a8-904d-6ffbe14b5259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c48a9b75-d4c1-44bb-a0fa-e6a591f0c61b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9f3f1fe3-b282-475b-8ad2-920c6eaf73d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c48a9b75-d4c1-44bb-a0fa-e6a591f0c61b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9f3f1fe3-b282-475b-8ad2-920c6eaf73d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_e65e417b-494c-4898-836f-b95470ed05dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c48a9b75-d4c1-44bb-a0fa-e6a591f0c61b" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_e65e417b-494c-4898-836f-b95470ed05dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6ce646f8-a98b-4ef1-9914-e9e566e5a177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7c089326-89fe-4aa9-956a-52564085c0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6ce646f8-a98b-4ef1-9914-e9e566e5a177" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7c089326-89fe-4aa9-956a-52564085c0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_9d788d93-43ec-4008-b8d2-d0d5efa8f5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6ce646f8-a98b-4ef1-9914-e9e566e5a177" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_9d788d93-43ec-4008-b8d2-d0d5efa8f5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AccruedExternalResearchAndDevelopmentCurrent_1828f7e6-b5e5-4e15-be57-08c24b0cce37" xlink:href="kron-20200930.xsd#kron_AccruedExternalResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6ce646f8-a98b-4ef1-9914-e9e566e5a177" xlink:to="loc_kron_AccruedExternalResearchAndDevelopmentCurrent_1828f7e6-b5e5-4e15-be57-08c24b0cce37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AccruedOfferingCostsCurrent_97b3c95f-a2d5-402e-a270-7648a7bfdd4d" xlink:href="kron-20200930.xsd#kron_AccruedOfferingCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6ce646f8-a98b-4ef1-9914-e9e566e5a177" xlink:to="loc_kron_AccruedOfferingCostsCurrent_97b3c95f-a2d5-402e-a270-7648a7bfdd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e2cb524a-689a-47b5-9bc7-d42edb27db19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6ce646f8-a98b-4ef1-9914-e9e566e5a177" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e2cb524a-689a-47b5-9bc7-d42edb27db19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_76109d08-4815-49bf-9fe5-2812a7fafbde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6ce646f8-a98b-4ef1-9914-e9e566e5a177" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_76109d08-4815-49bf-9fe5-2812a7fafbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_58f32509-4be3-4056-b0f4-7a83ed89009a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_14a556ea-5881-440a-b832-90dace98bbfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_58f32509-4be3-4056-b0f4-7a83ed89009a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_14a556ea-5881-440a-b832-90dace98bbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_1a6a4204-d7ac-4ef5-a1b7-402c9155f4e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_58f32509-4be3-4056-b0f4-7a83ed89009a" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_1a6a4204-d7ac-4ef5-a1b7-402c9155f4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_816687ba-6f42-4881-8c7a-c77a0e7bdd5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_58f32509-4be3-4056-b0f4-7a83ed89009a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_816687ba-6f42-4881-8c7a-c77a0e7bdd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStock" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStock"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_4aa2be0f-a7b6-4221-8329-826a6d638d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TemporaryEquityTextBlock_02491c40-0b69-4762-8db3-7bc6a4340361" xlink:href="kron-20200930.xsd#kron_TemporaryEquityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_4aa2be0f-a7b6-4221-8329-826a6d638d5b" xlink:to="loc_kron_TemporaryEquityTextBlock_02491c40-0b69-4762-8db3-7bc6a4340361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStockTables" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStockTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PreferredStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_8412544c-9472-426e-ae19-8f8bbb985d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_3fd442af-bede-4a1f-80e3-5a802ce1c89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_8412544c-9472-426e-ae19-8f8bbb985d7f" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_3fd442af-bede-4a1f-80e3-5a802ce1c89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStockNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_3a629867-3f89-4fbb-966e-9eb3e5fece8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_3a629867-3f89-4fbb-966e-9eb3e5fece8d" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7ec27a4c-11ad-48ac-aa5f-bb1c0b583922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7ec27a4c-11ad-48ac-aa5f-bb1c0b583922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1b467fa5-e3b3-4147-a036-f7960f58c838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ec27a4c-11ad-48ac-aa5f-bb1c0b583922" xlink:to="loc_us-gaap_ClassOfStockDomain_1b467fa5-e3b3-4147-a036-f7960f58c838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SeriesSeedPreferredStockMember_bb096548-bd9f-4882-ae1e-4c89b5e5915f" xlink:href="kron-20200930.xsd#kron_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1b467fa5-e3b3-4147-a036-f7960f58c838" xlink:to="loc_kron_SeriesSeedPreferredStockMember_bb096548-bd9f-4882-ae1e-4c89b5e5915f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_0b6ab33f-5686-4ec6-8e7e-52c7ef5309cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1b467fa5-e3b3-4147-a036-f7960f58c838" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_0b6ab33f-5686-4ec6-8e7e-52c7ef5309cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1f3a44a6-1b50-4fe1-a897-acbd23727461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1f3a44a6-1b50-4fe1-a897-acbd23727461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ee74108-8d24-498e-af44-f1083476f218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1f3a44a6-1b50-4fe1-a897-acbd23727461" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ee74108-8d24-498e-af44-f1083476f218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_94c20303-d7ef-4ece-a1a0-bb00907f6d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ee74108-8d24-498e-af44-f1083476f218" xlink:to="loc_us-gaap_PrivatePlacementMember_94c20303-d7ef-4ece-a1a0-bb00907f6d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_351f44a5-588c-48ba-b010-7e5981e57945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_351f44a5-588c-48ba-b010-7e5981e57945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_0bffdee7-b54f-445a-b9b5-27b4451b8913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_351f44a5-588c-48ba-b010-7e5981e57945" xlink:to="loc_us-gaap_DebtConversionNameDomain_0bffdee7-b54f-445a-b9b5-27b4451b8913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1a91d469-c98d-4f26-be5d-ddf63eff951e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_0bffdee7-b54f-445a-b9b5-27b4451b8913" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1a91d469-c98d-4f26-be5d-ddf63eff951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ca79b0d9-3a1b-400c-92c7-57e3421416cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ca79b0d9-3a1b-400c-92c7-57e3421416cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87f94a3d-e399-442b-91e5-d436b71da083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ca79b0d9-3a1b-400c-92c7-57e3421416cd" xlink:to="loc_us-gaap_EquityComponentDomain_87f94a3d-e399-442b-91e5-d436b71da083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6e9b7367-d6cc-4251-a189-ac654efd7ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87f94a3d-e399-442b-91e5-d436b71da083" xlink:to="loc_us-gaap_CommonStockMember_6e9b7367-d6cc-4251-a189-ac654efd7ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b50f2bb8-f981-4997-96a7-63c965203538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b50f2bb8-f981-4997-96a7-63c965203538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5d7b561e-a762-4d52-b1d1-c9bfbb5e359f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b50f2bb8-f981-4997-96a7-63c965203538" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5d7b561e-a762-4d52-b1d1-c9bfbb5e359f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4dc4d4f1-cb91-41e0-bf75-532fdd3a7e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5d7b561e-a762-4d52-b1d1-c9bfbb5e359f" xlink:to="loc_us-gaap_SubsequentEventMember_4dc4d4f1-cb91-41e0-bf75-532fdd3a7e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ddd2f067-abc0-4a46-a0f2-707903b2f41d" xlink:to="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68a89bea-b81b-4409-b490-579d6025acb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68a89bea-b81b-4409-b490-579d6025acb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_bfcd5fb2-5e7c-4e2c-a92e-7e310d80efa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_bfcd5fb2-5e7c-4e2c-a92e-7e310d80efa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_75f40454-c739-4b37-97d7-d9ca47ed84a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_75f40454-c739-4b37-97d7-d9ca47ed84a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_abd12cdf-12dc-466d-b972-35cc8d286b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_abd12cdf-12dc-466d-b972-35cc8d286b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60227ce2-9615-4895-8aad-3a2e8c9301fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_e08031a9-b004-4ed7-b1f2-c57185b2186b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60227ce2-9615-4895-8aad-3a2e8c9301fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/PreferredStockDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#PreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/PreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_81e86bf0-7a09-469c-b92c-fc3254513d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_5b0d922c-3429-4e35-8bd1-48b20e50c78d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_81e86bf0-7a09-469c-b92c-fc3254513d0f" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_5b0d922c-3429-4e35-8bd1-48b20e50c78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c246d093-7955-4d4e-b58d-1199be33f39f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5b0d922c-3429-4e35-8bd1-48b20e50c78d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c246d093-7955-4d4e-b58d-1199be33f39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f49b039c-302b-4d10-9072-b5ed92101d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c246d093-7955-4d4e-b58d-1199be33f39f" xlink:to="loc_us-gaap_ClassOfStockDomain_f49b039c-302b-4d10-9072-b5ed92101d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SeriesSeedPreferredStockMember_1364f816-18b2-4991-9272-3c63638b8b3a" xlink:href="kron-20200930.xsd#kron_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f49b039c-302b-4d10-9072-b5ed92101d75" xlink:to="loc_kron_SeriesSeedPreferredStockMember_1364f816-18b2-4991-9272-3c63638b8b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9f64c363-df05-4701-b820-e453ac1300ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f49b039c-302b-4d10-9072-b5ed92101d75" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9f64c363-df05-4701-b820-e453ac1300ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5b0d922c-3429-4e35-8bd1-48b20e50c78d" xlink:to="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_368be96e-f601-4f7e-acee-b83f976009c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_368be96e-f601-4f7e-acee-b83f976009c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_42d4fffc-5841-45cf-97ff-d0545c26a535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_42d4fffc-5841-45cf-97ff-d0545c26a535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_647fa358-3380-4f5c-8597-7cbdb2dc66d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_647fa358-3380-4f5c-8597-7cbdb2dc66d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fee60de6-81a0-4d20-ae0e-28bb4851f38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_fee60de6-81a0-4d20-ae0e-28bb4851f38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_3a98254d-226c-4fe0-9238-218ad48e16b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_3a98254d-226c-4fe0-9238-218ad48e16b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1a11fe2c-e278-427e-b6ec-a6bfd4b567bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_250ea9a3-ad96-4a13-87fa-f0620cd3b5be" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1a11fe2c-e278-427e-b6ec-a6bfd4b567bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommonStock" xlink:type="simple" xlink:href="kron-20200930.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_51be6848-5bc0-4ce1-a0ec-c4248f7a00c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0f09251d-3ab1-4c92-bbf3-888bcc391f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_51be6848-5bc0-4ce1-a0ec-c4248f7a00c0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0f09251d-3ab1-4c92-bbf3-888bcc391f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommonStockDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e0ee401f-c385-46df-b228-e27388909705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_367e760f-1991-46fb-8a5a-652315d9a7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e0ee401f-c385-46df-b228-e27388909705" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_367e760f-1991-46fb-8a5a-652315d9a7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_36a1e87e-a9cf-4e4d-b2e2-e7d6b489c7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e0ee401f-c385-46df-b228-e27388909705" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_36a1e87e-a9cf-4e4d-b2e2-e7d6b489c7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cdcc185a-1ca2-49c3-8bef-d5aeb8ae17be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e0ee401f-c385-46df-b228-e27388909705" xlink:to="loc_us-gaap_CommonStockSharesIssued_cdcc185a-1ca2-49c3-8bef-d5aeb8ae17be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_495dabb4-37e3-4c08-92ab-3f49c0972b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e0ee401f-c385-46df-b228-e27388909705" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_495dabb4-37e3-4c08-92ab-3f49c0972b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1f984bb-6277-4c3b-8709-73594571f051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60b770dd-3e23-4d67-8939-6f699a1a9a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1f984bb-6277-4c3b-8709-73594571f051" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60b770dd-3e23-4d67-8939-6f699a1a9a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4f3cacf-36a8-4a7a-867c-8323e070fbda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a764096e-2995-456b-91d7-0a3a7e843941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4f3cacf-36a8-4a7a-867c-8323e070fbda" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a764096e-2995-456b-91d7-0a3a7e843941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fff2a420-47e9-4a22-a80e-3df7422caab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4f3cacf-36a8-4a7a-867c-8323e070fbda" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fff2a420-47e9-4a22-a80e-3df7422caab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bd9cdd5d-d287-4e3c-bf73-4edd9e750529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4f3cacf-36a8-4a7a-867c-8323e070fbda" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bd9cdd5d-d287-4e3c-bf73-4edd9e750529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aad0cf29-d7e9-4533-9b96-3a26e3d692a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aad0cf29-d7e9-4533-9b96-3a26e3d692a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_29a806e0-ef85-4820-bcb8-18383b39fdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:to="loc_us-gaap_AwardTypeAxis_29a806e0-ef85-4820-bcb8-18383b39fdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e21a7e5b-4262-43b1-9bbe-0638a515d668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_29a806e0-ef85-4820-bcb8-18383b39fdbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e21a7e5b-4262-43b1-9bbe-0638a515d668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a7127b5-1d74-4de4-89ef-8f25a3ef14e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e21a7e5b-4262-43b1-9bbe-0638a515d668" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a7127b5-1d74-4de4-89ef-8f25a3ef14e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7e562729-2617-4ed3-adc6-754f125f088b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:to="loc_us-gaap_PlanNameAxis_7e562729-2617-4ed3-adc6-754f125f088b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a189dbc6-1163-4bd4-9c38-88fed02c4cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7e562729-2617-4ed3-adc6-754f125f088b" xlink:to="loc_us-gaap_PlanNameDomain_a189dbc6-1163-4bd4-9c38-88fed02c4cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_EquityIncentivePlan2017Member_5eec4573-3f85-45dc-9692-22ac38936266" xlink:href="kron-20200930.xsd#kron_EquityIncentivePlan2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a189dbc6-1163-4bd4-9c38-88fed02c4cf6" xlink:to="loc_kron_EquityIncentivePlan2017Member_5eec4573-3f85-45dc-9692-22ac38936266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_139f22a4-e4ae-413e-8e92-6bda9335035a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_139f22a4-e4ae-413e-8e92-6bda9335035a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a83114b5-92b6-41bc-b6a0-7863cb9b099b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_139f22a4-e4ae-413e-8e92-6bda9335035a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a83114b5-92b6-41bc-b6a0-7863cb9b099b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7b0134c3-b2d2-40f1-9096-db8d1a1aa2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a83114b5-92b6-41bc-b6a0-7863cb9b099b" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7b0134c3-b2d2-40f1-9096-db8d1a1aa2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_73e90e77-61b6-4622-b8db-fdd9223f4e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a83114b5-92b6-41bc-b6a0-7863cb9b099b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_73e90e77-61b6-4622-b8db-fdd9223f4e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_68402f4a-0f8b-4a22-a6eb-9a7e028a9b85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:to="loc_srt_RangeAxis_68402f4a-0f8b-4a22-a6eb-9a7e028a9b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8652593e-c548-43df-8369-4c83c72300f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_68402f4a-0f8b-4a22-a6eb-9a7e028a9b85" xlink:to="loc_srt_RangeMember_8652593e-c548-43df-8369-4c83c72300f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63e48881-2573-4eaa-918b-da6c4d3ce920" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8652593e-c548-43df-8369-4c83c72300f5" xlink:to="loc_srt_MinimumMember_63e48881-2573-4eaa-918b-da6c4d3ce920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_822e49e8-f793-492c-b0e7-1774545e2283" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8652593e-c548-43df-8369-4c83c72300f5" xlink:to="loc_srt_MaximumMember_822e49e8-f793-492c-b0e7-1774545e2283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8af7f2d-ab88-4aa6-b73b-b44979a53624" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7ff4f477-f4de-416f-b1bd-11517b2c73d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7ff4f477-f4de-416f-b1bd-11517b2c73d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_deb9332a-7ed8-4884-96be-08292ce1d7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_deb9332a-7ed8-4884-96be-08292ce1d7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_517e3498-5bd6-420c-8572-6df0ca296f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_517e3498-5bd6-420c-8572-6df0ca296f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce9177e1-020a-4762-9bca-0bd9393e9fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ce9177e1-020a-4762-9bca-0bd9393e9fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6ee1137e-95c2-4965-830a-732ea37a815c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6ee1137e-95c2-4965-830a-732ea37a815c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_05f692ca-bb2c-40b7-82fe-7a89f4aa73e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_05f692ca-bb2c-40b7-82fe-7a89f4aa73e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_738c3c65-b4da-4f2a-b9fe-1d94cf29093c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_738c3c65-b4da-4f2a-b9fe-1d94cf29093c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cea19a61-d3b9-49b0-93c7-a3f8fa05fd37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cea19a61-d3b9-49b0-93c7-a3f8fa05fd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53455406-8337-4de9-ab47-4f882fa705d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53455406-8337-4de9-ab47-4f882fa705d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares_4cae8ad4-1946-4a80-ba90-7cc7b7cc38a4" xlink:href="kron-20200930.xsd#kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares_4cae8ad4-1946-4a80-ba90-7cc7b7cc38a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_7dc45908-99ff-4eca-8194-97d5c87136a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_7dc45908-99ff-4eca-8194-97d5c87136a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_e5c86153-7ae5-4373-ab99-3a0c5d5e4e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1c9507b-3ccc-40ca-ba4d-f097ce1c28e1" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_e5c86153-7ae5-4373-ab99-3a0c5d5e4e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationOptionpricingModelAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_028b2c4c-fb0f-4b4f-9a51-e5f60fee8b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5276e5c-1a17-4ab3-b875-622be126d907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_028b2c4c-fb0f-4b4f-9a51-e5f60fee8b64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5276e5c-1a17-4ab3-b875-622be126d907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86eb49f1-f998-4bf7-a212-af77c662f5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5276e5c-1a17-4ab3-b875-622be126d907" xlink:to="loc_us-gaap_AwardTypeAxis_86eb49f1-f998-4bf7-a212-af77c662f5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_802d45f6-dcd8-473c-bbf3-01b3a8d76f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_86eb49f1-f998-4bf7-a212-af77c662f5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_802d45f6-dcd8-473c-bbf3-01b3a8d76f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ecb82bdd-15f7-4e73-8ea3-cdaef922cd7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_802d45f6-dcd8-473c-bbf3-01b3a8d76f9b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ecb82bdd-15f7-4e73-8ea3-cdaef922cd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b5276e5c-1a17-4ab3-b875-622be126d907" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SharePriceFairValueDisclosure_c0d43803-bb32-48aa-859a-f023cc9f5d89" xlink:href="kron-20200930.xsd#kron_SharePriceFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_kron_SharePriceFairValueDisclosure_c0d43803-bb32-48aa-859a-f023cc9f5d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_51f84c5c-e46b-43ae-b7b5-13a839c48f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_51f84c5c-e46b-43ae-b7b5-13a839c48f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3e0a293e-d5f8-4f0d-9892-8994306caa6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3e0a293e-d5f8-4f0d-9892-8994306caa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bb13fb9c-37b6-454d-8151-431ef458d165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bb13fb9c-37b6-454d-8151-431ef458d165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_72a23f68-6c86-4353-82ac-4d3ec479d151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d91743b9-ecbf-4827-b436-bdd6cca40093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_72a23f68-6c86-4353-82ac-4d3ec479d151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f05f0222-1d56-4a35-b34f-24333eec59eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d4bdeb0-00a2-4680-9aad-01c7a8a66a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f05f0222-1d56-4a35-b34f-24333eec59eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d4bdeb0-00a2-4680-9aad-01c7a8a66a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa690e21-35de-4c27-87af-a6cc9442c93d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d4bdeb0-00a2-4680-9aad-01c7a8a66a81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa690e21-35de-4c27-87af-a6cc9442c93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c9227b72-44fa-4676-ad56-3329a272324c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d4bdeb0-00a2-4680-9aad-01c7a8a66a81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c9227b72-44fa-4676-ad56-3329a272324c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_22c78a98-b768-490a-aa91-08344906601a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d4bdeb0-00a2-4680-9aad-01c7a8a66a81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_22c78a98-b768-490a-aa91-08344906601a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a97631b-d72f-405f-85ce-ab0662e7c47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d4bdeb0-00a2-4680-9aad-01c7a8a66a81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a97631b-d72f-405f-85ce-ab0662e7c47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a76af924-d447-49cc-ad9b-3769a474d232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d4bdeb0-00a2-4680-9aad-01c7a8a66a81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a76af924-d447-49cc-ad9b-3769a474d232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c8ed2147-dfec-4748-b368-6931e6cde4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f05f0222-1d56-4a35-b34f-24333eec59eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c8ed2147-dfec-4748-b368-6931e6cde4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_960c2624-aeab-47f0-96a4-d3b33d6f2df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f05f0222-1d56-4a35-b34f-24333eec59eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_960c2624-aeab-47f0-96a4-d3b33d6f2df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_709b26e9-d97a-43b9-8ba6-32f604bbadcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f05f0222-1d56-4a35-b34f-24333eec59eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_709b26e9-d97a-43b9-8ba6-32f604bbadcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b27d1492-a21e-49cf-9b40-ec15160b9db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_709b26e9-d97a-43b9-8ba6-32f604bbadcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b27d1492-a21e-49cf-9b40-ec15160b9db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c487a0b0-3009-4328-89ef-cc1364cb815d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_709b26e9-d97a-43b9-8ba6-32f604bbadcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c487a0b0-3009-4328-89ef-cc1364cb815d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_658aeb7b-acd4-411c-bef0-83bfe34f93d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_709b26e9-d97a-43b9-8ba6-32f604bbadcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_658aeb7b-acd4-411c-bef0-83bfe34f93d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c281eaeb-e6ec-4987-b443-479e58aafa1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_709b26e9-d97a-43b9-8ba6-32f604bbadcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c281eaeb-e6ec-4987-b443-479e58aafa1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fab0c09a-eb11-4217-9397-0a5a5c962d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_709b26e9-d97a-43b9-8ba6-32f604bbadcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fab0c09a-eb11-4217-9397-0a5a5c962d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_67dbca6e-668d-4867-b808-25a972713fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_709b26e9-d97a-43b9-8ba6-32f604bbadcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_67dbca6e-668d-4867-b808-25a972713fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e5ffa898-b54e-433a-aca1-a17301c487de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_709b26e9-d97a-43b9-8ba6-32f604bbadcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e5ffa898-b54e-433a-aca1-a17301c487de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3be50750-562a-404d-ab7e-4ff46dd7f9ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f05f0222-1d56-4a35-b34f-24333eec59eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3be50750-562a-404d-ab7e-4ff46dd7f9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_71070388-bf0a-4bbe-9b62-2e8eb9f8ee28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3be50750-562a-404d-ab7e-4ff46dd7f9ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_71070388-bf0a-4bbe-9b62-2e8eb9f8ee28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2bf3a956-85a3-4ffa-ae5b-79cac40cde1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3be50750-562a-404d-ab7e-4ff46dd7f9ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2bf3a956-85a3-4ffa-ae5b-79cac40cde1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_48ae68fd-85e5-4b17-b1fb-79d5709ee4d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3be50750-562a-404d-ab7e-4ff46dd7f9ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_48ae68fd-85e5-4b17-b1fb-79d5709ee4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8e43154f-e46d-422a-8284-c111cb66750a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3be50750-562a-404d-ab7e-4ff46dd7f9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8e43154f-e46d-422a-8284-c111cb66750a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_92e63561-4432-4758-9187-ecdc7f79ed6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3be50750-562a-404d-ab7e-4ff46dd7f9ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_92e63561-4432-4758-9187-ecdc7f79ed6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_cd3ff315-5174-48d2-952e-9bd2411ea103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3be50750-562a-404d-ab7e-4ff46dd7f9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_cd3ff315-5174-48d2-952e-9bd2411ea103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationClassifiedinStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e4365eb-91fe-47da-aa42-ccac4a552e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5e1a8223-6351-4b46-935b-7fc0da73940a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e4365eb-91fe-47da-aa42-ccac4a552e88" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5e1a8223-6351-4b46-935b-7fc0da73940a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_665cd82c-a0ff-49e8-ad42-a99fefc8aeb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5e1a8223-6351-4b46-935b-7fc0da73940a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_665cd82c-a0ff-49e8-ad42-a99fefc8aeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1f600607-a77a-4df0-909b-2d4f9694cba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_665cd82c-a0ff-49e8-ad42-a99fefc8aeb5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1f600607-a77a-4df0-909b-2d4f9694cba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_04a96462-3b91-4ece-9e8a-e6151e807586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f600607-a77a-4df0-909b-2d4f9694cba5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_04a96462-3b91-4ece-9e8a-e6151e807586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c8bac9bf-6ada-4857-ae12-f5c453a94d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f600607-a77a-4df0-909b-2d4f9694cba5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c8bac9bf-6ada-4857-ae12-f5c453a94d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d93e60e2-b83f-49ed-b042-ee0a510d2238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5e1a8223-6351-4b46-935b-7fc0da73940a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d93e60e2-b83f-49ed-b042-ee0a510d2238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2d7d05ab-67e2-4963-a836-7bb00948e614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d93e60e2-b83f-49ed-b042-ee0a510d2238" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2d7d05ab-67e2-4963-a836-7bb00948e614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#StockBasedCompensationRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26a8489b-328e-4f39-8708-7586a45659c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae2aefb6-b3d7-4a37-a227-5cd1de62fe70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26a8489b-328e-4f39-8708-7586a45659c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae2aefb6-b3d7-4a37-a227-5cd1de62fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3b3eec69-3805-4b49-8593-3a79869dcaab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae2aefb6-b3d7-4a37-a227-5cd1de62fe70" xlink:to="loc_us-gaap_AwardTypeAxis_3b3eec69-3805-4b49-8593-3a79869dcaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45af72c1-06f4-4ec1-bcc4-a41f6a5c787b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3b3eec69-3805-4b49-8593-3a79869dcaab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45af72c1-06f4-4ec1-bcc4-a41f6a5c787b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_08594b74-cddd-47c1-a72d-b3a296335b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45af72c1-06f4-4ec1-bcc4-a41f6a5c787b" xlink:to="loc_us-gaap_RestrictedStockMember_08594b74-cddd-47c1-a72d-b3a296335b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_10afcaf3-894f-4a9e-b6e0-2bc4c1cde3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae2aefb6-b3d7-4a37-a227-5cd1de62fe70" xlink:to="loc_us-gaap_GranteeStatusAxis_10afcaf3-894f-4a9e-b6e0-2bc4c1cde3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_55ca58cc-0a4c-4aaa-989d-82605a1cbf04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_10afcaf3-894f-4a9e-b6e0-2bc4c1cde3f4" xlink:to="loc_us-gaap_GranteeStatusDomain_55ca58cc-0a4c-4aaa-989d-82605a1cbf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_NonEmployeeMember_1c0affd1-f633-4f86-8738-e93ae810cf06" xlink:href="kron-20200930.xsd#kron_NonEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_55ca58cc-0a4c-4aaa-989d-82605a1cbf04" xlink:to="loc_kron_NonEmployeeMember_1c0affd1-f633-4f86-8738-e93ae810cf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ExecutiveEmployeeMember_e8be8c42-f4c9-465a-87fb-c2441ea0402d" xlink:href="kron-20200930.xsd#kron_ExecutiveEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_55ca58cc-0a4c-4aaa-989d-82605a1cbf04" xlink:to="loc_kron_ExecutiveEmployeeMember_e8be8c42-f4c9-465a-87fb-c2441ea0402d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae2aefb6-b3d7-4a37-a227-5cd1de62fe70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75de4fde-df4d-4186-aee7-ceaa8c2af0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75de4fde-df4d-4186-aee7-ceaa8c2af0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_203a707f-acb8-4556-aa64-f3788493a275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_203a707f-acb8-4556-aa64-f3788493a275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0fdedae2-4c85-42f5-b814-b3acd3a75a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0fdedae2-4c85-42f5-b814-b3acd3a75a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b9022fe0-6cce-4a7a-b3bc-1c1aa6cf2484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3edacf38-655a-4fce-a578-562bb9d50559" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b9022fe0-6cce-4a7a-b3bc-1c1aa6cf2484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="kron-20200930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c09eef55-12ec-48d8-90e9-dbe6a70332fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_35d16240-df86-4ab6-91b8-331ee020bce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c09eef55-12ec-48d8-90e9-dbe6a70332fc" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_35d16240-df86-4ab6-91b8-331ee020bce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_07c17d34-57ae-407c-8b65-568f51c0ced5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c3e338ec-a1ab-44fc-adce-1eb87f13721c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07c17d34-57ae-407c-8b65-568f51c0ced5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c3e338ec-a1ab-44fc-adce-1eb87f13721c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_540d1b11-af28-4d70-82da-816cbab6f2cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_780e2201-da30-4dc5-a771-12125cf6908f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_540d1b11-af28-4d70-82da-816cbab6f2cd" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_780e2201-da30-4dc5-a771-12125cf6908f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3c12f1b7-79d2-456d-872e-5c425953372c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fcaf9090-cd79-4eaf-92a8-938b9d38a820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3c12f1b7-79d2-456d-872e-5c425953372c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fcaf9090-cd79-4eaf-92a8-938b9d38a820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5dfb4da0-59be-4b8c-90b3-3dacd6111699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3c12f1b7-79d2-456d-872e-5c425953372c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5dfb4da0-59be-4b8c-90b3-3dacd6111699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b562835-3738-4198-81d5-ef01fa699666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12c91ddb-2642-4510-9cfd-1cfc0818e1f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b562835-3738-4198-81d5-ef01fa699666" xlink:to="loc_us-gaap_NetIncomeLoss_12c91ddb-2642-4510-9cfd-1cfc0818e1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6a11afad-a84b-4fb4-8807-131f22d01cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b562835-3738-4198-81d5-ef01fa699666" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6a11afad-a84b-4fb4-8807-131f22d01cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_a780f23b-e18f-4666-ba98-04a941f5ceee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b562835-3738-4198-81d5-ef01fa699666" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_a780f23b-e18f-4666-ba98-04a941f5ceee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_071c1f43-3098-48bd-b51f-a7742fbb99f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_11be80d2-d75b-40bb-be90-2f2f27b44894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_071c1f43-3098-48bd-b51f-a7742fbb99f7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_11be80d2-d75b-40bb-be90-2f2f27b44894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22f28526-fb28-4a77-9f3a-ed63d7eefa79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_11be80d2-d75b-40bb-be90-2f2f27b44894" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22f28526-fb28-4a77-9f3a-ed63d7eefa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22f28526-fb28-4a77-9f3a-ed63d7eefa79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_654b31e6-9c7c-488e-b57c-eafce85fe8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_654b31e6-9c7c-488e-b57c-eafce85fe8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_42c3a200-50d1-4fca-8d7b-529824a2f8aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_42c3a200-50d1-4fca-8d7b-529824a2f8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f528cf3e-4956-47f1-afcb-6d1f1e3bfa99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_us-gaap_EmployeeStockMember_f528cf3e-4956-47f1-afcb-6d1f1e3bfa99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_StockOptionsEarlyExerciseMember_fad83a20-2409-41b0-939a-c4979a79c13e" xlink:href="kron-20200930.xsd#kron_StockOptionsEarlyExerciseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_kron_StockOptionsEarlyExerciseMember_fad83a20-2409-41b0-939a-c4979a79c13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_79699533-c319-4225-b0c6-66a2adf78534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_52a07a3c-05d2-454b-bf04-6ad6c8b6ae22" xlink:to="loc_us-gaap_RestrictedStockMember_79699533-c319-4225-b0c6-66a2adf78534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e0d3e2f0-fc2c-4a53-ae4a-c0899469efa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_11be80d2-d75b-40bb-be90-2f2f27b44894" xlink:to="loc_us-gaap_DebtInstrumentAxis_e0d3e2f0-fc2c-4a53-ae4a-c0899469efa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_059eac48-ec9c-4636-8063-b7945c180fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e0d3e2f0-fc2c-4a53-ae4a-c0899469efa8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_059eac48-ec9c-4636-8063-b7945c180fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020ConvertibleNotesMember_c847898a-a9bf-4861-b52f-ccf573d497d9" xlink:href="kron-20200930.xsd#kron_A2020ConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_059eac48-ec9c-4636-8063-b7945c180fa9" xlink:to="loc_kron_A2020ConvertibleNotesMember_c847898a-a9bf-4861-b52f-ccf573d497d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020GileadNotesMember_2a96494b-800f-4669-9f9c-88cc20b4c9c6" xlink:href="kron-20200930.xsd#kron_A2020GileadNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_059eac48-ec9c-4636-8063-b7945c180fa9" xlink:to="loc_kron_A2020GileadNotesMember_2a96494b-800f-4669-9f9c-88cc20b4c9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d151a54-bbc1-42be-a40f-59184e11a1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_11be80d2-d75b-40bb-be90-2f2f27b44894" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d151a54-bbc1-42be-a40f-59184e11a1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c633f286-a78f-4df3-99de-8b6a524d081b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0d151a54-bbc1-42be-a40f-59184e11a1dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c633f286-a78f-4df3-99de-8b6a524d081b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d1dfaf4c-58f7-4356-8301-c5c27a019c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8581895a-7d78-40a2-8371-230e01f5fb88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d1dfaf4c-58f7-4356-8301-c5c27a019c27" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8581895a-7d78-40a2-8371-230e01f5fb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5247a264-72a4-4017-b1c6-659a3681a50c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2cf0d7c4-65ac-42b6-abe2-70d62e49eba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5247a264-72a4-4017-b1c6-659a3681a50c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2cf0d7c4-65ac-42b6-abe2-70d62e49eba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09e963cf-9b0f-48c9-aa48-0482772dfaeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09e963cf-9b0f-48c9-aa48-0482772dfaeb" xlink:to="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionAxis_a75bd848-5170-443c-8c6a-bdfecfc9410e" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:to="loc_kron_AssetAcquisitionAxis_a75bd848-5170-443c-8c6a-bdfecfc9410e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionDomain_1fecc2b2-c1eb-4392-a0e3-f912f3dc6fef" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_AssetAcquisitionAxis_a75bd848-5170-443c-8c6a-bdfecfc9410e" xlink:to="loc_kron_AssetAcquisitionDomain_1fecc2b2-c1eb-4392-a0e3-f912f3dc6fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GileadAssetPurchaseMember_31b2651f-5a7e-48d5-9ae9-ba07e89a1d3c" xlink:href="kron-20200930.xsd#kron_GileadAssetPurchaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_AssetAcquisitionDomain_1fecc2b2-c1eb-4392-a0e3-f912f3dc6fef" xlink:to="loc_kron_GileadAssetPurchaseMember_31b2651f-5a7e-48d5-9ae9-ba07e89a1d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_176175b7-a0ff-4d0e-8d93-dd1944d58c89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_176175b7-a0ff-4d0e-8d93-dd1944d58c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ce3e994f-1824-4b20-a0d1-b90323f9fd77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_176175b7-a0ff-4d0e-8d93-dd1944d58c89" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ce3e994f-1824-4b20-a0d1-b90323f9fd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseProvisionTermsMember_452764e7-dbd9-4005-9685-4914bfafe4f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseProvisionTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ce3e994f-1824-4b20-a0d1-b90323f9fd77" xlink:to="loc_us-gaap_PurchaseProvisionTermsMember_452764e7-dbd9-4005-9685-4914bfafe4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e783c119-2b51-4a4a-b0f8-7d7cf01d151b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:to="loc_us-gaap_DebtInstrumentAxis_e783c119-2b51-4a4a-b0f8-7d7cf01d151b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c57f9add-cc26-478a-93cb-e7af36747069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e783c119-2b51-4a4a-b0f8-7d7cf01d151b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c57f9add-cc26-478a-93cb-e7af36747069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020GileadNotesMember_801963bf-32f5-4ff9-b50d-18759313950f" xlink:href="kron-20200930.xsd#kron_A2020GileadNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c57f9add-cc26-478a-93cb-e7af36747069" xlink:to="loc_kron_A2020GileadNotesMember_801963bf-32f5-4ff9-b50d-18759313950f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_376c8b87-e4a4-4b36-9d46-74e282a344dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_376c8b87-e4a4-4b36-9d46-74e282a344dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9f04021e-262a-4c46-b845-cd69e09b5684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_376c8b87-e4a4-4b36-9d46-74e282a344dd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9f04021e-262a-4c46-b845-cd69e09b5684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_18ff1a50-5229-4627-976b-e968b717fd6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9f04021e-262a-4c46-b845-cd69e09b5684" xlink:to="loc_us-gaap_ConvertibleDebtMember_18ff1a50-5229-4627-976b-e968b717fd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:href="kron-20200930.xsd#kron_ScheduleOfAssetAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionTable_1158e190-5182-452b-b3f5-90ff6ffafe89" xlink:to="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsForAssetAcquisitions_9eabbd18-927c-4efb-8335-1c1e45904660" xlink:href="kron-20200930.xsd#kron_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_PaymentsForAssetAcquisitions_9eabbd18-927c-4efb-8335-1c1e45904660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_f6f0210f-be1b-4119-b6ab-925b226a3501" xlink:href="kron-20200930.xsd#kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_f6f0210f-be1b-4119-b6ab-925b226a3501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsForAssetAcquisitionsReimbursements_aa067381-e615-4825-9f8a-9397e257b901" xlink:href="kron-20200930.xsd#kron_PaymentsForAssetAcquisitionsReimbursements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_PaymentsForAssetAcquisitionsReimbursements_aa067381-e615-4825-9f8a-9397e257b901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment_d6a4ca30-1e08-4df1-a9ed-8ca7b988377c" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment_d6a4ca30-1e08-4df1-a9ed-8ca7b988377c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment_c4ef8d22-e292-43ad-aeb3-6bf7ff2b0a24" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment_c4ef8d22-e292-43ad-aeb3-6bf7ff2b0a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment_5f564af8-3ba5-449a-9427-dbd4d4b63459" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment_5f564af8-3ba5-449a-9427-dbd4d4b63459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ead05323-6a33-4eba-b3af-16dc8b9dbde2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ead05323-6a33-4eba-b3af-16dc8b9dbde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_RepaymentOfDebtPaymentToBeMade_2381de16-979a-4a50-85de-45e124f69867" xlink:href="kron-20200930.xsd#kron_RepaymentOfDebtPaymentToBeMade"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_RepaymentOfDebtPaymentToBeMade_2381de16-979a-4a50-85de-45e124f69867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_7f2f100f-427b-49b7-a9fc-526f49a08320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_7f2f100f-427b-49b7-a9fc-526f49a08320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument_357d72bc-518b-4d46-9023-51cb8ba1891a" xlink:href="kron-20200930.xsd#kron_GainLossOnChangeInFairValueOfDebtInstrument"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_ScheduleOfAssetAcquisitionLineItems_2ad71857-c62a-4862-aa7b-c207d703222c" xlink:to="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument_357d72bc-518b-4d46-9023-51cb8ba1891a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#CommitmentandContingenciesKeyValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b9c4beac-48c7-4473-be25-c3fa76bd2323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6e6cd03c-348f-4aab-83bc-bf214d4bfbcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b9c4beac-48c7-4473-be25-c3fa76bd2323" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6e6cd03c-348f-4aab-83bc-bf214d4bfbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_302c1011-5ad0-4757-a2a7-4e75601273a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6e6cd03c-348f-4aab-83bc-bf214d4bfbcb" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_302c1011-5ad0-4757-a2a7-4e75601273a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_302c1011-5ad0-4757-a2a7-4e75601273a3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_c729fcb3-4a82-49be-bfb5-ad61da21cc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_c729fcb3-4a82-49be-bfb5-ad61da21cc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d8f63ff7-e44b-4bb5-ba2c-bbab27c43bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d8f63ff7-e44b-4bb5-ba2c-bbab27c43bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_MeasurementInputWeightingMember_9815c2d7-19ad-43d8-b9e0-be9cdfbcc220" xlink:href="kron-20200930.xsd#kron_MeasurementInputWeightingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_667d43a7-8fc1-448e-970b-4c7253ffd185" xlink:to="loc_kron_MeasurementInputWeightingMember_9815c2d7-19ad-43d8-b9e0-be9cdfbcc220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanAxis_861d8eb5-a1cb-489f-8c8b-17169c766a6d" xlink:href="kron-20200930.xsd#kron_SettlementPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6e6cd03c-348f-4aab-83bc-bf214d4bfbcb" xlink:to="loc_kron_SettlementPlanAxis_861d8eb5-a1cb-489f-8c8b-17169c766a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:href="kron-20200930.xsd#kron_SettlementPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanAxis_861d8eb5-a1cb-489f-8c8b-17169c766a6d" xlink:to="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_FundraiseScenarioMember_d3648d6d-ebcd-4288-9f03-56d5549fee8d" xlink:href="kron-20200930.xsd#kron_FundraiseScenarioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_FundraiseScenarioMember_d3648d6d-ebcd-4288-9f03-56d5549fee8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IPOCashPayoutScenarioMember_5354c032-ac30-403e-8420-d9dc3cee8fd6" xlink:href="kron-20200930.xsd#kron_IPOCashPayoutScenarioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_IPOCashPayoutScenarioMember_5354c032-ac30-403e-8420-d9dc3cee8fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IPOConversionScenarioMember_8e5ddd42-91f5-4f02-b21f-9c3041132e03" xlink:href="kron-20200930.xsd#kron_IPOConversionScenarioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_IPOConversionScenarioMember_8e5ddd42-91f5-4f02-b21f-9c3041132e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LiquidationCashPayoutScenarioMember_e2837d66-ba77-44a2-b978-aab73ebda2de" xlink:href="kron-20200930.xsd#kron_LiquidationCashPayoutScenarioMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_LiquidationCashPayoutScenarioMember_e2837d66-ba77-44a2-b978-aab73ebda2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LiquidationConversionScenarioMember_bf2fd775-85b2-4fad-a04a-89612179bfb7" xlink:href="kron-20200930.xsd#kron_LiquidationConversionScenarioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanDomain_346896e4-fda5-4e5d-88eb-464ac2cec7ae" xlink:to="loc_kron_LiquidationConversionScenarioMember_bf2fd775-85b2-4fad-a04a-89612179bfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2c361237-8c87-494b-806e-bfe3b2274f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6e6cd03c-348f-4aab-83bc-bf214d4bfbcb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2c361237-8c87-494b-806e-bfe3b2274f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_b0b9a15b-731c-4e83-b988-fa4edacc4b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2c361237-8c87-494b-806e-bfe3b2274f5f" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_b0b9a15b-731c-4e83-b988-fa4edacc4b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/Leases" xlink:type="simple" xlink:href="kron-20200930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_16e3b197-91cf-4622-9fc6-d1d1bf3ad96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a5364035-7389-40b2-b9db-8e720845db97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16e3b197-91cf-4622-9fc6-d1d1bf3ad96f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a5364035-7389-40b2-b9db-8e720845db97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_5d16c634-1e7e-4b12-81fa-5bfe4bcbe1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16e3b197-91cf-4622-9fc6-d1d1bf3ad96f" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_5d16c634-1e7e-4b12-81fa-5bfe4bcbe1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_49778bf9-41bc-4321-98e2-09eceaa94b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock_f30a755c-4da6-455e-bb4d-bb93d913a9c7" xlink:href="kron-20200930.xsd#kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49778bf9-41bc-4321-98e2-09eceaa94b99" xlink:to="loc_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock_f30a755c-4da6-455e-bb4d-bb93d913a9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock_e21b0f0b-3891-468d-a51c-3879056fbec5" xlink:href="kron-20200930.xsd#kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49778bf9-41bc-4321-98e2-09eceaa94b99" xlink:to="loc_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock_e21b0f0b-3891-468d-a51c-3879056fbec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_d1d135ca-903a-421a-992a-7ca45661ef16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49778bf9-41bc-4321-98e2-09eceaa94b99" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_d1d135ca-903a-421a-992a-7ca45661ef16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a9881fdb-cfcd-4db3-ae5a-40ae2efe6eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49778bf9-41bc-4321-98e2-09eceaa94b99" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a9881fdb-cfcd-4db3-ae5a-40ae2efe6eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7db7f5b4-137d-4e49-8648-8c084a1cee05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_35782c7f-a7ea-46c5-9de9-c90aec276c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7db7f5b4-137d-4e49-8648-8c084a1cee05" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_35782c7f-a7ea-46c5-9de9-c90aec276c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_09b637fc-995f-4026-8b57-a9b7a8dda39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_35782c7f-a7ea-46c5-9de9-c90aec276c7f" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_09b637fc-995f-4026-8b57-a9b7a8dda39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_09b637fc-995f-4026-8b57-a9b7a8dda39e" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A21ErieStreetCambridgeMassachusettsMember_6de482c2-ca57-4d9b-8f54-93b0dac38b12" xlink:href="kron-20200930.xsd#kron_A21ErieStreetCambridgeMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:to="loc_kron_A21ErieStreetCambridgeMassachusettsMember_6de482c2-ca57-4d9b-8f54-93b0dac38b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A301BinneyStreetCambridgeMassachusettsMember_00d1e001-9555-4754-ae19-a73a03d5df3c" xlink:href="kron-20200930.xsd#kron_A301BinneyStreetCambridgeMassachusettsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:to="loc_kron_A301BinneyStreetCambridgeMassachusettsMember_00d1e001-9555-4754-ae19-a73a03d5df3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SanMateoCaliforniaMember_200431a3-6816-49ed-b30b-dcf60218a4be" xlink:href="kron-20200930.xsd#kron_SanMateoCaliforniaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:to="loc_kron_SanMateoCaliforniaMember_200431a3-6816-49ed-b30b-dcf60218a4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SanMateoCaliforniaAdjacentSpaceMember_129cca3f-8710-4cfb-a530-e0d92eea175d" xlink:href="kron-20200930.xsd#kron_SanMateoCaliforniaAdjacentSpaceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dc9b9d52-aada-43fc-8346-6cdfcaba93cf" xlink:to="loc_kron_SanMateoCaliforniaAdjacentSpaceMember_129cca3f-8710-4cfb-a530-e0d92eea175d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1cc3d8ed-3482-4a4a-9370-e610556dee0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_35782c7f-a7ea-46c5-9de9-c90aec276c7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1cc3d8ed-3482-4a4a-9370-e610556dee0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec69599-c69d-49b9-a3c9-75e593b2f1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1cc3d8ed-3482-4a4a-9370-e610556dee0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec69599-c69d-49b9-a3c9-75e593b2f1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_RDEquipmentMember_c78240a8-c3a7-42b4-a4d8-479ea54d10c2" xlink:href="kron-20200930.xsd#kron_RDEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec69599-c69d-49b9-a3c9-75e593b2f1d0" xlink:to="loc_kron_RDEquipmentMember_c78240a8-c3a7-42b4-a4d8-479ea54d10c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_35782c7f-a7ea-46c5-9de9-c90aec276c7f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b751a2f3-65c1-471f-9797-d0e041a345c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b751a2f3-65c1-471f-9797-d0e041a345c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f2f6c252-09d5-4c90-9874-05d756242650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_OperatingLeaseLiability_f2f6c252-09d5-4c90-9874-05d756242650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_251cb65b-ba8a-4e51-8fb3-04ba07005343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_251cb65b-ba8a-4e51-8fb3-04ba07005343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseIncrementalBorrowingRate_2b146136-c558-434c-bffe-c459cbf7a333" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseIncrementalBorrowingRate_2b146136-c558-434c-bffe-c459cbf7a333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d77513e1-7272-4a80-a4db-b556818cb8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d77513e1-7272-4a80-a4db-b556818cb8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_OperatingLeaseFacilitySize_97849802-5b35-4080-8268-30278cccbfc0" xlink:href="kron-20200930.xsd#kron_OperatingLeaseFacilitySize"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_OperatingLeaseFacilitySize_97849802-5b35-4080-8268-30278cccbfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseMonthlyBaseRent_db90afe9-f144-4425-9e98-42d3cc5ad359" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseMonthlyBaseRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseMonthlyBaseRent_db90afe9-f144-4425-9e98-42d3cc5ad359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent_ec4d6854-234f-4ed3-9e7e-fb80d7ca184c" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent_ec4d6854-234f-4ed3-9e7e-fb80d7ca184c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_7d18e1df-ba94-41cc-be51-af49635b715c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_7d18e1df-ba94-41cc-be51-af49635b715c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseTenantImprovementAllowances_fec12160-0241-4ff6-8d61-55b862df6ade" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseTenantImprovementAllowances"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseTenantImprovementAllowances_fec12160-0241-4ff6-8d61-55b862df6ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_93e54de5-94a6-44f5-a478-21e4760a4d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_SecurityDeposit_93e54de5-94a6-44f5-a478-21e4760a4d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseInitialAnnualBaseRent_fbda1126-8e53-424a-8675-a601b4a168fc" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseInitialAnnualBaseRent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_kron_LesseeOperatingLeaseInitialAnnualBaseRent_fbda1126-8e53-424a-8675-a601b4a168fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_139f0351-b9ba-46ff-b4df-2f0ee44828a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_OperatingLeasePayments_139f0351-b9ba-46ff-b4df-2f0ee44828a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_14705d63-ec2a-45e7-82d9-9db14e351d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d666ade2-5195-4ee2-9442-f25fce92cbf7" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_14705d63-ec2a-45e7-82d9-9db14e351d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesSummaryofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8777113e-f585-48bd-b3bd-18717375130f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5235bd06-9aa4-42a1-ba66-d4596068b496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8777113e-f585-48bd-b3bd-18717375130f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5235bd06-9aa4-42a1-ba66-d4596068b496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_edfbc866-8ff6-4143-96a4-7bb86d381a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5235bd06-9aa4-42a1-ba66-d4596068b496" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_edfbc866-8ff6-4143-96a4-7bb86d381a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94fb4ff0-5678-4938-bac6-e416af0de5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_edfbc866-8ff6-4143-96a4-7bb86d381a78" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94fb4ff0-5678-4938-bac6-e416af0de5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ResearchAndDevelopmentMember_d2485d18-2c56-4489-8dd5-00ac20c71c96" xlink:href="kron-20200930.xsd#kron_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_94fb4ff0-5678-4938-bac6-e416af0de5f4" xlink:to="loc_kron_ResearchAndDevelopmentMember_d2485d18-2c56-4489-8dd5-00ac20c71c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_554d4b58-0b3f-4c08-8f0d-f67140e00d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_94fb4ff0-5678-4938-bac6-e416af0de5f4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_554d4b58-0b3f-4c08-8f0d-f67140e00d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5235bd06-9aa4-42a1-ba66-d4596068b496" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_82d2bdf9-db1b-4814-9a74-9d05e784135d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_82d2bdf9-db1b-4814-9a74-9d05e784135d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_bfd3f9d5-344f-450c-9d49-d6b16bf12922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_bfd3f9d5-344f-450c-9d49-d6b16bf12922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_477d7ab3-ef68-41b8-9f6f-b522376319f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5d7d9eab-6ffd-455d-b28a-548b430724e5" xlink:to="loc_us-gaap_OperatingLeaseCost_477d7ab3-ef68-41b8-9f6f-b522376319f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3f174365-124e-4c4c-a8b4-d439232255b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_FinanceLeasesAssetsAbstract_d89ccffe-cb1c-4e0f-a114-55103810af2e" xlink:href="kron-20200930.xsd#kron_FinanceLeasesAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f174365-124e-4c4c-a8b4-d439232255b1" xlink:to="loc_kron_FinanceLeasesAssetsAbstract_d89ccffe-cb1c-4e0f-a114-55103810af2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_5be9915a-026c-46b9-bb0b-27b15df926e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_FinanceLeasesAssetsAbstract_d89ccffe-cb1c-4e0f-a114-55103810af2e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_5be9915a-026c-46b9-bb0b-27b15df926e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_7211ec1e-dd9c-499f-9523-a4191e9d93f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f174365-124e-4c4c-a8b4-d439232255b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_7211ec1e-dd9c-499f-9523-a4191e9d93f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a068010a-90c0-4a8f-afc4-809cd4b58b73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_7211ec1e-dd9c-499f-9523-a4191e9d93f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a068010a-90c0-4a8f-afc4-809cd4b58b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b823182e-a771-4240-829d-62b75023e64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_7211ec1e-dd9c-499f-9523-a4191e9d93f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b823182e-a771-4240-829d-62b75023e64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_324fbd71-2d59-4359-979e-9c6b78f04f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_7211ec1e-dd9c-499f-9523-a4191e9d93f0" xlink:to="loc_us-gaap_FinanceLeaseLiability_324fbd71-2d59-4359-979e-9c6b78f04f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_36ea0c70-8ee9-4e64-9a87-242a35f0c66b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_OperatingLeaseAssetsAbstract_baa8bb24-ffa5-4ab9-8821-7bd3b3d33d6b" xlink:href="kron-20200930.xsd#kron_OperatingLeaseAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36ea0c70-8ee9-4e64-9a87-242a35f0c66b" xlink:to="loc_kron_OperatingLeaseAssetsAbstract_baa8bb24-ffa5-4ab9-8821-7bd3b3d33d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd6043be-2fe7-49e9-ae23-9a91f6370cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_OperatingLeaseAssetsAbstract_baa8bb24-ffa5-4ab9-8821-7bd3b3d33d6b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd6043be-2fe7-49e9-ae23-9a91f6370cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_8371c5de-b791-42d7-9818-5e42713b6c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36ea0c70-8ee9-4e64-9a87-242a35f0c66b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_8371c5de-b791-42d7-9818-5e42713b6c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_13a8cd60-e214-46cd-8a09-490eb2ff9b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_8371c5de-b791-42d7-9818-5e42713b6c17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_13a8cd60-e214-46cd-8a09-490eb2ff9b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a5213883-6e08-4a93-b880-42d4ed85513d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_8371c5de-b791-42d7-9818-5e42713b6c17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a5213883-6e08-4a93-b880-42d4ed85513d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f5574bff-e560-4c13-8596-8d1ddce126b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_8371c5de-b791-42d7-9818-5e42713b6c17" xlink:to="loc_us-gaap_OperatingLeaseLiability_f5574bff-e560-4c13-8596-8d1ddce126b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7795ecdb-13a2-4871-bdd4-a23fade16557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7795ecdb-13a2-4871-bdd4-a23fade16557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_560e2726-80a3-4473-8e65-7064eb77f806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_560e2726-80a3-4473-8e65-7064eb77f806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2ee975fe-74c8-4b9e-b446-9c453ccea858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2ee975fe-74c8-4b9e-b446-9c453ccea858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9c14c429-839f-4c9d-9f13-ee25789d10cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9c14c429-839f-4c9d-9f13-ee25789d10cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_9457b1d4-c605-4217-b2c2-48dd1d17f08b" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:to="loc_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_9457b1d4-c605-4217-b2c2-48dd1d17f08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5baf84b9-0d93-4e29-90c1-2433a0dc04aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5baf84b9-0d93-4e29-90c1-2433a0dc04aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_21b72a88-1e82-4550-92b8-1c9075fa3372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_21b72a88-1e82-4550-92b8-1c9075fa3372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_0066e95c-4d22-44c7-8f63-1bc23a259b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:to="loc_us-gaap_TenantImprovements_0066e95c-4d22-44c7-8f63-1bc23a259b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7b8223e6-190f-43bc-92a9-f29fb2bb5af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c040c46-69a0-48f6-96c9-8eb096041e7a" xlink:to="loc_us-gaap_OperatingLeaseLiability_7b8223e6-190f-43bc-92a9-f29fb2bb5af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="kron-20200930.xsd#LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020Notes" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020Notes"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/A2020Notes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_81a08e23-afe7-44ed-ba83-14e638d4b107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a378a742-eeec-411a-be8d-519b938c608a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_81a08e23-afe7-44ed-ba83-14e638d4b107" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a378a742-eeec-411a-be8d-519b938c608a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020NotesTables" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020NotesTables"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/A2020NotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9ba07d65-0791-410f-bfee-a17c0a634f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_d7549bd8-4eb9-434c-850b-536c862b2268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9ba07d65-0791-410f-bfee-a17c0a634f0c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_d7549bd8-4eb9-434c-850b-536c862b2268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020NotesNarrativeDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020NotesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/A2020NotesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_59ce10f4-54dd-449a-bafe-59da97232c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59ce10f4-54dd-449a-bafe-59da97232c38" xlink:to="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_efe7164c-41d1-4623-89d7-346b7b1ec20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_efe7164c-41d1-4623-89d7-346b7b1ec20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb1998c0-7f13-422e-971a-e771911b7e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_efe7164c-41d1-4623-89d7-346b7b1ec20d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb1998c0-7f13-422e-971a-e771911b7e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_783ee1ef-f380-43ad-88b3-10284babe224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb1998c0-7f13-422e-971a-e771911b7e7f" xlink:to="loc_us-gaap_ConvertibleDebtMember_783ee1ef-f380-43ad-88b3-10284babe224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1fcf97b3-b891-4ecd-b3ff-7741189871c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_DebtInstrumentAxis_1fcf97b3-b891-4ecd-b3ff-7741189871c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_db100b84-9878-4f25-bad2-0b8c45d1fda5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1fcf97b3-b891-4ecd-b3ff-7741189871c4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_db100b84-9878-4f25-bad2-0b8c45d1fda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ConvertibleNotesPayable2020NotesMember_1ff5d695-9d2f-493e-ad02-658595507a9e" xlink:href="kron-20200930.xsd#kron_ConvertibleNotesPayable2020NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_db100b84-9878-4f25-bad2-0b8c45d1fda5" xlink:to="loc_kron_ConvertibleNotesPayable2020NotesMember_1ff5d695-9d2f-493e-ad02-658595507a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020ConvertibleNotesMember_8da9f11f-afa0-44f9-9eaa-f9e88e80acd1" xlink:href="kron-20200930.xsd#kron_A2020ConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_db100b84-9878-4f25-bad2-0b8c45d1fda5" xlink:to="loc_kron_A2020ConvertibleNotesMember_8da9f11f-afa0-44f9-9eaa-f9e88e80acd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dc3c9f34-324b-4657-b08d-17f951ed7631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dc3c9f34-324b-4657-b08d-17f951ed7631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3817cac4-59d9-4381-b64c-34951c3995cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dc3c9f34-324b-4657-b08d-17f951ed7631" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3817cac4-59d9-4381-b64c-34951c3995cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_993e2539-b96b-4a7f-8795-836426c3a0b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3817cac4-59d9-4381-b64c-34951c3995cd" xlink:to="loc_us-gaap_IPOMember_993e2539-b96b-4a7f-8795-836426c3a0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30f45884-8b4b-4531-9d4c-1f4328807e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30f45884-8b4b-4531-9d4c-1f4328807e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1386420e-d2c6-47ae-a4a4-5567f5678d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30f45884-8b4b-4531-9d4c-1f4328807e48" xlink:to="loc_us-gaap_EquityComponentDomain_1386420e-d2c6-47ae-a4a4-5567f5678d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2be67ae7-2586-4d31-849e-fdc1db5f4217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1386420e-d2c6-47ae-a4a4-5567f5678d38" xlink:to="loc_us-gaap_CommonStockMember_2be67ae7-2586-4d31-849e-fdc1db5f4217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_71d94528-361b-4602-a6f0-b7caebc77376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_71d94528-361b-4602-a6f0-b7caebc77376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d82fadcf-7d7c-4d5c-885e-d2d90b7b0979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_71d94528-361b-4602-a6f0-b7caebc77376" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d82fadcf-7d7c-4d5c-885e-d2d90b7b0979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d7d55886-c76a-4148-aab2-0b38fb061ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d82fadcf-7d7c-4d5c-885e-d2d90b7b0979" xlink:to="loc_us-gaap_SubsequentEventMember_d7d55886-c76a-4148-aab2-0b38fb061ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80847deb-503f-4d8a-a7a5-dd987db61971" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_be0dc4ad-493b-4129-a1b6-c733ad68bceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_be0dc4ad-493b-4129-a1b6-c733ad68bceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_49a31485-f059-4a9f-8489-e39ca62e06ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_49a31485-f059-4a9f-8489-e39ca62e06ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f3af09cb-0a26-49ce-abe6-f9014b1509ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f3af09cb-0a26-49ce-abe6-f9014b1509ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SaleOfStockPurchasePriceOfCommonStockPercent_b6eb32c9-8340-420f-8ad9-a6fab059dfc8" xlink:href="kron-20200930.xsd#kron_SaleOfStockPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_kron_SaleOfStockPurchasePriceOfCommonStockPercent_b6eb32c9-8340-420f-8ad9-a6fab059dfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_DebtConversionValuationOfCompany_6ea67268-f5fe-422a-b9e2-f3f16d2b0ae8" xlink:href="kron-20200930.xsd#kron_DebtConversionValuationOfCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_kron_DebtConversionValuationOfCompany_6ea67268-f5fe-422a-b9e2-f3f16d2b0ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_eaa94cdb-fe14-458b-961c-d01f3fba6332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_eaa94cdb-fe14-458b-961c-d01f3fba6332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument_1acbf121-ec1c-46eb-9ca8-19295eef620e" xlink:href="kron-20200930.xsd#kron_GainLossOnChangeInFairValueOfDebtInstrument"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_kron_GainLossOnChangeInFairValueOfDebtInstrument_1acbf121-ec1c-46eb-9ca8-19295eef620e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_57f28774-fd82-4543-9aa6-593d66dcdd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_57f28774-fd82-4543-9aa6-593d66dcdd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_PaymentsForLegalCosts_a80a8fd1-af32-476b-9100-3cbe56c3d520" xlink:href="kron-20200930.xsd#kron_PaymentsForLegalCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e3317f97-01aa-4667-87d1-f440f14c9ff9" xlink:to="loc_kron_PaymentsForLegalCosts_a80a8fd1-af32-476b-9100-3cbe56c3d520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#A2020NotesKeyValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f776f5ff-a9b2-4496-bd80-f3b314ca8be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d116c2cb-4a49-49af-a761-c79bf8007ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f776f5ff-a9b2-4496-bd80-f3b314ca8be5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d116c2cb-4a49-49af-a761-c79bf8007ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_927105c0-17b0-4c3f-9f7e-7ec0c7872571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d116c2cb-4a49-49af-a761-c79bf8007ac3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_927105c0-17b0-4c3f-9f7e-7ec0c7872571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_927105c0-17b0-4c3f-9f7e-7ec0c7872571" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_20b03586-32de-4759-a744-3ba61c02b2dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_20b03586-32de-4759-a744-3ba61c02b2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_73e3ddfe-e851-4866-b4ea-0f73b23ee2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_73e3ddfe-e851-4866-b4ea-0f73b23ee2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_MeasurementInputWeightingMember_fc478996-fca1-4ae7-a941-b810ec7ae0f0" xlink:href="kron-20200930.xsd#kron_MeasurementInputWeightingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b66397b7-aa73-4486-8b21-7c7e42ea8e89" xlink:to="loc_kron_MeasurementInputWeightingMember_fc478996-fca1-4ae7-a941-b810ec7ae0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanAxis_fb7f4ffa-2cc9-4892-9fda-8c3db28ca178" xlink:href="kron-20200930.xsd#kron_SettlementPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d116c2cb-4a49-49af-a761-c79bf8007ac3" xlink:to="loc_kron_SettlementPlanAxis_fb7f4ffa-2cc9-4892-9fda-8c3db28ca178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:href="kron-20200930.xsd#kron_SettlementPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanAxis_fb7f4ffa-2cc9-4892-9fda-8c3db28ca178" xlink:to="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_IPOScenarioMember_07909f73-edab-46b6-836f-4ca7b605a35a" xlink:href="kron-20200930.xsd#kron_IPOScenarioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:to="loc_kron_IPOScenarioMember_07909f73-edab-46b6-836f-4ca7b605a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_SeriesBScenarioMember_18d0551d-1ae2-48ee-9931-dbc0236e9a0c" xlink:href="kron-20200930.xsd#kron_SeriesBScenarioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:to="loc_kron_SeriesBScenarioMember_18d0551d-1ae2-48ee-9931-dbc0236e9a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_FinancingScenarioMember_12adc39f-4744-4e50-9b4d-03230d6f3795" xlink:href="kron-20200930.xsd#kron_FinancingScenarioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kron_SettlementPlanDomain_79bf9a20-af64-4a23-b4cd-c686d140ffa8" xlink:to="loc_kron_FinancingScenarioMember_12adc39f-4744-4e50-9b4d-03230d6f3795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_12cf69f8-ceeb-4742-9587-a1a47f0f3efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d116c2cb-4a49-49af-a761-c79bf8007ac3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_12cf69f8-ceeb-4742-9587-a1a47f0f3efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_b94654bf-0990-4db7-b0fb-e37c74d2a8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_12cf69f8-ceeb-4742-9587-a1a47f0f3efc" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_b94654bf-0990-4db7-b0fb-e37c74d2a8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/RelatedParties" xlink:type="simple" xlink:href="kron-20200930.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_84e887b6-4bf0-4418-b32b-0010ab12d2d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_08bf1099-884d-44c5-8a0a-1b6c1a7ef2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_84e887b6-4bf0-4418-b32b-0010ab12d2d4" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_08bf1099-884d-44c5-8a0a-1b6c1a7ef2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#RelatedPartyDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5ed337dc-28fa-4816-8cde-5673f6d0453c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e3d075b-1080-4dcc-b364-7b7ddcf42a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5ed337dc-28fa-4816-8cde-5673f6d0453c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e3d075b-1080-4dcc-b364-7b7ddcf42a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66969449-e39d-427c-a923-93291658412f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e3d075b-1080-4dcc-b364-7b7ddcf42a2b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66969449-e39d-427c-a923-93291658412f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_959fe112-c5d2-4886-876a-0b209b30dc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66969449-e39d-427c-a923-93291658412f" xlink:to="loc_us-gaap_RelatedPartyDomain_959fe112-c5d2-4886-876a-0b209b30dc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_d39a3a05-cead-4780-ba3b-b7b6b47d6de4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_959fe112-c5d2-4886-876a-0b209b30dc3e" xlink:to="loc_srt_AffiliatedEntityMember_d39a3a05-cead-4780-ba3b-b7b6b47d6de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_9df485ab-a02f-4ade-ac4a-4888885aeef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e3d075b-1080-4dcc-b364-7b7ddcf42a2b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_9df485ab-a02f-4ade-ac4a-4888885aeef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d036860c-f32c-40bc-98fb-41af06a00afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9df485ab-a02f-4ade-ac4a-4888885aeef2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d036860c-f32c-40bc-98fb-41af06a00afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_TwoRiverConsultingLLCMember_9713edea-0d85-44b9-bf4b-8787b2cfa90b" xlink:href="kron-20200930.xsd#kron_TwoRiverConsultingLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d036860c-f32c-40bc-98fb-41af06a00afd" xlink:to="loc_kron_TwoRiverConsultingLLCMember_9713edea-0d85-44b9-bf4b-8787b2cfa90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_BellcoCapitalLLCMember_3cf5570a-e758-4ab4-8a48-82a14a0c0576" xlink:href="kron-20200930.xsd#kron_BellcoCapitalLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d036860c-f32c-40bc-98fb-41af06a00afd" xlink:to="loc_kron_BellcoCapitalLLCMember_3cf5570a-e758-4ab4-8a48-82a14a0c0576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6e3d075b-1080-4dcc-b364-7b7ddcf42a2b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_ServicesAgreementTerm_5b0cd39a-b08e-45df-9696-6c522fcf6bea" xlink:href="kron-20200930.xsd#kron_ServicesAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:to="loc_kron_ServicesAgreementTerm_5b0cd39a-b08e-45df-9696-6c522fcf6bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_a25cfe56-ff09-4d99-b11b-2c83432734b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_a25cfe56-ff09-4d99-b11b-2c83432734b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty_e83d19d0-0d2a-459c-9ef1-2c860fe76dbb" xlink:href="kron-20200930.xsd#kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:to="loc_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty_e83d19d0-0d2a-459c-9ef1-2c860fe76dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_ca0e0271-755d-4e36-91a3-d97ae9ab4885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f4149119-f1aa-4ea9-a36c-3ab101b8e26f" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_ca0e0271-755d-4e36-91a3-d97ae9ab4885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="kron-20200930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_910575ee-59a0-4f84-8fda-7e9564d73d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9d7b8426-5fd0-4abc-ad24-6b37618e26ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_910575ee-59a0-4f84-8fda-7e9564d73d80" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9d7b8426-5fd0-4abc-ad24-6b37618e26ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kronosbio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="kron-20200930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.kronosbio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_981a47a0-2fbc-4834-8785-30038cb30b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_981a47a0-2fbc-4834-8785-30038cb30b1c" xlink:to="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f2239b10-c06c-45e3-8851-057d0dc28223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f2239b10-c06c-45e3-8851-057d0dc28223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7434c658-a6f5-4a8d-8e01-bae62c7d1413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f2239b10-c06c-45e3-8851-057d0dc28223" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7434c658-a6f5-4a8d-8e01-bae62c7d1413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a893e98a-705a-447a-8345-fc88f7cee4be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7434c658-a6f5-4a8d-8e01-bae62c7d1413" xlink:to="loc_us-gaap_SubsequentEventMember_a893e98a-705a-447a-8345-fc88f7cee4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d0cc9df1-e8f0-4748-8e14-1041ff1a08d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_PlanNameAxis_d0cc9df1-e8f0-4748-8e14-1041ff1a08d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3b5b070d-4693-442b-8c77-701fd7195537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d0cc9df1-e8f0-4748-8e14-1041ff1a08d0" xlink:to="loc_us-gaap_PlanNameDomain_3b5b070d-4693-442b-8c77-701fd7195537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020StockOptionAndIncentivePlanMember_9bc8a402-9ccc-438c-bc5e-cc9a2de4d592" xlink:href="kron-20200930.xsd#kron_A2020StockOptionAndIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3b5b070d-4693-442b-8c77-701fd7195537" xlink:to="loc_kron_A2020StockOptionAndIncentivePlanMember_9bc8a402-9ccc-438c-bc5e-cc9a2de4d592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020EmployeeStockPurchasePlanMember_caef6cd1-f541-4d84-affa-b8d88eb39d8f" xlink:href="kron-20200930.xsd#kron_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3b5b070d-4693-442b-8c77-701fd7195537" xlink:to="loc_kron_A2020EmployeeStockPurchasePlanMember_caef6cd1-f541-4d84-affa-b8d88eb39d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6c229079-5cf6-47c2-bdd7-2f4bf11b4705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_AwardTypeAxis_6c229079-5cf6-47c2-bdd7-2f4bf11b4705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5178c10c-6777-445c-a864-3400a3b9fc9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6c229079-5cf6-47c2-bdd7-2f4bf11b4705" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5178c10c-6777-445c-a864-3400a3b9fc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c5bbccca-60d0-4f2f-9995-72fda20e99e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5178c10c-6777-445c-a864-3400a3b9fc9c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c5bbccca-60d0-4f2f-9995-72fda20e99e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2e82b143-b6a7-4d6d-9e16-471e87a45a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5178c10c-6777-445c-a864-3400a3b9fc9c" xlink:to="loc_us-gaap_EmployeeStockMember_2e82b143-b6a7-4d6d-9e16-471e87a45a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_290efea0-96fb-4889-ac02-e627ab38347f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_290efea0-96fb-4889-ac02-e627ab38347f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_69959e86-0f23-4f56-9473-2905b8a920ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_290efea0-96fb-4889-ac02-e627ab38347f" xlink:to="loc_us-gaap_EquityComponentDomain_69959e86-0f23-4f56-9473-2905b8a920ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_268f89d2-8757-4253-974d-095feccc803b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_69959e86-0f23-4f56-9473-2905b8a920ce" xlink:to="loc_us-gaap_CommonStockMember_268f89d2-8757-4253-974d-095feccc803b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cece934d-ab53-4fd5-b788-704383bf0044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cece934d-ab53-4fd5-b788-704383bf0044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64395970-b985-4383-b0d9-28c4e84e86f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cece934d-ab53-4fd5-b788-704383bf0044" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64395970-b985-4383-b0d9-28c4e84e86f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_b9cad982-243c-4f6d-a803-b2cf4f884b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64395970-b985-4383-b0d9-28c4e84e86f0" xlink:to="loc_us-gaap_ConvertibleDebtMember_b9cad982-243c-4f6d-a803-b2cf4f884b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dbd96570-4edb-470f-a72a-2e9870e0fa9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_DebtInstrumentAxis_dbd96570-4edb-470f-a72a-2e9870e0fa9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_71f65a65-c120-4cfb-9e2b-70185f3fc865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_dbd96570-4edb-470f-a72a-2e9870e0fa9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_71f65a65-c120-4cfb-9e2b-70185f3fc865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020ConvertibleNotesMember_2160ddf0-bb68-4e50-af8c-7133a31c2145" xlink:href="kron-20200930.xsd#kron_A2020ConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_71f65a65-c120-4cfb-9e2b-70185f3fc865" xlink:to="loc_kron_A2020ConvertibleNotesMember_2160ddf0-bb68-4e50-af8c-7133a31c2145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_A2020GileadNotesMember_9672dfb1-c719-438c-b07a-548aded91074" xlink:href="kron-20200930.xsd#kron_A2020GileadNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_71f65a65-c120-4cfb-9e2b-70185f3fc865" xlink:to="loc_kron_A2020GileadNotesMember_9672dfb1-c719-438c-b07a-548aded91074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_15fec7b7-3c54-4d5b-8115-ed0a032321ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_srt_StatementGeographicalAxis_15fec7b7-3c54-4d5b-8115-ed0a032321ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6f1cfb60-7f70-4464-8b3d-1ddf5f590c44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_15fec7b7-3c54-4d5b-8115-ed0a032321ae" xlink:to="loc_srt_SegmentGeographicalDomain_6f1cfb60-7f70-4464-8b3d-1ddf5f590c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_CambridgeMassachusettsMember_e6da1daf-52a2-4e59-8d16-d0d09f09e54b" xlink:href="kron-20200930.xsd#kron_CambridgeMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6f1cfb60-7f70-4464-8b3d-1ddf5f590c44" xlink:to="loc_kron_CambridgeMassachusettsMember_e6da1daf-52a2-4e59-8d16-d0d09f09e54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8ed11e5d-1aea-4232-8381-114025659e5f" xlink:to="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9b4c1daa-a576-4b1b-9c6d-33860730f69f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9b4c1daa-a576-4b1b-9c6d-33860730f69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_00bc206d-37de-45de-883f-630381cb97da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_00bc206d-37de-45de-883f-630381cb97da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e2d3abeb-a4a2-464d-8874-66302d74f456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e2d3abeb-a4a2-464d-8874-66302d74f456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1835e0a6-6a4e-4697-b2d7-16b31ad4fe4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1835e0a6-6a4e-4697-b2d7-16b31ad4fe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_da319491-3539-499f-a12e-55b657fb29ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_da319491-3539-499f-a12e-55b657fb29ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_54eb23ad-cb85-4cfc-b955-f17fc7cec24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_54eb23ad-cb85-4cfc-b955-f17fc7cec24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kron_LesseeOperatingLeaseEarlyTerminationCost_3388ac11-98e6-4ff5-87ce-e1b7b7d7a0b4" xlink:href="kron-20200930.xsd#kron_LesseeOperatingLeaseEarlyTerminationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8a61d526-9017-483f-b1d8-993311a34738" xlink:to="loc_kron_LesseeOperatingLeaseEarlyTerminationCost_3388ac11-98e6-4ff5-87ce-e1b7b7d7a0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>kron-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:kron="http://www.kronosbio.com/20200930"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="kron-20200930.xsd" xlink:type="simple"/>
    <context id="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic875b4ec6f6440d5a5659f163d10c799_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="i2277693b6fbc4690a6679221de27b1a2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4f43e48d5ab84516a4275b0e2940ce84_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3f8e95f9bad0404484cd92bc97317806_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6fc452a116164f07ab8c6db2e41a54a2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie21cf7c43c804ff58bb10d3f479807f1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id0b70948b6ee4fedbe87831200d026b1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id950e5b1ee3743abb012a5fa0a2d1172_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id87511770e86434c8b397546525820c3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9dc0f3c260074cab9565bcf4c504aca2_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i03886d7b8ad440cf91b6f137373f3fe4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if4d088ea318046c28ff574bbc24a4539_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia3ddd1ef68df4a7491812cbb786883ba_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ifa65bad82b9e4ad2a2bd21cd489827cd_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i96feaae211f5437abfe5df9cb2556889_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i398f3cb912cc4c3b8389921c5e59690d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6a73e8597e49499c83e7d630d13b969f_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i215f3d19ff10462fac7d04a82c46e12b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7e4b14f7eb2344feb5abbff653d77cc3_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6e94cc8395934b1f8041da5f310ddcd6_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="icf12f6d5105c4cb49c04cb538332565f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i33964ca9f59949bd8a0dad9cc8ddf198_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4fa48a0f98ad4d87aab5fba5718268f5_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i87fb0d1895c24824b9493d143c45cf5f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i765953ff2adb498fa37b7ff3e73d477d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7da5cd1e28af4f31bab4ef99a9a22778_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4488d94b40c645b8b0eec4586e9ffaa1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7b3d2666a19540bd8e3b415b1e862d28_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i47a2ad7dc20e45f8a10245fcd852cd7f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia81288a6a3fa4a88a8f294d3b0df8299_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie7b7bb754ddc40bbbd810ba27db95742_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic7a3a26575a447b0a22f44539d68c78f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia08a06283a2d4d1391878f6cd94cc735_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i873ef3d6e24746a29e6379448312fad6_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i50164c6c882d42f3919eca44154397d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if0f99d002a8a4eaaa64cf919ecdea498_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia1dd1ee47d2a4d7e94466a527f95e4dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3528d13cf33844ac95aedb7d3764991c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07bca622fbaa4a77834306e2dc4158cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0c535b861b90421a981086e2092d7c25_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i115b646974a740c39cf4aca40b4727a2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i30a2c5294eeb4d659c07857d5b23eecc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5ae1bc220d124171941ce912959a757d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i843c9dde5a3b4b64b5716b83abdb8982_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic1fcf856179f4d0a8fb0794daa7e6d02_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic7b0100128e94091ac9bab9b50f79c03_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8deeaad6f2634e11b9f9c0316139d717_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6646e83b8de940969fc96333ff6a7d2a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id7c5ebc92f654f8491c5de314a112730_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i45b83d5eb6d345538b2d5d4cb90f98e1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if07042dba8294acc85fb47df8bbcc218_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7555544cb3f7417ab92209c0d2f251b7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1310705bc7ae4f78af0e8a824858b5c5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie28a26a8d7224bd8901bf199a0538658_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i40dd880b211e46408cac612575b17ac5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i35a6843fec8241b0882996b9484b444f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id09b579f33f344c7b796c94598c93ab2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie598b98bcf9d47bd8f9ada78c710b752_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad6f77124e9847649d247673b804dde9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9dc2dc2098a3453c85866e5fdf18f779_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8e14aee510204c7b89e48f9e27f07afc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idd881c372af5476a8da370cfe8309eeb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia328bcbcb2f049488186eac987fe0643_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i96c4ed6efa7740e18904bfe97dd36b05_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i47233a942abf4a268c14b15bafb9f5e0_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i312337076930421489dbae527af0c6a2_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="iba04a0b8630a43e7a31aa41fb7a542f6_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ib50ec0c321854506a6168bb676c9bb98_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="if9ec867a047842948219312d9ab1388e_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="iafb3c774af9d4c178d3cac868b3c195a_D20170602-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2017-06-02</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5c23b681d5c84ca1bf3cfe7435c3e188_D20201002-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-02</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i58709a1025434a858b79101128c97c2e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kron:AssetAcquisitionAxis">kron:GileadAssetPurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaddbc37c40784a41b4cba75355474170_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kron:AssetAcquisitionAxis">kron:GileadAssetPurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7368251cdbf04660970e56374215be24_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ica62b3a4be464cb3bc3599acf158c2ae_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icebd3a6e85524ddfae7ab2d335391a20_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if3525e299a5b4af0be5bf6819c729869_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iefc9cad03a70461aa7360544a7db02b8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3880408e89894aeda2c8f29fbbd3aabb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibf34c2cfcabc444f928cf7c4d4f21f48_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib0ea2ec1be444c429b071d6fbb31c541_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i34a2a0c9723b4043be099d02b2adcda9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i31eb8916a43d46619bd5de6a14b21fcf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic1322d5329804324b8862de983107090_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i37d7755090cf442b9c9553d09c0c78e4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3736170b03754b159e40f2cbb89bdfc6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i680604ecdff84d6583da30f5932ef047_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i98808ce4a14e4f6d9893eafb8348f14f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icae3269eca18443ca8f367f8ca760d4d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2fc21197ebfa4519b5f3821c2e7bd9cd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0c6f85d2f9144b0f9c6655f0a45deb0b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i573369416f3145549249238391de4f54_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2166333152034a59828414d7b029805f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i96c12e5ec7e247b29b2dbcedcb33e438_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i474c4138d7474661a524846e44986c19_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ieb3393bbb6f14657970ffb6c3b9bf796_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8ed0d5b5fee34c9da760299481d92409_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia3e139b86417413ba1c2ca3b42137fc7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i35673f0d42234a1a87f1a231ace9457d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie5bdf1d474b04179a7a68c046db8a473_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibd30a89a052a4593801ad15c7befa88a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iecd9407ea32a46d29a98b1840c00b5e5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4bf649645154449d937a12dc7b650d3b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if583afaf5b244bcca3ee512b9be88c54_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i84e2789cb4b74177b02829790b3e940d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37461a4dccc543c794502b870925d09a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia34dc0fe00ef4ae7b9326ac0de29b988_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f8d077e88bd4026bd1bb0363cba99a1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a45a3c22d2a4df687077e2744eeadf4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib1d31ded16544421a9103017ada1e3d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8e7dcee3fb74a77a44721d2eede0234_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4076df8add474ba29dc5b999506194be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i56e6b6f0456e4402a51dcd58d9f97704_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ideaf848d46684b1688cbb86308ac9126_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2dff33c792e472cb04f1f4a0c4177c6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i230135e8439a495f98bb16d12950f814_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6f054c8a6945414f871dddd891074dfd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i779c812cecca45018028a8b1b19645f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7fbc7564af4d4ca8ab0b6d6ee3eca9e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id4779748a74d4a69825b5e0020c5ba68_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93643158b5c54d28a5f5e8c68a1277e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6335bb67f9274f448c80b37b25c8a24b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i799ef75758464399a4c6a7a23c3f174d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b6a69f036854687b46ff68bdaa0cd34_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf3accbd97d64e20abccd18a3f976641_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9ccd829968847d0a85a4e061e73e94a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4218d1af33444d8792019dd29458c211_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1bef37ea13804aa98d20b37c8a9755f2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc6a9845420549d1b467cec0513db1ff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia172359196044363a8d21deea37250a0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica89d2973d6e42c69a454cbcfad99204_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76a3c48f37e74d588132870025f958b3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i903c1dd51d3f4f3294ec6e9659628839_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1522d2b251964ba5a986cdf9d5591a43_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if34c5b72f428403a99b45063852c073b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b10d2d52aec4721944b453f9433b17a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i62e3f25eb0c84772add6ec6f825655e0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc04e4557db74cd5a579218a21c7f715_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee26b5d7183c4798998478356fcefae4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie80dcec257aa4382b7cd1712a6f7b431_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c206960ada7462e824eea778e31e777_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i23250faf272245f5a94cf235af7afc83_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i32dc3ea144344868a7ed2a838d5f9fc6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b3898290b234512a7b35eb92edd64fb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1515d6ea7fa64e37b804f072218ceeaa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd7af7df3693489cbbd3c087fa18aa9b_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kron:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="i1737f19c2c5741778344526c60c0bf8b_I20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kron:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-22</instant>
        </period>
    </context>
    <context id="icacd7aa366554a0abf8c53a9d66b1c77_D20190701-20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="i20ce35e12ca14274b80c3a91dc888b6c_I20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-01</instant>
        </period>
    </context>
    <context id="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kron:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i72eae238362f4c8b8de479d633195c0d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idfef7d206519439a936e6eb262b31e71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kron:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1dc130be29104c028617076697807621_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3690868d9bd846d58fea672236b4ef2f_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i0bc479aee05e472aaa0315eec9166109_I20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
        </entity>
        <period>
            <instant>2019-07-01</instant>
        </period>
    </context>
    <context id="i13481663bdd345c8b1e8be6825bfce9d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f9c2bbd688841678d9a85d7983c2cfd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0730288162bf44dea2732ca595d2a797_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0d5a83c4e52a4e4b837319163fdc11bd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if6347ac3253f4253ba6ddc43e9544f3d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i608787e5e840492dac11e9916bd81793_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4c0d6cc50b8e49aca2ce81649e3efb0a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id555f67142ab472db96a2d992d964d82_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icb629f251d5f424b8c936814babcc4f6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b76d71920eb47b9b25ad42914b7f4b0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1fa6a9b2386942c4a674dfa9c9918c8a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0eb0c54a250748e2bd702dfc80c5dca5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ice6bc89ef445474790f3d6a61419f2a0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic510c74d485b4029bb4fefcd43dd7a70_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7ef266f587f64a7798fcaaa861326c3c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8b5e3dc5e7d94133a087d964992323e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i38dd8b9841e644e0a406a3e2b3439dec_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i08c6c6f783f041ae92c761672b2966aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iffb0ef90a61349be85e69f64dcaf4055_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i36ebb89160a743719ce7b11be1918ff8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:ExecutiveEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3eea990477a54f47bacea5aed627224f_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:ExecutiveEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="icd203f8d19ab4cb7ba2e8763e4797437_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7a4a632dbe23409c87fb1cb29d8c6158_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i694e0708e4ee460d962dcdf8b06c84b3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic973ed0f6744448cac474a05a81e7803_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b46cef6f87e4fecbc3caaa9619f38f5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">kron:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie3fb6aa27992434fbc43f1d769315cae_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ba0aba4eac64967a28041b82683a193_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i223930fbcee8485494d93864723c1094_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iff773b2225814be2bd54a5fabb6156f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i987eec82cc864592a298066957f8a94b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i24fc0801a2ef47149bd82ac3437499a4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie7ca6bc47f334d828c27e5e2e5f3288d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21e4dfab6f3d4306b4f260d7d24f30cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6e439c793aa6461ba7288faa23830525_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">kron:StockOptionsEarlyExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4bc87606b0ba41f9a3cf5ea58af93b90_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">kron:StockOptionsEarlyExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic5bab20c255c46269a25294cdd840266_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2bef5ce38731457493cfc788f479063e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia4dd19cf017640d5a992af85e6743b2b_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kron:AssetAcquisitionAxis">kron:GileadAssetPurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="idcdc628eb6df4f0bb5c79f1d07222825_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i7aa8d7617e6248f49f8f5e9c3f2f946d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7b189c5eff6848ada547002d5d66c700_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i486cac36f7944dbfbac5953889346c1e_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ib714cc1a7a1046e1bed70ca7b135cbda_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i88cd4588864e407facd4e99fbcae11bc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i51068c8029ef42c399d8e6f8a7fe8997_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3b0031b2310d43fd96017f1c5a5a7ecd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iafc78d3feb68447fad1581a1f5d31298_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9a405d92641543f7bddb7edda6fa1ae2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie0a507464b5342f5bf93741aebc293b7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1e7237fee96140989757ebe5aca441fa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibcb97e3d8c6848998adba729a721a4cc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icb03e961bb854f9fa74406cd020a41d8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7d9088eb63e343bf87263a6d2eacd1cc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i620aab95020a4e98b682a7a22af3c0a7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0f897da9f4b94b72b44c2e02de325360_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7c0e7dc1935d48da9c69163a1164cb59_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iac4e5e570b0944eaa1dd8ba60b2886df_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if1ced39808984c03a296264c3ea65adc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i851ff4900ea249cda09f664b0212918d_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ia99e131dd6404121b4e194d9356f67ad_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i616172ed102541feb61d3c1b5cead753_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ib79a6a6966a34788a0429125557e239f_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="idd88330648594bcabdc951197524d855_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i631c46c59d354aa580f1ad4e832c8861_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ib2666b9ac19e49baab7aca87809bf7c6_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ib728710261c742538e0fcb8346b1c830_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i86502c45f58b4b9f9337f25a9ea085a3_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ibcfcef6f36724f44b53de7181f6c587d_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i001fd52a7b1e4106a06c40add33e03e1_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FundraiseScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i17af873f453147b4b57bd13a9c4f867d_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i163397f07fc24c7fa96b425b3dae61a6_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i9a50cdf7028c44ca97bad3a2559a8ea7_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationCashPayoutScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i0c37e34655d34543ac8add2eaa2cbb87_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:LiquidationConversionScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ib041367f98b84d5faa59bdf5673a3592_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:A21ErieStreetCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1a92a2894224488c9e94058000096ced_I20200301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:A301BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-01</instant>
        </period>
    </context>
    <context id="i8f951b9cc2d342b394ec7ff04e4d40a9_D20200301-20200301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:A301BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-01</endDate>
        </period>
    </context>
    <context id="i4b773488624d4ae486e3123cdebd12c2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:A301BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3234c4fd018b4ff6ae61cebd2fd7b666_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="idad0893c755d45138461981a7756615e_I20180801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-01</instant>
        </period>
    </context>
    <context id="icffc314b519d440aa9f7fa06b641a760_D20180801-20180801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-01</endDate>
        </period>
    </context>
    <context id="i6517aa7d879f44528a2d88e8c188d509_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i676113738ba64cf9bfb99cf6d7419962_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i623e9b9d16b249bda0eeafb5a7270517_I20200701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaAdjacentSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="i3b09b6cd908145558102a1d2ebca38a9_D20200701-20200701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaAdjacentSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">kron:SanMateoCaliforniaAdjacentSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifbecda89de7840548904aa4dd3124d22_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kron:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i77faf9def6034a17a43362f8c79b789c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">kron:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i07a7c2fa9dca4beab08872d278639b3d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">kron:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iff1ad401e98742ddb6abcc5503e71ad1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">kron:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id688172e6cde48eeae48e9a213f81cb5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">kron:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ieed7f26a9c4d41b290ef0ca4f65ed6b7_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ie0b7d39d86434ec791e9c67d78593194_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ie5ac0bb41ed144069f9ed35f0501c5ff_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i4ea6fedb22e248bdb67c280feee123df_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i7f6001b206b54c728c11f91d8f95efb7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i32a5d81edc2c45aaa7af987dd2ec57b2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:SeriesBScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iee8c0d66302445e9a58d268bbad55dc8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FinancingScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7d56dfa261f8415b8e8a2412f974446b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i48c80af886534e0e839a947a487fabc6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:SeriesBScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i15541111cc0147dcaa8140563fa4f2f2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FinancingScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i23666d2a49a44d07afcdc32b368ec048_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:IPOScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i81df50dc201b4b8ea1c8247921d8ca17_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:SeriesBScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i35f23e6018f34b819e4f9ad667f5b07e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kron:MeasurementInputWeightingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kron:SettlementPlanAxis">kron:FinancingScenarioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0c9e8411b1234b0ea5b11006c170b729_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i19dd6da6c7b34b17b50df3ce81d9dd81_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i732fa4350e424f4bb60a16a35c6aa5cf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:ConvertibleNotesPayable2020NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i013165bd63c141f78e3b0ec48d6aeb39_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b1c4ce7e09f4609b89a6586759b8444_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id2997d3b39e44c049e46716565e334c4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9e930125986d43ccab7955e01aa7d87f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifef3396d498f4831ab1ac220e09caad2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7e707633da84487498c2674c190517d8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0d8ea9d54ffb45dc8de4f5d3a62c8776_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i51fbcc82facb4e78bbf3571c3a7b333b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if2696f8ecf0246daa8d17d75de9abb4d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1fbdca86d2ea46a5a02388d0823daea8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc38fa9749f94b56b8bd462c4e5b894b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:BellcoCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i447ffc13a5e74bdf9f0ed1c954749058_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:BellcoCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3a3abdc990ab4085bba504ea15586fb0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:BellcoCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib6bc7aed10264332996827a2e1c4b226_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kron:BellcoCapitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i75d1b3f7102a450088f5769228278051_I20201014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-14</instant>
        </period>
    </context>
    <context id="i354b6c38321f418e8ea03e729e783986_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ide813d6d56e94d6eab30a8e7472b2e0d_I20201008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:A2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-08</instant>
        </period>
    </context>
    <context id="ia5bf533181c044de8807c924d489d6e6_I20201008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kron:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-08</instant>
        </period>
    </context>
    <context id="if63f36e0c9f049a4a09953343fbdb606_D20201001-20201118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-11-18</endDate>
        </period>
    </context>
    <context id="ifd40f9ae2ea3456890d775273e5e0e55_D20201001-20201118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kron:A2020GileadNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-11-18</endDate>
        </period>
    </context>
    <context id="i2ac6a536633140c584616f4aaff231e3_I20201118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001741830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">kron:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-18</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>kron:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzMtMS0xLTEtMjIwNA_5c7ea0df-1340-496a-be95-43aba84ffc40">0001741830</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzQtMS0xLTEtMjIwNA_85f1a89b-fab3-4e72-9407-aba8ccd70fca">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzUtMS0xLTEtMjIwNA_20cb3805-01ed-4075-af6e-3bead042d50e">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzYtMS0xLTEtMjIwNA_a647f88a-2b08-433c-8aac-bd76fde83842">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NTkvZnJhZzpiMjU1YmViZWE5YzM0MjIwYjNlNDk3MDhiY2JkZjIyYS90YWJsZToyYWY0YThjZDEwMDQ0NDAwYmQxMTIxMjBlOThmYWM4MC90YWJsZXJhbmdlOjJhZjRhOGNkMTAwNDQ0MDBiZDExMjEyMGU5OGZhYzgwXzctMS0xLTEtMjIwNA_b5a44acb-1636-4bca-b801-d0d86c3b4efd">false</dei:AmendmentFlag>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84MzkvZnJhZzo0YzcwMmZlZTU3Zjk0OTRkYTY3YTEzYjdkNDI2N2QwZi90YWJsZTpjODJiZjQxYTdjZTE0YTMyOTIzODJkOGIxMTUzNjVlZi90YWJsZXJhbmdlOmM4MmJmNDFhN2NlMTRhMzI5MjM4MmQ4YjExNTM2NWVmXzItMS0xLTEtMTA0OTY_145d7972-71a7-4821-980c-6bbdef49232d">P10Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84MzkvZnJhZzo0YzcwMmZlZTU3Zjk0OTRkYTY3YTEzYjdkNDI2N2QwZi90YWJsZTpjODJiZjQxYTdjZTE0YTMyOTIzODJkOGIxMTUzNjVlZi90YWJsZXJhbmdlOmM4MmJmNDFhN2NlMTRhMzI5MjM4MmQ4YjExNTM2NWVmXzQtMS0xLTEtMTA1MTk_b701b4c6-8e94-4c2f-bd6d-2f93001e8c5b">P4Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <dei:DocumentType
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA4OTI1_bc86c5b7-87ef-449c-b29b-3ee55d6b5c07">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4MQ_1f726a62-ba3d-4163-a2ef-5ab3e98543aa">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA4OTI4_b325ed50-00ef-4ead-8b06-8972107f7af5">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4Mg_bd27019c-f65d-4471-8c43-6a9a85183ee0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA5Njc2_656be3b3-0b8a-450a-ba2f-3a4d18043734">001-39592</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA4OTI2_91c60985-a4c0-4b60-9473-8e1d855053fa">Kronos Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDIyYTU4NjQzMGM2NGU1MTliZWZhNjMxYjE4NGQ4YjUvdGFibGVyYW5nZTpkMjJhNTg2NDMwYzY0ZTUxOWJlZmE2MzFiMTg0ZDhiNV8wLTAtMS0xLTIxODI_fd9b3512-7e2f-495c-9390-bcea504ccffe">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDIyYTU4NjQzMGM2NGU1MTliZWZhNjMxYjE4NGQ4YjUvdGFibGVyYW5nZTpkMjJhNTg2NDMwYzY0ZTUxOWJlZmE2MzFiMTg0ZDhiNV8wLTEtMS0xLTIxODI_7b47963c-fb24-41a3-ba28-85ac2431b818">82-1895605</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4Mw_8bfe4e9e-25d5-418f-9d13-28c211fea704">1300 So. El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4NA_a8b7ea4c-a080-4e61-aa66-1f0b1bf06500">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4NQ_97570029-bf73-4294-b4fe-a49eb205d3dc">San Mateo</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4Ng_c1901580-d8ca-42d9-bf1a-d3f513586556">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI4OA_323436bd-548b-41b6-b92e-0982509f6fa4">94402</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI5NQ_24fcad6f-da45-4046-91b4-fcf6921add6c">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjI5OQ_8271fed2-eaee-4365-a006-01413c554655">781-5200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDYzMDg4OTRkZTdjNGYyYTkyNDNkZWU1ZjM4NjM5YjAvdGFibGVyYW5nZTpkNjMwODg5NGRlN2M0ZjJhOTI0M2RlZTVmMzg2MzliMF8xLTAtMS0xLTIyODA_a48193e4-ee07-4a02-990d-86883c32d99f">Common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDYzMDg4OTRkZTdjNGYyYTkyNDNkZWU1ZjM4NjM5YjAvdGFibGVyYW5nZTpkNjMwODg5NGRlN2M0ZjJhOTI0M2RlZTVmMzg2MzliMF8xLTEtMS0xLTIyODA_56d2727a-4565-49a9-891f-c39a0d19975a">KRON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6ZDYzMDg4OTRkZTdjNGYyYTkyNDNkZWU1ZjM4NjM5YjAvdGFibGVyYW5nZTpkNjMwODg5NGRlN2M0ZjJhOTI0M2RlZTVmMzg2MzliMF8xLTItMS0xLTIyODA_a388e54c-cc60-4d37-a901-e75caa11cea8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV83Njk2NTgxNDA5NzE5_06546c8e-aa5c-4cd1-8a92-54ff41b13716">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjMxMg_e0d2a824-8274-490c-a19e-551fb1e37f12">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6YTBmOTQ4OGI5ZTNlNDk2ZTllZmUxODBiNzhlMWQ4ZmYvdGFibGVyYW5nZTphMGY5NDg4YjllM2U0OTZlOWVmZTE4MGI3OGUxZDhmZl8wLTMtMS0xLTIyNjg_d4074c26-2eec-4484-8352-89302a1ebd36">false</dei:EntitySmallBusiness>
    <dei:EntityFilerCategory
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6YTBmOTQ4OGI5ZTNlNDk2ZTllZmUxODBiNzhlMWQ4ZmYvdGFibGVyYW5nZTphMGY5NDg4YjllM2U0OTZlOWVmZTE4MGI3OGUxZDhmZl8xLTAtMS0xLTIxODU_f957bdbd-1d58-4241-9d87-f288109257b5">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGFibGU6YTBmOTQ4OGI5ZTNlNDk2ZTllZmUxODBiNzhlMWQ4ZmYvdGFibGVyYW5nZTphMGY5NDg4YjllM2U0OTZlOWVmZTE4MGI3OGUxZDhmZl8yLTMtMS0xLTIyNjE_0fe14b87-3bb2-4c41-8c55-e8bf51a13f8a">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjMxMw_d44f9000-cf5a-493f-94de-46b83a2b423c">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8xMDk5NTExNjI5MjMxMA_f3a80d41-37cb-4812-b121-49f004226dcf">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic875b4ec6f6440d5a5659f163d10c799_I20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xL2ZyYWc6YjNjZDU1NDFmYWVmNDg2MmE1NjUzYzJjNjdiZTBlZDUvdGV4dHJlZ2lvbjpiM2NkNTU0MWZhZWY0ODYyYTU2NTNjMmM2N2JlMGVkNV8yNzQ4Nzc5MDg0Njgy_1b8a6ad7-4541-414d-b364-93ba149f2021"
      unitRef="shares">56033504</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNC0xLTEtMS0w_fbbeefba-e23e-4c5c-9f0d-fa990c2632b7"
      unitRef="usd">156196000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNC0zLTEtMS0w_398e2a31-5dad-4e0e-a749-cfb32aafa8c2"
      unitRef="usd">32570000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNS0xLTEtMS0w_c22331bb-5b5f-45d3-9e43-d49766fdc063"
      unitRef="usd">55069000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNS0zLTEtMS0w_752d2bc5-71cf-447b-a301-5119a2ce6b62"
      unitRef="usd">59614000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNi0xLTEtMS0w_0738f9e2-da26-44d7-860a-4897e688b662"
      unitRef="usd">1628000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNi0zLTEtMS0w_df2df7a5-df8d-4c50-b410-d192c470f3ba"
      unitRef="usd">1119000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNy0xLTEtMS0w_f25e69b7-c79b-4f8b-bdb2-52480cccc52d"
      unitRef="usd">212893000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNy0zLTEtMS0w_7b294014-cf51-4f5d-abac-68c1e70d5d4a"
      unitRef="usd">93303000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOC0xLTEtMS0w_fa966a65-0f96-45d9-a427-b91ea253adf6"
      unitRef="usd">4774000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOC0zLTEtMS0w_5b95e419-e2ea-434e-833a-e07994cad3b6"
      unitRef="usd">4762000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOS0xLTEtMS0w_e997dc1b-20f1-4df2-ab4c-aed400da5ea7"
      unitRef="usd">10301000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOS0zLTEtMS0w_af194b14-52ad-4435-8abc-ada345b8a0a3"
      unitRef="usd">3721000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTAtMS0xLTEtMA_53b1dc3f-64db-41d8-9ba0-6412f1415ea4"
      unitRef="usd">29355000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTAtMy0xLTEtMA_8f4a915b-acb5-498f-bbff-81d6ed20c39c"
      unitRef="usd">473000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTEtMS0xLTEtMTcx_577cdd16-eb01-4310-9471-49272cc0d7dd"
      unitRef="usd">2026000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTEtMy0xLTEtMTc1_238e1a5e-cfcb-4dfc-93ac-9e82ee1ea9b1"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTItMS0xLTEtMA_55afc55a-8259-49ed-ab01-f91a57785470"
      unitRef="usd">3207000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTItMy0xLTEtMA_c5bdbdb7-9e21-44ad-8ac8-e2ab8ec88e9e"
      unitRef="usd">427000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTMtMS0xLTEtMA_b4a63fc9-2b36-4774-8b82-75391ddf5a47"
      unitRef="usd">262556000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTMtMy0xLTEtMA_9276a3d8-cc19-42c6-b38f-6cfc9f4c097f"
      unitRef="usd">102686000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTYtMS0xLTEtMA_5c578959-5ea6-4e7c-bd9a-4b6a1ca9f980"
      unitRef="usd">4443000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTYtMy0xLTEtMA_8035d86e-f487-45d9-8e4b-7ecba505e96e"
      unitRef="usd">1506000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMS0xLTEtMA_bc21192b-e6d5-4628-92b3-20d15845aa3d"
      unitRef="usd">1780000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtMA_d05a5384-e248-4030-a9cf-17cdd1ccf138"
      unitRef="usd">818000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMS0xLTEtODQ2_3d241ef7-eaea-4c61-8eca-43fe73b163ba"
      unitRef="usd">173944000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtODQ2_252d2175-5e02-4f30-827b-5a392ef0b3fe"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTgtMS0xLTEtMA_2cdffab6-3cf7-42d4-a298-684fbef2db12"
      unitRef="usd">1300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTgtMy0xLTEtMA_414422d2-b987-4a31-90f8-d3a1822608ff"
      unitRef="usd">285000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTktMS0xLTEtMA_cf4a583d-3795-4a8f-b59a-20854a1b3b17"
      unitRef="usd">2137000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTktMy0xLTEtMA_5df9ec80-449c-4bc2-9cd5-fde54eefbebe"
      unitRef="usd">88000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjAtMS0xLTEtMA_574b665f-c3ff-46e1-8ac9-91e8f3fe82ed"
      unitRef="usd">183604000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjAtMy0xLTEtMA_6d8f280b-3a43-4309-a1c7-f19dde7db983"
      unitRef="usd">2697000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjEtMS0xLTEtMA_6c878bd8-c949-4e68-a7a1-8cf8530c871b"
      unitRef="usd">29484000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjEtMy0xLTEtMA_f84feb2d-73c3-4aba-9559-c0ead7335b39"
      unitRef="usd">211000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjItMS0xLTEtMA_989009cf-2e07-4d7d-b1eb-057726473ccb"
      unitRef="usd">2841000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjItMy0xLTEtMA_7336a50e-0972-47cb-b658-c50350b82e43"
      unitRef="usd">74000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjMtMS0xLTEtMA_9b6cd3ef-875d-436c-a57c-1d0bbf0d05c0"
      unitRef="usd">215929000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjMtMy0xLTEtMA_6db15a62-3bd4-461c-a3e1-cfe3c6484b36"
      unitRef="usd">2982000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjQtMS0xLTEtMjMyNg_d80f4d6a-ae69-4b1b-87fe-2afe6ed70180"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjQtMy0xLTEtMjMyNg_adb29f22-92ac-48ab-ad38-e05bc106e22c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTMx_b659a2f7-54ab-4fe5-bdc7-677c467b986f"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTMx_fbd37fdd-7d4a-411b-9ff7-7038f049aa5d"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTQ0_9f47fabd-94e9-4b18-8edf-fea021dcb145"
      unitRef="shares">21506977</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTU3_caac549b-9462-47a8-a19e-ab521f5e010b"
      unitRef="shares">21506977</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTY5_0f275e9b-ee6d-40ff-a3da-8e2c1be3520d"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTY5_332d7641-032a-46e2-a61a-a4f516d37d7d"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTgz_b83fbdfb-21b4-49dc-ad9b-b6e69c7a7a31"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTgz_c678ef70-5044-4789-a0ea-8fe3f5224199"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MTk0_9bfae45e-1480-46ef-a5a2-cfa8940e5343"
      unitRef="usd">123016000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmRlMDU3MjcxOGUzMjQwM2FhNzJmZjAyMzRjYjgxMzZjXzEwOTk1MTE2Mjc4MjA1_a523fa16-3acd-4bf6-8842-b83a01e29fd3"
      unitRef="usd">123016000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMS0xLTEtMA_c17b20c9-e158-4ab9-88e1-1fa86019de4c"
      unitRef="usd">122907000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMy0xLTEtMA_c07a24f2-af19-4588-ae47-664036655373"
      unitRef="usd">122907000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzEwOTk1MTE2Mjc4MTAw_a0ebb75e-830c-4223-8690-5663fe047e00"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzEwOTk1MTE2Mjc4MTAw_b0b88bd1-0730-4f95-b7b5-a773de1b394e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzI3NDg3NzkwNjk3MDk_0f4bd288-aa25-4bdd-b902-704780699eb8"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzI3NDg3NzkwNjk2OTY_c0fb3cd9-6f60-4b09-99c8-80de2f30ac46"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzMyOTg1MzQ4ODM2MzQ_710c7f4e-5cb0-4eb5-8489-33759bb2ce58"
      unitRef="shares">6284326</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzMyOTg1MzQ4ODM2MzQ_81e42231-5184-4ee5-9738-73eacfa3078c"
      unitRef="shares">6284326</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzMyOTg1MzQ4ODM2NDY_b1a4f1c4-65c3-4873-990d-f540cf8f64a4"
      unitRef="shares">5660391</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmQ5OTMyNjFiNWI4YjQzOTZiMmU1NjhmOTI1NTg3NmJkXzMyOTg1MzQ4ODM2NDY_c2968248-1163-4492-8d5b-2fbed1dbf96e"
      unitRef="shares">5660391</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMS0xLTEtMA_bed538c9-f98f-4b0a-9c8b-cb44932eb3f5"
      unitRef="usd">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMy0xLTEtMA_45216b21-6194-4072-a7f8-9dee72f84077"
      unitRef="usd">6000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjgtMS0xLTEtMA_fea2efbf-1558-4020-ab93-56e6243c62c2"
      unitRef="usd">2416000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjgtMy0xLTEtMA_303524e9-a85d-41a3-bff2-33bd1fe342e2"
      unitRef="usd">271000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjktMS0xLTEtMA_671f5bf9-f968-4b57-b8f0-77b6355c92aa"
      unitRef="usd">-78749000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjktMy0xLTEtMA_f4797447-8a55-441e-9d79-ec2e08d271ea"
      unitRef="usd">-23462000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzAtMS0xLTEtMA_8383369e-2487-49f5-91a4-61efa1536427"
      unitRef="usd">47000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzAtMy0xLTEtMA_87a8dcbc-3d64-46d4-9cc5-e3d3fcc55f25"
      unitRef="usd">-18000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzEtMS0xLTEtMA_92cdf59e-e33d-4c27-8e67-c49baa4109f4"
      unitRef="usd">-76280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzEtMy0xLTEtMA_0ca701ee-1ad6-4424-b3dd-17217e95139c"
      unitRef="usd">-23203000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzItMS0xLTEtMA_d9f897c5-4a76-4f6d-be48-a80e5f6045a5"
      unitRef="usd">262556000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzItMy0xLTEtMA_a61ba345-c4d1-4570-b74e-56cf78a59d83"
      unitRef="usd">102686000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNC0xLTEtMS0w_dc61e6fe-6b93-4b00-82d9-20b50213f60a"
      unitRef="usd">16755000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNC0zLTEtMS0w_b677717b-49a2-4669-af68-5cc62f322972"
      unitRef="usd">3526000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNC01LTEtMS0w_17414d4f-5ed9-4b69-97d8-52d24e96d79d"
      unitRef="usd">30125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNC03LTEtMS0w_6e57eb4a-cfa5-4231-887c-037b8a7cd753"
      unitRef="usd">8698000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNS0xLTEtMS0w_ab3912ce-cd26-4742-9bc8-db57e650fa5e"
      unitRef="usd">4054000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNS0zLTEtMS0w_a30394c6-f6f4-44ec-b581-040aec78d21f"
      unitRef="usd">797000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNS01LTEtMS0w_e383d446-ac1e-4145-8083-a34d77ef9ea6"
      unitRef="usd">6831000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNS03LTEtMS0w_9d6538a3-3f17-4aa5-a18d-1177ca734f7c"
      unitRef="usd">2262000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNi0xLTEtMS0w_0c6e829a-bc7a-4885-9f6d-7d1fb9d557fa"
      unitRef="usd">20809000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNi0zLTEtMS0w_b773b31b-4b18-4f1c-875d-32b729ef46bc"
      unitRef="usd">4323000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNi01LTEtMS0w_aa8ccc8d-4f79-409c-be6f-c8ba7e25c71f"
      unitRef="usd">36956000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNi03LTEtMS0w_80bd24eb-d386-41d3-b3a2-1ad110ffabb4"
      unitRef="usd">10960000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNy0xLTEtMS0w_eba211b4-6161-43bc-97cb-ad3f2f25b464"
      unitRef="usd">-20809000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNy0zLTEtMS0w_c5667a4b-b9e1-43a9-9da5-df93398e6bd0"
      unitRef="usd">-4323000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNy01LTEtMS0w_60aeaf38-4d8c-4760-8208-7e0d58c9565d"
      unitRef="usd">-36956000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfNy03LTEtMS0w_55c48669-73c5-4500-8063-8bb93b26589e"
      unitRef="usd">-10960000</us-gaap:OperatingIncomeLoss>
    <kron:NotesPayableFairValueGainLoss
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC0xLTEtMS0yOTg3_cc825369-182a-4330-b128-3b6355a2494b"
      unitRef="usd">-15215000</kron:NotesPayableFairValueGainLoss>
    <kron:NotesPayableFairValueGainLoss
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC0zLTEtMS0yOTg3_5360de3b-7377-4f49-a180-83a5d3cc4807"
      unitRef="usd">0</kron:NotesPayableFairValueGainLoss>
    <kron:NotesPayableFairValueGainLoss
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC01LTEtMS0yOTg3_51045922-41e6-4f26-863b-8804af682d29"
      unitRef="usd">-15215000</kron:NotesPayableFairValueGainLoss>
    <kron:NotesPayableFairValueGainLoss
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC03LTEtMS0yOTg3_1fed9771-4b4b-439f-8f52-025fecd447eb"
      unitRef="usd">0</kron:NotesPayableFairValueGainLoss>
    <us-gaap:InterestExpense
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS0xLTEtMS00ODU5_1629a4a9-111c-4978-934d-accf05cff5b7"
      unitRef="usd">3889000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS0zLTEtMS00ODU5_0e3aa208-4671-4ef9-86f2-c30de168713c"
      unitRef="usd">1000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS01LTEtMS00ODU5_e86f340e-de74-4edc-b16a-8974c30c5018"
      unitRef="usd">3890000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS03LTEtMS00ODU5_edd65273-d99a-447a-a8b5-5436176115ab"
      unitRef="usd">3000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC0xLTEtMS0w_fe1f8511-344a-4263-98d6-06e05f2bd78b"
      unitRef="usd">200000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC0zLTEtMS0w_dca4cfa7-905a-4364-a262-8e1c7d150063"
      unitRef="usd">311000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC01LTEtMS0w_4f61f360-2f56-4298-b360-6bf93e1225b6"
      unitRef="usd">774000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOC03LTEtMS0w_290a262c-a205-4d7d-9a19-63aeccbcd6c9"
      unitRef="usd">311000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTAtMS0xLTEtMjk4Nw_80e5740e-65af-44a8-8d24-104b0906a753"
      unitRef="usd">-18904000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTAtMy0xLTEtMjk4Nw_31b50767-e752-4641-80e1-54f674a57d05"
      unitRef="usd">310000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTAtNS0xLTEtMjk4Nw_5e3b47d1-a0db-4032-88c8-41534aaa03c7"
      unitRef="usd">-18331000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTAtNy0xLTEtMjk4Nw_2235932e-af25-4f20-996d-ec93c0216d31"
      unitRef="usd">308000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS0xLTEtMS0w_88f77181-d567-4cc3-9334-bfcb523f9219"
      unitRef="usd">-39713000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS0zLTEtMS0w_c5072f48-1bb0-4355-b34f-97a3eb4657eb"
      unitRef="usd">-4013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS01LTEtMS0w_5796d762-6a4b-48e5-a6a4-dd121865e471"
      unitRef="usd">-55287000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfOS03LTEtMS0w_c0813a67-76bb-4c30-9a01-95b527db52f4"
      unitRef="usd">-10652000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTEtMS0xLTEtMA_bf7d46b9-6f33-423e-89ce-102bf370a95c"
      unitRef="usd">-117000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTEtMy0xLTEtMA_3961fd05-80b0-4fa3-86d3-a602421bd477"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTEtNS0xLTEtMA_b05de2f2-6522-469a-8d42-e7050666380c"
      unitRef="usd">65000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTEtNy0xLTEtMA_e6bfe4b0-0ca8-4b69-8e9a-af97095fb2fd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTItMS0xLTEtMA_19c68600-c986-49af-b96e-f22158383b66"
      unitRef="usd">-39830000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTItMy0xLTEtMA_9f9ea0e2-8197-44da-879e-c5211c23d1ea"
      unitRef="usd">-4013000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTItNS0xLTEtMA_8f3181ab-4e6e-4fd7-bdb1-0b448c8e17c2"
      unitRef="usd">-55222000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTItNy0xLTEtMA_044a5525-f826-4b2a-a022-9b65c2e4aa72"
      unitRef="usd">-10652000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTMtMS0xLTEtMA_2eb7b5fe-9138-4cae-8f72-ed0bada4381e"
      unitRef="usdPerShare">-6.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTMtMy0xLTEtMA_2502b6fe-52f5-4ffd-8c9f-2837bd017e46"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTMtNS0xLTEtMA_1ce587b1-0429-40ea-ac62-e3b90a5d9eb1"
      unitRef="usdPerShare">-9.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTMtNy0xLTEtMA_bf69a86d-279d-4904-bdbe-64cb99e02015"
      unitRef="usdPerShare">-2.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTQtMS0xLTEtMA_23aa5311-491d-4bc7-95bd-48262c6c2042"
      unitRef="shares">6127146</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTQtMy0xLTEtMA_4d5648a6-9cb1-4ba0-9f62-758a0193949a"
      unitRef="shares">5409433</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTQtNS0xLTEtMA_6576a178-862c-453e-ad34-e846a0be79d0"
      unitRef="shares">5886191</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85MS9mcmFnOmFiOWRlNDE3MWI5ZTQ4MmE4MTMxZWY2YzJiNTdiYzg4L3RhYmxlOjAyYzcyYjYyYjUwZTRlNGFhNDcwZGIxZWM0Zjk4OWM4L3RhYmxlcmFuZ2U6MDJjNzJiNjJiNTBlNGU0YWE0NzBkYjFlYzRmOTg5YzhfMTQtNy0xLTEtMA_4e780dee-bfba-4d67-b42a-88f22c69e106"
      unitRef="shares">5196681</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i3f8e95f9bad0404484cd92bc97317806_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xLTEtMS0w_984e4b30-98f7-4617-8900-12b255e52cf8"
      unitRef="shares">7806977</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i3f8e95f9bad0404484cd92bc97317806_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0zLTEtMS0w_6091afd9-2552-4f9a-9b99-d1ff389eb878"
      unitRef="usd">17985000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i6fc452a116164f07ab8c6db2e41a54a2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi02LTEtMS0w_edf40f62-cbc9-47e7-88c8-898b0ef9508a"
      unitRef="shares">4966227</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6fc452a116164f07ab8c6db2e41a54a2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi04LTEtMS0w_c06c4e2a-9169-4982-9903-a8d0415c1a60"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie21cf7c43c804ff58bb10d3f479807f1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xMC0xLTEtMA_21952b69-be67-4270-a649-b9bc6f811eff"
      unitRef="usd">44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0b70948b6ee4fedbe87831200d026b1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xMi0xLTEtMA_0a12e6c2-cef6-4918-b422-5f6d3c66764b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id950e5b1ee3743abb012a5fa0a2d1172_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xNC0xLTEtMA_ede0694b-8b3a-45a5-8927-6002e1335c5f"
      unitRef="usd">-7345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f8e95f9bad0404484cd92bc97317806_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMi0xNi0xLTEtMA_9a404019-2c26-4e1c-a4ff-4cc8289ca05c"
      unitRef="usd">-7296000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id87511770e86434c8b397546525820c3_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMy02LTEtMS0w_938e94c7-65b1-4942-bb85-7528be0c0b0f"
      unitRef="shares">29704</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9dc0f3c260074cab9565bcf4c504aca2_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMy0xMC0xLTEtMA_ba1792c0-6c4e-46a2-93b3-9d0ba8ede06e"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i03886d7b8ad440cf91b6f137373f3fe4_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMy0xNi0xLTEtMA_f5a90754-fab8-45da-bfd8-f8be59c8bcde"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9dc0f3c260074cab9565bcf4c504aca2_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNC0xMC0xLTEtMA_143ca5cb-d1d1-4925-b8af-2856be07e3f1"
      unitRef="usd">16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i03886d7b8ad440cf91b6f137373f3fe4_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNC0xNi0xLTEtMA_260e2104-13f7-4ad1-9065-abf2d1c2c169"
      unitRef="usd">16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="if4d088ea318046c28ff574bbc24a4539_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNS0xNC0xLTEtMA_27340155-582b-46e9-b9ba-9e203cafe8f0"
      unitRef="usd">-3130000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i03886d7b8ad440cf91b6f137373f3fe4_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNS0xNi0xLTEtMA_efc42f6e-f3d7-456f-921d-baf90000782b"
      unitRef="usd">-3130000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ia3ddd1ef68df4a7491812cbb786883ba_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xLTEtMS0w_12eb3266-ed6b-4660-a415-232297aa9a6f"
      unitRef="shares">7806977</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ia3ddd1ef68df4a7491812cbb786883ba_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0zLTEtMS0w_43d88cb7-7017-4f14-9076-a422f764a5d7"
      unitRef="usd">17985000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="ifa65bad82b9e4ad2a2bd21cd489827cd_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi02LTEtMS0w_eff8655c-a10b-4245-868e-9a6c6d20a7b2"
      unitRef="shares">4995931</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifa65bad82b9e4ad2a2bd21cd489827cd_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi04LTEtMS0w_269dfbf6-bf1c-49e3-94ed-ee8aa20fb602"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96feaae211f5437abfe5df9cb2556889_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xMC0xLTEtMA_58b0f0d2-079f-4fb4-a966-f417c99bdaba"
      unitRef="usd">61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i398f3cb912cc4c3b8389921c5e59690d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xMi0xLTEtMA_5952dd7c-accc-489e-a92a-c5ac938250e0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a73e8597e49499c83e7d630d13b969f_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xNC0xLTEtMA_42c979d3-31fd-4508-b54f-30bacbb2e9a8"
      unitRef="usd">-10475000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3ddd1ef68df4a7491812cbb786883ba_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNi0xNi0xLTEtMA_4e4c7985-e541-4a8a-9125-87bb4410ce25"
      unitRef="usd">-10409000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i215f3d19ff10462fac7d04a82c46e12b_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNy02LTEtMS0w_0d5bf34e-b2e2-4000-b14c-11cf963e73be"
      unitRef="shares">386239</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7e4b14f7eb2344feb5abbff653d77cc3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNy0xMC0xLTEtMA_60a6e48a-0886-4882-a8de-ec51c5a2685f"
      unitRef="usd">45000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfNy0xNi0xLTEtMA_9fa7d169-0274-45eb-9c29-65dee8be0623"
      unitRef="usd">45000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7e4b14f7eb2344feb5abbff653d77cc3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOC0xMC0xLTEtMA_74b8b0ab-b42b-4acf-a5ff-e6b1a87c4747"
      unitRef="usd">21000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOC0xNi0xLTEtMA_2b9af085-b555-42f3-bb2d-38869caf10d1"
      unitRef="usd">21000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i6e94cc8395934b1f8041da5f310ddcd6_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOS0wLTEtMS0yNTUvdGV4dHJlZ2lvbjozMmI2MzlhN2FiZmI0YWUxYTEyMzU1Njk1ZWZjNDU1Zl83Njk2NTgxMzk0NTM4_59dddc61-c7d7-448e-8c8d-c6c9ab5102d9"
      unitRef="usdPerShare">7.67</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="icf12f6d5105c4cb49c04cb538332565f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOS0wLTEtMS0yNTUvdGV4dHJlZ2lvbjozMmI2MzlhN2FiZmI0YWUxYTEyMzU1Njk1ZWZjNDU1Zl83Njk2NTgxMzk0NTQ0_adde5abb-70f6-46bd-b2fd-c945b4fea0dc"
      unitRef="usd">70000</us-gaap:PaymentsOfStockIssuanceCosts>
    <kron:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOS0xLTEtMS0w_5dfc7f83-42e8-4d87-96e9-826ac6e1f47d"
      unitRef="shares">7142488</kron:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfOS0zLTEtMS0w_a474c307-e631-486c-9da0-e70458942334"
      unitRef="usd">54680000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="i33964ca9f59949bd8a0dad9cc8ddf198_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTAtMTQtMS0xLTA_09d12a05-8618-4258-9ed0-95109971a4bd"
      unitRef="usd">-3509000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia1f06f75beb9477a8272c59298b5b74f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTAtMTYtMS0xLTA_de6a4b8d-1b96-4e95-b450-52f8d78cb8c7"
      unitRef="usd">-3509000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6e94cc8395934b1f8041da5f310ddcd6_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMS0xLTEtMA_82e17432-f720-4f3c-8631-89762830a5fd"
      unitRef="shares">14949465</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i6e94cc8395934b1f8041da5f310ddcd6_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMy0xLTEtMA_66cac36a-602f-49e5-9dc7-844f2ca9865d"
      unitRef="usd">72665000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i4fa48a0f98ad4d87aab5fba5718268f5_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtNi0xLTEtMA_bce12331-2dff-49fc-958e-7273e670a297"
      unitRef="shares">5382170</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4fa48a0f98ad4d87aab5fba5718268f5_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtOC0xLTEtMA_719aa294-cb84-4c87-a48d-6fc45495ad7c"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87fb0d1895c24824b9493d143c45cf5f_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMTAtMS0xLTA_43b50502-0873-40aa-84b2-05af0d390ebc"
      unitRef="usd">127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i765953ff2adb498fa37b7ff3e73d477d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMTItMS0xLTA_ef10b6f4-00d0-49cb-9ff2-bc0c6770a67e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7da5cd1e28af4f31bab4ef99a9a22778_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMTQtMS0xLTA_aaa8b0f0-8e82-44ba-ac1f-b4ee5475ca03"
      unitRef="usd">-13984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e94cc8395934b1f8041da5f310ddcd6_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTEtMTYtMS0xLTA_08e7db54-0062-4ea0-8feb-bb784cea3527"
      unitRef="usd">-13852000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4488d94b40c645b8b0eec4586e9ffaa1_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTItNi0xLTEtMA_03dd3b52-7886-4067-876f-dded44a9e39c"
      unitRef="shares">106091</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7b3d2666a19540bd8e3b415b1e862d28_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTItMTAtMS0xLTA_18d9bef3-dc5b-440e-bfd0-81763f2ecefa"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTItMTYtMS0xLTA_fccab8c7-ba40-4adf-8a7d-336344bca669"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7b3d2666a19540bd8e3b415b1e862d28_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTMtMTAtMS0xLTA_5388efa5-7b67-4459-98ad-8080bcf9c6e1"
      unitRef="usd">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTMtMTYtMS0xLTA_1ea1045e-63b4-425a-b101-f1ac1d1e182e"
      unitRef="usd">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTQtMC0xLTEtMjU1L3RleHRyZWdpb246MTAwMTM0ZjY2ZWNmNGE0NzhlNzhiMzQ1MjRjMmVkMDBfNzY5NjU4MTM5NDUzOA_42a5c064-ee6e-4ac4-b302-d797c6ef930b"
      unitRef="usdPerShare">7.67</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i47a2ad7dc20e45f8a10245fcd852cd7f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTQtMC0xLTEtMjU1L3RleHRyZWdpb246MTAwMTM0ZjY2ZWNmNGE0NzhlNzhiMzQ1MjRjMmVkMDBfNzY5NjU4MTM5NDU0NA_0c5be8ea-99b2-409e-9c7f-202184384a49"
      unitRef="usd">78000</us-gaap:PaymentsOfStockIssuanceCosts>
    <kron:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTQtMS0xLTEtMA_bc71a0c2-8a20-45b8-9d01-4823e43cb6c6"
      unitRef="shares">6555428</kron:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTQtMy0xLTEtMA_e5c693df-0b3b-4c7e-aac8-972c5f073f70"
      unitRef="usd">50242000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="ia81288a6a3fa4a88a8f294d3b0df8299_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTUtMTQtMS0xLTA_e0acb646-84e8-4b1b-88e3-75d3df61980a"
      unitRef="usd">-4013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTUtMTYtMS0xLTA_6dd2ba3e-cde9-44bf-b767-090fd898fd58"
      unitRef="usd">-4013000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMS0xLTEtMA_2b8bc96f-7d3a-4af3-a34e-0c867a9485de"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMy0xLTEtMA_6b640f61-3fee-4637-9195-23f22bc96111"
      unitRef="usd">122907000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="ie7b7bb754ddc40bbbd810ba27db95742_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtNi0xLTEtMA_b1d45022-6422-4a90-94fb-5c5af5aa0336"
      unitRef="shares">5488261</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie7b7bb754ddc40bbbd810ba27db95742_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtOC0xLTEtMA_407df4d3-5d80-464a-a545-008ff4aa2a33"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7a3a26575a447b0a22f44539d68c78f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMTAtMS0xLTA_54f26a71-f2b0-473c-9840-20db9cc96880"
      unitRef="usd">161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia08a06283a2d4d1391878f6cd94cc735_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMTItMS0xLTA_87955abe-25d2-44ea-b9a6-30097136a2c3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i873ef3d6e24746a29e6379448312fad6_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMTQtMS0xLTA_cef70120-c133-441a-9c78-63c96722514e"
      unitRef="usd">-17997000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjQyNWZhMGQyYWU5NTRmZTdiODFkMDc1ZGNiMGIyYThiL3RhYmxlcmFuZ2U6NDI1ZmEwZDJhZTk1NGZlN2I4MWQwNzVkY2IwYjJhOGJfMTYtMTYtMS0xLTA_99ff3d0c-fa66-4d4a-b2ca-08d3be539c37"
      unitRef="usd">-17831000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xLTEtMS0xMTQ2_9b8830aa-1197-4c71-a500-4f3f77e6bb47"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0zLTEtMS0xMTQ2_5370c25e-5ec1-487d-b0cc-a4c4dc0a1b7b"
      unitRef="usd">122907000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i50164c6c882d42f3919eca44154397d9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi02LTEtMS0xMTUw_65e8b780-dd94-468a-a5d1-703711c38bb1"
      unitRef="shares">5660391</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i50164c6c882d42f3919eca44154397d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi04LTEtMS0xMTUw_fbb80d63-04dc-4276-a821-cf3737378c91"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0f99d002a8a4eaaa64cf919ecdea498_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xMC0xLTEtMTE1MA_505df8d6-90dc-4533-b457-3cddbec51a1a"
      unitRef="usd">271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1dd1ee47d2a4d7e94466a527f95e4dd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xMi0xLTEtMTE1MA_bbab05c3-12d2-4e1c-b314-b1529a21882e"
      unitRef="usd">-18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3528d13cf33844ac95aedb7d3764991c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xNC0xLTEtMTE1MA_45c19956-2769-4b80-8c40-38797b8d6ddd"
      unitRef="usd">-23462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMi0xNi0xLTEtMTE1MA_c35b8d0c-dcfa-4f6b-9d0d-fdc81c4c01af"
      unitRef="usd">-23203000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i07bca622fbaa4a77834306e2dc4158cf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMy02LTEtMS0xMTUw_f016818e-27e4-486d-b3e8-bf1a3564fda0"
      unitRef="shares">119939</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0c535b861b90421a981086e2092d7c25_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMy0xMC0xLTEtMTE1MA_1355ebb0-3484-464e-85ee-4f09aa5b35aa"
      unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMy0xNi0xLTEtMTE1MA_29b332b6-b66b-4931-b61b-d9e1e1bef2ba"
      unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0c535b861b90421a981086e2092d7c25_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNC0xMC0xLTEtMTE1MA_e9e3b9f3-5bda-46fd-bce2-e83968328bf8"
      unitRef="usd">188000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNC0xNi0xLTEtMTE1MA_975b043f-5918-4f95-9240-0eece4a0ebfe"
      unitRef="usd">188000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i115b646974a740c39cf4aca40b4727a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNS0xMi0xLTEtMTE1MA_fda953b2-c187-4855-a7e2-7d17b182661f"
      unitRef="usd">158000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNS0xNi0xLTEtMTE1MA_1ddff845-5bb3-40fb-9825-d4bde8c5b08c"
      unitRef="usd">158000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i30a2c5294eeb4d659c07857d5b23eecc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNi0xNC0xLTEtMTE1MA_363a890c-7690-43f8-a8d1-c4ae24678e96"
      unitRef="usd">-6995000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iefeea7e630c94b5aaf12e7c40e1b361e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNi0xNi0xLTEtMTE1MA_614e7b7c-c1fc-47eb-bc32-c42ec7f10eab"
      unitRef="usd">-6995000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5ae1bc220d124171941ce912959a757d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xLTEtMS0xMTQ2_fbb97f0e-f3ce-4f62-b1d6-a733cff1bcbb"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5ae1bc220d124171941ce912959a757d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0zLTEtMS0xMTQ2_55c6393f-b240-406c-9dc0-1489e4d11f76"
      unitRef="usd">122907000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i843c9dde5a3b4b64b5716b83abdb8982_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy02LTEtMS0xMTUw_5035d88e-a172-4934-920c-775538c1f06a"
      unitRef="shares">5780330</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i843c9dde5a3b4b64b5716b83abdb8982_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy04LTEtMS0xMTUw_96cc1488-a787-4515-b287-039b436ca28c"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1fcf856179f4d0a8fb0794daa7e6d02_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xMC0xLTEtMTE1MA_b39deb7c-fda7-442f-8265-57bf47b97038"
      unitRef="usd">479000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7b0100128e94091ac9bab9b50f79c03_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xMi0xLTEtMTE1MA_1e46de9a-f750-4925-a3a6-6a594eb888de"
      unitRef="usd">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8deeaad6f2634e11b9f9c0316139d717_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xNC0xLTEtMTE1MA_da69a066-c14d-40a4-9f1f-cf657447e136"
      unitRef="usd">-30457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ae1bc220d124171941ce912959a757d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfNy0xNi0xLTEtMTE1MA_26626df9-8c03-4b5d-be09-c41391fa1f13"
      unitRef="usd">-29832000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6646e83b8de940969fc96333ff6a7d2a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOC02LTEtMS0xMTUw_699b74f5-7386-41e4-9fcd-cb992681d915"
      unitRef="shares">171713</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id7c5ebc92f654f8491c5de314a112730_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOC0xMC0xLTEtMTE1MA_9ad9fa81-bffe-4a38-b98a-0db11591f0b6"
      unitRef="usd">113000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOC0xNi0xLTEtMTE1MA_8482a930-8cf3-43ae-9e72-58ce89f05708"
      unitRef="usd">113000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id7c5ebc92f654f8491c5de314a112730_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOS0xMC0xLTEtMTE1MA_92b71544-72e4-4d3c-896c-a58d66da718e"
      unitRef="usd">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfOS0xNi0xLTEtMTE1MA_03684022-13dc-41d0-a775-104751988550"
      unitRef="usd">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i45b83d5eb6d345538b2d5d4cb90f98e1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTAtMTItMS0xLTExNTA_28ea48e2-6014-4066-bb03-d3a124740b2d"
      unitRef="usd">24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTAtMTYtMS0xLTExNTA_13f94570-1a7b-4c70-b6d6-4e17df79d66a"
      unitRef="usd">24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="if07042dba8294acc85fb47df8bbcc218_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTEtMTQtMS0xLTExNTA_8d023b0f-fddf-418d-95c4-68e80309d01a"
      unitRef="usd">-8579000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1a3a2a3eacec49228938d21d4a090f9a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTEtMTYtMS0xLTExNTA_df7cf200-d18b-4bc9-9038-4252415055a8"
      unitRef="usd">-8579000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7555544cb3f7417ab92209c0d2f251b7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMS0xLTEtMTE0Ng_7bce5ca6-2fe9-4ab8-8ab6-8cebb01b3111"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7555544cb3f7417ab92209c0d2f251b7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMy0xLTEtMTE0Ng_4a74c7f7-f784-4fe1-b0a3-545921010c19"
      unitRef="usd">122907000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i1310705bc7ae4f78af0e8a824858b5c5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItNi0xLTEtMTE1MA_bcc91295-8ea5-4406-9f65-76b9bd1af6a1"
      unitRef="shares">5952043</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1310705bc7ae4f78af0e8a824858b5c5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItOC0xLTEtMTE1MA_896b8c63-20ca-4eca-9949-fd45aab60967"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie28a26a8d7224bd8901bf199a0538658_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMTAtMS0xLTExNTA_ec29ae44-fa65-4040-8408-950c3f274ad7"
      unitRef="usd">885000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40dd880b211e46408cac612575b17ac5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMTItMS0xLTExNTA_fc276c28-9af8-4470-abb0-b4193a9128d6"
      unitRef="usd">164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35a6843fec8241b0882996b9484b444f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMTQtMS0xLTExNTA_b6444a50-05b0-4434-8fff-bd592fb536ab"
      unitRef="usd">-39036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7555544cb3f7417ab92209c0d2f251b7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTItMTYtMS0xLTExNTA_062f44ee-09c5-44cc-9d1d-6c763d68e15b"
      unitRef="usd">-37981000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id09b579f33f344c7b796c94598c93ab2_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTMtNi0xLTEtMTE1MA_5daae430-d866-4f11-ada6-eddeef7a1352"
      unitRef="shares">332283</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie598b98bcf9d47bd8f9ada78c710b752_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTMtMTAtMS0xLTExNTA_81528156-c2a8-47bb-b18d-1c6502103886"
      unitRef="usd">278000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTMtMTYtMS0xLTExNTA_512ac89b-c671-4c09-9486-cc535ca70a49"
      unitRef="usd">278000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie598b98bcf9d47bd8f9ada78c710b752_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTQtMTAtMS0xLTExNTA_bc05e69c-d95b-410a-8ed4-eb0b026b14ed"
      unitRef="usd">1253000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTQtMTYtMS0xLTExNTA_e98ef1d6-8d0b-4293-97d6-16965b3ce368"
      unitRef="usd">1253000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iad6f77124e9847649d247673b804dde9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTUtMTItMS0xLTExNTA_b0404d15-4db6-412a-a9b1-4a44230e0129"
      unitRef="usd">-117000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTUtMTYtMS0xLTExNTA_952fff3d-b3b8-4f03-a38b-7ac6f57aafda"
      unitRef="usd">-117000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i9dc2dc2098a3453c85866e5fdf18f779_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTYtMTQtMS0xLTExNTA_101fea20-beb7-4101-bab0-11480196121c"
      unitRef="usd">-39713000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTYtMTYtMS0xLTExNTA_9dbab2fd-5367-449e-aaf8-251699527e12"
      unitRef="usd">-39713000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMS0xLTEtMTE0Ng_12bb57e6-c5fd-4fd0-adf0-81ad4837ddc6"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMy0xLTEtMTE0Ng_3dc50dcc-35a0-48da-bcac-07ef3df99ec4"
      unitRef="usd">122907000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i8e14aee510204c7b89e48f9e27f07afc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctNi0xLTEtMTE1MA_0ab90013-bc82-437b-96dd-53f4af2ef04e"
      unitRef="shares">6284326</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8e14aee510204c7b89e48f9e27f07afc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctOC0xLTEtMTE1MA_d7c506d9-97f4-4ced-83ac-6ac383bd804b"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd881c372af5476a8da370cfe8309eeb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMTAtMS0xLTExNTA_11e25ea7-89ed-4613-ba11-0f8016a2c80d"
      unitRef="usd">2416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia328bcbcb2f049488186eac987fe0643_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMTItMS0xLTExNTA_6d0e5e6d-7af8-4a27-bde8-4742392a85ef"
      unitRef="usd">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96c4ed6efa7740e18904bfe97dd36b05_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMTQtMS0xLTExNTA_0d357146-243a-4ab8-83c6-28e11b30119e"
      unitRef="usd">-78749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85NC9mcmFnOmQ4Y2VkMjkzNzYzYjQzYzNiOGE3NjM1ZDRhMmQwMDM1L3RhYmxlOjkwOGM1OWI0MjcwMTQ2ZWJhYjQ3ODY0YjA2YmNmNDJlL3RhYmxlcmFuZ2U6OTA4YzU5YjQyNzAxNDZlYmFiNDc4NjRiMDZiY2Y0MmVfMTctMTYtMS0xLTExNTA_6019f086-0135-43d5-af0a-6e084bbfbde3"
      unitRef="usd">-76280000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNC01LTEtMS0w_b0e49f7f-90dc-4a20-af57-d6f227759a80"
      unitRef="usd">-55287000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNC03LTEtMS0w_f01e70dd-e450-48b2-a779-996e36e73f82"
      unitRef="usd">-10652000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNi01LTEtMS0w_4f1002c8-1d46-45b2-b5a5-fc607d7e0bed"
      unitRef="usd">539000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNi03LTEtMS0w_8b4118a3-ffa4-4715-8a25-17af94597a50"
      unitRef="usd">215000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNy01LTEtMS0w_1ab40832-9d51-48e3-a5bd-1ea07d1ddd96"
      unitRef="usd">-105000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNy03LTEtMS0w_11083501-83a7-4c7d-98b9-992fb97059c0"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfOC01LTEtMS0w_d93ad85c-ed1c-4190-87d6-24e842acf5a4"
      unitRef="usd">-71000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfOC03LTEtMS0w_4fd24cdd-1aac-4739-bd28-7072c5fbe896"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTAtNS0xLTEtMA_b5f0bd5d-92c5-4348-89f8-0f40373794dc"
      unitRef="usd">1734000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTAtNy0xLTEtMA_4ff328b6-207c-4f2c-b0cb-9f8b7f3b79c9"
      unitRef="usd">60000</us-gaap:ShareBasedCompensation>
    <kron:LeaseExpenseNoncash
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTEtMS0xLTEtMjg0_f869cbba-1135-4868-be32-26618f6a0ee7"
      unitRef="usd">1994000</kron:LeaseExpenseNoncash>
    <kron:LeaseExpenseNoncash
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTEtMy0xLTEtMzA1_a756c535-6e55-47cd-81aa-693e640be9fd"
      unitRef="usd">183000</kron:LeaseExpenseNoncash>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTItMS0xLTEtNDA1Ng_eb03b550-47ea-4d95-a227-a1f1a575a8b5"
      unitRef="usd">-15215000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTItMy0xLTEtNDA3Mw_75724472-be9d-4729-b7ba-179c80e40233"
      unitRef="usd">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtMS0xLTEtNDA1Ng_f6200b57-44e1-49df-b793-40a547f2ff34"
      unitRef="usd">3889000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtMy0xLTEtNDA3Mw_ce3f1b2a-5426-472c-8b06-d35367cae861"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtMS0xLTEtNzk0Mg_a7edca72-4475-4ed6-98a1-6f3576ca584d"
      unitRef="usd">3565000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtMy0xLTEtNzk0Mg_fd0f430e-1025-468c-8ec7-30394ea94366"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtNS0xLTEtMA_cfacfc8b-110a-454f-8e7d-f324dabdebd9"
      unitRef="usd">493000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTMtNy0xLTEtMA_5894591c-7df5-479d-a75b-d68d2929e166"
      unitRef="usd">271000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTQtNS0xLTEtMA_097f222d-7788-416b-bc83-f52ddff0962d"
      unitRef="usd">-150000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTQtNy0xLTEtMA_c38721c6-ba15-418d-b3e8-3948ec63dbb8"
      unitRef="usd">152000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTUtNS0xLTEtMA_179ba853-4b08-48b5-ad19-b935716878e0"
      unitRef="usd">1129000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTUtNy0xLTEtMA_2c93cc9a-3150-4c6b-97fd-678fa6f3bcb7"
      unitRef="usd">258000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTYtNS0xLTEtMA_a345a59a-b9e1-4adb-aea0-98832c9fab6c"
      unitRef="usd">879000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTYtNy0xLTEtMA_bc2ec257-ddd3-4671-a069-92aba3281443"
      unitRef="usd">434000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <kron:IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTctNS0xLTEtMA_da9e33ba-cef6-4159-baf0-faacb6fb9bd6"
      unitRef="usd">588000</kron:IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet>
    <kron:IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTctNy0xLTEtMA_02667a17-9c4c-4a80-8cce-efdc41c0a7c3"
      unitRef="usd">183000</kron:IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTgtNS0xLTEtMA_bced80c1-81a6-49f8-923d-0c92adc7db90"
      unitRef="usd">4816000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTgtNy0xLTEtMA_57af7d76-4c2b-4344-b3da-62682e9d7f06"
      unitRef="usd">-32000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTktMS0xLTEtMjg0_63fa3716-6c5e-4d7c-bee1-a5908b022b06"
      unitRef="usd">-22282000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMTktMy0xLTEtMzA1_1f3630f9-c29f-4013-b506-4780e8bb7740"
      unitRef="usd">-10140000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjItNS0xLTEtMA_22ad3250-cfa6-4b33-9f60-a4facd175028"
      unitRef="usd">5886000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjItNy0xLTEtMA_04ab1d3e-83fc-430b-8fbd-9d3327b81abf"
      unitRef="usd">2311000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjMtNS0xLTEtMA_01b29326-3cb0-4148-9ccf-8de0283b0c40"
      unitRef="usd">41205000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjMtNy0xLTEtMA_498979d7-c0da-4573-a751-1a5b25d2894b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjQtMS0xLTEtMjg0_28b11bab-0f3d-45e4-bcbf-96571edfc17e"
      unitRef="usd">45611000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjQtMy0xLTEtMzAy_003f7668-cafe-408d-8c7f-81496eb6f665"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjUtNS0xLTEtMA_c59ebb1c-94c9-4e34-93e6-d561df24a29f"
      unitRef="usd">-1480000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjUtNy0xLTEtMA_255c5a2c-e2e7-41ae-8ddc-e005af372f67"
      unitRef="usd">-2311000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjgtNS0xLTEtMA_3d900b16-5fa1-4410-b334-b154ba6446cb"
      unitRef="usd">24000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjgtNy0xLTEtMA_d1ff8ff7-392d-40e3-a927-ad45c5034e3e"
      unitRef="usd">22000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjktNS0xLTEtMA_165676aa-8a0e-43a6-aeda-9c8be0cfa3e7"
      unitRef="usd">411000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMjktNy0xLTEtMA_aa8d62d7-0d8d-48d9-87e7-8ed0e62e4b66"
      unitRef="usd">56000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzAtNS0xLTEtMA_245fb5dd-d786-43f6-98ec-cabe34dcf56f"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzAtNy0xLTEtMA_8d79b160-aab0-40f8-b735-a63ded4d8452"
      unitRef="usd">104929000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzMtMS0xLTEtNDA3Nw_acb8d2ab-55cc-4014-b59c-257b494a2b8a"
      unitRef="usd">151275000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzMtMy0xLTEtNDA4MQ_14498745-0409-4065-ba7a-d161aded5cb8"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzQtMS0xLTEtNzk0OQ_82571e6b-b569-4b85-afa5-782cf0857438"
      unitRef="usd">2248000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzQtMy0xLTEtNzk1Nw_c1463289-3001-4f6b-9ae0-bb13cee3394e"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzEtNS0xLTEtMA_18b446b5-1c75-49ba-baf0-0e60b3f0679b"
      unitRef="usd">149414000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzEtNy0xLTEtMA_bce83539-a7d1-4520-9872-7db9b209b40d"
      unitRef="usd">104963000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzItMS0xLTEtMjg0_f7fbe6ff-30ac-4c0c-887e-777d0ddb9e91"
      unitRef="usd">125652000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzItMy0xLTEtMzEw_bd7fe038-47c7-4746-8cda-d367653549ab"
      unitRef="usd">92512000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzMtNS0xLTEtMA_cfa7d105-37f7-4d12-b71f-84347ca341a0"
      unitRef="usd">32570000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f8e95f9bad0404484cd92bc97317806_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzMtNy0xLTEtMA_9d21c4cb-57bd-4748-8726-cf3e611e9804"
      unitRef="usd">10226000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzQtMS0xLTEtMjg0_5be3bfe2-482a-4d23-a27f-3506f3894f87"
      unitRef="usd">158222000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfMzQtMy0xLTEtMzEw_bc21e6ce-d0ec-4d86-8363-f5ce4338ae74"
      unitRef="usd">102738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDAtMS0xLTEtNzg1MQ_1ad031e5-b688-462b-9574-abd6ffdcd08c"
      unitRef="usd">1325000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDAtMy0xLTEtNzg1MQ_1305f929-550c-434d-baf7-df224adea2f4"
      unitRef="usd">478000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDEtMS0xLTEtNjc1OA_92e3d03f-c3d1-4fa1-8b8c-8714c344e412"
      unitRef="usd">30898000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDEtMy0xLTEtNzg1NQ_9f1b097f-52ba-437a-a129-cd87f675a861"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <kron:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDItMS0xLTEtNzg0Nw_4ef6492d-3dd7-4611-9851-a91079087705"
      unitRef="usd">682000</kron:DeferredOfferingCostsIncurredButNotYetPaid>
    <kron:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDItMy0xLTEtNzg0Nw_23af3fe5-9fb6-4466-93d3-23e4bff5f7b0"
      unitRef="usd">0</kron:DeferredOfferingCostsIncurredButNotYetPaid>
    <kron:TemporaryEquityIssuanceCostsIncurredButNotYetPaid
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDMtMS0xLTEtNzg0Nw_985fb286-f7c4-4023-ae26-b0864ad05523"
      unitRef="usd">0</kron:TemporaryEquityIssuanceCostsIncurredButNotYetPaid>
    <kron:TemporaryEquityIssuanceCostsIncurredButNotYetPaid
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF85Ny9mcmFnOmY1MDdmZTkzYjkxODRhOWFiMzZlMTE3ZTRhOTMyNGYxL3RhYmxlOjFjMTkwZjYxZWE3MTQ0Yjc5M2ZiMjYzMWI0YThkZmZlL3RhYmxlcmFuZ2U6MWMxOTBmNjFlYTcxNDRiNzkzZmIyNjMxYjRhOGRmZmVfNDMtMy0xLTEtNzA1Mg_164b64d9-6ccf-479d-bc32-d79b78088814"
      unitRef="usd">8000</kron:TemporaryEquityIssuanceCostsIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzc2OTY1ODE0MDAzNzE_5bbcea6f-d913-43df-9ee5-b13a90401c5d">NATURE OF OPERATIONS AND BASIS OF PRESENTATION&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kronos Bio, Inc. (Kronos or the Company), a Delaware corporation, was incorporated on June 2, 2017. The Company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in one business segment, the development of biopharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company completed an initial public offering (IPO) of its common stock.  In connection with its IPO, the Company issued and sold 15,131,579 shares of its common stock, which included 1,973,684 shares of its common stock issued and sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a price to the public of $19.00 per share.  As a result of the IPO, the Company received approximately $263.9 million in net proceeds, after deducting underwriting discounts and commissions of $20.1 million and offering expenses of approximately $3.5 million payable by the Company.  At the closing of the IPO, 21,504,893 shares of outstanding convertible preferred stock were automatically converted to 22,687,625 shares of common stock and the 2020 Notes (See Note 15) were automatically converted into 9,610,713 shares of common stock.  At the closing of the IPO, the Gilead Note (See Note 13) was also converted into 188,567 shares of common stock. Following the IPO, there were no shares of convertible preferred stock outstanding.  As of September&#160;30, 2020, the Company had incurred $2.9 million of deferred offering costs, which will be offset against the net proceeds received from the sale of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Need for Additional Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net operating losses since its inception of $78.7 million as of September&#160;30, 2020.  The Company expects that its cash, cash equivalents and investments as of September&#160;30, 2020, in addition to its approximate net cash proceeds of $263.9 million from the Company&#x2019;s IPO, which closed on October 14, 2020, will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of issuance of these condensed financial statements.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared the global novel coronavirus disease (COVID-19) outbreak a pandemic. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#x2019;s results may be adversely affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations.  The Company&#x2019;s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue business strategies.  The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaboration arrangements or obtain government grants.  The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders.  If the Company is unable to obtain funding, the Company could be forced to delay, reduce, or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.  In the event that the Company requires additional funding, there can be no assurance that it will be successful in obtaining sufficient funding on terms acceptable to the Company to fund its continuing operations, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Forward Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 2, 2020, the Company filed an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&#x2019;s common stock on a 1.055-for-1 basis (the Forward Stock Split).  In connection with the Forward Stock Split, the conversion ratio for the Company&#x2019;s outstanding convertible preferred stock was proportionally adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split.  The par value of the common stock was not adjusted as the result of the Forward Stock Split.  All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these condensed financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzc2OTY1ODE0MTUxNjI_165fd8a8-5dac-4722-bb62-7143f58d2823"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0MzM_b8192982-634a-4e19-a58a-eb0f7a8c75db"
      unitRef="shares">15131579</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i47233a942abf4a268c14b15bafb9f5e0_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0Mzk_dbcdeb4b-c625-476d-b8cc-735690f003ce"
      unitRef="shares">1973684</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i312337076930421489dbae527af0c6a2_I20201031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0NDU_ba6f9d10-8036-4b9d-85ed-6046308169a1"
      unitRef="usdPerShare">19.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzM4NDgyOTA3MDczMDA_4042688d-aca6-420d-95eb-bd876bb9fea0"
      unitRef="usd">263900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <kron:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0NTE_a0964054-68d8-4b40-a6b5-025efe331a9d"
      unitRef="usd">20100000</kron:PaymentsOfUnderwritingDiscountsAndCommissions>
    <kron:PaymentsOfOfferingCosts
      contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4OTM0MDU_1f5561df-db14-44c0-811a-ef81505ac4ad"
      unitRef="usd">3500000</kron:PaymentsOfOfferingCosts>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0ODE_8ba57036-aec7-481f-a95b-00aff1701f22"
      unitRef="shares">21504893</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iba04a0b8630a43e7a31aa41fb7a542f6_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0ODY_bf49b9c2-8ccc-463c-ba55-7ec596e61234"
      unitRef="shares">22687625</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib50ec0c321854506a6168bb676c9bb98_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODg0OTI_0d33dbed-2537-4164-b306-a08a6ac9333e"
      unitRef="shares">9610713</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="if9ec867a047842948219312d9ab1388e_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzQzOTgwNDY1MjE0MDU_c91d48ad-01b9-4266-8166-0926291bb620"
      unitRef="shares">188567</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i312337076930421489dbae527af0c6a2_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzc2OTY1ODE0MTM0MTA_ef8fffc5-65dc-490d-b21d-766e272888f1"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:DeferredOfferingCosts
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzI3NDg3NzkwODgzOTg_0a0ff5ee-6ff8-4093-8bc5-8ec27aa9c8c3"
      unitRef="usd">2900000</us-gaap:DeferredOfferingCosts>
    <us-gaap:NetIncomeLoss
      contextRef="iafb3c774af9d4c178d3cac868b3c195a_D20170602-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzMyOTg1MzQ4ODk4NDA_b623c964-db76-4816-9c2b-db7fba50d147"
      unitRef="usd">-78700000</us-gaap:NetIncomeLoss>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ibe629ec7b8ae4d3c8896308050ed7ced_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzM4NDgyOTA3MDczMTg_4042688d-aca6-420d-95eb-bd876bb9fea0"
      unitRef="usd">263900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i5c23b681d5c84ca1bf3cfe7435c3e188_D20201002-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDMvZnJhZzpiMzdjZDRjYzgwYWM0ZmU0OGE3MjZkMGFmZDEzMGJmYS90ZXh0cmVnaW9uOmIzN2NkNGNjODBhYzRmZTQ4YTcyNmQwYWZkMTMwYmZhXzI3NDg3NzkwOTIzMjI_f4f07e72-81f0-48a5-81f3-b3bf204cf1aa"
      unitRef="number">1.055</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTI3_bb47ba20-c3fa-4f6e-862d-46c07e4e65c1">SIGNIFICANT ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying balance sheet as of September&#160;30, 2020, the statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019, the statements of convertible preferred stock and stockholders&#x2019; deficit as of September&#160;30, 2020 and 2019, the statements of cash flows for the nine months ended September&#160;30, 2020 and 2019, and the financial data and other financial data and other information disclosed to in the notes to the condensed financial statements are unaudited.  The unaudited interim financial statements have been prepared on a basis consistent with the Company&#x2019;s audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of September&#160;30, 2020 and the results of its operations the three and nine months ended September&#160;30, 2020 and 2019. The results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2020, any other interim periods, or any future year or period.  These financial statements should be read in conjunction with the Company's audited financial statements included in the prospectus dated October 8, 2020 that forms a part of the Company's Registration Statements on Form S-1 (File No. 333-248925), as filed with the SEC pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended, on October 9, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of convertible notes and investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (R&amp;amp;D) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, discovery research performed by contract research organizations (CROs), materials and supplies, licenses and fees and overhead allocations consisting of various support and facility-related costs. The Company expenses R&amp;amp;D costs as the services are performed or the goods are received.  Research and development expenses for the three and nine months ended September&#160;30, 2020 included $6.6 million related to acquired intangible assets as research and development costs pursuant to the Asset Purchase Agreement with Gilead (See Note 13) as, at the time of acquisition of the asset, the technology was under development; was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing; had not reached technical feasibility; or otherwise had no foreseeable alternative future use.  There were no acquired intangible assets expensed for the three and nine months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CRO costs are a significant component of R&amp;amp;D expenses. The Company monitors levels of performance under each significant contract through communications with its CROs. The Company accrues costs for discovery research performed by CROs over the service periods specified in the contracts and adjusts our estimates, if required, based upon its ongoing review of the level of effort and costs actually incurred by the CROs. All of the Company&#x2019;s material CRO contracts are terminable by the Company upon written notice and it is generally only liable for actual services completed by the CRO and certain non-cancellable expenses incurred at any point of termination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has deposited cash of $2.0 million as of September&#160;30, 2020 to secure a letter of credit in connection with the lease of the 301 Binney facility (See Note 14).  The Company has classified the restricted cash as a noncurrent asset on its balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has not experienced any credit losses in such accounts or investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks common for biopharmaceutical companies, including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition, and untested manufacturing capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments are available-for-sale and are carried at estimated fair value. The Company&#x2019;s valuations of available-for-sale securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the balance sheet date are classified as short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses are excluded from earnings and are reported as components of comprehensive loss. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income (expense), net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest income (expense), net on the Company&#x2019;s statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value estimates are made at a discrete point in time based on relevant market information and information about the financial instruments. Fair value estimates are based on judgments regarding future expected loss experience, current economic conditions, risk characteristics of various financial instruments, and other factors. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company recorded both financial assets and financial liabilities requiring fair value measurement.  The financial assets include cash equivalents and investments.  The financial liabilities consist of the convertible promissory note (Gilead Note) from the Gilead Asset Purchase Agreement (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2019, the Company recorded financial assets, including cash equivalents, and investments, requiring fair value measurement.  There were no financial liabilities as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Option&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. GAAP, the Company has the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument by instrument basis, with changes in fair value reported in the statements of operations.  The option was elected for the treatment of the Company&#x2019;s convertible promissory note from the Gilead Asset Purchase Agreement entered into in July 2020 (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15) in order to more accurately reflect the economic value of the notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;over the estimated useful lives of the respective assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Repairs and maintenance costs are expensed as incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated useful lives in years are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Offering costs, including legal, accounting, and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO.  As of September&#160;30, 2020, $2.9 million of deferred offering costs have been capitalized, which are included in the accompanying balance sheet within other noncurrent assets.  There were no deferred offering costs recorded as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and noncurrent operating lease liabilities on the Company&#x2019;s balance sheet. Finance leases are included in property and equipment, current portion of other liabilities, and other noncurrent liabilities on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments and initial direct costs incurred, net of lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures stock-based awards granted to employees and nonemployees based on the fair value on the date of the grant and recognizes stock-based compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates the fair value measurement of stock options using the Black-Scholes option-pricing model. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeitures are accounted for as they occur. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has only issued stock options with service-based vesting conditions and records the expense for these awards using the straight-line method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#x2019;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. For the three and nine months ended September&#160;30, 2020, other comprehensive loss consisted of unrealized gains and losses from available-for-sale securities. There was no difference between net loss and comprehensive loss for the three and nine months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and the effect of dilutive securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect on net loss per share is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).  The Company adopted ASU No. 2018-13 on January 1, 2019. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the FASB issued ASU No. 2016-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Statement of Cash Flows, Restricted Cash &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2016-18). This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet.  The Company elected to adopt ASU 2016-18 on January 1, 2019 and has reflected the adoption in its financial statements. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash as shown on the statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company adopted ASU No 2016-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Statement of Cash Flow&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2016-15) in 2019. The guidance reduces diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The adoption of ASU 2016-15 did not have a material impact on the Company&#x2019;s condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The standard will become effective for the Company in the first quarter of 2020, with early adoption permitted beginning the first quarter of 2019. The modified retrospective approach should be applied upon adoption of this new guidance. The Company&#x2019;s financial instruments that are in the scope of ASU 2016-13 include available-for-sale debt securities. The Company adopted this standard on January&#160;1, 2020 and this amendment did not have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company has adopted this standard as of January 1, 2020, which did not have a material impact on its financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzc2OTY1ODE0NDQ5MDc_a8a30b00-ce82-4296-a60d-bc29b668ee29">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying balance sheet as of September&#160;30, 2020, the statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019, the statements of convertible preferred stock and stockholders&#x2019; deficit as of September&#160;30, 2020 and 2019, the statements of cash flows for the nine months ended September&#160;30, 2020 and 2019, and the financial data and other financial data and other information disclosed to in the notes to the condensed financial statements are unaudited.  The unaudited interim financial statements have been prepared on a basis consistent with the Company&#x2019;s audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of September&#160;30, 2020 and the results of its operations the three and nine months ended September&#160;30, 2020 and 2019. The results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2020, any other interim periods, or any future year or period.  These financial statements should be read in conjunction with the Company's audited financial statements included in the prospectus dated October 8, 2020 that forms a part of the Company's Registration Statements on Form S-1 (File No. 333-248925), as filed with the SEC pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended, on October 9, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTI4_19852236-bdc9-437a-9d13-687358717366">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. &lt;/span&gt;&lt;/div&gt;Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of convertible notes and investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  Actual results could differ from the Company&#x2019;s estimates.The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets.</us-gaap:UseOfEstimates>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTI5_21e64dff-f0cc-4a99-9bc9-4eb52ed0b245">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (R&amp;amp;D) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, discovery research performed by contract research organizations (CROs), materials and supplies, licenses and fees and overhead allocations consisting of various support and facility-related costs. The Company expenses R&amp;amp;D costs as the services are performed or the goods are received.  Research and development expenses for the three and nine months ended September&#160;30, 2020 included $6.6 million related to acquired intangible assets as research and development costs pursuant to the Asset Purchase Agreement with Gilead (See Note 13) as, at the time of acquisition of the asset, the technology was under development; was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing; had not reached technical feasibility; or otherwise had no foreseeable alternative future use.  There were no acquired intangible assets expensed for the three and nine months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CRO costs are a significant component of R&amp;amp;D expenses. The Company monitors levels of performance under each significant contract through communications with its CROs. The Company accrues costs for discovery research performed by CROs over the service periods specified in the contracts and adjusts our estimates, if required, based upon its ongoing review of the level of effort and costs actually incurred by the CROs. All of the Company&#x2019;s material CRO contracts are terminable by the Company upon written notice and it is generally only liable for actual services completed by the CRO and certain non-cancellable expenses incurred at any point of termination.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i58709a1025434a858b79101128c97c2e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzQzOTgwNDY1Mzk4NzA_0ab26e4e-24a8-49cb-9564-f751f3d34701"
      unitRef="usd">6600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaddbc37c40784a41b4cba75355474170_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzQzOTgwNDY1Mzk4NzA_60bf892f-92bc-479a-8b68-3d8aff16da11"
      unitRef="usd">6600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTMw_d1f601ff-a955-4cef-84d0-d0088a5605b9">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;The Company has deposited cash of $2.0 million as of September&#160;30, 2020 to secure a letter of credit in connection with the lease of the 301 Binney facility (See Note 14).  The Company has classified the restricted cash as a noncurrent asset on its balance sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzk4OTU2MDQ3MDE5NzA_eb5ab7e2-10f1-424d-a3fe-7fe6480e9a8f"
      unitRef="usd">2000000.0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTMz_46a53a5c-64fa-4287-b093-7c1515f27a5c">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has not experienced any credit losses in such accounts or investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks common for biopharmaceutical companies, including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition, and untested manufacturing capabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM0_54f6622a-fd24-4a6a-a5bc-28fc3874f64c">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments are available-for-sale and are carried at estimated fair value. The Company&#x2019;s valuations of available-for-sale securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the balance sheet date are classified as short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses are excluded from earnings and are reported as components of comprehensive loss. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income (expense), net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest income (expense), net on the Company&#x2019;s statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM1_9086bc3e-687e-40c7-8d0c-a1acf46331a5">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value estimates are made at a discrete point in time based on relevant market information and information about the financial instruments. Fair value estimates are based on judgments regarding future expected loss experience, current economic conditions, risk characteristics of various financial instruments, and other factors. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company recorded both financial assets and financial liabilities requiring fair value measurement.  The financial assets include cash equivalents and investments.  The financial liabilities consist of the convertible promissory note (Gilead Note) from the Gilead Asset Purchase Agreement (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2019, the Company recorded financial assets, including cash equivalents, and investments, requiring fair value measurement.  There were no financial liabilities as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Option&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. GAAP, the Company has the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument by instrument basis, with changes in fair value reported in the statements of operations.  The option was elected for the treatment of the Company&#x2019;s convertible promissory note from the Gilead Asset Purchase Agreement entered into in July 2020 (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15) in order to more accurately reflect the economic value of the notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM2_0e943087-8190-4a27-9bb2-899fd24f3340">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;over the estimated useful lives of the respective assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Repairs and maintenance costs are expensed as incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated useful lives in years are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTc1_21d48bde-6e0e-4558-8552-d3770aa664c7">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated useful lives in years are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease on R&amp;amp;D equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7368251cdbf04660970e56374215be24_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZTplNTc0ZTk0MmY1NmE0ODgwOWNjNGJiNjllZTc3MjU3ZC90YWJsZXJhbmdlOmU1NzRlOTQyZjU2YTQ4ODA5Y2M0YmI2OWVlNzcyNTdkXzEtMi0xLTEtMzI2Ny90ZXh0cmVnaW9uOmVlM2RiNDJlYzZmMTQ3YTZiNWI1YmI0ZDkzYzUwZDllXzk4OTU2MDQ2NTAwMDE_ac875c3e-a856-420a-9480-d752d06998ba">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ica62b3a4be464cb3bc3599acf158c2ae_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZTplNTc0ZTk0MmY1NmE0ODgwOWNjNGJiNjllZTc3MjU3ZC90YWJsZXJhbmdlOmU1NzRlOTQyZjU2YTQ4ODA5Y2M0YmI2OWVlNzcyNTdkXzEtMi0xLTEtMzI2Ny90ZXh0cmVnaW9uOmVlM2RiNDJlYzZmMTQ3YTZiNWI1YmI0ZDkzYzUwZDllXzk4OTU2MDQ2NTAwMDc_5314dbe4-1fa4-45cd-96bd-ae3cdaf6cca4">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzc2OTY1ODE0MzEwMjg_c09b1faf-bcd3-4e71-b33c-a2013501dc36">Deferred Offering CostsOffering costs, including legal, accounting, and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzI3NDg3NzkxMTIzMTQ_0a0ff5ee-6ff8-4093-8bc5-8ec27aa9c8c3"
      unitRef="usd">2900000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM4_fa725879-6153-457f-ae52-24daab7d6028">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and noncurrent operating lease liabilities on the Company&#x2019;s balance sheet. Finance leases are included in property and equipment, current portion of other liabilities, and other noncurrent liabilities on the balance sheet. &lt;/span&gt;&lt;/div&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments and initial direct costs incurred, net of lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTM5_1a1c5026-71ec-4600-9349-551978721b31">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQw_f7956c08-2e9c-4f02-9240-0ca66d756805">Stock-Based Compensation&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures stock-based awards granted to employees and nonemployees based on the fair value on the date of the grant and recognizes stock-based compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates the fair value measurement of stock options using the Black-Scholes option-pricing model. &lt;/span&gt;Forfeitures are accounted for as they occur. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has only issued stock options with service-based vesting conditions and records the expense for these awards using the straight-line method.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQx_aecbc2d5-ae04-4b34-a3c8-b92a433c918d">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#x2019;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQy_26de2fd3-b30e-4870-9cdd-4a9f55509f70">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. For the three and nine months ended September&#160;30, 2020, other comprehensive loss consisted of unrealized gains and losses from available-for-sale securities. There was no difference between net loss and comprehensive loss for the three and nine months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQz_8ddaa98f-9c2a-4cde-90e3-1c22adf23ab0">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and the effect of dilutive securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect on net loss per share is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTQ0_80f10a7e-edae-453e-ade2-08ca079e1adc">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).  The Company adopted ASU No. 2018-13 on January 1, 2019. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the FASB issued ASU No. 2016-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Statement of Cash Flows, Restricted Cash &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2016-18). This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet.  The Company elected to adopt ASU 2016-18 on January 1, 2019 and has reflected the adoption in its financial statements. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash as shown on the statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company adopted ASU No 2016-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Statement of Cash Flow&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2016-15) in 2019. The guidance reduces diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The adoption of ASU 2016-15 did not have a material impact on the Company&#x2019;s condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The standard will become effective for the Company in the first quarter of 2020, with early adoption permitted beginning the first quarter of 2019. The modified retrospective approach should be applied upon adoption of this new guidance. The Company&#x2019;s financial instruments that are in the scope of ASU 2016-13 include available-for-sale debt securities. The Company adopted this standard on January&#160;1, 2020 and this amendment did not have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company has adopted this standard as of January 1, 2020, which did not have a material impact on its financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90ZXh0cmVnaW9uOmYzYjhhY2IzOWE0YzRhNDRhZGIwZWRmNTMyOGIzY2FjXzE3NTkyMTg2MDY3OTc2_2417de02-15d9-4c81-8e94-0f2a6d6cef45">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash as shown on the statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzMtMS0xLTEtMjA2OQ_fcf60f0c-eed9-447e-8ee2-023efbe0cbd9"
      unitRef="usd">156196000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzMtMy0xLTEtMjA2OQ_90f036fc-bf49-4647-afcf-5696462c76a8"
      unitRef="usd">102738000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzQtMS0xLTEtMjA2OQ_1ae391e4-e711-4911-a679-37b5e9b7826c"
      unitRef="usd">2026000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzQtMy0xLTEtMjA2OQ_dc7e478e-a8f9-435e-a528-0c70f8b17b03"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzUtMS0xLTEtMjA2OQ_a6b9b747-c642-4f2b-9b37-de722c2cc54b"
      unitRef="usd">158222000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7f0b4204c0e941c0b44a13e342d5bca4_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDYvZnJhZzpmM2I4YWNiMzlhNGM0YTQ0YWRiMGVkZjUzMjhiM2NhYy90YWJsZToxODU1YzA1OThkZmY0NzVjOWYxYzFhMGYyMzVjNWE4My90YWJsZXJhbmdlOjE4NTVjMDU5OGRmZjQ3NWM5ZjFjMWEwZjIzNWM1YTgzXzUtMy0xLTEtMjA2OQ_352c07c0-7e38-454d-a33f-afa69af07350"
      unitRef="usd">102738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90ZXh0cmVnaW9uOjZmYzliMDk0M2QwYjQ0OTU4Y2RlYjc5MDQ4ODQ4ODlmXzk4OTU2MDQ2NTMxNDQ_b25c4dc1-229d-4216-a442-b58e1ee16aa7">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and reports its cash equivalents, investments, and convertible notes at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds are measured at fair value on a recurring basis used quoted prices and are classified as Level 1.  Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classed as Level 2 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 liabilities consist of the Company&#x2019;s convertible notes payable.  The determination of the fair values for the Gilead Note and the 2020 Notes and the change in the fair value of these notes are discussed in Note 13 and Note 15, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gilead Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities. The Company&#x2019;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category as of September&#160;30, 2020.  Recorded losses associated within the Level 3 category include changes to fair value and are recorded within change in fair value of convertible notes in the statement of operations. Refer to Note 13 and Note 15 for the fair value determination of the Level 3 financial liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any financial assets or liabilities as of December 31, 2019 that required Level 3 inputs. There were no transfers of assets between the fair value measurement levels during any of the periods presented in the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90ZXh0cmVnaW9uOjZmYzliMDk0M2QwYjQ0OTU4Y2RlYjc5MDQ4ODQ4ODlmXzk4OTU2MDQ2NTMxNDU_0dcc867c-f6d0-44ad-88be-4898826cf556">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gilead Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities. The Company&#x2019;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category as of September&#160;30, 2020.  Recorded losses associated within the Level 3 category include changes to fair value and are recorded within change in fair value of convertible notes in the statement of operations. Refer to Note 13 and Note 15 for the fair value determination of the Level 3 financial liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any financial assets or liabilities as of December 31, 2019 that required Level 3 inputs. There were no transfers of assets between the fair value measurement levels during any of the periods presented in the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icebd3a6e85524ddfae7ab2d335391a20_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzUtMS0xLTEtMzUy_1ce657ca-cd90-4ba1-8692-9dd965ff7e42"
      unitRef="usd">84635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if3525e299a5b4af0be5bf6819c729869_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzUtMy0xLTEtMzUy_ea5c0a28-0dbc-4a54-b20c-83080ef4be05"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iefc9cad03a70461aa7360544a7db02b8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzUtNS0xLTEtMzUy_ad2d64b4-2f1f-494f-a4b3-7a8846e9823c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3880408e89894aeda2c8f29fbbd3aabb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzUtNy0xLTEtMzUy_dfa8cfcd-dabb-48a2-ae4a-9910955b46e5"
      unitRef="usd">84635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibf34c2cfcabc444f928cf7c4d4f21f48_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzYtMS0xLTEtMzUy_b0bd9508-3901-42f8-ae9c-e99f573f8a9d"
      unitRef="usd">1234000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib0ea2ec1be444c429b071d6fbb31c541_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzYtMy0xLTEtMzUy_1f837ec1-183e-4ea7-8842-7230eaef1d90"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i34a2a0c9723b4043be099d02b2adcda9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzYtNS0xLTEtMzUy_dedbdf32-9533-4f9f-9607-73a7477f9ffa"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i31eb8916a43d46619bd5de6a14b21fcf_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzYtNy0xLTEtMzUy_e477d8d5-d0bc-4957-8a68-01d9c4c81339"
      unitRef="usd">1234000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic1322d5329804324b8862de983107090_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzctMS0xLTEtMzUy_99decda2-6251-450c-a001-7f81f3632f5f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i37d7755090cf442b9c9553d09c0c78e4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzctMy0xLTEtMzUy_7d0de2b5-6de5-472f-bb84-6cf2255979be"
      unitRef="usd">18021000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3736170b03754b159e40f2cbb89bdfc6_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzctNS0xLTEtMzUy_bdf596dd-11d7-40e4-a6f4-ff41015ee75e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i680604ecdff84d6583da30f5932ef047_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzctNy0xLTEtMzUy_4398d604-4290-4194-bdb7-beca28600475"
      unitRef="usd">18021000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i98808ce4a14e4f6d9893eafb8348f14f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzgtMS0xLTEtMzUy_f71ed7ad-dba0-49b4-ae14-7fad7c031510"
      unitRef="usd">40926000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icae3269eca18443ca8f367f8ca760d4d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzgtMy0xLTEtMzUy_0f53685f-b069-42bd-8384-228ddd18d8ba"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2fc21197ebfa4519b5f3821c2e7bd9cd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzgtNS0xLTEtMzUy_d32caefb-ccc5-4b95-90de-eddd36e72abd"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0c6f85d2f9144b0f9c6655f0a45deb0b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzgtNy0xLTEtMzUy_94b3f81a-88bf-431a-bcc5-fdfd7a5d859b"
      unitRef="usd">40926000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i573369416f3145549249238391de4f54_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzktMS0xLTEtMzUy_0d26171b-290f-4468-a8d1-85e14540f886"
      unitRef="usd">126795000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2166333152034a59828414d7b029805f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzktMy0xLTEtMzUy_4eb04697-3bb0-430b-a473-d59ad05451a2"
      unitRef="usd">18021000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i96c12e5ec7e247b29b2dbcedcb33e438_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzktNS0xLTEtMzUy_f6cde3a7-a1c4-4e75-b040-d03a07c03e1e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i474c4138d7474661a524846e44986c19_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzktNy0xLTEtMzUy_c68131ca-9b98-4d55-a758-a2034aeeab35"
      unitRef="usd">144816000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ieb3393bbb6f14657970ffb6c3b9bf796_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEyLTEtMS0xLTI1OTE_aebac88c-d517-40a4-a51d-48cdc861301a"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i8ed0d5b5fee34c9da760299481d92409_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEyLTMtMS0xLTI1OTE_c9b173dc-5619-4500-9ecd-b897c832920a"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ia3e139b86417413ba1c2ca3b42137fc7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEyLTUtMS0xLTI1OTE_380bb05a-59fd-4e61-ae95-b694ad94a7d5"
      unitRef="usd">168506000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i35673f0d42234a1a87f1a231ace9457d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEyLTctMS0xLTI1OTE_a859e3f5-d71c-40c6-81ff-53c295189800"
      unitRef="usd">168506000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ie5bdf1d474b04179a7a68c046db8a473_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEzLTEtMS0xLTI1OTE_7e22c3d6-d8fa-40ca-844f-a5e763771029"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ibd30a89a052a4593801ad15c7befa88a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEzLTMtMS0xLTI1OTE_e4fac8e4-f020-4b8b-9dac-22a57340b8b8"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="iecd9407ea32a46d29a98b1840c00b5e5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEzLTUtMS0xLTI1OTE_2568ee69-fbd9-4267-b25c-3c3eda5d09bd"
      unitRef="usd">5488000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i4bf649645154449d937a12dc7b650d3b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzEzLTctMS0xLTI1OTE_0856c30a-a12d-42fa-85ee-d0c1adce30e9"
      unitRef="usd">5488000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i573369416f3145549249238391de4f54_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzE0LTEtMS0xLTI1OTE_dd6006b9-c70a-49cf-ac2f-7cf18fac9994"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2166333152034a59828414d7b029805f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzE0LTMtMS0xLTI1OTE_8da6f045-0a1d-4157-87ef-f5b348761c93"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i96c12e5ec7e247b29b2dbcedcb33e438_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzE0LTUtMS0xLTI1OTE_f2dc0b1f-52b8-4b9f-9e9c-9fd055c9a851"
      unitRef="usd">173994000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i474c4138d7474661a524846e44986c19_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTo5NmNiNGU3ZDZhZGI0OTM2YWNiNTdkMzI5YzJjMjkxNC90YWJsZXJhbmdlOjk2Y2I0ZTdkNmFkYjQ5MzZhY2I1N2QzMjljMmMyOTE0XzE0LTctMS0xLTI1OTE_c237892a-7107-4edd-b442-3ae195183526"
      unitRef="usd">173994000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if583afaf5b244bcca3ee512b9be88c54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzQtMS0xLTEtMzYw_3b7de633-c17f-4e36-b3f3-35e0e98afd80"
      unitRef="usd">112000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i84e2789cb4b74177b02829790b3e940d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzQtMy0xLTEtMzYw_b07ea56c-df13-44af-9348-acd82bf56048"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i37461a4dccc543c794502b870925d09a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzQtNS0xLTEtMzYw_c7da6274-d06e-4f85-9fba-4871d5ddc558"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia34dc0fe00ef4ae7b9326ac0de29b988_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzQtNy0xLTEtMzYw_a33ce441-ce13-4956-9669-d5885d3b7156"
      unitRef="usd">112000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8f8d077e88bd4026bd1bb0363cba99a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzUtMS0xLTEtMzYw_170593c8-07f6-40d9-bbff-756b05e742fc"
      unitRef="usd">1715000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1a45a3c22d2a4df687077e2744eeadf4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzUtMy0xLTEtMzYw_f475524e-3291-4e1b-920c-04a3ff6cd1c0"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib1d31ded16544421a9103017ada1e3d8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzUtNS0xLTEtMzYw_2daab628-166b-450e-aa9a-d7e23657ecbf"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie8e7dcee3fb74a77a44721d2eede0234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzUtNy0xLTEtMzYw_4f28ee60-b7c1-4d71-8fe6-804b039e78a6"
      unitRef="usd">1715000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4076df8add474ba29dc5b999506194be_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzYtMS0xLTEtMzYw_bb664d4a-92c5-4340-ab13-81040a199f60"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i56e6b6f0456e4402a51dcd58d9f97704_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzYtMy0xLTEtMzYw_e5815385-d93a-4c66-bd16-040581476ddd"
      unitRef="usd">4489000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ideaf848d46684b1688cbb86308ac9126_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzYtNS0xLTEtMzYw_ce192758-0751-4354-bb14-2e968e6c33bf"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib2dff33c792e472cb04f1f4a0c4177c6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzYtNy0xLTEtMzYw_3c6ff3a2-b680-4b72-b712-40d5b0f8a5df"
      unitRef="usd">4489000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i230135e8439a495f98bb16d12950f814_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzctMS0xLTEtMzYw_efcf1707-365e-44ff-8dcd-29373dd904ef"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6f054c8a6945414f871dddd891074dfd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzctMy0xLTEtMzYw_d7f42b09-979e-4a8b-a943-f059d5fbbaf1"
      unitRef="usd">26432000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i779c812cecca45018028a8b1b19645f8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzctNS0xLTEtMzYw_0875e54f-86b5-49a0-8435-e57a8604a3ea"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7fbc7564af4d4ca8ab0b6d6ee3eca9e4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzctNy0xLTEtMzYw_b0735ca0-3963-43fc-b595-dd1caedb3ce6"
      unitRef="usd">26432000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id4779748a74d4a69825b5e0020c5ba68_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzgtMS0xLTEtMzYw_2289558c-3b42-425d-bd80-ab41a96b95b5"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i93643158b5c54d28a5f5e8c68a1277e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzgtMy0xLTEtMzYw_9035aa6c-aead-4024-8a01-618953bc654e"
      unitRef="usd">1499000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6335bb67f9274f448c80b37b25c8a24b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzgtNS0xLTEtMzYw_83f05b75-83a8-4f5b-9004-ac7ee51277d8"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i799ef75758464399a4c6a7a23c3f174d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzgtNy0xLTEtMzYw_9c097d82-cb64-47b2-b35e-69986d6df3eb"
      unitRef="usd">1499000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4b6a69f036854687b46ff68bdaa0cd34_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzktMS0xLTEtMzYw_51bc6336-9756-4642-9f2d-3bd5ff3b3f55"
      unitRef="usd">36880000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="idf3accbd97d64e20abccd18a3f976641_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzktMy0xLTEtMzYw_31c09bc9-2665-4ca3-aaae-33f1f1ab4491"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic9ccd829968847d0a85a4e061e73e94a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzktNS0xLTEtMzYw_e66311ba-ebdd-46c6-8374-f23d0141764e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4218d1af33444d8792019dd29458c211_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzktNy0xLTEtMzYw_605c5700-af9b-4292-89d5-e740867ee613"
      unitRef="usd">36880000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1bef37ea13804aa98d20b37c8a9755f2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzEwLTEtMS0xLTM2MA_dc5b8364-e80d-4891-917f-53bc9a9c419d"
      unitRef="usd">38707000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icc6a9845420549d1b467cec0513db1ff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzEwLTMtMS0xLTM2MA_6c56e660-7c24-4705-90cb-379861ebc5c9"
      unitRef="usd">32420000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia172359196044363a8d21deea37250a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzEwLTUtMS0xLTM2MA_e7b2b9ba-ab83-446b-a5f1-56df38660aae"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ica89d2973d6e42c69a454cbcfad99204_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMDkvZnJhZzo2ZmM5YjA5NDNkMGI0NDk1OGNkZWI3OTA0ODg0ODg5Zi90YWJsZTpkN2ZjYThjMTc1YWY0NGE2OTgyZTdiNmQ0ZTVjNTMzZS90YWJsZXJhbmdlOmQ3ZmNhOGMxNzVhZjQ0YTY5ODJlN2I2ZDRlNWM1MzNlXzEwLTctMS0xLTM2MA_eff53d5f-4c51-40cd-ac21-e912eeb790bf"
      unitRef="usd">71127000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90ZXh0cmVnaW9uOmE5MDliZDExYmU1MDQ5Zjk5MmMwOTFkM2U1Y2M4ZmYzXzEyNjQ0MzgzNzIxMDk3_7013b126-ae92-416d-bfd2-92dbce038bf3">INVESTMENTS&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of available-for-sale securities by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These available-for-sale securities were classified on the Company&#x2019;s balance sheets as of September&#160;30, 2020 and December&#160;31, 2019 as:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale securities by contractual maturity as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1 year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments not due at a single maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of September&#160;30, 2020 and December&#160;31, 2019, the remaining contractual maturities of available-for-sale securities were less than 23 months and 18 months, respectively. There have been no significant realized losses on available-for-sale securities for any of the periods presented in the accompanying financial statements. Based on the Company&#x2019;s review of its available-for-sale securities, the Company believes that it had no other-than-temporary impairments on these securities as of September&#160;30, 2020 and December&#160;31, 2019 because the Company does not intend to sell these securities nor does it believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for any of the periods presented in the accompanying financial statements.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90ZXh0cmVnaW9uOmE5MDliZDExYmU1MDQ5Zjk5MmMwOTFkM2U1Y2M4ZmYzXzEyNjQ0MzgzNzIxMDk5_4c859e90-d56f-4f2b-a00e-c606e2b7b328">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of available-for-sale securities by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These available-for-sale securities were classified on the Company&#x2019;s balance sheets as of September&#160;30, 2020 and December&#160;31, 2019 as:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale securities by contractual maturity as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1 year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments not due at a single maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i76a3c48f37e74d588132870025f958b3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzQtMS0xLTEtMzkx_80332d35-e928-476d-9321-704e040ee8e7"
      unitRef="usd">84635000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i76a3c48f37e74d588132870025f958b3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzQtNy0xLTEtMzkx_0ae33e3e-878e-4c54-ae3f-196969eac8bc"
      unitRef="usd">84635000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i903c1dd51d3f4f3294ec6e9659628839_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzUtMS0xLTEtMzkx_da1d4acd-29aa-449e-82ed-599d9d49b3c4"
      unitRef="usd">1225000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i903c1dd51d3f4f3294ec6e9659628839_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzUtMy0xLTEtMzkx_7c074357-7a73-4145-863b-0a57d37a8ec0"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i903c1dd51d3f4f3294ec6e9659628839_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzUtNS0xLTEtMzkx_4f4e3e04-853d-4a90-bfe1-c0eac60093d7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i903c1dd51d3f4f3294ec6e9659628839_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzUtNy0xLTEtMzkx_650d8681-931e-4286-89a7-fb8fea79d41a"
      unitRef="usd">1234000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzYtMS0xLTEtMzkx_0ca0e8ca-aa67-4c70-aeea-9b7b9c4d509b"
      unitRef="usd">18011000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzYtMy0xLTEtMzkx_93ffdd9e-9c9a-46f9-bc2e-8914784bfdfd"
      unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzYtNS0xLTEtMzkx_a5f58392-d5d9-4b6d-ad2f-66653e16eefc"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf05bd7c9b21462aacb8c6ac0c4fb8be_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzYtNy0xLTEtMzkx_b5ff777f-14be-4d33-8f43-312c2f5288d9"
      unitRef="usd">18021000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1522d2b251964ba5a986cdf9d5591a43_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzctMS0xLTEtMzkx_f1776be6-5c0f-4ea3-b798-e94a6320fca8"
      unitRef="usd">40898000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1522d2b251964ba5a986cdf9d5591a43_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzctMy0xLTEtMzkx_c5345440-488e-46b0-8d17-c74ed6450a71"
      unitRef="usd">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1522d2b251964ba5a986cdf9d5591a43_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzctNS0xLTEtMzkx_36e6808f-3979-42c5-848d-5c44613a2059"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1522d2b251964ba5a986cdf9d5591a43_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzctNy0xLTEtMzkx_2b2c1961-fa8e-4ea8-8eef-7f078bfaf1ff"
      unitRef="usd">40926000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzgtMS0xLTEtMzkx_0bf77d55-1e3c-4d4c-a2b9-5a932ea1a657"
      unitRef="usd">144769000</kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzgtMy0xLTEtMzkx_09e42bfe-2327-4ca6-a4f0-aa373695320a"
      unitRef="usd">57000</kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax>
    <kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzgtNS0xLTEtMzkx_04df060a-f89d-4cdc-b0e4-da42da063b90"
      unitRef="usd">10000</kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjZmE5MTdlY2U4NzA0YThiYTIzYzBiNjc4NWIzNmFjNy90YWJsZXJhbmdlOmNmYTkxN2VjZTg3MDRhOGJhMjNjMGI2Nzg1YjM2YWM3XzgtNy0xLTEtMzkx_87ccfe6d-d254-4adb-a395-4c07ec2c668a"
      unitRef="usd">144816000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="if34c5b72f428403a99b45063852c073b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzMtMS0xLTEtMzk2_eb824c45-68ec-4c00-80a5-dcf4a67bb914"
      unitRef="usd">112000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="if34c5b72f428403a99b45063852c073b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzMtNy0xLTEtMzk2_b55745d7-36a9-4f2c-91a8-d22ab6c89204"
      unitRef="usd">112000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7b10d2d52aec4721944b453f9433b17a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzQtMS0xLTEtMzk2_1e5cedc9-dc19-4623-a346-83bfc861e21e"
      unitRef="usd">1715000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7b10d2d52aec4721944b453f9433b17a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzQtMy0xLTEtMzk2_efc47cbd-cf53-4e8f-9c4e-d51292e530ff"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7b10d2d52aec4721944b453f9433b17a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzQtNS0xLTEtMzk2_aa5a188c-0624-4aa7-9064-2277c17609b6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b10d2d52aec4721944b453f9433b17a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzQtNy0xLTEtMzk2_ae73db06-a8ba-4b26-a727-66fae5c6cbfa"
      unitRef="usd">1715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i62e3f25eb0c84772add6ec6f825655e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzUtMS0xLTEtMzk2_c6c7439b-3fa1-4ea8-b58d-da19e3b36d3c"
      unitRef="usd">4490000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i62e3f25eb0c84772add6ec6f825655e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzUtMy0xLTEtMzk2_e8c16751-e654-41b4-8e1a-f47ae90520a4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i62e3f25eb0c84772add6ec6f825655e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzUtNS0xLTEtMzk2_0568dc53-e7fb-4232-87db-dc76969c73fe"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62e3f25eb0c84772add6ec6f825655e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzUtNy0xLTEtMzk2_aa03a50f-0c2e-4c2e-88d6-e4ae434ed69c"
      unitRef="usd">4489000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibc04e4557db74cd5a579218a21c7f715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzYtMS0xLTEtMzk2_92d84224-285a-47e9-be77-e2da7c5e41aa"
      unitRef="usd">26444000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibc04e4557db74cd5a579218a21c7f715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzYtMy0xLTEtMzk2_2a94dacd-f854-4dab-ad34-3f32a0dac4be"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibc04e4557db74cd5a579218a21c7f715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzYtNS0xLTEtMzk2_6710c6d0-65d5-46ea-8728-04ddafdcb740"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc04e4557db74cd5a579218a21c7f715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzYtNy0xLTEtMzk2_3039e508-84da-4cea-b98e-b2b4715d5bd2"
      unitRef="usd">26432000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iee26b5d7183c4798998478356fcefae4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzctMS0xLTEtMzk2_9f6bcfdc-f8be-45f9-a3a5-ce3995c8b24b"
      unitRef="usd">1500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iee26b5d7183c4798998478356fcefae4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzctMy0xLTEtMzk2_38eca6ef-b520-4f10-8fe0-f0a56d8af7bb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iee26b5d7183c4798998478356fcefae4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzctNS0xLTEtMzk2_8ff47623-f8dd-45e9-8d50-d69e36997030"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee26b5d7183c4798998478356fcefae4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzctNy0xLTEtMzk2_313982c8-554f-4b96-b611-7e6130210a8d"
      unitRef="usd">1499000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie80dcec257aa4382b7cd1712a6f7b431_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzgtMS0xLTEtMzk2_383e5262-3d73-4101-aed0-eaf5a11c2bbe"
      unitRef="usd">36884000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie80dcec257aa4382b7cd1712a6f7b431_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzgtMy0xLTEtMzk2_2c1d9265-a2f5-45f2-a536-ab742fbecae5"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie80dcec257aa4382b7cd1712a6f7b431_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzgtNS0xLTEtMzk2_80f41967-ef1e-40f4-8bf9-bc0b13d0e536"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie80dcec257aa4382b7cd1712a6f7b431_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzgtNy0xLTEtMzk2_5d119104-bd4f-4e38-893e-ee76db7c9685"
      unitRef="usd">36880000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzktMS0xLTEtMzk2_b4335340-519c-4251-9306-a617cc38fd41"
      unitRef="usd">71145000</kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzktMy0xLTEtMzk2_5a1bf0e8-cdcb-4c80-85fa-73584b4f290b"
      unitRef="usd">2000</kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax>
    <kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzktNS0xLTEtMzk2_33bb65ab-acf8-42e2-8c40-2c8e877d07ca"
      unitRef="usd">20000</kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTo1ZmFhZmI2MmRhYWU0ZTFkOTY1YjJmZjJmNTBjMzIzMi90YWJsZXJhbmdlOjVmYWFmYjYyZGFhZTRlMWQ5NjViMmZmMmY1MGMzMjMyXzktNy0xLTEtMzk2_fb4759b4-d2c7-402d-854a-82be44a14a77"
      unitRef="usd">71127000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzMtMS0xLTEtNDA5_9e902398-5560-4da7-9d8c-cc401764c998"
      unitRef="usd">84973000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzMtMy0xLTEtNDA5_e3a875df-dd61-4248-b1f6-ba4f89ccb3d2"
      unitRef="usd">6751000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzQtMS0xLTEtNDA5_875dd458-2a78-430c-97e3-9a24ae485a50"
      unitRef="usd">55069000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzQtMy0xLTEtNDA5_72fb0596-2949-4339-b7d4-bc840feefecb"
      unitRef="usd">59614000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzUtMS0xLTEtNDA5_e349331a-1b57-424f-8435-469a44bb931d"
      unitRef="usd">4774000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzUtMy0xLTEtNDA5_7263bc82-622b-49ff-95ec-06bd55df2c31"
      unitRef="usd">4762000</us-gaap:LongTermInvestments>
    <us-gaap:InvestmentsAndCash
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzYtMS0xLTEtNDA5_99dd6046-b544-4841-918a-a37cf09c89c6"
      unitRef="usd">144816000</us-gaap:InvestmentsAndCash>
    <us-gaap:InvestmentsAndCash
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTpjOTAxODE3NTk1OGQ0MzcxOGEyNzFhZmI1NzQ1NDBlMC90YWJsZXJhbmdlOmM5MDE4MTc1OTU4ZDQzNzE4YTI3MWFmYjU3NDU0MGUwXzYtMy0xLTEtNDA5_183b67e3-946c-4808-b8fe-48f3d6124162"
      unitRef="usd">71127000</us-gaap:InvestmentsAndCash>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzItMS0xLTEtNDE3_6a04155c-427a-4cf4-97d3-ae00499a41ea"
      unitRef="usd">55407000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzItMy0xLTEtNDE3_4efd0a3c-5a60-4be4-a114-cac01c66b971"
      unitRef="usd">66253000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzMtMS0xLTEtNDE3_1814edf7-da1f-45d1-b443-4b5b5e0e3044"
      unitRef="usd">4774000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzMtMy0xLTEtNDE3_3eccea42-2e24-477a-8d34-033f8ff02abd"
      unitRef="usd">4762000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzQtMS0xLTEtNDE3_a419f831-6322-408d-9ee9-61c408312495"
      unitRef="usd">84635000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzQtMy0xLTEtNDE3_f4a8f13b-c52b-4915-89a4-e8abc0dd08b0"
      unitRef="usd">112000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:InvestmentsAndCash
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzUtMS0xLTEtNDE3_c5a63243-8ca1-4fbb-ace0-3191437c8f5c"
      unitRef="usd">144816000</us-gaap:InvestmentsAndCash>
    <us-gaap:InvestmentsAndCash
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90YWJsZTozNWUxZjJhZGYxZTE0MDIyOTBmNTAwNmU2ZGM3MWEwMC90YWJsZXJhbmdlOjM1ZTFmMmFkZjFlMTQwMjI5MGY1MDA2ZTZkYzcxYTAwXzUtMy0xLTEtNDE3_c2fa3622-748c-4aa8-8ca9-5ae33e428739"
      unitRef="usd">71127000</us-gaap:InvestmentsAndCash>
    <kron:DebtSecuritiesAvailableForSaleRemainingContractualMaturity
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90ZXh0cmVnaW9uOmE5MDliZDExYmU1MDQ5Zjk5MmMwOTFkM2U1Y2M4ZmYzXzEyNjQ0MzgzNzIxMTA2_edb21eaa-cef0-456e-ac9a-9e56fffb3496">P23M</kron:DebtSecuritiesAvailableForSaleRemainingContractualMaturity>
    <kron:DebtSecuritiesAvailableForSaleRemainingContractualMaturity
      contextRef="i6c206960ada7462e824eea778e31e777_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTIvZnJhZzphOTA5YmQxMWJlNTA0OWY5OTJjMDkxZDNlNWNjOGZmMy90ZXh0cmVnaW9uOmE5MDliZDExYmU1MDQ5Zjk5MmMwOTFkM2U1Y2M4ZmYzXzEyNjQ0MzgzNzIxMTIy_2c017393-705c-4f66-bb39-5922e22d043e">P18M</kron:DebtSecuritiesAvailableForSaleRemainingContractualMaturity>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90ZXh0cmVnaW9uOjE2NjhjMzc0ZmI5ZTQ1OTU4ZTYwNjgxMGMwYzQ4ZTRkXzEzMTk0MTM5NTMzNTMz_0d2a5daf-93e1-459e-ac64-157f7ad2e20c">PREPAID EXPENSES AND OTHER CURRENT ASSETS &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest on short-term available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid equipment service contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid external research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90ZXh0cmVnaW9uOjE2NjhjMzc0ZmI5ZTQ1OTU4ZTYwNjgxMGMwYzQ4ZTRkXzEzMTk0MTM5NTMzNTM0_230bfc93-93a1-4754-b5b5-c38c970b8a5a">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest on short-term available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid equipment service contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid external research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <kron:DebtSecuritiesAvailableForSaleAccruedInterest
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzItMS0xLTEtNDQ2_91f95ce4-212c-4d3d-9788-d590eaeb0ff3"
      unitRef="usd">217000</kron:DebtSecuritiesAvailableForSaleAccruedInterest>
    <kron:DebtSecuritiesAvailableForSaleAccruedInterest
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzItMy0xLTEtNDUy_b1d7c133-863b-433c-ab46-e82c2bb320e4"
      unitRef="usd">198000</kron:DebtSecuritiesAvailableForSaleAccruedInterest>
    <kron:PrepaidEquipmentServiceContracts
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzMtMS0xLTEtNDQ5_254434c1-7ca3-413b-ac7a-aac8f02e82a9"
      unitRef="usd">432000</kron:PrepaidEquipmentServiceContracts>
    <kron:PrepaidEquipmentServiceContracts
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzMtMy0xLTEtNDUy_bea6518a-b976-48ee-b5f7-7916e8e15ccd"
      unitRef="usd">191000</kron:PrepaidEquipmentServiceContracts>
    <kron:PrepaidExternalResearchAndDevelopment
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzQtMS0xLTEtNDQ2_c3a66a3d-ebc9-40d2-a1fb-f858cb85be5f"
      unitRef="usd">410000</kron:PrepaidExternalResearchAndDevelopment>
    <kron:PrepaidExternalResearchAndDevelopment
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzQtMy0xLTEtNDUy_591d3c98-f392-459c-80f5-b40c9bdb23b9"
      unitRef="usd">113000</kron:PrepaidExternalResearchAndDevelopment>
    <kron:PrepaidSoftware
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzUtMS0xLTEtNDQ5_94ffd776-4699-4ab9-9a39-09b82d6b6209"
      unitRef="usd">254000</kron:PrepaidSoftware>
    <kron:PrepaidSoftware
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzUtMy0xLTEtNDUy_2c93fe78-c7f8-420b-8248-c927ff494b41"
      unitRef="usd">180000</kron:PrepaidSoftware>
    <us-gaap:PrepaidInsurance
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzYtMS0xLTEtNDQ5_6c9a01c1-74e8-4b4f-91c7-da54b9d35ed8"
      unitRef="usd">36000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzYtMy0xLTEtNDUy_c9e13ac2-7d4b-477b-85cc-e0fbfa8f2b71"
      unitRef="usd">23000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidRent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzctMS0xLTEtNDQ2_04e9c18b-cde1-4ee6-b0dd-e3a11d404ea1"
      unitRef="usd">3000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzctMy0xLTEtNDUy_764b76ba-7c4e-48e9-a654-6ef2096535da"
      unitRef="usd">196000</us-gaap:PrepaidRent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzgtMS0xLTEtNDQ5_3f2273e8-5800-4587-98d4-63283d18d4d4"
      unitRef="usd">276000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzgtMy0xLTEtNDUy_18318cb4-b897-4588-866b-223d47740138"
      unitRef="usd">218000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzktMS0xLTEtNDQ2_264e6031-7654-4a0d-90c1-3382a6f26544"
      unitRef="usd">1628000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTUvZnJhZzoxNjY4YzM3NGZiOWU0NTk1OGU2MDY4MTBjMGM0OGU0ZC90YWJsZTpiNzRhNGJkMmI4YjA0YTc5Yjc3MjZmNGYyZmMxMzc0ZC90YWJsZXJhbmdlOmI3NGE0YmQyYjhiMDRhNzliNzcyNmY0ZjJmYzEzNzRkXzktMy0xLTEtNDUy_60f19a2b-0c34-4a33-b344-99c2ab37f21d"
      unitRef="usd">1119000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzEzMTk0MTM5NTMzOTQx_536393ee-c2e1-4f98-8a8a-7f8b07f93a0d">PROPERTY AND EQUIPMENT, NET&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease on R&amp;amp;D equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation and amortization expense was $0.2&#160;million and $0.1 million for the three months ended September&#160;30, 2020 and 2019, respectively, and $0.5 million and $0.2 million for the nine months ended September&#160;30, 2020 and 2019, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i23250faf272245f5a94cf235af7afc83_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzMtMS0xLTEtNDY4_2da96ad0-3ae5-4ade-8179-e7c1f2f02a28"
      unitRef="usd">5256000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i32dc3ea144344868a7ed2a838d5f9fc6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzMtMy0xLTEtNDY4_1824853e-ba07-4b0f-8b7a-40d7f985e72a"
      unitRef="usd">3978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzQtMS0xLTEtNDY4_653c686c-8df9-470d-984e-1eaf2b046180"
      unitRef="usd">139000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzQtMy0xLTEtNDY4_58e02bb3-0959-4b84-8c68-73fcf598cf72"
      unitRef="usd">139000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4b3898290b234512a7b35eb92edd64fb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzUtMS0xLTEtNDY4_843c5dc7-4bf9-4217-98b0-8a92814f9d76"
      unitRef="usd">5891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1515d6ea7fa64e37b804f072218ceeaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzUtMy0xLTEtNDY4_1447ef74-0020-45ce-a304-3c3e105e452e"
      unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzYtMS0xLTEtNDY4_ea2f9d5b-7676-4b02-a86d-e5ee1b17457a"
      unitRef="usd">11286000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzYtMy0xLTEtNDY4_279ea4b2-1ef4-42fc-8f52-197750cb3f3b"
      unitRef="usd">4167000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzctMS0xLTEtNDY4_4db4f5a6-7aaa-40b2-b9e3-488ac7ebd143"
      unitRef="usd">985000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzctMy0xLTEtNDY4_6431d8a1-c3a1-4217-8bd1-8f7107d71820"
      unitRef="usd">446000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzgtMS0xLTEtNDY4_af23f6bf-ffc4-4726-b86c-ca4f34d5de34"
      unitRef="usd">10301000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90YWJsZTplNzE4YzViMmUxMTA0MGFhODFmZjYwYmY4YmRkYmU3Ni90YWJsZXJhbmdlOmU3MThjNWIyZTExMDQwYWE4MWZmNjBiZjhiZGRiZTc2XzgtMy0xLTEtNDY4_b609d13b-500d-4ed5-8be4-da4b55d95d7e"
      unitRef="usd">3721000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzMyOTg1MzQ4ODM3NDY_3592eba5-a860-4cdd-8105-ae85884b720d"
      unitRef="usd">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzMyOTg1MzQ4ODM3NjY_d184ae35-9cc0-4edc-a542-a290e5bf107e"
      unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzMyOTg1MzQ4ODM5NDI_a5ceb7f5-e58b-4cde-830c-804ec7702b2f"
      unitRef="usd">500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMTgvZnJhZzpmY2NmN2Y2ZmUxMmM0ZjkyOGM1ODM2YWZhNmNmODI5OS90ZXh0cmVnaW9uOmZjY2Y3ZjZmZTEyYzRmOTI4YzU4MzZhZmE2Y2Y4Mjk5XzMyOTg1MzQ4ODM5NTA_f54f0158-5148-44e9-985a-3f71fcc11475"
      unitRef="usd">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90ZXh0cmVnaW9uOjFlYWI0ODU1NmFlNDQ0YzNiZTBiYjg0ZGY5NTA4Mzc5Xzk4OTU2MDQ2NTAzNjI_bee88d1b-2290-4992-8b6e-04895743a34e">ACCRUED EXPENSES AND CURRENT PORTION OF OTHER LIABILITIES&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued franchise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of other liabilities consist of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of unvested early exercised share liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current portion of other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90ZXh0cmVnaW9uOjFlYWI0ODU1NmFlNDQ0YzNiZTBiYjg0ZGY5NTA4Mzc5Xzk4OTU2MDQ2NTAzNjA_46b729de-887e-419d-b922-aac0c7f51db1">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued franchise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzItMS0xLTEtNDg4_be47b987-41d8-461b-9069-935722ad022f"
      unitRef="usd">1107000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzItMy0xLTEtNDk1_53ed6c70-e4c8-4279-8830-dcfdb065c845"
      unitRef="usd">528000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzMtMS0xLTEtNDkx_ec08ca8e-8ceb-4e6e-95e3-43a8221ec95b"
      unitRef="usd">38000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzMtMy0xLTEtNDk1_8239f197-44e5-479b-bd2f-95738b025955"
      unitRef="usd">43000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <kron:AccruedExternalResearchAndDevelopmentCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzQtMS0xLTEtNDkx_894c5593-f7eb-4f87-ab6a-eadba411aff6"
      unitRef="usd">469000</kron:AccruedExternalResearchAndDevelopmentCurrent>
    <kron:AccruedExternalResearchAndDevelopmentCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzQtMy0xLTEtNDk1_efbec855-85cd-49e7-a60b-774bf89c88ba"
      unitRef="usd">241000</kron:AccruedExternalResearchAndDevelopmentCurrent>
    <kron:AccruedOfferingCostsCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzUtMS0xLTEtNzI5MA_77a45231-c885-4d23-bc3f-eb0311b49467"
      unitRef="usd">83000</kron:AccruedOfferingCostsCurrent>
    <kron:AccruedOfferingCostsCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzUtMy0xLTEtNzI5MA_20ad7c5e-6797-4c6e-bce9-faf7364eba70"
      unitRef="usd">0</kron:AccruedOfferingCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzUtMS0xLTEtNDkx_311ece8b-017e-461a-82c1-8041df7f13aa"
      unitRef="usd">83000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzUtMy0xLTEtNDk1_540b5283-30d9-49f2-8f21-143e7c260384"
      unitRef="usd">6000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzYtMS0xLTEtNDg4_9a71bf37-0924-4628-8fc7-73c4e008f449"
      unitRef="usd">1780000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZTowOTc1ZTA1MGQ1MmY0NmQ2OGVkYTcxMTE5NWVkMTI1My90YWJsZXJhbmdlOjA5NzVlMDUwZDUyZjQ2ZDY4ZWRhNzExMTk1ZWQxMjUzXzYtMy0xLTEtNDk1_8281dc73-1b14-4f4a-923a-673003211c8d"
      unitRef="usd">818000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90ZXh0cmVnaW9uOjFlYWI0ODU1NmFlNDQ0YzNiZTBiYjg0ZGY5NTA4Mzc5Xzk4OTU2MDQ2NTAzNjE_ed028b70-41f1-4b11-8f74-7f5c6c4b4676">Current portion of other liabilities consist of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of unvested early exercised share liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current portion of other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzItMS0xLTEtNTAz_09c3a1d1-edb4-4717-85ba-38a8c70b1ddc"
      unitRef="usd">14000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzItMy0xLTEtNTA2_c8d5e576-32bb-4e07-b94a-6393d5e4d433"
      unitRef="usd">32000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzMtMS0xLTEtNTAz_c4174ead-b4df-4d7f-825c-08ecec6e889c"
      unitRef="usd">2123000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzMtMy0xLTEtNTA2_9b0bf884-8139-4242-a119-6ff0f3dcd938"
      unitRef="usd">56000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzQtMS0xLTEtNTAw_8054924a-78fc-4bac-9e6f-7ba2813ec274"
      unitRef="usd">2137000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjEvZnJhZzoxZWFiNDg1NTZhZTQ0NGMzYmUwYmI4NGRmOTUwODM3OS90YWJsZToyY2NmOWZlOGI0ZTU0YWU1ODlhYTEwMjhlNjE1YWY1Yi90YWJsZXJhbmdlOjJjY2Y5ZmU4YjRlNTRhZTU4OWFhMTAyOGU2MTVhZjViXzQtMy0xLTEtNTA2_3e668506-f24e-4351-a1ef-c580cb852521"
      unitRef="usd">88000</us-gaap:OtherLiabilitiesCurrent>
    <kron:TemporaryEquityTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzE0MjkzNjUxMTgxNTYw_18b82db2-6c55-4286-8cdb-fadb6b4e5470">PREFERRED STOCK&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2018, the Company completed a private placement (Series Seed Financing) in which it issued an aggregate of 7,806,977 shares of its Series Seed Convertible Preferred Stock (Series Seed Preferred Stock) at a purchase price of $2.30769 per share, for aggregate gross proceeds of $18.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2019, the Company completed a private placement (the Series A Financing) in which it issued 13,697,916 shares of its Series A Convertible Preferred Stock (Series A Preferred Stock) at a purchase price of $7.6654 per share, for aggregate gross proceeds of $105.0 million less issuance costs of $0.1 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Preferred Stock (as defined below) consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;br/&gt;Stock&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;br/&gt;Preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Issuable Upon&lt;br/&gt;Conversion&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands, except share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series Seed Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,806,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,806,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,697,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;104,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,451,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21,506,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21,504,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;122,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;123,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;br/&gt;Stock&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;br/&gt;Preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Issuable Upon&lt;br/&gt;Conversion&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands, except share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series Seed Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,806,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,806,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,697,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;104,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,451,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21,506,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21,504,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;122,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;123,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the completion of the IPO (See Note 1), all outstanding shares of convertible preferred stock were automatically converted into 22,687,625 shares of common stock.&lt;/span&gt;&lt;/div&gt;</kron:TemporaryEquityTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ibd7af7df3693489cbbd3c087fa18aa9b_D20180522-20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODgyNTY_47a5f219-52d4-45e1-919b-0dbf8772f5e2"
      unitRef="shares">7806977</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1737f19c2c5741778344526c60c0bf8b_I20180522"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkxMDIwMjc_e700a422-9a78-4e8e-b3e3-d3f05ed846e0"
      unitRef="usdPerShare">2.30769</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="ibd7af7df3693489cbbd3c087fa18aa9b_D20180522-20180522"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODgzNzY_d289e135-87eb-4ba9-9a63-ca1cd897023f"
      unitRef="usd">18000000.0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icacd7aa366554a0abf8c53a9d66b1c77_D20190701-20190701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk0NTU_31114f4b-cf06-4c65-9a88-bdfdcf578035"
      unitRef="shares">13697916</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i20ce35e12ca14274b80c3a91dc888b6c_I20190701"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk1NjA_63602ad1-5fef-40a2-a361-09793a684262"
      unitRef="usdPerShare">7.6654</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="icacd7aa366554a0abf8c53a9d66b1c77_D20190701-20190701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk2MDc_e5492934-2181-4774-a47e-dc81dcff27e0"
      unitRef="usd">105000000.0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="icacd7aa366554a0abf8c53a9d66b1c77_D20190701-20190701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk5NTk_367ac3b7-4451-4647-a10c-885a756e5d47"
      unitRef="usd">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzE0MjkzNjUxMTgxNTYx_df7e28db-f7a4-4da5-b2d6-aa2614efdba7">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Preferred Stock (as defined below) consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;br/&gt;Stock&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;br/&gt;Preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Issuable Upon&lt;br/&gt;Conversion&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands, except share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series Seed Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,806,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,806,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,697,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;104,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,451,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21,506,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21,504,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;122,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;123,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;br/&gt;Stock&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;br/&gt;Preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Issuable Upon&lt;br/&gt;Conversion&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands, except share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series Seed Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,806,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,806,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,697,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;104,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,451,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21,506,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21,504,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;122,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;123,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtMS0xLTEtNTI1_d3dd6184-ccde-415e-9d98-01829376839d"
      unitRef="shares">7806977</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtMy0xLTEtNTI1_2031a361-72df-47b0-b72f-574688cbe3b5"
      unitRef="shares">7806977</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtMy0xLTEtNTI1_d555fce0-beb6-4e27-b340-d05824fe829a"
      unitRef="shares">7806977</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtNS0xLTEtNTI1_51316d32-784c-495d-b5e2-72f8b9e5b53b"
      unitRef="usd">17985000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtNy0xLTEtNTI1_d1e4f839-cada-4b42-9d55-e284ba2513b1"
      unitRef="usd">18016000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="ia4d2cea370534ae6a6e8cf43fd8c517d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzQtOS0xLTEtNTE0_07e65d61-c3d8-442d-bf22-fce855d8becd"
      unitRef="shares">8236347</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtMS0xLTEtNTI1_4ff916c4-d4d2-47cf-bb71-f7d4798ca8ea"
      unitRef="shares">13700000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtMy0xLTEtNTI1_1e7aa695-e790-4532-801e-8178bc48f332"
      unitRef="shares">13697916</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtMy0xLTEtNTI1_79f0c871-de53-4b1e-bd62-e2847d42da52"
      unitRef="shares">13697916</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtNS0xLTEtNTI1_69cbb07a-dc46-4816-b689-52eaf2e9c2d3"
      unitRef="usd">104922000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtNy0xLTEtNTI1_de90bc5d-b98e-4fe5-86e7-9832a3e6e23e"
      unitRef="usd">105000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i72eae238362f4c8b8de479d633195c0d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzUtOS0xLTEtNTE0_5c8a78b8-9901-4d17-9626-0692b577e184"
      unitRef="shares">14451278</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtMS0xLTEtNTI1_dd3c477e-4c69-4ca5-a19a-ff734179f609"
      unitRef="shares">21506977</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtMy0xLTEtNTI1_cf47ce55-99d8-45c0-9dc1-5123b423167b"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtMy0xLTEtNTI1_ef3469c7-f58d-4c6c-bc0c-f5b09b579aa8"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtNS0xLTEtNTI1_4b53ce29-7bc8-42c3-8787-9c64d7eec964"
      unitRef="usd">122907000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtNy0xLTEtNTI1_37887ec7-4f87-4721-b8b6-27a7ffa66032"
      unitRef="usd">123016000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo2Nzc5NTMxOWY5MmQ0MGExODc4NWYxNDQ1Yzc0MmY2Ny90YWJsZXJhbmdlOjY3Nzk1MzE5ZjkyZDQwYTE4Nzg1ZjE0NDVjNzQyZjY3XzYtOS0xLTEtNTE0_9eb5a1b7-b7d3-4ecb-aae3-b5bf10f03b89"
      unitRef="shares">22687625</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="idfef7d206519439a936e6eb262b31e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtMS0xLTEtNTMx_4e4da09a-35c1-49ad-89ef-0209fb6380d4"
      unitRef="shares">7806977</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="idfef7d206519439a936e6eb262b31e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtMy0xLTEtNTMx_1c517f19-8305-4e02-af25-9d96efdce4cd"
      unitRef="shares">7806977</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="idfef7d206519439a936e6eb262b31e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtMy0xLTEtNTMx_37200905-44f3-4e3f-96ea-34f53281c482"
      unitRef="shares">7806977</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="idfef7d206519439a936e6eb262b31e71_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtNS0xLTEtNTMx_3dc383e5-550a-465c-b003-2982c436f21a"
      unitRef="usd">17985000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="idfef7d206519439a936e6eb262b31e71_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtNy0xLTEtNTMx_68bfa5bc-57a3-488b-a512-21fc5da260fb"
      unitRef="usd">18016000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="idfef7d206519439a936e6eb262b31e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzMtOS0xLTEtMA_560ccd4b-079c-4ec6-a4f7-dc2ea2262e13"
      unitRef="shares">8236347</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i1dc130be29104c028617076697807621_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtMS0xLTEtNTMx_5ceae56c-9933-4086-8ebe-f8a149f569b7"
      unitRef="shares">13700000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i1dc130be29104c028617076697807621_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtMy0xLTEtNTMx_0ca4770d-5b32-4c6d-aae0-4ee798a99010"
      unitRef="shares">13697916</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i1dc130be29104c028617076697807621_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtMy0xLTEtNTMx_d7db5187-161a-4bba-aa59-324f7df3501c"
      unitRef="shares">13697916</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i1dc130be29104c028617076697807621_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtNS0xLTEtNTMx_67887f4a-b0da-4431-8d71-95c4c6f280e9"
      unitRef="usd">104922000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i1dc130be29104c028617076697807621_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtNy0xLTEtNTMx_e9062cf4-3b86-4f7d-91b1-08b024fded76"
      unitRef="usd">105000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i1dc130be29104c028617076697807621_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzQtOS0xLTEtMA_363084c3-4bbf-4c6b-98b5-ef69418d5e60"
      unitRef="shares">14451278</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtMS0xLTEtNTMx_00fe17a1-aa22-4527-86a0-c50a419e90ab"
      unitRef="shares">21506977</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtMy0xLTEtNTMx_87ff17ac-d723-4893-8f99-81b2033dfd47"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtMy0xLTEtNTMx_b9c08e55-0cfd-4055-89c7-6004d0525f3a"
      unitRef="shares">21504893</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtNS0xLTEtNTMx_ed07a317-f838-4712-b4f8-5ce692498da0"
      unitRef="usd">122907000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtNy0xLTEtNTMx_05bb1ed1-eb75-4a01-94de-1a00bb54ef5b"
      unitRef="usd">123016000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90YWJsZTo4YWFhZjIwY2I3ZTc0OWY1OWY0ZDM1ODJkY2I0NDMxMC90YWJsZXJhbmdlOjhhYWFmMjBjYjdlNzQ5ZjU5ZjRkMzU4MmRjYjQ0MzEwXzUtOS0xLTEtMA_426c93fb-6419-4f44-b08a-69ea64473612"
      unitRef="shares">22687625</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i3690868d9bd846d58fea672236b4ef2f_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjQvZnJhZzpjMGI0ZjY2ODJkM2M0YzhlYmFiNDcyODQxMzJhM2ZhNy90ZXh0cmVnaW9uOmMwYjRmNjY4MmQzYzRjOGViYWI0NzI4NDEzMmEzZmE3XzI3NDg3NzkwODk4Nzk_ba03fcfe-7cfb-41ed-a0e5-a9eb0cb6656d"
      unitRef="shares">22687625</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzEzMTk0MTM5NTMzOTMz_8eea75ec-abf6-401a-a122-1261f22f0b45">COMMON STOCKPursuant to the Company&#x2019;s amended and restated certificate of incorporation, filed on July 1, 2019, the Company was authorized to issue up to 40,000,000 shares of its common stock, par value $0.001.  As of September&#160;30, 2020 and December&#160;31, 2019, there were 6,284,326 and 5,660,391 shares issued and outstanding, respectively.Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Subject to the rights of the Preferred Stock, holders of the Company&#x2019;s common stock are entitled to receive dividends, as may be declared by the Board of Directors.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0bc479aee05e472aaa0315eec9166109_I20190701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzEzMTk0MTM5NTMzOTIy_93c4bd76-1c48-4e65-b9ac-bae178adbe46"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0bc479aee05e472aaa0315eec9166109_I20190701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzEzMTk0MTM5NTMzOTAz_45772285-ee3d-4872-ab50-d7e510388c3b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzMyOTg1MzQ4ODM4NjE_710c7f4e-5cb0-4eb5-8489-33759bb2ce58"
      unitRef="shares">6284326</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzMyOTg1MzQ4ODM4NjE_81e42231-5184-4ee5-9738-73eacfa3078c"
      unitRef="shares">6284326</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzI3NDg3NzkwNzAyMjY_b1a4f1c4-65c3-4873-990d-f540cf8f64a4"
      unitRef="shares">5660391</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMjcvZnJhZzo2NDYzN2E2YzA0NTU0ZWMxYmVmNTNiNzI5ZmVkNjVhOC90ZXh0cmVnaW9uOjY0NjM3YTZjMDQ1NTRlYzFiZWY1M2I3MjlmZWQ2NWE4XzI3NDg3NzkwNzAyMjY_c2968248-1163-4492-8d5b-2fbed1dbf96e"
      unitRef="shares">5660391</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzE0MjkzNjUxMTczMjQ1_127c5737-eca5-43be-874e-797d7e49cb93">STOCK-BASED COMPENSATION&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2017 Equity Incentive Plan, as amended (the 2017 Plan), provides that the Company may sell or issue shares of common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of shares of common stock, to employees, members of the Board of Directors, and consultants of the Company. The exercise prices, vesting, and other restrictions are determined at the discretion of the Board of Directors, or a designated committee thereof, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the common share on the date of grant and the term of stock option may not be greater than 10 years. The Company recognizes the impact of forfeitures on stock-based compensation expense as forfeitures occur. The Company applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Vesting periods are determined at the discretion of the Board of Directors. Stock options typically vest over four years. The maximum contractual term is 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he total number of shares of the Company&#x2019;s common stock that may have been issued was 6,857,500 and 3,692,500 shares, respectively.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, there were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 358,596 and 1,365,647 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares, respectively, reserved by the Company under the 2017 Plan for the future issuance of equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model. This model requires the use of highly subjective assumptions to determine the fair value of stock-based awards, including:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In order to determine the fair value of the Company&#x2019;s common stock underlying option grants, the Board of Directors considered, among other things, valuations of the Company&#x2019;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Other objective and subjective factors considered included the Company&#x2019;s stage of development and material risks related to its business, the progress of its research and development programs, its business conditions and projections, its financial position and its historical and forecasted performance and operating results, the lack of an active public market for its securities, its Preferred Stock, biopharmaceutical company performance, the likelihood of achieving a liquidity event, the hiring of key personnel and the experience of management, industry trends and developments, and external market conditions and industry trends. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of the options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Since the Company is not yet a public company and does not have any trading history for its common stock, the expected volatility is estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies are chosen based on their size, stage in the product development cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Expected Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model assumptions that the Company used to determine the grant-date fair value of stock options for the three and nine months ended September&#160;30, 2020 and 2019 were as follows, presented on a weighted-average basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of common stock per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.35&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.72%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.97%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value per share of stock options granted, using the assumptions listed above, was $4.66 and $1.54 during the three months ended September&#160;30, 2020 and 2019, respectively, and $3.16 and $0.88 during the nine months ended September&#160;30, 2020 and 2019, respectively. The weighted-average grant-date fair value per share of stock options vested was $0.69 and $0.09 during the nine months ended September&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the 2017 Plan as of September&#160;30, 2020 is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,217,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and expected to vest at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,147,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#x2019;s common stock, as determined by the Board of Directors, as of the end of the respective period.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The intrinsic value of options exercised for the three months ended September&#160;30, 2020 and 2019 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.5 million a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd $0.2 million, respectively, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.0 million and $0.4 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the nine months ended September&#160;30, 2020 and 2019 respectively, determined as of the applicable date of exercise.  There was no future tax benefit related to options exercised, as the Company had accumulated net operating losses as of September&#160;30, 2020 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the Company&#x2019;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019 as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, total unrecognized compensation cost related to the unvested share-based awards was $14.1 million, which is expected to be recognized over a weighted average period of 3.53 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Early Exercised Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allows certain of its employees and its consultants to exercise options granted under the 2017 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#x2019;s lapsing repurchase right upon termination of employment or service on the Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company.  The early exercise by an employee or consultant of a stock option is not considered to be a substantive exercise for accounting purposes, and therefore the payment received by the employer for the exercise price is recognized as a liability.  For accounting purposes, unvested early exercised shares are not considered issued and outstanding and therefore not reflected as issued and outstanding in the accompanying statements of convertible preferred stock and stockholders' deficit until the awards vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deposits received are initially recorded in current portion of other liabilities and other noncurrent liabilities for the noncurrent portion. The liabilities are reclassified to common stock and paid-in capital as the repurchase right lapses. During the three months ended September&#160;30, 2020 and 2019, and nine months ended September&#160;30, 2020 and 2019, 850,937, 60,924, 1,551,361, and 60,924 shares of the Company&#x2019;s common stock were early exercised, respectively.  At September&#160;30, 2020 and December&#160;31, 2019, there was $2.1 million and $0.1 million recorded in current portion of other liabilities, and $2.8 million and $0.1 million recorded in other noncurrent liabilities, respectively, related to shares held by employees and nonemployees that were subject to repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;In 2017, the Company issued 538,050 restricted stock awards to a non-employee at a fair value of $0.05 per share. In July 2020, the Company issued 274,341 restricted stock awards to an executive employee at a fair value of $4.14 per share.  As of September&#160;30, 2020, the restricted stock awards outstanding were 271,683 which are subject to lapsing repurchase rights. In order to vest, the holder is required to provide service to the Company. For accounting purposes, unvested restricted stock awards are not considered issued and outstanding and therefore are not reflected as issued and outstanding in the accompanying statements of convertible preferred stock and stockholders&#x2019; deficit until the awards vest.  The Company recorded stock-based compensation expense for these awards of $599.1 thousand, $1.3 thousand, $601.7 thousand and $3.8 thousand for the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, respectively, in research and development in the statements of operations and comprehensive loss.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i13481663bdd345c8b1e8be6825bfce9d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzExNTQ0ODcyMTA2MDA2_b1afa8cf-dc95-4a35-b2d3-1d556bc6844c">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0f9c2bbd688841678d9a85d7983c2cfd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzExNTQ0ODcyMTA2MDIz_9c509229-0280-49af-983d-fc91e686ef5a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0730288162bf44dea2732ca595d2a797_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzExNTQ0ODcyMTA2MDM5_3a2bec3a-d892-437e-b2d9-afaff5d4d934">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i0d5a83c4e52a4e4b837319163fdc11bd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODA0Nzk_3ff648cd-21ed-4100-9c7c-d84fec326458"
      unitRef="shares">6857500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if6347ac3253f4253ba6ddc43e9544f3d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODA0NDE_15e8b762-b3f1-4b54-9787-826deaaabae2"
      unitRef="shares">3692500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0d5a83c4e52a4e4b837319163fdc11bd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODA1MDU_2ee35b18-d11b-4c99-a54a-abfbfd1aa8f3"
      unitRef="shares">358596</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if6347ac3253f4253ba6ddc43e9544f3d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODA0OTI_6f0858fe-c4d2-4d54-a8fc-01ac64eca7b8"
      unitRef="shares">1365647</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzE0MjkzNjUxMTczMjQy_066cc48e-53f6-4332-b7e3-8256a11b0200">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model assumptions that the Company used to determine the grant-date fair value of stock options for the three and nine months ended September&#160;30, 2020 and 2019 were as follows, presented on a weighted-average basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of common stock per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.35&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.72%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.97%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <kron:SharePriceFairValueDisclosure
      contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzItMS0xLTEtNTQ4_76de46c4-133b-4021-a508-d032efe2f624"
      unitRef="usdPerShare">6.79</kron:SharePriceFairValueDisclosure>
    <kron:SharePriceFairValueDisclosure
      contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzItMy0xLTEtNTUx_72cce877-84c3-47e1-85a4-cf30fea80a4f"
      unitRef="usdPerShare">2.53</kron:SharePriceFairValueDisclosure>
    <kron:SharePriceFairValueDisclosure
      contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzItNS0xLTEtNTU3_02c59122-9690-4aee-89e1-33496b91580f"
      unitRef="usdPerShare">4.70</kron:SharePriceFairValueDisclosure>
    <kron:SharePriceFairValueDisclosure
      contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzItNy0xLTEtNTYw_38afc2e3-f146-401a-b42e-42765ca95ce9"
      unitRef="usdPerShare">1.35</kron:SharePriceFairValueDisclosure>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzMtMS0xLTEtNTQ0_6b3da980-52e4-464e-8a34-b8bf61f0d06f">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzMtMy0xLTEtNTUx_55b18a2e-471a-48b0-87c7-94ce8856850b">P6Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzMtNS0xLTEtNTU0_2b3f8e99-8baa-4900-9d10-ed647db41771">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzMtNy0xLTEtNTYw_f095c0f7-9ccb-43b5-8329-e485d1de656b">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzQtMS0xLTEtNTQ4_706b11cd-417f-4bbe-89cc-84639def498a"
      unitRef="number">0.8172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzQtMy0xLTEtNTUx_a081a386-b2ef-4839-a2d8-de10d3cd3c48"
      unitRef="number">0.6688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzQtNS0xLTEtNTU3_3309863b-8966-40d2-a298-23ef5e5ee680"
      unitRef="number">0.7693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzQtNy0xLTEtNTYw_405630b1-3fb4-46c6-b818-7fd010b54495"
      unitRef="number">0.7697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzUtMS0xLTEtNTQ4_cd653b5a-6396-4eb1-a915-36754bca287b"
      unitRef="number">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzUtMy0xLTEtNTUx_e2af4cf3-7a52-4547-9436-b807bcef05ee"
      unitRef="number">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzUtNS0xLTEtNTU3_9b8e9c94-b16d-46fc-b818-17966207575b"
      unitRef="number">0.0073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzUtNy0xLTEtNTYw_d2580f2e-33bf-4e91-9da4-2d5a04c67312"
      unitRef="number">0.0215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i20fd1d6838d143bc929529203014ed4d_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzYtMS0xLTEtNTQ0_6e11a84a-c82a-411e-8c03-4febbe7b1e4b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6ba8aafcb50c42b68711b4af05cfcbd5_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzYtMy0xLTEtNTUx_605a46ed-1f1a-4ce0-87ac-96decf65c19b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzYtNS0xLTEtNTU0_50055abe-b098-4394-8f84-8fe265036a87"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i608787e5e840492dac11e9916bd81793_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo5NTNmMTdlZWZlM2I0YTVkOTdiYzUyM2I1MDlkNDM1Yy90YWJsZXJhbmdlOjk1M2YxN2VlZmUzYjRhNWQ5N2JjNTIzYjUwOWQ0MzVjXzYtNy0xLTEtNTYw_e9592ad8-2127-43b9-93b9-ecc569ecda1d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzk5ODY_741f700d-2e4a-4627-b436-86b406667c38"
      unitRef="usdPerShare">4.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzk5OTk_24dfac1c-2ef6-46fd-91d2-2706e04f86ef"
      unitRef="usdPerShare">1.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODAwMTA_ab61c3f3-29f2-4fe0-8a97-bdc3f54a4818"
      unitRef="usdPerShare">3.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODAwMjQ_c51ec624-e6d5-4924-939c-1dffc7e3710d"
      unitRef="usdPerShare">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4MTE_dc791821-946e-4b66-92b5-69c1c63929bd"
      unitRef="usdPerShare">0.69</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4MTU_337bae59-f0f5-4a8f-81a3-2b566fa0884a"
      unitRef="usdPerShare">0.09</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzE0MjkzNjUxMTczMjQz_bac2daf7-1157-4f14-adc2-7e01ded406d9">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the 2017 Plan as of September&#160;30, 2020 is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,217,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and expected to vest at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,147,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEwLTEtMS0xLTA_1603cd0f-781f-4448-94ce-a270629a50bf"
      unitRef="shares">1726233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEwLTMtMS0xLTA_2e5839fc-9c0c-4e36-805a-75e9520b187b"
      unitRef="usdPerShare">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6c206960ada7462e824eea778e31e777_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzItNS0xLTEtNTc3_a91b6290-a3ca-4cc0-b77c-856f1478e549">P9Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzItNy0xLTEtNTc3_1d307fc5-bd51-4f80-843a-ff840fc2739e"
      unitRef="usd">27287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzExLTEtMS0xLTA_65aae4f9-95ac-46f1-badf-9b4f9fd5155c"
      unitRef="shares">4015631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzExLTMtMS0xLTA_fbbd83f2-eb3a-456a-a164-3b51cc2ca760"
      unitRef="usdPerShare">4.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzQtMS0xLTEtNTc3_a8666d72-3c5b-4a1b-b825-40d95e721b3c"
      unitRef="shares">117921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzQtMy0xLTEtNTc3_e2471de3-ddfc-4eb5-a2a6-00ac89240fa2"
      unitRef="usdPerShare">0.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEyLTEtMS0xLTA_23ed87e0-681e-4679-b18c-ba3eeb698e68"
      unitRef="shares">406057</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEyLTMtMS0xLTA_33e87631-f33f-431b-9688-28f3dd2b7598"
      unitRef="usdPerShare">1.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEzLTEtMS0xLTA_fc4ada6a-4a3c-4c52-8f71-b84800f44d4f"
      unitRef="shares">5217886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzEzLTMtMS0xLTA_579e91c6-8b30-46aa-913a-23b12d8da8fb"
      unitRef="usdPerShare">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzYtNS0xLTEtNTc3_dd7e0984-4698-4f4f-b5a9-d45398d9f8c7">P9Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzYtNy0xLTEtNTc3_6bf47815-ec8e-48ac-8e27-1477bdd1e779"
      unitRef="usd">68291000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzE0LTEtMS0xLTA_75b752e2-1e91-4eba-9a75-e2d6b48d656c"
      unitRef="shares">69910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzE0LTMtMS0xLTA_1bdd7535-d84a-46f9-a0bc-d96f2957ec7f"
      unitRef="usdPerShare">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzctNS0xLTEtNTc3_06b5f9cf-ba0e-438c-b279-9de4677c7cda">P8Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzctNy0xLTEtNTgz_d72a02a6-bed1-4084-86ae-1ad2ecee7a3d"
      unitRef="usd">1096000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzE1LTEtMS0xLTA_8205bd0e-7eba-4c29-8820-f1f71fa3bb16"
      unitRef="shares">5147976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzE1LTMtMS0xLTA_30595b79-6678-41c5-aaae-6a48fdb247a5"
      unitRef="usdPerShare">3.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzgtNS0xLTEtNTc3_2cae472b-e0fd-4726-b5e8-3812acdf5741">P9Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTo4MjMwYzNiZGIyNGU0ODk5YjQxYTkzYWZjYmI5YTdmNy90YWJsZXJhbmdlOjgyMzBjM2JkYjI0ZTQ4OTliNDFhOTNhZmNiYjlhN2Y3XzgtNy0xLTEtNTgz_76f15965-6fde-4bfe-a3f4-66d7dc2e4dfb"
      unitRef="usd">67195000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE1NzQ_376f6a5b-257f-4727-8303-af47cd94fced"
      unitRef="usd">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE1ODk_e1b73b0f-75a9-416f-ae49-09c0dc2fa80e"
      unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE1NDE_bd600970-d175-4c7b-9489-d303052fbf69"
      unitRef="usd">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE1NTY_c124fbf1-6055-4521-89a7-11720d4281f0"
      unitRef="usd">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzE0MjkzNjUxMTczMjQ0_12945a49-5028-4100-b478-8dd27326510b">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the Company&#x2019;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019 as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c0d6cc50b8e49aca2ce81649e3efb0a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzMtMS0xLTEtNTk1_dc729a79-f156-484f-9786-6e05f82c36cf"
      unitRef="usd">246000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id555f67142ab472db96a2d992d964d82_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzMtMy0xLTEtNTk1_a07a262d-ab13-4932-b85b-956439ada691"
      unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb629f251d5f424b8c936814babcc4f6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzMtNS0xLTEtNTk1_bbe0de6e-5f06-4d50-b8b3-59cd54b8fb0e"
      unitRef="usd">541000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b76d71920eb47b9b25ad42914b7f4b0_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzMtNy0xLTEtNTk1_dc9c0594-23d0-40c1-a5de-4192bf229914"
      unitRef="usd">20000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1fa6a9b2386942c4a674dfa9c9918c8a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzQtMS0xLTEtNTk1_75ac4545-745a-4199-ae21-8e174f4324c9"
      unitRef="usd">1007000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0eb0c54a250748e2bd702dfc80c5dca5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzQtMy0xLTEtNTk1_3138ceac-dd11-457d-9677-ca1bc807aa6d"
      unitRef="usd">14000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice6bc89ef445474790f3d6a61419f2a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzQtNS0xLTEtNTk1_6f0de992-de9c-453c-a4c2-0a3079be0ce8"
      unitRef="usd">1193000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic510c74d485b4029bb4fefcd43dd7a70_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzQtNy0xLTEtNTk1_d13a3d68-796e-4354-bd37-a41dae95e744"
      unitRef="usd">40000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzUtMS0xLTEtNTk1_64727aea-c8a6-43c4-8cce-0a2af8cacf36"
      unitRef="usd">1253000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzUtMy0xLTEtNTk1_a1829510-79fa-43d9-8e9c-58b5b0bff39f"
      unitRef="usd">23000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzUtNS0xLTEtNTk1_ef559dd3-4b24-41ee-ad44-d0e972524d49"
      unitRef="usd">1734000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90YWJsZTpjZjgxYjQ4ODliZTc0OTFlOGVmMjBhMTM4YjA2NDg5NS90YWJsZXJhbmdlOmNmODFiNDg4OWJlNzQ5MWU4ZWYyMGExMzhiMDY0ODk1XzUtNy0xLTEtNTk1_b99fa141-ab30-4631-a9e2-f7dc1639525d"
      unitRef="usd">60000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE3OTU_d9c9a0fc-4bf0-446f-ba7f-40ba46698089"
      unitRef="usd">14100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i45eb7bce6959455fb59bd7667c6fb5b2_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4MDM_ae2c2632-62bc-4711-9741-4a7f147e8364">P3Y6M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzMyOTg1MzQ4OTU2MjI_0e809c12-a4cf-4698-a0e5-1d437bb083f0"
      unitRef="shares">850937</kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares>
    <kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzMyOTg1MzQ4OTU2MzI_ed90abbd-1352-4115-8acf-c6749c7d1d4f"
      unitRef="shares">60924</kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares>
    <kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzMyOTg1MzQ4OTU2MDk_bd9ac610-125f-4c3e-ac2d-736ae85224f9"
      unitRef="shares">1551361</kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares>
    <kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzMyOTg1MzQ4OTU2NjY_8bedbfc8-c72c-41ea-bfc7-4e3baa83b33b"
      unitRef="shares">60924</kron:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i7ef266f587f64a7798fcaaa861326c3c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDkzODI_e379b937-61e6-4a00-8c0d-db9bcd69594e"
      unitRef="usd">2100000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i8b5e3dc5e7d94133a087d964992323e8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDkzOTM_6814796c-27cd-474d-b740-d6f06b7fede5"
      unitRef="usd">100000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i38dd8b9841e644e0a406a3e2b3439dec_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0MDM_9b854586-08c9-4429-b682-8391accd2f1a"
      unitRef="usd">2800000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i08c6c6f783f041ae92c761672b2966aa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0MTQ_5fbccd43-9fec-429d-b0b5-8d4598ef92b0"
      unitRef="usd">100000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iffb0ef90a61349be85e69f64dcaf4055_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzk0MDY_be5bdacf-aa0d-400b-81e8-efaf5fe2ee88"
      unitRef="shares">538050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iffb0ef90a61349be85e69f64dcaf4055_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4NjQ_014b088c-6c49-4a76-88f5-e33bc5f1f099"
      unitRef="usdPerShare">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i36ebb89160a743719ce7b11be1918ff8_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzkzOTI_3923940c-422d-44b1-bef8-35b5fa360397"
      unitRef="shares">274341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3eea990477a54f47bacea5aed627224f_D20200701-20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwODE4NDY_de3e6aef-48e6-4005-99a5-3bb32a057e9c"
      unitRef="usdPerShare">4.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="icd203f8d19ab4cb7ba2e8763e4797437_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzI3NDg3NzkwNzkzOTY_36d0a9b2-85bb-4b2c-9ba6-869e08581a7a"
      unitRef="shares">271683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7a4a632dbe23409c87fb1cb29d8c6158_D20200701-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0Mjk_366ec6fc-b2bf-4793-86af-e2b27ffd523f"
      unitRef="usd">599100</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i694e0708e4ee460d962dcdf8b06c84b3_D20190701-20190930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0Mzg_8a8c7bf9-7dd8-46b2-a73e-8e629eb06efa"
      unitRef="usd">1300</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic973ed0f6744448cac474a05a81e7803_D20200101-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0NDc_b8fab1ec-cb68-490d-aba6-848ff652dd05"
      unitRef="usd">601700</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b46cef6f87e4fecbc3caaa9619f38f5_D20190101-20190930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzAvZnJhZzoyNTRlNjI2ODUzNDQ0OWJiYTI2ZjJhYzc1YmFkMDY3Yi90ZXh0cmVnaW9uOjI1NGU2MjY4NTM0NDQ5YmJhMjZmMmFjNzViYWQwNjdiXzM4NDgyOTA3MDk0NTY_8dabaf8d-d34d-49a0-9b83-d46e14365f5d"
      unitRef="usd">3800</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzEzMTk0MTM5NTM4Mjgx_3c8970a2-f74c-421d-b0b7-f3564ff1b3db">INCOME TAXES&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not recorded any income tax expense for the three and the nine months ended September&#160;30, 2020 and 2019. The Company has incurred net operating losses for all the periods presented and has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has recorded a full valuation allowance against all of its deferred tax assets as it is not more likely than not that such assets will be realized in the near future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to record penalties and interest related to income taxes as a component of income tax expense.  The Company has not recorded any interest or penalties related to income taxes during the three and nine months ended September&#160;30, 2020 and 2019.  The Company has not identified any new uncertain tax positions as of September&#160;30, 2020.  Unrecognized tax benefits are not expected to change during the next 12 months.  The reversal of the unrecognized tax benefits would not affect the effective tax rate.  The Company is subject to examination by U.S. federal and state tax authorities for all years since its inception.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzc2OTY1ODE0MDI0Mzg_24f96769-4e65-4a29-acd0-e0e4fa676026"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzc2OTY1ODE0MDI0Mzg_6aa6fd09-f472-48d6-b00f-3434a16a2637"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzc2OTY1ODE0MDI0Mzg_b2ecd64e-c61d-47d3-b80a-4399a0694a35"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzMvZnJhZzo1YmY0YTFlNTIyMjQ0ZTJmYTY4ZGM3OTA0MGQxZWU2My90ZXh0cmVnaW9uOjViZjRhMWU1MjIyNDRlMmZhNjhkYzc5MDQwZDFlZTYzXzc2OTY1ODE0MDI0Mzg_c5c1d2d3-e81c-49ea-a13d-93abb9108378"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90ZXh0cmVnaW9uOjRhM2IxMTI5ZDA4ZDQ1MjRiMzk0YmRkMGE5ODI4NmJhXzk4OTU2MDQ2NTExOTM_5049b20f-4b61-4a69-ba8e-7a8da06165c6">NET LOSS PER SHARE&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share of the Company for the three and nine months ended September&#160;30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands, except share and per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,127,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,409,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,886,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,196,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities, which include the Preferred Stock and options to purchase shares of the Company's common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,741,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gilead Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,359,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock award subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,129,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,172,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90ZXh0cmVnaW9uOjRhM2IxMTI5ZDA4ZDQ1MjRiMzk0YmRkMGE5ODI4NmJhXzk4OTU2MDQ2NTExOTQ_27e7a03d-8f37-4203-b7d6-b084ec39b9b0">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share of the Company for the three and nine months ended September&#160;30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands, except share and per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common stock outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,127,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,409,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,886,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,196,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzQtMS0xLTEtMA_e0324f33-f3af-4d50-b299-becd46d05743"
      unitRef="usd">-39713000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzQtMy0xLTEtMA_c960c16e-f36e-41c9-840f-0d4e8cdb8cd1"
      unitRef="usd">-4013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzQtNS0xLTEtMA_14c587ce-ea10-44a2-bfaf-af3a6f33dfc7"
      unitRef="usd">-55287000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzQtNy0xLTEtMA_fa5f737c-31e5-4f62-b81b-0676e1168d22"
      unitRef="usd">-10652000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzUtMS0xLTEtMA_0df1194b-ceda-482b-8343-08ed33c04e46"
      unitRef="shares">6127146</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzUtMy0xLTEtMA_ee763d33-47c8-4714-bbf1-3802449651e9"
      unitRef="shares">5409433</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzUtNS0xLTEtMA_05bd9e82-89eb-4b6f-a390-44d1f9143927"
      unitRef="shares">5886191</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzUtNy0xLTEtMA_2520efc0-57c5-462b-869f-ad79482a61a4"
      unitRef="shares">5196681</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzYtMS0xLTEtMA_9e80a320-2302-4334-a75f-c51f7df7913c"
      unitRef="usdPerShare">-6.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzYtMy0xLTEtMA_d2ccbb61-c40e-4381-8c5e-821472ba28dc"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzYtNS0xLTEtMA_942a6ff7-67e7-493e-8fbf-41d571f405db"
      unitRef="usdPerShare">-9.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTpkNzhiMzA3YzJkZWY0YWQzOGU1N2EyM2QxMGE3ODI5OS90YWJsZXJhbmdlOmQ3OGIzMDdjMmRlZjRhZDM4ZTU3YTIzZDEwYTc4Mjk5XzYtNy0xLTEtMA_a68160e5-654c-46be-b05c-d9226f002299"
      unitRef="usdPerShare">-2.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90ZXh0cmVnaW9uOjRhM2IxMTI5ZDA4ZDQ1MjRiMzk0YmRkMGE5ODI4NmJhXzk4OTU2MDQ2NTExOTU_946302ae-e548-423b-9cbd-63c770bfc12f">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,741,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gilead Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,359,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock award subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,129,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,172,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie3fb6aa27992434fbc43f1d769315cae_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzMtMS0xLTEtMA_33f17b37-7026-4834-8d8d-cdda43e60b50"
      unitRef="shares">22687625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4ba0aba4eac64967a28041b82683a193_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzMtMy0xLTEtMA_af1be9dd-b010-46dd-8afa-b29a6853ba7a"
      unitRef="shares">22687625000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i223930fbcee8485494d93864723c1094_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzItMS0xLTEtMjY0NA_70746e64-38c6-4d32-a3b1-7eb924ebe7ce"
      unitRef="shares">10741406</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff773b2225814be2bd54a5fabb6156f0_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzItMy0xLTEtMjY0NA_329fb598-6ef4-4edc-b32f-e813e3ae002e"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i987eec82cc864592a298066957f8a94b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzMtMS0xLTEtMzQzOA_9d17bc4b-2a9b-4c6e-a4e3-8c6fd6930931"
      unitRef="shares">210752</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i24fc0801a2ef47149bd82ac3437499a4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzMtMy0xLTEtMzQ0Mg_c071d12a-95cc-4585-8841-68ce7db1ecfc"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie7ca6bc47f334d828c27e5e2e5f3288d_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzQtMS0xLTEtMA_f789597f-11c6-4212-9833-4d4449484de4"
      unitRef="shares">3359622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i21e4dfab6f3d4306b4f260d7d24f30cd_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzQtMy0xLTEtMA_7cff470d-0b73-40a9-a5c8-410830d28695"
      unitRef="shares">389086000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6e439c793aa6461ba7288faa23830525_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzUtMS0xLTEtMA_20d76afa-2657-45da-8bba-2293c3e23719"
      unitRef="shares">1858264</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4bc87606b0ba41f9a3cf5ea58af93b90_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzUtMy0xLTEtMA_0d1520c4-4fc7-4681-975b-8b83790de5b9"
      unitRef="shares">854123000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic5bab20c255c46269a25294cdd840266_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzQtMS0xLTEtNjM1_4f7fad0b-d197-4670-a990-9360890c0179"
      unitRef="shares">271683</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2bef5ce38731457493cfc788f479063e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzQtMy0xLTEtNjM5_9c5f634d-6641-4edb-b671-43b52c1283a7"
      unitRef="shares">242123000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzUtMS0xLTEtNjMx_8071cf92-4503-4d94-b281-7221ed8f4c80"
      unitRef="shares">39129352</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c206960ada7462e824eea778e31e777_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xMzYvZnJhZzo0YTNiMTEyOWQwOGQ0NTI0YjM5NGJkZDBhOTgyODZiYS90YWJsZTplYWZiMmYxZWYyMWM0NTMxYTY1ZGJjMjNjNDQ4M2Q5OS90YWJsZXJhbmdlOmVhZmIyZjFlZjIxYzQ1MzFhNjVkYmMyM2M0NDgzZDk5XzUtMy0xLTEtNjM5_11e88443-6d93-40ff-bf2d-b795723d63d8"
      unitRef="shares">24172957000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzEzNzQzODk1MzU5MzYw_7b17923b-d95a-4c15-a85f-5d077a9628dc">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into an asset purchase agreement (Gilead Asset Purchase Agreement) with Gilead Sciences, Inc. (Gilead), pursuant to which the Company acquired certain assets from Gilead related to entospletinib (ENTO) and lanraplenib (LANRA), and patents and other intellectual property covering or related to the development, manufacture and commercialization of ENTO and LANRA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for such assets, on the date of the Gilead Asset Purchase Agreement, the Company made a $3.0 million upfront cash payment and issued a $3.0 million principal amount convertible promissory note to Gilead (Gilead Note)The Company also made a $0.7 million payment to reimburse Gilead for certain liabilities assumed by the Company pursuant to the Gilead Asset Purchase Agreement. In addition, the Company is required to make milestone payments upon successful achievement of certain regulatory and sales milestones for ENTO, LANRA and other selective spleen tyrosine kinase inhibitor compounds covered by the patent rights acquired pursuant to the Gilead Asset Purchase Agreement and developed by the Company as a back-up to ENTO or LANRA (Other Compounds). Upon initiation of the Company&#x2019;s planned registrational Phase 2/3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations, the Company will be required to pay a milestone to Gilead of $29.0 million, and upon successful completion of certain other regulatory milestones in the United States, European Union and United Kingdom for ENTO, LANRA and any Other Compounds, across up to two distinct indications, the Company will be required to pay to Gilead an aggregate total of $51.3 million. Upon achieving certain thresholds for the aggregate annual net sales of ENTO, LANRA and any Other Compounds combined, the Company would owe to Gilead potential milestone payments totaling $115.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead is also eligible to receive (i) tiered marginal royalties ranging from the very low-teens to high-teens on annual worldwide net sales of ENTO, (ii) tiered marginal royalties ranging from high-single digits to the mid-teens on annual worldwide net sales of LANRA and (iii) tiered marginal royalties ranging from low single digits to mid-single digits on annual worldwide net sales of any Other Compounds. The royalties in the foregoing clauses are subject to reduction, on a country-by-country basis, for products not covered by certain claims within the assigned patents, for generic entry and, in the case of ENTO and LANRA, for any royalties paid for future licenses of third party intellectual property required to develop or commercialize ENTO or LANRA. The Company&#x2019;s royalty obligation with respect to a given product in a given country begins upon the first commercial sale of such product in such country and ends on the latest of (i) expiration of the last claim of a defined set of the assigned patent rights covering such product in such country; (ii) loss of exclusive data or marketing rights to such product in such country; or (iii) 10 years from the first commercial sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Gilead Asset Purchase Agreement, the Company is required to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize either ENTO or LANRA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Gilead Note accrues interest at a rate of 6% per year, compounded annually, and has a maturity date of July 14, 2020.  The Gilead Note provides that, upon the completion of the Company&#x2019;s IPO, the Gilead Note will settle through the Company payment to Gilead of $6.0 million plus unpaid accrued interest unless Gilead elected, within a specified time, that the Gilead Note, including unpaid accrued interest, be converted into shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On issuance, the Company elected to account for the Gilead Note at fair value with any changes in fair value being recognized through the statements of operations until the Gilead Note settled. The fair value of the Gilead Note was determined to be $3.6 million on issuance and $5.5 million as of September&#160;30, 2020. For the three and nine months ended September&#160;30, 2020, the Company recognized $1.9 million in the accompanying statements of operations and comprehensive loss as the change in fair value of the 2020 Gilead Note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the fair value of the Gilead Note as of September&#160;30, 2020 by determining the present value of the Gilead Note if they were to settle either upon closing of an IPO, a deemed liquidation, or a qualified or non-qualified equity fundraise.  Key valuation assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fundraise scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO cash payout scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO conversion scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation cash payout scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation conversion scenario&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the fair value of the Gilead Note at inception by determining the present value of the Gilead Note if they were to settle either upon closing of an IPO, a deemed liquidation, or a qualified or non-qualified equity fundraise.  Key valuation assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At inception&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fundraise scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO cash payout scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO conversion scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation cash payout scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation conversion scenario&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts with CROs for preclinical studies and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#x2019;s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Company&#x2019;s amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. There have been no claims to date, and the Company has a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <kron:PaymentsForAssetAcquisitions
      contextRef="ia4dd19cf017640d5a992af85e6743b2b_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTA1MDA_abfb31c4-53ee-4cfb-8de5-da111e22d096"
      unitRef="usd">3000000.0</kron:PaymentsForAssetAcquisitions>
    <kron:AssetAcquisitionConsiderationTransferredLiabilitiesIncurred
      contextRef="ia4dd19cf017640d5a992af85e6743b2b_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODE2MTA_3bae8b4f-79a8-4dda-941a-2625d9830c87"
      unitRef="usd">3000000.0</kron:AssetAcquisitionConsiderationTransferredLiabilitiesIncurred>
    <kron:PaymentsForAssetAcquisitionsReimbursements
      contextRef="ia4dd19cf017640d5a992af85e6743b2b_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTA1MTU_164e7e57-3601-4de3-a7c0-e86e5c7a39b9"
      unitRef="usd">700000</kron:PaymentsForAssetAcquisitionsReimbursements>
    <kron:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment
      contextRef="idcdc628eb6df4f0bb5c79f1d07222825_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTUxNjQ_6ae5df0f-7daa-4c67-ab9a-29d6e4dffb41"
      unitRef="usd">29000000.0</kron:ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment>
    <kron:ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment
      contextRef="idcdc628eb6df4f0bb5c79f1d07222825_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTUxODE_384f4d2b-c235-4143-acc6-de307b24c891"
      unitRef="usd">51300000</kron:ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment>
    <kron:ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment
      contextRef="idcdc628eb6df4f0bb5c79f1d07222825_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ4OTUxOTk_40f7dea0-a670-4bb5-bf8f-979f25cde087"
      unitRef="usd">115000000.0</kron:ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7aa8d7617e6248f49f8f5e9c3f2f946d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ5MDExNDU_ee5c4396-ea9b-4843-80a0-a19957418b9a"
      unitRef="number">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <kron:RepaymentOfDebtPaymentToBeMade
      contextRef="i7b189c5eff6848ada547002d5d66c700_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzMyOTg1MzQ5MDExNjA_a335ec6d-ba56-46db-a621-a046f3f43bd8"
      unitRef="usd">6000000.0</kron:RepaymentOfDebtPaymentToBeMade>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i486cac36f7944dbfbac5953889346c1e_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODEwNjY_63de18f6-cdc4-48ea-a5a3-9a392a294e7d"
      unitRef="usd">3600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i7aa8d7617e6248f49f8f5e9c3f2f946d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODEwNzA_13c2a8b4-fc0a-4aaa-9103-90bb7ee21492"
      unitRef="usd">5500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <kron:GainLossOnChangeInFairValueOfDebtInstrument
      contextRef="i7b189c5eff6848ada547002d5d66c700_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODEyNDE_04dd2159-ffef-4850-ab00-993450ea4268"
      unitRef="usd">1900000</kron:GainLossOnChangeInFairValueOfDebtInstrument>
    <kron:GainLossOnChangeInFairValueOfDebtInstrument
      contextRef="ib714cc1a7a1046e1bed70ca7b135cbda_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzI3NDg3NzkwODEyNDE_dd558ea9-1048-401c-b3c4-c3b516505e69"
      unitRef="usd">1900000</kron:GainLossOnChangeInFairValueOfDebtInstrument>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90ZXh0cmVnaW9uOjg0M2FkMDA2MWU3ZjQ4MWRhODhmMjc0YWY5NWJmOTUyXzEzNzQzODk1MzU5MzYx_db42e4d6-e76a-4f10-afbd-d2111534b256">Key valuation assumptions are as follows:&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fundraise scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO cash payout scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO conversion scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation cash payout scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation conversion scenario&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the fair value of the Gilead Note at inception by determining the present value of the Gilead Note if they were to settle either upon closing of an IPO, a deemed liquidation, or a qualified or non-qualified equity fundraise.  Key valuation assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At inception&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fundraise scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO cash payout scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO conversion scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation cash payout scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation conversion scenario&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Key valuation assumptions are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO Scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing Scenario&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i88cd4588864e407facd4e99fbcae11bc_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItMS0xLTEtMTkyNQ_825bf1b3-9b9f-434b-ace6-509862d22987"
      unitRef="number">1.78</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i51068c8029ef42c399d8e6f8a7fe8997_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItMy0xLTEtMTkyNQ_ac41e9cf-45ab-4c5b-b68a-37e5b4e29459"
      unitRef="number">0.08</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i3b0031b2310d43fd96017f1c5a5a7ecd_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItNS0xLTEtMTkyNQ_9fa2f198-200a-49a4-bae3-96ec75db8a45"
      unitRef="number">0.08</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="iafc78d3feb68447fad1581a1f5d31298_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItNy0xLTEtMTk2NQ_dcd929e6-b307-4713-b788-7d3ffa9a0f39"
      unitRef="number">1.79</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i9a405d92641543f7bddb7edda6fa1ae2_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzItOS0xLTEtMTk2NQ_1935e6cc-c5c1-47ad-990f-44e367cd533c"
      unitRef="number">1.79</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="ie0a507464b5342f5bf93741aebc293b7_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtMS0xLTEtMTkyNQ_218d5d6e-fd3d-4b4c-bef5-a2964b32380f"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i1e7237fee96140989757ebe5aca441fa_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtMy0xLTEtMTkyNQ_7f7133a7-5199-4bb1-89bd-a25064a357c4"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="ibcb97e3d8c6848998adba729a721a4cc_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtNS0xLTEtMTkyNQ_87eb8e97-a0a9-4e5c-94a5-ec1e1465ce25"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="icb03e961bb854f9fa74406cd020a41d8_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtNy0xLTEtMTk2NQ_a616866d-f5b4-46d3-90e9-be99ef348fa1"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i7d9088eb63e343bf87263a6d2eacd1cc_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzMtOS0xLTEtMTk2NQ_5dbb7319-d5ca-42d9-b7b6-7cc0862f9779"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i620aab95020a4e98b682a7a22af3c0a7_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtMS0xLTEtMTkyNQ_4f418a68-e634-4b96-8b6d-1abb857d8b1e"
      unitRef="number">0.015</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i0f897da9f4b94b72b44c2e02de325360_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtMy0xLTEtMTkyNQ_f19adb5c-16e4-4784-bbf6-c0a3390f1823"
      unitRef="number">0.950</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i7c0e7dc1935d48da9c69163a1164cb59_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtNS0xLTEtMTkyNQ_ff2f0e2b-6d16-47d3-9ec9-280a96934ad1"
      unitRef="number">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="iac4e5e570b0944eaa1dd8ba60b2886df_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtNy0xLTEtMTk2NQ_def2c6e4-d435-43ee-83de-2eefba6a0b07"
      unitRef="number">0.020</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="if1ced39808984c03a296264c3ea65adc_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo2YzU0YWViZWMyNjg0YmUwYWNmMjU3YjlhMGE3MmVlZi90YWJsZXJhbmdlOjZjNTRhZWJlYzI2ODRiZTBhY2YyNTdiOWEwYTcyZWVmXzQtOS0xLTEtMTk2NQ_017349ea-a71c-4e70-b571-df7ac27672eb"
      unitRef="number">0.015</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i851ff4900ea249cda09f664b0212918d_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItMS0xLTEtMTAxNjU_bd9466fa-9a01-42e9-8fae-8b1fadabd0ae"
      unitRef="number">2.00</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="ia99e131dd6404121b4e194d9356f67ad_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItMy0xLTEtMTAxNjU_a3b3f27b-d37f-4f0e-8779-385648050a16"
      unitRef="number">0.30</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i616172ed102541feb61d3c1b5cead753_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItNS0xLTEtMTAxNjU_75d32b5e-6a52-438c-af91-bc137cec2aa8"
      unitRef="number">0.30</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="ib79a6a6966a34788a0429125557e239f_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItNy0xLTEtMTAxNjU_af41bb1b-c00c-4ae9-af42-d15e81067539"
      unitRef="number">2.00</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="idd88330648594bcabdc951197524d855_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzItOS0xLTEtMTAxNjU_0ca9e782-574b-483e-bda9-2483e7c71387"
      unitRef="number">2.00</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i631c46c59d354aa580f1ad4e832c8861_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtMS0xLTEtMTAxNjU_ce1f3b77-0c7e-47f9-b93f-4846295c3bf9"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="ib2666b9ac19e49baab7aca87809bf7c6_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtMy0xLTEtMTAxNjU_a66524e9-1106-413e-9085-50766124f7b1"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="ib728710261c742538e0fcb8346b1c830_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtNS0xLTEtMTAxNjU_0d305837-cf43-4d3b-801b-9543bfdced47"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i86502c45f58b4b9f9337f25a9ea085a3_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtNy0xLTEtMTAxNjU_254c12cc-de76-474b-8561-73f3e3278e63"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="ibcfcef6f36724f44b53de7181f6c587d_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzMtOS0xLTEtMTAxNjU_38e69d13-ef80-41c2-abb4-2eee96c5e381"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i001fd52a7b1e4106a06c40add33e03e1_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtMS0xLTEtMTAxNjU_4091e513-9617-4c2c-94ef-55b013255dad"
      unitRef="number">0.186</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i17af873f453147b4b57bd13a9c4f867d_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtMy0xLTEtMTAxNjU_d3119418-5eac-4d60-9a67-e58acd5e3023"
      unitRef="number">0.129</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i163397f07fc24c7fa96b425b3dae61a6_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtNS0xLTEtMTAxNjU_3a401228-da13-4545-b563-a7969294990c"
      unitRef="number">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i9a50cdf7028c44ca97bad3a2559a8ea7_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtNy0xLTEtMTAxNjU_755dab9b-1002-4b54-9a4d-6efc898fc273"
      unitRef="number">0.500</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i0c37e34655d34543ac8add2eaa2cbb87_I20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDIvZnJhZzo4NDNhZDAwNjFlN2Y0ODFkYTg4ZjI3NGFmOTViZjk1Mi90YWJsZTo0NzA1ZGU3Y2Y4Njk0NTE3ODc0ZDQ5M2FlZmVmYmI4MC90YWJsZXJhbmdlOjQ3MDVkZTdjZjg2OTQ1MTc4NzRkNDkzYWVmZWZiYjgwXzQtOS0xLTEtMTAxNjU_dbc221b6-2221-4cb6-b047-f508318f6d70"
      unitRef="number">0.186</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzE3NTkyMTg2MDUxODAy_c6a8ff2d-6208-408a-85f6-22b59f4febf5">LEASES&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company amended its month-to-month rental agreement for the 21 Erie Street, Cambridge, Massachusetts lab space, to extend its non-cancellable lease term.  The amendment was executed on May 5, 2020 and has a term expiration date of May 31, 2021.  As the lease term is longer than 12 months, the Company determined that this amendment requires assessment under ASC 842.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $1.6 million and an aggregate lease liability of $1.0 million on the September&#160;30, 2020 balance sheet. The remaining lease term is 8 months, and the estimated incremental borrowing rate is 12.71%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company entered into an 11-year lease agreement to move its research and development operations from 21 Erie Street, Cambridge, Massachusetts, to a 40,514 square-feet facility at 301 Binney Street, Cambridge, Massachusetts.  The new lease commenced on March 1, 2020 with a monthly base rent of $0.3 million. The initial rent payment was paid as of September&#160;30, 2020, with rent payments escalating 3.0% annually after the initial 12 payments. As discussed in Note 2, the Company executed a letter of credit for $2.0 million in connection with the lease.  The lease includes $3.7 million in certain tenant improvement allowances, which the Company included in its calculation of the right-of-use asset in the lease at commencement. In connection with the lease, the Company recognized an operating lease right-of-use asset of $25.7 million and an aggregate lease liability of $27.7 million on the September&#160;30, 2020 balance sheet. The remaining lease term is 10 years and 5 months, and the estimated incremental borrowing rate is 8.50%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Company entered into a lease agreement for a 4,661 square-foot office space to be used for general and administrative activities in San Mateo, California. The lease commenced on August 1, 2018 and has a 37-month initial term expiring on August 31, 2021. The lease also contains an option for the Company to extend the lease upon its initial expiration. In connection with the lease, the Company made a one-time cash security deposit in the amount of $27.8 thousand. In May 2020, the Company amended its agreement to extend the lease for its office in San Mateo, California through April 2025. The initial annual base rent is $26.1 thousand, and such amount will increase by 3% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $1.2 million $0.5 million and an aggregate lease liability of $1.2 million and $0.5 million on the September&#160;30, 2020 and December&#160;31, 2019 balance sheets, respectively.  The Company expanded to an adjacent suite in July 2020, which is treated as a separate lease for accounting purposes.  The additional space is approximately 3,414 square feet and will similarly be used for general and administrative activities.  The lease commenced on July 1, 2020 and will expire on April 30, 2025.  In connection with the additional space leased, the Company made a one-time additional cash security deposit in the amount of $24.8 thousand.  The initial base rent for the expansion is $19.2 thousand, and such amount will increase by 3% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $0.9 million and an aggregate lease liability of $0.9 million on the September&#160;30, 2020 balance sheet.  The remaining lease term is for both spaces is 4 years and 7 months, and the estimated incremental borrowing rate is 12.07%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Company entered into a finance lease for R&amp;amp;D equipment that has a bargain purchase option at the end of its three-year term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The finance lease is included in property and equipment, net, other current liabilities, and other noncurrent liabilities on the Company&#x2019;s balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation of the Company&#x2019;s finance lease in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current portion of other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation of the Company&#x2019;s operating leases in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of finance lease costs in the Company&#x2019;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Statement of Operations and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Comprehensive Loss Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of operating lease costs in the Company&#x2019;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Statement of Operations and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Comprehensive Loss Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made cash payments of $0.7 million, $0.1 million, $1.3 million, and $0.2 million under the lease agreements during the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; undiscounted future non-cancellable lease payments under the Company's operating leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of September&#160;30, 2020 for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining three months of 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzE3NTkyMTg2MDUxODAy_fa8c6dc5-bf15-4ef3-a4ff-1ffd3025e3d8">LEASES&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company amended its month-to-month rental agreement for the 21 Erie Street, Cambridge, Massachusetts lab space, to extend its non-cancellable lease term.  The amendment was executed on May 5, 2020 and has a term expiration date of May 31, 2021.  As the lease term is longer than 12 months, the Company determined that this amendment requires assessment under ASC 842.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $1.6 million and an aggregate lease liability of $1.0 million on the September&#160;30, 2020 balance sheet. The remaining lease term is 8 months, and the estimated incremental borrowing rate is 12.71%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company entered into an 11-year lease agreement to move its research and development operations from 21 Erie Street, Cambridge, Massachusetts, to a 40,514 square-feet facility at 301 Binney Street, Cambridge, Massachusetts.  The new lease commenced on March 1, 2020 with a monthly base rent of $0.3 million. The initial rent payment was paid as of September&#160;30, 2020, with rent payments escalating 3.0% annually after the initial 12 payments. As discussed in Note 2, the Company executed a letter of credit for $2.0 million in connection with the lease.  The lease includes $3.7 million in certain tenant improvement allowances, which the Company included in its calculation of the right-of-use asset in the lease at commencement. In connection with the lease, the Company recognized an operating lease right-of-use asset of $25.7 million and an aggregate lease liability of $27.7 million on the September&#160;30, 2020 balance sheet. The remaining lease term is 10 years and 5 months, and the estimated incremental borrowing rate is 8.50%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Company entered into a lease agreement for a 4,661 square-foot office space to be used for general and administrative activities in San Mateo, California. The lease commenced on August 1, 2018 and has a 37-month initial term expiring on August 31, 2021. The lease also contains an option for the Company to extend the lease upon its initial expiration. In connection with the lease, the Company made a one-time cash security deposit in the amount of $27.8 thousand. In May 2020, the Company amended its agreement to extend the lease for its office in San Mateo, California through April 2025. The initial annual base rent is $26.1 thousand, and such amount will increase by 3% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $1.2 million $0.5 million and an aggregate lease liability of $1.2 million and $0.5 million on the September&#160;30, 2020 and December&#160;31, 2019 balance sheets, respectively.  The Company expanded to an adjacent suite in July 2020, which is treated as a separate lease for accounting purposes.  The additional space is approximately 3,414 square feet and will similarly be used for general and administrative activities.  The lease commenced on July 1, 2020 and will expire on April 30, 2025.  In connection with the additional space leased, the Company made a one-time additional cash security deposit in the amount of $24.8 thousand.  The initial base rent for the expansion is $19.2 thousand, and such amount will increase by 3% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $0.9 million and an aggregate lease liability of $0.9 million on the September&#160;30, 2020 balance sheet.  The remaining lease term is for both spaces is 4 years and 7 months, and the estimated incremental borrowing rate is 12.07%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Company entered into a finance lease for R&amp;amp;D equipment that has a bargain purchase option at the end of its three-year term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The finance lease is included in property and equipment, net, other current liabilities, and other noncurrent liabilities on the Company&#x2019;s balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation of the Company&#x2019;s finance lease in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current portion of other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation of the Company&#x2019;s operating leases in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of finance lease costs in the Company&#x2019;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Statement of Operations and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Comprehensive Loss Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of operating lease costs in the Company&#x2019;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Statement of Operations and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Comprehensive Loss Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made cash payments of $0.7 million, $0.1 million, $1.3 million, and $0.2 million under the lease agreements during the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; undiscounted future non-cancellable lease payments under the Company's operating leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of September&#160;30, 2020 for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining three months of 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib041367f98b84d5faa59bdf5673a3592_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODgzMTM_ec5e2422-d0bd-4970-a96f-af550c484031"
      unitRef="usd">1600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib041367f98b84d5faa59bdf5673a3592_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODgzMjg_a813e38c-d900-4de3-b779-3a9c80741679"
      unitRef="usd">1000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ib041367f98b84d5faa59bdf5673a3592_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODgzNDI_69da84ac-ae50-4adc-8d41-85f3e0acd0b4">P8M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <kron:LesseeOperatingLeaseIncrementalBorrowingRate
      contextRef="ib041367f98b84d5faa59bdf5673a3592_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODgzMzc_cf65139d-5ea9-4c03-b10b-11b0bdda110d"
      unitRef="number">0.1271</kron:LesseeOperatingLeaseIncrementalBorrowingRate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i1a92a2894224488c9e94058000096ced_I20200301"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0NjA_5fc32c1f-83cd-4994-b32d-c274f22c684a">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <kron:OperatingLeaseFacilitySize
      contextRef="i1a92a2894224488c9e94058000096ced_I20200301"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0Njc_4cfdce3e-e7c7-4622-a1dc-87d61566d6f9"
      unitRef="sqft">40514</kron:OperatingLeaseFacilitySize>
    <kron:LesseeOperatingLeaseMonthlyBaseRent
      contextRef="i8f951b9cc2d342b394ec7ff04e4d40a9_D20200301-20200301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzczMzA_edd06870-205d-463b-9335-fa9411020d06"
      unitRef="usd">300000</kron:LesseeOperatingLeaseMonthlyBaseRent>
    <kron:LesseeOperatingLeaseEscalatingRentPaymentsPercent
      contextRef="i8f951b9cc2d342b394ec7ff04e4d40a9_D20200301-20200301"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzc5MTA_a53af824-607d-409f-ba1a-0aa7f2217649"
      unitRef="number">0.030</kron:LesseeOperatingLeaseEscalatingRentPaymentsPercent>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzc2NzE_69b11b42-24f8-4e2c-a72c-8ac92ec7bd46"
      unitRef="usd">2000000.0</us-gaap:LettersOfCreditOutstandingAmount>
    <kron:LesseeOperatingLeaseTenantImprovementAllowances
      contextRef="i1a92a2894224488c9e94058000096ced_I20200301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzc0OTE_c6761030-cac8-448e-a6ca-f1ab69732ea0"
      unitRef="usd">3700000</kron:LesseeOperatingLeaseTenantImprovementAllowances>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg1NjU_9bbd3cac-11d3-4eec-b897-12942080fd96"
      unitRef="usd">25700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg1ODE_54a73d2b-c5a5-4e52-a785-07acdf808b36"
      unitRef="usd">27700000</us-gaap:OperatingLeaseLiability>
    <kron:LesseeOperatingLeaseIncrementalBorrowingRate
      contextRef="i4b773488624d4ae486e3123cdebd12c2_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg1ODk_179dd887-be24-4e63-a339-a709743b7fe5"
      unitRef="number">0.0850</kron:LesseeOperatingLeaseIncrementalBorrowingRate>
    <kron:OperatingLeaseFacilitySize
      contextRef="i3234c4fd018b4ff6ae61cebd2fd7b666_I20180731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0ODI_67e054ac-6ed9-42e9-80db-ba5bfef24f6c"
      unitRef="sqft">4661</kron:OperatingLeaseFacilitySize>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idad0893c755d45138461981a7756615e_I20180801"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0ODk_4ab83732-2d27-45ae-8a34-8fc00fb45cc0">P37M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SecurityDeposit
      contextRef="idad0893c755d45138461981a7756615e_I20180801"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxNzc_9aa83769-31b5-4cff-8bcf-bdeedb301bf9"
      unitRef="usd">27800</us-gaap:SecurityDeposit>
    <kron:LesseeOperatingLeaseInitialAnnualBaseRent
      contextRef="icffc314b519d440aa9f7fa06b641a760_D20180801-20180801"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxNjI_f755c9f6-65d3-46be-baf6-f5e91eedf9c9"
      unitRef="usd">26100</kron:LesseeOperatingLeaseInitialAnnualBaseRent>
    <kron:LesseeOperatingLeaseEscalatingRentPaymentsPercent
      contextRef="icffc314b519d440aa9f7fa06b641a760_D20180801-20180801"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxNjc_feade6cd-b7bd-46bb-93ba-70275d37606c"
      unitRef="number">0.03</kron:LesseeOperatingLeaseEscalatingRentPaymentsPercent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6517aa7d879f44528a2d88e8c188d509_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg2Mjg_da8ff37d-527d-45fe-b00c-03b70d302527"
      unitRef="usd">1200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i676113738ba64cf9bfb99cf6d7419962_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzM4NDgyOTA3MDc3ODc_07f89ca8-7867-48a5-9298-9c998b440403"
      unitRef="usd">500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6517aa7d879f44528a2d88e8c188d509_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODg2OTc_ce4dafbe-aefc-4261-be03-25cb34793529"
      unitRef="usd">1200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i676113738ba64cf9bfb99cf6d7419962_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzM4NDgyOTA3MDc3OTc_4ad538d6-35e9-4e66-b005-a9bbbb1a5b67"
      unitRef="usd">500000</us-gaap:OperatingLeaseLiability>
    <kron:OperatingLeaseFacilitySize
      contextRef="i623e9b9d16b249bda0eeafb5a7270517_I20200701"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA0NzU_c92d92ab-2bc2-4d95-a159-bb5cc577cefd"
      unitRef="sqft">3414</kron:OperatingLeaseFacilitySize>
    <us-gaap:SecurityDeposit
      contextRef="i623e9b9d16b249bda0eeafb5a7270517_I20200701"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAyMDg_9e999671-dfa1-446f-8f07-f89f28b84cab"
      unitRef="usd">24800</us-gaap:SecurityDeposit>
    <kron:LesseeOperatingLeaseInitialAnnualBaseRent
      contextRef="i3b09b6cd908145558102a1d2ebca38a9_D20200701-20200701"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxOTA_24f930ad-dd9b-46d7-bbbc-ee72df3e09f1"
      unitRef="usd">19200</kron:LesseeOperatingLeaseInitialAnnualBaseRent>
    <kron:LesseeOperatingLeaseEscalatingRentPaymentsPercent
      contextRef="i3b09b6cd908145558102a1d2ebca38a9_D20200701-20200701"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxOTU_194b5747-e098-4360-9a7f-dbdb80021041"
      unitRef="number">0.03</kron:LesseeOperatingLeaseEscalatingRentPaymentsPercent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAwNjU_a650aaf1-25f1-4fdc-b629-da9df578889b"
      unitRef="usd">900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4OTAxMDU_6d51f523-9f5e-484a-9bd0-b57c1f860f89"
      unitRef="usd">900000</us-gaap:OperatingLeaseLiability>
    <kron:LesseeOperatingLeaseIncrementalBorrowingRate
      contextRef="ie9ab2bd4c06140f5bc146f43f7f1666a_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzMyOTg1MzQ4ODk4MjI_be8ca1ce-3248-4758-b00d-88bb995dced8"
      unitRef="number">0.1207</kron:LesseeOperatingLeaseIncrementalBorrowingRate>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="ifbecda89de7840548904aa4dd3124d22_I20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA1MTY_8553eb74-8d1d-4511-8432-bcd5125fc2c4">P3Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <kron:AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA1MTc_82899502-e9fd-46fd-a716-0341df359355">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation of the Company&#x2019;s finance lease in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current portion of other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</kron:AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzMtMi0xLTEtNjU3_f80e86b8-e65b-4836-8c16-2020b35a6c1b"
      unitRef="usd">88000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzMtNC0xLTEtNjU3_dbc9a419-7eab-4b06-b022-1b83016200f3"
      unitRef="usd">103000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzUtMi0xLTEtNjU3_907b4d98-1ca0-44ab-b442-28adcb509b6c"
      unitRef="usd">14000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzUtNC0xLTEtNjU3_270d0337-6801-4148-aa72-e05637b59b12"
      unitRef="usd">32000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzYtMi0xLTEtNjU3_e90fef9f-f6d8-4d0f-90ea-41ea8ec8a42e"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzYtNC0xLTEtNjU3_928fffcd-19d1-4009-9d14-772415876fee"
      unitRef="usd">5000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzctMi0xLTEtNjU3_987abf16-6382-4df5-a18d-3502f5e7d35b"
      unitRef="usd">14000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpmYzU4MzNkZmJmN2Q0NDNjOWUwODg1ZGIwZmY5ZjQ1OS90YWJsZXJhbmdlOmZjNTgzM2RmYmY3ZDQ0M2M5ZTA4ODVkYjBmZjlmNDU5XzctNC0xLTEtNjU3_d8e86454-7e94-43d1-b76c-9fe2e0b564b2"
      unitRef="usd">37000</us-gaap:FinanceLeaseLiability>
    <kron:AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzk4OTU2MDQ2NjA1MTg_f54981e9-eea9-42c1-9e86-03774aaf4637">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation of the Company&#x2019;s operating leases in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</kron:AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzMtMi0xLTEtNjY5_30b446e5-37f8-485f-9e29-20f6737b98c6"
      unitRef="usd">29355000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzMtNC0xLTEtNjY5_ce138805-5af0-4a77-b0eb-de7f8fe3859f"
      unitRef="usd">473000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzUtMi0xLTEtNjY5_a5c13e4c-8aca-47bf-95d5-17ea15cedc5e"
      unitRef="usd">1300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzUtNC0xLTEtNjY5_fa122314-70c8-4d84-8be7-7dcddaed8f9c"
      unitRef="usd">285000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzYtMi0xLTEtNjY5_5b18ba05-f762-4016-81fb-2d9bfee565eb"
      unitRef="usd">29484000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzYtNC0xLTEtNjY5_345bcfee-3718-490b-9145-3caaf1a77fce"
      unitRef="usd">211000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzctMi0xLTEtNjY5_8f88ac09-99e3-4f7f-a899-cf231b8256c5"
      unitRef="usd">30784000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTowMGVjMDVhYjI2ZGM0ZjhlOGQ4ZDBhNmJlYjE5ZGEwNC90YWJsZXJhbmdlOjAwZWMwNWFiMjZkYzRmOGU4ZDhkMGE2YmViMTlkYTA0XzctNC0xLTEtNjY5_bc06e36c-a096-4dc1-bf22-fe436b725e08"
      unitRef="usd">496000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzE3NTkyMTg2MDUxODA2_a6d7463f-c719-42a8-93ed-298ed32031e9">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of finance lease costs in the Company&#x2019;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Statement of Operations and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Comprehensive Loss Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of operating lease costs in the Company&#x2019;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Statement of Operations and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Comprehensive Loss Caption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine months ended September&#160;30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i77faf9def6034a17a43362f8c79b789c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzMtMi0xLTEtNjg4_e54cb291-532b-41b9-abaa-ab58add1dc34"
      unitRef="usd">5000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i07a7c2fa9dca4beab08872d278639b3d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzMtNC0xLTEtNjkx_b960b875-d63b-4460-b9be-110502ead129"
      unitRef="usd">5000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="iff1ad401e98742ddb6abcc5503e71ad1_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzMtNi0xLTEtNjk0_36e61a28-3131-4791-937b-c5b22b842b32"
      unitRef="usd">15000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="id688172e6cde48eeae48e9a213f81cb5_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzMtOC0xLTEtNjk3_d5abdfbe-5df3-4313-b1f9-6d89d07b4b5c"
      unitRef="usd">15000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzQtMi0xLTEtNjg1_ef0626bb-c4c2-444e-a1dc-f8eeb5227927"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzQtNC0xLTEtNjkx_606e6a3d-6350-4a2f-b0c1-e704ddd1bfb1"
      unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzQtNi0xLTEtNjk0_1536d4a6-7fb3-427e-b75e-aea723809028"
      unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzQtOC0xLTEtNjk3_c10fbbfa-73e3-4d37-9bff-386a07970370"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzUtMi0xLTEtNjg1_609c9105-bb1d-4b5c-aed1-0c4fc85063a5"
      unitRef="usd">5000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzUtNC0xLTEtNjkx_692f30b1-7f25-4d48-ae17-1e84d72d3922"
      unitRef="usd">6000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzUtNi0xLTEtNjk0_aa633199-c3cd-4392-8590-9dd22351cfdf"
      unitRef="usd">16000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTozNTgwZmEzZWEyYzA0ZDVmYmYwYTdkMjYxODlkNTQxNC90YWJsZXJhbmdlOjM1ODBmYTNlYTJjMDRkNWZiZjBhN2QyNjE4OWQ1NDE0XzUtOC0xLTEtNjk3_4167d840-4e0b-4d70-b49a-afb5b5b5d7b8"
      unitRef="usd">18000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:OperatingLeaseCost
      contextRef="i77faf9def6034a17a43362f8c79b789c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzMtMi0xLTEtNzAx_340ba2de-1d82-49cd-9efc-bb64607aa342"
      unitRef="usd">1397000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i07a7c2fa9dca4beab08872d278639b3d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzMtNC0xLTEtNzA0_f7f710a5-2a75-4cf8-9712-237a749584b0"
      unitRef="usd">0</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="iff1ad401e98742ddb6abcc5503e71ad1_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzMtNi0xLTEtNzA3_3ebf0e3e-f6da-4826-9019-13018e3a7932"
      unitRef="usd">2843000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="id688172e6cde48eeae48e9a213f81cb5_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzMtOC0xLTEtNzEw_f45a3f35-88e6-41c7-82cb-23dbd43ebd15"
      unitRef="usd">0</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i1fa6a9b2386942c4a674dfa9c9918c8a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzQtMi0xLTEtNzAx_13c8366f-bdfb-4616-aa23-d26d5f3539ee"
      unitRef="usd">388000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0eb0c54a250748e2bd702dfc80c5dca5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzQtNC0xLTEtNzA0_d97b6d13-4a33-41d9-ac23-9553c864f8fc"
      unitRef="usd">78000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ice6bc89ef445474790f3d6a61419f2a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzQtNi0xLTEtNzA3_13c535de-722e-447c-8e40-61fe95d3fd40"
      unitRef="usd">890000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ic510c74d485b4029bb4fefcd43dd7a70_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzQtOC0xLTEtNzEw_40d6182c-7a75-4d45-850a-6f6b45ee278d"
      unitRef="usd">233000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzUtMi0xLTEtNzAx_018f8b92-35b5-4ea4-8ec5-cd5b562cca1a"
      unitRef="usd">1785000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzUtNC0xLTEtNzA0_8c83b8d6-9bc5-4c1a-81bd-8e2109a5cb95"
      unitRef="usd">78000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzUtNi0xLTEtNzA3_8cc08ca0-d408-4c1b-853c-c313b847fad5"
      unitRef="usd">3733000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTpjNmNhMWQ4MmNiNjQ0MTNhOGE1NGRjNTQ1ZWYwNTMxOC90YWJsZXJhbmdlOmM2Y2ExZDgyY2I2NDQxM2E4YTU0ZGM1NDVlZjA1MzE4XzUtOC0xLTEtNzEw_2649abcf-ce9b-46fc-a393-fe287f77a712"
      unitRef="usd">233000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzgwMDc_2cc441f6-547b-4918-b46f-728f943e7296"
      unitRef="usd">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i4510bd62d2044fd1b72e65ab611d4cd4_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzgwMjI_51e58484-d5b6-40b7-a71c-ee6a435333f1"
      unitRef="usd">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzgwMzc_8f37159b-279f-4ae0-af4b-e7bd14714546"
      unitRef="usd">1300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i37dc3fcb96a54be3ae2e7bf71448aa65_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzI3NDg3NzkwNzgwNTI_d200f9cb-caad-4bd6-bf6e-ea5e3925dda9"
      unitRef="usd">200000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90ZXh0cmVnaW9uOjgyNmZiMzJiMmE0YTQzMmNhNGEyOGUyNzIwNmFmN2NiXzE3NTkyMTg2MDUxODA0_3bbda419-785e-41c0-b5b6-fdd6b5b32975">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; undiscounted future non-cancellable lease payments under the Company's operating leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of September&#160;30, 2020 for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining three months of 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzItMi0xLTEtNzE1_533b986c-896c-4905-a547-783dde0f8f23"
      unitRef="usd">1329000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzMtMi0xLTEtNzE1_558881f3-fb98-4e07-a335-bb4622cf3912"
      unitRef="usd">5770000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzQtMi0xLTEtNzE1_364b4b5e-381d-45c6-a3bf-383b7b2259f2"
      unitRef="usd">4789000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzUtMi0xLTEtNzE1_f0509d5f-9016-4362-ac9d-195dcd743702"
      unitRef="usd">4933000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <kron:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzYtMi0xLTEtNzE1_a629bccc-5a49-428c-8b15-9c1b074709f6"
      unitRef="usd">35915000</kron:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzctMi0xLTEtNzE1_0f266eb6-aa1c-4a80-a560-711f47b5f2c8"
      unitRef="usd">52736000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzgtMi0xLTEtNzE1_4e2754ef-4696-4081-a40b-4b89b7e4abb9"
      unitRef="usd">18238000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:TenantImprovements
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzktMi0xLTEtNzE1_0b953257-8108-40ed-b94b-7bbd3630803d"
      unitRef="usd">3714000</us-gaap:TenantImprovements>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2277693b6fbc4690a6679221de27b1a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDUvZnJhZzo4MjZmYjMyYjJhNGE0MzJjYTRhMjhlMjcyMDZhZjdjYi90YWJsZTo3ZTI0NWUwZTA4NmM0YmVhYWIzMjhjMjc5MDZhMjg0MS90YWJsZXJhbmdlOjdlMjQ1ZTBlMDg2YzRiZWFhYjMyOGMyNzkwNmEyODQxXzEwLTItMS0xLTcxNQ_49796cdb-a513-4a23-9fbe-3533a2bc1e7f"
      unitRef="usd">30784000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzEzNzQzODk1MzU0Nzc5_217bc05e-2ffe-4fbc-b77b-93ebd59f7675">2020 Notes&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into a note purchase agreement pursuant to which it sold and issued and aggregate of $155.2 million in convertible promissory notes (2020 Notes) and received net cash proceeds of $151.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Notes do not accrue interest.  The 2020 Notes were settled in exchange for 9,610,713 shares of common stock in connection with the closing of the Company&#x2019;s IPO (See Note 1) at a settlement per share price equal to 85% of the IPO price per share.  The 2020 Notes also contained other settlement provisions if an IPO did not occur within 18-months of the 2020 Notes issuance date.  If the Company was acquired, completed a business combination resulting in a change of control or sold all or substantially all of its assets (each, a liquidation transaction) prior to the 18-month anniversary of the issuance dates of the 2020 Notes, the 2020 Notes unless previously settled into shares of common stock in the IPO, will settle into shares of the Company&#x2019;s common stock at a price per share equal to 85% of the estimated fair value of the consideration per share payable to the holders of its common stock in connection with such liquidation transaction.  If neither the IPO nor a liquidation transaction occurs prior to the 18th-month anniversary of the issuance dates of the 2020 Notes, the 2020 Notes will be converted into shares of newly designated Series B convertible preferred stock of the Company at a settlement price that will be determined based on a stipulation $500.0 million valuation of the Company and its fully diluted capitalization as of immediately prior to the conversion of the 2020 Notes.  The 2020 Notes contain additional redemption features contingent upon the occurrence of certain future events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On issuance, the Company elected to account for the 2020 Notes at fair value with any changes in fair value being recognized through the statements of operations until the 2020 Notes settled.  On issuance, the fair value of the 2020 Notes was determined to be equal to $155.2 million, which is the principal amount of the 2020 Notes, and total debt issuance costs of $3.9 million were expensed and recognized as interest expense in the accompanying statements of operations and comprehensive loss.  An additional $50 thousand was reimbursed to investors for legal costs incurred and netted against total proceeds received on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the fair value of the 2020 Notes as of September&#160;30, 2020 by determining the present value of the 2020 Notes if they were to settle either upon closing of an IPO, in shares of Series B convertible preferred stock 18-months after issuance (February 2022), or upon a financing scenario.  Key valuation assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPO Scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Scenario&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing Scenario&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the 2020 Notes was determined to be $155.2 million on issuance and $168.5 million as of September&#160;30, 2020. For the three and nine months ended September&#160;30, 2020, the Company recognized $13.3 million in the accompanying statements of operations and comprehensive loss as the change in fair value of the 2020 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ieed7f26a9c4d41b290ef0ca4f65ed6b7_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzY3Nzg_d4f947b3-c8f1-45e7-8f37-25fade72b829"
      unitRef="usd">155200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ie0b7d39d86434ec791e9c67d78593194_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwNjg_114441e8-06c8-4d1b-b856-cc7663c83b9a"
      unitRef="usd">151300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib50ec0c321854506a6168bb676c9bb98_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTA0MzQ_c01a8960-d620-4c22-a87a-89d1f0ca4e40"
      unitRef="shares">9610713</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <kron:SaleOfStockPurchasePriceOfCommonStockPercent
      contextRef="ie5ac0bb41ed144069f9ed35f0501c5ff_D20200801-20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwNDg_f25df7e1-c6b9-436b-ae23-d1281fc47f42"
      unitRef="number">0.85</kron:SaleOfStockPurchasePriceOfCommonStockPercent>
    <kron:SaleOfStockPurchasePriceOfCommonStockPercent
      contextRef="ie5ac0bb41ed144069f9ed35f0501c5ff_D20200801-20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwNTQ_f25df7e1-c6b9-436b-ae23-d1281fc47f42"
      unitRef="number">0.85</kron:SaleOfStockPurchasePriceOfCommonStockPercent>
    <kron:DebtConversionValuationOfCompany
      contextRef="i4ea6fedb22e248bdb67c280feee123df_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwMzU_ca895428-4a2f-4d5b-aaf3-a7bb9c0c0143"
      unitRef="usd">500000000.0</kron:DebtConversionValuationOfCompany>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ieed7f26a9c4d41b290ef0ca4f65ed6b7_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTYzOTI_383033fd-28fb-42b0-958f-b604615f5f3a"
      unitRef="usd">155200000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ie0b7d39d86434ec791e9c67d78593194_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzcwNDE_89b4dee9-e0ce-4826-b76a-e4e9dd1ac856"
      unitRef="usd">3900000</us-gaap:AmortizationOfFinancingCosts>
    <kron:PaymentsForLegalCosts
      contextRef="ie0b7d39d86434ec791e9c67d78593194_D20200801-20200831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzI3NDg3NzkwNzc2Njg_8bb0dfe3-6db4-4d3c-b9c4-5821946a75b6"
      unitRef="usd">50000</kron:PaymentsForLegalCosts>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i7f6001b206b54c728c11f91d8f95efb7_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzItMS0xLTEtMTkxOQ_06773348-3726-4f87-871f-3260202b3211"
      unitRef="number">0.08</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i32a5d81edc2c45aaa7af987dd2ec57b2_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzItMy0xLTEtMTkxOQ_c06a5256-f90a-4536-a9b5-32a7ec6da3a9"
      unitRef="number">1.39</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="iee8c0d66302445e9a58d268bbad55dc8_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzItNS0xLTEtMTkxOQ_e259d7cc-b34b-4f7d-83c7-4d12c7e8b74a"
      unitRef="number">1.39</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i7d56dfa261f8415b8e8a2412f974446b_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzMtMS0xLTEtMTkxOQ_5b449bc2-2dfd-4ad5-9974-71da6d7a05f2"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i48c80af886534e0e839a947a487fabc6_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzMtMy0xLTEtMTkxOQ_52b52b6b-3de2-4f7f-8981-9005ea917f42"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i15541111cc0147dcaa8140563fa4f2f2_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzMtNS0xLTEtMTkxOQ_966a380b-7f94-4b52-9a2e-b0f4f839379a"
      unitRef="number">0.242</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i23666d2a49a44d07afcdc32b368ec048_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzQtMS0xLTEtMTkxOQ_b16a9cb7-5c81-461d-98c0-fa2ab2511901"
      unitRef="number">0.950</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i81df50dc201b4b8ea1c8247921d8ca17_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzQtMy0xLTEtMTkxOQ_0967f423-f998-4cc3-b85c-290b2f15c568"
      unitRef="number">0.025</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i35f23e6018f34b819e4f9ad667f5b07e_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90YWJsZTpjMDc1Njc4Y2E5MTE0ZDljOGZlYTlmZWE3YWYwNDVjNi90YWJsZXJhbmdlOmMwNzU2NzhjYTkxMTRkOWM4ZmVhOWZlYTdhZjA0NWM2XzQtNS0xLTEtMTkxOQ_0c37bf3f-0abc-48d9-b91c-2d2513c05116"
      unitRef="number">0.025</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ieed7f26a9c4d41b290ef0ca4f65ed6b7_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTU5NzI_383033fd-28fb-42b0-958f-b604615f5f3a"
      unitRef="usd">155200000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i0c9e8411b1234b0ea5b11006c170b729_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTU5OTI_472cbda8-f8fe-45be-89f1-b8b6135f6f41"
      unitRef="usd">168500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <kron:GainLossOnChangeInFairValueOfDebtInstrument
      contextRef="i19dd6da6c7b34b17b50df3ce81d9dd81_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTYwNzE_b3df546d-6cf6-44b2-810b-234c21e9ae78"
      unitRef="usd">-13300000</kron:GainLossOnChangeInFairValueOfDebtInstrument>
    <kron:GainLossOnChangeInFairValueOfDebtInstrument
      contextRef="i732fa4350e424f4bb60a16a35c6aa5cf_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF83NDcvZnJhZzoyMGEyOWQ3Y2EwNTM0OTI3YjIyYzhmNTNiOTU3M2NlZi90ZXh0cmVnaW9uOjIwYTI5ZDdjYTA1MzQ5MjdiMjJjOGY1M2I5NTczY2VmXzMyOTg1MzQ4OTYwNzE_e8c33b58-8ea5-4565-9ee7-4ce70d27070f"
      unitRef="usd">-13300000</kron:GainLossOnChangeInFairValueOfDebtInstrument>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5Xzk4OTU2MDQ2NTI1ODE_7878f542-5945-43aa-a774-47d3a672690a">RELATED PARTIES&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 1, 2017, the Company entered into a three-year services agreement with Two River Consulting, LLC (Two River) to provide various clinical development, operational, managerial, accounting and financial, and administrative services to the Company. Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman of Two River. Mr. Joshua Kazam and Mr. David Tanen, each a director of the Company, are each partners of Two River. Mr. Tanen additionally serves as our Corporate Secretary.  Mr. Christopher Wilfong, a strategic advisor to the Company, is an Operating Partner of Two River and Mr. Sean Algeo, serving as the Company&#x2019;s Treasurer, is the Chief Financial Officer of Two River. During the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, the Company incurred expense of $0.3 million, $0.2 million, $0.8 million and $0.6 million respectively, for these services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s expenses are periodically paid by Two River. The Company reimburses Two River for these expenses and no interest is charged on the outstanding balance.  These reimbursable expenses totaled $15.0 thousand and $7.4 thousand for three months ended September&#160;30, 2020 and 2019, respectively, and $24.1 thousand and $44.9 thousand for the nine months ended September&#160;30, 2020 and 2019, respectively.  As of September&#160;30, 2020 and December&#160;31, 2019, the Company had payables to Two River of $92.5 thousand and $75.0 thousand, respectively. All balances owed as December 31, 2019 were paid in full during the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a consulting agreement with Bellco Capital, LLC (Bellco) to provide various executive services to the Company.  Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman of Bellco. Rebecka Belldegrun, M.D., a director of the Company, is the President and Chief Executive Officer of Bellco. During the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, the Company incurred expense of $6.3 thousand, $6.3 thousand, $18.9 thousand and $18.9 thousand, respectively, for these services.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <kron:ServicesAgreementTerm
      contextRef="i013165bd63c141f78e3b0ec48d6aeb39_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5Xzk4OTU2MDQ2NTI3NDc_4bb9562b-4c50-4365-9301-6562e1ab301b">P3Y</kron:ServicesAgreementTerm>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i3b1c4ce7e09f4609b89a6586759b8444_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2MzM_aa79f470-cf77-49a8-93bf-27930d5ba38d"
      unitRef="usd">300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="id2997d3b39e44c049e46716565e334c4_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2Mzc_fa1b975d-8d3b-4fde-86d5-6d4e06df1491"
      unitRef="usd">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i013165bd63c141f78e3b0ec48d6aeb39_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2NDE_76033aae-e4da-4a46-8b22-aced219f8c4a"
      unitRef="usd">800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i9e930125986d43ccab7955e01aa7d87f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2NDU_55c1b1bc-5229-4829-bdac-7a7361ae203a"
      unitRef="usd">600000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty
      contextRef="ifef3396d498f4831ab1ac220e09caad2_D20200701-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2OTk_3a68a8f2-1497-4af3-93e9-d798414b5938"
      unitRef="usd">15000.0</kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty>
    <kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty
      contextRef="i7e707633da84487498c2674c190517d8_D20190701-20190930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI3MDM_44a75082-3276-434c-be95-cbfc3dc52b09"
      unitRef="usd">7400</kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty>
    <kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty
      contextRef="i0d8ea9d54ffb45dc8de4f5d3a62c8776_D20200101-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI3MDk_b4661dcb-c82e-490d-acac-edc338d13df6"
      unitRef="usd">24100</kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty>
    <kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty
      contextRef="i51fbcc82facb4e78bbf3571c3a7b333b_D20190101-20190930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI3MTQ_bdd5fbc6-1a25-43f6-b1d9-3753ca9b29ab"
      unitRef="usd">44900</kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="if2696f8ecf0246daa8d17d75de9abb4d_I20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2Mjk_5a05c247-de65-4e16-97ed-2b2ab2a7bcd5"
      unitRef="usd">92500</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i1fbdca86d2ea46a5a02388d0823daea8_I20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI2MjU_104d4813-82a5-4147-b35b-069cd3fbada2"
      unitRef="usd">75000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="idc38fa9749f94b56b8bd462c4e5b894b_D20200701-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzMyOTg1MzQ4ODYwOTY_59209d8d-a77e-4630-893c-ed5f1f192df5"
      unitRef="usd">6300</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i447ffc13a5e74bdf9f0ed1c954749058_D20190701-20190930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzMyOTg1MzQ4ODYxMDE_a55ab796-0f21-4cff-ae1a-41f5fd6e32de"
      unitRef="usd">6300</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i3a3abdc990ab4085bba504ea15586fb0_D20200101-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5XzI3NDg3NzkwNzI0NTY_1b760a54-9b1c-4655-9fb9-4df87764af5f"
      unitRef="usd">18900</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib6bc7aed10264332996827a2e1c4b226_D20190101-20190930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNDgvZnJhZzo5N2YxYmRiMTMwN2Y0N2UwOTMxM2FjODgzZjk0ODg3OS90ZXh0cmVnaW9uOjk3ZjFiZGIxMzA3ZjQ3ZTA5MzEzYWM4ODNmOTQ4ODc5Xzk4OTU2MDQ2NTM3ODc_a2c0aeee-ef9d-46f9-8f73-29c783a709fb"
      unitRef="usd">18900</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzEzNzQzODk1MzU4ODg2_d0b3b6e4-771c-49ca-9538-6db329e5e20e">SUBSEQUENT EVENTS&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the interim financial statements as of September&#160;30, 2020 for the three and nine months periods then ended, the Company evaluated subsequent events for recognition and measurement purposes.  The Company concluded that no events or transactions have occurred that require disclosure in the accompanying financial statements, other than the following.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt"&gt;Authorization of Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 14, 2020, the Company amended and restated its certificate of incorporation.  Among other things, the amended and restated certification of incorporation authorizes 10,000,000 shares of undesignated preferred stock with a par value of $0.001.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt"&gt;Increase in Authorization of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 2, 2020, the Company amended its certificate of incorporation to, among other things, increase the number of authorized shares of common stock from 40,000,000 to 200,000,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt"&gt;Amendments to Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2020, the required holders of the Company&#x2019;s Convertible Preferred Stockholders authorized the automatic conversion of all shares of the Convertible Preferred Stock in the IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;d.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt"&gt;Forward Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 2, 2020, the Company effected a 1.055-for-1 forward stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing ratios for each series of the Company&#x2019;s Preferred Stock.  In addition, the number of shares subject to each stock option outstanding was proportionally increased by the forward stock split ratio, and the exercise price per share was proportionally decreased by the forward stock split ratio.  Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retrospectively, where applicable, to reflect this forward stock split and adjustment of the preferred stock conversion ratios.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company&#x2019;s board of directors and stockholders approved the Company&#x2019;s 2020 Equity Incentive Plan (the 2020 Plan), which became effective on October 8, 2020.  The 2020 Plan provides for the issuance of up to 11,938,152 of share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;f.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.9pt"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company&#x2019;s board of directors and stockholders approved the Company&#x2019;s 2020 Employee Stock Purchase Plan (the ESPP).  The ESPP became effective October 8, 2020.  The ESPP provides for the issuance of up to 688,000 of share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt"&gt;Conversion of convertible notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, upon the closing Company&#x2019;s IPO, the 2020 Notes automatically converted into 9,610,713 shares of common stock (See Note 15).  Upon the closing of the IPO, the Gilead Note was also converted into 188,567 shares of common stock as the result of Gilead&#x2019;s election (See Note 13).  The Company will record a loss of $14.1 million and a gain of $1.9 million in the fourth quarter of fiscal 2020 upon the settlement of the 2020 Notes and Gilead Note, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;h.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt"&gt;Lease termination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a lease termination agreement for its lab space in Cambridge, Massachusetts.  The lease will terminate as of January 31, 2021 rather than continue through May 2021.  The cost for early termination is a payment of $0.1 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i75d1b3f7102a450088f5769228278051_I20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkwODExMDE_d6d075d4-449f-439b-a9ff-c99824e44e51"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i75d1b3f7102a450088f5769228278051_I20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkwODExMDY_bd3358c9-fd1e-493c-9544-769b2fe4d1a1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4f43e48d5ab84516a4275b0e2940ce84_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkwODEwOTY_0f4bd288-aa25-4bdd-b902-704780699eb8"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i354b6c38321f418e8ea03e729e783986_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkwODEwOTE_6669ee6f-0a82-462d-a6ff-94afd32c0969"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i5c23b681d5c84ca1bf3cfe7435c3e188_D20201002-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzI3NDg3NzkxMDIzMDg_f4f07e72-81f0-48a5-81f3-b3bf204cf1aa"
      unitRef="number">1.055</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ide813d6d56e94d6eab30a8e7472b2e0d_I20201008"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzMyOTg1MzQ4OTQ4NTM_cf45fd54-1967-4eda-9120-e48eafbfd0a2"
      unitRef="shares">11938152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia5bf533181c044de8807c924d489d6e6_I20201008"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzMyOTg1MzQ4OTQ4NTk_73b0ea1c-dcbd-4cb5-a8fc-fe2fa1b5ca48"
      unitRef="shares">688000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib50ec0c321854506a6168bb676c9bb98_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzMyOTg1MzQ5MTM2MDc_0d33dbed-2537-4164-b306-a08a6ac9333e"
      unitRef="shares">9610713</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="if9ec867a047842948219312d9ab1388e_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzMyOTg1MzQ5MTM3MTg_c91d48ad-01b9-4266-8166-0926291bb620"
      unitRef="shares">188567</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if63f36e0c9f049a4a09953343fbdb606_D20201001-20201118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzM4NDgyOTA3Mjk0NjQ_1c41b87d-b12f-4cce-817f-d8dd6ad76210"
      unitRef="usd">-14100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifd40f9ae2ea3456890d775273e5e0e55_D20201001-20201118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzM4NDgyOTA3Mjk1MjE_36e34da3-9a28-4181-91a8-532c5b8a5194"
      unitRef="usd">1900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <kron:LesseeOperatingLeaseEarlyTerminationCost
      contextRef="i2ac6a536633140c584616f4aaff231e3_I20201118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF8xNTEvZnJhZzo3OWM4YmM1NThjM2E0MGRmYWI3YmMzNjY1ZGViOTYxNy90ZXh0cmVnaW9uOjc5YzhiYzU1OGMzYTQwZGZhYjdiYzM2NjVkZWI5NjE3XzM4NDgyOTA3MzAwNDM_7298d837-077d-4aaf-8a34-7d529fb91a44"
      unitRef="usd">100000</kron:LesseeOperatingLeaseEarlyTerminationCost>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNC0zLTEtMS0w_398e2a31-5dad-4e0e-a749-cfb32aafa8c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNC0zLTEtMS0w_398e2a31-5dad-4e0e-a749-cfb32aafa8c2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTgtMy0xLTEtMA_414422d2-b987-4a31-90f8-d3a1822608ff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTgtMy0xLTEtMA_414422d2-b987-4a31-90f8-d3a1822608ff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOS0zLTEtMS0w_af194b14-52ad-4435-8abc-ada345b8a0a3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOS0zLTEtMS0w_af194b14-52ad-4435-8abc-ada345b8a0a3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTEtMy0xLTEtMTc1_238e1a5e-cfcb-4dfc-93ac-9e82ee1ea9b1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTEtMy0xLTEtMTc1_238e1a5e-cfcb-4dfc-93ac-9e82ee1ea9b1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTktMy0xLTEtMA_5df9ec80-449c-4bc2-9cd5-fde54eefbebe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTktMy0xLTEtMA_5df9ec80-449c-4bc2-9cd5-fde54eefbebe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMy0xLTEtMA_c07a24f2-af19-4588-ae47-664036655373"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMy0xLTEtMA_c07a24f2-af19-4588-ae47-664036655373"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjItMy0xLTEtMA_7336a50e-0972-47cb-b658-c50350b82e43"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjItMy0xLTEtMA_7336a50e-0972-47cb-b658-c50350b82e43"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTAtMy0xLTEtMA_8f4a915b-acb5-498f-bbff-81d6ed20c39c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTAtMy0xLTEtMA_8f4a915b-acb5-498f-bbff-81d6ed20c39c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjQtMy0xLTEtMjMyNg_adb29f22-92ac-48ab-ad38-e05bc106e22c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjQtMy0xLTEtMjMyNg_adb29f22-92ac-48ab-ad38-e05bc106e22c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTMtMy0xLTEtMA_9276a3d8-cc19-42c6-b38f-6cfc9f4c097f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTMtMy0xLTEtMA_9276a3d8-cc19-42c6-b38f-6cfc9f4c097f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTYtMy0xLTEtMA_8035d86e-f487-45d9-8e4b-7ecba505e96e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTYtMy0xLTEtMA_8035d86e-f487-45d9-8e4b-7ecba505e96e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMy0xLTEtMA_45216b21-6194-4072-a7f8-9dee72f84077"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMy0xLTEtMA_45216b21-6194-4072-a7f8-9dee72f84077"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjEtMy0xLTEtMA_f84feb2d-73c3-4aba-9559-c0ead7335b39"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjEtMy0xLTEtMA_f84feb2d-73c3-4aba-9559-c0ead7335b39"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzAtMy0xLTEtMA_87a8dcbc-3d64-46d4-9cc5-e3d3fcc55f25"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzAtMy0xLTEtMA_87a8dcbc-3d64-46d4-9cc5-e3d3fcc55f25"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzItMy0xLTEtMA_a61ba345-c4d1-4570-b74e-56cf78a59d83"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzItMy0xLTEtMA_a61ba345-c4d1-4570-b74e-56cf78a59d83"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtMA_d05a5384-e248-4030-a9cf-17cdd1ccf138"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtMA_d05a5384-e248-4030-a9cf-17cdd1ccf138"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNS0zLTEtMS0w_752d2bc5-71cf-447b-a301-5119a2ce6b62"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNS0zLTEtMS0w_752d2bc5-71cf-447b-a301-5119a2ce6b62"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjAtMy0xLTEtMA_6d8f280b-3a43-4309-a1c7-f19dde7db983"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjAtMy0xLTEtMA_6d8f280b-3a43-4309-a1c7-f19dde7db983"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOC0zLTEtMS0w_5b95e419-e2ea-434e-833a-e07994cad3b6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOC0zLTEtMS0w_5b95e419-e2ea-434e-833a-e07994cad3b6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzEtMy0xLTEtMA_0ca701ee-1ad6-4424-b3dd-17217e95139c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzEtMy0xLTEtMA_0ca701ee-1ad6-4424-b3dd-17217e95139c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTItMy0xLTEtMA_c5bdbdb7-9e21-44ad-8ac8-e2ab8ec88e9e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTItMy0xLTEtMA_c5bdbdb7-9e21-44ad-8ac8-e2ab8ec88e9e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNy0zLTEtMS0w_7b294014-cf51-4f5d-abac-68c1e70d5d4a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNy0zLTEtMS0w_7b294014-cf51-4f5d-abac-68c1e70d5d4a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtODQ2_252d2175-5e02-4f30-827b-5a392ef0b3fe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtODQ2_252d2175-5e02-4f30-827b-5a392ef0b3fe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjMtMy0xLTEtMA_6db15a62-3bd4-461c-a3e1-cfe3c6484b36"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjMtMy0xLTEtMA_6db15a62-3bd4-461c-a3e1-cfe3c6484b36"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjgtMy0xLTEtMA_303524e9-a85d-41a3-bff2-33bd1fe342e2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjgtMy0xLTEtMA_303524e9-a85d-41a3-bff2-33bd1fe342e2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNi0zLTEtMS0w_df2df7a5-df8d-4c50-b410-d192c470f3ba"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNi0zLTEtMS0w_df2df7a5-df8d-4c50-b410-d192c470f3ba"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjktMy0xLTEtMA_f4797447-8a55-441e-9d79-ec2e08d271ea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjktMy0xLTEtMA_f4797447-8a55-441e-9d79-ec2e08d271ea"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNC0zLTEtMS0w_398e2a31-5dad-4e0e-a749-cfb32aafa8c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTgtMy0xLTEtMA_414422d2-b987-4a31-90f8-d3a1822608ff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOS0zLTEtMS0w_af194b14-52ad-4435-8abc-ada345b8a0a3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTEtMy0xLTEtMTc1_238e1a5e-cfcb-4dfc-93ac-9e82ee1ea9b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTktMy0xLTEtMA_5df9ec80-449c-4bc2-9cd5-fde54eefbebe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjUtMy0xLTEtMA_c07a24f2-af19-4588-ae47-664036655373"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjItMy0xLTEtMA_7336a50e-0972-47cb-b658-c50350b82e43"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTAtMy0xLTEtMA_8f4a915b-acb5-498f-bbff-81d6ed20c39c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjQtMy0xLTEtMjMyNg_adb29f22-92ac-48ab-ad38-e05bc106e22c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTMtMy0xLTEtMA_9276a3d8-cc19-42c6-b38f-6cfc9f4c097f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTYtMy0xLTEtMA_8035d86e-f487-45d9-8e4b-7ecba505e96e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjctMy0xLTEtMA_45216b21-6194-4072-a7f8-9dee72f84077"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjEtMy0xLTEtMA_f84feb2d-73c3-4aba-9559-c0ead7335b39"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzAtMy0xLTEtMA_87a8dcbc-3d64-46d4-9cc5-e3d3fcc55f25"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzItMy0xLTEtMA_a61ba345-c4d1-4570-b74e-56cf78a59d83"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtMA_d05a5384-e248-4030-a9cf-17cdd1ccf138"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNS0zLTEtMS0w_752d2bc5-71cf-447b-a301-5119a2ce6b62"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjAtMy0xLTEtMA_6d8f280b-3a43-4309-a1c7-f19dde7db983"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfOC0zLTEtMS0w_5b95e419-e2ea-434e-833a-e07994cad3b6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMzEtMy0xLTEtMA_0ca701ee-1ad6-4424-b3dd-17217e95139c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTItMy0xLTEtMA_c5bdbdb7-9e21-44ad-8ac8-e2ab8ec88e9e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNy0zLTEtMS0w_7b294014-cf51-4f5d-abac-68c1e70d5d4a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMTctMy0xLTEtODQ2_252d2175-5e02-4f30-827b-5a392ef0b3fe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjMtMy0xLTEtMA_6db15a62-3bd4-461c-a3e1-cfe3c6484b36"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjgtMy0xLTEtMA_303524e9-a85d-41a3-bff2-33bd1fe342e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfNi0zLTEtMS0w_df2df7a5-df8d-4c50-b410-d192c470f3ba"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RhYmxlOmJhOTRiMmZkZDFhZTQwYWY4OTI3ZWIxNDYyZDEzM2I2L3RhYmxlcmFuZ2U6YmE5NGIyZmRkMWFlNDBhZjg5MjdlYjE0NjJkMTMzYjZfMjktMy0xLTEtMA_f4797447-8a55-441e-9d79-ec2e08d271ea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ0YmI0ZTRmOTg2MzQyMmFiNWMzZjNlNzg2ODI2MmQ0L3NlYzpkNGJiNGU0Zjk4NjM0MjJhYjVjM2YzZTc4NjgyNjJkNF84OC9mcmFnOjcyMzMzNmFlODM0NzQ3M2Y5NDYwZDIzMmE1MjI1MTA2L3RleHRyZWdpb246NzIzMzM2YWU4MzQ3NDczZjk0NjBkMjMyYTUyMjUxMDZfNzY5NjU4MTM5NjI3Ng_b94d38f4-5251-4a56-86e8-36fe2f659524"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139692000161704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Kronos Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1895605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1300 So. El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Mateo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">781-5200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,033,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001741830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691994171032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 156,196<span></span>
</td>
<td colspan="2" class="nump">$ 32,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">55,069<span></span>
</td>
<td colspan="2" class="nump">59,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,628<span></span>
</td>
<td colspan="2" class="nump">1,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">212,893<span></span>
</td>
<td colspan="2" class="nump">93,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">4,774<span></span>
</td>
<td colspan="2" class="nump">4,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Total property and equipment, net</a></td>
<td class="nump">10,301<span></span>
</td>
<td colspan="2" class="nump">3,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">29,355<span></span>
</td>
<td colspan="2" class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,026<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">3,207<span></span>
</td>
<td colspan="2" class="nump">427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">262,556<span></span>
</td>
<td colspan="2" class="nump">102,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,443<span></span>
</td>
<td colspan="2" class="nump">1,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,780<span></span>
</td>
<td colspan="2" class="nump">818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, at fair value</a></td>
<td class="nump">173,944<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,300<span></span>
</td>
<td colspan="2" class="nump">285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current portion of other liabilities</a></td>
<td class="nump">2,137<span></span>
</td>
<td colspan="2" class="nump">88<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">183,604<span></span>
</td>
<td colspan="2" class="nump">2,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">29,484<span></span>
</td>
<td colspan="2" class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">2,841<span></span>
</td>
<td colspan="2" class="nump">74<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">215,929<span></span>
</td>
<td colspan="2" class="nump">2,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.001 par value; 21,506,977 and 21,506,977 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 21,504,893 and 21,504,893 share issued and outstanding as of September, 2020 and December 31, 2019, respectively; $123,016 and $123,016 liquidation preference as of September 30, 2020 and December 31, 2019, respectively.</a></td>
<td class="nump">122,907<span></span>
</td>
<td colspan="2" class="nump">122,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholder's equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 40,000,000 and 40,000,000 shares authorized as of September 30, 2020 and December 31, 2019 respectively; 6,284,326 and 5,660,391 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively.</a></td>
<td class="nump">6<span></span>
</td>
<td colspan="2" class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,416<span></span>
</td>
<td colspan="2" class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(78,749)<span></span>
</td>
<td colspan="2" class="num">(23,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">47<span></span>
</td>
<td colspan="2" class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(76,280)<span></span>
</td>
<td colspan="2" class="num">(23,203)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</a></td>
<td class="nump">$ 262,556<span></span>
</td>
<td colspan="2" class="nump">$ 102,686<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691916521416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jul. 01, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 7.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">21,506,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,506,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,949,465<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 123,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,284,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,660,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">6,284,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,660,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691916579576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,755<span></span>
</td>
<td class="nump">$ 3,526<span></span>
</td>
<td class="nump">$ 30,125<span></span>
</td>
<td class="nump">$ 8,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,054<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="nump">6,831<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,809<span></span>
</td>
<td class="nump">4,323<span></span>
</td>
<td class="nump">36,956<span></span>
</td>
<td class="nump">10,960<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,809)<span></span>
</td>
<td class="num">(4,323)<span></span>
</td>
<td class="num">(36,956)<span></span>
</td>
<td class="num">(10,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_NotesPayableFairValueGainLoss', window );">Change in fair value of convertible notes payable</a></td>
<td class="num">(15,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,889)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3,890)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest and other income, net</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(18,904)<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="num">(18,331)<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,713)<span></span>
</td>
<td class="num">(4,013)<span></span>
</td>
<td class="num">(55,287)<span></span>
</td>
<td class="num">(10,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(117)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (39,830)<span></span>
</td>
<td class="num">$ (4,013)<span></span>
</td>
<td class="num">$ (55,222)<span></span>
</td>
<td class="num">$ (10,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (6.48)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (9.39)<span></span>
</td>
<td class="num">$ (2.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock, basic and diluted (in shares)</a></td>
<td class="nump">6,127,146<span></span>
</td>
<td class="nump">5,409,433<span></span>
</td>
<td class="nump">5,886,191<span></span>
</td>
<td class="nump">5,196,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_NotesPayableFairValueGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Fair Value Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_NotesPayableFairValueGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691917287928">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,806,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,806,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,966,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,296)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (7,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,130)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,995,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (10,409)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,475)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,806,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,966,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,296)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,652)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,488,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (17,831)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,997)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,806,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,142,488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A convertible preferred stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,949,465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 72,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,995,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,409)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,475)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">386,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,509)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,509)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,382,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (13,852)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,555,428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A convertible preferred stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50,242<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">106,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,013)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,013)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,488,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (17,831)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,997)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,660,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,203)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(23,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">119,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,995)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,995)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,780,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (29,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(30,457)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,660,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,203)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(23,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(55,287)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,284,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (76,280)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">2,416<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(78,749)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,780,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(30,457)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">171,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">293<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,579)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,579)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,952,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (37,981)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">885<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="num">(39,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">332,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon vesting and exercise of options and vesting of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(117)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39,713)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,713)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,284,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (76,280)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 2,416<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="num">$ (78,749)<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911529576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.67<span></span>
</td>
<td class="nump">$ 7.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691912406024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,287)<span></span>
</td>
<td class="num">$ (10,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization/accretion on available-for-sale securities</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Change in accrued interest on available-for-sale securities</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,734<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LeaseExpenseNoncash', window );">Noncash lease expense</a></td>
<td class="nump">1,994<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of convertible notes payable</a></td>
<td class="nump">15,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs on convertible notes payable</a></td>
<td class="nump">3,889<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">3,565<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(493)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">150<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">879<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet', window );">Right-of-use operating assets and liabilities, net</a></td>
<td class="num">(588)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">4,816<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,282)<span></span>
</td>
<td class="num">(10,140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(5,886)<span></span>
</td>
<td class="num">(2,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available-for-sale securities</a></td>
<td class="num">(41,205)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of available-for-sale securities</a></td>
<td class="nump">45,611<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="num">(1,480)<span></span>
</td>
<td class="num">(2,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of financing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="nump">151,275<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="num">(2,248)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">149,414<span></span>
</td>
<td class="nump">104,963<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">125,652<span></span>
</td>
<td class="nump">92,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">32,570<span></span>
</td>
<td class="nump">10,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">158,222<span></span>
</td>
<td class="nump">102,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment additions included in accounts payable and accrued expenses</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">30,898<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_DeferredOfferingCostsIncurredButNotYetPaid', window );">Deferred offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid', window );">Preferred stock issuance costs in accounts payable and accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_DeferredOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_DeferredOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Right Of Use Operating Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_LeaseExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Expense, Noncash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_LeaseExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Issuance Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910075432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Operations and Basis of Presentation</a></td>
<td class="text">NATURE OF OPERATIONS AND BASIS OF PRESENTATION<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kronos Bio, Inc. (Kronos or the Company), a Delaware corporation, was incorporated on June 2, 2017. The Company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one business segment, the development of biopharmaceutical products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company completed an initial public offering (IPO) of its common stock.  In connection with its IPO, the Company issued and sold 15,131,579 shares of its common stock, which included 1,973,684 shares of its common stock issued and sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $19.00 per share.  As a result of the IPO, the Company received approximately $263.9 million in net proceeds, after deducting underwriting discounts and commissions of $20.1 million and offering expenses of approximately $3.5 million payable by the Company.  At the closing of the IPO, 21,504,893 shares of outstanding convertible preferred stock were automatically converted to 22,687,625 shares of common stock and the 2020 Notes (See Note 15) were automatically converted into 9,610,713 shares of common stock.  At the closing of the IPO, the Gilead Note (See Note 13) was also converted into 188,567 shares of common stock. Following the IPO, there were no shares of convertible preferred stock outstanding.  As of September&#160;30, 2020, the Company had incurred $2.9 million of deferred offering costs, which will be offset against the net proceeds received from the sale of common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses since its inception of $78.7 million as of September&#160;30, 2020.  The Company expects that its cash, cash equivalents and investments as of September&#160;30, 2020, in addition to its approximate net cash proceeds of $263.9 million from the Company&#8217;s IPO, which closed on October 14, 2020, will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of issuance of these condensed financial statements.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the global novel coronavirus disease (COVID-19) outbreak a pandemic. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations.  The Company&#8217;s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue business strategies.  The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaboration arrangements or obtain government grants.  The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders.  If the Company is unable to obtain funding, the Company could be forced to delay, reduce, or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.  In the event that the Company requires additional funding, there can be no assurance that it will be successful in obtaining sufficient funding on terms acceptable to the Company to fund its continuing operations, if at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward Stock Split</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&#8217;s common stock on a 1.055-for-1 basis (the Forward Stock Split).  In connection with the Forward Stock Split, the conversion ratio for the Company&#8217;s outstanding convertible preferred stock was proportionally adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split.  The par value of the common stock was not adjusted as the result of the Forward Stock Split.  All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these condensed financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908383384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies, Estimates and Judgments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies, Estimates and Judgments</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying balance sheet as of September&#160;30, 2020, the statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019, the statements of convertible preferred stock and stockholders&#8217; deficit as of September&#160;30, 2020 and 2019, the statements of cash flows for the nine months ended September&#160;30, 2020 and 2019, and the financial data and other financial data and other information disclosed to in the notes to the condensed financial statements are unaudited.  The unaudited interim financial statements have been prepared on a basis consistent with the Company&#8217;s audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of September&#160;30, 2020 and the results of its operations the three and nine months ended September&#160;30, 2020 and 2019. The results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2020, any other interim periods, or any future year or period.  These financial statements should be read in conjunction with the Company's audited financial statements included in the prospectus dated October 8, 2020 that forms a part of the Company's Registration Statements on Form S-1 (File No. 333-248925), as filed with the SEC pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended, on October 9, 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of convertible notes and investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, discovery research performed by contract research organizations (CROs), materials and supplies, licenses and fees and overhead allocations consisting of various support and facility-related costs. The Company expenses R&amp;D costs as the services are performed or the goods are received.  Research and development expenses for the three and nine months ended September&#160;30, 2020 included $6.6 million related to acquired intangible assets as research and development costs pursuant to the Asset Purchase Agreement with Gilead (See Note 13) as, at the time of acquisition of the asset, the technology was under development; was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing; had not reached technical feasibility; or otherwise had no foreseeable alternative future use.  There were no acquired intangible assets expensed for the three and nine months ended September&#160;30, 2019.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRO costs are a significant component of R&amp;D expenses. The Company monitors levels of performance under each significant contract through communications with its CROs. The Company accrues costs for discovery research performed by CROs over the service periods specified in the contracts and adjusts our estimates, if required, based upon its ongoing review of the level of effort and costs actually incurred by the CROs. All of the Company&#8217;s material CRO contracts are terminable by the Company upon written notice and it is generally only liable for actual services completed by the CRO and certain non-cancellable expenses incurred at any point of termination.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has deposited cash of $2.0 million as of September&#160;30, 2020 to secure a letter of credit in connection with the lease of the 301 Binney facility (See Note 14).  The Company has classified the restricted cash as a noncurrent asset on its balance sheets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks common for biopharmaceutical companies, including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition, and untested manufacturing capabilities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are available-for-sale and are carried at estimated fair value. The Company&#8217;s valuations of available-for-sale securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the balance sheet date are classified as short-term investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are excluded from earnings and are reported as components of comprehensive loss. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income (expense), net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest income (expense), net on the Company&#8217;s statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value estimates are made at a discrete point in time based on relevant market information and information about the financial instruments. Fair value estimates are based on judgments regarding future expected loss experience, current economic conditions, risk characteristics of various financial instruments, and other factors. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company recorded both financial assets and financial liabilities requiring fair value measurement.  The financial assets include cash equivalents and investments.  The financial liabilities consist of the convertible promissory note (Gilead Note) from the Gilead Asset Purchase Agreement (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15).  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, the Company recorded financial assets, including cash equivalents, and investments, requiring fair value measurement.  There were no financial liabilities as of December&#160;31, 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, the Company has the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument by instrument basis, with changes in fair value reported in the statements of operations.  The option was elected for the treatment of the Company&#8217;s convertible promissory note from the Gilead Asset Purchase Agreement entered into in July 2020 (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15) in order to more accurately reflect the economic value of the notes.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over the estimated useful lives of the respective assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Repairs and maintenance costs are expensed as incurred.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives in years are generally as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offering costs, including legal, accounting, and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO.  As of September&#160;30, 2020, $2.9 million of deferred offering costs have been capitalized, which are included in the accompanying balance sheet within other noncurrent assets.  There were no deferred offering costs recorded as of December&#160;31, 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and noncurrent operating lease liabilities on the Company&#8217;s balance sheet. Finance leases are included in property and equipment, current portion of other liabilities, and other noncurrent liabilities on the balance sheet. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments and initial direct costs incurred, net of lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock-based awards granted to employees and nonemployees based on the fair value on the date of the grant and recognizes stock-based compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value measurement of stock options using the Black-Scholes option-pricing model. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeitures are accounted for as they occur. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has only issued stock options with service-based vesting conditions and records the expense for these awards using the straight-line method. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the three and nine months ended September&#160;30, 2020, other comprehensive loss consisted of unrealized gains and losses from available-for-sale securities. There was no difference between net loss and comprehensive loss for the three and nine months ended September&#160;30, 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and the effect of dilutive securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect on net loss per share is anti-dilutive.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).  The Company adopted ASU No. 2018-13 on January 1, 2019. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the FASB issued ASU No. 2016-18, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows, Restricted Cash </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-18). This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet.  The Company elected to adopt ASU 2016-18 on January 1, 2019 and has reflected the adoption in its financial statements. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.658%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as shown on the statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company adopted ASU No 2016-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flow</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2016-15) in 2019. The guidance reduces diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The adoption of ASU 2016-15 did not have a material impact on the Company&#8217;s condensed financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The standard will become effective for the Company in the first quarter of 2020, with early adoption permitted beginning the first quarter of 2019. The modified retrospective approach should be applied upon adoption of this new guidance. The Company&#8217;s financial instruments that are in the scope of ASU 2016-13 include available-for-sale debt securities. The Company adopted this standard on January&#160;1, 2020 and this amendment did not have a material impact on its financial statements.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span>, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company has adopted this standard as of January 1, 2020, which did not have a material impact on its financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691909892456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports its cash equivalents, investments, and convertible notes at fair value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds are measured at fair value on a recurring basis used quoted prices and are classified as Level 1.  Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classed as Level 2 inputs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 liabilities consist of the Company&#8217;s convertible notes payable.  The determination of the fair values for the Gilead Note and the 2020 Notes and the change in the fair value of these notes are discussed in Note 13 and Note 15, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,795&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities. The Company&#8217;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category as of September&#160;30, 2020.  Recorded losses associated within the Level 3 category include changes to fair value and are recorded within change in fair value of convertible notes in the statement of operations. Refer to Note 13 and Note 15 for the fair value determination of the Level 3 financial liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any financial assets or liabilities as of December 31, 2019 that required Level 3 inputs. There were no transfers of assets between the fair value measurement levels during any of the periods presented in the accompanying financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908428824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTS<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of available-for-sale securities by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,816&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These available-for-sale securities were classified on the Company&#8217;s balance sheets as of September&#160;30, 2020 and December&#160;31, 2019 as:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale securities by contractual maturity as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments not due at a single maturity date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of September&#160;30, 2020 and December&#160;31, 2019, the remaining contractual maturities of available-for-sale securities were less than 23 months and 18 months, respectively. There have been no significant realized losses on available-for-sale securities for any of the periods presented in the accompanying financial statements. Based on the Company&#8217;s review of its available-for-sale securities, the Company believes that it had no other-than-temporary impairments on these securities as of September&#160;30, 2020 and December&#160;31, 2019 because the Company does not intend to sell these securities nor does it believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for any of the periods presented in the accompanying financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910338792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses And Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses And Other Current Assets</a></td>
<td class="text">PREPAID EXPENSES AND OTHER CURRENT ASSETS <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on short-term available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid equipment service contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid external research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910458968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">PROPERTY AND EQUIPMENT, NET<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease on R&amp;D equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation and amortization expense was $0.2&#160;million and $0.1 million for the three months ended September&#160;30, 2020 and 2019, respectively, and $0.5 million and $0.2 million for the nine months ended September&#160;30, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908165624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Current Portion of Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Current Portion of Other Liabilities</a></td>
<td class="text">ACCRUED EXPENSES AND CURRENT PORTION OF OTHER LIABILITIES<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued franchise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of other liabilities consist of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of unvested early exercised share liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current portion of other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691907300440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_TemporaryEquityTextBlock', window );">Preferred Stock</a></td>
<td class="text">PREFERRED STOCK<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2018, the Company completed a private placement (Series Seed Financing) in which it issued an aggregate of 7,806,977 shares of its Series Seed Convertible Preferred Stock (Series Seed Preferred Stock) at a purchase price of $2.30769 per share, for aggregate gross proceeds of $18.0 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2019, the Company completed a private placement (the Series A Financing) in which it issued 13,697,916 shares of its Series A Convertible Preferred Stock (Series A Preferred Stock) at a purchase price of $7.6654 per share, for aggregate gross proceeds of $105.0 million less issuance costs of $0.1 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Preferred Stock (as defined below) consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred<br/>Stock<br/>Issued and<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Stock<br/>Issuable Upon<br/>Conversion</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series Seed Preferred Stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,806,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,806,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series A Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,700,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,697,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,451,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,506,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,504,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred<br/>Stock<br/>Issued and<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Stock<br/>Issuable Upon<br/>Conversion</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series Seed Preferred Stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,806,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,806,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series A Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,700,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,697,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,451,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,506,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,504,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the IPO (See Note 1), all outstanding shares of convertible preferred stock were automatically converted into 22,687,625 shares of common stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908164600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">COMMON STOCKPursuant to the Company&#8217;s amended and restated certificate of incorporation, filed on July 1, 2019, the Company was authorized to issue up to 40,000,000 shares of its common stock, par value $0.001.  As of September&#160;30, 2020 and December&#160;31, 2019, there were 6,284,326 and 5,660,391 shares issued and outstanding, respectively.Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Subject to the rights of the Preferred Stock, holders of the Company&#8217;s common stock are entitled to receive dividends, as may be declared by the Board of Directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908374696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2017 Equity Incentive Plan, as amended (the 2017 Plan), provides that the Company may sell or issue shares of common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of shares of common stock, to employees, members of the Board of Directors, and consultants of the Company. The exercise prices, vesting, and other restrictions are determined at the discretion of the Board of Directors, or a designated committee thereof, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the common share on the date of grant and the term of stock option may not be greater than 10 years. The Company recognizes the impact of forfeitures on stock-based compensation expense as forfeitures occur. The Company applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Vesting periods are determined at the discretion of the Board of Directors. Stock options typically vest over four years. The maximum contractual term is 10 years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, t</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he total number of shares of the Company&#8217;s common stock that may have been issued was 6,857,500 and 3,692,500 shares, respectively.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, there were</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 358,596 and 1,365,647 </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares, respectively, reserved by the Company under the 2017 Plan for the future issuance of equity awards.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model. This model requires the use of highly subjective assumptions to determine the fair value of stock-based awards, including:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In order to determine the fair value of the Company&#8217;s common stock underlying option grants, the Board of Directors considered, among other things, valuations of the Company&#8217;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Other objective and subjective factors considered included the Company&#8217;s stage of development and material risks related to its business, the progress of its research and development programs, its business conditions and projections, its financial position and its historical and forecasted performance and operating results, the lack of an active public market for its securities, its Preferred Stock, biopharmaceutical company performance, the likelihood of achieving a liquidity event, the hiring of key personnel and the experience of management, industry trends and developments, and external market conditions and industry trends. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expected Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of the options. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expected Volatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Since the Company is not yet a public company and does not have any trading history for its common stock, the expected volatility is estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies are chosen based on their size, stage in the product development cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the awards.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expected Dividend</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model assumptions that the Company used to determine the grant-date fair value of stock options for the three and nine months ended September&#160;30, 2020 and 2019 were as follows, presented on a weighted-average basis:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of common stock per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.35</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.72%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.88%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.93%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.97%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of stock options granted, using the assumptions listed above, was $4.66 and $1.54 during the three months ended September&#160;30, 2020 and 2019, respectively, and $3.16 and $0.88 during the nine months ended September&#160;30, 2020 and 2019, respectively. The weighted-average grant-date fair value per share of stock options vested was $0.69 and $0.09 during the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the 2017 Plan as of September&#160;30, 2020 is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,910&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and expected to vest at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,147,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock, as determined by the Board of Directors, as of the end of the respective period.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The intrinsic value of options exercised for the three months ended September&#160;30, 2020 and 2019 </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.5 million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd $0.2 million, respectively, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0 million and $0.4 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the nine months ended September&#160;30, 2020 and 2019 respectively, determined as of the applicable date of exercise.  There was no future tax benefit related to options exercised, as the Company had accumulated net operating losses as of September&#160;30, 2020 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019 as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, total unrecognized compensation cost related to the unvested share-based awards was $14.1 million, which is expected to be recognized over a weighted average period of 3.53 years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercised Options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows certain of its employees and its consultants to exercise options granted under the 2017 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company.  The early exercise by an employee or consultant of a stock option is not considered to be a substantive exercise for accounting purposes, and therefore the payment received by the employer for the exercise price is recognized as a liability.  For accounting purposes, unvested early exercised shares are not considered issued and outstanding and therefore not reflected as issued and outstanding in the accompanying statements of convertible preferred stock and stockholders' deficit until the awards vest. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposits received are initially recorded in current portion of other liabilities and other noncurrent liabilities for the noncurrent portion. The liabilities are reclassified to common stock and paid-in capital as the repurchase right lapses. During the three months ended September&#160;30, 2020 and 2019, and nine months ended September&#160;30, 2020 and 2019, 850,937, 60,924, 1,551,361, and 60,924 shares of the Company&#8217;s common stock were early exercised, respectively.  At September&#160;30, 2020 and December&#160;31, 2019, there was $2.1 million and $0.1 million recorded in current portion of other liabilities, and $2.8 million and $0.1 million recorded in other noncurrent liabilities, respectively, related to shares held by employees and nonemployees that were subject to repurchase.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div>In 2017, the Company issued 538,050 restricted stock awards to a non-employee at a fair value of $0.05 per share. In July 2020, the Company issued 274,341 restricted stock awards to an executive employee at a fair value of $4.14 per share.  As of September&#160;30, 2020, the restricted stock awards outstanding were 271,683 which are subject to lapsing repurchase rights. In order to vest, the holder is required to provide service to the Company. For accounting purposes, unvested restricted stock awards are not considered issued and outstanding and therefore are not reflected as issued and outstanding in the accompanying statements of convertible preferred stock and stockholders&#8217; deficit until the awards vest.  The Company recorded stock-based compensation expense for these awards of $599.1 thousand, $1.3 thousand, $601.7 thousand and $3.8 thousand for the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, respectively, in research and development in the statements of operations and comprehensive loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908215752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not recorded any income tax expense for the three and the nine months ended September&#160;30, 2020 and 2019. The Company has incurred net operating losses for all the periods presented and has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has recorded a full valuation allowance against all of its deferred tax assets as it is not more likely than not that such assets will be realized in the near future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to record penalties and interest related to income taxes as a component of income tax expense.  The Company has not recorded any interest or penalties related to income taxes during the three and nine months ended September&#160;30, 2020 and 2019.  The Company has not identified any new uncertain tax positions as of September&#160;30, 2020.  Unrecognized tax benefits are not expected to change during the next 12 months.  The reversal of the unrecognized tax benefits would not affect the effective tax rate.  The Company is subject to examination by U.S. federal and state tax authorities for all years since its inception.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908379480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share of the Company for the three and nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share and per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127,146&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,409,433&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886,191&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,196,681&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.48)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include the Preferred Stock and options to purchase shares of the Company's common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,741,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock award subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,129,352&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,172,957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910406328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Purchase Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into an asset purchase agreement (Gilead Asset Purchase Agreement) with Gilead Sciences, Inc. (Gilead), pursuant to which the Company acquired certain assets from Gilead related to entospletinib (ENTO) and lanraplenib (LANRA), and patents and other intellectual property covering or related to the development, manufacture and commercialization of ENTO and LANRA. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for such assets, on the date of the Gilead Asset Purchase Agreement, the Company made a $3.0 million upfront cash payment and issued a $3.0 million principal amount convertible promissory note to Gilead (Gilead Note)The Company also made a $0.7 million payment to reimburse Gilead for certain liabilities assumed by the Company pursuant to the Gilead Asset Purchase Agreement. In addition, the Company is required to make milestone payments upon successful achievement of certain regulatory and sales milestones for ENTO, LANRA and other selective spleen tyrosine kinase inhibitor compounds covered by the patent rights acquired pursuant to the Gilead Asset Purchase Agreement and developed by the Company as a back-up to ENTO or LANRA (Other Compounds). Upon initiation of the Company&#8217;s planned registrational Phase 2/3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations, the Company will be required to pay a milestone to Gilead of $29.0 million, and upon successful completion of certain other regulatory milestones in the United States, European Union and United Kingdom for ENTO, LANRA and any Other Compounds, across up to two distinct indications, the Company will be required to pay to Gilead an aggregate total of $51.3 million. Upon achieving certain thresholds for the aggregate annual net sales of ENTO, LANRA and any Other Compounds combined, the Company would owe to Gilead potential milestone payments totaling $115.0 million.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead is also eligible to receive (i) tiered marginal royalties ranging from the very low-teens to high-teens on annual worldwide net sales of ENTO, (ii) tiered marginal royalties ranging from high-single digits to the mid-teens on annual worldwide net sales of LANRA and (iii) tiered marginal royalties ranging from low single digits to mid-single digits on annual worldwide net sales of any Other Compounds. The royalties in the foregoing clauses are subject to reduction, on a country-by-country basis, for products not covered by certain claims within the assigned patents, for generic entry and, in the case of ENTO and LANRA, for any royalties paid for future licenses of third party intellectual property required to develop or commercialize ENTO or LANRA. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first commercial sale of such product in such country and ends on the latest of (i) expiration of the last claim of a defined set of the assigned patent rights covering such product in such country; (ii) loss of exclusive data or marketing rights to such product in such country; or (iii) 10 years from the first commercial sale of such product in such country.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Gilead Asset Purchase Agreement, the Company is required to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize either ENTO or LANRA.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Gilead Note accrues interest at a rate of 6% per year, compounded annually, and has a maturity date of July 14, 2020.  The Gilead Note provides that, upon the completion of the Company&#8217;s IPO, the Gilead Note will settle through the Company payment to Gilead of $6.0 million plus unpaid accrued interest unless Gilead elected, within a specified time, that the Gilead Note, including unpaid accrued interest, be converted into shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On issuance, the Company elected to account for the Gilead Note at fair value with any changes in fair value being recognized through the statements of operations until the Gilead Note settled. The fair value of the Gilead Note was determined to be $3.6 million on issuance and $5.5 million as of September&#160;30, 2020. For the three and nine months ended September&#160;30, 2020, the Company recognized $1.9 million in the accompanying statements of operations and comprehensive loss as the change in fair value of the 2020 Gilead Note.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the Gilead Note as of September&#160;30, 2020 by determining the present value of the Gilead Note if they were to settle either upon closing of an IPO, a deemed liquidation, or a qualified or non-qualified equity fundraise.  Key valuation assumptions are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fundraise scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO conversion scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation conversion scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the Gilead Note at inception by determining the present value of the Gilead Note if they were to settle either upon closing of an IPO, a deemed liquidation, or a qualified or non-qualified equity fundraise.  Key valuation assumptions are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At inception</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fundraise scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO conversion scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation conversion scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts with CROs for preclinical studies and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Company&#8217;s amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. There have been no claims to date, and the Company has a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908450040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company amended its month-to-month rental agreement for the 21 Erie Street, Cambridge, Massachusetts lab space, to extend its non-cancellable lease term.  The amendment was executed on May 5, 2020 and has a term expiration date of May 31, 2021.  As the lease term is longer than 12 months, the Company determined that this amendment requires assessment under ASC 842.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $1.6 million and an aggregate lease liability of $1.0 million on the September&#160;30, 2020 balance sheet. The remaining lease term is 8 months, and the estimated incremental borrowing rate is 12.71%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into an 11-year lease agreement to move its research and development operations from 21 Erie Street, Cambridge, Massachusetts, to a 40,514 square-feet facility at 301 Binney Street, Cambridge, Massachusetts.  The new lease commenced on March 1, 2020 with a monthly base rent of $0.3 million. The initial rent payment was paid as of September&#160;30, 2020, with rent payments escalating 3.0% annually after the initial 12 payments. As discussed in Note 2, the Company executed a letter of credit for $2.0 million in connection with the lease.  The lease includes $3.7 million in certain tenant improvement allowances, which the Company included in its calculation of the right-of-use asset in the lease at commencement. In connection with the lease, the Company recognized an operating lease right-of-use asset of $25.7 million and an aggregate lease liability of $27.7 million on the September&#160;30, 2020 balance sheet. The remaining lease term is 10 years and 5 months, and the estimated incremental borrowing rate is 8.50%</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company entered into a lease agreement for a 4,661 square-foot office space to be used for general and administrative activities in San Mateo, California. The lease commenced on August 1, 2018 and has a 37-month initial term expiring on August 31, 2021. The lease also contains an option for the Company to extend the lease upon its initial expiration. In connection with the lease, the Company made a one-time cash security deposit in the amount of $27.8 thousand. In May 2020, the Company amended its agreement to extend the lease for its office in San Mateo, California through April 2025. The initial annual base rent is $26.1 thousand, and such amount will increase by 3% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $1.2 million $0.5 million and an aggregate lease liability of $1.2 million and $0.5 million on the September&#160;30, 2020 and December&#160;31, 2019 balance sheets, respectively.  The Company expanded to an adjacent suite in July 2020, which is treated as a separate lease for accounting purposes.  The additional space is approximately 3,414 square feet and will similarly be used for general and administrative activities.  The lease commenced on July 1, 2020 and will expire on April 30, 2025.  In connection with the additional space leased, the Company made a one-time additional cash security deposit in the amount of $24.8 thousand.  The initial base rent for the expansion is $19.2 thousand, and such amount will increase by 3% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $0.9 million and an aggregate lease liability of $0.9 million on the September&#160;30, 2020 balance sheet.  The remaining lease term is for both spaces is 4 years and 7 months, and the estimated incremental borrowing rate is 12.07%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company entered into a finance lease for R&amp;D equipment that has a bargain purchase option at the end of its three-year term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finance lease is included in property and equipment, net, other current liabilities, and other noncurrent liabilities on the Company&#8217;s balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the Company&#8217;s finance lease in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion of other liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the Company&#8217;s operating leases in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion of operating lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Noncurrent operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of finance lease costs in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Statement of Operations and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive Loss Caption</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income (expense), net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of operating lease costs in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Statement of Operations and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive Loss Caption</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments of $0.7 million, $0.1 million, $1.3 million, and $0.2 million under the lease agreements during the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> undiscounted future non-cancellable lease payments under the Company's operating leases </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of September&#160;30, 2020 for the next five years and thereafter is expected to be as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining three months of 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Tenant improvement allowance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company amended its month-to-month rental agreement for the 21 Erie Street, Cambridge, Massachusetts lab space, to extend its non-cancellable lease term.  The amendment was executed on May 5, 2020 and has a term expiration date of May 31, 2021.  As the lease term is longer than 12 months, the Company determined that this amendment requires assessment under ASC 842.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $1.6 million and an aggregate lease liability of $1.0 million on the September&#160;30, 2020 balance sheet. The remaining lease term is 8 months, and the estimated incremental borrowing rate is 12.71%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into an 11-year lease agreement to move its research and development operations from 21 Erie Street, Cambridge, Massachusetts, to a 40,514 square-feet facility at 301 Binney Street, Cambridge, Massachusetts.  The new lease commenced on March 1, 2020 with a monthly base rent of $0.3 million. The initial rent payment was paid as of September&#160;30, 2020, with rent payments escalating 3.0% annually after the initial 12 payments. As discussed in Note 2, the Company executed a letter of credit for $2.0 million in connection with the lease.  The lease includes $3.7 million in certain tenant improvement allowances, which the Company included in its calculation of the right-of-use asset in the lease at commencement. In connection with the lease, the Company recognized an operating lease right-of-use asset of $25.7 million and an aggregate lease liability of $27.7 million on the September&#160;30, 2020 balance sheet. The remaining lease term is 10 years and 5 months, and the estimated incremental borrowing rate is 8.50%</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company entered into a lease agreement for a 4,661 square-foot office space to be used for general and administrative activities in San Mateo, California. The lease commenced on August 1, 2018 and has a 37-month initial term expiring on August 31, 2021. The lease also contains an option for the Company to extend the lease upon its initial expiration. In connection with the lease, the Company made a one-time cash security deposit in the amount of $27.8 thousand. In May 2020, the Company amended its agreement to extend the lease for its office in San Mateo, California through April 2025. The initial annual base rent is $26.1 thousand, and such amount will increase by 3% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $1.2 million $0.5 million and an aggregate lease liability of $1.2 million and $0.5 million on the September&#160;30, 2020 and December&#160;31, 2019 balance sheets, respectively.  The Company expanded to an adjacent suite in July 2020, which is treated as a separate lease for accounting purposes.  The additional space is approximately 3,414 square feet and will similarly be used for general and administrative activities.  The lease commenced on July 1, 2020 and will expire on April 30, 2025.  In connection with the additional space leased, the Company made a one-time additional cash security deposit in the amount of $24.8 thousand.  The initial base rent for the expansion is $19.2 thousand, and such amount will increase by 3% annually on each anniversary of the commencement date.  In connection with the lease, the Company recognized an operating lease right-of-use asset of $0.9 million and an aggregate lease liability of $0.9 million on the September&#160;30, 2020 balance sheet.  The remaining lease term is for both spaces is 4 years and 7 months, and the estimated incremental borrowing rate is 12.07%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company entered into a finance lease for R&amp;D equipment that has a bargain purchase option at the end of its three-year term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finance lease is included in property and equipment, net, other current liabilities, and other noncurrent liabilities on the Company&#8217;s balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the Company&#8217;s finance lease in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion of other liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the Company&#8217;s operating leases in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion of operating lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Noncurrent operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of finance lease costs in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Statement of Operations and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive Loss Caption</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income (expense), net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of operating lease costs in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Statement of Operations and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive Loss Caption</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments of $0.7 million, $0.1 million, $1.3 million, and $0.2 million under the lease agreements during the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> undiscounted future non-cancellable lease payments under the Company's operating leases </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of September&#160;30, 2020 for the next five years and thereafter is expected to be as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining three months of 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Tenant improvement allowance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691909203064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2020 Notes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">2020 Notes</a></td>
<td class="text">2020 Notes<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a note purchase agreement pursuant to which it sold and issued and aggregate of $155.2 million in convertible promissory notes (2020 Notes) and received net cash proceeds of $151.3 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Notes do not accrue interest.  The 2020 Notes were settled in exchange for 9,610,713 shares of common stock in connection with the closing of the Company&#8217;s IPO (See Note 1) at a settlement per share price equal to 85% of the IPO price per share.  The 2020 Notes also contained other settlement provisions if an IPO did not occur within 18-months of the 2020 Notes issuance date.  If the Company was acquired, completed a business combination resulting in a change of control or sold all or substantially all of its assets (each, a liquidation transaction) prior to the 18-month anniversary of the issuance dates of the 2020 Notes, the 2020 Notes unless previously settled into shares of common stock in the IPO, will settle into shares of the Company&#8217;s common stock at a price per share equal to 85% of the estimated fair value of the consideration per share payable to the holders of its common stock in connection with such liquidation transaction.  If neither the IPO nor a liquidation transaction occurs prior to the 18th-month anniversary of the issuance dates of the 2020 Notes, the 2020 Notes will be converted into shares of newly designated Series B convertible preferred stock of the Company at a settlement price that will be determined based on a stipulation $500.0 million valuation of the Company and its fully diluted capitalization as of immediately prior to the conversion of the 2020 Notes.  The 2020 Notes contain additional redemption features contingent upon the occurrence of certain future events.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On issuance, the Company elected to account for the 2020 Notes at fair value with any changes in fair value being recognized through the statements of operations until the 2020 Notes settled.  On issuance, the fair value of the 2020 Notes was determined to be equal to $155.2 million, which is the principal amount of the 2020 Notes, and total debt issuance costs of $3.9 million were expensed and recognized as interest expense in the accompanying statements of operations and comprehensive loss.  An additional $50 thousand was reimbursed to investors for legal costs incurred and netted against total proceeds received on the Company&#8217;s balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the 2020 Notes as of September&#160;30, 2020 by determining the present value of the 2020 Notes if they were to settle either upon closing of an IPO, in shares of Series B convertible preferred stock 18-months after issuance (February 2022), or upon a financing scenario.  Key valuation assumptions are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO Scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing Scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the 2020 Notes was determined to be $155.2 million on issuance and $168.5 million as of September&#160;30, 2020. For the three and nine months ended September&#160;30, 2020, the Company recognized $13.3 million in the accompanying statements of operations and comprehensive loss as the change in fair value of the 2020 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910458136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">RELATED PARTIES<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2017, the Company entered into a three-year services agreement with Two River Consulting, LLC (Two River) to provide various clinical development, operational, managerial, accounting and financial, and administrative services to the Company. Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman of Two River. Mr. Joshua Kazam and Mr. David Tanen, each a director of the Company, are each partners of Two River. Mr. Tanen additionally serves as our Corporate Secretary.  Mr. Christopher Wilfong, a strategic advisor to the Company, is an Operating Partner of Two River and Mr. Sean Algeo, serving as the Company&#8217;s Treasurer, is the Chief Financial Officer of Two River. During the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, the Company incurred expense of $0.3 million, $0.2 million, $0.8 million and $0.6 million respectively, for these services. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s expenses are periodically paid by Two River. The Company reimburses Two River for these expenses and no interest is charged on the outstanding balance.  These reimbursable expenses totaled $15.0 thousand and $7.4 thousand for three months ended September&#160;30, 2020 and 2019, respectively, and $24.1 thousand and $44.9 thousand for the nine months ended September&#160;30, 2020 and 2019, respectively.  As of September&#160;30, 2020 and December&#160;31, 2019, the Company had payables to Two River of $92.5 thousand and $75.0 thousand, respectively. All balances owed as December 31, 2019 were paid in full during the first quarter of 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a consulting agreement with Bellco Capital, LLC (Bellco) to provide various executive services to the Company.  Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman of Bellco. Rebecka Belldegrun, M.D., a director of the Company, is the President and Chief Executive Officer of Bellco. During the three months ended September&#160;30, 2020 and 2019 and the nine months ended September&#160;30, 2020 and 2019, the Company incurred expense of $6.3 thousand, $6.3 thousand, $18.9 thousand and $18.9 thousand, respectively, for these services.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910341800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the interim financial statements as of September&#160;30, 2020 for the three and nine months periods then ended, the Company evaluated subsequent events for recognition and measurement purposes.  The Company concluded that no events or transactions have occurred that require disclosure in the accompanying financial statements, other than the following.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt">Authorization of Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2020, the Company amended and restated its certificate of incorporation.  Among other things, the amended and restated certification of incorporation authorizes 10,000,000 shares of undesignated preferred stock with a par value of $0.001.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt">Increase in Authorization of Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020, the Company amended its certificate of incorporation to, among other things, increase the number of authorized shares of common stock from 40,000,000 to 200,000,000.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt">Amendments to Convertible Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2020, the required holders of the Company&#8217;s Convertible Preferred Stockholders authorized the automatic conversion of all shares of the Convertible Preferred Stock in the IPO.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt">Forward Stock Split</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020, the Company effected a 1.055-for-1 forward stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing ratios for each series of the Company&#8217;s Preferred Stock.  In addition, the number of shares subject to each stock option outstanding was proportionally increased by the forward stock split ratio, and the exercise price per share was proportionally decreased by the forward stock split ratio.  Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retrospectively, where applicable, to reflect this forward stock split and adjustment of the preferred stock conversion ratios.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.67pt">2020 Equity Incentive Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company&#8217;s board of directors and stockholders approved the Company&#8217;s 2020 Equity Incentive Plan (the 2020 Plan), which became effective on October 8, 2020.  The 2020 Plan provides for the issuance of up to 11,938,152 of share-based awards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">f.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.9pt">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company&#8217;s board of directors and stockholders approved the Company&#8217;s 2020 Employee Stock Purchase Plan (the ESPP).  The ESPP became effective October 8, 2020.  The ESPP provides for the issuance of up to 688,000 of share-based awards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt">Conversion of convertible notes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, upon the closing Company&#8217;s IPO, the 2020 Notes automatically converted into 9,610,713 shares of common stock (See Note 15).  Upon the closing of the IPO, the Gilead Note was also converted into 188,567 shares of common stock as the result of Gilead&#8217;s election (See Note 13).  The Company will record a loss of $14.1 million and a gain of $1.9 million in the fourth quarter of fiscal 2020 upon the settlement of the 2020 Notes and Gilead Note, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">h.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.13pt">Lease termination</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a lease termination agreement for its lab space in Cambridge, Massachusetts.  The lease will terminate as of January 31, 2021 rather than continue through May 2021.  The cost for early termination is a payment of $0.1 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691917201512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies, Estimates and Judgments (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying balance sheet as of September&#160;30, 2020, the statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019, the statements of convertible preferred stock and stockholders&#8217; deficit as of September&#160;30, 2020 and 2019, the statements of cash flows for the nine months ended September&#160;30, 2020 and 2019, and the financial data and other financial data and other information disclosed to in the notes to the condensed financial statements are unaudited.  The unaudited interim financial statements have been prepared on a basis consistent with the Company&#8217;s audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of September&#160;30, 2020 and the results of its operations the three and nine months ended September&#160;30, 2020 and 2019. The results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2020, any other interim periods, or any future year or period.  These financial statements should be read in conjunction with the Company's audited financial statements included in the prospectus dated October 8, 2020 that forms a part of the Company's Registration Statements on Form S-1 (File No. 333-248925), as filed with the SEC pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended, on October 9, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. </span></div>Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of convertible notes and investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  Actual results could differ from the Company&#8217;s estimates.The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, discovery research performed by contract research organizations (CROs), materials and supplies, licenses and fees and overhead allocations consisting of various support and facility-related costs. The Company expenses R&amp;D costs as the services are performed or the goods are received.  Research and development expenses for the three and nine months ended September&#160;30, 2020 included $6.6 million related to acquired intangible assets as research and development costs pursuant to the Asset Purchase Agreement with Gilead (See Note 13) as, at the time of acquisition of the asset, the technology was under development; was not approved by the U.S. Food and Drug Administration or other regulatory agencies for marketing; had not reached technical feasibility; or otherwise had no foreseeable alternative future use.  There were no acquired intangible assets expensed for the three and nine months ended September&#160;30, 2019.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRO costs are a significant component of R&amp;D expenses. The Company monitors levels of performance under each significant contract through communications with its CROs. The Company accrues costs for discovery research performed by CROs over the service periods specified in the contracts and adjusts our estimates, if required, based upon its ongoing review of the level of effort and costs actually incurred by the CROs. All of the Company&#8217;s material CRO contracts are terminable by the Company upon written notice and it is generally only liable for actual services completed by the CRO and certain non-cancellable expenses incurred at any point of termination.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div>The Company has deposited cash of $2.0 million as of September&#160;30, 2020 to secure a letter of credit in connection with the lease of the 301 Binney facility (See Note 14).  The Company has classified the restricted cash as a noncurrent asset on its balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks common for biopharmaceutical companies, including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition, and untested manufacturing capabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are available-for-sale and are carried at estimated fair value. The Company&#8217;s valuations of available-for-sale securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the balance sheet date are classified as short-term investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are excluded from earnings and are reported as components of comprehensive loss. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income (expense), net. The cost of investments sold is based on the specific-identification method. Interest income on investments is included in interest income (expense), net on the Company&#8217;s statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value estimates are made at a discrete point in time based on relevant market information and information about the financial instruments. Fair value estimates are based on judgments regarding future expected loss experience, current economic conditions, risk characteristics of various financial instruments, and other factors. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company recorded both financial assets and financial liabilities requiring fair value measurement.  The financial assets include cash equivalents and investments.  The financial liabilities consist of the convertible promissory note (Gilead Note) from the Gilead Asset Purchase Agreement (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15).  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, the Company recorded financial assets, including cash equivalents, and investments, requiring fair value measurement.  There were no financial liabilities as of December&#160;31, 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, the Company has the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument by instrument basis, with changes in fair value reported in the statements of operations.  The option was elected for the treatment of the Company&#8217;s convertible promissory note from the Gilead Asset Purchase Agreement entered into in July 2020 (See Note 13) and the convertible promissory notes (2020 Notes) sold in August 2020 (See Note 15) in order to more accurately reflect the economic value of the notes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over the estimated useful lives of the respective assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Repairs and maintenance costs are expensed as incurred.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives in years are generally as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or lease term</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">Deferred Offering CostsOffering costs, including legal, accounting, and filing fees related to the IPO, were deferred and were offset against the offering proceeds upon the completion of the IPO.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and noncurrent operating lease liabilities on the Company&#8217;s balance sheet. Finance leases are included in property and equipment, current portion of other liabilities, and other noncurrent liabilities on the balance sheet. </span></div>ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments and initial direct costs incurred, net of lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (short-term leases) and elected to not separate lease components and non-lease components for its long-term real-estate leases.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock-based awards granted to employees and nonemployees based on the fair value on the date of the grant and recognizes stock-based compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value measurement of stock options using the Black-Scholes option-pricing model. </span>Forfeitures are accounted for as they occur. As of September&#160;30, 2020 and December&#160;31, 2019, the Company has only issued stock options with service-based vesting conditions and records the expense for these awards using the straight-line method.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the three and nine months ended September&#160;30, 2020, other comprehensive loss consisted of unrealized gains and losses from available-for-sale securities. There was no difference between net loss and comprehensive loss for the three and nine months ended September&#160;30, 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and the effect of dilutive securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect on net loss per share is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13).  The Company adopted ASU No. 2018-13 on January 1, 2019. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the FASB issued ASU No. 2016-18, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows, Restricted Cash </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-18). This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet.  The Company elected to adopt ASU 2016-18 on January 1, 2019 and has reflected the adoption in its financial statements. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.658%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as shown on the statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company adopted ASU No 2016-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flow</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2016-15) in 2019. The guidance reduces diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The adoption of ASU 2016-15 did not have a material impact on the Company&#8217;s condensed financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The standard will become effective for the Company in the first quarter of 2020, with early adoption permitted beginning the first quarter of 2019. The modified retrospective approach should be applied upon adoption of this new guidance. The Company&#8217;s financial instruments that are in the scope of ASU 2016-13 include available-for-sale debt securities. The Company adopted this standard on January&#160;1, 2020 and this amendment did not have a material impact on its financial statements.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span>, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company has adopted this standard as of January 1, 2020, which did not have a material impact on its financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910014536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies, Estimates and Judgments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives in years are generally as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease on R&amp;D equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents, and Restricted Cash Equivalents</a></td>
<td class="text">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.658%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as shown on the statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908355240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,795&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities. The Company&#8217;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category as of September&#160;30, 2020.  Recorded losses associated within the Level 3 category include changes to fair value and are recorded within change in fair value of convertible notes in the statement of operations. Refer to Note 13 and Note 15 for the fair value determination of the Level 3 financial liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any financial assets or liabilities as of December 31, 2019 that required Level 3 inputs. There were no transfers of assets between the fair value measurement levels during any of the periods presented in the accompanying financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908403304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of available-for-sale securities by major security type as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,816&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These available-for-sale securities were classified on the Company&#8217;s balance sheets as of September&#160;30, 2020 and December&#160;31, 2019 as:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale securities by contractual maturity as of September&#160;30, 2020 and December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments not due at a single maturity date</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908351368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses And Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on short-term available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid equipment service contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid external research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910007480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives in years are generally as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease on R&amp;D equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691912887128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses And Current Portion Of Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued franchise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities</a></td>
<td class="text">Current portion of other liabilities consist of the following as of September&#160;30, 2020 and December&#160;31, 2019:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of unvested early exercised share liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current portion of other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910007480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Preferred Stock</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Preferred Stock (as defined below) consisted of the following as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred<br/>Stock<br/>Issued and<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Stock<br/>Issuable Upon<br/>Conversion</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series Seed Preferred Stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,806,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,806,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series A Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,700,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,697,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,451,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,506,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,504,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred<br/>Stock<br/>Issued and<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Stock<br/>Issuable Upon<br/>Conversion</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series Seed Preferred Stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,806,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,806,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series A Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,700,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,697,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,451,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,506,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,504,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910036984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Option-pricing Model Assumptions</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model assumptions that the Company used to determine the grant-date fair value of stock options for the three and nine months ended September&#160;30, 2020 and 2019 were as follows, presented on a weighted-average basis:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of common stock per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.35</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.72%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.88%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.93%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.97%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the 2017 Plan as of September&#160;30, 2020 is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,910&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and expected to vest at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,147,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based Compensation, Classified in Statements of Operations</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019 as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691999058440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share of the Company for the three and nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share and per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127,146&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,409,433&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886,191&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,196,681&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.48)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,741,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock award subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,129,352&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,172,957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910009704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Key Valuation Assumptions</a></td>
<td class="text">Key valuation assumptions are as follows:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fundraise scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO conversion scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation conversion scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the Gilead Note at inception by determining the present value of the Gilead Note if they were to settle either upon closing of an IPO, a deemed liquidation, or a qualified or non-qualified equity fundraise.  Key valuation assumptions are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At inception</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fundraise scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO conversion scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation conversion scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>Key valuation assumptions are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO Scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing Scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908533656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock', window );">Assets and Liabilities, Finance Leases, Lessee</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the Company&#8217;s finance lease in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion of other liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total finance lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock', window );">Assets And Liabilities, Operating Leases, Lessee</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the Company&#8217;s operating leases in its balance sheets as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current portion of operating lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Noncurrent operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of finance lease costs in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Statement of Operations and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive Loss Caption</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income (expense), net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of operating lease costs in the Company&#8217;s statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2020 and 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Statement of Operations and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive Loss Caption</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September&#160;30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September&#160;30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities on Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> undiscounted future non-cancellable lease payments under the Company's operating leases </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of September&#160;30, 2020 for the next five years and thereafter is expected to be as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining three months of 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Tenant improvement allowance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Finance Leases, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Operating Leases, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908417096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2020 Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Key Valuation Assumptions</a></td>
<td class="text">Key valuation assumptions are as follows:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fundraise scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO conversion scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation conversion scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the Gilead Note at inception by determining the present value of the Gilead Note if they were to settle either upon closing of an IPO, a deemed liquidation, or a qualified or non-qualified equity fundraise.  Key valuation assumptions are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At inception</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fundraise scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO conversion scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation cash payout scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation conversion scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>Key valuation assumptions are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September&#160;30, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPO Scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Scenario</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing Scenario</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691917109704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Consolidation and Presentation of Financial Statements (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">14,949,465<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,816<span></span>
</td>
<td class="nump">$ 71,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,713<span></span>
</td>
<td class="nump">$ 8,579<span></span>
</td>
<td class="nump">$ 6,995<span></span>
</td>
<td class="nump">$ 4,013<span></span>
</td>
<td class="nump">$ 3,509<span></span>
</td>
<td class="nump">$ 3,130<span></span>
</td>
<td class="nump">$ 55,287<span></span>
</td>
<td class="nump">$ 10,652<span></span>
</td>
<td class="nump">$ 78,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,687,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Forward stock split ratio</a></td>
<td class="nump">1.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,131,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in private placement, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Payments of underwriting discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_PaymentsOfOfferingCosts', window );">Payments of offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,687,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock | Subsequent Event | 2020 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,610,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock | Subsequent Event | 2020 Gilead Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,973,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_PaymentsOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_PaymentsOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Underwriting Discounts And Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kron_A2020ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kron_A2020ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kron_A2020GileadNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kron_A2020GileadNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691999111096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies, Estimates and Judgments - R&amp;D Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ScheduleOfAssetAcquisitionLineItems', window );"><strong>Schedule Of Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,755<span></span>
</td>
<td class="nump">$ 3,526<span></span>
</td>
<td class="nump">$ 30,125<span></span>
</td>
<td class="nump">$ 8,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_AssetAcquisitionAxis=kron_GileadAssetPurchaseMember', window );">Gilead Asset Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ScheduleOfAssetAcquisitionLineItems', window );"><strong>Schedule Of Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_ScheduleOfAssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_ScheduleOfAssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_AssetAcquisitionAxis=kron_GileadAssetPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_AssetAcquisitionAxis=kron_GileadAssetPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908354120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies, Estimates and Judgments - Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 2,026<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691993989656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies, Estimates and Judgments - Property, Plant and Equipment (Details) - Lab equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_LabEquipmentMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_LabEquipmentMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911665400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies, Estimates and Judgments - Schedule of Cash, Cash Equivalents, and Restricted Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 156,196<span></span>
</td>
<td class="nump">$ 32,570<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 102,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,026<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash as shown on the statements of cash flows</a></td>
<td class="nump">$ 158,222<span></span>
</td>
<td class="nump">$ 32,570<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 102,738<span></span>
</td>
<td class="nump">$ 10,226<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691913027384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 144,816<span></span>
</td>
<td class="nump">$ 71,127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">173,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">84,635<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">18,021<span></span>
</td>
<td class="nump">26,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">40,926<span></span>
</td>
<td class="nump">36,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">2020 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2020 Notes</a></td>
<td class="nump">168,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Gilead Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Gilead Note</a></td>
<td class="nump">5,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">126,795<span></span>
</td>
<td class="nump">38,707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">84,635<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">40,926<span></span>
</td>
<td class="nump">36,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | 2020 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2020 Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Gilead Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Gilead Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">18,021<span></span>
</td>
<td class="nump">32,420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">18,021<span></span>
</td>
<td class="nump">26,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | 2020 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2020 Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Gilead Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Gilead Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">173,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | 2020 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2020 Notes</a></td>
<td class="nump">168,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Gilead Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Gilead Note</a></td>
<td class="nump">$ 5,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910545208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Fair Value and Amortized Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Money market funds, amortized cost</a></td>
<td class="nump">$ 84,973<span></span>
</td>
<td class="nump">$ 6,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Total cash equivalents and investments, amortized cost</a></td>
<td class="nump">144,769<span></span>
</td>
<td class="nump">71,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and investments, unrealized gains</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and investments, unrealized losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash equivalents and investments, fair value</a></td>
<td class="nump">144,816<span></span>
</td>
<td class="nump">71,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Money market funds, amortized cost</a></td>
<td class="nump">84,635<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,011<span></span>
</td>
<td class="nump">26,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">18,021<span></span>
</td>
<td class="nump">26,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">40,898<span></span>
</td>
<td class="nump">36,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 40,926<span></span>
</td>
<td class="nump">$ 36,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691912560376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 84,973<span></span>
</td>
<td class="nump">$ 6,751<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">55,069<span></span>
</td>
<td class="nump">59,614<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">4,774<span></span>
</td>
<td class="nump">4,762<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total cash equivalents and investments</a></td>
<td class="nump">$ 144,816<span></span>
</td>
<td class="nump">$ 71,127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691995806312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Due in 1 year or less</a></td>
<td class="nump">$ 55,407<span></span>
</td>
<td class="nump">$ 66,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Due in 1 to 2 years</a></td>
<td class="nump">4,774<span></span>
</td>
<td class="nump">4,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Instruments not due at a single maturity date</a></td>
<td class="nump">84,635<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total cash equivalents and investments</a></td>
<td class="nump">$ 144,816<span></span>
</td>
<td class="nump">$ 71,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity', window );">Available-for-sale, remaining contractual maturity</a></td>
<td class="text">23 months<span></span>
</td>
<td class="text">18 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Remaining Contractual Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691994032792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses And Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_DebtSecuritiesAvailableForSaleAccruedInterest', window );">Accrued interest on short-term available-for-sale securities</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_PrepaidEquipmentServiceContracts', window );">Prepaid equipment service contracts</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_PrepaidExternalResearchAndDevelopment', window );">Prepaid external research and development</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_PrepaidSoftware', window );">Prepaid software</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,628<span></span>
</td>
<td class="nump">$ 1,119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_DebtSecuritiesAvailableForSaleAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_DebtSecuritiesAvailableForSaleAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_PrepaidEquipmentServiceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Equipment Service Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_PrepaidEquipmentServiceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_PrepaidExternalResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid External Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_PrepaidExternalResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_PrepaidSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_PrepaidSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691993546360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease on R&amp;D equipment</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">11,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(446)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Total property and equipment, net</a></td>
<td class="nump">10,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,721<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">5,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,978<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 5,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691916519128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses And Current Portion Of Other Liabilities - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,107<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued franchise tax</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_AccruedExternalResearchAndDevelopmentCurrent', window );">External research and development</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_AccruedOfferingCostsCurrent', window );">Accrued offering costs</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,780<span></span>
</td>
<td class="nump">$ 818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_AccruedExternalResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued External Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_AccruedExternalResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_AccruedOfferingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Offering Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_AccruedOfferingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6419918&amp;loc=d3e35281-107843<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691916586120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses And Current Portion Of Other Liabilities - Current Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liability</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Current portion of unvested early exercised share liability</a></td>
<td class="nump">2,123<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total current portion of other current liabilities</a></td>
<td class="nump">$ 2,137<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691917153160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2019</div></th>
<th class="th"><div>May 22, 2018</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,248<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,687,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kron_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in private placement, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kron_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds received in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement (in shares)</a></td>
<td class="nump">13,697,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds received in private placement</a></td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in private placement, price per share (in dollars per share)</a></td>
<td class="nump">$ 7.6654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kron_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kron_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911336520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">21,506,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,506,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">21,504,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,504,893<span></span>
</td>
<td class="nump">14,949,465<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 122,907<span></span>
</td>
<td class="nump">$ 72,665<span></span>
</td>
<td class="nump">$ 17,985<span></span>
</td>
<td class="nump">$ 17,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="nump">$ 123,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,016<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">22,687,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,687,625<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kron_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">7,806,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">7,806,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">7,806,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,806,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="nump">$ 17,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="nump">$ 18,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,016<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">8,236,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,236,347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">13,697,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,697,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">13,697,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,697,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="nump">$ 104,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">14,451,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,451,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kron_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kron_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691908346472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,284,326<span></span>
</td>
<td class="nump">5,660,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">6,284,326<span></span>
</td>
<td class="nump">5,660,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910754408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value, options granted (in dollars per share)</a></td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value, options vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Stock options exercised, intrinsic value</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock options, unrecognized cost</a></td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares', window );">Early exercised stock options, shares</a></td>
<td class="nump">850,937<span></span>
</td>
<td class="nump">60,924<span></span>
</td>
<td class="nump">1,551,361<span></span>
</td>
<td class="nump">60,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Current liabilities related to shares that were subject to repurchase</a></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Current portion of other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Current liabilities related to shares that were subject to repurchase</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Non-current liabilities related to shares that were subject to repurchase</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kron_EquityIncentivePlan2017Member', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares that may have been issued (in shares)</a></td>
<td class="nump">6,857,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,857,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,692,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">358,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kron_EquityIncentivePlan2017Member', window );">2017 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kron_EquityIncentivePlan2017Member', window );">2017 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options recognized, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kron_EquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kron_EquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691912592104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option-pricing Model Assumptions (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_SharePriceFairValueDisclosure', window );">Fair value of common stock per share (dollars per share)</a></td>
<td class="nump">$ 6.79<span></span>
</td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years 10 days<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.72%<span></span>
</td>
<td class="nump">66.88%<span></span>
</td>
<td class="nump">76.93%<span></span>
</td>
<td class="nump">76.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">0.73%<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SharePriceFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Price, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SharePriceFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691912333592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Option Activity Under the 2017 Plan [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at December 31, 2019 (in shares)</a></td>
<td class="nump">1,726,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">4,015,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(117,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(406,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at September 30, 2020 (in shares)</a></td>
<td class="nump">5,217,886<span></span>
</td>
<td class="nump">1,726,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at September 30, 2020 (in shares)</a></td>
<td class="nump">69,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Unvested and expected to vest at September 30, 2020 (in shares)</a></td>
<td class="nump">5,147,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at December 31, 2019 (dollars per share)</a></td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (dollars per share)</a></td>
<td class="nump">4.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (dollars per share)</a></td>
<td class="nump">0.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (dollars per share)</a></td>
<td class="nump">1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at September 30, 2020 (dollars per share)</a></td>
<td class="nump">3.91<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Option Activity, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance, Weighted-Average Remaining Contractual Term</a></td>
<td class="text">9 years 4 months 2 days<span></span>
</td>
<td class="text">9 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-Average Remaining Contractual Term</a></td>
<td class="text">8 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Unvested and expected to vest, Weighted-Average Remaining Contractual Term</a></td>
<td class="text">9 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 68,291<span></span>
</td>
<td class="nump">$ 27,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Unvested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 67,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691918400504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Classified in Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,253<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 1,734<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 1,193<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910599128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,253,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 1,734,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock | Non-Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 599,100<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 601,700<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock | Executive Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=kron_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=kron_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=kron_ExecutiveEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=kron_ExecutiveEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691912570664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691916546200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (39,713)<span></span>
</td>
<td class="num">$ (8,579)<span></span>
</td>
<td class="num">$ (6,995)<span></span>
</td>
<td class="num">$ (4,013)<span></span>
</td>
<td class="num">$ (3,509)<span></span>
</td>
<td class="num">$ (3,130)<span></span>
</td>
<td class="num">$ (55,287)<span></span>
</td>
<td class="num">$ (10,652)<span></span>
</td>
<td class="num">$ (78,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock, basic and diluted (in shares)</a></td>
<td class="nump">6,127,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,409,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,886,191<span></span>
</td>
<td class="nump">5,196,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (6.48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9.39)<span></span>
</td>
<td class="num">$ (2.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691912043256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">39,129,352<span></span>
</td>
<td class="nump">24,172,957,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">22,687,625<span></span>
</td>
<td class="nump">22,687,625,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt | 2020 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">10,741,406<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt | 2020 Gilead Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">210,752<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">3,359,622<span></span>
</td>
<td class="nump">389,086,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=kron_StockOptionsEarlyExerciseMember', window );">Early exercised stock options subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">1,858,264<span></span>
</td>
<td class="nump">854,123,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">271,683<span></span>
</td>
<td class="nump">242,123,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kron_A2020ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kron_A2020ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kron_A2020GileadNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kron_A2020GileadNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=kron_StockOptionsEarlyExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=kron_StockOptionsEarlyExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691917193768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=kron_A2020GileadNotesMember', window );">2020 Gilead Notes | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ScheduleOfAssetAcquisitionLineItems', window );"><strong>Schedule Of Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_RepaymentOfDebtPaymentToBeMade', window );">Repayment of debt, payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2020 Notes</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_GainLossOnChangeInFairValueOfDebtInstrument', window );">Gain (loss) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_PurchaseProvisionTermsMember', window );">Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ScheduleOfAssetAcquisitionLineItems', window );"><strong>Schedule Of Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment', window );">Sales milestone payment</a></td>
<td class="nump">29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment', window );">Regulatory milestone payment</a></td>
<td class="nump">51.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment', window );">Aggregate sales milestone payment</a></td>
<td class="nump">115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_AssetAcquisitionAxis=kron_GileadAssetPurchaseMember', window );">Gilead Asset Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ScheduleOfAssetAcquisitionLineItems', window );"><strong>Schedule Of Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_PaymentsForAssetAcquisitions', window );">Upfront cash payment</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred', window );">Convertible promissory note issued</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_PaymentsForAssetAcquisitionsReimbursements', window );">Payments for reimbursements</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Liabilities Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_GainLossOnChangeInFairValueOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Change In Fair Value Of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_GainLossOnChangeInFairValueOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_PaymentsForAssetAcquisitionsReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Asset Acquisitions, Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_PaymentsForAssetAcquisitionsReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_RepaymentOfDebtPaymentToBeMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Debt, Payment To Be Made</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_RepaymentOfDebtPaymentToBeMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Aggregate Net Sales Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Regulatory Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Sales Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_ScheduleOfAssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_ScheduleOfAssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kron_A2020GileadNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kron_A2020GileadNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_PurchaseProvisionTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_PurchaseProvisionTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_AssetAcquisitionAxis=kron_GileadAssetPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_AssetAcquisitionAxis=kron_GileadAssetPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691910560600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Key Valuation Assumptions (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining term (years) | Fundraise scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">1.78<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining term (years) | IPO cash payout scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining term (years) | IPO conversion scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining term (years) | Liquidation cash payout scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">1.79<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining term (years) | Liquidation conversion scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">1.79<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Fundraise scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.242<span></span>
</td>
<td class="nump">0.242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | IPO cash payout scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.242<span></span>
</td>
<td class="nump">0.242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | IPO conversion scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.242<span></span>
</td>
<td class="nump">0.242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Liquidation cash payout scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.242<span></span>
</td>
<td class="nump">0.242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Liquidation conversion scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.242<span></span>
</td>
<td class="nump">0.242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember', window );">Weighting | Fundraise scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.015<span></span>
</td>
<td class="nump">0.186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember', window );">Weighting | IPO cash payout scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.950<span></span>
</td>
<td class="nump">0.129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember', window );">Weighting | IPO conversion scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember', window );">Weighting | Liquidation cash payout scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.020<span></span>
</td>
<td class="nump">0.500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember', window );">Weighting | Liquidation conversion scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.015<span></span>
</td>
<td class="nump">0.186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SettlementPlanAxis=kron_FundraiseScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SettlementPlanAxis=kron_FundraiseScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SettlementPlanAxis=kron_IPOCashPayoutScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SettlementPlanAxis=kron_IPOCashPayoutScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SettlementPlanAxis=kron_IPOConversionScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SettlementPlanAxis=kron_IPOConversionScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SettlementPlanAxis=kron_LiquidationCashPayoutScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SettlementPlanAxis=kron_LiquidationCashPayoutScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SettlementPlanAxis=kron_LiquidationConversionScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SettlementPlanAxis=kron_LiquidationConversionScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911149944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 01, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_RDEquipmentMember', window );">R&amp;D Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_A21ErieStreetCambridgeMassachusettsMember', window );">21 Erie Street, Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_A301BinneyStreetCambridgeMassachusettsMember', window );">301 Binney Street, Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_OperatingLeaseFacilitySize', window );">Facility size | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseMonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent', window );">Escalating rent payments, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseTenantImprovementAllowances', window );">Tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_SanMateoCaliforniaMember', window );">San Mateo, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_OperatingLeaseFacilitySize', window );">Facility size | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent', window );">Escalating rent payments, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseInitialAnnualBaseRent', window );">Initial annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_SanMateoCaliforniaAdjacentSpaceMember', window );">San Mateo, California, Adjacent Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_OperatingLeaseFacilitySize', window );">Facility size | ft&#178;</a></td>
<td class="nump">3,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent', window );">Escalating rent payments, percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseInitialAnnualBaseRent', window );">Initial annual base rent</a></td>
<td class="nump">$ 19,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Escalating Rent Payments, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_LesseeOperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_LesseeOperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_LesseeOperatingLeaseInitialAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Initial Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_LesseeOperatingLeaseInitialAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_LesseeOperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_LesseeOperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_LesseeOperatingLeaseTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Tenant Improvement Allowances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_LesseeOperatingLeaseTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_OperatingLeaseFacilitySize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Facility Size</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_OperatingLeaseFacilitySize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_RDEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kron_RDEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_A21ErieStreetCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_A21ErieStreetCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_A301BinneyStreetCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_A301BinneyStreetCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_SanMateoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_SanMateoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_SanMateoCaliforniaAdjacentSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=kron_SanMateoCaliforniaAdjacentSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911818904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease cost</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest income (expense), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">3,733<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=kron_ResearchAndDevelopmentMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=kron_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=kron_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691994056184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information - Finance Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_FinanceLeasesAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Property and equipment, net</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liability</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_FinanceLeasesAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Leases Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_FinanceLeasesAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911869224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information - Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_OperatingLeaseAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 29,355<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">29,484<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 30,784<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_OperatingLeaseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_OperatingLeaseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911436952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities on Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining three months of 2020</a></td>
<td class="nump">$ 1,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">5,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">4,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">4,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter', window );">2024 and thereafter</a></td>
<td class="nump">35,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">52,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(18,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Less: Tenant improvement allowance</a></td>
<td class="num">(3,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 30,784<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911100552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2020 Notes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,275<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Total debt issuance costs expensed and recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,889<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares)</a></td>
<td class="nump">22,687,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_SaleOfStockPurchasePriceOfCommonStockPercent', window );">Settlement price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_DebtConversionValuationOfCompany', window );">Valuation of company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares)</a></td>
<td class="nump">22,687,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=kron_A2020ConvertibleNotesMember', window );">2020 Convertible Notes | IPO | Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares)</a></td>
<td class="nump">9,610,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | Convertible Notes Payable (2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2020 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,200<span></span>
</td>
<td class="nump">$ 168,500<span></span>
</td>
<td class="nump">168,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_GainLossOnChangeInFairValueOfDebtInstrument', window );">Change in fair value of 2020 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Total debt issuance costs expensed and recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_PaymentsForLegalCosts', window );">Reimbursement for legal costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_DebtConversionValuationOfCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Valuation Of Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_DebtConversionValuationOfCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_GainLossOnChangeInFairValueOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Change In Fair Value Of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_GainLossOnChangeInFairValueOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_PaymentsForLegalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Legal Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_PaymentsForLegalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SaleOfStockPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Purchase Price Of Common Stock, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SaleOfStockPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kron_A2020ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kron_A2020ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kron_ConvertibleNotesPayable2020NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kron_ConvertibleNotesPayable2020NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911552280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>2020 Notes - Key Value Assumptions (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining term (years) | IPO Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining term (years) | Series B Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">1.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining term (years) | Financing Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">1.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | IPO Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Series B Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Financing Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember', window );">Weighting | IPO Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember', window );">Weighting | Series B Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember', window );">Weighting | Financing Scenario</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Key valuation assumptions</a></td>
<td class="nump">0.025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SettlementPlanAxis=kron_IPOScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SettlementPlanAxis=kron_IPOScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SettlementPlanAxis=kron_SeriesBScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SettlementPlanAxis=kron_SeriesBScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_SettlementPlanAxis=kron_FinancingScenarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_SettlementPlanAxis=kron_FinancingScenarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=kron_MeasurementInputWeightingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691911607640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures (Details) - Affiliated Entity - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty', window );">Reimbursable expenses to related parties</a></td>
<td class="nump">$ 15,000.0<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">$ 24,100<span></span>
</td>
<td class="nump">$ 44,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Payables to related parties</a></td>
<td class="nump">92,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Two River Consulting, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_ServicesAgreementTerm', window );">Services agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transaction with related party</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Bellco Capital, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transaction with related party</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Reimbursable Expenses To Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_ServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Services Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_ServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=kron_TwoRiverConsultingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=kron_TwoRiverConsultingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=kron_BellcoCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=kron_BellcoCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139691917585032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 18, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 14, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 08, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=kron_CambridgeMassachusettsMember', window );">Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kron_LesseeOperatingLeaseEarlyTerminationCost', window );">Cost for early lease termination | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2020 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on settlement of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2020 Gilead Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on settlement of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Forward stock split ratio</a></td>
<td class="nump">1.055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | The 2020 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares that may have been issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,938,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | The ESPP | Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares that may have been issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kron_LesseeOperatingLeaseEarlyTerminationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Early Termination Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kron_LesseeOperatingLeaseEarlyTerminationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kron_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=kron_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=kron_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kron_A2020ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kron_A2020ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kron_A2020GileadNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kron_A2020GileadNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kron_A2020StockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kron_A2020StockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kron_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kron_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M6IQHF>1[B4NIM8SSPPUG 5?F ;B_DE(?3LP/E-O1DW\!4$L#!!0    ( )M
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MQMJ;UN"#/;Z#2;]GQC<<Q#S@L;,^OA0:\_A<NOA[($C9KQ5_97'GI"\1B05
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M8UX"5/^&,7ELE%>%]LX]_0]02P,$%     @ FT!R40^GVK\Q!0  B!,  !@
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M7\O&)]%H6=7%;%U8:3#+YZO_TQ_KGMBF %H70$:!!#L*X'4!O&T!LBY MBU
MUP6H40!Q1P&V+L", H0Y"O!U 6[6X.HEL2X@VJ>[>ASMLWR?UNG9:5G<1V4C
MK>[6?&@'1%M:/<)\W@S>J[I4O^:J7'UV7LS':BAFX^BJ3NM,#<NZBHJ;2%V_
MR\HZOYYFT6<UG+*R;&6*T?<HG:\_38KI."NK?T3OLYM\E-?1BV_S=#G.ZVS\
M,AI$WZ[>1R]^>1G]$N7SZ.ND6%:J9'4ZK)7>3>W#T5K'\Y6.R*'CUZ).IT"Q
M"W^Q\V(V4[.CU10H_<%?^NU8M4/-KG0:?4[S\4 UX3Q=Y+ F'P/W&HV6L^54
M]>\X^G<]R4K5O3-E:R:-$;C+HD_S43'+HA?_+*KJ)7#[R^UOOWX2_9L,U:#8
MC RT&1FHO2MQCXS-"%AL1D#5].:OT75VF\_G^?Q6&8YI.A\IY54'59.TS*J7
M45HK/4:O(IS\&J$X$= C7U5.V\H;"WMWQD7,).>GPSM :[S1&A]3ZVTT757(
M.IHF7 H*ZTDV>I+]]<SF8T_7_IZ6&X4EI##9K6OI1F5Z-)6W49/NTJ]LHR0+
M*-E.^F,-TPMF]261C"'DZ$N^49-[U7RWUTCDEC(#CB3;J+)2F5O]2OL2'VP)
M0OHB'VV1N"]Q:4L,.":.QR<V_2+:8MC1+\H2*A>L4L])=4;[Z64#CSYM+OY:
MYO7/Z(\OQ70:*0_F/BW'?WHLGMQ4+KT/Y5-5+=MGH?@WZHRC:+E0'^^RJFX>
M6$._[$=6CO*JE2P6#2:J]OJ#C+JL1EA=YJ/Z88IT1QXTT*3U;)'D,8&[,XDU
MWN/G:Q.(\MAJ2&(,/Z](OYT=-R;QMK,=(8/&BQTW[52^?96VSG'VH_F<@:HF
MMA[,U-4KTU=6DS7QH_5?*BB9*M:#2ME@'. $F[,O*-973>,S"?&S:S\/ ]'%
MNJZ^]9148M?CUO1,_/@$[6>0..N;]FQ6$I-8&A84D#--:&)#EAGC_",@8SU&
M6Z31B#O,:*)9G1P Z\.]MW7M6_L8B>9W$@+XT1VX=8U;>AJ)9GCBA_@!/MQ5
MME ZQYZA:K,>)30F0F*'VAJQB3BF'Q=65=C=BY",74-!XSCQ\_C8OEQB,];K
MS"%-6>2G['[N'+(Y"/ES:S&?-0+N9'ET@(QIC4"%G#X=TG!&R=-[=:@3R(9Q
MNYRK>J?Y_]1(OTU5W2\:_KZ,FNS979I/4S49!C=%.:A2-2NJ;+0L5?2?@81&
M-GH=V$4:N\B/79]'@&R**D8PBAR5:HBB4 RZ/>M#5N "V22C1 C$'*Q'&F7(
MCS)P<@6M$K+#RT'"!4[,V67+6;/+AEUBP1X0LJ:7+:)4DM)E?C0ST5&9N6L^
M =E!L!?V2!,4'4!0$/9A9>VXU -[I*F)]HI,OV:S15&FY<_=[9?F(-H^+KW*
M2F66HK<JR/%TW5R9$R6</Q0<%55=!2+0<V3CD2<$J4GL2,EI/.+M@] #&@ F
MYP X$B8<!AEK9&%_/'F ;_?;<NXW31B(*8E4?\PQ2K%&'3X@:6O[=F%5D=6]
M'#&GGITL[2YAYL$FZ@+O&&EB#4G\&)$FAN,Z*]+$X4@3N)4%'T#&A(]#(U>D
MB36>,7UZYPYK]F$_^YXU:8=M,F+!$):.3M5@Q'XP/GG:#MOQ)K%&HE>FWU+-
M5>R/1O=)W*UOV0^.366],GUE-8FQG\0^-QW;^!Q@:L[XRZ!8?SE),Y;X&;N+
M,Q\R^Q?$#@0I%BCA#JX2S57BYRIH3H,86M^T[\QCT0F!UGK;<N8@)@!\.PF
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M0:5W73.E&N/TJ&NF855W6S.EFLSTT=9,83MF0Y4R%F.7#\$T6=F!:Z;@Y&/
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M40CUHASBR65'#RO E5LZ'93S?_W+^6AX]C=$B(W"-HC(YN@%0N:YIH=P4M0
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MJ!;::! !+PY$,YK5#(F")C)_UMZZ.G& F#",)XEHF^^>W7"V_]GDA73?54L
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M:&5E=#DN>&ULO5QK<]O&DOTK*&_VKE1%R1)E.W9>5;)LYRKEV%[+SMVJK?T
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M6='?^R0+8]"P%#OP719_HNK\$_HAN^B'_JO*UK(<!898XIZM2S*QB*% L)^
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MJ*@!5PBJO&#H711#Q*GV9L5#_P-Y8XIHW2(W(+(=.5-L*?US(FJJ1YQ<FD]
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M/+TPNX8#@R22'6'6(7X%0R1ZX@'H0C<+82^QJ,[.YWX,B(DH[[#NRX.R^,9
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M?;%Q(_2!Y+&N'KL81_M'\Z!I>@P)I^G "T.1EQ53$$?Y**.\QD:\SA>) %]
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M+W=O<FMS:&5E=',O<VAE970Q,"YX;6RU6%MOVS@6_BN$=[#8!51?9">V,TF
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M,J24$[+R:V.UEX1OP#PQ5>%UL1*K2J>R2%0D-FN=K(7,#4Z-7RLK_!H4+B(
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MY1K-4EDBP/.E0>S#A@2T7Z*N_P902P,$%     @ FT!R49TY^ZQ*!   _@H
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MMA ZM<8_I98U[6C/OB-7&'NC<>*-P]'K^LQ^2)S9CRN3]$>CX>#GA F&>V5
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MH63=9:5)9FPG:3-GFGCB-'TX<QX@$K+04(0"@G;47]]O%P ODNPD;<^+38+
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M-IC?G)\Y!F_P&4Y9F#*.$\2:Z3*UBKW4 PSAL!*+2WU3R"A-[9Q2M,(JLTK
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MF1K"M:?3?, X[S'8&Q@9?):-*35<-@46+_6GQ&<DQ;:DSME!P"6V$X@"'UC
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M#7PS0NOXQ*IRDOL9V]='5M0QJSSP_1_FOC=[9;=J7*6@IJ&37%KP!M@]K0+
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MBPA8I23H<RU+QOYX\:15RDKBUV[W@^!DZ0P[Z$&=",] SF[9L>96,?DYH7)
M'I1F*@O(F32M;8@)44Z/?ZMB)S;F>U8X_5+#D0QY'XG76T&+M80?Z>=:H<R&
MC-ZJ),_5(I(:()%SO)@H+7UD80>V8_!@58HF&0%W[2W("VF)A5?&YQH-A\I4
M>+^/BSF*$S8= D51D4R+(325"CYDT0@Z5#L9DO:,080>@,M>MW$"#(W2LP['
M2!OR5IR/ #'<!:;6)8>'H^Q6F=K!OTVAP=[^FFKR.P3Z""@*[<H\5EA;>D)1
M[53(HY6$ME X?.!6+I45M[*LJ?T&U)W*R$;<>G4I[R4W<0-;@8P K!;[;_6(
MJ\$@>Q(2"DB3"K7:%KI&AO:F,%:JVTVD+WYB*D,B$FH)[&$*-:V1WXR<6NJ
MY0U9A4^7.YQ'.5DFW(C-=AX?\D#(GB^PWCJ0H7EL%=J91P4T-;<),KBJRXC,
MP6(R&4TZUN5TQ@^[QIBYD:R\YL[)5%FSVZE<*2]+]27*R)C3JJ),(2QLW$(Y
MQN9ZVC>8/6"CAHB$S#+%RE&(0(*J5;"4D_2U;;:A_SG^>F5B,X0,6^*,<;L
M3E:4URPAZ!9[8>ZM[O*Z<\CQ@(;8^(A+4U-#,[/[3HH!<J_^0YVR<&0@QV7<
M^YP04Q0.*+/4Z@OK+JRIEY'^04@^)#" A^DVM@\3@E?EKMV&$Q[Q_V$[]BL2
MJ>D5 V)+>NV]??0.VT/;!2U(H4[5"CME%=!XI/ZY.KQ!)< (1IRN85+C8E@'
M\]%)5V3A%*4[S/&N&01ZT$C7';_MGI;D.!TA1XSF7MA8'^^S5/"L?DL"YRL2
M?K%52ZA[Z 3/\G9&QY*J$A!#1$>A4M%TX G.?8DAI6R" 1AUZ$D6Q*@13J<E
M"LSY!H)N[.@FDJ8N=PDXD65 *4S+(W'%"?P0$OB^5X_]M'TKS;$!,;8"F@2,
MV,ZN(MGH8?!B7LEQV^S3I<+*?<P6LU<\6!JN#<W6FUSB.##D5&UH[KM8;3,L
MR!P>;HKGZ14EMF8>AE>S9T,^P(-9*7(, "A*+H.4M 3)C,1?\'5#7SC0Z\@5
MT(L )&>RQ)7/O1 7^U#BP^.F4;AQOENYZJQV2^^(+YH!4H KGMZ3M)A'0:G'
M O/F2?S#(W]H'<NS[NP0O?9DY^=CN*ZQHI,%^!CKHT7W]_T/M??.0&TVA!%J
M]V#Z_!C:V\_[2@=UV; ?2(NB* (FT22-^*[UB-PVJ?8:_& ZWPSB/Z.UV?5P
MO,3I;YMZ'QXTCUVUQKT+:T5V&:[E?+@@:?'NVJUV-_^+>.'=;(__-G@C[1)D
M ,[((3H9'2T&PL:K>'SQ9A6NOXGQN$R'QX(D!B+>@.^Y@9O-"QOH_A]R_C]0
M2P,$%     @ FT!R46[*5(_N!   [@P  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&ULS5=9;^,V$/XK W=1M( KG[FV20#'3K!I$\2(T^Y#T0=:&EE$
M*%)+4G;<7]\9RI85Y^AN7]J'Q+SFFV].4J<K8Q]=ANCA*5?:G;4R[XN/G8Z+
M,\R%BTR!FG928W/A:6H7'5=8%$D0RE6GW^T>=G(A=>O\-*Q-[?FI*;V2&J<6
M7)GGPJXO4)G56:O7VB[<RT7F>:%S?EJ(!<[0_U9,+<TZ-4HB<]1.&@T6T[/6
MJ/?Q8LCGPX'?):Y<8PQLR=R81YY<)V>M+A-"A;%G!$$_2QRC4@Q$-+YL,%NU
M2A9LCK?H5\%VLF4N'(Z-^BP3GYVUCEN08"I*Y>_-ZA-N[#E@O-@H%_[#JCH[
MH,-QZ;S)-\+$()>Z^A5/&S\T!(Z[;PCT-P+]P+M2%%A.A!?GI]:LP/)I0N-!
M,#5($SFI.2@S;VE7DIP_OT<E/"8P%=9+=*<=3Z"\U8DW !<50/\-@!.X-=IG
M#BYU@LES^0Z1J1GUMXPN^N\"SK"(8-!M0[_;[[Z#-Z@M' 2\P5=8N(8'*[03
M(2,<_#&:.V]I]N<[>H:UGF'0,_SWGOP'@,N;T</E!*:C^X?KRQG<:9A@C/D<
M+?38';VC-O@,86SR0N@UH/9H2:/4WH"@+8OXTQH%U1S:I8S1@5C0&M60I[3R
M&3RL#-Q3%5C"T(X25^I%&VYNQO!#O?4C$%IAS5(F"$MAI2D=Q$16QD)1PB^I
MD N&; .U!BO8E4*U*2DU5;&5/!9Q;$K-Z"!T JG40L?5#DU%0HDLV?-<D3NR
MI+=A7@0C*Q&H;Z@$%[;4;;B-)E$;KD;CV<81F9!4F1I,&N871MB$)Q-IJ>J-
M=6V0[L71VM0(;NGO%^.R4L"OXB^1!WZ\.!%D/SP(C:0719R1@Y,-ZE;=AB@9
M9;$Z4U#L-5KWBI8 1:8GLG*86@?#.49TO.2(V,*02Q!F&%OTU"(KR7%FR5FF
MR"ALGR4U8HZ9@. _7,B80)?2$:WG_@NFD\%W59 H%-.*W3-RM<$SI+,CM4#3
MKB+"L7--P.^_.^[WCGYV5$,H7&G1-KPK,86K;9CA+DTIHG;/#9/2,BH+A%R%
MO.H<R)V#"!2^2O9M\0=NE/8G8<!BFDKFJZ6>%XO4<6FY6O")+C2'S.U#-QI0
M4U6*(M+F6?_9['@["Y"T<%@O6'0%A@M%D:-3=GZ&;I?+Y$^3XUZBU [<4' A
M<2@\TB1<7)02A:"LFZ^;7GMH&&%1YO/2LN@N@COM.USBJPTW!FH0SG.8XDS8
M!9E/Y)D2W<_.TS$.R%PHBAL&582R52+FJ@'IC1>*Y#_T#J(N05!7"+7,GCF*
MAKN5BLZWA+>]Y\Z V1]&O3TUPV%TLJ_GFW.BJ8I:3"C5-P3J[CNHVN]>1F4B
MH7BMV4VA=^TBPJEUTH\.]MW4]-P+)DIM T&<5F0&5=\+!K!"3AG.$JDA+4DH
MV555*BT%^TM)=5ZQ8%,BN-:OL-^[/.+Z/MB_,[@!QP;&HI">.WBX+:K%5Z\*
M?,*X_&\:>\4J@GN<8_PH7E'Q3A/?X$TI+&0.6<\QJQK;96U2H[%ME?W_NMHA
M=;5=FNU/>\?-*@J)^6QIOQI?:6ZOO98ZC3=HCM1J^*5-;8?? =5SM%ZM'_.C
MZ@V[.UY]"=Q2IY+T/%.8DF@W.CIH@:U>U]6$+L/PHIT;3^_C,,SH@P0M'Z#]
MU!B_G;""^A/G_&]02P,$%     @ FT!R47U5<I>D!@  -A$  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&ULO5CO;]LV$/U7#EXQM( K6T[2)ET2H,FR
MK</:>G7;?1CV@99HBZLDJB05U_OK]^XH*\K/%ABP#W$LD7SW[O'N>/3QQKI/
MOM ZT)>JK/W)J BA>3&9^*S0E?*);72-D95UE0IX=.N);YQ6N2RJRLEL.GTV
MJ92I1Z?'\F[N3H]M&TI3Z[DCWU:5<MLS7=K-R2@=[5Z\,^LB\(O)Z7&CUGJA
MPX=F[O TZ5%R4^G:&UN3TZN3T<OTQ=D^SY<)'XW>^,%W8D^6UG[BAU?YR6C*
MA'2IL\ ("O\N];DN2P8"C<\=YJ@WR0N'WW?H/XGO\&6IO#ZWY1\F#\7)Z'!$
MN5ZIM@SO[.87W?ESP'B9+;U\TB;.G1V-*&M]L%6W& PJ4\?_ZDNGPV#!X?2>
M!;-NP4QX1T/"\D<5U.FQLQMR/!MH_$5<E=4@9VK>E$5P&#58%TX7[=+KSZVN
M UU<XM,?3P)@>7"2=1!G$6)V#\01O;9U*#Q=U+G.KZ^?@$[/:;;C=#9[$'"A
MFX3VIF.:36?3!_#V>A_W!&_O6WVD/U\N?7"(B+\>@-_OX?<%?O^_2/@5B ]G
MBXO?/UR\>4\7'_&YH%<U(<D:Y4R]IE!H,G70SE2T,K6J,Z-*\D$%78D_RI-=
M$73#BZ5VO7B$K)75H7!:DZISJF&:JKAA#1!M[GE&39IW;RRSSVW5J'I+^E*5
M+8SDR-G>1QTE9&2G,[NN34PO8%=:^=8))VI:UUBO?4+O!XB9K;.RA2'848%J
MNX-CGD[57DFR>BK4I2:;9:USN\D.!(S3E!N?E98-013AJ[(LXK-8=PDT)HMY
M+(6**U:V1#G"](140B_;4%AG_E'B"92<HS1HL;P(-OM$;VMZFP7+TJ;[4=KK
M2JE*Y!,5G!;#.1GXE6D7S,ID>,' ILXL='%B"8:Q$>N>&^CX"'LGW!54Q_(:
M&*G.">TIG8ZG4_DC7R@ \.P6B-ZL:\%J>@>].+@QH2!%B#?B/1>NCZ;)=)HF
MM$P0C1DJOA?!;XD%#>#&;:5F#PGU-6THV#$FWY;'[*@P:MU*N&-Q[WT^<#F+
MS**+*V<KVK]2)EC0ZQ\3RG@[0"YF%$;/;7W)#)>E?C @AFYV,9I38<M<.V$Q
M</_[[PYGZ?,?_$/8NY4#CR0D6AP%D";C',):WZFORG+@<;1U/^\N85[-WR:4
M)X2#;:/<;G#1E"9\=0?U:H43E8.3TF1Z</ 4E>!IRO5 H*+87J!X4Z&E\;[M
M@AEM :*YSCE1[]DGGH9(=!:AP)& 1%;YWS@)I:Q@7YB,_F)\8!")EEB-M,H*
M\BAI^E[9;\C!@0WP7"K8^$9$=?10^?Z&OVPX&A"2MHG1/W!G@R(\9%UN^UC-
M:;GMRLYMD<2#L;@=/=,N,XCOQIE,<XF.3.["S_6WXB.V42,=$RVWXZN@$;-7
M-I!P[:ZX\YS= 8%RX:$^Y^TW5MQXUMB@Y71Q&O))25]J77?[J;FV!6=]HZ4U
M8V(;GDNJ ?-,(8#'K#LVK90M*(R_TT4)F:L8Z3;_9HT;Y$V,FH1T$H_)"V1M
MV'*9PWI0H7F)@^+5(!-NID$?4DO+;& R1]YCMHNN^VNIW&#C+KM$O@GP (''
M/%_&^?$)RV,0@DN=H8QVB<B3[171PYBR\=3MEW+@7!K4_[XAX)S$IDGA;1M6
M.4W'1WN'X_1@UD?_TZ4$EV+!H=8JH8NJ*>T6K42L&//69047X_]=KX=XB&P7
MB_G\292!O]X6[4[%9.HWB/7L\% .D7N40EMQ?JU*9X.:'+/BEEAM8V-N<7/#
M:773<13M**DH\$90^E-!ZD%G1=(4)(_&S] )/$_W[BNUCQ=0D($H/8!6'VXR
MZ!*I-_RS*7'OBRNX'*G2VYM&4RAS\.SYO=7==^>DQ[6)1R-F[V1_71MPVWMR
MO8G<&)0F[CT=GQ3@*F8>I?M)BBM26>[:445KW$KC6'+4#YE="]@Z-#V?6P7R
M4O%7:"Q1Q$3>?C>\#J'4P[HRE!]6!J*,V:^^FB54)/1;[%6TP]TM-C;8^#<(
M[NK.-"&NLFZG)9R[M5RMT<D+'8Y./EY+M40=5)ET9^>J6CJ3K\'EM?)HIXN6
M/>C:\ @G^NTP=7=Y^%754&)+>[&?2;E&]BTS]ABG;2OW"-NN"V!O95:$S:P/
MW1'L$(9#NJC8W%9N=P*BJ>PW*;GK\C49W&4K[=9R8T>OR =3O-;V;_L?!5[&
MN_#5]/B+PFOEU@9WB5*OL'2:/#\8D8NW]/@0;",WXZ4-2"/Y6F OM>,)&%]9
M;&KWP ;ZGTI._P502P,$%     @ FT!R4?+H<RXQ'   @5H  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&ULM5QID]M&DOTK".WL;'<$N]5DZY;MB%;+
MFI%#MK1J:V8C-O9#$2B298$H&$>WZ%^_^3+K @A2AV<^V&J2J*JLK#Q>'H7O
M[FSSL=UHW66?MF75?G]OTW7UL_OWVWRCMZH]M[6NZ)>5;;:JHX_-^GY;-UH5
M/&A;WE]<7#RZOU6FNO?#=_S=N^:'[VS?E:;2[YJL[;=;U>Q>Z-+>?7]O?L]_
M\=ZL-QV^N/_#=[5:ZQO=?:C?-?3I?IBE,%M=M<966:-7W]^[FC][,7^* ?S$
M/XR^:Y._,VQE:>U'?'A=?'_O A3I4N<=IE#TSZV^UF6)F8B.W]VD]\*:&)C^
M[6=_Q9NGS2Q5JZ]M^4]3=)OO[SVYEQ5ZI?JR>V_O_J[=AAYBOMR6+?\_NY-G
M']'#>=]V=NL&$P5;4\F_ZI-C1#+@R<6! 0LW8,%TRT),Y4O5J1^^:^Q=UN!I
MF@U_\%9Y-!%G*IS*3=?0KX;&=3_<F'5E5B9759==Y;GMJ\Y4Z^R=+4UN=#O+
M?FP[0YO7;::J(ONI+]9T)EV;G?A'3K^[WQ$AF.Y^[A9](8LN#BSZ-/O95MVF
MS7ZL"ET,Q]^G#81=+/PN7BR.3GBCZ_/L\F*6+2X6%T?FNPQ<N>3Y+@_,-\&)
M['^OEFW7D!3]WY$%'H0%'O "#PXL\$*UILWL*GO7Z);XJ2"B4XS\AFFR7S>:
MI#VWVUI5.^RAKU1?F$X766Z)XU5+?ZU,I:K<J#)K:9B60]VH6YTMM:XR4O%:
M-?2<J7BNIJ"G-0EGM^'/CCMU8VB2NB3^K'6E&U66._RNZT[&=D3+AXK7ONE8
MC(C:JZUN2.2RD[]=7;T[S<BVT*,=?;=-R#*5V!S671*]NF_:'F+:V0P*F<TO
MSOZ;?[EJ.I.7FK[ Y._UNB]EV,W9_^ ;T'"C\[XQG7%R_..G?*.JM<ZN[79K
M6K8Q)S<_7I^>LQ8T!6VNW,TP=)<5-JML1P3E95\0:\O2SSJF<65M1X_2(HW^
MO3?@WW*789>\21Q)J3L]R?QSXI,_IM>.&Z_"<Z^3E?;.=ZE*/AVQXXIY?(,C
MV"YU$_2"=Y.>-CU%UKWA284MF+/1&QA=$H32MBW3C7'=IM&:'ZI("+.M*+"&
M D^LQ0\N+N9/IQ8E(;S5=&9+.C-:;J4;,(I,7?Z1Q_%?&UL6NFG_^A]/%O/'
MSV%H20T/;^[X@JK=9"MR0'$[7[D)_(5A\> *LK;\M:7OF\,_I")2F#8GIM)B
M),-..41<Z#,^?$8]22&C+I^S'$35WM>@XXH-D85#(P-"R](_'3TI"@Y2KD6\
M'/]I;;>,JJJ>YIZFKRIF?E^V-A7V3.S?JHH</!Z9P9'#(;,2J>(W<G \=.9I
M@#BWMM1D1FAD!=:5-(B4M\%/@R&5SG7;$I8(I[I2IL$.HRUTBCK>322_MJT1
M_3TF69B#IB57ST\9_!-5YT_HAYRBG_I;E:UA.0H,,<0]4Q5D8@%Y0+!?@.1L
MJ3/]J:8S@)2Y]79:-9@>+'Y)D\CT<V\WB'-!FD7(:._&%G0&- %^7?5=W[AY
MZ"OYF??63EL[LE6V+PM0 S )J2$)^*VO!*R-Q?"_H@!.SN9L<W Y=6-;[+%O
MH8_T_=N\L]C4$\>R;J,Z;']+$V>D$-U(4FA!<B0&'E]<26)0*O$_-V?S[.25
M(2/VBR7T<7EYMGCPY.GBX>D,LK2B'XJX#_(M P_VOJ=Q#Q8/0.FV+]=,9$\'
MW(S=U57.M,V?7E[RQ&K+<C #'7Y73V57YT>0R<. 3!X>A10?6A:8 /NF0,G1
M&1!'/&MKE>OO[[$J-K?ZWMZT+/9BBX*B'CA9" 9.RG0[X2?[4^=@V\2Z@*];
M]9'D>X!954LA1^TUE8Y=K58P0:+3M6W8K&T!:5BYZ7DMQBPKC5J:DL]!_(JS
MX)#U@T]F2N:&X'FI.F0N#Q(!%25'0.+;L^&+SS'L$O4[SXX<^*-PX(^.'OA[
M.B+5Y!LFYZ6^I4"M9F[^Z$B8DH _.64V>*)(GCAY_U>UK9^_/(T<<)X!6',K
MMHWX0QQH;57IDGYNX0S$ K#[(#34\(DM"9*NC.,THXHS1'""<VAREKP9'ZHE
M1+*#F12R:'J(G. W(H"!?_R9HF!5F3^<^3^Y?O^V):V'R#5TQFZ]OJY+)H,"
M"-D)0T3M_L"*&Y@^<H4V=U,E7I V>4O[L&3",!6=O(Q7.>1L=];H4@FD;P$>
M?XVV*[+.,5.>@?%@;$0:210)G(@;=:Y@;4FP^"?RNIK<!YGQ@Z<5%OI&QQ7,
M]E\>G3^B\+8L)=B7G9$ZJ]S!:'(\A-<9,GJM:^-YC.F2_:;V%L1=86#VKJ<1
M) 79U9IHW0;0\S<RV'0:)S<:!IU4=WYY2HO,O#J321&E!TD.,SCM9HK$0'0Z
MWU2VM&NR542A6/2$M.?\-9RUJLGTWXJ$<91T?G-.CL46HC5-O\ZN"HKXHP\B
M'HL7;B3$L22Q9/HJ#D]Q J0>'S6$YSD!OH)7(>>:;\!+T$6 @)";)LS'MFKW
M/$QY9X@A,@8S$5^U8EZ7)-*5P CGX_M6L[31GW>:@<>Q4W(24GR3A  >D6YY
M\:7%5-8F"0NHL:UP@HC[G*Q[F1RJ!*UCB&%M5N(L6F="&)HC<I)S J]&"SC-
M)ZIMO]Y@Q6U?&:^N+#@P,+  PP4I0&MZMEZM W:?,S.8@ZU"JJ7>U&> ,T16
MA#B>-N?D&!C3^+Z)[H^LXBI$HK-,;%]/+!, 6ZTM#$VC;Y$]<[+,_&$/M%IY
MF^/X3W"*XWO2VKYIHN3*YJ]B6#Q&V]XPNL,,=#?0%W+L%<N:G\TQD.F\(Q!$
M<0E$&<P ,10$FC3;8"OZ']PO30$V"YG1ROF@.R57=D4QJ#*8NSK+(05ER9,$
MHQ;V"<Q %-7$+L&)0C1DX!CD>AP\\..C[O(:X2DHXC]^I..Z565 "&1\N\8P
M7,?O4][X6Z=/Y94]#R)N#LTV9KUAMM+3D+A;[:(NEP&",3)KXD&)PP54W<GA
M0[F=3M-9E!H9!$*X T!4>PLLT0A'YSJ2=7Y\RP,6/PDL?G*<!Y;.M^HBUKRF
M<R5)>F]:R3F\9<.*C\+U#Y43#R"Z*9[_.]=+\CZF(E;T+N"]VQ@8#8M(W;#P
MM_WR-X]E_4D25T<V+)(BZ1"AI:'%9]/H*O<B,SX;T< H#N<.QV,LC61BR%=$
M0# V!7%L!DBSLN3QQ1!(/ "U#4S+56TZ8H('RJ@RT-[98M//(ITD>D/+6U@M
M'E8C6(5/LJR^R=+$#4)_$FHRI8UBZ$A_PLYR_I \'@EJ;<>N9'HKA/&@+EO3
MM0-UH;6]G>EVM:0_DS.E P1\:?DA/C&7(BTT)R9F4":]<YY]* UV69JU.U5#
M,<X(2JSA2BHFCP5L_)T'#K3XG48V!J:2]MM 2PN][,B$^B!4$F!UJ7).;8IV
MBCA5W@#XU.I WI@BVK?(#8AL1GX91TK_M2)J+I/)89_^A&P&0RX7%]%C?>)W
M7KU\?3U:TH7<2%K+:= 75<^08A!@@I&FZWD/YR&AVOLDFT,+LE028&*QY.-2
M$\"'M'-8.8SSTA5XSO 3U):6*F:2+U-IOAEX#QFO1$6)#Z;UAI=X7[.^,Z)M
M#RU(WOA8-FN4XO%)4W\F&X=0X0@ID"+>%JQ CBBDA>6$1'@]XSB+/[(,?DK3
M1E-%VIB<2<,F$+C*Z>+2V'JC")?EFC8#Q"J9;A;#$.41FND[IM(?<V=GT!H@
MR2H'+!"41):9)W'I[:UN) SO<R]=4%F"XD5/Q)'%+$PAV$D">K:G=LD:G.)N
M1N^J/#8!IW>UP[ZT?0K]V6X36"LX?HAY5$3XP-$;R!-/N+842,X(F'J_P(9Y
MV5A$C(6MO8WD\-:'$HX* 7[$]QGDM][L6D.;=CG^FA13#,@82E/H( $Q'J,C
MI:/4+._]"J"*\Q!DDD.BXQCV>1H<\].CCO)UE)@I+_O%@[/T;XX4;I5A/'=&
MW#]K52DV"#_EJFF,P#H/E0M)'=.!]GK:VN.GZ$(G9F^3"A,M$@$J@2J$T8*#
M3.5EE%TNGWR J@E _[VW'1^H<=90RM?.$8A_;4GR2]4,[#1;"3=*8@(G?SNC
M2PDMH^X5:M=*TDP@'*=SA0C$"%5!PQO$3@5"IKX%L5S>,%7=LP0Y[\5I8>)E
MUH2LFZ.!+2-)&(!>06%(W@%A+#DKR#D',GZ-75JQW7O[/,]^CN:VT *\M>0Q
M6.II&?BKO*1X4_QGHA>I(Z:I1TYM'-A[6'H^D"5FZ!CL8O12[RSCD@3RCC)_
M >B"(0+>> +ZHIL%?$PLJK+YPL\!,1';,2SK\:0LOFZOD&#.HS?=&1@SM+X?
M*@K]2_,'/;5F_\I92C'=F(6\JZ1>6"PI'*5P?-T&'8DYR3:&V:YZ-ZX1#DV]
M!*RPN7326M2&UKS;:(:\A89)%IF..A<,\7'%6J*+!+RA<>CTD,%,,*<QSL!+
M8L86,*9A7$B>1P?=]6B7EVO)U)*&DJH1GSI!?-C^[\@9^2]@^9 V(-.OV$N[
MX)R&PC=PXJEO!K6F/G*>*Z@)P)HLK#DW(\BZ<WELE#]%R@\R9 <;;6A>SM@0
M?,)QT1^28[ Y/00@$'R-JV?'# 5DH4V.AGP[7#_!O(K-0@NJ9;MN0=NX\'M+
M*Y+G_8@Z'<LO/#'KND$ZC<9Q8<>EA?Q<O.IG#AA[27;AI&*+Q/<?+MLI54N$
MB0<%G/.!4X*6_=87:R%IZ81&-A"$)OI.% 4_:^?3RE,P@_2E):-RXE()IZA5
M=J(FO $. J*-:7'8IHVFEYDN"9_\S,!91-NVI<-";>WU:#&VV(F]:[^"-+_F
M6#:_LEG@&""87\2.I(NC7OT5#NL??%@_:P7$#PHFNXR^92)) ^]7;2!S32&P
M()$7+I/' K04S%T*;F"@6X<M.KTF=P&Q3-SY(+/VFVNB@@;:W(2HQ;64P+4B
MR\I"NA7"G<U+#.9Y]BH2222A0:(2>XUIM&]P83\LJGD7*ZZ2V9=\626Y6BGE
M(MKH)@?5RC!%'#NO2&U48-\NEEVY'0BPN"$;0>*FBENRIN3!4<=P4:S/#81E
M!_-P;HDP$RQ+$J8O=7>'_@4W!TJV!DNYBBRG!Y)#AK<\Y\,7K9'\]^_P-&/6
M)H>])<"#[CH"5G](2J*7NJ4@%DX/N@/B4!#1VNC)OMI[U@68/>EMX_W*NC?2
M464'UBG90@MP2K,8DBX4J1EHG)&HIF*04<#0()6\"RGF6)X\-"^JT[9$.\RS
M[ T+Y9PU?O'\[=XV/<+K*X\F9U^$3<5H<> EZI8<<X*]]H],"%HX@EX+%2>)
MH1ZO'FV<V\NIX!LC<"-@SH9;(@8(-.2,IZ71]R_XQJ_ARBD"G][C/F<$7HQG
MB;SZDBG]7%+*=IT?LH[GWJ7C'H' ?<$-XUQ549(<-']'S]!RE?4ZQI-Z:!*'
M)5&C*ZREYC*IB(VI%SU('D[J]$BZ*#37T2(LQ@WZY"3C#N,"C![<8Z/)EF+]
MD!8;MN$-/B]M/Y6;<6FT@1D=TA.6^RTTO484Z(IAH9.&D5Y,F,PR+AV@1$J0
MTVY-SKU=C,0H;N*\#AEHU$%H!"V;MVG!=Y+46=IN)K#42^B0<)=I@>"AO.$B
M#DG<VO)6)TD%G[2CP1UR_X#%R?E&3X5,%59F?#9#1 >Q0U#G@[+"QYX$6]!/
M>9Y=LP<2/4AZ,'+V*,DR:!F-+1EA+X>36$,<&QSWDGB3L"[ISHA?#CT^\"F?
MYJ2E=/(ZGM";@R_+C4\O[;/N3EV&'9$6':E(,J$W,#MQA6G4I$]C,<5]>["F
M/:ICNPSZD87(RG*"$&/:4X=)J^RJ7\,I\D_)G ]/_?%\)ID83F?,Q[1E8\S*
MV9B7LR\[K*0F/<UW-4VRLP*"%=]*;NT#EX0Y;8Z&H_T4*:,U4O);F[-]=3DY
MLHD2/ L ^@IYW >>5:+_L-+I)P!1E^_)HZ(E$X00WH&S0V!>Y-11C^X$OC*1
MENPIGI4ZQX'Z[C'Q_6*!Y6J-]!!P<^Q//=F%L=C]>T09/S+F9%B( %0A>B9V
ME;O0L<JVR1OS@;/C)8_&/LEMC/G1D.5=@W-Q+A>EVEK:9G_1TP'0-\^6#7[3
M_C=.U'<<D2AIHY$<%?BQ[:4MI]!LXZ.[==&YU,-)N8[\[!N++!E_A$B24Q3I
M;!1NT)R5W!;"06[LAHAY6H+9JQYZ<RM)(]>96SN'YY0,2(C$B[,H9LO9\20U
M'+()87YL4G*B$F@-5VG<*BA6@=[2K,+AEYI3AO^D.#AH..^QX]3'H,&&<$W-
M[=]V-7,RW$I1R;<\?3&?W2);&S++^QG#8>,R"$>BA$$9T(IIO6R+C4C">Q_.
M<2HO"^DLI%PH#&P\9HC5V-BA$QI^5&R@. ]]GZ/SHW70,CS.F*<!RDM-6-"(
M<8JS?)!9WN @WJAE(L"7T.'';MH#0G"#G*D<=R!GI24ARWT)A&B.J?,BJO/B
MJ *^])<;WA*^8>=U#49-JO(WS10^[75!E@15RUER5V?F/$_)/E0S_@E]=CCM
MU^_>SL1]%GXQSEMKCB97,-N*,VUB"ZU?FAB;:UVT,=/A6FZ2G"C-?=1 QHM9
M\\NC?. 3G6;@T8'37<DRV[![(!89. ](HMG NWKKJ)R,*$ZEZ5J,WEO1'>:[
M:B=2@W;X $4 L'5V=8:TP<G[MQ]. RSRD0,W^PH+QZ,'?<E<T[&5'W;DV4-I
MOH'9.'?=)_K05NI)SS%--P<K>]3*UPG-$S2.:#HF//'2W?SX=;G76U@OCV3>
MV&I]]H;S8)(2G)2J/S6C?%/R-_NH]Q CQ;2C*<^!,!-7N2,_@^(#1X#LFG+3
MD,] ;1GY!)?VX'1O)?UQ#=GD\&FKT#2T7NNVBUT+*(CR1;( :P9)0?YCW=B^
MYN$N\',Y>D#?<UC47@H6")RU(-<B+<>%+0R!-(K,D@4)\TDFD/NNZ9G0_9Y
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M']Z3#@;_H;,UOV-X:;O.;OE/O-M*-WB ?L>+4?T'+!#>.OW#_P-02P,$%
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M&N&3ER,51L99>Q&2)JLH'_S?=N-B-AU=PL5P.+X\ZZ7-Q =(XG 0)S[*29K
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M&#AH8=I!W$B\J25&)R0NQ ==N-2*WXJ$DD/^ :QK38QV)MY$SPJ\H[(O1L-
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M \BQ8(VP=VK_!W;YC!Q?IH3Q_[!O?8=I %ECK*HZ,"FHN&R?[+FKPQ%@&G\
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M66YY@7#+MH!]"@.P"B8=[2W2]2B5R(%7M59/Z%P,W)=*6]2@BE<Y1*0T" <
M>E?!3R7J^4.0-)<R13/ ."%$84OLY'*Y<]K)1D?#8K6E&(?SX6FN,>NLB;,F
ML_E[GK]XP1D5RI:J,41BSC^0-G]3B4\P"M/1F)Z#<#:9PF<NF<RPRY'*>?<;
MJ^K?KX\@R6#F?U>4G]5-.Z8H-M5N1[TTQ#B=)3"*X4%9)IS]'2&0)&$Z'<,P
M3,83ZH&A-EYF65,UPC<O1SH8&6?M$"0DJZ@?_)_6<#:;CL[A;#@<GY^,TG;B
M$R1Q.(@3G^4D3>"]RQ$=3:,*]<[/7$-=;*1M!U-O[<?Z93O-7MW;;\(7IG=<
M&BIB0=#X8C(*0+=SMMU85?O9ME66)J5?EO1I0NT<Z'VAE#UL7(#^8[?Z%U!+
M P04    " ";0')1HK;+."T#  #R!P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6S%55MOTS 4_BM'84(@3<NMW;+15NH&""00U<;E ?'@)B>-A6,'
MVUFW?\^Q<Z% 6QYYB>/C<[[SG9L]VRK]W52(%AYJ(<T\J*QMKL+0Y!76S)RI
M!B6=E$K7S-)6;T+3:&2%-ZI%F$31>5@S+H/%S,M6>C%3K15<XDJ#:>N:Z<=K
M%&H[#^)@$-SR366=(%S,&K;!.[2?FI6F73BB%+Q&:;B2H+&<!\OXZGKJ]+W"
M9XY;L_,/+I*U4M_=YFTQ#R)'" 7FUB$P6N[Q!H5P0$3C1X\9C"Z=X>[_@/[:
MQTZQK)G!&R6^\,)6\R +H,"2M<+>JNT;[./Q!',EC/_"MM,]OP@@;XU5=6],
M#&HNNY4]]'G8,<BB P9);Y!XWITCS_(ELVPQTVH+VFD3FOOQH7IK(L>E*\J=
MU73*R<XNEGFN6RS@U0.5V:"!I2S@IM4:I865TCYU'TKX8"O4\(ZS-1?<<E)\
M]I&M!9KGL] 2#X<6YKW/Z\YG<L#G);Q7TE8&7LD"B]_M0^(_!I$,05PG1P'O
ML#F#-#J%)$JB(WCIF)34XZ4'\%;LT<<&C)+A,\2$@:_+M;&:VNC;$1>3T<7$
MNY@<HDS35;0"094PU& GN_N2>A30#>^5:5B.\X"FTZ"^QV"L+@[5S16-D[$D
M(K]44BB5H+GD<@/,.!FETF*]IEH/^?1)>(EY+XV=-+Z\VJ?YEQ8\XY+<J-80
MB'D^1IJKVA%BOKM.(#Z-HPM:ITDVJI2:R;SB!L&R!T@SF*34I!:U9 )<@$SG
ME>=6X#W=+4WM.G9R?@G))!Y15%FB=M'ERE@#60I/GV1)G+SH&YK]F2#2.(>/
MRI*3O\X<T8LLHC6+,SC2!-.Q":9'FZ#C,$S;/\I_%&I_^0?DII]CJJ_R+L7.
M'/<M\7\:8@_#DDNJ/() NFQ'IH\N^Q/ZI,D^HU;>HV]K:@OQ2"5#G5/O%& J
MIG=1DM,X26$ZU#@_E*'A8#=3)\XZ=8V:[2]_N',/UZ@W_K5Q&6ZE[:[D43H^
M:,ON'O^EWKV&[YG><&DH"R691F<75'[=O3#=QJK&W^IK9>F-\+\5/<JHG0*=
METK98>,<C,_\XB=02P,$%     @ FT!R423<;MWM @  : <  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL[57=;YLP$/]7++2'5;**,21 E41*VTV;
MM$I5VVT/TQX<N 2K@*EMFG9__<XF8=GZH6G/>\'G\_U^]V'N/-LJ?6LJ $L>
MFKHU\Z"RMCL)0U-4T ASK#IH\62M=",L;O4F-)T&47I04X><L6G8"-D&BYG7
M7>K%3/6VEBU<:F+ZIA'Z\11JM9T'4;!77,E-99TB7,PZL8%KL)^[2XV[<&0I
M90.MD:HE&M;S8!F=G";.WAM\D; U!S)QF:R4NG6;C^4\8"X@J*&PCD'@<@]G
M4->.",.XVW$&HTL'/)3W[.]][IC+2A@X4_576=IJ'F0!*6$M^MI>J>T'V.4S
M<7R%JHW_DNU@&^<!*7IC5;,#8P2-;(=5/.SJ< #(V L O@-P'_?@R$=Y+JQ8
MS+3:$NVLD<T)/E6/QN!DZR[EVFH\E8BSBTLL F@-);FVJK@E;V_$J@9S- LM
MLCN;L-@QG0Y,_ 6FG%RHUE:&O&M+*'_'AQC5&!K?AW;*7R6\ANZ8Q(P2SCA[
MA2\>4XT]7_P"WPTTG=+XYY%W=[VTC^1<FJ)6IM= OBU7QFK\1;Z_XB@9'27>
M4?)W-7VNE*\2N$8\,9TH8!Y@IQG0]Q L;BH@3VY+&/<+(KPD*]=@1Z10V##&
MHD*MB47,6M5X(-L-06/485DM-"O08VV):$MR#L5.&SEME)\\9_EG ,O>5DK+
M'ZCX=70FM'YT#C])+'0I?/N=J:;!Y:UL,2K5&_1I*(&' IT04PF\!-&HOK7F
M"!UK"0:7WV@'CRG-V)3F:7H@O2%12O-LXH2,LFA*,LKC*8V3=,^U?$(4Q31E
MC#+&G#C-D0&!$4MHSCFND^$HH<DDHCS-R(VRHB8\HI.=6R\F-,MCYYASFC,?
M"X]]#*B89BF=\LG3XOXOY+\5\KGN# ^F7P-ZXV>\P4; &@R#<-2.S\ARF)Z_
MS(<WZ$+HC6P-J6&-4':<3@*BA[D^;*SJ_"Q=*8N3V8L5/H6@G0&>KY6R^XUS
M,#ZNBY]02P,$%     @ FT!R43/!8?L3!0  2 P  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&ULM5=9;]M&$/XK [4N8H"F>(BDY-@&)#=)\Y#4L)WD
MH>C#BAR)"Y-<=7<EV?WUG5G2E-Q:2H&B+^)><W]SZ&*K](,I$2T\UE5C+@>E
MM:OSX=#D)=;"^&J%#=TLE*Z%I:U>#LU*HR@<45T-HR!(A[60S>#JPIW=Z*L+
MM;:5;/!&@UG7M=!/,ZS4]G(0#IX/;N6RM'PPO+I8B27>H?VRNM&T&_9<"EEC
M8Z1J0./B<C -SV<IOW</ODK<FKTUL"5SI1YX\[&X' 2L$%:86^8@Z+/!:ZPJ
M9D1J_-'Q'/0BF7!__<S]O;.=;)D+@]>J^B8+6UX.Q@,H<"'6E;U5VU^PLR=A
M?KFJC/N%;?LV30:0KXU5=4=,&M2R:;_BL?/#'L$X.$ 0=021T[L5Y+3\65AQ
M=:'5%C2_)FZ\<*8Z:E).-AR4.ZOI5A*=O;JS*G\XFY%=!5RKFF)MA'/7FWLQ
MK]"<7@PMB>''P[QC.6M91@=83N"3:FQIX%U38/&2?DCJ]3I&SSK.HJ,,[W#E
M0QQX$ 51<(1?W-L<.W[Q(7ZET'@V=S;?B">"F(6IUJ)9HEO_-IT;JPDOOQ\1
M-NJ%C9RPT2%AE$;%ND)0"_AUQ:X]6VF9RV9);BJP@JFAA' 7YC5?'^=^7R+,
M*D$A)#F*X@7JI8S:R1 [&6!+8>D'7;A%\P1K]H-5A&6+FB"&[G9)_K!GA; (
M"R$U;$2U=D881DPGQ@"5!??<EAH11%- PQSJ%@'(" "*G\5ZCKH/HGL8!>$$
MMJB)C/E45!^,!U1:# 6!R#AGZ9[3"HLSL4%-58)34)ISN'?RCHCY_&_4<"KL
M5N]?&)JKFN@[>U=$9A@W\".D?C:A3^0G,7U&?A;0)_3C!-X]KJC:L#O)D_!&
M-O"$0IM32/S)A.B"N%^EN\<;55'.5=(^P3CTL^@$TM0?CT\@2_U)W'ZR$[B5
MYN%LP69+\@^YR8+F\ 1^G)Z0_)3>!'Y&!)$?)B<[_H7<R()\ #_],(["Z.W)
MD<41Q"<]XI/CB'<.:[$.4ZZZ9-EKT#[*AKO1N5F)'"\'#A-Z@X..=PN^MJ*S
MU]84WQ:&%,8,;BK1,*8HAJ_$7)JN \D_R3<[Z)W#Y[5[V2>J@6_/Z)MVZ'OW
MB#J7!N&&\@O_>7^+W @Y\:X)>EQ#UJ*">T;#=+G4N.2 ?:0;26TMAZ\.:WLX
MX:4MU=I0@M!V)L@4DD,9^S/FG2&AUZ(U]+(H]:(X=NBC@XD?)(S+S(O&&7S@
M!"8+1UX0)EX:ARU2J9<M4/+%FS#,O$D4GC)JTMXTNA@%J1<DV2FQ#<)])5YQ
M9^)%Q&8\3DER[$]"TB(><9*,O8AV'5?N)0<8I!-O$G89%,/8'SE[O&"2PI=F
M0RCG*!%XL<\M!7Q\4)]P1&9EG3X)Z\/K-/-"VAW!=]KC._T^OKOVL=\R/;BN
MJ-#*A:0+BN.=I6!S0S$MI @A!ZO\48E'4J%3(]_OW.RHAB"Z)6SG+S3:J_HN
MW[.WE LOM%2]EL[GS%=CR3/8!J%2YK\7_/V$^U^*^-]2Z);\)71>.@T*W- 8
MNG)=OG.3X8P9,4*XIB>CD/<!?,"&/%$Y*E%05Y0\$O $N2,DD 89A"-:A),8
M1@'<*TLTYGN187Q'KGE$+=BS-F6"5^$YW)ON:M1+-\-2:-6ZL>V@UY_V8_*T
MG0YWS]L9^Y/02ZH\4.&"2"GMJ03K=FYM-U:MW*PX5Y8F3[<L:=1'S0_H?J&4
M?=ZP@/[/P]5?4$L#!!0    ( )M <E$)@V]9300  -T)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;(U6VV[C-A#]E8%:% F@M25*LJ74-I!DTPO0
M#8(D[3X4?:"E4<1&$K4D%6?[]1U2MN+L.D8 0QY>YLR9&\G%1JI'72$:>&[J
M5B^]RICN;#K5>84-UQ/984LKI50--S14#U/=*>2%4VKJ*0N"V;3AHO56"S=W
MHU8+V9M:M'BC0/=-P]77"ZSE9NF%WF[B5CQ4QDY,5XN./^ =FC^[&T6CZ8A2
MB 9;+60+"LNE=QZ>721VO]OPE\"-WI/!>K*6\M$.?B^67F )88VYL0B<_I[P
M$NO: A&-+UM,;S1I%??E'?HOSG?R9<TU7LKZLRA,M?12#PHL>5^;6[GY#;?^
M.(*YK+7[PF:[-_ @[[61S5:9&#2B'?[Y\S8.[U%@6P7F> ^&',N/W/#50LD-
M*+N;T*S@7'7:1$ZT-BEW1M&J(#VSNJ:\_R&UAAM4<%=QA7!RS]<UZM/%U) !
MNVV:;\$N!C#V!E@&GV1K*@U7;8'%:_TI$1O9L1V["W84\ Z["42!#RQ@P1&\
M:/0V<GC1&WA77+6B?=CW]N_SM3:*BN.?(_CQB!\[_/@MOM0S15\CR!*^M^7#
M!=<B!]X6\%'4O?DV1D-(CINXKQ!*65,S$3@8FZIM1XG_4(.AY5PV76^XJWHB
MLAZ-%H-1:"GIM4UZ1]2T"P/MLZJ7I,K;KV1!N;&I%*+3)5\0FB&]:-,+E!R#
MS9H@=AER&UD09F=P[Q2/[+]^#Y[%VI-.1$N,9*_)CO8!GW-2V3I@3;^XPQO9
MMT:?PO7.U1_A),K\>1B=6C'V@ZV4)#Y+YTX, W^6L%/X[%H9BP_\"16=3#:@
MQ!2H&?-'H)--&[)&X?</Q';FAVSNA_$,$C\.,C^.(I+2E.:SD*0PF_FS-'PA
M-I(^A$:L9I,X=?2"R3QV0C:),B>P29"<'BG;9"S;Y-UE>]X:X:S384DIR7LE
MC*#"NGK.Z]ZFJ52R<76R5V+?U_JAPCY*PMX^9[KC.2X]NEXTJB?T7+7O:A)W
M#,RK%NBD0>+,ZR&*VO+93Y@/#JZUX;3G=P'V,ACJ8S^9P T@SRO2XG8OY47(
MPM:F/_A\H+6.--2N@P88#8*,Y YXC3GO-=*,]<=U,=VT='OU=0$5U1Q]"JH"
M^AGQ8<P%EB7=9&>'VN3;*6J52]E2\1IACP?ROT2ER/10P8Q1!<[]&4M>B1;I
MFH*I@1IA'H=4OC/XZ8>4A>QG^%74=.6[=6!V/6'CVMW0%YV-"IU $KI>Y16%
M^G7C1'Z49&2*091F?I#.;-G4-J^H<J%'>CL@W:__)8\M8-F;GF+ZA-K8>(5^
MFJ0^F\60)C'U6P2WM*)$;D80ON&J. +!YB%Y'@&+F0.XEX8JB$Z(D&7$D]&"
M'\Z9GR5S.-1AT[TKMT'UX!X6FARFLAINWW%V?+N<#U?VR_;AX?.)JP=!_M98
MDBIU.?6)&AX3P\#(SEW@:VGH.>#$BI*!RFZ@]5)25K8#:V!\T:W^!U!+ P04
M    " ";0')1EHT3GV$#  "]"   &0   'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6S-5MUOVS80_U<.&C:T0";)LMW:F6T@3I>N6+L%<=<^#'N@I9-%E!\*
M2<7U?]\C)<O.8"<;]K(7BG>\^]T'[WB:;;7Y8BM$!U^E4'8>5<[5ETEB\PHE
ML[&N4=%)J8UDCDBS26QMD!5!28HD2]-7B61<18M9X-V:Q4PW3G"%MP9L(R4S
MNR4*O9U'@VC/N..;RGE&LIC5;(,K='_4MX:HI$<IN$1EN59@L)Q'5X/+Y<C+
M!X%/'+?V: \^DK767SSQKIA'J7<(!>;.(S#Z/. U"N&!R(W[#C/J37K%X_T>
M_2;$3K&LF<5K+3[SPE7S:!)!@25KA+O3VU^PBV?L\7(M;%AAV\J.LPCRQCHM
M.V7R0'+5?MG7+@]'"I/TC$+6*63![]90\/(-<VPQ,WH+QDL3FM^$4(,V.<>5
MOY25,W3*2<\MKK64W%&6'3!5P+56CJL-JIRCA1<?V5J@?3E+')GR"DG>P2Y;
MV.P,[!0^$%)EX6=58/%8/R$7>S^SO9_+[$G %=8Q#-,+R-(L?0)OV,<]#'C#
M9^.V)P)_PVTNM&T,PI]7:^L,%<]?3U@=]59'P>KHC-5?<0>?F&A8J,@K2ZU0
M^ZT]E>'GH1YZ*':  D9>,PNE%M1Q]I+,@"Z!$NA0KM'T682;1A6&<8M@<U3,
M< WO;G^'G-D*:K:C%O[;@58/:$([]OSW_+[A1>O$2<5' B< [M _'91Z<&@D
MO-@A,_8E#.+7$TCCM%N(G+:+OQK=4+D:YA"R49S!]T]^/H?&] 8&\9CHZ3A.
MZ?/#=Y-LD/WDY0+='GZLD$I!UDSMJ+>]1Y3V ARQ2\9-R#CZ='K.6R[H&83?
M-#G"''"58[@"6!^40V D2R^F]4UV%H 'U@ZV2-?G-%AT3B @)ZZ!IO;IHY+T
M>*3-E+^1"V!D""5Y* YIO@!MZ."^88*7G,Z(5%K]>& @R;H=E/O[C^%?5--Q
MH/_G"J)K3:EXAMT2R+#\EPJ:Q*]\K63Q]%$)C=.VAMKCLPWG4[#:N[U"XY^:
MY8%SPQ6C]X?LK)Z)K>N)X;1=_D%$AQBZ^L]"O8?UU,.6'(T4B683!J>%8*:=
M+CVWG\U7[4@ZB+>#_0,S&TZ5)+ DU31^/8[ M,.R)9RNPX!::T?C+FPKZ@LT
M7H#.2TT-TA'>0/_'LO@&4$L#!!0    ( )M <E%G.8(-(P4  +X/   9
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MEI%4=^"X8.U:DG]1@(X^>V'EA">\7OBY2UU60CU]^TT:!LE+"XO6QX)]!*E
M4B1S4?A)3R0*S+(V5<)A.4?3E<-'_ -F[6S L\'T!"Y:]1O?1RY%Y1W8H?^)
M+AR2!VZI:TO0]@B:S)[ M:&^8]R3MX@?:UE1)W!#4(1_ &E*/\$X6L_^"5S6
MQI 05-JL$J I P:*9RD(8HA"N/+S2JNLU5D7\:D*7\($;K43Q5;&UB4/&.X
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M3'-;;%Z<KOP-;:X=W??\<$D7;#0L0-\76KO5"QOHKNRSOP%02P,$%     @
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M:ECG$:4] TOLG''M,XXNG8[SD@MZVWQ+ +/ 98K^"F"Y,_:!D2X]@P;)ZX,
MW+,VL$:Z/JO H+4" 3EQ-=252Q^5I,,C:R;=C1P!HX.P) _%+LU'H#0)KFLF
M>,Y)1J14\NF.@:1K-Y!O[S^$OZBF_4#_YPJB:XVI>/KMXDF__$L%C<)GKE:2
M<'RKA(9Q4T.-^&##N10LMFXO4'-Z2N<[S@673*;NG,5O8FM[HC]NEC^(:!=#
M6_^)KW>_WO6P17MSHD2]\M/0@#^F&1D=MQNXI\V<V:DWT_H=TRM.E20P)],X
M/!X&H)L)V!!657[J+)6E&>:W!?4%:J= \EQ1@[2$.Z#[#9G]!%!+ P04
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M;]HP%/XK5E1-K=0U(8'0=H $A6V=5@W!NCU,>W"30V(UL5/;@>[?[]@)&:7
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M7."S MW4-5/_/F E=S,O]-X77OBF-';!GT^W;(,K-%^VSXIF?L^2\QJ%YE*
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M8=)=5/Q?].TMYR^F-EQHJ+ @5\'-A%12[<VAG1BY=2?=6AHZ-]VPI,L6*FM
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M8_QY9T7*CS5+VI[VX$0C?KCH&S 32FLZDB? *,<Q6B_A;4@J/#/ 1"Z]S P
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M!>7:0'V_9$P^W>C7S>U_+\S^!E!+ P04    " ";0')1KEMJ_ X#  !U"
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MV^'>Y00,95Q?H=?3PX1<7ER1"\($><QEJ:E(==\W6+VMP4_J2F^K2J,3E3[
MHD7BX .)@B@X A^?AT\@07AHX>&GMW ?-6N$BQKA(A<O/A%O2C=TQI$KLB%.
M1<HU>1[-M%'8S+_/I(B;%+%+T3Z18JOOHCX&F9&,"2H2(!RPUPFO)=\<4[.*
MW76Q[>5?#L-VWU_N*G;H$D>-RYN2VTW)[?>67(HE:(,M!E3Q#8$UJ(1I7.N<
MJG]PJ))U=@J,PBC>8W'HU.D>9]%I6'3.LGB4AG*\?0=<I.OT[09_[?ACQ7<.
MU(W"N+=7_*'3]?5;E\GY6I_#<ZW6]?8,O4:"WOO"5IS.@QYSP$>8NPZMAA;5
M5C:\>U#,4+GM_2-,X^.L\,5/2:9D05!70LN4V3ZI>ISA"6A##>",,;H.9')J
M2(K&UC'._LXS6(":NW&B22)+8:I;UUBKB37&B>5>]CW[J'LSZ1ZQW_;J">>_
MAJ_&XP^JYDQHO)<9I@I:/3PT58V<:F'DPCW",VGP27>?.4YI4-8!]S,IS79A
M$S1S?_@74$L#!!0    ( )M <E$W^;V%PP,   D.   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4Q+GAM;,5776_;-A3]*X30AP3(+%&V9;NP#=1.LJ58.Z-N
MMH=A#[1\'0N11(6D[ ;HC]\EQ4A*(JGI@F O-DGQW(]S+X^HZ9&+6[D'4.1;
M$J=RYNR5RMZ[K@SWD##9XQFD^&3'1<(43L6-*S,!;&M 2>SZGA>X"8M29SXU
M:RLQG_)<Q5$**T%DGB1,W"\@YL>90YV'A2_1S5[I!7<^S=@-K$%=9RN!,[>T
MLHT22&7$4R)@-W,^T/>7=*(!9L>?$1QE;4QT*AO.;_7D:CMS/!T1Q! J;8+A
MWP&6$,?:$L9Q9XTZI4\-K(\?K%^:Y#&9#9.PY/%?T5;M9\[8(5O8L3Q67_CQ
M-[ )#;6]D,?2_)*CW>LY),REXHD%8P1)E!;_[)LEH@:@@Q: ;P'^4T"_!="W
M@/Y+/0PL8/!2P- "AB\%!!80&.X+L@S3YTRQ^53P(Q%Z-UK3 U,N@T:"HU1W
MUEH)?!HA3LU76$@0 K9DK7AX2WXAGYD03)>;G)R#8E$L3W'U>GU.3MZ=DG?$
M)7+/!$@2I>0ZC90\PT4<?]WS7+)T*Z>NPL"T>3>T02R*(/R6(#[F<8]X](SX
M'ITTP)?=\$_LGOB^08\;T.?=Z#]"U2-]X]SW&N 7W? U9 CW6N&7+X8_3=W%
M4I;U],MZ^L9>O\7>5T@R+E CR,5='JE[\O?ON(-<*4CD/QWV^Z7]OK$_:+%_
M)67.TA!(R*5J*O5%@0\,7NO:8>[[ ZS+H4[*\TU>N>-17(,RKD%G7$N>)"A4
M11-_)^M\(^$NAU21BP/^=F0^+#T,WX39H+0?=&:PMJ<*"<;3F&>83<C3 P@C
MXGQG9RK:Q$"R\MA*D_$)'L#B6)XVG8#"\_!138+Q*/"'S:R/RIA'W3&#B##F
M-6 @3Y7D.UG6 O[,%<@.EL:EQ_&;5&%2VI_\1!60U4Q$!Z:0\9B%@*]4=::7
M\ !D( K*#?E;'L=,R&JUJ0[+PC?UZH7H];U1,&FN _4J&?=>48F536+UD$0'
M4[3VZJ!O4@M:B1GU7UF-'W3^TCJHM_YH[ 63T:B%\4H(:;<2_BJXQ'H+'B+G
M$F]9(>!+LSG*QLB>:R =>UZ+#M)*"&FW$MI.^/#:-JATD;Z-,-)*&>G/2.-_
M:(,%?:Z M(]=,*%!"]^5!-)N#7QE'RRL^4=]X W;&Z%22CK^_Z1L89U36C]9
MO2 8#EKBKA28=DOP#Z\8"VO@,65/^7)KEV+]D?2)B9LHE22&':*\W@B;013?
M'<5$\<S<DS=<X:W;#/?XK09";\#G.X[O,#O15^_RZV_^+U!+ P04    " ";
M0')1$0I39ND$  #+%P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6RU
M6&UOFSH8_2M6M ^;=&_!YKU*([5)NC;:=*NEW?TP[8.3. DJX,R89KV__IJ7
M0 P$G*IKI1;,.8^/\>/S& _WE#W'6T(X^!T&47PUV'*^N]2T>+DE(8XOZ(Y$
MXLF:LA!S<<LV6KQC!*\R4AAH2-=M+<1^-!@-L[8'-AK2A =^1!X8B),PQ.SU
MA@1T?S6 @T/#-W^SY6F#-AKN\(;,"7_:/3!QIY515GY(HMBG$6!D?36XAI<S
M9*>$#/'=)_OXZ!JD0UE0^IS>W*^N!GJJB 1DR=,06/Q[(6,2!&DDH>-7$710
M]ID2CZ\/T6^SP8O!+'!,QC3XUU_Q[=7 '8 56>,DX-_H_HX4 [+2>$L:Q-E?
ML,^QENAQF<2<A@59W(=^E/_'OXL7<41P]1,$5!!0C0#-$P2C(!BJ!+,@F*H$
MJR!8=8)Q@F 7!%NU!Z<@.*H$MR"XJ@2O('BJ!*@?9D[/,BB?\BQ?)ICCT9#1
M/6 I7L1++[*DR_@B3?PH71]SSL137_#XZ$&D(V&,K,"<T^4S^#@A'/M!_ G\
M#9[F$_#QPR?P ?@1>-S2),;1*AYJ7/2;LK5ET<=-W@<ZT<><["Z H?\%D([T
M%OJXFSY+HD[ZI)O^%3-!AR?ITV[ZA"P/=.BUT#\KC[V5?J<\]E;ZO?+86^DS
M];&[,ET3>58F&RJ3#67QC!/Q'DFXHTS8,)C^2GS^"GY\$0APSTD8_^R(;Y3Q
MC2R^J9C,UPG?4N;_1U9M29O'LK)8:1EY&2%HZ;;G.$/MY3A!%("27+.4:YXE
M]SZ.DW:I9JL"T_6,FE0%H"35*J5:9TG])^$Q%V[@1YLVO9:BWK$J<*(*G*H"
M/ZL"[YI :'KBU[9DX'T3Z+@M^33KQTES9)=S9'?.T1@S]BHF!'S'04+:IB7G
MV\<C0<C3:_K&:K")&FRJ!KOM'ML/^+/->]5BWS5A#K(;T]<2S/'<&FK6AY*F
MSBFGSND<WA=?^.$*9SO&?*F1:-DZA4[+B T=VK67W@N39+JE3+<[PV@8"H65
M6^%%0,#33K2-:?1"6+IK;E/M-M<:LEW'1K6W.U4 2LJ]4KG7J7Q.F$]B,"?"
MP6I>UE%WH%[MHO0_4MG@T3X-OF-M*X+U>M%4 2@+KFH]1.]4W8I "F+[@;+8
M:N, S]LY]-0WV-P2G%#<#Y055WL'V+UYZ'?[(D"/H4U[8;+ :L< N[<,ZIY6
M!)(4N$U/ZX7)0JNR"7OJYEM=K8A[/+DN,FS#;&1!/U#67M4-V%TX"E^[/L?4
M*K>'[I\QM<J58;<MGVEJ7G,G9CAZ^E-_X0I(^0NF<GJDOY.M%8%D$6+I>XW,
M5D'*<JNR@<XK&SW&AIKEX)1F!:2L^>@KL;MR]%M;$4"R MWT$*J+[,7)$JMZ
M@;KKA;JY%8%D"58S9?MQLM2J4*">0O%6>T/-CTEHFA9$CEO7KH"4U:=51&ZI
M[!J]Y5/@IH?UN"5@@0,L9@GD!\\X!G0-)F1)P@5AY2D)\&.P$J[Z(I;,FM$0
M<,'$R<KG:8,?B0@^#H!81,(&2<3C(A#?8@Y$1I"+-F?4CD[H0L(VV8EP#)8T
MB7A^OE&VYJ?.4WAYFQW.UMJOD74Y0U;+$_$&#@?56M5%?LS]%;.-'\4@(&O1
MG7[AB*EB^<EQ?L/I+CLC7%#.:9A=;@D6[R$%B.=K2OGA)NV@/+\?_0]02P,$
M%     @ FT!R46%&'^YU @  60<  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3,N>&ULE55=;YLP%/TK%MI#*W6Q X1^B""U8=-6:5+4:-O#M <';H)5@ZEM
MDG:_?K:A*&WSF8?@:Y]SN.<XL>.UD(^J -#HN>25&GN%UO4-QBHKH*1J(&JH
MS,I"R))J4\HE5K4$FCM2R;%/2(1+RBHOB=W<5":Q:#1G%4PE4DU94OER!URL
MQ][0>YUX8,M"VPF<Q#5=P@STSWHJ385[E9R54"DF*B1A,?9NAS=I9/$.\(O!
M6FV,D74R%^+1%M_SL4=L0\ ATU:!FL<*)L"Y%3)M/'6:7O]*2]P<OZI_==Z-
MESE5,!'\-\MU,?:N/)3#@C9</XCU-^C\C*Q>)KARWVC=8L-+#V6-TJ+LR*:#
MDE7MDSYW.6P0AN$.@M\1_&,)04<(CB6$'2%TR;167 XIU32)I5@C:=%&S0Y<
MF(YM[+/*;OM,2[/*#$\G$U&6)OZ9%MDC.DM!4\;5.?J,/B&,5$$EJ!AK\R(+
MQUDG>M>*^CM$9U /4$ ND$]\LH4^V4]/(3/TH:4/K[?0T_WT^X8/$-E*QR:=
M/B*_C\AW>L$.O2]/#=,OZ,_M7&EI?J=_]V@&O6;@-,/]L2L;^T67,Z*-+H1D
M_R!'9ZSJ9L^WQ=^*CYRX_6.ODI"TGQBO-H,^%I@> 7QC-.R-AB<8K:E$*\H;
M< 9SP3F5"M4@6[-;O;;ZEQN=D0$APW=&CT*EAU!O+(YZBZ/3]Y(IU1S>Q]&'
MU"/_*@S\Z)V[C[A1%)'@>D?G4=]Y='KGYFY0FE8YJY:'VH^.;/\C;GO[>.,<
MLY?.#RJ7K%*(P\(PR>#22,CV(&\++6IWM,V%-@>E&Q;F[@-I 69](81^+>QI
MV=^FR7]02P,$%     @ FT!R47;4QF1W!0  *Q@  !D   !X;"]W;W)K<VAE
M971S+W-H965T-30N>&ULS5EM;]LV$/XKA-$/#9!8(F7)=N 82&(;*[!T0;.T
M'X9]H"7:YBJ)+DG9\; ?O]-+)%N2:7<ML!1((U'/O1_OCLQH*^17M6),HY<H
MC-5-9Z7U^MJRE+]B$55=L68Q?%D(&5$-KW)IJ;5D-,B(HM BMNU9$>5Q9SS*
MUA[E>"02'?*8/4JDDBBB<G?'0K&]Z>#.Z\(GOESI=,$:C]9TR9Z8?EX_2GBS
M2BX!CUBLN(B19(N;SBV^GI%A2I A/G.V57O/*#5E+L37].5#<-.Q4XU8R'R=
MLJ#P:\/N61BFG$"/;P733BDS)=Q_?N4^RXP'8^94L7L1?N&!7MUT!AT4L 5-
M0OU);']AA4%NRL\7H<K^1]L":W>0GR@MHH(8-(AXG/^F+X4C]@B 3SL!*0A(
MG:!WA, I")P: 3DFH5<0],Z5X!8$[KD$7D'@9;[/G95Y>D(U'8^DV"*9HH%;
M^I"%*Z,&!_,XS:PG+>$K!SH]?M+"_WIU![$)T+V((&$5S4)^A3Y2*6D:=_1^
MPC3EH;J U>>G"7K_[@*]0Q92*RJ90CQ&SS'7ZA(6X?GWE4@4C0,ULC1HF,JQ
M_$*;NUP;<D0;!SV(6*\4FL8!"UKH)V;ZH8'> L^4[B&O[KDC1H9/;-U%CGV)
MB$WL%GWNSR;'PS9S?DSZ],>DS\SD$^8#.6XC/_"E4Z::D_%SCJF39LO5O)EJ
MMY!G\9)!O=)HOD/[N$>ZRY9OMU0&Z(]?@27ZH%FD_C0HU"L5ZF4*]8XH]"4K
M.RRXHALFH8RB)>BAKP*J&5I0+M&&A@F[1&*=JJGRSZ#4>TCR0(0AE0JMF<RW
MP45;MN?R!YG\M,9OQKVNYXVLS7X*-4&XZ_8.09,FR.GB&J=I$V1W!X,2=. D
MMW22^U.=M&'JNWPT<5N4]@;#@W\U.]M([&&[G5YIIV>T,RN$I17LA4F?0P9>
M0D73DD,G]7-+V\*<<_;V(^C:=BW,31"I8R:MF!IHV@3U]C 'QO=+X_OG&W^)
MDE@R7RQC_C=$TA=*MQG=;QK=PPV+3J$.U!V4Z@Z,ZDZI#'=5C) Z5#]O2VTZ
MYVS=/6T&KCUT^K50-6&>/23U+=E$8=?%CH=K\3K%[< %P](%0Z,+[A,IT\(8
M<CKG(=<<^K!D(4WWGA:OG5FOJ$9;)AE,CO._8)A+OTFV3J2_@OK:YJ)A,P4Q
M<6JFGP.:-4&NUVXTMJMIQ3[+[+606>L0"R3T"NK+GA\,G0'OC47X;30K3"J5
MR/\3\D*N>Q#.QDX^"S5K01W=[KB:'+!C-/VW+,:QB/VF#TR^K28!W'LCX:[Z
M+C8WWH\BOFHQ]R>%W&WNX$$SY.>@9BVHXR&OVC$V]V,8.OMH^BWA>H<^Q#YX
M(3V)/(8T-GFW:GBX_T8"7C4U?**KO:RYS)6 B8F+]O./F0>VT8[!S&52J&HQ
MV-QC/B;1'+8=U-C]1(OH#JU@&$1SQF+$E4J*<2\'M<[!A:"#'CAP^XTA:7(N
M<-8"=+PA<8\E'JE:##&WF(;5\,/D!HQ<"(D6B4Y@HZ5F4\C*4X87L@[4= ?N
ML#:Y3\[$S5IP,'&X7J]_Q.RJX1'\'_<;^@<]\)A'260Z4%=MC)"WL?-(U5Z(
MN;U\AC,+CY>&;7>"0>_DKB-5*R+F4ZDY$/3E5""J!D/<-Q*(JN@3<]$_(Q!F
M!F?4/U+U"/(=IR(3QZK$D\$;<7E5Y(FYR!^>>ZMSWR5,%/G)'[V>_ U1,<MP
M\J @#T7Y]1R$*:"[5I]:>W>9$9/+[-99P2DTB75^UU2NEC?;M]E];FW]#E_?
MXY;U";Z>YO?6%?O\&OV!RB6<]%'(%B#*[O9A_\C\9CI_T6*=W:3.A=8BRAY7
MC 9,I@#XOA!"O[ZD LJ_#XS_!5!+ P04    " ";0')1>W>PDW4#   9#
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M8D!R _*; 79:# :YP2"=:,8LG=8=570R%OR A!X-WO1#&IO4&F83)GH9%TK
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M;R8D2HW10,_=L]& ;D4<I7#/$-\F"6$O8XCI;FA@8S_Q$*TW0DV8HT%&UK
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MGCICYQAX)+M<F8 ;1R7>P1K44[D2>N9V+!DI@$G"&1*PG3JS\609FGR;\(U
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M@#\4"&H@& J$-1 .!:(:B(9F*:Z!>*B'I :2+A">6CAX6#FH=U"UY'J_S)!
MTS&C>\"47MI3#;WI-"^W24[4\5@*)I_FDA/3+_($_D4Y!T^8@66&& 9G,RQ0
M7O!S< F>ES-P]ND<? (VX.HI!SD!SR07_$(.RO:WC.XX(BD?VT+&HZS:J]KW
M3>7;/>'; Y\I$1D'=R3%J8&?]_/)__&+?MZ'/09LF<@FF^XAFS=NK\4EWHZ
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M*%8PN/R.A7]RL<RH3.T%7:%8E+FN[IC-;/,1L+!77[\UK[X@;HE,6:X0ISN
M0BC(7E:7\NI!B\)>4[="PZ77#O?0H%0: WB_$U#4^L$$:#Z-YO\"4$L#!!0
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M0]ZH@(1ALI([:!V+G)=XE>4T<2%2BH/,BG-'8J&9G"921<-@EK X(*:U4'J
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M?-W/'U? YR#- /Q_(7 5E0UCH+IV&OX+4$L#!!0    ( )M <E'9W5R(-0,
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MKX]PC JJ%G4P@,W\ 4>D8/-ZU:.YB&I5,_]ACN=-RH3-MW/X%U!+ P04
M" ";0')1EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " ";0')1F5R<(Q &  "<)P  $P
M            @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M )M <E'R6Z709@4  )H6   8              " @0X(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " ";0')1O/&H1VT'  #['0  &
M            @(&J#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ FT!R47.+ +RQ P  ?P\  !@              ("!314  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( )M <E$/I]J_,04  (@3
M   8              " @309  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " ";0')1@FJ_(]T+  "'4P  &               @(&;'@
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ FT!R4=&]2K.1
M @  3@8  !@              ("!KBH  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( )M <E'/_'*Y10<  .D>   8              "
M@74M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " ";0')1
M5<0:M0,+  #?'   &               @('P-   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ FT!R4=LI0O)M'@  NUT  !@
M     ("!*4   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M )M <E'FUOCK,@<  )42   9              " @<Q>  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ FT!R49TY^ZQ*!   _@H  !D
M             ("!-68  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " ";0')1)QW2E"<#  #1!@  &0              @(&V:@  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( )M <E%UG,TEVP(
M $<&   9              " @11N  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ FT!R42_I2G,Y P  F@<  !D              ("!
M)G$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " ";0')1
M+U!!O/X#  !M"@  &0              @(&6=   >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( )M <E&JE@/>+0,  +0&   9
M      " @<MX  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ FT!R42;Z'P(W#@  GR@  !D              ("!+WP  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " ";0')1)#-Q*,D#  "X"
M&0              @(&=B@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( )M <E&'SNM"G 0  *L*   9              " @9V.  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ FT!R48"8I-5<
M"P  @!\  !D              ("!<),  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " ";0')17!ZMU+,)  !M.   &0
M@($#GP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( )M
M<E'-4-GFHP8  !L1   9              " @>VH  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ FT!R46[*5(_N!   [@P  !D
M         ("!QZ\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " ";0')1?55REZ0&   V$0  &0              @('LM   >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( )M <E'RZ',N,1P  (%:
M   9              " @<>[  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ FT!R40.QRMX)!   ;@D  !D              ("!+]@
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " ";0')16#K
MHY4%  "[#0  &0              @(%OW   >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( )M <E% WZ\J5P0  ",+   9
M  " @3OB  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
MFT!R4=?HN;H1 P  M 8  !D              ("!R>8  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " ";0')1H$$QAC$#  #X!@  &0
M            @($1Z@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( )M <E&BMLLX+0,  /('   9              " @7GM  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ FT!R423<;MWM @
M: <  !D              ("!W?   'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " ";0')1,\%A^Q,%  !(#   &0              @($!
M]   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( )M <E$)
M@V]9300  -T)   9              " @4OY  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ FT!R49:-$Y]A P  O0@  !D
M     ("!S_T  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )M <E%0L^MBL@(  .L&   9              "
M@:,3 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ FT!R
M4=]=RL%3 @  -P8  !D              ("!C!8! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " ";0')1L?<&CE<#  #*"0  &0
M        @($6&0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( )M <E$$=$V(F <  '$]   9              " @:0< 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ FT!R4>TMD+<"!0  :A@
M !D              ("!<R0! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " ";0')1KEMJ_ X#  !U"   &0              @(&L*0$
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( )M <E%2"F:\
M" ,  %,(   9              " @?$L 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ FT!R457YZP[# P  )0L  !D
M ("!,# ! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " ";
M0')1%T+N$!($  !P#P  &0              @($J- $ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( )M <E% X<F;4@,  )()   9
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M970U,RYX;6Q02P$"% ,4    " ";0')1=M3&9'<%   K&   &0
M    @($$2P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M )M <E%[=["3=0,  !D,   9              " @;)0 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ FT!R4;4TU;C4!   5A,  !D
M             ("!7E0! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " ";0')1N86>G"X#  #'"@  &0              @(%I60$ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( )M <E%S]QA;P@,
M "L/   9              " @<Y< 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ FT!R40'GL/]& @  :08  !D              ("!
MQV ! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " ";0')1
MGX< *G\#   8#   &0              @(%$8P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( )M <E'%7$A@S0,  )$1   9
M      " @?IF 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ FT!R45"?%OO- P  )@T  !D              ("!_FH! 'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " ";0')1/\O8^&8$  #B&P
M&0              @($";P$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( )M <E$(%";(T@8  *LC   9              " @9]S 0!X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ FT!R4:#A> IQ
M P  M0P  !D              ("!J'H! 'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    " ";0')1@MRT8(T"  #+!@  &0
M@(%0?@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( )M
M<E'<S9K,% ,  !@)   9              " @12! 0!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ FT!R4>!1TN3_ @  ? @  !D
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M=#<R+GAM;%!+ 0(4 Q0    ( )M <E$[=#7(= (  $@/   -
M  "  ?F7 0!X;"]S='EL97,N>&UL4$L! A0#%     @ FT!R49>*NQS
M$P(   L              ( !F)H! %]R96QS+RYR96QS4$L! A0#%     @
MFT!R49P O$:E!0  7B\   \              ( !@9L! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( )M <E&L;5!7/ (  *\J   :              "
M 5.A 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )M
M<E% :Q>Z  (  ,8I   3              "  <>C 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !0 %  YQ4  /BE 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>296</ContextCount>
  <ElementCount>373</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited</Role>
      <ShortName>Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals</Role>
      <ShortName>Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation</Role>
      <ShortName>Nature of Operations and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies, Estimates and Judgments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments</Role>
      <ShortName>Significant Accounting Policies, Estimates and Judgments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Prepaid Expenses And Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses And Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Accrued Expenses and Current Portion of Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities</Role>
      <ShortName>Accrued Expenses and Current Portion of Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2141111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143112 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2151114 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2158115 - Disclosure - 2020 Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.kronosbio.com/role/A2020Notes</Role>
      <ShortName>2020 Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2162116 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2164117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies, Estimates and Judgments (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies</Role>
      <ShortName>Significant Accounting Policies, Estimates and Judgments (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Significant Accounting Policies, Estimates and Judgments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables</Role>
      <ShortName>Significant Accounting Policies, Estimates and Judgments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/Investments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Prepaid Expenses And Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses And Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Property, Plant, and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant, and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Accrued Expenses And Current Portion Of Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables</Role>
      <ShortName>Accrued Expenses And Current Portion Of Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2329307 - Disclosure - Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PreferredStockTables</Role>
      <ShortName>Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/PreferredStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2335308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/StockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2344309 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/NetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/CommitmentandContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2352311 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2359312 - Disclosure - 2020 Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.kronosbio.com/role/A2020NotesTables</Role>
      <ShortName>2020 Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/A2020Notes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Organization, Consolidation and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Significant Accounting Policies, Estimates and Judgments - R&amp;D Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails</Role>
      <ShortName>Significant Accounting Policies, Estimates and Judgments - R&amp;D Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Significant Accounting Policies, Estimates and Judgments - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails</Role>
      <ShortName>Significant Accounting Policies, Estimates and Judgments - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Significant Accounting Policies, Estimates and Judgments - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies, Estimates and Judgments - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Significant Accounting Policies, Estimates and Judgments - Schedule of Cash, Cash Equivalents, and Restricted Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails</Role>
      <ShortName>Significant Accounting Policies, Estimates and Judgments - Schedule of Cash, Cash Equivalents, and Restricted Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Investments - Fair Value and Amortized Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails</Role>
      <ShortName>Investments - Fair Value and Amortized Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Investments - Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails</Role>
      <ShortName>Investments - Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Investments - Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails</Role>
      <ShortName>Investments - Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Prepaid Expenses And Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses And Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Accrued Expenses And Current Portion Of Other Liabilities - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses And Current Portion Of Other Liabilities - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Accrued Expenses And Current Portion Of Other Liabilities - Current Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses And Current Portion Of Other Liabilities - Current Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Preferred Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PreferredStockNarrativeDetails</Role>
      <ShortName>Preferred Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/PreferredStockDetails</Role>
      <ShortName>Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/PreferredStockTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/CommonStock</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436417 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Stock-Based Compensation - Option-pricing Model Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option-pricing Model Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Stock-Based Compensation - Classified in Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails</Role>
      <ShortName>Stock-Based Compensation - Classified in Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Stock-Based Compensation - Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/IncomeTaxes</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/NetLossPerShareTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - Commitment and Contingencies - Key Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails</Role>
      <ShortName>Commitment and Contingencies - Key Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2453427 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454428 - Disclosure - Leases - Summary of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails</Role>
      <ShortName>Leases - Summary of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2455429 - Disclosure - Leases - Supplemental Balance Sheet Information - Finance Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information - Finance Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2456430 - Disclosure - Leases - Supplemental Balance Sheet Information - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information - Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457431 - Disclosure - Leases - Schedule of Maturities on Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities on Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2460432 - Disclosure - 2020 Notes - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.kronosbio.com/role/A2020NotesNarrativeDetails</Role>
      <ShortName>2020 Notes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2461433 - Disclosure - 2020 Notes - Key Value Assumptions (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails</Role>
      <ShortName>2020 Notes - Key Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2463434 - Disclosure - Related Party Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails</Role>
      <ShortName>Related Party Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="kron-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2465435 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kronosbio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kronosbio.com/role/SubsequentEvents</ParentRole>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="kron-20200930.htm">kron-20200930.htm</File>
    <File>kron-20200930.xsd</File>
    <File>kron-20200930_cal.xml</File>
    <File>kron-20200930_def.xml</File>
    <File>kron-20200930_lab.xml</File>
    <File>kron-20200930_pre.xml</File>
    <File>kronq3fy2020ex101.htm</File>
    <File>kronq3fy2020ex311.htm</File>
    <File>kronq3fy2020ex312.htm</File>
    <File>kronq3fy2020ex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "kron-20200930.htm": {
   "axisCustom": 2,
   "axisStandard": 25,
   "contextCount": 296,
   "dts": {
    "calculationLink": {
     "local": [
      "kron-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "kron-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "kron-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kron-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kron-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "kron-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 507,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 7
   },
   "keyCustom": 44,
   "keyStandard": 329,
   "memberCustom": 30,
   "memberStandard": 39,
   "nsprefix": "kron",
   "nsuri": "http://www.kronosbio.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.kronosbio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Fair Value Measurements",
     "role": "http://www.kronosbio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Investments",
     "role": "http://www.kronosbio.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Prepaid Expenses And Other Current Assets",
     "role": "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses And Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Property and Equipment, Net",
     "role": "http://www.kronosbio.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Accrued Expenses and Current Portion of Other Liabilities",
     "role": "http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities",
     "shortName": "Accrued Expenses and Current Portion of Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kron:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - Preferred Stock",
     "role": "http://www.kronosbio.com/role/PreferredStock",
     "shortName": "Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kron:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Common Stock",
     "role": "http://www.kronosbio.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Stock-Based Compensation",
     "role": "http://www.kronosbio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141111 - Disclosure - Income Taxes",
     "role": "http://www.kronosbio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143112 - Disclosure - Net Loss Per Share",
     "role": "http://www.kronosbio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets (Unaudited)",
     "role": "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
     "shortName": "Condensed Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Commitment and Contingencies",
     "role": "http://www.kronosbio.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151114 - Disclosure - Leases",
     "role": "http://www.kronosbio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158115 - Disclosure - 2020 Notes",
     "role": "http://www.kronosbio.com/role/A2020Notes",
     "shortName": "2020 Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162116 - Disclosure - Related Parties",
     "role": "http://www.kronosbio.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164117 - Disclosure - Subsequent Events",
     "role": "http://www.kronosbio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies, Estimates and Judgments (Policies)",
     "role": "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies",
     "shortName": "Significant Accounting Policies, Estimates and Judgments (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Significant Accounting Policies, Estimates and Judgments (Tables)",
     "role": "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables",
     "shortName": "Significant Accounting Policies, Estimates and Judgments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.kronosbio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Investments (Tables)",
     "role": "http://www.kronosbio.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Prepaid Expenses And Other Current Assets (Tables)",
     "role": "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses And Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Property, Plant, and Equipment (Tables)",
     "role": "http://www.kronosbio.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant, and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Accrued Expenses And Current Portion Of Other Liabilities (Tables)",
     "role": "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables",
     "shortName": "Accrued Expenses And Current Portion Of Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329307 - Disclosure - Preferred Stock (Tables)",
     "role": "http://www.kronosbio.com/role/PreferredStockTables",
     "shortName": "Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.kronosbio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344309 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.kronosbio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - Commitment and Contingencies (Tables)",
     "role": "http://www.kronosbio.com/role/CommitmentandContingenciesTables",
     "shortName": "Commitment and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kron:AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352311 - Disclosure - Leases (Tables)",
     "role": "http://www.kronosbio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kron:AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359312 - Disclosure - 2020 Notes (Tables)",
     "role": "http://www.kronosbio.com/role/A2020NotesTables",
     "shortName": "2020 Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)",
     "role": "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
     "shortName": "Organization, Consolidation and Presentation of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Significant Accounting Policies, Estimates and Judgments - R&D Expense (Details)",
     "role": "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails",
     "shortName": "Significant Accounting Policies, Estimates and Judgments - R&D Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i58709a1025434a858b79101128c97c2e_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Significant Accounting Policies, Estimates and Judgments - Restricted Cash (Details)",
     "role": "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails",
     "shortName": "Significant Accounting Policies, Estimates and Judgments - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7368251cdbf04660970e56374215be24_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Significant Accounting Policies, Estimates and Judgments - Property, Plant and Equipment (Details)",
     "role": "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails",
     "shortName": "Significant Accounting Policies, Estimates and Judgments - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7368251cdbf04660970e56374215be24_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Significant Accounting Policies, Estimates and Judgments - Schedule of Cash, Cash Equivalents, and Restricted Cash Equivalents (Details)",
     "role": "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails",
     "shortName": "Significant Accounting Policies, Estimates and Judgments - Schedule of Cash, Cash Equivalents, and Restricted Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7f0b4204c0e941c0b44a13e342d5bca4_I20190930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i474c4138d7474661a524846e44986c19_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i474c4138d7474661a524846e44986c19_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Investments - Fair Value and Amortized Cost (Details)",
     "role": "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails",
     "shortName": "Investments - Fair Value and Amortized Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "kron:CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Investments - Balance Sheet (Details)",
     "role": "http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails",
     "shortName": "Investments - Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Investments - Contractual Maturity (Details)",
     "role": "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails",
     "shortName": "Investments - Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "kron:DebtSecuritiesAvailableForSaleAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Prepaid Expenses And Other Current Assets (Details)",
     "role": "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses And Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "kron:DebtSecuritiesAvailableForSaleAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Property, Plant, and Equipment (Details)",
     "role": "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant, and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i4f43e48d5ab84516a4275b0e2940ce84_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Accrued Expenses And Current Portion Of Other Liabilities - Accrued Expenses (Details)",
     "role": "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails",
     "shortName": "Accrued Expenses And Current Portion Of Other Liabilities - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i3f8e95f9bad0404484cd92bc97317806_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)",
     "role": "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
     "shortName": "Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "id87511770e86434c8b397546525820c3_D20190101-20190331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kron:AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Accrued Expenses And Current Portion Of Other Liabilities - Current Other Liabilities (Details)",
     "role": "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails",
     "shortName": "Accrued Expenses And Current Portion Of Other Liabilities - Current Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Preferred Stock - Narrative (Details)",
     "role": "http://www.kronosbio.com/role/PreferredStockNarrativeDetails",
     "shortName": "Preferred Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i1737f19c2c5741778344526c60c0bf8b_I20180522",
      "decimals": "5",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Preferred Stock (Details)",
     "role": "http://www.kronosbio.com/role/PreferredStockDetails",
     "shortName": "Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Common Stock (Details)",
     "role": "http://www.kronosbio.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436417 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i20fd1d6838d143bc929529203014ed4d_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "kron:SharePriceFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Stock-Based Compensation - Option-pricing Model Assumptions (Details)",
     "role": "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Option-pricing Model Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i20fd1d6838d143bc929529203014ed4d_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "kron:SharePriceFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i4f43e48d5ab84516a4275b0e2940ce84_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Stock-Based Compensation - Classified in Statements of Operations (Details)",
     "role": "http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails",
     "shortName": "Stock-Based Compensation - Classified in Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i4c0d6cc50b8e49aca2ce81649e3efb0a_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Stock-Based Compensation - Restricted Stock (Details)",
     "role": "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "iffb0ef90a61349be85e69f64dcaf4055_D20170101-20171231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Income Taxes (Details)",
     "role": "http://www.kronosbio.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7f0b4204c0e941c0b44a13e342d5bca4_I20190930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)",
     "role": "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals",
     "shortName": "Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i47a2ad7dc20e45f8a10245fcd852cd7f_D20190701-20190930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Net Loss Per Share (Details)",
     "role": "http://www.kronosbio.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7aa8d7617e6248f49f8f5e9c3f2f946d_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "role": "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7b189c5eff6848ada547002d5d66c700_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "kron:RepaymentOfDebtPaymentToBeMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i88cd4588864e407facd4e99fbcae11bc_I20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - Commitment and Contingencies - Key Valuation Assumptions (Details)",
     "role": "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails",
     "shortName": "Commitment and Contingencies - Key Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i88cd4588864e407facd4e99fbcae11bc_I20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453427 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454428 - Disclosure - Leases - Summary of Lease Costs (Details)",
     "role": "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails",
     "shortName": "Leases - Summary of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i92a4376bc0f243048fe2b056cf4f7d8b_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kron:AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455429 - Disclosure - Leases - Supplemental Balance Sheet Information - Finance Lease (Details)",
     "role": "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information - Finance Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kron:AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456430 - Disclosure - Leases - Supplemental Balance Sheet Information - Operating Leases (Details)",
     "role": "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information - Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457431 - Disclosure - Leases - Schedule of Maturities on Lease Liabilities (Details)",
     "role": "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Maturities on Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460432 - Disclosure - 2020 Notes - Narrative (Details)",
     "role": "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
     "shortName": "2020 Notes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "ie5ac0bb41ed144069f9ed35f0501c5ff_D20200801-20200831",
      "decimals": "2",
      "lang": "en-US",
      "name": "kron:SaleOfStockPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Statements of Cash Flows (unaudited)",
     "role": "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7f6001b206b54c728c11f91d8f95efb7_I20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461433 - Disclosure - 2020 Notes - Key Value Assumptions (Details)",
     "role": "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
     "shortName": "2020 Notes - Key Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7f6001b206b54c728c11f91d8f95efb7_I20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "ifef3396d498f4831ab1ac220e09caad2_D20200701-20200930",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463434 - Disclosure - Related Party Disclosures (Details)",
     "role": "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails",
     "shortName": "Related Party Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "ifef3396d498f4831ab1ac220e09caad2_D20200701-20200930",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "kron:RelatedPartyTransactionsReimbursableExpensesToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2277693b6fbc4690a6679221de27b1a2_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465435 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.kronosbio.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i2ac6a536633140c584616f4aaff231e3_I20201118",
      "decimals": "-5",
      "lang": "en-US",
      "name": "kron:LesseeOperatingLeaseEarlyTerminationCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Operations and Basis of Presentation",
     "role": "http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation",
     "shortName": "Nature of Operations and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies, Estimates and Judgments",
     "role": "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments",
     "shortName": "Significant Accounting Policies, Estimates and Judgments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kron-20200930.htm",
      "contextRef": "i7c99a4c64d564635a6224bcf2724f933_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "kron_A2020ConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Convertible Notes",
        "label": "2020 Convertible Notes [Member]",
        "terseLabel": "2020 Convertible Notes"
       }
      }
     },
     "localname": "A2020ConvertibleNotesMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_A2020EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "terseLabel": "The ESPP"
       }
      }
     },
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_A2020GileadNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Gilead Notes",
        "label": "2020 Gilead Notes [Member]",
        "terseLabel": "2020 Gilead Notes"
       }
      }
     },
     "localname": "A2020GileadNotesMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_A2020StockOptionAndIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Stock Option And Incentive Plan",
        "label": "2020 Stock Option And Incentive Plan [Member]",
        "terseLabel": "The 2020 Plan"
       }
      }
     },
     "localname": "A2020StockOptionAndIncentivePlanMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_A21ErieStreetCambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "21 Erie Street, Cambridge, Massachusetts",
        "label": "21 Erie Street, Cambridge, Massachusetts [Member]",
        "terseLabel": "21 Erie Street, Cambridge, Massachusetts"
       }
      }
     },
     "localname": "A21ErieStreetCambridgeMassachusettsMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_A301BinneyStreetCambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "301 Binney Street, Cambridge, Massachusetts",
        "label": "301 Binney Street, Cambridge, Massachusetts [Member]",
        "terseLabel": "301 Binney Street, Cambridge, Massachusetts"
       }
      }
     },
     "localname": "A301BinneyStreetCambridgeMassachusettsMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_AccruedExternalResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued External Research And Development, Current",
        "label": "Accrued External Research And Development, Current",
        "terseLabel": "External research and development"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentCurrent",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_AccruedOfferingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Offering Costs, Current",
        "label": "Accrued Offering Costs, Current",
        "terseLabel": "Accrued offering costs"
       }
      }
     },
     "localname": "AccruedOfferingCostsCurrent",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kron_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred, Liabilities Incurred",
        "label": "Asset Acquisition, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Convertible promissory note issued"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities, Finance Leases, Lessee",
        "label": "Assets and Liabilities, Finance Leases, Lessee [Table Text Block]",
        "terseLabel": "Assets and Liabilities, Finance Leases, Lessee"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesFinanceLeasesLesseeTableTextBlock",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kron_AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets And Liabilities, Operating Leases, Lessee",
        "label": "Assets And Liabilities, Operating Leases, Lessee [Table Text Block]",
        "terseLabel": "Assets And Liabilities, Operating Leases, Lessee"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesOperatingLeasesLesseeTableTextBlock",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kron_BellcoCapitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bellco Capital, LLC",
        "label": "Bellco Capital, LLC [Member]",
        "terseLabel": "Bellco Capital, LLC"
       }
      }
     },
     "localname": "BellcoCapitalLLCMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_CambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cambridge, Massachusetts",
        "label": "Cambridge, Massachusetts [Member]",
        "terseLabel": "Cambridge, Massachusetts"
       }
      }
     },
     "localname": "CambridgeMassachusettsMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost",
        "label": "Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost",
        "totalLabel": "Total cash equivalents and investments, amortized cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails": {
       "order": 3.0,
       "parentTag": "kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax",
        "label": "Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax",
        "terseLabel": "Total cash equivalents and investments, unrealized gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails": {
       "order": 1.0,
       "parentTag": "kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax",
        "label": "Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax",
        "negatedTerseLabel": "Total cash equivalents and investments, unrealized losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_ConvertibleNotesPayable2020NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Notes Payable (2020 Notes)",
        "label": "Convertible Notes Payable (2020 Notes) [Member]",
        "terseLabel": "Convertible Notes Payable (2020 Notes)"
       }
      }
     },
     "localname": "ConvertibleNotesPayable2020NotesMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_DebtConversionValuationOfCompany": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Conversion, Valuation Of Company",
        "label": "Debt Conversion, Valuation Of Company",
        "terseLabel": "Valuation of company"
       }
      }
     },
     "localname": "DebtConversionValuationOfCompany",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_DebtSecuritiesAvailableForSaleAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Accrued Interest",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest",
        "terseLabel": "Accrued interest on short-term available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterest",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_DebtSecuritiesAvailableForSaleRemainingContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Remaining Contractual Maturity",
        "label": "Debt Securities, Available-for-sale, Remaining Contractual Maturity",
        "terseLabel": "Available-for-sale, remaining contractual maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRemainingContractualMaturity",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "kron_DeferredOfferingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Offering Costs Incurred But Not Yet Paid",
        "label": "Deferred Offering Costs Incurred But Not Yet Paid",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncurredButNotYetPaid",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_EquityIncentivePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Incentive Plan, 2017",
        "label": "Equity Incentive Plan, 2017 [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2017Member",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_ExecutiveEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Executive Employee",
        "label": "Executive Employee [Member]",
        "terseLabel": "Executive Employee"
       }
      }
     },
     "localname": "ExecutiveEmployeeMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_FinanceLeasesAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Leases Assets",
        "label": "Finance Leases Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "FinanceLeasesAssetsAbstract",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kron_FinancingScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing Scenario",
        "label": "Financing Scenario [Member]",
        "terseLabel": "Financing Scenario"
       }
      }
     },
     "localname": "FinancingScenarioMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_FundraiseScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fundraise Scenario",
        "label": "Fundraise Scenario [Member]",
        "terseLabel": "Fundraise scenario"
       }
      }
     },
     "localname": "FundraiseScenarioMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_GainLossOnChangeInFairValueOfDebtInstrument": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) On Change In Fair Value Of Debt Instrument",
        "label": "Gain (Loss) On Change In Fair Value Of Debt Instrument",
        "negatedLabel": "Change in fair value of 2020 Notes",
        "verboseLabel": "Gain (loss) in fair value"
       }
      }
     },
     "localname": "GainLossOnChangeInFairValueOfDebtInstrument",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_GileadAssetPurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gilead Asset Purchase",
        "label": "Gilead Asset Purchase [Member]",
        "terseLabel": "Gilead Asset Purchase"
       }
      }
     },
     "localname": "GileadAssetPurchaseMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_IPOCashPayoutScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IPO Cash Payout Scenario",
        "label": "IPO Cash Payout Scenario [Member]",
        "terseLabel": "IPO cash payout scenario"
       }
      }
     },
     "localname": "IPOCashPayoutScenarioMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_IPOConversionScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IPO Conversion Scenario",
        "label": "IPO Conversion Scenario [Member]",
        "terseLabel": "IPO conversion scenario"
       }
      }
     },
     "localname": "IPOConversionScenarioMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_IPOScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IPO Scenario",
        "label": "IPO Scenario [Member]",
        "terseLabel": "IPO Scenario"
       }
      }
     },
     "localname": "IPOScenarioMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Right Of Use Operating Assets And Liabilities, Net",
        "label": "Increase (Decrease) In Right Of Use Operating Assets And Liabilities, Net",
        "negatedTerseLabel": "Right-of-use operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lab Equipment",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_LeaseExpenseNoncash": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Expense, Noncash",
        "label": "Lease Expense, Noncash",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "LeaseExpenseNoncash",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_LesseeOperatingLeaseEarlyTerminationCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Early Termination Cost",
        "label": "Lessee, Operating Lease, Early Termination Cost",
        "terseLabel": "Cost for early lease termination"
       }
      }
     },
     "localname": "LesseeOperatingLeaseEarlyTerminationCost",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_LesseeOperatingLeaseEscalatingRentPaymentsPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Escalating Rent Payments, Percent",
        "label": "Lessee, Operating Lease, Escalating Rent Payments, Percent",
        "terseLabel": "Escalating rent payments, percent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseEscalatingRentPaymentsPercent",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kron_LesseeOperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Incremental Borrowing Rate",
        "label": "Lessee, Operating Lease, Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kron_LesseeOperatingLeaseInitialAnnualBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Initial Annual Base Rent",
        "label": "Lessee, Operating Lease, Initial Annual Base Rent",
        "terseLabel": "Initial annual base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseInitialAnnualBaseRent",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_LesseeOperatingLeaseMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Base Rent",
        "label": "Lessee, Operating Lease, Monthly Base Rent",
        "terseLabel": "Monthly base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyBaseRent",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_LesseeOperatingLeaseTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Tenant Improvement Allowances",
        "label": "Lessee, Operating Lease, Tenant Improvement Allowances",
        "terseLabel": "Tenant improvement allowances"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTenantImprovementAllowances",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_LiquidationCashPayoutScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liquidation Cash Payout Scenario",
        "label": "Liquidation Cash Payout Scenario [Member]",
        "terseLabel": "Liquidation cash payout scenario"
       }
      }
     },
     "localname": "LiquidationCashPayoutScenarioMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_LiquidationConversionScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liquidation Conversion Scenario",
        "label": "Liquidation Conversion Scenario [Member]",
        "terseLabel": "Liquidation conversion scenario"
       }
      }
     },
     "localname": "LiquidationConversionScenarioMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_MeasurementInputWeightingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Weighting",
        "label": "Measurement Input, Weighting [Member]",
        "terseLabel": "Weighting"
       }
      }
     },
     "localname": "MeasurementInputWeightingMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-Employee",
        "label": "Non-Employee [Member]",
        "terseLabel": "Non-Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_NotesPayableFairValueGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes Payable, Fair Value Gain (Loss)",
        "label": "Notes Payable, Fair Value Gain (Loss)",
        "terseLabel": "Change in fair value of convertible notes payable"
       }
      }
     },
     "localname": "NotesPayableFairValueGainLoss",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_OperatingLeaseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease Assets [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAbstract",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kron_OperatingLeaseFacilitySize": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Facility Size",
        "label": "Operating Lease, Facility Size",
        "terseLabel": "Facility size"
       }
      }
     },
     "localname": "OperatingLeaseFacilitySize",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "kron_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Asset Acquisitions",
        "label": "Payments For Asset Acquisitions",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_PaymentsForAssetAcquisitionsReimbursements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Asset Acquisitions, Reimbursements",
        "label": "Payments For Asset Acquisitions, Reimbursements",
        "terseLabel": "Payments for reimbursements"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitionsReimbursements",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_PaymentsForLegalCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Legal Costs",
        "label": "Payments For Legal Costs",
        "terseLabel": "Reimbursement for legal costs"
       }
      }
     },
     "localname": "PaymentsForLegalCosts",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_PaymentsOfOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments Of Offering Costs",
        "label": "Payments Of Offering Costs",
        "terseLabel": "Payments of offering costs"
       }
      }
     },
     "localname": "PaymentsOfOfferingCosts",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_PaymentsOfUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments Of Underwriting Discounts And Commissions",
        "label": "Payments Of Underwriting Discounts And Commissions",
        "negatedTerseLabel": "Payments of underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfUnderwritingDiscountsAndCommissions",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_PrepaidEquipmentServiceContracts": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Equipment Service Contracts",
        "label": "Prepaid Equipment Service Contracts",
        "terseLabel": "Prepaid equipment service contracts"
       }
      }
     },
     "localname": "PrepaidEquipmentServiceContracts",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_PrepaidExternalResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid External Research and Development",
        "label": "Prepaid External Research and Development",
        "terseLabel": "Prepaid external research and development"
       }
      }
     },
     "localname": "PrepaidExternalResearchAndDevelopment",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_PrepaidSoftware": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Software",
        "label": "Prepaid Software",
        "terseLabel": "Prepaid software"
       }
      }
     },
     "localname": "PrepaidSoftware",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_RDEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "R&amp;D Equipment",
        "label": "R&amp;D Equipment [Member]",
        "terseLabel": "R&amp;D Equipment"
       }
      }
     },
     "localname": "RDEquipmentMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_RelatedPartyTransactionsReimbursableExpensesToRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transactions, Reimbursable Expenses To Related Party",
        "label": "Related Party Transactions, Reimbursable Expenses To Related Party",
        "terseLabel": "Reimbursable expenses to related parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsReimbursableExpensesToRelatedParty",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_RepaymentOfDebtPaymentToBeMade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayment Of Debt, Payment To Be Made",
        "label": "Repayment Of Debt, Payment To Be Made",
        "terseLabel": "Repayment of debt, payments to be made"
       }
      }
     },
     "localname": "RepaymentOfDebtPaymentToBeMade",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Aggregate Net Sales Milestone Payment",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Aggregate Net Sales Milestone Payment",
        "terseLabel": "Aggregate sales milestone payment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAggregateNetSalesMilestonePayment",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Regulatory Milestone Payment",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Regulatory Milestone Payment",
        "terseLabel": "Regulatory milestone payment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRegulatoryMilestonePayment",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Sales Milestone Payment",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Sales Milestone Payment",
        "terseLabel": "Sales milestone payment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayment",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development",
        "label": "Research And Development [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_SaleOfStockPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock, Purchase Price Of Common Stock, Percent",
        "label": "Sale Of Stock, Purchase Price Of Common Stock, Percent",
        "terseLabel": "Settlement price, percentage"
       }
      }
     },
     "localname": "SaleOfStockPurchasePriceOfCommonStockPercent",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kron_SanMateoCaliforniaAdjacentSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "San Mateo, California, Adjacent Space",
        "label": "San Mateo, California, Adjacent Space [Member]",
        "terseLabel": "San Mateo, California, Adjacent Space"
       }
      }
     },
     "localname": "SanMateoCaliforniaAdjacentSpaceMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_SanMateoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "San Mateo, California",
        "label": "San Mateo, California [Member]",
        "terseLabel": "San Mateo, California"
       }
      }
     },
     "localname": "SanMateoCaliforniaMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_ScheduleOfAssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Asset Acquisition",
        "label": "Schedule Of Asset Acquisition [Line Items]",
        "terseLabel": "Schedule Of Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAssetAcquisitionLineItems",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kron_ScheduleOfAssetAcquisitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Asset Acquisition [Table]",
        "label": "Schedule Of Asset Acquisition [Table]",
        "terseLabel": "Schedule Of Asset Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfAssetAcquisitionTable",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kron_SeriesBScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series B Scenario",
        "label": "Series B Scenario [Member]",
        "terseLabel": "Series B Scenario"
       }
      }
     },
     "localname": "SeriesBScenarioMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_SeriesSeedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series Seed, Preferred Stock",
        "label": "Series Seed, Preferred Stock [Member]",
        "terseLabel": "Series Seed Preferred Stock"
       }
      }
     },
     "localname": "SeriesSeedPreferredStockMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_ServicesAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Services Agreement Term",
        "label": "Services Agreement Term",
        "terseLabel": "Services agreement term"
       }
      }
     },
     "localname": "ServicesAgreementTerm",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "kron_SettlementPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Settlement Plan",
        "label": "Settlement Plan [Axis]",
        "terseLabel": "Settlement Plan [Axis]"
       }
      }
     },
     "localname": "SettlementPlanAxis",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kron_SettlementPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Settlement Plan",
        "label": "Settlement Plan [Domain]",
        "terseLabel": "Settlement Plan [Domain]"
       }
      }
     },
     "localname": "SettlementPlanDomain",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Shares",
        "terseLabel": "Early exercised stock options, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kron_SharePriceFairValueDisclosure": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Price, Fair Value Disclosure",
        "label": "Share Price, Fair Value Disclosure",
        "terseLabel": "Fair value of common stock per share (dollars per share)"
       }
      }
     },
     "localname": "SharePriceFairValueDisclosure",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kron_StockOptionsEarlyExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Options Early Exercise",
        "label": "Stock Options Early Exercise [Member]",
        "terseLabel": "Early exercised stock options subject to future vesting"
       }
      }
     },
     "localname": "StockOptionsEarlyExerciseMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kron_TemporaryEquityIssuanceCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity Issuance Costs Incurred But Not Yet Paid",
        "label": "Temporary Equity Issuance Costs Incurred But Not Yet Paid",
        "terseLabel": "Preferred stock issuance costs in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCostsIncurredButNotYetPaid",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kron_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "kron_TemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity",
        "label": "Temporary Equity [Text Block]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTextBlock",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kron_TwoRiverConsultingLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two River Consulting, LLC",
        "label": "Two River Consulting, LLC [Member]",
        "terseLabel": "Two River Consulting, LLC"
       }
      }
     },
     "localname": "TwoRiverConsultingLLCMember",
     "nsuri": "http://www.kronosbio.com/20200930",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r219",
      "r340",
      "r341",
      "r343",
      "r452"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r221",
      "r222",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r379",
      "r426",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r221",
      "r222",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r379",
      "r426",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r211",
      "r221",
      "r222",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r379",
      "r426",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r211",
      "r221",
      "r222",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r379",
      "r426",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r209",
      "r210",
      "r427",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r209",
      "r210",
      "r427",
      "r437",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Current Portion of Other Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesandCurrentPortionofOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Net amortization/accretion on available-for-sale securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "auth_ref": [
      "r12",
      "r43",
      "r267"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "terseLabel": "Accrued franchise tax"
       }
      }
     },
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails",
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r58",
      "r59",
      "r60",
      "r415",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r102",
      "r103",
      "r104",
      "r291",
      "r429",
      "r430"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r26",
      "r261"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r258",
      "r259",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r224",
      "r227",
      "r264",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r227",
      "r255",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r72",
      "r85",
      "r318"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Total debt issuance costs expensed and recognized",
        "verboseLabel": "Debt issuance costs on convertible notes payable"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r142",
      "r144",
      "r148",
      "r165",
      "r289",
      "r292",
      "r305",
      "r395",
      "r414"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r54",
      "r96",
      "r165",
      "r289",
      "r292",
      "r305"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r155",
      "r172"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value",
        "terseLabel": "Due in 1 year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "terseLabel": "Due in 1 to 2 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value",
        "terseLabel": "Instruments not due at a single maturity date"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r153",
      "r156",
      "r172",
      "r401"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r229",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r101",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Operations and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NatureofOperationsandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment additions included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r34",
      "r87"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r15",
      "r88",
      "r93",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails": {
       "order": 2.0,
       "parentTag": "kron_CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "verboseLabel": "Total cash equivalents and investments, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r82",
      "r87",
      "r92"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash as shown on the statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r82",
      "r307"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "netLabel": "Money market funds, amortized cost",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r94",
      "r96",
      "r114",
      "r115",
      "r116",
      "r118",
      "r120",
      "r126",
      "r127",
      "r128",
      "r165",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r48",
      "r191",
      "r403",
      "r418"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommonStockDetails",
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommonStockDetails",
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommonStockDetails",
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommonStockDetails",
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 40,000,000 and 40,000,000 shares authorized as of September 30, 2020 and December 31, 2019 respectively; 6,284,326 and 5,660,391 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r66",
      "r70",
      "r405",
      "r423"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r131",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "2020 Notes"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Convertible notes payable, at fair value"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r18",
      "r396",
      "r412",
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "2020 Notes",
        "verboseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r23",
      "r24",
      "r201",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Common Stock Issuable Upon Conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]",
        "terseLabel": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]",
        "terseLabel": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "2020 Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020Notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r20",
      "r21",
      "r396",
      "r397",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r317",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Key valuation assumptions"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r46",
      "r99",
      "r201",
      "r203",
      "r204",
      "r205",
      "r316",
      "r317",
      "r319",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Current liabilities related to shares that were subject to repurchase",
        "verboseLabel": "Current portion of unvested early exercised share liability"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Non-current liabilities related to shares that were subject to repurchase"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r52",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "verboseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r140"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited",
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r100",
      "r341",
      "r402",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Payables to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.kronosbio.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r121",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock options recognized, weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock options, unrecognized cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r111",
      "r113",
      "r125",
      "r166",
      "r200",
      "r206",
      "r258",
      "r259",
      "r260",
      "r280",
      "r281",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Key Valuation Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesTables",
      "http://www.kronosbio.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r297",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r296",
      "r297",
      "r300",
      "r301",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r212",
      "r213",
      "r218",
      "r220",
      "r297",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r212",
      "r213",
      "r218",
      "r220",
      "r297",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r297",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r302",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "negatedTerseLabel": "Change in fair value of convertible notes payable"
       }
      }
     },
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r323",
      "r330",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r322",
      "r335"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finance Lease Liability [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails",
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r324",
      "r332"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Principal payments on finance lease"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r323",
      "r330",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Finance lease on R&amp;D equipment"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r160",
      "r161",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r85",
      "r196",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (loss) on settlement of convertible notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r223",
      "r225",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r181",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r274",
      "r275",
      "r278",
      "r282",
      "r284",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r112",
      "r113",
      "r141",
      "r273",
      "r283",
      "r285",
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r93",
      "r271",
      "r272",
      "r275",
      "r276",
      "r277",
      "r279",
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r68",
      "r139",
      "r315",
      "r318",
      "r406"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "verboseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r164",
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "totalLabel": "Total cash equivalents and investments"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails",
      "http://www.kronosbio.com/role/InvestmentsContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments, fair value"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r163",
      "r393",
      "r408",
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Finance lease, term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails",
      "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails",
      "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities on Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "Remaining three months of 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r96",
      "r145",
      "r165",
      "r290",
      "r292",
      "r293",
      "r305"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r96",
      "r165",
      "r305",
      "r398",
      "r417"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, convertible preferred stock and stockholders' deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r96",
      "r165",
      "r290",
      "r292",
      "r293",
      "r305"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total financial liabilities",
        "verboseLabel": "Convertible notes payable, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r46",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Remaining term (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesKeyValueAssumptionsDetails",
      "http://www.kronosbio.com/role/CommitmentandContingenciesKeyValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r62",
      "r64",
      "r69",
      "r86",
      "r96",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r117",
      "r142",
      "r143",
      "r146",
      "r147",
      "r149",
      "r165",
      "r305",
      "r404",
      "r422"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.kronosbio.com/role/NetLossPerShareDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Gilead Note"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Gilead Note"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r142",
      "r143",
      "r146",
      "r147",
      "r149"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r331",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSummaryofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails",
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails",
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r325",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails",
      "http://www.kronosbio.com/role/LeasesSupplementalBalanceSheetInformationOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r43"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Current portion of other liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r43"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Current portion of other liabilities",
        "totalLabel": "Total current portion of other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesCurrentOtherLiabilitiesDetails",
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r7",
      "r179"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments of deferred offering costs",
        "terseLabel": "Payments of stock issuance costs",
        "verboseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r75",
      "r77",
      "r154"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchase of available-for-sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r229",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r4",
      "r7",
      "r177",
      "r179"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r5",
      "r7",
      "r178",
      "r179"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Net cash proceeds",
        "verboseLabel": "Proceeds from issuance of convertible notes, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of preferred stock, net of financing fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r75",
      "r76",
      "r154"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of available-for-sale securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r183",
      "r323",
      "r330"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r55",
      "r184",
      "r330"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Total property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r16",
      "r182",
      "r321"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "totalLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails",
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r182"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r93",
      "r184",
      "r440",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment",
        "verboseLabel": "Property and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentTables",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails",
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "terseLabel": "Property Subject to or Available for Operating Lease [Axis]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease.",
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "terseLabel": "Property Subject to or Available for Operating Lease [Domain]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseProvisionTermsMember": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Terms of the purchase provisions under research and development arrangements accounted for as a purchase contract to perform research and development for others.",
        "label": "Purchase Provision Terms [Member]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "PurchaseProvisionTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r219",
      "r340",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r219",
      "r340",
      "r341",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transaction with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r219",
      "r340",
      "r343",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r338",
      "r339",
      "r341",
      "r344",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r268",
      "r453"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRDExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r93",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r9",
      "r17",
      "r92",
      "r438"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsRestrictedCashDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsScheduleofCashCashEquivalentsandRestrictedCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r206",
      "r261",
      "r416",
      "r432",
      "r434"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r111",
      "r113",
      "r166",
      "r258",
      "r259",
      "r260",
      "r280",
      "r281",
      "r429",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r333",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from stock offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Gross proceeds received in private placement"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued in private placement (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares issued in private placement, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/AccruedExpensesAndCurrentPortionOfOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents, and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r227",
      "r254",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationClassifiedinStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r227",
      "r254",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based Compensation, Classified in Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Held-to-maturity Securities [Line Items]",
        "terseLabel": "Schedule of Held-to-maturity Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": {
     "auth_ref": [
      "r160",
      "r161",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity [Table]",
        "terseLabel": "Debt Securities, Held-to-maturity [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r38",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PropertyPlantandEquipmentDetails",
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r98",
      "r342",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r229",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r235",
      "r243",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Option-pricing Model Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r236",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Restricted stock awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares that may have been issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Option Activity, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at September 30, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Stock options exercised, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value, options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Balance, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r237",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at September 30, 2020 (in shares)",
        "periodStartLabel": "Balance at December 31, 2019 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Option Activity Under the 2017 Plan [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at September 30, 2020 (dollars per share)",
        "periodStartLabel": "Balance at December 31, 2019 (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Unvested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Unvested and expected to vest at September 30, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r226",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails",
      "http://www.kronosbio.com/role/StockBasedCompensationRestrictedStockDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r93",
      "r229",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r249",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationOptionpricingModelAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance, Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Unvested and expected to vest, Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value, options vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r19",
      "r399",
      "r400",
      "r413"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/InvestmentsBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies, Estimates and Judgments"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r94",
      "r96",
      "r114",
      "r115",
      "r116",
      "r118",
      "r120",
      "r126",
      "r127",
      "r128",
      "r165",
      "r200",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r51",
      "r102",
      "r103",
      "r104",
      "r106",
      "r111",
      "r113",
      "r125",
      "r166",
      "r200",
      "r206",
      "r258",
      "r259",
      "r260",
      "r280",
      "r281",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r125",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r50",
      "r200",
      "r201",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Shares issued upon conversion of convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r24",
      "r25",
      "r200",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r200",
      "r206",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r24",
      "r25",
      "r206",
      "r228",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon vesting and exercise of options and vesting of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r29",
      "r30",
      "r96",
      "r152",
      "r165",
      "r305"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Beginning balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholder's equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r206",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Forward stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r314",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r314",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r314",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r314",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails",
      "http://www.kronosbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r346",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/A2020NotesNarrativeDetails",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r14",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Convertible preferred stock, ending balance",
        "periodStartLabel": "Convertible preferred stock, beginning balance",
        "terseLabel": "Carrying Value",
        "verboseLabel": "Convertible preferred stock, $0.001 par value; 21,506,977 and 21,506,977 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 21,504,893 and 21,504,893 share issued and outstanding as of September, 2020 and December 31, 2019, respectively; $123,016 and $123,016 liquidation preference as of September 30, 2020 and December 31, 2019, respectively."
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnaudited",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
      "http://www.kronosbio.com/role/PreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockDetails",
      "http://www.kronosbio.com/role/PreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Liquidation Preference",
        "verboseLabel": "Convertible preferred stock, liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://www.kronosbio.com/role/PreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnauditedParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Preferred Stock Authorized",
        "verboseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://www.kronosbio.com/role/PreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Preferred Stock Issued",
        "verboseLabel": "Convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://www.kronosbio.com/role/PreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Convertible preferred stock, ending balance (in shares)",
        "periodStartLabel": "Convertible preferred stock, beginning balance (in shares)",
        "terseLabel": "Preferred Stock Outstanding",
        "verboseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited",
      "http://www.kronosbio.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
      "http://www.kronosbio.com/role/PreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofConvertiblePreferredStockandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r14",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/PreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "negatedTerseLabel": "Less: Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/LeasesScheduleofMaturitiesonLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r160",
      "r161",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r212",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r212",
      "r220",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/FairValueMeasurementsDetails",
      "http://www.kronosbio.com/role/InvestmentsFairValueandAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Change in accrued interest on available-for-sale securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/SignificantAccountingPoliciesEstimatesandJudgmentsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares of common stock, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.kronosbio.com/role/CondensedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.kronosbio.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121578510&loc=d3e41551-112718"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r454": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r455": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r456": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r457": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r458": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r459": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001741830-20-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001741830-20-000018-xbrl.zip
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MR;U&*3S<'7QX1 >^T/QH=+63/LKS5^&/_M-^N1GV4@^K:YWUI3.X<^[141'
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MQA"G]!&8T#YR[YG4,GAT#GG]\5(OJK=8=#]3^)*=5BB#$%&0Q<Z:K#2!61B
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MZHV'N<S%3PL36DIG,C,Y" @FH].>F*B7$9/FV&C?Y-[-Q4\)$PX5"S$;)FP
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MM8X"P2% 9,0P0PQ2>*EM"@QJS"?JO0JJ>3;#\I@5(U^#7% @!H$\6 '&"7)
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M31#;2/ (#!J5U)H,(+"@RJX&.@-BSD+R=+:K<1TQ4QS:BSII+])@=X@'>YV
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MA2TA!SV"RW!FFU<CT^3P9:?8993X/TNY5DJ:AI)Z$QX$45PG$QD$RV2FI*!
M2V(!M5%1:NUDH23:E4RW*&*9]R;,$P7O(S@0%;QS!^_8GPB)A:2L@)!T*%E/
M @XI@4 -\ZA(XLX6\%(ZL_??OG1#"[V(W:.AW9^'PW#VQ+=N_%[=^UT50GH$
M;Z)2S[VIYW1RPX6)*(U3X)5Q@$D[<,$Q$ PU\?E_.=196V>4=;7A<XIE[@R'
M)<I+/#F(/X+/42$^ \0GLA6NV(1BZ7=,,\1% )OG,4CM:50DB(#9NS"\R\G2
M('P5"N%NAN"_C@X_SF>#8X4#GD?P+XH=:L+T_A2T<ZFLPQHIK11 DI%E?\-
M62_ &1HM$]R&)-?6L:O4S/G2FIUH&U@?P5.H8)T9K&-_03@C(E(#D44+R#&"
MYMQ"),H8]#9DWFW *EF+P+JZV8@_^D?'^29.F[V,4L)Z7"9XMW,8A[7P80&[
M&"-K_+%O#X<;A^'5N4'RZY$4>?Q7M(/XNCS!3GH[B$T8LU'.N&YX?W)PLF^'
M,;R,Q_W\!YJ3T?F3&P='>9B_-]]6YIJ&N2;+**(Q*GCJ@)&4(YV06(YTT(.-
M(4^M8$6TI7J4Y$B'MFA?MI91+(N?4<'?-O"/W1:;J$%'$00K19O(!6CK,OB#
MY2B<ML269@)=Q=J$_=5-9)PUW3C\V-DOD.@T@P%'"4[R-[4(8T'NRX55;N*I
M2CY3D$_^FX5X1M['Q@?!'0V>)Y 8'" -&HRS)']+6:)(L^^!:^O,=+D0+0J;
M:HYCP;Y'A><#PO/T IXZH354.+#>"4"C$SB7$F@:9 R,>&Y\D:&=>0>DIC3N
M@*S7<3#L]WQVA9N#N36-\>A^P-@"Y1#9]M&AK]NL]^"85V,78-=_^R"4\B%0
M"=$1"L@I 8,JOS),,>])4*%44W0)F_GP:LT_M VU\\D_?(_]HY A60'[4( ]
MO0 L_<"XCM2*"#YY5S*&'@RW^4O4+$8:K7%T;;UI0\G^T2+(KG#:H#FL<7@Q
MOVNJ8&&I@G&%=Z6;>]+-YJ44@;#)YR^@F3#9)XBE$"O["<ED"E)*"U2D9"@9
M42V*0FJ&H%T9@HK*>:!RG!GPPH7\G\IK/LN>.MH VGH-D65+1:]U-'%M/5NK
M19A<W<S Z.C%S6O^P]9@MV0 [BZ=,_53+SF#/MJADLJF4['IUJ2/X]!*GKP!
MYK@$5 I!.\U "6YH"$E85&OK3+*N$//*@2S+>9+*7T^:OQ[MQ$SEKVGY:^P-
M&J:DY4&#]S3':,Q+<%PGD#Z36D)/C$JEA(QUI5X:_EJ%;-'-LM'_ZEG7VV^:
M]74+VIH[*HKWQ_V88K^T]QL,C_SGIG:V>;5WM)\'>_"?&6*IYWNWE]!.)^C,
MLVG"T4GYTU<MUR+9Z;O>Y>K&%^?:SOOCB5,%GI=8\&?#^Z8K1N?8GI:N%577
M>04551\C\CN;1W^,IE$]='P?3^K=I6RW%TH;84!$FR/!J#RX8"R@DY9Z:Y+1
MI!PC0FQ3S4T5<JZT\Y@!6Z6=N=#.1*$?X2)H&2&A5J.CQCJB Q6]LX*(:&0L
M6DJ"M$D__@E(-^>IWC^)8VG&6O2W"">GF& B:*Z$<Q_"\9<RWIY1:IB#*(,
ME$Q#_HX#(X&*O&Y8RT,A'*5GUHJO-7]M ^V\=O4K,N>&S+$K$(BP@FN$R% #
M$D[ &I^ -D6ZWB?*]=JZIC,KHK:OL*_-CL"+B33MX=$P7N1NNAT[["3;ZW>^
ME/XELV1F?Y"(7$*6>8R^5F.C;!>;U(!D+O[!SLL_V0<>&-*8%$1;!%6\I#DD
M\45:)47%'94C>5?%NP:OZQ_- P:U&.\Q2_4KEAYD16^PQ$KK!:H$B$@88,IK
MNLXD",)RPV(B+F-J;@7[-<"_S];:<5&SR/@[2IVC*QH $[MN-?Q?\-G_\UCC
MM/+2?7CIXV0.@/F0DG42N,_+/+* 8)G1(#4F%Q,+CC;=%SBI.8"50^[#G/VO
M\)P5GN-$ %)$EOT&<*;L"93.CH8D#8%;JAF31*>TML[TS,(<-1$PJ\/0G/Z;
MU4U8X<CEL<[]U4SDC 3T>=(_\ FMT#P 5T9D BKJ(\)88$0+M-1Q1TM5?)?R
M-ITRJLF&=OD'%9?SP>78,1 AF>@U 43C 9UG8'P0D$(46!K11Q?7UG6;6J:M
M;FGNY:Y+<TH5/+F^+(_1&J%RT$P<].FR<*!")Z5(X'E*@#+2<O[8@*%1)YZ*
M$$FI']"\*\F\NLDNRXFYBO0%]U6H2)\9Z6-O0P:=F"8.N$4.R(D!2[V"1$T(
M405G-"]1@#0S1P'U9-FL0!R+:\Q]%V.%8YW%[6)4,91[4M2K26=$>JVT*\=?
M#1K *#589;-'XI,6G.1WJ6M4C%'73DTKA]X'WLFH$+T_1,=>1-*8HF,!%/?9
MB[#.@A'"@"?1!L6Y<-R4CJTS=SFH28O[R!76$H<V[5U4RKDGY5P2+C3:9+/X
M!"P2!1A4 $>C R*48A(S$?GB%70UMJFU2BUO:)=34*$Y-VB.O8&\X$LK2 1B
M% -4WH&3(OOO@G!!G&81^=KZ[&U5VU?9T$)G8+2#,:?TP)/+9S[NSD4EG:E(
MYY+(GW'2!QX3:"4"()<>K% >:"#.)1*(\*2$(*)KF)E3&-*:+8LYYA">',0?
M=\NB0GQ:B$_N53@JK&3 74! 23/$>:3@4^1>HD;'97'YC9Y7$^CV[54L31+B
MQ='!06_4]KP1NBN8RW<<#WU&0>=OY1!2A_*_SZ)S=B?KG'/APZSYWP:]YX>]
M_?]_;=@_B=?/7%T,P<9A>#$Y !7\=P#_G^/U_=/6Z?;'#T&3A$%:L%$:0$==
M7NU3!&93E#$H0HM\TPVG%1<D@/= $W2:%:M.T(>=H*>7)J@-CIG$&!AF/:"V
M#FS@&B(1SE,B(V/^U@GZV#%HZ'TYO_;9):#\_G.JSR_2.PQY;CP'TTS0Q9S&
MOR*:VNW\QX^0\D?LO]FS_3@7'V]S^[>KB-F-!\='?=L_+5VVAZ=_V/Y._\VP
M],_^=Y$'&/_Y,R^/5!S= 4=OAULOSG#TPI#W_W>/^(-_']J_S,G.P>O]K9=O
M^=8G_VWG][??,^:^;K'?]K:___/@_:>-_$RO/[W[]/%;&:W_^_W5UYW=S_D9
M7K'\^YBO_^V#D\)8EA0(S&#$% 6XX!5(I?+BKIS1,OV8?&^94O?+#-0IM?Q3
M*KG 50H!5$ +2+,78E*>88IPG0@::T586R?/"+F^\W#M!YUC>R8M\H_.K;-P
M4"; 8'X3\,Z!ZY6YV4S$P<;)<.^HG^D\U#G9BCGY)_E@$JID70"#L?&,->@8
M$J1H29X2WE$4)?M5) :[1EVOY6MBM.DFX R+:IV *S4!W_(/WEHOT&0J1%GV
M?*P&2TT$ZP2C241"B?OQ!!S-L8Z],&['#LKQRS?Q>!@/7.QW..EV"J<U<_5E
M]&<_I>6GU'0[^>/',5_M2]P_71HVW1P,3NI$;LE$?B<^D)19+.:)'*,,@"0E
ML#S83*?,4Q>Y8"3\P&%LU^3:.1D.AADM.;:K,ZPM,XQS%I1$"H0S6P[7,+"2
M6K"8\BJ:?<N@PAE58E>;ZTKD2[UX5[YKT6S\^/V#TSP'-,D!HPX!3?!@@RD5
M&U$:KZRR>0I,R7<+FUR5[UHXP[Q4.B9%(/-9GF%*&[ DYA4U19X$8TB-F9+O
MFEG7Z354TI#?T=CP5]W&:7S&'^86'[\TY,H<_U<O_Q-LN;$_FJQH//2Q;BBW
M8IY_SC&X2S:BB$"QG-Z7,7N.PC+PR>I,?%'P4O:66:]+Z'6=_V:"3C/_'J%N
MH<Z_99E_GS;H!RL83Y9*X-;GR,4E"5HC@[S"6T+SO$CA1_-O?VS=LTV78MZ9
M@O!G%[O[H?>E'FE:W,KQPO;[IWD8-PY*9Y>-X;#?<R?#(@"[>_2'K?7.]X'Q
MA)(258X1;R!2H<OI)Y.!%RG03/PR@R)$] 5XK&M(U5):.3@__D)<X3Q_.(_+
M##U1EF%B8%-IMRNTANS7*9 2"9=2"*YX&^&\NK6$;\9-<O]ST(D-!FJ'U(>N
M V)T\75 !P='AZTH_!G=2C,1:X7&7#C7_R 2^E/L[&[EYRECLHGO/OWY?6?W
M?;ZGMW3[TUX>LTVZO?N1;Q_\\_/U2'SCZP=+HG,J1^*:$P_(& >=_6P04O(4
M":I(R&*+?NIT6J+IY(C3V@4*1'$"F(P IYP JQ0/D3IN,-ZCX*?;PBV;B7E9
M:RU:,1\W^?;+_/K[YZ_;GS[SK9>?/Y"$+K#BE5HF(+\.X QAH#*Q:2*-B4ZO
MK2/IYB6Y_'\>VX6/L8-=YUZKYQ[;V7V78Z/DN \&9)*9"ATQ8(S7H$F>"8D3
MFV?'C^?>K&4^K:_RN3:-ZX[W J?PUFD>0YK'$/,SEK'\H"CQ*F$$X5V>PC$O
MY!JU <Z5,,XQ'X5N8X'/M7E5-[O;-[DTC27<H""HQCRYH@"CN ;%H_7)<J*T
M7UN77::QR]GU79AE*>VI)-?>>9CO[T,F'4S4(TA1!-FTXGF=)@&2R',@Z231
M8ANK>BK)+<'D\LQ(7=H74RIY:5/ (,\*!RRY&&APR<@<#XNNE*3+S5UBXC.G
M\&X%/74+>I%;T+?BM4E>U7VG:3$ZWD;.X!%<>P/)Z%1B*PLYM'+@78889]'Q
M)++OT*(=I[J!W"HUNPK&6<$XT9Y/,"H=HR"IR8X\40RL2AI,B%&QI/-/5+O
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M0(H"--$<+,>@5$PF6ED:G&D^LQAR17#;$/R8X7I%\%P1/ [839"":\N!)ZH
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M6#:5.YQV.XQ0_<1;-$]9"I!T-"(99P-!@JC1!\.<-XI3I8G\L%F&E#).)RL
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MPB-('37AQ 1"<]2IN^(&P=NIU8HJ=MN#W3DDEBIV'QN[ES-&(2F?LFD@4.T
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M/\]&F;?L^I4V%+)*>:R7>&D_FQJ'[*Y37,AS;G,!V_NLP4(_7RY@V.8"MKF
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M;P[-W_7J%Z%4LS_\6#()PK&N&NK0<ZN2GX^HT5K$B299;"CA7!HBA,+N&JG
M"I@L6O3R21;(1&59F$6,4RE%*+2,9,(M:&S4W U>^'D9]]U\#'B^G58^5:<(
MD JJQ!40@,ME<<EV?2<9L.&REYS3@JM<<'CF-NJBT+V*("$H)A=GMC#J[]Y
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MJ$!2I]G*FEA4FX"JQ.WQZG^V%E>O?AXMGO'JA4K*4).)L!J]>AXD,6 B6F<
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M)(5":P_/GW2V]PL4[+L/J>-3.NX<#SHC- O]C(S]^+1SV;>L<S@8C0JR'/\
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MJH1+3*L*O-9#GPO172:9C"HYG9V")+0W%#+52/4-F@CG;G[HLRKH(A5T)IP
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M&GF@EFUWSEQHO1>WJ EYS.C] 'SL>NWUBMIW0>V7TV3KXUM#)5B.?J V.1!
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M6+0^68:5]J_>R";5O,GH':[3%7BPBG'&6MD796'F_[<O-L];1WO[H'P\@>&
MI,@IWEHQ9 P.* E8AZ23Y):O9@RY5O8[+;"G1FH*AB$A$A:8&XI@91RBR<5
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M4?'DM-L_CQ$VU),BOC+=GR_OHLW"^@*Q'HZ[8'^-EK?RC4:>X_@M#GQGF,^
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M.WKE,4F-)2^!);.RM)_9/J9>F%P0Q4B#$;<Q(FT 4!CC1CI#A,: )7Q#7;Y
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MFYB(IF3DL9AU VX\E[/S3*QIZZ;Z*W0?:_B8"S5UB.-QJC\+<23G@F:)HNC
M0N%"6F2)Y(@Y0;RGWBJ)G[(@^S,HXDJV\43'7:ML3+WO#U+L/-2<6K=#KE]^
M8'NJ6LDQ#&,"N#6HW@M4Y^M^Y7"2EE(&11'SPB%NB4-.4Y$KGA@1%26.@4%%
MB&H:>MF<NI114(>-:TOJX9;4%=I=FU-/J?GSL9](N2(A,A1"RD=&3B!+K408
M6Z\-Y3A96O!!7[X+ORJL5RO9QD\0G)IHX<\1GEII>RK?TM@>#L<Q;!6W:DO4
M+%!V.']O9[ID-6C>SP<]GP\_41:#5A$CJ4E$7"J#'-$>.<MB=-+H*#,;$I9-
M+"X'S.]N+=5QI]I:NM5:FJAT;2L]C]K/0D^,1:TD(R@QEA!GX"09J36B.K$0
MJ%/"Z)Q=@R][2'7HZ?E#3RMH(<UE6D\O1C8F=R(?$X6Z6]+]2MM3]S.G*%5*
M&N9D<IY+@ZV$79=2\%RH<L32G)SPO:-2=1+V(]'V8M[(2I[;8*5%W#)P3+V@
M2"=%D--<8YPX#SR]>B.:E*BFUI>]TX?E)=SY-LLJIV<_ AU6!#COG8AUQR&O
M%1!>;X0^# WKE.ZU@<&9T2F4B89XB;1C&'Q-:Y$AS"+*'*%!!ZN3RUR5YM%9
M#NN$@/=IXT$7%%<,')Z.\Z5. U]K<-A;3 ,/045L="Z)GNM6))Z0$]:@P 4S
M.IBDO<IIX(RO0AIX;9?\*';)D]@C=>KX>@+0_/&A=(DK302*7D?$M?5(PZ(C
MPI5R(>3K2.;5&ZF;=$T,E"<ZMUM![*IL\H)"Z^D"4M7PYQ:%P<R'_C@_IHY(
M?=^(U-R2UQ&IA[AB>#XBI813@D:*2"[8R\'V1<8J@#X:I.,Z2"$]8)UI&G(Y
M^?1A*>=W5*OO?"KXG."P(N!Y=\/OGF->*R!<^8C4'.#5$:DGA<%91(J 7:<$
M$RCHHA94,LABYU$P,E$C5/2JJ.7S>&*4M0+!^[1Q]Q&M,#RL74SJ>G"X+B9%
M:GBX SSXQ9@4EDXDXQ-R%H-+R')B%%4&F1"Y5,HK'^RK-WJ#LR>)2=6V26V;
M?-^HU-- TF)4BM1AJ?MBT#0L=7"Q'Q2U.*>QNQC 5<.YE+.T$1$;:/0Q*LM"
M9G##YM&) R]CI/RX.5*?>U7]L5S:)U:EDW,-C/SVTV=.U=&H[Q:-*@ML;?;"
MI$#V;C^_5:=-/=([(_-!*DVQ< $,+Y7C4]Q3@S2\AQ))BB3+G",RITT1KIKF
MBDL]:\\#5W-1K:/IMMIAI=N1JXXV/2F>S27=8V&$ _<15EXC3KQ UH(E)RW7
M*3C*E15%_I/X\:#LQ[R;O'9QHWMK?QU.>HS^'RR&DZBWD2OJ4,0I('@%3IV(
M&C%-J/4A"<5)D>(D5R'%J;8N5M&Z6+]TI=LQ9UK<I4YG>AS8S,>-E$Q$&"F0
M3"'7P4X1698XRN0HP=/(0\ZVEJI)5LK>**)#?R\*W;V9JX$\CX6/*3%X;=#K
MV32ZJ#V8J]O;:0FCSK2$45'0OJ@V.*E@WY^I1;,19S'59N.FV-)9',0&3*D?
M=^VHK$J82QJ&3DKP2;ZWY^+H+,9>\7:<5-DZS39]?GI^=]*#_(#B6\,1P$%N
M+=G.H.SJY+L9"6SO_/_^'TV)^L<0,.GDI)\GN>^/F_GI(8[ 2H!Y" UW7OSD
MMSY 0O[]5F< G>\/ALVJT&+QL%Z8O)Q5PVZ<%K> IQ5N7P2!B_5J-/**+:W3
M_#)-IC!D'"VZ/3H<Q'M6_FY<-;#O)*%G=GAE=Y[WJ?]UCZW.4,N9DL[C1#G#
MX#-%ZK"0/O&D@G:57:VNN:Z.Q,MGJ\UNLN_V1[9[S?8FUW1[>WBQV6W6WCI@
M[8OCLYVM=Z1]\6$?%C9)*QRB0J5L&BND&6;()JY\,#SYF$\Y-BYO50T0QFY1
MTG6%M D4_#ZBS07!+D@:*.8\!>(4C5)8)PD)W =>54%0516$6K371;3!TMN/
ML)S,Y1),^3H+)S(A< ,-PL9C,,22U3AF6BIZK6@WY_;$[GFSV#]6&ZL?22U2
M"_2J"G1[Z]T^(!6LF,(H$"40]\HAP[5! 0 ;"YI<DN;5&[IQ.7-XAM7W!$@&
M+@M+WAG8([B+S$8:E4N*<*ZME6*I3$PM3VLC3[M[^YX *+A$D,0"Y$E0@K2Q
MN>R\HCAPJDG"&2#Y]?*T0EO_Q!_HP2?W= <647[.A9KY2?;TM N^<T[("-F5
MA+<GKLA&X;2 'YA-^5Z_D<:9=[(QLM_ ^>O%U!G! TKW$-S&2XY,<^(T5KY=
MX]#"@[T?GU0^92^.X%=Q .K0.VAT^T,0\:IG-XWLY3>J2270JC-5.="I%UD&
M%6X*(CQUL*]HYW4'4*#C%_J_7.JX['_!<H<*>&G,0U!C<01/?02QA(+^,(9Q
M-^ZD=R>GW?YYC)_BX*^.C]? 8[?;]\6KG?0Q^OY!#Z8@E/CWMC\<#7>A<[_!
M=XY_.L![!_TYOF@???[6VO47K:,/>)]0PX4%&U!@FD\",4:.*XUT"%0Q*K,[
M\*H188\XA249#6##>%S8ZWD5KA38XLPI1X)F IOC5+UAB4B^:X?#3NK =SJ]
M*X-(PQ'@3,$35T9:"JB91*1RNX-X",WEP%!&GZ7(2_[2 S#7YG9 >,^&KQOW
M0H@B1#G=:\J4.9CFKCT=QM>3%_\(G>%IUYZ_[O2*:2M^M!P '?5/_W'6":/#
M'/[?P.410)4@5[5??;Q1?+04CBT_XV:#&W'MQWB#7/O93<T2O*$Q?U"S-W_&
MZLZN6V?UG9I][*WC:S,'S*62[M^E&KM>@L1+>S@N _YWB 8_1?7ZM9J5]AWP
M^3Z5Z^^3;?(0ZIQ5F;<;,X7O,\:[3U2UURVUL^:SF(L%/U[E?HZYJB7N&23N
ML7A&R;UN9*[RC%U#35_X!OTQ-!&&O]YG[M;XWLC'.(QVX \+KR3$OV*W?YK]
MH(G_-'Q4AE.=NK6:J5O<XR"]%]CIR(WUEOJHB>0FLI@<MK>=9[/ED$T5@XGA
MZA#-NU*8?I"LJM.CKT<'W_:./O"=K6X'VL8[N^^[.[__>=(Z^NVPM=OB>T>;
MM+UU(-J?EK*J3MHG.ULPCJT##L^!<7P0K2^?^=<O>^>MW]]!OPX[\*R<I47^
M<]&:JRYU3/:#5]1895 B0B*N>4)&:8EDQ")IZIGT"7"?U[=1:M!91= )0H@D
M%>'4.JYHR"=J-!@#?R0/FMZ6:5"#S@N!SOD<Z%BL+)4T(.L(0]PPBIP6#ADA
M.3.96MSDO/$:<FK(64'(\4Y2DZ@@021.N=/>,*D)=]9YSY.\+1>DAIR7@9SV
MO)WC7,0ARHA$PF#G!($!<AQ#PO@@8 W!0(VOW@C^5$R8->C4H/.4H&.<DD$1
M0W$$.\<91X4-G!J '96XP[<E#-6@\T*@<[[@7!F/A>&(LH 1QYX@*_+E%5A'
MER@UL'PYJ+9"F//C<NS^'GMQ8+M%3,J&DTZO,QSE _F_XK5AJ?NP[*X_><EE
MT"')2@M0P[0TG'INI>(A6>-!<+77=XGHW#E+L<:C9\"C#XO!'B6LYX(+I+BP
M&84,LC%G)T:B>.*,<F\*ZB5\N33FPZB75I$$\B=59C <L!?<4H$5UY&ZH# -
MR6MX-W@KZDC)BFCLO 7!"-,^6H]"( 1QH0(R4BGD+7&P<LI:F:\17<XDKM5U
MS=751PDK;&+B@-B**X,3"])* K"=J,5WB#+4>^_WU>2% (1,.$1C*(*_/6@R
M\\AR3Q&V#"OC(O8Q5ZAM$O-4W,RU,J^.,@N"/=C.7 O',37.\123#YR%H*RJ
MO?=5T=@%[YTP"Y"KD3(RDR4+CEQ@"M26!!N-B(KS7$I^A=3UI5-*BKSR%]$X
MDG. BXMG)2G##=GYBUGO]RQ=5"5M+?/$_KSET1XW(6N.VX^E:*B-L.\,Z9\7
M R R$S'8:)'75@*D>XXTB#L88=0F[:U/3&8CC(I'&V%/J$4K?GY4(V>-G$_.
M %);O"\$CPMY.413 PL'%F^R (_!()V]5:&=<-BEQ$Q.!JRQL<;&&AL?CHV/
M)9.IK<KO#IL+H;V8A# A,,0=Y8B3&)$-G*. HU%44!YX<:RFV*/C]#5RULCY
M$R/G8VF3:JORA>!QWJIT!JQ)P@FRCF$$&QZ\,I&B!(M))#."BO#JC7RJ+*CO
MB8WW(_N]=%WQB=3N;HRP=R<'^;YD+)LW,3(U&Z,B)CSN#:8D/8M!8=\?+O!$
M98*5\:2N55&OJ0HEVTQY-BRH7>[#Y/9 PO+[$+C=B;"HW:\&55"W#8M0^?SG
MF;2HW1_MQ=&,SJC@N:E8WFH&MY+!C>WL?MX/QAN+D\\TXP!97.:*F9G'%3O+
MI30:ZVS1\8W+Z>(SCLNSPXX_;'2&"^S6+O-!3R6U#VC2L(VSJD9%PY9%*BJ>
MZ"SW-[%B<1&=<CY*(PP7(CEA7% @?QZ$43CZF,(<SR9S)876^_Z@>BM_;UV+
M;SR1R/'65FL?3!E/):-(4@=RIPA!1L&FR4'N"%=1,\ES,1UQJ31K(Z_?<'WH
MX-[90?>\\6Y*.%X!T+KL1[MSE(*V(-IJ>+ );*>7];4S GVO=*<D^LKO@-H.
MQ]V1S51@  )3OOH):>'! #Z"J0!K)I8<8&"^JL8?71C4*>C+8$*,#P;*1D'E
M7E8:G-_88C&M,Q[WXIAT1H(_@-^,W1$ T6077*8KRP1?F0EQ$$_' W\(RMXH
M3)[&^!2VP)*[L=Q3,TEC,<;B4C_T;EBB1*/?NX8:/Q>+S)]TXQ"^.V7HA_:A
MS6YC^L"*P']04O3#RA_'44567[4PZIP4+)&S7FXTMJ%+@V+FREEJ%M\\['?A
MO7+H@_B_8^A+,5&G@_Y?G1 ++.WTQGFJJNXO3DS)/[DTKYG]'Q9ELL2YJ[/%
MS?VR"Q.?X;_7'Q7?@6<.IIN S:N1"R-4">A5ZYD"SGH/9FU!2@E#/.T/X[ Y
M*6(PB/"-6/3RM&1JS=M)A#:F=0FJK@VF=')+U1$ZP_D="*P=V^AVK.MT.Z,\
MY/?7]6!J-%T2M%(4\S0O#;4S'(ZK"@]S92"6QI)_ R^[Y18)_;GF5Q7)7NY;
ML3SYO46&/9^W([#.L[%_"DW&P6"J![FUXE4E%?\-QECJ^ Y(-PRT6S9=6H!Y
MF!M+YG&&W$I>"A58 *@*'@0'_(#)*K:TUX5FPKK,F/#^MLAY6.$9GOW$.G!'
MQJ/K?W(-$E[A0KSY'S?X^YO'0VK=SDI/]#,XCW?;!"E=TH^YOP\',_J? _"N
M!M$>(YN@BZ]M]\R>#U_]?7%L,+"J<9U]U\=+_R/GP-S&A51,P;\^[K1W/C5^
MV]YI-K;;;Z^WO[YK+\'\CH7-\;:?92[C]7O8<GL>&FY\FL+G]Q<\\T!K\I?/
M/3L.'=@[?KU*))=PN_0S2,ZFEHXQ91QW7#OO" 8#W'!.HC#BU<PVV,RNDC<<
M>Z^)DDG#]ZES2O! .26,&"O=2I/99ALFQ&*3&<Z,A;Q;=[+W!2;L>6$0#$+)
M9.O'L&V"77':'TR,O7[>K:=60J<R;,MWP1&9_&+^"U/6\-G'58.E_;K06&&@
MS?'I@KC.%V JGG9J.P'E[MG3+!L3<N]+QFI!4SO<:&R-!]E">& EH^8#Z7>;
MC?O5!G]D@MG=BH0?#\"X>'05@&SU39RV3]58UKQX[L/]]]8YC(/ ./C.;O[-
M]CZ.&AM/:,[J3XA+HY'%42 28(&=PYIETG\M<-.PR[?K[BLWCTROJ>5F->3F
M8GL_!H.M<P$1)BCBA BD+4B0EXH;KP*L9\JG(TU#+Y\>WU=L'IEY4(O-:HC-
MUO&^"\9Z23 B5 #<>!:1]30@Q:2-6M"\GCGG0 C29/)RF+HJNG0OZ7GDZ6LM
M/2LA/>VCO7WM8G#):^05]3ECQ2+XIT(\,F>M9F :NVM!9Q+PN4/IS+*.YU+
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MS/9VMR^^;KT[VX.^MHZ.Q7\N/DQ+1;<V]R-FE"?&4&(V(1X$1HX:@UST@<N
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M7$EKYW?PL?[='PYW>F\+'-_N3:6OM']F]GXM@J4(GK>WWNUCGBOW"H-2B@E
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MW&1:0$4\XE%AY(0B*"1E/552T>CJL$,5.?V?PHSRFIF?<B,.'POAS4LD>EJ
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MD[;6/_YHT@V^LPWC?M\DK?6_.[N':Z1YL<&GR(TNUG[L,8Z=I2$B$C1%W/B
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M#_"[I-Y;8G-VB](U=5&-DC5*+A%U40V%]X;"J<B1]IHY'20RSN=\&V*1)BX
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MRP*P7D@KJGK=SV5@E5(,8,A;:4)!/D>?R1S:\3+@AW\Y-0'';GL_'\.WMM?
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M7D)Z?/F+T.-_RA7(,7RP_9/S[4NRM,'24>;_:*WOCY17M.C.CYVC3^WF-OB
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M==W>:UR?P?Y;ICK4 Z9?]M^^<7$49_[6T5RN"4376-*/6?8=3^/#P?7;HU_
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M*VK*#3^5=TJE]9B$W2TYOVYD0O^Q?3F>2#;_FMUA0;Q?US9RGVDS45>=CO(
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M<IY3"]$XH]&/+,Q/LH-I_E=SS21^N?_F6'7NJRBI%_N,M05+R-IV1+"^+@
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M]4! 3C- M$*G4\[4</UBFG'GK;;& 2NB@1Z_:92O84X_ABPB?DPI7=+<!M3
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M((!:,3RVLV*W-9O:FC%"TEM*(_S:R<!831AS-BM$/[;(TE0E7/'=;<6&3HG
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M#=QEE1%0,U76F\8V*Q*\>CN:P#; ;:W92Q)3TMQ66E^[^IW=!$F)U1UGODS
MQ;T:+2S,I\Q]P>UG*[R"J#K,R:S/AXY"K19=Z;21*5W2*!"^.VYW8T1Z>3:>
M5?Z2\[=47^F#S$5PIDVOW)).R-5OB;EV^<%->=G2JD(.4HV?8:T"'JT]) KM
MB!LB91*J<,RDC2G9C+IFT@(-4>"IYX"R9@%+22-33+I?NJT0,%=PHQ0'W6-N
M75W!!++TMI.5#45DZL?=7%Z7G]_M*71CB/[ D97:I20Y2ZXJ"A4F2(2:Q*DJ
M$]YCX5FD_":#AV!7N;W-U!K;7=AS4SNK\PK-#D$ODV2FDZM'TA@N.E%8&PK8
MKV(D/> EXH+BQC;+:O(VUD!&GP4DQ']@3S+X?X-]) O+(A\QF&,Z%0K^<;G4
M+!49K>[&"P:I'54906K+!H9Q1O98OA?E,49>7(-5:/UFWNNXIWIBR5=Y43&(
MRQP"AT_ / \C &--3A#H]EJA)I\# 14]^J:3]XU94^R%P)8H:J<95;G3X0\]
M<SP)U M3*S*L2)((AZL4:\@ BV&0$.-B*5THH5T:]S$V6\QG,FBF="8M^50K
M.$A7BJRGX[I-V^2FH6<!?^"")3B+XUD!CD= O5(IZ8AA6NR32B:+N#V:FA,K
MI<J8<!5X*439M%P>-EIZ*KDX Z&T3"K$@?9AG$KW-H(C)=1=RT"*T'LR<!$.
M?>3!E&+17*I6>)<7-.B_?CIG/$B9JZ#TSC]]I%]_^N?%7H!!:ZK%++(DAH=4
M$TW^P!J(>&3#/)ZR_8;^621=3X2$M!/*30IEP. .DC6P9=$_ H/E-@#MH&/S
MZ#S[# '3%@NK$.<&H:"[J?=8G)>)1Z8^P_=T@IQYJN+"H)8TV[ C@37N6H,B
M!@<-5%TIO*1MQI%+7--)SF,8V+J*6/^L(R(:&<;:Y&X,-]"=LA0OU-9/QPV=
MJB'CL-4]+/+'DE@5/V MH\1-B HK]6ZP 3<&=PA>24-<8.<[N4$?2=&X_"EP
M&FZVU28U@J*Z0ZWNXT[M=KD==BG,:X)\IX$UOXR.2HB]DL._?/JRS'#N@"@O
MY#E;M]!/!T0Y>WY E.[R63VZ4XOVZC*4H'9UZ'"&7%4@!2@"#;CR0T,PDF3\
M+:4DT75I3 ]I3ZL-V9KQ0R@1XZGAQ11/AE5>2$\]4ZO:P&^SI4THD3PV%DX.
M-U66MR.UZ79*P)C+<L>V9]J\SA[:E$AJRLP([ MN'+\,+W&/D>*(20?M?43%
MX11/.-R5[9AW89P4GDLIU'Z MM@FPL&E&_?)J4;2$#)8*X*O8'$2F;"2.Q&J
M(6K!S58[$R!A9*$JA(5X"<,Z43L0S0U^G+/WR]J!Z.1<#1AX#X;&01?BR#46
M<94KH,;:WLYQ6V08;*5+1= (8O1;V(+!N/6\-LY[B^>Q$ N-9] E_9QQ^*&$
M@=.[UGFY+0.U%?":AE7_+3*]NG8*VK9R![+67<F#N%"&.0.AK?0L#%X@PM3T
MV,,X!%%44K8)A!IO=%AZNH(5 DA2PD4ZF^;F6^!W-WDPF9-KOK$%+;-#<#I;
MUE]#?2XIPD<K)4U5Z)@H#A.&;6SD<U0!"5"0[HB[CFD&AV6D^.;BE5Z%?$#F
MT"2:A=841=?IW5UTRH+.2SA)W;(B57>M9Y#3,JV%O&@[+(;.U:!AK,T$J=?^
MI.5:T6]C[ZGU@)N7Q1;.DH::<ZS:>ABC:<_VO _,8X^AY7O'XN;T,^STT<2_
MV[YV;:4[WGD89L0%AY9XK36A;<"Q7$4LDE*1ESIE2YW;7U[#ZJ3ER7A_Z)RI
MP2[S_H;C#)$)ELJ? O$8!(V([87A3)98S<*9"#AJVX=KQF0.0,V/P<#T.?B+
MUTR-M <NMTG!'5!*A"6:[>,2X84YQ[*UW04Y2&A129L+=J(4K&4VD8Z$AFN+
M)8JL+[XFD[EN&0Z4W;'PYM;;H+-_(UPL=V:AENX&@"XJQ<4CNF*AA5WNYH;8
M"CU/DYU'7^!!+<N".2 64C* F*Y'(.49S </#2'[AZ5>#/I%S9_#[(MIPH>Z
M$<9<C..I*+P$(XPA&P;.P:RYE0B=CT-L[X5G)\^17&YB^\'5@KEK7I.466Z3
M(O?V)+M[E:MS-5WL7J:.+;3X7MVE:Q6+%[#OJL_=5U%:*.M?ZEME#%/:PT5V
M$+Q,]#/H]UVFGWN(? A5:5HD"X4@WRU_4+,).'2O!L<'O3/SR#BE*A'!TA46
MAGOYY<J!3,/'KL"?0. MOHNTU! V&JUJU$V^P$H,U%Y'QJV"QSO>%]M"TD9:
M^$ /PN]#C8T>U@QJ/*&5+CTQ>K)!_ 0?@G$=NNP+K@'> ED5BP,\E9C.(NN:
M+V.T<P9_/FCR,,#7" +?EG2]O,!?8\:TWI3Q\Y=/?6]2E0YIZ/+!\-O[?QZT
MO%W0[H9+B=*TNF4-Z%1F&',3M#WOK]F=*>BBD@;>)**%M?U'ZAM6.Y4P+M%)
M15%-IEHQ2E$2][&AT@OO+L_0'K>4HGAC$^<E;72<A]6D*%FMX7==1Q.Y=JN)
MU45U0/"(:#:78H!;[^V"T,!T\4[@HI9KUW[=7-E#6\-7'^>\I^S*%QDL3,^Q
M\,9DXP_TF?#!.K595O8M^V0-QYRA?8BJ< [EWB':-YE,A^MI"A)$-Q#Q &O*
MWT#ZH1:/I#-:3_)]6J0#J#_IUJ^@H;L=VN .P6J(#6 *S@C3NJ *#G:!ZM.Z
M/?CII\38^?[B@,L2#L$%I7O+TET=;.*%/&?K%OK)8!-'^QULXL7I7U*QON;V
M8!8&ZMN.:G>^/'AQGDE'TTW)5EM+Y@Y?\,CVBX$EPE)R"(_1X5PYKR]"W?:U
M/5U8 \AV^[7AL^90H<P'(-VTE@T&/#2=XM^?\*GS+^IRV/G442<'&Y>#9K9*
M1^X$N0 69+EG-T(7I^+Y9.-V06WL''.K6[W3[>)F=M'D>KB4S=<G1ZA)&CTF
MEB#4?=T<;/DI77(PNQOU,30T>)G3("<=.XH3K5RQ'1<U'$6E'-#EZ]( ^!:D
M9+E4Z0>&DCF/04)5W85L*;Z,:PU&2N>;6SZZIS/O81+$DX(0@IU0;$@HN#A<
M+"T;(+(9UF;NU5[;];_,8\ON+=;##[19T7/O7 IC=&I2:N/)D GN-LO=)"RJ
M,TGE;RX%^GB=UN[+C2XD0Y+TB,L=THH4:LTB-SM3M/'K9TOXLGK>>3IK&<X>
M)LU=,B1,.,'"JYQA#!/30M%4[\:Y%P6SO3+;BY#'S[$>+0G.?9 ( Y!O\%>H
MU=MOU!#*.].^#0_VNQJ X%T]VHOS_R*3O3"3W26L(Q,8&KXJFR\?@YN@&:2Q
M86,=Y&6X_BW_T3Q5IJ5N)'S,L(H326<Z3/$[!:6XX\ZF899/,^;E<YL^"7&'
MCFX(=DJN:1"G.HF=4\ ,ST)$XS#.+)"JF""-VR1+L'.;\J[_^3=XUS@>Q@2K
M7L1O9[M^W;>GB,:!S?JWH)!LGUEXB\JETUQ 9)Q\51$FKD9V%DPR-%"$NH.!
M1OP,W9JSI5\?T98[^(K_@*'"U=V&G+S19<".7]+@A;:10A4AQRJ#UFP74.8]
MI%4PRANCC1FFV2W8 ^]!AB/5H5?4L:HFK\B)VNANX"*X+ ?K(M[=$5XQ-N^O
M"3+ +ZNO;\RU0:G0[&G$GKK-DEO\%*Q3$A5UF(E:^-:\KLG,4PR%QS*@'9,;
MV9ZN*!1QVH[E6K92SMKJ2FT#TM.9'&E!&R. S;181NR%1@/Q6KLHR5HK5_X^
M"I7*=Z9:XCQ!L/S-N*D6&"E#-+Y@"E1:RTCJES[83/\6*$FL#7P&AICCZK*)
MZA2:T(FVUJ6)K/#SEZ%!E^&FEQ7SUYI-KY'7=G@VI4@.)<02I+;0;@J:ZR8F
MO.+0:H.(\88U. ^+F(M5W:5K7"O:7+%AAGLHE%%F.Y@E%:-*JN1KBC.0M<ND
M#H!T/D7^AG5JB'.#N;!VK,K D,76&5EI0JA_:JLQ0E2X[EV"/X*9S)T-_?5O
M;5?ZFX2V^L9<A<&68-#8WW6:%06UW]3?)HFWUY%CIE$ $0_.C6ABPE\'95!G
MO)CY5 9ZHV&\MM&[XZ9H#0T3:MPQA3.!1>JE3AUNNI8[$+5VYXK @(TKS;P,
M%WIU=?/S4)>^)R@K)Y:;L97,%H&[KAQ'(K2VP)P)W"R0:#2S[AB;7G?7P*'J
M4 HO_CE;M]!/AU+H/S^4PA-W'W<JR,2KJ^>+M3ZG8CO=5+N1*.8H -Q/\/\2
M(_UW!C>"AXJ?6F40]8 M0&"M"U<T_H@L=?8MTG*"61P:]@U=!>;*7F#G^,VB
M^M4L'9<*?)GG!=, 7XL,]R74X+YT)4X2\@%_Z4+RFPG)@V/J%&HDL?%&7?/!
MF YD#TMS%/; 8?OKDMEE13>T,VX[FIHU:JU&'03R&\HCG2^YJ17S:.70[=7&
M,MC$^\IE0M\5>,B@B[.9ZH[#!H\#6O*RQ$[R!LM+.526A8;=PL30:J$OIL33
M7T0'U5Q<M4+.^:O6O1G-481_6Z>QV^<-[;-F,"";9JZI%96N:K4F^1',S)J@
M J43K>ZS>8.JZ#9I@X>QR*NI)LUB@S+A):?::(%@Z0PY$>_FFF(R+YH%><QO
MZUJ/'>QBD^Q9.O1UEX,UO9>-1NP_@ T7YZ0+08_E-]KFHXA7B]%G78IY);DS
MF83+D6>9EPKME5 G+]<IR;!I8XV8R(T6NR:S;C8@W2?<FV*1:]2LO=4DX36_
M"C57XR)JI"$=S /-HI[JR@KEFO#NK84^H*,BPQSD0S)*) QP*OE],(0D2&^J
M@!K5<_P_G.FWN0T8=4^_,OB#:H0I8!<*5H_^A 7Q=;U,K/J&;4:X*>(0'XPN
MB.:H=6'S[$(VH)ZV!8+F[=L9:?S0[E"#>M7!1)VP"Y(BTQH3>T(Z:Q_%2444
MS=A6(#"KCE<GDUT@RBZ7%",N.J$/<B7=*I#_PA>2E1O<?]<)Y/:DL$=-?AH$
M.CO:9$2\NAA2]_7Y8LP,CQ[[IG)%M<EG8B\9FN'NY(ZNYC@R%G 4X4$E<Y2[
M=Z3PA:3.L$TM9!G\5 ^)8Y*.9#^9[46@6%)+S.XD,XQOR/Q M:ZRRA3[,?2R
M$>A?T(IP 17<[B!.,,BU>'.P@\/"74#(-]Y_=/-%LT+6 16GRY;O5<S@,M_;
M!:LH8_)-)K@56 QB.%%CW#?P!U5^8U )IL&CVV]>#S[6)-;8 XV3DT$16Z"<
MQK,AV$R^XDZWM9HH5X8,/B':+ D*VK>K6V35"E6S-=,(%'=LF<?E)6X=A?,>
MTZ^&[U9W1C !D)0Q+A5SSL@F280/KD2=XK\S="6^?6"S=1VV@[6K2+DY7)\&
M/,!FO#$^VDB\2S,KAI;H2"<^[=O7SX4(!/]1\O.,5Z0MAR&%&3P=/4<^]GB-
M-SC/-&)#6Q#PPE%,6PJ+,9Y-T2_!C27JH!FGZ_5G8MI^@R*PS"3.+XDZQ"MG
M4QWCU2RITVQ:B36^E"H5&_>: *N8#&RYB\(A,51_4$[67K.\-,Z8=$95L\S
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MK0*>>"G@3KA>5\4D&3B%^=&)=T*&@S87;"^2\BYSCQ#6'K1Y<4U.=*-@B4;
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M[A$9+=F@W+MOKYJZH=ZV4;2\&\%9%$:8@)%,3R-X6QQ*XUA=5L2QY#IWL24
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MXC'UCB,*!&]G].HPR*7H5K+Y_(/=-?@=E6DVC5 ^UUSDH4'$2UI!U$W+!>J
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M91_K>;\W:EP>H8V)[L-ED]O87US=D>5."'AXUWV-3J@\%P=67XT)W+A5+G'
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MK7N__V%TV\!+ 2]'DFE+EEU%(0H(*G$SAYO[&W=78%YZ%L(%CZ6"@FQ<&\9
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M?,"(.MPS22!PK5'QNP%RRI >*?\>I^,V)=2QYLA&;)S55(NX2I"UX,P$0S>
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M*"H0H6;X$-(M?E>H_S,TNUI_0+G^CH&:9XE.L\"^Q8UI5$O)V[9>%-B4<7-
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MBB;TH>D[ 5-VZI_"$T3B)?EQ_JOP02@=(80,&)BY7)A,N0M([N<'\=WHE=F
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MM-VL1''B%EH1E_P'BF@;^:. .+!*N/('@,C9M$8BAQC[A)T=]9)'N#2IXO:
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M#B-).[W9P\FI".29^1MNL/8,,T14G9"@=P3$Y<1BF+>0/<NL&L8NWT?5SE:
MM.,T8N @6]51XY\T>3ZH)._2K1N'&W<\=G4T-;H$IW*[@;/!ZHIRY\M14>GV
M>;28 \*OSP4=N 0U4'Q!#EDDO_ZI%6N94.*F5#<+@_K- )TO!%C1-&+D,W!R
MWR]XAR>I-BA^$+/=G2[Z>S>#1BJ3=">Q5)2-]V,VKCW(%DU5+(Y<@[<X2=[G
M0HBNFLD"8+.(!S=5Q%&GL-DZ,$7>]<+=)=68XQ3=XA09O'3H0H\X&A(39)RS
MXV3<&C>G845BY ;SWT_%=H(ZFM?O :Z4-Q4RG8E":VZG%)&,$/M! (RAR)OG
M+]^:5*G"&;DTJFH\8"R39YST8N$&K9OC_OPHYUP 1]00WTSL2"24@#Z-O!O8
M3-!I/\[(;<Z(\3=(7OW2!Y=KQ]U^'%/%#@>B*T*3"L5--F]B:(]-M^31/?Q=
M1+D1JD4%$W?0K"D^/R4$7-\-J*Z%_>WT[6DV>W[ZS],LQ?UVW$\?<3\%[SX5
M-0^$V$U!E%-HQ[FYQ;D9*%NB3S\%>B$,U7Z0A\7=L[(IP"CK1TES_?EQ\FYQ
M\KP_Z:IUMPGQER#Q@&G3#W^/T\;]J\>AOZ6A[ZM5?EDWQ-S1STNB9:"R-R#J
MZPA:.*N3Z5MPYWSP##6BH2V<NB20TD0N!Y6;CES\'RT#A1$:^@>QY1-@#D+[
M+1??0W'J7EQ78[ U&L#!+&O \MD*0Q4<8FUNB-TS6V-0->RI(D,H0IAF"R7U
M0!Y#9((R;=8".6>2DB0SG4 ^0_^ZX' 7@K 9T9\?DC,XXEX^D?O<NX&^.]S+
MEW\ZW,O=L_L&-A0NP0_<.$CX@#>PSBOI>8*_EA\;?IJ(=P94$?0^0RI18H.2
MG@C7 KL4\'RFGKS(=Q2W,;$3+CO(\=>S'.JCVP WC5P1N+/4:9 P'KHC)G*<
M!B,Y)!>[CM7IX4#NDW.-8YR9@4=E>^.X1\/_'TQ\]'0@\JNH\1?8T^AJJ=47
MU:K)_1OXZQ D'\AO>"E."V/\[ SJ@ZAAQE\XBDV$ZU'H!0=,,C:G1N>K]Z\V
MQ8Z>A^7U &2%I*B+J(PI(81)(&Y%FQ>U8KBU/LB2#V[1]$67(2T0:ADP\3_S
MRJ8VB/($09< U)9Y 5/"Z4.Y<^@K9"ZL:J[0G:'N!T+QJ:57B7;]6]&'5^@F
M$2UW_/G1Q[IJ0UB&/L)JV!7WD-S8V*ZAGP@@,#0DD973=7;]TK1C$69 R-8M
M<W$P@+Q4AS?/$G?7N0/?M_'>9[-4(59<6[1,U#:L!@UKQFZ>SGZHKQR)TB!:
MBEOCO:7(V[9O<B+Z(+P;LX7-QB< 8O,*$KR@RI/]2&1KE; 74&"M=)HB6U'&
M?^*9D+LOO06I,R4CQ%10&*?!*)9(RW@)$Q=X.&DPD,3)P >OG;'3V1FV+E)P
M<.44GFDQ.=!D.6.X"#)!$"?]X#1+U,Y">XTR1#$A?-?1 JQJX9":0>;?M/G&
M%N3@DS5PB8(<L;YT ^FF#T _FH5-/N!17$Y%>354,<I+-N)H8E8Y,ZI@F8F4
M:)'6D)" *X4WF@/?+S5H$.K;P*N06LCF@Z>.DH=B>-Y]\&83KACEN0LC-'WR
MU\W$)HU.Q+$5BDU,=+@ 6P0X##+Z24T<Z*7$%M;\@^;D'K"AJSR0@X$JL?/&
M,C. F)5AB06&"ZI.P$04"3>9&^<C=C>9:RT/XO[UISS?ZS:D&1_,&1R/^OM=
M#50KQ+EG1WX\XJ1)5E0;0O;R0C1Y3G]X +8;#E'O-/6 F^P;L:'1^6A*?@;$
M<*K\$.&ABS(OMI+\417%:9G'E/*#Q%-X%!"*<.Q[9T)899YG%/DJZ)7-9L]?
M'J;5W<>2W4HW0[!&Q/D/):\&S>U$=6H&S_\;'&!L>_S?&V-#OS:?PM_[>]Y5
M/MJVVHF$)71(+KAQ?I@Q1P>6%2G]+L;C7QG=254BR _S(:ZIRDFDD_:]HLHY
M-M^!  B20<'OO 5=-OD5I7RU9PZH*,$]*TV1; L*:&2:8<WT<$G? 5U -EYG
MJMAG]0M),A.6WQ:G(&;[0.S +WVSEW)"XW;<RYFQQ"8>)RO'3=="T@#3N)96
M7'^H@-7A-1-B#DBU/_[F:8O4D\;)L*$7],  227R,OBPHD/-S"L_#J0!@JVK
MU.E2[(C,LC&\/^.(=[SW@PV5\Q)[5RX#_FS7%%(2)E9EL+/^4X:2!>B:,9\5
MVVI0P(,.2?AE&UHBK0]V(/4]\*_/*ONVTC*!9_%>'BCNH;BPYK ("))U#OVW
MINM'1@-=5FYU@<6?#;N$<R,TDQI"('4!O@I2US.,%23#6H"*84HC:'[3<P[\
M_!G<MJY8=J?E#@\(J='QD\\K:S0MJ."#'%SC%^>M063PMW%2'KM4/_G[W+N!
MOKML_5?';/TM<^.;:,EV^*BO:AF#_-GY"V="+5@@#LX,J##&$NYJ@!209(5-
M?T:_ 8J68L$$&BR;C-54Y)'?"@^%MW":OQ SR^+>2C;TH!JS(C 9NKZDROL1
M<)HB1LT<*:* &]";R+1PB3HV/ 'R!GAJN@9S@.!T+6EN;"4GXA =O1(<Y^"?
M,\\D>L1M9]I%:YM6R"&GL@PG?13^O)7,_>%:/Y[$!T1 ;-[,^(;0)8O]VI.R
MNIQR%7K43-SUE)PR>;;3+RGY%!QHU%4PFV>9GET,U,+,,("!EE%)+$;@;LI?
M$">1?RLAGK+11(T"7D#AJ3=<-- &7>13Q:M(Y"3.P$SEOZ0!U+XT>Y74ZAE"
MG7AUYUL L-JW "^829*HEZVLKX0+/YE3$CXWXP)B;41R1G9C4<.Q<$U"U$?$
M;^?3MLVH8U.<+\%/)D29"&CW2R"+$E0Q/)1IUEQPO8?+-9[T\7O ;HS6 3P^
M_LG!14%A133G!R;Z/_P2VZZ=).&##$E0;#CPV:WS.T,0,3GLDB#N<^ R1CH5
MC7G\H+H$RB,%,B,MC ZGMSX,<C.B(1IGH)K*Y%,S& )_$LI&NM$#,ZZ3^2OW
M4A4<#M?#J6R]$]XAFT-33?<N4#,B.=[ \!V:4&60&F$/<;F-#'DV2\'RYOGB
M8MT N\,)C\,*_^?IQQV5PP>X',GPT>$PQUP%_=12.;_$-O:&?DU_*)9&M6T'
MJ4$HJ6RA"(ZY8U 7Q00.,2%(S6YPFOW1*,;_]7_NTPP!3I)(V X?V'_\*!$K
MZ3E&9)0<U"7P_^?;W=.P"-ZZYA(<[-FC\Y=O/\OPZ%N[:K''-*%I(YD] Z.J
MS&P_L-?H/_2'WI]NYD8__/#VLWLT2RAA"%@"H1H);("RJG5P>$MD@0&D32ZX
MC_O&5QN'_G). )8K<%EYX^5$W\J'[#5^8H]Z#O)QI[-7E1O;3TV2RB=K$X1D
M^-3 $O4+DN;R&P#6E4OR 30+Y4&AC2. "OGZ =J1O+-I"!SSJ8>?QJ_)"7XX
M/(C $5*])Z@]M)7J"7C;)6JHDH.)%Y#\,WD2?6L_UU#_X-62GQ2(D+SKN*F5
M_,U\L4F<4N*20&2 )<QQ(?4F@9U66L%G<$OAJZ3\,Z2/T>.@.@TQ* /5GY A
M/AB/X'O3AANQ=_*:)O:J'9@<2?OG 8*=33E>$X/*^>' 9Q41(,\=2;1S2803
M[M20*@2P [$%/'OQ9/ K61D'8>K5,TUZGJ%0W;6N7$FL8"@Q&UK RQYY/!/-
M[:!PW;IE%**%(# @/#@ZT3&;>7]3&.>/OOBGZXN_,#65+)6QH>0;3#N=GMYP
MX8D0<'=B2/WT;6D_[/S.E0-U2;K!?25:1R7 :7@[X1I!VEV:.CF@^9^!LWDM
M1%I,S13F71G42%XCO&Y4)TK>.D/AW^#FRLV)[4ER<(V[+-R5RHE IFI4D1Z\
M5I3P>&=U06RLPRI]@#ZZP2K%SQ_$-6QLWHWG"QZ'X7RX(Z1K=FZ!1UP**(4E
M>[TUS$\VNZA LI?H8^MF"U8RL"V@> =J/C-C,92[OW]V=A*_WY@".R2=%& F
M]4UA; W9/MZ--5#/U:#;V78^%G)<(E:FHP,3F)XR>X*?SGZ"(O#&E2@0<("&
M3N1+&:4*)I>>65J2,(Q/[4.I9*SJI\%5.C#?>NAKGH;X<4.V10K+PWS,$@N\
MTPF?C)Q+&#'M:TH^^]@D],G?Y]X-]-V5';_^TY4=[QI61ZJTB81<5%:)Q$2\
MX611,""Y#:7((&P=Y\4PX<Y@95N54O[/M:A>J)BRX'3@O8(3,7-;?Q2U!9Z4
M:-WAKO[8)O,:*I)PH#_O&__2&:@VY<L\1<*!:MSX0#"U<*L",-#@?O8=4@S@
M(<'E)"M$T[>,$XI80"*EN807\@+2[\@:QR^0Q9$/^3;R<ASUT&?X]?#/"F."
MH9LC_EL3584O_1'(R<HP]OY:(+0MVBU2[&-$ (E:F6,N,K9['_%M-5';NNB%
M>10JMZZ[@E<$NIK1G)LB)N*7N_PBG-CDY",R#+:G(6[E\F";+%.\JX/\991K
M;L+<2#%1Q C,FP<XDA)367KZ(1R*70.D:6S5[3PYY,.8T@N$/91)4L]!^[IQ
M8'D#9<-YI"@;5Q+/@TQM*(A&6/Q$,OUT]FJPT*DL%S7HK(KW'.:!>\E/7]46
M( @=V=ZY0VJN7)2H:VGT8;[++HJTX0[>OE3#3:^(3F)4Q@TJDQ;V?P"P4@T4
M*Y%4<K1LRA(D4E!R0,?,O]EB46/?"\146OYJ58T[8?<([#CT^J-DDZXC_T?1
MK6JLWN.X2*UR/G'=4SL/@_]8[BT(3AHS&)V'X_U@(MJ#_:"$CL7]?)-4D3C>
MK*.8B TXN3&NW> R6M:[@&TV0B&MZ971;AYQ^P<*6]A!"H$7KB6H3F>\9$=:
M7 /F-9&P:JA7=4JJ9( *U3JW('9&/8N4XHQ'JM%(B>G+<U*@!(L;:O\!-70H
MA>07<$\T#1VG-W$SV"9 &<:HVBPXCX10<4;"G(GG1U\Y]4VPB0 ^#W]MLJVX
M*AX.!??/CEJ@+ C:M$/9?&' =#-#-F9Q+K&&D@DXC+M[;11JVP3\J(%A#L!W
M"R40@<=E_: ZHT88[45*OW.02-0!\4L:\LF$I!"R0TP1C%K3T*I#*8M]*VQI
M)>AY6C!!/,IK[Y2$;03E )A]5!LRC5V#27;Q!LC("&[S7^I1=[*>_AGEH+RO
MMY]NX3W4RWQ5-^72ATM.$FMX*!ON<93K_:#N:'2V%,X_;.VWC1M8+(0>6<D&
MVF40>JX">TXD:X47%-!Q%C'JQ,8+M0#,OIKP+=Z"@REB8DF>84,4*#)XJJ1A
MBUU@&?/%1@8"'3Y.I?-ZDY\8,L'!_>!FC>/Z"?4ZA?N>SEYK0T#@6VVI)JBI
MPX4_>B&[!T6KHNLY(K/$DE"?UK91JC B/Q6[)P2,4#V'&(W(#G7%CKZ(<^ "
M!\UAVDT=R;2(N C["J81_7+0&[W"\T_N%O5UC=NY1B;BP?A2=J/1]C(:'S??
M:/%Q$:*L(%D7R'E19D&D'%75?1XO=75YT]CE>"ME-Y0Z.9V]9"QIV%MLEN*M
MN;!*DQR%ZQ;"Q7U15+37-\4<U_R#F?'@/8?3VE"TP>>#JA^ERK'E;32J**;,
M=!'(7:'M01.'#E: #)-'"(JME66]; %&B ;<I'9(4*"8/2H^F_WP\O6/)U\]
M^0+ZQ][^^Q]A;OS:@J_B1Q'<]H>^6VP*'PTAFH)6^NS'SB\1$7GQ;\GZXS.0
MXNESZ2??N*WW/+%HZ <!4I8Y6J^G_BW\:Z0)\$CU,_W9F+ G\DK*2X$\$9FK
MN>NN0.KHY8\_$M3K^4\O?H+[^;\XH>CY>@5%"2TL80V%%Q'W",UZ *0]RC^;
MO?WIV?\]^>KKQWY0$X/X=E\M\_<P3,9.^ >^J!:GI#,E(SCL"6LA 2 *F#-N
M"=]Q<V/C5@VJC.SAX^AH>C3_;/:/5R=???%M\DW^T3?Y[%6U0+MTRR_PE%Z@
MF)A<%4 :#2:\&,MM*T.&"G2-I^W[']]]$:8M5$[MOK'K)B6[B?<(1FDXG9!>
MZNI%F;^'3?+=^8\G3PYOD[/Y_++P^QV&__SU_SWYXJO'<&59[.JVWE)>9BM9
M%NAOS/NJ;OHY9&#H9-S[E>T#ULJE;O_W_+??QLL'AWOA'WA^\JVW@-_"$[TY
M=O/2/^3Y%_[I:YC4K9\*C %3=_ZN*5J_24]>[L&C>?MK7\SGIS-N?5YL:HB3
M@_N;Z6A/VL0?SWYZ<R;E4DA[G6!>:;L#^!O<BK;/56 3@G5!5]$)-W+;%36!
M1(S<PWJLRWWR][EW WUW=;EOCG6Y/]KY^\=W)Y]_\^6321\/9!:!W !U[T[.
MGQE':\K;0^?GA)K@4RY0Y,J=_<^S+[_Z)NUPG $@Y'_\(;;(G\[>O3YY_.2O
MW\P>G967]:)8%O//DA>]JTO7U,-CYNGL_-_G)Y]__57RFO.]/R07KAQ?]3^U
MCX?S1>&_8YZ\% SZ3U+Z8LGZ%QSYNJ>S9_Z\/G#U2Q]&7C"D^[P^)=_C7_Y(
M/73-\Q?\GH$(B0^AHK,4<S*%_WKQ^O%73^!8??WN^??SO_A)_-;X 3>8,7CL
MOPKXMIP?34X7':2OW[Q[\M63;^ !XUOO&C=UQ]?^-(.,P3L3=_E#^\%D#P>#
M?U!G.Z:/I$*Q\1\QG:J)BECS7>K!+\X)K?_RC)DM?(B-?F5(HT!FI3/_^M*O
M>;^VRF(%6&/O!Q1+49@U79V-'X-%4^P$Y8K049369!'2!Q/LFGC?1ON\#Z+,
M''MFE,$8_<):PB@U2O0/!OOGAVL-8^T&M,V&H@1I,+L"\P<AK85D6I-YIBS:
M.$HMQ(DO3%K$6H 6,STN>P_9S20G&GYC>=UM*M];J+7C]9(OO&--;J4JE%R;
M-?)KH6^I?AS7(5"T%A=^&"XR=_XKP?L@V4.2 ,UG[19PGXU)6#$II*0A3V=O
M^2=A;4>&31>$$MWLC)2OQ7.:NX[ %40$>B"5B!N:DFM1^E%*O%41=(YC=KK(
M)/0M+1=D^Y0Y(XY/^-.O?2[;6E/ TL:MM8P4L9UR@6;AU<;KR0^'U)Q%8:-Q
MZ]!>CEF]X0HT>GD0#RX49"RK03Z2ZFXYT@9A1VVDRJJP32)T>BC&YU7,45IC
MMPF)SBI]N]3Z@9 )0+T5*7N.UK(6:H;I9A?M4D[RYRM 3=,9(L"2C"S5R@'&
MHVZH6MI"JP\L=:6N9&7N2.)XWM3YTEEPKR5-,DHK?#$^V.]9OY\+1M+ 7Y?,
ML2:]_F!43*DJ+E#Q]Y[.7@T& O>IH2_Z_IDA]DKT_X>^@X"S0!OC3].EE"GA
M-0)C@+/W9Y3&@(W"5$\'[Q?MH1S:[FNUP$%WG0NG ^0)1EB&<G/0MX$5FU#\
M%^O Y6O!$A >!?!@.9 9S??*ZA#&*=$&  43E@%QE?]( I:'MBB$E 1\N;=8
M?QO\S<#Q9WP;?SGJP(7*5K26+ A':G"<D@D(H.@IH@E.IAJY2VS/NQ]W>=TY
MX?J$RI2)IO;^'"""A:FR 0M%C!?4*,>#_&P"[4!\TI(XIV("0;<M^BV]B$B\
M2K%C/+10A[YP\:]8>9GG.604,8Z#8<6<(VZTXL)1ZPJ@&KI6584SYM[S_W_A
MHP<<XHB0;I7\8)R)@1A6A*-X. "),XQ?'7\#<C@.>[T,-^.$NDA,#,(689LC
MG0:YRP/43D1;\Y#"&84*I#S(:;H3@<'Q7A_!UC+06@D N@"A-%!3L_5IG@QG
M *.&D3%.H8$!EDA,J&R_X04B;P)_G/B>HZ3Y[<L1$6C H#&AIL(X67*.4Q.8
MX6D!#5P[Z&A!2FKXI[V>7GF*M =AU^"5;*[R/0'[O&TL'84-V-.F9SPZP[:'
M,($HNV8=H\E' '+I3WB.,N;J_4"+,KUI>(C%$8]N^/1##,-QU1T4.E/_P.""
M?7CA5V.+"@E+0+@T?JTUC#WGT.P]0QL37043"_@X:[<U:]H%>.7RBPJ[]4+U
MLJA6);/#0N11 _,HB8.#NRV<HK834:P*WS8*>X^S=FNSAM%[0?2RB-F!VK+S
M?U?O.;6_W19KX: #?Q.R)/[_7A$2B'X*"K=E<<G9-[]!+QVEHC#T/,[6;<V6
M; H_2R[:7S!WF[I<,B6YCPF]^2OI=\?AO^WAIR!YX9V4$A2+(J#.*,' ?6J0
M)%*WE[(H"FFG'!*W&5AAZ'I>*J&YOT^Q9)S5LH:[*#<Q@C5L%]O^..>W[P)S
M8Q(DD/>:D1WT([AUL3VD-GP$@7PB][EW WUW()"__OE ($>+>8W%1*8F<-J]
M>^__I+(I58X\+W*0AO;QXX%U6\-_53<7J%L2,786-L%VA5T#Y,GW%?35 F*:
M$Q_;+6;^)YJ(C_-T6_,TUN+8&S(U9'C\GK?)>=TT_:Z;O1;V]=G9HIL]^O[\
M]=EGW/H%G%Y,1(.7&/:$XY3=6K <",Q(&TBJ#)AO J@'IR:AQ.!_27\!>C(.
MJ?3A]BV4Z:G1CM!UU/0[SH(3DU>-O$;2',CMWJA[<N@9THN!R&1IR&B/N_DC
M[F:JHD"6I-T 9^\:&\<A",0##[#B4#=$V29;!&SR*ZT](:4E\4;&36JQ(B\G
M56 Q'*?O=J;/A-)^*L#88LP]F,"UJT]"[I)Z?.(T3,XDL?X>=5.TVP<#=B'X
MDDF7)VNKD^0_4/^[KH)JH ]$&S 0   6"P( Z'WO4O_Q8!WZ#0[/FU#2?!/*
M"V>V2$64*S^Z-:")0Z[UI1\!/T(/IN[^\[1H%WHJ=3/T/.)*'!6-+8?PZ'8W
MTJAX*-OI3;&N&X#9)U"?,8LQ8>T(HU$9KJS$, :NY+X=R $S84'I#/E%2A*%
MD$4R5;_XTZ4%:##N8<8T$:,U48B2Q"P57:#_]JW?ENV*FQNU#_?:(AM$%U11
MS8C@2?F@LQ"D4$W7*A@! 0:(_&'Y%QDY+5FCL)HB]BLF;D[K7L3(--5]7D.#
MG^) E00J.6L&DY!<YA%0@6FLYVX-M%,,S@4.U@>SBI'TFVF=,I4?A,%GW#)2
MG.]'BYE%?U*X^0IDH^ N.!ND430QG+K<M9F<L8(("A^N-Q4")?05+C/+Z,53
M%^9*V_?@KLDE;-G*@,:Y MI<OUN(J).RO_B UK;CQ#*N84,/!XFIHO<[YB@%
M*$)+^Q/A;1FK'L&J4<%P_W.7\2/>"XMJ5?L5W2E0?C3L-") *+,D&4VA&)4O
M+ZBM/P0@KH%*+#)70[*@TA;J,:[8/R!'0X%#B.S;4K1?DO.*IB1"Q@N+#7QP
MT1EJ;V1]QS&F2<?%I3F,37T5H_68=%VI:JE[H^)/F!D< 1/Z8@N+E&-(]&E)
MU'Y@\PRE140^&/P[[ADH 3DM7;--I-0%X/&%%KH-? '&&IF,]C(N.%<@-;O$
MUMO1**6."+A+9&2! /GAV)-J'V2/5WE1,FNZ8%>5+Y\0/;QYPY:],H*=(6@B
MH&E*O--XG,JH%DG:XQ0$S,$U6DD#E@GJN: W#W2$D98JK-^490O47RS?,,;/
M6?3I(='AOG6\KB=H:\@UQX<AS0T\CCEPRGQ.=7JCK$P<>^1\1^AE,1@;3B0$
MY644ZB+>^7SVYOG+MY9&DEZ4P-0_@9(S;!CB=PR(7,N"C]D0&L38B:CCUY.1
MB 3L\=1U= #%9-S2H7'PED2<+<PW..Q4^7/04#5G?+4X+,K53]+1S,!))1:V
MLKA6,:NW!G8T3OSX+0.4*K30L_"<P$D$AE#9!39^M3@_??)<  &?P&>*!IPY
MB_0V;AFI]KD* 0%(JL"-'WL9$KN\Z$YV2 !"&K5'$7DYII?04U\-<>*ZS'!G
MTHZ\@1SB@S%C/[M )&-V;-7[^ 5\_D0D%*TZ.F<()(_-4 KJK]:MJ*L0(1+(
M2PZ[<@[)T?.F_(VQ5I:<=E+4D]R# ^&;.F*(O6[YI0W<$VX?J']Y^R"]J*R.
M=#H!_0]YR)+V&!C\.71QF>8COKJC?2X!(R4XXX"DK!?8KJ>GMP6H1N'.Z>RE
M_^L:I7*Z&SB,%#L@&$#.#A2N'%U@/^K(!O')W^?>#?3= 0&^_=,! >Y'5BYN
M:):C8Q@^3/,A'Z(]9JI"#16G2XW#B%DT.0#$O^LH3D3#B?WO]%(/KIEF,-1*
M1*3GM:' '65%#I'J!Z T4[O3J4R#AYDM?[J!OLK>C.3P"2$K,_DLRI^0PV'/
M0Z&^X!3+S:9YGXA;Q$F%=RFTU]2J7^$G<9-=23JSU.I(L(3P>9J2& ;"#;&L
M^:6 !Z^?4O(7X .H87!5)YM)4YG1$-E@6B'X,;AX=]Q2OG$B146N!MVH!55.
M;E%<Z?OB%_05]LL"LQWZP_!WW)EK!*VTU!^:<'&;X=\%3G\J^S-#';&74@X)
M!FSG&J#Q(C(1'2L21@;T*#0=8L??HO9N_&].>>,JN&4@1XM>T\CH^($KR&'S
MJXK[L;BS&+ICJA-H+0<D_\XEEA)29<@?Y:XBBE#9RZC?45.H85Z 9YK'"]]%
M-(7P925QFWX5#6QQ(KT[#-=N75X)&_Y5T3KJ5U+Q(N7 "3G.CMOGKVN,8T'F
MT 17S5[\](RH?S'&'2U=UC#,X]4JZRR,@68:,3H8:!+4%&?.@6HPO#6V[$.;
M7D#WK^O:9+9E7<T>_>W\]6=QC&+MOI0;IB<A",@-U1+,Y SGQJ\+2/XY$#/
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MI?,WHDQFK<*U!!Z!>2,/G*=N,H;.F$*:4@Y3X#S#<=<CULS8(HR: /^%)+_
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MFM1.<J.ICP_2FTK%XSPESM(/. ON^, ,VTJ)#HWQ29 D8D#$JP8:^XM\7=5
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M$7%#4Z/T1NB);%W>(H'V3>P/UV#\KBMK++ /3"Q:6)P?1;5-!@H4JC->4_F
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MR(IJK:\9.*%YC]B*/?XRXS'-9^^\W]/2T?U,GGZ.3_\[K P<VV6HU\$W0LT
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M7R/A]T$;+0>&,BS8 )]-IY?]A]#)GDO ^UW9._\E5:?9(.]]U%=.'XM33!\
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M7N85@MFTQ%13B0FMJ,1^AC(]7LN(%@O=/EH3T3.#LT\3TZF#;1D%<FF--9O
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M ^?/NI,RMDPN"PXOS#VDK%'].'PWLOIAS<GN7MRTO.7A1=4GGO?E!2!CO2&
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M'H?'7YY^!=]MDP-GD$/_A^30WS+,:L>:P6W:@%.RO^6:>&?8,T&TC=*P0F!
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MDH<2;!@C3*!7(M4 Z (Z. T8KE4B5ZH$ ?K [O7TQ0OU:H&UUB]P? @?F0U
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M8,@1(T(@=\''),X$^&<,'K88K^1Y?"#?B1H%F]SXT(G+U,H/4(AS@"URQ":
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MKL&<W^2B.TSS18@MX$=08A%^*#@5C.?!1&F0AN((F>ZQA23',3!;R,(U7=;
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M6$PVBH)3%.4^2H@+[V /5+DB]8NHIX@GL CL)M38F?%2#QOX'P,ECQZ%TK]
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M-NU:R]$JY1J.D*,S$->R-$).N"5A5S)=4]1IT[B#^DPU6&OX%[&KO;(.;#^
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M7!"V 2J2!:.IU&\A!LRVFV4LLRVT"R43A;(%P/AN SV$H$1B3LW(:]+&M-
M'\$(RAUX=53_E0[K8N%7_D;J&41J00J3$\X)8;&SR95[89SE%:;\>7Z7C?W0
M'2UX1<@Z[*H&K/)88Y.Q\D_T"=$$/M^43")J(X;!GK!1V$]P?V&@EN#VI#R]
MQ/7B'Z/?#HHJ8NFM?UZ_N2;2._Y6$EGA8YS(4I%65QWA;^HFL <@ZT+@@LIU
M4-,*X*64DP6; :TCF"C@=*5WC%@J=D%[>.?\.5*A(3'JHEBCY[_ %AB@,KTC
M.'&$X1FEGF^^.ML.?BZF^WE_QRH''$\)5AR+RFUGS'0G%:."P5O].Z7Y[4UN
M<Q9!.S6Z!'":.1GF#X+_YCKY')V%%+6)D<UJX^*4ET''T8]B6^$=:NA.]Z8'
MNCLCSN%8]96A83 ($=@&:4;D29-U;$VFO&YER-($2Y_E^+\#WAP+[Z5 >L#T
M.K85<04HR[)H=D YO1LR@AC(66!R7)Z8#^!9'* 6N8,W0?Y/36JSU)WR#2F*
M\93ET=&$9[5=EKG<T(D%*3.1<B14C,LSU!#IE$8GKS;J\H+A"KT%N%E@7C)6
MY,00A2@<FJ[#V*@:"0]0PU'M&J%80IH2!I'N6AT@ E8B:RM0?I0^N,4]*=PX
M>G<$VT%C2-^+6\W,DH;U@_8FDK1"+B0BLM9&^O"Z><--([QJ.Z8?499-N[N4
MY!4;>7_9UZ%7I,Q<6%M:,5LDUH1P+)$9$>O2Y<D!9]H!&+DU1_AA^E5NQA*U
MSH0N*&S1M!X+$?JS__HFGFV6[&S*[;%W$U#L= $&^B'#@10P'3$-"]/VQ*,Y
MO4+9B=@?;^Q-VX'4.-#M=+AID;-]8DZH.XT?T>\VE-3F_J'NF-LKISV)NYC#
M%B(:%NVO3C%G%(91L]&]%5*$X^?GT1]BP(9%5 G6#$SI+Q-?/')Y#;LL/B\#
M:B>U6%FE_6+<$P"R3UK!P\&8\S&IIRO'3:J4UD@E0X3GTF&"L<$%N?5(>:YP
MX "ES_9HJ:#T0" ;W[@;JMJCU[#R-N>2!'ZD6:A 49L.$]6I+8>!8"K1WB,2
M>'\*M$WCM@FCTF4^'FD^:,%;AQ:38)>JQV,-\+3A,^9!.QDGF,!&CQ E3/2.
M GDDH H )5.@3$:5@)G2*9Z_[6!B&:1N1G)0S-R4APM*Y9._SD<WT$^'4OGS
M!:7R2=EJX4 8(_1 0FT?]6TI51-G<10RV))E[8<KU0M9^."^OARLCS59<1[!
MLG*&4M]$4M4?@9?Q_Q";!:TS-?9U[;'<$M.LD5W3IN+,KBEORWI;\K8)#A(R
M.)?>_[?J;)"!0:9G_*=-+$U)$FP'9 C_4A 3,!_@(U(YE,L(?;F+.G7/IE*P
MA2K\S0:8("Q+.Q!9JP\IK,YSZ0HF@R!^04[N4RH9TZH],TP6$5JDW6;KP:;,
M:47!,LXN^L=$1TPY/2G"TOS9Y;8'O@.SY6G-,;:>JH9<XJ?T#+WEE23*+:&+
M?5L<%;B_X .H'=2]X^YMUX 0IJU+3_C$L\3\6 :$]*W@2R+;%?HMLR"%*-'8
M.=@+\GC4<8RE B'#IC( @-&I<U@FMHA(C.G&G!I3?B]D&M;-6%"5+JK *8?O
M3++UVT#+0TDR8?V<4 O74,[K:D@.<V<Z"@%$1663H>$V=:J;J Q<]&E,+8CR
M0$@54)9SM]^V1^<,]Y#2-@?:G) I9K9][<%7DA58PL D:MG&#9>&YI4%TLH#
M7C'#0@0^DI2DO@^2V,X;PZE4)4P7&D-;U3&,4)S6YF0G]W+7JX7*JN+2D2[&
MZ7)0LH<Y&II?;6&SM?TDIWNR3J8L[@XEA>^S!Z%,!@"7R.CA8&IVVEN-U:KM
M8,]MCQ'CTY1T?H&T*JR'6E;^;S6.-*--N?Y?2(8?R)1@-L* AYRX,.44B<&4
MY(&IS*>(&56AF-4<G>&HRDHM$?J"D&W^P@QW.YM#\+7F_]%R"[-:,/1)_VX_
M]KRH'#KM:*1$3I%/2&.,L+YN=0"1T>0@XG244QM -0[++L9(^<_>(-]Z%RQ1
M0A<EW^=C-P^R ;:1%BLW:F PL=TTHLL)8(L\<,:\R*D%VTN5%[$^B!H@YD##
M4A65Z"TR.\<=C)5S94E)]C@81FVHYY-UHD)= W]VJ>N3N=.BDOM$W^%^&KLF
M8.A* (X99/)Z1-X+"RM[F'#O#%QT?N.=(894=8(FJCZ"K\HL-E6!MK1]741#
M<S_@7FSBEH[=!3RBH,QP%1?6QB;0EYR-37MA#M2 C9O6.X/#YW>=(>S+ R-C
MB9X.V)6\ZXT'T/XHY.#X>^\'KSIWYU1<+]ZVU.*!G[ ';/0\;'[H2O0TK"#C
M C1#R&,8_/+@RZG[R<N#M$-U<1#08KH^[E6D2CQ,9>H@6BAEB=(*5F+P=B;Q
M3^:C[&I5Y.HC2QS3C48PB*IF=LV31PQO,")@([Q"2FMISS#K3=:*E E8&$:>
M2G>L.C(.Q$=8&2T**+G.( N8T17DEFGPD_F[.#, >77=;0W:KB\S#X1#@>9#
M;@N^[::5QB(<X*'NA=[4/WRCB!<&%6J?R=CG3U,%FA.@ED)#?*CS<8P,5.$@
M-27UB_Q27;F:S+:.HCBB[6W[SFG@HHS-? G>\%-'"[KRN!4@QFG?SSSQF(=#
M@#EB3QT%==AF1,88/9IAUQ6<F05*SG8=^M\ FAEW\=0CS*%ABN365B]N,()7
M$WUL6.VJXAZ7_7H! .W:!@D8KQ=OB'  PI3<88 >D^SU"+ <)DDR'*7?1?YA
M.P.*F#!*Y#Q*ECO3NF(Q.XZQ+![[;'TLR027"Y+GL?+=I3SYJ5_GHQOH)RM/
M_OF+WU]Y\LDY?H,R3N3 V#Q.-BH6& 6R@'@K2ETNY1  VV1!D3EN_I3!5HR6
MFWNH'TND,NGXM)W2$14K*N_!;[C'#I/^1H(OHI1:E"QDGPI:FE>*1>LL"WW$
MQ0Y$>'N GQ3L6^DH@$\]=*,SK0'JV/&12*J#1']K!^WQ7U1X*V^Z%L/YY/27
M!^*[KD2H(5PI4IY4Y3[*EMI\BCW'M*7)NADG.K[8F8J<$CZEF>4\*-K3VYLL
M:^ 37(UP9F^YN1%*!RZ]$Z9PJU0EU#"=1Q3GAM,HUTI/?/-$R5]!-89Z%UI-
MEF,Q/%&^381OXZV@LI_QP#%SO/?=3[56:%(8F5A+).3IA=6_8%QSMRGW/9<1
MYU0D]8:4Y<_0@2Y>*/E[U8T<J.%&@K:9=DN<LCQ3PGJ@[59V^<&MO*4V/&#4
MJ05N)VI)^ZW4-C<B?4:OEK:.<:JE"%XW^6QQITXV$M,<@([>TDGZ61@6J"@G
MEZ47AO=KJ.$*DJ+R0/JVJ5#6BII%5EH*RR+][2K3P#J(0X=?2:*,6N*FZ;3(
M/6:5!]IDFNO(M2 4:L]A0K6TMA")7QP*P]2N==6[0@B] )DMV=U"&Q=?;>81
MH9+;C]@"94F&PV/Y.4$1/4''8\46&/S-[*9ZO-U*&.3*W@D.GD0&-"ET-E&N
MT?10N;\D>13.*IIA/'M@V_DQH [.$J*ZG\<F+A*O*55OF]RY&GQDS?%^ /XO
M:"SS:Z#QX[L#'62H[F@]-P @N.-&<!"-\L N.O^@U?'I:@,?-OLORM[A?N*)
ML%5@&TH _ 54_Z Z0*ST_/8FJ;YQ94<EBUVKM=B0).CJ713ZME&#/YU?D!OK
MJ*9/'3X#BR/<^B4$.5?)CK ED[L/^)S2,6 X).ZN$: =Z&K*E_6;DJGCV0#Z
M90.^SNJ=S<;1G' ><ZH^+F(^7'92Q9U@&75<HMQ@T-TRBD%9NTA+=SCN 9X/
M311PM )8@3H$0X_SD3,5"%T X4BS*8WQ,?5TH^-#^U,W#FHPBSTR[E;HDS.5
M?TR1WI&LS>5G>=J\:X>V!4.!I6O<NAY(P(QF/V&?HCG4I74V)C)1J$GS1KC_
MJ!)VAY.F*N(X\4F!9]E6(:>=](J9SO=RA#:VFD0S,.JP1 %0YO-#%7,+L)#W
MSJTVI;_AKF>0#$S4E>G<SS;N%]-.??X<=VW&9=#*#_%M*0+;4<<_&%@_/'&(
MB"\L[V9[U?K%9^[ZYMHR#=BO?9Y1)T^A%?YIVQ6_V0HV_G8;2KE^?5>B#6\]
M9]E<Y<*'_NJ#P+'C'4E(\W+ P[5'91^?Z?[7\&?=@MH]VO'8N>\3[YZ*;LG*
M00IUF]Q;?,_!&35[Z[>5VRT<+'!2@H\+KFG 4^R<TZ[.'AH;@>7$K[;1&W ]
M#7?:>,N8JFVY>@??:/P8;)&<=WD+:BY4NG6(/I16[T,'XFJ-7Q+]JJOWM!*C
MQVZF+QIBGLGSFTPKG*S@2O-![=],J@ZI@)")5N CV/NA;9;V'-;".?)-L)1S
MA:=2W0--*08WL!W)*>)#>?9VUXN?$I'G-#40E1.-.O0I$(_Z&4TK:Z9D/2WP
M<$MJ3A&&BOO1+M^EL12$C30 0WVC(E7JB6(T_DC\,[YFI*&6J #)*:6-.V"<
M$%/6!0J"Z= G1;@)'VT8'17K%B=@^A9IH?@]1PTLO# F &\]ITN6;EN[6S=I
M]\TJ7>OR4.)[VA4HONS':4NZ>0F@L7.(GXNM&JX5SCY8K.OCY!]F,PD/S2.T
M<8P\ST:"L3(Y.6UOFXFCI,0IYS*O$)U%FOQ*$K-+P>43N<Y'-]!/5W!Y]KLK
MN#PQ:NPUT[) \+ #"^W=$IM"$)HB-*PQ/)  @!"E^P@8'3 E'(S=%W."YUR
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M!D\OF1\L2[CFIKSA;"C3%!"K49@W:CFKJ0F<[QEIV\PCE=Z8/H"P+IB51VZ
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M@#2W8_#IQ %>NF,+Y0H_K ,MNV=_L+Z];6/4=Y%%BMFW!E5F6E742LDI922
ME5$N 0T$Q&[/M2HD)<5"7/2'H/'%'TC&^WKQ.CL$ENPRB^";L$'2EC6C??=.
MO%[\K3TX9$')V4:3,<,N)*XLZ3,&QKR$CP:2+C7IM@&HE3!WD%<AA"NJK+FR
M OO39SY-O5?H6]I 3NE/4MT29+4W5X$%VJ^/]G:VSS?A?+,?0S]?NA2[.Y&5
M&+&Y*M2,L*57Q![@GMX 2-%L,KPE4=3$,@_Y#=%VD2V1WD?9"I+""E^ &#+S
M+,6D"(Y$B5S=,NMEI=RKZKL'0BH3-(09*C23C<2F8U1)P]BT$)*=HSDAM8^V
M(#9D"%.!Q[3//^I0O@,B-%@& ,!0B#80"8H:1FH<5WY=4* !M\2$M,2I"@N0
MCU &RNG/?IN45#<OQV:5Z%1PRJ"C46;\HB[(I=/V@?-)9?T4%R)Y;=KT53[O
MKGJ4': -6DY]'-IN>S[.C\%*(.9)D#&AC1C>_BIDI", /JX20K>P"_6@-FK5
M@D@;=$0-U&:)"72\CNZ#URZ1&EP.A-QLA X[?\%-O:Q99<V(.LD^/CG3D&X&
MF%*XFZ45C-^/*371(+&)0JK/LN%C-S<JUXM7:?.HVE[_TM_]X^TKDRG3+MTX
M??C="(]-K_2WUG_M?Y#G>9I6H\Z2-;W3]&CE*$'VP>D]8!08\6W1=1+4-WK/
M\'3S/2J(&N_!8#<#U7;R>](Q)\2D 7Z/F7XU;@: ,%DB\Y,&&!4$.3!/>4NZ
M1%U\*"#@G9R?S*T:)C;)7IU6>@1H5\YOM??H7M@+,QX^9GX\(,N=<#R'>"Z$
M"^;4-NKC9,UAKUOEH4*(B MF?X.W-H;=T!/KU^ E7=?!@\,3Z@/E 3O3AX)D
ML6WU8=47Y2:'?U%'3';!O!55*YF5(Y^<TKDV$XC)5I\\YOVDX:Q^*2_/H,B.
M"!W;PAM6K-M%"5B_)<_EC/@!?"U%%S((L&$M(C\AEMG CQ*P6_9<XQ/+%1OO
MNXQLMO&#HE#JUB.:FYYU>8_SQ@O;J*8]9>OH #LUV6&YQEW\._#)?&03),,8
MO6<%)5*B_%.=)6;Q&5K\K%,*O"HJ2!?BG 2+Z8,LTV:?]*6<?HJ[IN*>1=B*
M5.\0MP-1 _\Z<"F38C*.?LFT^_PZH9+*3?KC<*_1*P>B%@<Z2<>2&=J"WG:A
M>]+_*%HA#[M'TK$8[H>"5=X[DN6>ZIS9$\OHG*4"9]C3.!N5)FK1*H5I8*#Q
M%T6O*Q3@1.I;K1P2PR.6GV""5(!LCH4U<1$B;^=*2$N V&6,R#@U?+($DI5X
MTA:4V$%J'+ELH5F!BA'%BCZP"9V,\.LI_(^*DBL4X]QLM9A!M-5@0L9MWZH>
M-)$4'WK.'Y)="[I"@%117#J8GRV#>(B6132ER>DSRSHG2!D>A01JC"DVJBRI
M. UU\E$P>P,A*ZU7\VN#]I,R>N]L"&&R=.&%<#C$>Y9UGQIVS6/GVZ.M6-')
M-$> 'K'^@\)>TX&;M&<&-J8I 6XPC;/ "MDE2%<@Z*W' :AHS3]AL3F5[[^4
M,C^1ZWQT _UTI<P__.Y*F4][KL64(,(OF"1F36QIJ 61VJ-&&!7:V5L&,@G#
M$3"\5.UJ1*(@Z(1;.S@ZCII+S;!FHEHQ,1C9#G3X=#BD JN!'&+!$L_Q<!M4
M$Q07X*QJT'F%\$(ZJ>S;#"P>8U+]Y^*KO,::0[V:(-W@)&K< 1!HC@:M&<%3
M6$L#EDPAS4PTXOB9MK$!WG]"?<IZ[<)46HTN9KJSUTZDT%J(\QQZ_+J VAHC
M-N&4!%P?%E,2QM#,(Z"73Z(Z',I"O SZN]3QX&>]XFARCPH;,,DR&!45-Z"/
ML9D&%O'G(2O3P(MZ3UV1WB3M^X"7EA:,=/%9?L,';B=!11EN7E-#S5!1:@'U
M)^E2](_E8S;,#7IO%NC%=C:@]U]8NYZ@C#@R&[?=PZ#B6W#S4]VPGPJ\(P7Q
MM9*XMT-*G7VOZDBKL:,=+R]#?'<0A, K^AD&U#_>&@(DRDUC=!0&#&A/^JCX
M)ARYPH,41=JF5HD<5 2D5A*2A2K_><M@Y@8>V+0H+/V+MHVPZ= [Q3C'+!&G
M^(,41M,CDN 3D24-+E45"&D#*E^SXQJ_T<NUMFY0:DS$%; $]B"]*^O2GD^Y
MZ:5"XD,A5)+LW*&D'+)&!25JRDPP.)1OR$0"6O@X,TQ.W!IFK5V$(,X/36AD
M'1M:F7[?2O=MD=((G^QM11$@(3.>)>JT'<<L,(M,,MZR[_NTEA@WUY*04>8I
MPTN@]\IITW:R.DRW#/L#$ZV865D],H#*TIM>*M]L5]@P%_E?O?W&+NJ#(>,B
M$"U85E64$[K;[7;2YQ,ZOZH1ZW*V[:BT>I]64XS:@@C.8/KR,/-(O<Z3U&C4
MMAQWR2>+B(_93!%*TDV1L&+-70OX9MROY,^J?S;,:?1OE]%#,^2;JW9_),0#
M&SFHM3BHBG*--$F0AB(,YZQ@ANHJ7LD ^FBP/(-[P3S*V+MHI)#GL^Y#.EL'
M@!/IL# CDFY:V_%ZGS(A9O>4$L5+V>1Z\9TRZPEUJFI=0V*N1FDKRLE(%SLD
MRA,"D#*:Q.1]M-A+F="(FR]D1U6(>:(E%C>J<1FXP^.NI[5>G:@L@KG'6C"\
MO%)_RP_V!+#+\&SLM047I=)__0#SS;L&P2X),0)7[IS@+ZEK0QQ$^V%X/2:5
MW(;N==.BU;1!UWM:>A,];^CIBQK4$XL?E1%'EJ.V5HC9U@BT@Q>@-*"62]'X
MF(-*T+2)D8D2BY.AX53;#?"Y81\\Q8420M[KP)]+4/*V)NR905^:9U9$&F4\
M43A5YXQ>F,U]>&\]*T\X,M8L9,_BN?,*QZN9D1W(J&1UIX[>W$C_[%J_<"ML
M&3DG=U+?C>2:T9;AJS;ECFT/3C:?6%LM:[J*QS1_TBW'&CB=2^P#0D$)85 G
MV@,H4_;2-P]8O4FB^7W2Q1^9:7N%Z+X;X:='NVU^-N/>=M&P2P5%^:X++0C[
M?Q(9):NA8P>L/_?@@MBN5Z_H=U:Q;AFA,%J!39&2]N)N$%L$U8$JQ.R**8*<
MA/=!JA-+H=P!3L,R"FVWY1(@FTPVM!I[/XO,=3.S:KS_/."!C(YFC(4IJW8_
M1,/:1FM=3@GNIXJXFIWZ=L9<T(LL._1]T<@PL:WB-$7'$EU_>%@T2&-?L\)/
M!*+J#.0S#$-XWNAQ%QD%9/\H$#F@' (3C@H_4&YMT4^,BEFUW1[&VF'^)A "
MM^^Y9*\7KS27U3+LO# MW"%>#2KHDR6Q).*$Y@ZK=-+PR &L'N+V^!#3(IM!
MZFUWV,>T'"<\!#TSSR]'8<@2 G\XX?G:"5N!1#XWH_]?Q'KCZ;H1;9KYIQ#"
M"Z2:*"6X49?#W(<\WS&0Q^>N2A>%1:7GON.[A&/.VH6:"%%LS?.F;2MTUGT,
MUZ[(QU9HU?RK$(HQ5^_O9N,#?@C+,*+7+Y)U$_M05;M#'M:2[<?^*$2^IV%<
M"B4(Z*T V[@7M$5D4X+R>;A 5N7C(I]YAD7-C^TZ']U /UV1]8^_NR+K!QJ_
M?.3P8]U[X_UC,+E@MOV/5$3PMNTMGHJOZ50\FX#H)TH74WH LCZ$J<$4<L*D
MGM;/;$[0Y!I"JPPUW0 7C:0_7_SX"LXD3,P2U'@N81<:;/IAK$0L8;_U,;2;
M-.Q@X,Y^>I11X< ]L.ELH7C5=7#0#PSN%G 4G'?5.-3B6'-36MPC9AH5K2PD
M%+'<P.,'?8"A=^UD6C37BX?9CRY#$YBCO$C=/'6OS4G\(9J,E^7JW0WB#:]X
MQ:[Q_[[YL$9,ZL =2)Y7E *3=9%?MIHF^U7KUHI;?* U3/=I@48* CI&;@#S
M$K6825+,AQHM 9Q=W).67M8OEYNN!$I.F?;?$*S@H\NQ%$X8)TQVS_O>[Y+7
M3!BW>"Y>NE+=H81]OX?LO'1U:]L3OW<Z;'ZTL=,'QN#OS__QX_/KQ>)<LB4_
M2:VN$UU2+=R9Z@TUSJ::R@];787*T8 A0I/7;@N],38X\V\SZ[E@4PE-0[<U
MH5?_ ;47_^LMNN@<\\KU$)@3SR/2!6M&6<(UI!DSC\^3BES<N+M8L"U!!B1-
MN1 GM2MX(:Q\%)%=C2G+1"6OM]VHX1#/'R*.>FW0ZB!)L,D;A .!WQ>2)SA"
M/SF]A;4?EGI3SD0</$LG:P^@[U^\CHX;23C1=Q(\58BD5:Z'U4:@TUY*WR6I
MY0B Q0Z7415!8K%MVAW>VP,(^2^E$S9TU5Y[SRA[20EN:9S]FVD/(C=5^RFJ
M&UQXDI_!);' P<7"J8^"?3"XS]MI^FR-+4^:S(^J$1/N97@UG ,D DS&WBPR
M>%@J0L2]O\08-@1=I-1"<>Q<@:VK,+GDU]MRZR)>!@:*W&]BB%73:AC[P4-]
M)$-0.6EJ)D8H\C,DUQ>Q<L2 *RY78$7:+8[M2#L7S],P1;"Z_!@@(U;F:8^<
M'LK]B4R%)7XL51(W-X[3/:%K/TDU9F=A[+DW0^P*7DB<*OHOS@_4A5??_Y#<
M -Q]6"%CY])%(JC"L!6G$]1Y-Z,<IF;9\B;ZG4MPM*Q?J)"N4#Z\7X:/.U3F
MM@!U1QF94"@G8O_INBM'UL]=8@(-1F ;2#"RND*0OW/E=MBL2(>WOBU7;(7]
M$8;S#M\[FXJ&D@\,S!B?BVFT:A31+FO)%=;Y)&DK1S"#!$K<2G(X% F]G&;-
M(N;Y>N=D!0U N^HM<,M=/O/QPB1V>IM9%(JZ$'>;9G=3[WNK=&CZAK X<%I/
M@3A #AMJ*SI&#":\+;,>GJ'4GW+;J$N2" >K3G3=B7640QZWC=N4VS4>$C8&
MB*>W34X&'E_+<J?93/9T[R7@47!1&"_^?C$JCLIRRT2OIT-0I,WPXZWE*9A1
MQ,]6_"#PY/\:N? ,?I[?J;!M&?@8'WAX+5'A(K/<M;L:"AD&(VQL95EM!+5H
M#;-X;7VQ.!%8KTWK'5#;]S/F/2;-*<B8T@N*H#7# =XW(H]GZ![AN;@@<35(
MG/QX4*$62!/'50@*,^?D!N@X*2P!DM)OJ<JVT9WL\2GI'$B'[J"[+T/].)]F
M)]""[O_0]#1/AI8"+J0KJU?U.7UH\9Q-,5(<+:&/,=D.,]D8&(W N0,6"0;[
M;(X:R6Z@6=BV*W$J7VS\ZL41>>E'LD1V"K^F2<\0YC%P $'Q=0O*GL8Q"5V%
M:;G&X(6KNN_&O44L6)MC#X 0@?$2-5:7/)B(=:EQ-R47):'%CEPMT@$5'5$3
MRH:D!3I<.!*$F1/-2292H TM<6F"Q0QZ2@1JPH4/$H\(2M=WIJIA02YMO"N4
M)KXOUXZ"-A\6-V2Y\?/4CMN#7$*S.EZ?3<X!> &HB->+>7_QZO^\_/;JV9_]
MZ>\?:N=#L+@U!Q#Z!'HDY"*:20S(>,&RIU E7<4\WSQ8M%K8<G!W*<_2ONR!
M?0#.H[ .>VDY,,D\XLV'QA?RRNRR#8(#IHAHS(<T=VL0C*#\]\DV7\J*G_IU
M/KJ!?KJRXM>_N[+B$S=SK&T.)!-YF1C>5"3"F3A7<L*U06T1/KHH&5C%%_4!
M.SD4XGX0'M3')MZRWZ4Q=;UXXR^RVC!2&_(PD% *J2B\(FL+]5&.JF48)/NV
MO16;P.Y ^..Z74U$80A-5H.[*J3^WEMI&-C+!(W8SE>BZK!_!'H)[*T !;G$
MV477I9>^*G9J@+0O4!S(>1:?*QAVP>\JUZ-[GDN(DA0!A&-I:R&.#>*ORM4[
M<JI+?QN^.)P$W7*Q\0O$D?#=MBTKFAX@U6DC41W[S7[<$RN5?S((_ (D"Z'(
MG:,XADM,,VLMG-N,WJ/FOJ8-C2K:4Z%9#F4[4KRAHCI9?@E'.C[9D7B(Y&-Z
MIY,1?55O,-?K%OL;)_%#]P4*?83E>O2!(-<+(:ES[PR,5#(!H.0RN!MPY+94
MV\!?6PM@E)C"AZU92(K_M"%X#R.-S[3MQ]L%C(;A>TL?K*UK\C%)<R!ZRB)^
MLOPSG(]3G9N6S"04+#>_^!F:H1<0FZ!;C8%;/#P/G:YI.YMNS"67K7#_D.,K
M[:WE>$/_'+LI*:K)<%!B04"**0'+B60C\HW1#L]\0IX0QHYO;T4!^S3S.$VK
MUQ#38:M_!]GE3C@/.#VY\<N$4Y*45B!K6%)Y'6"[5\RCBY2<.!L%T79*NEI'
MLJK!):<,KPC5]T.[>K=IMQ5K=G(XPJ652#9)6V_/9E&G;:48>"6L4<J=#N!/
MO^J5WYVZS,QJA56)@&W)'37NIAWJJ%T=SO.XU\P$:[_8RD?LXL1J699"+4)?
MEYG'08TQR3!:+RC:72=26D)Q/1CE62[U4:H5#K6V12;@(W7!]\),;+?<.C8"
MMX[?(>!/HN0\O#GIQLQL/LR;"$, ;AHHBUK8/>2S=WZ@<4PXT5'0!U;P#RK6
M("X,\MU2QN%$Z93//Y_N1!=2)XQR.2W0 PR85)^FS+EK.7XAKAQPGP4V]O-J
MPUJ*#)LKN/%+_0P4;K)WX P33OI49(#60>;S?6&N%XE")T82VU+Q$0;+#8X,
MW.76)9R%MGQA<[9D98)1XM;G"J 9[Y(AZS)/$:Z[8'EFX#"EKDX'"42<*;=E
M"SY_7U B&)&/\OYW9 >,%#-YH[I8)C?R6<'[L8*1$Y%;$F'$FX <:5;=]ERL
MJM83$[>-7"OEZ,G+6QGQRF;T$P L).R+A>&C^ANM/Z5D_\M#CIT]A7!76[<>
M_O+5U\F07?WF8P:LB%]^_<UOC6.+Q^'9'Z[_".\==VT1+8TY%*'GNG-R)@JZ
M00RQI?8TM4,5SJ0&$NPS1?WI:)%\<YG##S*'RA<*J$5W#T=XMK K#=ID6.&:
M7.JO0>X CP9(1MQI3.=OH UC2;V"ZW0%^+P8+5/\5MO8"O,HMD:+O/6B+[E>
M1#W2#/8JQ PK_20<!YSIH=,2:I =*B 2JBUTA)46F+Q;U@TWC9,[#?C!WNP"
M& D,C_J(Q[=FU--E]7^XU4^NS02<)/UY=6,@#S+_B Y,OE,0G?/TUTRK!!P5
MZ9HN!!M%Y4O\(VR2# Q$8C]*Z4&T/09BY\RER:G6ZY#^XF4=?9AU) 5\0SHA
MAHZUHHDG.$>\$Q.T2$,K:5YNF71"?SK!5W^9V\>:6^MZ(*I[V-BPA<APJ-T7
M]E]HE[=!520W0,#S'? :GP!0U=V)VURF]P,[0-CNBU4!8?%2C?<[Z<?9]1$]
MCOQGVWFB(\2C'$HF%@=$,<8VA""CRV"1 %V$!I6A5>><S088(-NOW1E&^_=[
M*&R] /92P5EKY \8;O2)3BS*"Q[@$[G.1S?03X<'^*_?'Q[@<I*<.$G\^;P?
M!X&,=Z1K-QR GG#D&E#L2I"MEIQY@ P*@('=>4I;]Z[L *+W_A%SH:7E@'L$
MV %PUX0#!&*9;ED/729"M84<56.)$C@7O^3Q_1+MHUFZ!,!-@';]5<%EP0!J
MQ63SFI$H<9H9SW!*\RB$\!Y+:]IO. D\8$%<5L&'\DY9;7'57L&_\FZ<:O).
M*3\%Q4X:2F-4:?-?$%S53FFN";) --=*FJC8$\SD_K+:CLB0J;#DN"< +Y%]
MTGRAC$LCX;I6.D8%7&D$7,="07U@DY.GSMZRB+^MS6)\;]5:P0#,<I_-],U/
M.GM2GL60$5!:L(DT%U8VE=/P;"HX$6R,^+X,5".R8"G5;K;^W!OII-E#+(_I
MRR!N%'"#<+B2^VASM&11/PNLFIN.(?6[D&-1J$/2_4$*=W[3^5$P *&H#0 :
MGP7V%C<%G"1\HLYI@)1S"RJTAW%/.NSFP@@-VY*^>6$SHH5BT\K5!G$PY%F0
M C& =5BIWA\;1!.W8TS;SV,//>/^V=/Q))!*P+'%I-.8O#R!R;+0 [,^#)O7
M3.Y_E72)_II"A=$)OW%0X=YOI.5;?@\IMY7@D6R?*C3OQ+VGBJ2;!]ME&XD>
M H9Y>N1=PM&02$D$'7<WZ7/#T0=$YK9V,6YN7IF"&I(%J(CPF#GC  V^+$%_
M/O"BGY0NFP]W6A8LO@=@+LHA"U4Q=&/$@)X"C\4P[EB5*%>6@"%<)L=RI)4Y
M:<M;MQV7S2'T<-2+/T-_I!^.)GYVPZW;N-$D;L6ETD0!1;.#0PY!!@1I?UUR
M%Q0]2VG-F1LZ."&L]H:T*C=E5^$^W@8AW#U3L53<';-EAGMH?X2;$-/?'C9\
MN7+CP/0X-T#UC4;KL^>O7_:?RR+-O7-,SD(>&+.]4*O]O?AA%%\<XTC$AY>M
M!0\-3Q2/;M6--_21HSY2L?B?_[[ZXK_^\*5&% "+WK0M)1RE6%'[>^.#%R*'
M&&#W9D8Z6FV\GI.UF\)J2;EFS4"AI@+4@'DZ?'[&FTULB&TN7:0 /61Q\4N,
M[BTM3H2VP]-K3>(S\/.;__L_ED_Z8$3,[13YQ_W?(#+PY1=??J%V2S64CV[0
M"W=\HW@[FEOH8O#_I;6 "(>Y$<4!C>:<QW%NWPU6X3A=A2-IB$\JG+%'*PU?
M1/_:27_E:UR-7_[G5VG17;B',*40ZMOH/+U\ ;]^_L/?@6R[#AC=?[S^X=EB
M-PX//P"?W%Q'LR'P3<?,0EPPL%VC4X"R4/Y[&U-!A"!3R<M_WGK.]VUKBPJJ
M%]NFE+1?).F:B1<JE[J[/G</5>@(*A86M&"Z+K09A%LN0'Y)CQNVL5OMGD?V
M(S%=N.TBF[*@@KF8P[8#<[DL^YI&$^@! H29AS!O;'Y*-BVFWRI[B$2P;,2M
MFD>IZ$G,:=3[32 S/S,EZ\"\,]L>G_08..7U;7)=2SGQEIPM3H].>SID7[F0
MXM5R@ES-H0[/9]/^&%%;S0V7@ZV[521AL(F6&0O4(/P R+HG=X;'T9\T;:-!
M+C8R^:%&0HDU\/0!6^"XEWG0?=_VSGXW.".X%7QHUVXI0K.WUJOX S"P%"$(
MO./ +?_Y#(H[W)M=^QW%/2&P,6U)QXC')3PL\#4TZOG9_ =N "5*P7"9N,B)
M3DPR-]3DS[YH$#@1#'$\2/(.J $(+ ?^0: ^F;H#2$L.)SAVT8$U(K-MT?#3
MKGX"ULB(2;L7]%\-FV,4MX!5ZVKHIC-Q,%@_> &@H@Z]VR)<1A1,/;8*TMEO
M;^9? %K3M>F/T>_^<[2.CI.'2\D,XK9" &SG>:<5H5TE9\"Q=ELBAD.K94/>
M*8L!(IPID,6=@M'MI37\D[_.1S?03U<*_M/OKQ3\Y-0=(;^!X@?"%B1N=W*R
M9])2&7]/J/$DAV09(Q7E>R=7I*1D+7TC)2:8$30P[^%$PXG0CTO @_D!M.*E
MC$Y^P.TC11?A,9U&HYI'6P<^U*732!D!B\($ICR"TY'%2TD[&_N:D=(KL >&
M_D=AKYJAN%I/7_8$'^>]$T[7B_]VQQ;R,L*K67JG;J!2@N349*A4E=?@O.]:
M5ASP:4PD_&'*;">_"*WB,"+!*_0/UK<^WMX*?;<,0GE/*LQCH&;EI<O^DMDD
M#TO2$1M:3?1)54?\AH8)+&V*CIN;UJ!#;'L(YU*3<3I=4,UP9>QG[="M@CJ.
MZ2M)W1NJ)X4/S/(3! SNG0QG7*J[5YKY#?7V0U*5^27G PQEYSG8)+JPZMFI
M^1>P1G,7V7PR8-"UM867\TO P;Y&C32.P>>V&VY*T$JD"-8@4>6;\ # +TLD
M>CO] G)5B"AG>^@9$2A5)1!0K@<>]YB:\QX,!('*S/!-E,U4&N5A&?XGKIG\
M$*W_N4I4+PV^47RA)!*J2EE3V8HO(?+(6'U5P@DHU-DO%.END%3.G1FG-%]O
MB:$RK0E)RH&CLCQ%'?1([,^I5/.66G+Y[$S,VOVF%1A,,#N-V_*<7CY*X>7+
M=0\\F-^>R$5*!M+JE1$J ZID%J;,$X*;8JYFG/=_V%]"2XR>P-;;<C!WX@X@
MF -C9T"V8&]->.&C0D\R3\,BQ/;CIB$.Y0TJB.6QBYI7E.0RV>'H&8@%(KI;
M5]TX&3#\JE2D>6/EX_+HK6U"2P:(I-@-H3.!A)B#R!RU\?AU(]7R2^ZRPYR'
MF;IBX1?M)N0.Z!F30]K2<N*9@EG)]&.ARG_/174NV^GY7!D[\$(J(_P]S>_0
M'H#1/[@S63!$ 7Z=MTK*D(N3#EJ T$5MQ#OFXP:)9-#'8V6"QF2JVOW@=]*_
MG=F;!OK@?2;$8'&#IB4S*;US4I&#(LGWBJO2UEE3@G;3[1U@C+)@((6V[E#1
MCBJL_&'</I.D5WA4SO9A6'EG\IZ=$]THRZZN;H@2A28*3&)$S2OTM>>S5*.$
M*C;#8+W:*+],M4A.X+>B\IG@"*.2#ZXH;3$!A#+PUQBGF&E13Q\=RQ,@+V-[
MXF6@1:QDYC-%=)C=SX)-?>= M1I.0N[8PKPVJ+S3 43N;/\Y87,1$'8D+&<_
M7 4YP1V47KO",#HD&6UQ^9&=Q\+-*WH#=.BOQGW$?<'.NT;A<'NBO\"=,CN.
M)Y!R%#CX^]P_K$1HI@8:&A=3-(RBJD4*Z"H$$Y)W.-=DO7('_C'Q-NMF[><<
M=%@*2]8?Q7^Q\[HMQT;4-.]Y$X3Q8'SIJN+$Z3>!CIVP!I>4^2=RG8]NH)\N
M9?[GWUW*_",1?)^U]".26/_;.Y M]RLM:P LH;G5TTO8TN&,,AU,\/N?QP[/
M,]51,8TBV_)@80VL^P-';%7N_"R>D=_^BL0 L!^+&K.S*AQ*$4GA#<:36Y#5
M(0%FZ]R$46>QPD3>9+4!+G)VYW.34DCUXP0J[U44#LK1;GB46/4&F"L$S 34
M^]N\N@TG@/_98+S\9L ))Z9TH?@9 7-N;HF<&)V?[,*_<0.:'-K8[H\H0I&!
MMR1O&H9%7_1Z\7P[*'FK\#GB,FS3]^/HG/SZ"CF\" "'H; \ 3U4_"B8S!$<
M75CY5ND(Y=6V$.V[?M752P<M#:4(JAT4CF$J*@Z2"\+5CQ 3HIIIAC*T^W6R
MCRA4PFPYPJ%X7/P'\L,26C&49(WZ7+*7U[U(M)':PHWM C#IQ6)%FE6X%B!!
MP)I(J?J6Y:_CI9V.F[K"R@@94"4& /]R*E10KE9U);!732!NW+;*6!#L7G<-
MPGU9TVI-LB]"M!A>DZ[E?EE!$,+J'@2*L/!5 JTV1Z1]H<+-N@VCA7ZUG\=[
M3]*+I#IF[*-K;NNN19&!V1W7,VV==_HB:#A.#U&+QI=)A;@@,51W\KZ9AE*#
M7C8TI[$;.W%<B[N:'MH9\92GS-\_3.'X!VA\A6D&(_I]UQX&/W#?L;J5_^LP
M")_G*PRN\ )G4YQX-:JD#RPR3E#; G!:._ OC,506J)83.-O]>]J/.58IO,6
M#(*/>61X5!'L?([[MQSU8CC'T*W.K;H1$/'T\H60AV,IO?6OK65@S#-)T%H8
M_<V"$.%ZV)G>:BT'*\[L).$LJ:(*""VJ)O]$G6ZY&25R41&0W+G=$NN3ZQQC
MKU$-Q4=E,^?/AO5:2D]6O(L3@K1(Y&BEH8*?,H7O@BH(JQ$+J0O"&=K'P/(F
M)BY9U2S7-V=6**T_ES1G@3@R>19LPZ:X-3B&PK,P?+"E<D^&)C6SSDVA:^AJ
M-L5$W,G-%>0:\"+R0U8/+*J-&&5%+&N.B+QMS/Y/9CXSF.*;>4_1=AT I@_V
M-P(F65BJM!V<.=2Q;0S*[/K<W4,)6IN(Z' 2&\-#%W4Y"F>6_3P>OUK#/-H%
ME5WOJJO&$%,#;+&*8<3J&FVG<&H%<*3P)XN5Y^G23>%'@!D0^)@\F[;='X(&
M)B<#XY5"XV>)TX6'K+SQD]X/LPL/9^P&>8DZ,ZBE\I ;]4:86(?N"[K"B!K8
M2J82X?S^\YNZQ_P<+PP_8M[\=H@>;LCJX*Y@]428;"EKXR8EW*M_2U2 &)N0
M"UTZ.+,3K380@P#RZ^H6?#22[WT#7;#JU */NE^"?MQ[;R$TR[QC/5EH0B;8
M,IC<*P4"F8X"?' >5N& ;F$D\KWP=^R_Z#;&FF*$(5&<[#NXJ8!/H,0!!*U$
M(BY-7FFY:!8H)_4?J9>*AQU8H6 \HVSQ34>HN,@BRW5(!>^LU"=XK4,QNBOW
M=<4PE:BV86<//KJP"H1X_G0W?J<)<32U9"J!0+G7.&,6<9Y 0G;BJ&*KXPUZ
MJM?_<3:^UG,\'/[A%R6X(XMG!;?;X5ZI%E\_6\!:ND)HO'$E%_2]_^VC?SAV
M\&O/_JQ?:T!3.?-%GB\_5&1=MB"^]NQ+OYN;86/@@30G'"B& W]PY<Z(L'-Y
M1H^W%YO:K1<_L*_TBKP#O.5W>HG_XW^W>.V-(D>Y+Z2Z\:VM?X2KO0F.&%_0
M_O65.C/V;M^C6.36!Y^C/_6W@:""OO17M=+\I:15RRPV>V+2TA*[W(PX7^(3
M10,<D;\;GPN;Z2.OCR]60F4.4R,9^: B_-9>)\$YV,K.>NUC7MI A1& GC%L
MT#2*A'M35O^":.N+$[2,UY-.5':+H=6,Q7K\'*RO3!&L7"%F2RY'IR9:EG$O
MJ]-X-04[L"1&7+/MG?1O8YN:S0::VZ"F!.>6:N\(P]%BY$_JAEF,9YYL/38,
M.GO;2N"#WK>!"[('=\.ALL1-]C%KE5_!_-".8*LA^B"Z7)UD=B."4]$?^\&!
M&H$QF0;N.AT5\K9Q278)]7X6BBLV?CG6D%1C7,[6$>\T;A;N\F*"'A_][B%0
M Z'2<H<X %<L?BB],[S:C+WW. +>U9GA0JFM_9$@XRR/X>W>,^;@0:S&WH<@
M-?H$5F3*8 -5)RHZ$I2]9-?>,MDU]%P!9S -U='FF0TAMG>_6OC51!$S3@;=
MU0V$5 67RN;E.A_=0#]99=.OS=]=:?,NKQ':7N% :ZHK'MPU_M\W'W:HOQU5
M:UT"E5RD'\H#]!GC\DSS8>CU64^[U'P#&EMB_#='(7M*XFOB<4)5O:Q[$X.1
MM'1RXCRNFW7G/==N7,6]&(GHI>"+@M0AD;?MRT8Z0V/OC/+V#STUW]YQ411X
MQ';<-LEH2BL'TO CX^0I];"H;A&J-^<2Z:CXS2%/S3//OR/J=;'#5Q"T"JO'
M&'^#UX?J&,H7%GQ!;6:RX2>XR-5MW;>=.D_@)98,Q92\BES/O_=MG=2IH;\)
MM<KL@[! =KU,&Y$$.RC.>%YC6G=G!F VK7_E\,"A-Q[[K]SBV([:RZ[O$=CB
M?LU 3>9F1KU),KO,80'JK-29'DA:.4F#K51AI]D<<1)MY)CM,KL>]^,XT(:I
M(K4J[/F"09&,$D 00086%,\X8:CCQ0M"&R^%R83$*W1$N/NA:W>UA=.2<FX1
M(RMCF"RHJ30X) 9>9]E.YZE09I79I#9^LO$M8N<CUH=)NCJ_H,0OCQE3A$E>
MAU^I!&?&K.UHV@-C N::)Z0QZ>J#7+3_N46P2$:>V&)*S\50AJ0H#OC\NC;G
MK(D([<:=.QIC9+"&I8B++:$2'#75)6RYF9QIQ*I5&#6]?;U'#LB9=7=:(A3S
M%^ "=&!KP>++JTCCW>FZ_I03\:8%5,+9Y%Q?86XB*!*8BH7F I1-Q;:$3Q3"
MM;U8[/MT#]+H0E=,@:4\DC/EKK41\O4BB^IME=]GJXU+<!*6AUD%FODZQC62
M)/QQ B43O<78)-W1%9F8JK/)_'[KO82:H5&Z!96Z4X=ZYRT:2=-&F2HPD2.V
M/=)"8*>A[2>N OI6M,=P*93&S(:UD!I6,#^WXQ82J4*)A)@C@OWHW6_K;D2B
M9'\ $TSJWWC"4C^8J+/[&??NNA.NX $ZPOS>'!OI^D<3!FUB'9Z*W)H%!T]$
M68@*XZ8.JI@O76TT&MK;U4[6++T)T#[5:XE<E*6FHZ,4SG\:D)*XXQC()2C
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M,HAV[PD/&Q_+OD-EO?8 ]LB?RB ZWA?3@[?7H]9O!82PF$^OMVT+T.Z-=R3
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M9ZD##X^Q!*R^7J87*F+,;79.V/V:UO!QHT,5JAM@^\11AF<^-3&<B>9WB=[
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M&DS0VJ0D=SAL+BOD0ZP0&/W;<E5B2M/Z-HT[0!<IX@FJL'8V]9Y\KP+U-??
MDAJY-ZS$Y;<]=B8OH5R FH'<J)Y;.9#2^KGM& EL3B-@S@7CCG(,!1*20:_S
M%A-'T)9<+OXUMMVXNRR.1UH<:!'<G.'POF3+W<>K+8"7+G;[L09>.B2468[<
M?W;I!Q]K-L)X&L<!H+RRE!PP.,_^ZXMJA,U;XL8KFX;#'DCP8G.3(]YD)!$P
MUP+KSNRY>L.#WY: *,(L:S-<YOM#6.%H%GKGWC'=(B0(F"L3-;1[:?HM9^<0
MHD=HI&(Q:D-NA4JB6P9M8DE$MC4NF;D+X@*3IP60!K7!P;HXT7"$9 &XWM9'
M.14XI])+ P@2;$@)B %QI;VYDCW0;2]K[[&,/'7:R:2B..*X&[=Z*J-D*@9S
MB\\&21J KT B?ZFG%QW?V,BCP6+$[  YEV%+&40\^V'Q-,>P*M-8U!%*F#Q$
M0N3)7]5'M,NZ8+JV(W#[866E]=%(V_;N$A1^&,,5GRB:[XLMB% 'X7$D42$V
MB6Y0L7P]XV]8^;L@JR?R=U!_/\Z$DXO]V ''"&41; 1:5NW>L/3%ZW9HH507
M0EL3[X9(%4S6I;KVJ5_GHQOH)ZRN_>%W5UV[' $/R@N^\'8:W;<7&T"A=VI0
MWPR<[-?ZF2BHH)O0<K.S^V6U'7LP[FN(Y@U!D[H<QSTY%*6!X4!#EJOPW$FJ
M=% [&!&XTVK)PO_I+XO/ZL^)M]LA'1>68E:25 X77"P[P/,'3(W;E-OU-_[K
M_/WLER B[@:6#=N6]0X>F.'-Z">MZVKTYR50&(Q(D!9X&C*B1]X]AFJD.0U%
MA%X3X$&,E=6'NLGQBP_]L*<6(?!14X6_\NF*1=G5/6$>B1"MBT_HYAAJ4;)V
M=#*#QFTH%_T=DDOX2*>*2CP<5$*"@;@],0Y0^P#CZ8,N:+/8[P&MZ0"%M'+4
M]47R1+1V;[V]K=AU>/!SG'H,BH\"&]==PX#],##L/X]^C(&F@],&#]N8Z-;X
M)XM7R@/6QCW7*8&B0CXP8)M)RA>J[T/G1QDUS\#U7Y5,ED7<<MZ)[)6ZD:I9
M@R8<(Q@R?P4*PX.&DIOR-FJ7C49-:?8@-0X\8SUBQP3G!BV(2(Y8N;5K*@#F
M?A.4LB8EU0]5^PX4,;A(2>0(J,C$:$'DQ.NV9$MC^?XEJ<LS\(;P;O""W_W"
M%;7GA(=[]N>O_A!U'GQF/_%YH4N JG&X0 (?.<X7=W#@)"C/D5A[._C?<*E0
M1Q.:G<8&<[T')_DGFWK@^>UM^ @YX2UW0\AQ4MQS\131$Y/R\VJ01^>-\\\&
MN?G>$%>H_^5S;P;]/$+,&TZVN0,M+H7!T"%/(R""X[U6<FND[$,VGZ.2P9I9
M"Y/U53Q9\6<^/QOT/;#4XTM(FV1$4A]V6!$$VJD884X/P\9W5ZU[MK3-?<Q2
MI;YGB1L3)M!9=HBH;U1!AK?=':6R.^MA9S.;,2LE4/?HD6:,7B%X76.]F4AW
M\>477]W7*4"02VR&(?W@?]S4R]J/LQ\;%_E'A?#2D%+]@@4M#DBY^.R/_RNE
M%K+SP:DRQD%@PP7 P4CM F9K6>-E<)F.E((ME0J7"#CQS6I@*WZ>'1@JR>X'
M<9U0XSLX2WXUN5\02&9^"53'J#18W]2HH'6'<P(^J.XWV!?^RW=_!\\BAFB@
M#86OV:&]7OS-N[BW+(2JLE:4@,F^SMDL:EIEED4XQ14^^-@O3I[Y\+LY$"(P
MI47,9[C0TK)  +TAEJ9C&R@R&0)]F[67J$/DMS&:0HM-@R=J]X2"5U$^;[DD
M6L@E]HPLO6#XZMW>'[WW1E0&:!_#TOS<'\](;NC5>[F&[!_U[Q5[J]#3>[HX
M-G9//!RR;489&""$VVWHNUFZX>!< U90&FUB*VP;(I D8/(9Z;F>:KR4AMWN
M9[^L,"<=/*^X^2>$R9F0!5U:C5;.!W+["*OIOF[R;QYC%0]=YW5_T@E__*S2
MI;;T.(G%]\_,76;@\6;@SBQA2&D^34+S,MF_X61_H)3PTV6$)0M[644?>!7]
MNH3ZP[T9MA4GHJC+I/\&IN,)RQ<76,:G?IV/;J"?$);QQPLLXU.UR8]?M\5\
M4_V ^NWY$ :_C3/J%<CF/5IUU19,KQ=_)1&2'?;@:GGC2SW6XJ(>70II4,7-
MCDY)2&A(+H^XB!'RS<D\U-;;;HG4)+DRYSNN_0_>@ZJ0NK58^ G9\$60>C%3
MNTU/:;1K).R'W#VPUJ#3.+"M<#(HT*,X_A0DRG?C=JCWV_BZ@8"3."_%TVOZ
MNA^,.DD'<6<W;C%5LR3J68>C1$\,"?70GHS?KP(+SOOYF*(B,\W#?H"D*DXP
MEHRYA?VQRL77BY\V0',;.6AVFM4UKQCGBY.[:;D1G)[.U#S@^^MR17E?].2+
M&,I/JAI0"_+WQ)H^M#E@=TMGS10F<TD94[K*RX9K<EJ)K51H,AFO\$3(KLT\
M0I"2AO:Q@^.2+' R4>[RMKYI.Y(UI_&,0Q'$IM%>-_7DTW=^[_@%2I<UE2NE
M9CPC9<BD0(G:8%@HQ)6U4@IR',CL#CO%(DNM__I:LDYY/!A!C8N&I@/+IM-;
MG5E)[\3$PLQ092+?I6+J$IE%G=0EZ#Q%SOVJ-^6+]ZE73-!V%'YACWT@QH
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M&#GO,_/8;V*;U13I6E%B0Y28)!;EW)A;7A[VL(D8^DM5EA1Z(^!9G-C3L7B
M*M)L#,G&H*:C8YR:%CC-X$SC\J)'U.V!,$G@M%04V7!:W8!\(M+HQ)"H%[/_
M7.MN)3>+AN#7TL_M[$=H^!EAFD:E#VA_RLC)%G5<.<Y,!&QA/#,.M4S=QVKJ
M:6!VF:J;/+[858Q>\.']J1D$:WRT'AMZ1)?ZNTSU)CG;DC"JHD^#=\"LXS'G
MFH?D@\4L6*K9L XC!Y:^XL^-20Q@(*QPX39<3C,<SN\N=&+0=525>-C4]G.
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M?N(?.^[.WIC%4EQH[FB?^$=!W3\.FJL.]\Z @'5?^'0']5JCB6M^_T2O!0D
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M7!Y'/>BDT0S^KS\>#O[GOU!+ P04    " ";0')1%\C"]U\3   )V0  $0
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M!>Z"8B^?9P4T",0'/D24_%"U $T7+""^^@,Z)]LE;'!-X)E'4# ?!I<X1,3
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ME.?IO6-$JI2)$]H1KH+G!CSDT.0UR8UHVN;M&(C4&R"">D&DL)X$$0.ASNC
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M]HPS[64[N\\\<06 @,TNB721E#-=OWX"I"1+O$B;Y 9)4ZZ+K.O>7T1\ "*
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M,0Z5\'(2-#XB TXF]V4_P7_\O/X!\_U"26)[(RTK4=;[#IUCH2A@F*W*#K&
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M8@_]'Y8AUKJL%4'RI=X^I3U29,@C19U.&E7OR/9-#N\/S8Q'=F$.38QMU'X
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M7M?,6*M)0W3@<P85L 6QMD9ZK+*;WBBRW!:[J:E:-%O?!O!U'EX7R"T+_7?
M?)P. (W9L _W]C#EB; PIQ!#-O5:PDS#5)$07FG+;,HE082@4I/%\V38]TB7
M@=,GWS86[+\7M/AY,L2WLPGB[">XC)-A?H^_PG0*Z</5%&>SFR;'-B,%%$FR
M!*0+G4-DOAC-@HH\0U(^BJ6:\XWMH3N^\O N>G/KC9NKON^ZJ&>*BQ^'HQ%^
M[@"4\RR0TUP1C#&U<8=F@"*0!Z& JVQRZ7@IW39O/7>:M#) [[6L,/H59CC^
M"2Z&93P9#>$:%!E7*P&*62\LTP$SBXI'EE.Q7 H/.G:L9]WPAC-G0"^*[;T6
M?074L_P_4,\YWWZD?VYZX,J0$JC"O!.<Z50B Z,X0YZ#1 3A3,=.!5U>]^1X
ML*_*&Z2DW6BDUBO-GHWRS_^\&LYO9;I[M5=**GMBJ]*UP4Z]42,H1Q"MX,;0
M:H>\2>/)#MC.-1#ORQP]3B./0KS3V:4+Q$.$V@]@/&YHW9M]N_)G3^,T#)X?
M@NHQV6 "C1T;<FWM1:Z12H$Y@X:\:5E$;E)S<33^= R.CTF?;6S2M\_ZYODM
MHMOF;UYJ#IZEVDA*RZAKDJXG7SH@&)T%3]W"W)5''\\[Z4W[X]Y4=Z +#Q85
MCV^O+B]A\GE<YE_^-)[.]KG8X-%G]E<*VA7X4B%H0!MY *YS*=HD%Y7AM:Q;
MQ\B]_?_;N];>-G(E^WW_"P&^'U\6R.3.#(+-C(-D@/M1*)+%6%A;RDIR[N;^
M^B5ERY%EM]12DRU;.X/!8/)P]V'5:;)8+)[R:G+PZ6VO@:IH8J:$)SJES#FE
M\KZ%6R!*6B\%-5QBPSL)S:Z!;A^_[MQ!?'<[7ZRF_UY?M9U8'KF/R9'H65$_
M8I(X,/D_D2HT5C*QNRFJI+O>#]_K.QD_AB_/M- ;.*6%T/\6S ^S%2YPN98F
MG2UQXE,4J5Q7%++4#2L:2F.BC%1[IGW*&S[>1.US#Z;+Y<@0XS<(:I]F$,H<
M/9'&1 ->$$PZ+Z[,%Y4LG8A7G NC!7.I"1V>0[DL%@PT=8.=\;ZD@.)"^4AU
MGJ5*MS(.C'C0FD2IG*8Z#]<U415X S4S0TA0R^2OI6;FPRR'E/AE!:OU<S^6
M'R@N63>V+=*U-@_ EB)RR:0@3N>1&>^MCL(R,+8%A?9@>HWIMZ/</F]C_@8K
M2P>T3;/J'N!:)MSVHCM/JJV:+_MQ9( C1F>+D\G+E"A1VN1UT@F;/Y&@"4JF
M(=&(*C5I*7H&EAQ(J)V'),?8OWH*#9>8GW;];A;_@=_Q9KZ=$HI<6A69)3RH
M<G'%.F)C#J8IA<!I,"SL1BE=V;0];QD_#*WHC7D+4S;8H/Z.LQP>WV1H[^)M
M-O!R58+E[_BP3]J(O:JBIZXLH5[DW5*@-I.=1I*T89(BI9$V*;CMA>X2>-+.
M'9WS0IN,[+=O-QM%%;@IN^\OUXBK+46Z[4UYA6SM2>^KF<D=/N"=+*])$9FE
MVKN4)/<1G("0-ZM!..J=,I-:0V_EX:<;[AHI^5-?.:J?^PQ[M_.P]1QCZ39,
MN51,>1.I$BH&8(JC8/U=?=@ IWD[7&.\N\%Y^@-6Y>KJ%)?9@MO::],:'C[J
M-16]>OKP=CSIG5,J*LY4*JU'N',)M&+::J%,$FXR<*!'>N]=,?*?\]5I<K);
M/UW#UEU@=DQH#47N*#@NI PAVL!3D%)AWIE3#VSR,JR3+7.ZW.ZS9]2U4@_9
M7>%L7NI%B(ZY]>E?8!2-8-%#3,+RR3Z()UOL3UC<1R,#/O@]3ZMKQ?U@=R=B
MD,R6%3?H*)-&*[FF>;75/G(NJ)[L>6[-7N,_DYTH!#/)F1P40RD.TX98$QE)
M4M(\Q80<'+@6$7<'GKHMU7^#@ ^J*!YI#+)TWW+"Y\TS=P28UR08(2!JZP,V
MJ1GL C3^9J(& _9W/S_1W UVFY\6\X 8E[]E*]Q+U:^F>7HJ<"?2@6!Y+TP2
M58Y(*,V#RFX8A0N@.5*-K2X\=6&Z##+4,GJ#]..7U3S\]X?E\@[C/^Y*P[=/
MN)C.XY=K6.#R9R^#]87W#>X'$95IT<P1>3_M@B<4>"F4#TCR.S1)CC+IF:(.
MFDP>PV!?!JM&=%W].PXW>)76 _ATMPC717IC,0U8L-[>SF?W?_*@[N8U>L&#
M*\7\E$A.\Q<",4^;.H'/'TU,P1X*>HY^Z]NF2%LCUVY%4T;^DZ^/S2;7.+_!
M[,=$(VA3!#^32IC!<2A=0CE)(C$=N:> _1APZ$T7X/6JQJPHEKL9\,[Z]]B>
MM+0!OIF7;J1Y\ !.ANA)0B:)5-83IUD@D;*,TH,6HDDA3@]L;YLAK9Q06W3W
M]VR8C_/E\FKV_AIF7_'#[!'B57IJD F#4*K%&,&0T<D\CY$<.5G"''<*,6F^
M>S+2,3D<\=*WS8*F)JXHPKL9^W8YZ56ZSZGG<&==5SU1)G%K3.G952Y1J'+V
M"Z")<B)J'4.,MLG!V#Y0;YL>U<U>47)W3=V-2MMO\\5'_ HW]XC 4K I%CE7
MD1$9G4G**"4B>%0ZB*AZ-F9_\?%OVZ65S%91%/?E4=[7A5EJI8EYDE&T'*Y&
M"P0,*!*CRR/UFCG#VF>D1JV\;)^".MZTKZ72\N-\]G6%B]LRGL>[<YC0,"WS
M:L2R.:3F@E@7#1%2>^,9!DZ;7/5X"<RY:BL'.WBW1'>HH5OT==K!M"G>ZX&J
M917ER[#.4SXYW&T'>## YB,RPC/G;*#$)%:T>SF23'4@: QSC'F#C:0N1V3"
M@1+)T8APA*D;$&!G\_I0D66L0&282!*6$BF@].[U@C#*K?3Y*9PWJ91]$<T9
M[N]4<-7^),$)=FYP?O5TS;N_1I]"CI R!&]=9CB&(M:3$LF[$\9L7O98:.+Y
MYU N)1 8:.0&%[:>(OH3;A\E,GK@:AD(= $[3R@PU'%[>3#0Z@U6@DY\T><M
MK+>RM""U1":NB(?(2?Z](%5DI;_[VV?#@7!@+#(<8^S:=R2VUJAU;= G^%%F
MO\=:H8UT5THJ:E?DG7@JE1=((%).M++**44-[,I5=^2&^KWOW,FB4YTS;VO9
MZ@J:!<PNS@=<-H)+C"4""6AI[.*(0P"2'%J+ED*(K)?'][SD$MQ<RX8M2E/N
M_'(:I[#XL762O9[&8A#!)2&)X-+G/8TRQ%,;24F5*8:Q7"!O4G72A>A2 K\Z
M)F\@?K@%I[#^*OVU@-D2PM:EGSX(6T:"AR&>)R:LY--=IK1Q2(MIY#!289D)
M$"11+KJ\I[6,^)(R$3(##<(Y%9HDD\]%F0.!X]D8<XP?6ES%_G3UL/*Y',=P
M)1PI!>A$@BFBKSG(L4)+KH, ZIMTW'I$,'YH4=L]N]>L3[)M@P32XYW1(K*W
M^E&JHN:S<BRZ)KB@22J;XRCK"\&58$64*!"6I.#64H.RB7+'7E07$UU4,WV#
MNK0=3!O*]P#5,JAX$=69XHAZWINW,GV#1>%E<$S8/%O1_!GQH(DTD+>]$O+,
MJ+1)Y=9Y%$WFB1'Y<"A(&)D.QUB\R:'38\GTID> 1YU1&,*5S8!B'J*5#DF*
M@46ODN2L20/&9TC&CQ4J>.C96=,0\[8($W(,C/]S5_C]_4'7=TULPZ*3BELB
M=%&SU)27$GE*?(Z,T =CA&FB#M>!YV)"@PKFKEB$O ?6 ]G[ &N:;>A"=KXD
MPV#_'>;$ .,W2E"^##!:GB"&1$PT(7\**A!K59D9HZ/>>.I,D[O#([.B1QYA
M/%(<8_/V9-AH2YFH<AQ4KO=J*,IDE@#XDI<7-GFJ&:8QEHNS)17J>&L_!TXP
M]4@B^3\U"_X+?ZRO5KQ;+N]NUQ*80S1;>CVWKIA#WP'LR#IPSZU68)).41JK
MG$@B8@C.<T>3<9->;QBH +ZYU[+6)E^^F\4MI9<_$,IUIW@U^URNQI9KM/DO
M_#F?+3:__ 66T^7C/;J_,%S/IIE\RX^/1=J,AZ1=LB1@CGZDD9PX90T!!M(D
MF@2FT.(C;SVPNN49#X#*_WZ8?;M;3;R36DF?"'6.YBG EV1R\@2%"49&#A:;
MW/+;#VO\2?)5\7-_U<<@'[80]V]CNOO]3&1,!QY*CEHZ(AV4/F&:Y?7%^60I
M-1":' *T'-18]UE>-:=?#6M>RPV;W<_Z,5)WW#"J B4L1V1$AKRO=\D@,1AH
M,-9PU>8F5A>@<Z4[7@]CY@T\UV W]!*NC3AK#V0M,R?=T,Z3.JGCPAZ\&&#_
M<1GBM1;.Y% "P(@BR%S:Q'-&<DB!DF..*6R3[,G8S#B0/AF;&,>8?01"%,'E
ML,+X%RYN']LR>RK*<8#@$4L3[M)_6THB/&@6:-YLQB9U.H>AC;]KJ.7( _P8
MZ(4&,?\NPJ)94I3U/L-JH\YM!(H8$Q*TBA%9.@-XB4!H,L)S@9B-, 9/GD.[
M6)X,]$+M>P&[\/Z)I4-=#L4>L*4@C75.DQ0@8ROGC. D(]XRBL$ TM1/+.+
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M 5J'..G#;Y?_>%CB?_['_P%02P,$%     @ FT!R4=2D(J@,YP  $-4) !4
M  !K<F]N+3(P,C P.3,P7VQA8BYX;6S4O6N3W+:6)?I]?@7NF8@9.Z)P3!+@
MZTQW3Y0>]BBNK%)(\NGI<-S(P%-BGZQD'9)55O6OOP ?F<P7$V""+-H?9*F*
M)-9>(!<V@(V]_^5_?[]?@R=1E%F^^=>_^'_U_@+$AN4\VWS]U[_\]N5GF/SE
M?__;?_MO__+_0/A_7WUZ#][D[/%>;"KPNA"D$AS\D57?P+]S4?X#R"*_!_^>
M%__(G@B$_U;?]#I_>"ZRK]\J$'B!=_C;XF\!EBA -()(>"'$09I"&GD4"AYS
M3Z98T%#<?/T;33B+$Y] )D(*,8DI)"GR8.P%@G..L8]D_=!UMOG'W_0?E)0"
M*.,V9?W/?_W+MZIZ^-M//_WQQQ]__4Z+]5_SXNM/@>>AG[JK_])>_OWH^C]0
M?;6?INE/]6^WEY;9J0O58_V?_N^O[S^S;^*>P&Q35F3#= -E]K>R_N'[G)&J
MYOPB+G#V"OTOV%T&]8^@'T#D__5[R?_R;_\-@(:.(E^+3T("_?_?/KT[VV3Z
MD[[BIXWXJGOVHRBRG'^N2%&])U2L%?KZ:=7S@_C7OY39_<-:=#_[5@AY^K'K
MHMA[JD:9:I1^I%'^]W.-_70%?$=XJV.L#L#5YGYPA7&(TP_.X'Y1^B"F!]QK
MYFK(S0OU=L/G>G>W35T-?7K$KEZ+O"+K&5Z+73,]R&O]@_?J;VTS^D$#8EJW
MTTIW#ZKX7HD-%XU:[CT:9/Q?_Z+^MGHLX5="'E:?OY%"O%)"RU_G]P]B4];Z
M?5L49/-5Z"'QU?/NDH_D6?_H]@]2\+?_?,RJYW=J$"CJH;.\J[Z)XLLWLKE[
MT(\H?U&/J,IWF^9%6L42"X%2'Q(4)!!S3T B_%2-=1XE))9QF/BK:ONMK,0&
M_O:Y,ZO&_C+ _V+1$]4912E$F3\6;#<6WZ]/#;!J;-6C<?+3AMR+\H&T-RCK
MM=O2$/)OGX0"GC'MI)15SOX!B#:J!%E9/JJ?_9!M0*GM+G_\EY]VW"WH15C_
M:;MW/6W/UO9 [?1PT#<:]*P&]!GTKVLM![7I-Z Q'O2L![7YH%+V@Y: &]!0
M -2KTI!P]DW)V9ZU:^W>Y<5AM^7LQ;IM3X;K+I.DI#7G+:2?M(?^DUA79?<3
MJ'\"/;]U*?_[[-A_.OH:;XN.:%*P"Z]B>\5/+%?.]T,%]]Y*/5EYV1ZI\I?]
MD)LW59'T%Y 77!1J^G>"\*W\<9&MNMG?%W7K*B81I8&:B:4X]""FG$$2I&I.
M%L>>%!@CQ!.3<>KPP4L;1[937@W.;*@XXFI8RJ]A8&*I-3/>6/W.6;I3I[*3
MIU*POW[-GWY2MS3*I/YR*$A'CYM%,,X9T7W09W]O]\%=K0OMUW_W6.GU![VD
M\VZC/*)-F;&_D_6C6&&B^$QD!'&$!<1"^9RI1 B2..%QRKCT4#R+IWD)Z=(D
MX159ZP6=&W#[]6M1SU+ %C"H$<_D4E[LXHE]2)<=MWRG<>L6]NR],>[Y^5Q$
MTUY9A$]X$>R?PPDTY=R9UV?<X+A11Z&YSZK:G;S=*&R;2K4@-BP3Y9NL9.N\
M?"S$%_&]>J7H^\>*>I0+%@9J[,!2+UK$D,8"0X8IB4D2ADD@;(82N^:7-C[T
MT /5-V /O]W08-D/9GH_';L3B_@@L6"''?RNT8,:_O_G3I''\>929BT1S*J=
MX]@Y%,213WD9WWI_9OU+D9?E*J(^\K''8,R%#S'Q$4Q]E,*8AEPDJ1][ L_I
M59_ N#2]K"&^R)KL0#_.XSI?V3M_(J?Y<"U5_T19NQQ_>: KEN0IGX+YI_*1
M!WAV[1T/-35NQ/@DUO6F+RFJYR_JZ25A=4NOGON_N?V>E2M/HH!&40@)8VH@
MX)PH[Q@%,(@"*9&,9$JLEE?,FUZ:OK?X0 T0_*XAGO?*KJ7=3+>G(7-B.;;B
MT5H_[2EQ*8L6K<^J=O:L'(K8B">,]&:5RHGR]J/J%5$4@G_6V]Z_BGLJBE48
M^U% (@35A%S]X<4")I*D,"0$^R%+XY1Z5E[I^;:6ICX-5' +MF!!C=;2Q1P@
MU]!5=$/9U"[?&;; [PU4AX)C0(A3QVN@N7D=J,MV'SE"!K>,$PWE-1&Z%GJR
M?<M8\4C6Y2TMJT*)E.%[/?"$!;W7'<IZW:C#J<;0%JG#U]J #Y>O]5!SL[[6
M!G8?OM8FMXQ[K=]MGD39+".]V[P1M%)-_$J*?XA*-]B$3'P6[+'(JJQN_[4H
M*I)MU "MU])ORU)4)U=8B9<&RG\7,";*E\=Q2& 2>@0& 4Z11'$:"F(SD$X%
M=&FC<,].NX%WLIXT4[<E],_$TM@S42_/:"-KE=R9V<7+[0P%/]3K[XVMH#46
M--;^./U*_-2]XE*@)\,ZJ[I/S?CAT#!Y>^/&E2_B_B$O2/'<(%!3M[OB<Z5G
M<?6NZT=1U M2*XK5I,KG'&(4)Q S%D :X@1&!".1^#Z/2& S3!BVNS35?YVK
M;BRJ3&O(PW9"4<=CWX '4H GC;Y>^.?Y>DV*$CR(HMD$L-P#,.T9,]F?@.^)
M57R+N!7K&[U,I-YMT,!NHE/TVGNS6N].BRVI<BFMIDW/JI26?!P*G^WM=CKV
MCR+?K-X+I8[B3GUI1.^NOA>D%.\V2DC)^G:S45ZX7D__I*1WY2.2)%X2PD0J
M1Q<+GL($DQBRV.<^"Q(J260B8W;-+DW%6I#**=(H07TJLU XS03*DO)A?9J.
MR(GEJ<&L]P-;U*"&K>/G&G(;Y$!#!Y^F(I>W<;GU/M(+D+S7_I^!;./18!QG
MS6"@[ZTEWDN15PN\Y=-FT?=Q%G;R/O+N<5[JSR0KZM'BW>;AL2K?BR>Q1NUB
M=8 Q]VCB018ERC/UA0\I5>*>"D&B( Y387>^<*"MI>EXC0T@.[]RB$LS7](1
M0Q,+M$;9.(E:)C30&] 2-L':OP$G+AW%H>9F=0X-[#YT"$UN&2<3C1S5*E1^
MS-<9>]ZMCK&4QS3TU;2540EQ$$5J AN&,(PCGZ$X]L/(Z'B705O+DPD-TDXE
MAJ@T4PE'!,WDQC4XP>\-4C#)(I\!(RXU8JBY637"P.Y#C3"YQ6G T]OO.AQ+
ME#\K]/V@AG_/JF_]6U:>1U$4>3$,6.1#'":QFD'R!"*.DH1A'H=F,TA'>):F
M-1WN)GM2M4/>9%8JVHB?!XW=2<B4<<>9J=:,W3&QLNT'5_5 WX#]3NK;T_32
MWJV3!V39<CM#E)8QI"6$;MGR9QC/9?W8$0MWOY!L\SXOR[O-ZV\Z!/;=9NL<
MWDF]2;++ K#"S/-(R 243'4EQI1"(@B!?AJ% GMQC)-T]20*FALMWEDT;?-1
M]P%,]VUK\."'M8+_H][AE'JJ\V1^3M>:>RH83S'U8"B)XCZ@""91F$(1DH!R
MZA/&Q*J?C6E>[B\FG'*Z!51#WJ<=Y+))"/@AKTP];>M.,%A(G>BEGGBD:M[F
M]_7;?+<!+<'O-F WA0=WLMG'WQDP$<L6*ZH3L3W3FJICUNT65D=0-[BT:O.\
M^1971UBYM[PZYGZ[4;@LJM4G_>AV 3!-6.J'2N,I)7I_S&-*Z)7;))"R/67$
MC\S"J@^>N[19BMY_S,HJ8V0-?E63S,>B.?KU^YO\7G%N>)CCD+QA@;Z"DHGU
M=S0;QM_\&=L'/'EU1\^+5_\Z]. /'SG+5WW&CNZC/??KD:N9&:'9N@L'JB.D
MO^5K=7_9[*1OPYHII0@1E$(<Z:5-X7&8>.H/(2F-?!Z)0'*KI4W#AI?V5?=P
MWP!V/E*G#@8L>V;]3\"%S%AFZ%-8=Y#A@ND$M$^]>KJ#7)/:AE5.$85NRX[3
ME533MN==5K5DY&B-U?9^1Y$Y;TLUT-3_U#O#[2G7\J-0[Z3ROT.2R$C2& J*
ME:(Q@B'Q$C7-1[$OHB@)4FD4CSZN^:5)V@YL': #'EJX-SJLD%T?53+<%P8S
MSDD9GFGOYRBJI,>ZMJ!+ :!8_S@#ZU?&]#AC_Z5C>\;WPO5!/D8D6@?[##_U
M98-^C"R^&/QC]I29D]N\SS;B727NRU7DQ=3W PG#*!40QP&':CBA,)8R]#!&
M@F"KS;OK(2UMP+DZ0PKX7=L&:N,LDR(XZ& S3WO>;IMZ]CY/C\V7ON:(Y$5D
MJ]FA^G,DISEBT5DNFN,GCPSJS#8ZZVP];GS2-97NY&^EJ \ZW=[G:NK^7XT'
M%& N*??TR@;U($XYA03%'D1)S%.?LA!+:17@:=;NTI2YA0W6&C=@>6FY6F%*
MMYF$3D#BQ#K9\==ZES5HF$NH8#?G/&] '[G#T% [JIR&B1HV/6_(J!T?1^&C
MEK>//6_/"MW"&]'\_]VFKD+P09GX6.BI>&_U9!6$- UD(B"*_1CB1*AQEI$4
M$E^P.%!B)8/4[@R]>>-+DZFF[,AZ!]#V=+P%[V92-16;$^M5!QO\T &O8ST:
M?G?@P7L#JD><1[?GS.T9<XOV9SXW;L_,\5GP$<\8F0[G5'XGK5=437>A%+HD
MEX\(I!$+H20ZVP?QD?"M#G/_&;)F]4]N7Y4XZXJ,60M/E35]AJRY4F.]?$XL
MFV18#K-@Z5HM;1:)Y[??61TU\D%U^<KS?"(]E$ OD0AB%"&8Z/SV*$[](&)$
M_8^95C<ZU<#2/O<.(^A  HW2O-S121*'OW(7U$R]5F3'BE4=I"'3KZB'=/*Q
ML]5%&C*J7Q]I\+HQ^Z;9/Q\S7D]DFH%+%[3^S,2&%%G>CCD<>9Z:8820)BF#
M.)4A)(@PB!@C*/&"2/W2?*?T<H-+^\1[D-MH#XT9E"UHFSTZ [9-]D+=<CCU
M[F>/OAU<T.&]//J/?&LM=C?=\CG7?N8PKZXV+<VY&=ZF-'C.C!N3YE;M;T5:
MW#=N'G7[1+*USM3U<UY\)FNQ2]6EXW!_)57[+WTZ)G^L/F>;KVO1_OCY#:G$
M-G)WQ63((UV<SH]BI!>U$YA0@6'(*0N9X,(+K/*HNX.V-(7OE[/=Y!7@CP*0
M"A!0UC: ^]8(H+K>LD2=P_XTF_N]3"]-/(;4AP-VEMR K950Y@4LE9TWH#/B
MICY<J&P#C7';7P!MWDWOW(&[":=[UEU.4QVBFW5RZY[5PRGQ!"V,73_+F1"\
M/@796T+2*%9<QHF05$VB0Q%#K$-*$AG'T ^(Y,H)CPF*S$XD&K1F\]7/<PBQ
M ]N<(M9EZ.O]M5SNQ5YO](FX&[ 1E?[-]BJ]?VFY-3#4%3$141H)J@91+B&F
M/H<D2#B,DT#-@A+"B&>U1^RH(^88)#\H9ADIOX&'%K,[5DU7-9UP-?GB9O]M
M[:\&:Z NES@OLN%VI?-\<S,O>%ZT^WC=\_(MSD-+7@GEF8A;IN:"C_4A]KW@
MAT@(&H<!@7Z"*,0H26$2\ CZH5*8)$Y#+JR.THP%LC21V0\^4=/93_^#W#_\
MKS= J(G7@_EQW*L[R$R2YJ!]8KTR"%>AM2F@9\O\$2Q&=,X4TC*,92DQ+D:,
M602]F#UOG(YN@[O?;5A^+_19Y!7S/$F",(!<,KV31'U(F>_!U">8*(^8"R16
M55Z1M9E$GFC#2OVV+4VXI*<P-7Y#WH#--Y9>UBDBS:3L2GHF5JG=H8T&7IM0
MP)WT#)CO4E5.-3.K8 S8>:@%0Y=>?=+X=1. LA("I9*$ L:1C"!.$@\F)$"0
MD)@+(D(4HM3F*S]N8FD?^1?=!NBBJD8'L)W@TNQ#OXZAR3>+>D>K6WB3G.T]
M,'VB4[Q=*R]U7O? RH&3N8=7CHX">R 9;U-ZW6YX'6_6U!3IWM(X\)&7D! &
M,8\AIFD"J4 $,HJQ1$Q@CUHE2#5H<VFSG!8R$%U^/'VF/:\#+CM=(#5^ZXBQ
MB^P3ZJ>2D@C&W!<0$UV&*Y4,>@%)_50DB>2)C=ZZ9G\& 7Y!]DT7NIQR.OF"
M5T-G"[=FLPD>;A!/H.,6!#F.]KO8[-S!?Z8\G(@%-+YU1%S19[+Y5<T1\]=D
MG:EIXR8CM_P_B3Z<^UF_1FV,!O8"'L8HA7X44(AE0B -TD Y?PE*?.H'.#1*
MJ6_>Y-)& @4:U*C55[+%?0,ZY*"&;A$98\;[L Q-P^;$*F1$Y)A8(S-&+:*-
MG#,[4[S1=:^J7=21%4>#<4=F3YHO\LC*LKW8([L[Q_GOK_/[^ZPI'J@K ^8;
M/?T7&Z8/01%$)&640R&\4/GM401)E&(H A+[B:=/HUEM60RTM325[D&MW1O6
M!PM^T,E8@8\LZ^X-<6WF)SIB<&)E/B1O#Z<[G]" #)>^X%!SL_J !G8?^GXF
MMXR,7JS]QVT^NC0(=%R$U@CA02SB4/EW40#5')_P)(T]@D.K",2]QR]-)6Y'
M3!H/"#/[[L?3,/&GW@";)"W?:9N=!LGMMS!OH-M)ZXZ"U4Y?-3++$?LF^.-:
MW,F/A=YMJIX_JK[4U8+?=EOM7W1@W(H1+Y!"!#!D0:CSX7-(DT!"C_$4!6K.
MAE)DE<O(L.&E?=X=VAM0X]WFH7QH<MC6F&T3$9GV@9DN3,'LY(M'UY!JGRO(
MDB&G&8%,VYXW[X\E(T?9?6SO'[&8=!OX;XM,?*X*(:K7Y)X6&?\J?B5E2=BW
M1Z6)5=E.PPEA5,U#="K/.((X\%-(?8)AC$3HASB.L%GQ-;MFEZ94@0\T<- @
MU]/U%KN.D>^AMU@%,>\"@[6E28B=6*A,.1VSQ&1.KL4RTR0DS[34=/4+;+?:
M9$W5X(J3^=/F6W6RMG!OY<G^[I&[Q^K]^49*H4:2ITR?K/LBBOONU9>,1:%(
M.8PHTV69_ @2R@G$"4WUOB4AU,H-'6IL:8)>._Z@0PQNOZJ.L(^%':37<&?2
M$6E3>Y4=4UN<H 8Z1:81 T:<[D$.M3?OYJ.!Y4>[CB;WS)RUM_[C[Z+4BV ?
M19'EW%]1PK OH@!Z-%9BPR76QWP"R)*(<4_-?D5BE;C();BEB5.+3B>*5_!F
MRL1[JM,,)\DOU!53[W]>FYWWIDW2VW7GQ^'NG"]-[P#OBTC8>PK?GR-U[P"S
MSI+X#K4Q8BG@-2F_Z3T+]3^]OO!$UJ)>;-!GN79G=P]/]?Y2Y&7YVZ809)W]
ME^ ZDKDYS?"%?%]Q',<>"@+($0^4UI,(IEKP@Q"QB+" A3SN:DY^,5PZ< _3
M2&KVZU-^F4'\VV!F?2Q4; UM]OFRS9/J]K:2PN/6*J"KB5K5KIR@SPT6*5ZH
M"V?:D]4==JLW8_5?=O;5/SM(MK#+M0"4D4!;"6HSP<Y.4)]<:2P%RM27[5V+
M59*7[>69EE->K+?MEF&FZXO!]9H)FIUO86<ZSO96@"9L9F2@ 6/Y8QVW\#%?
M9SIRP78/_>P#%B33.Y"@0SG-YOI%,IQNM)]O;=Y-]XM6'VW 7[YC9-S=J>^K
M_*3\IR)CRI4[_?L:Q/,J",.$H2B B/H)Q!()F/H)A9P+%O@!\GR[#?IKP"QM
M<:(>\<CQT->XJ#N;ZM];QN]=TV=F(C573\SA;9[JA)O#'CAS56,1^+W]_Q?Q
MO0*OU*?\#X<:Z()KIP&&U^"9-P+1 7-'(8HNGCER(5DGQWY7EH^"OU&.3;=L
M42?Y.KT,LO(8PP'U(A@E#.N]*033U(LAE2BF(DZ]U#.J9CX>PM)T]]U>EJ[[
M>YTOM\[U_OB@_OK4KC'JKUU\%P7+ROK*_*%.>5#_O+M&_;C8B41IGT=_1'\:
MKB1/VDMSK!>7H(%_TZ1#O#F].KQ;Y+L!1*JW1\\,I<BJQ\)A!L7Q;#I=!;9'
M,>]:[VB6CE9TQS_)OE3 6^4T5\^WG*MWKOQ<D4K<%?4>H#)Z%<4I1T@YK#B6
M <0H#&"*9 Q3P6@<QE&J_C M&3#4T-(TLL$*6K#JX]-P%:6@ VQ>16"0WV$U
M<\G:Q)HUGC"K @,F;%Q1:&#P\;,5'# QLE]XP.CZ$1LZRJ43ZHYO]6+2DUCG
M=<AH;\S1QU/T#/M+K@1*YL6]&GSJL\K*&_RJ$U'EQ?.OV5JY"/E&M&/62@KF
M>7Z$84@BI2LATS72)%=_\Z0,,$(A-7+(IH.X-#':(07W'=2N"KS%:OXTW6FP
M7?/BG32Q]G7VM6OV6POWW;/.2/ E!ZV9]3)^8ZB>;F][>6MKY^B]>"];;-N\
M>&_/M'/S@KUNMW<S:8<,;M],T_)\.SB3,K>WB3-M2U<F?JPS3K;/+%<\EMPC
M+(010KH4L^?!5(8)I"A :@!/*5+/L%A0.=W,TL;@&EPWZ(Y-_+A/I-E*QO7T
M3#SZ[=(_MFEJ/UXB:7P"R),<3)(#<K^EETD#>=+:LYD@3U]]U19NJ1ZG]XRW
M"2$)Q23!& :)I.T1+DH#R,-0(AQSQ*A5AOW3S2SMT^]0ZJ]?P[0\17Z:2JN=
M\"L(FF<7O 0MP@D2B@US,,'F]V%++['Q?<;:,YO>YZX>FVAFFX9?9T_I'MX=
MXT248L$3&(DTU"&9"*9AY,$@#KV849X*;%6Y:K"UI4F!?G% #=,VG\P0I<)'
M,9=I#/U$!PEX@L#48Q*&-!2$^1%-$\^NAHPS4N>I(M.OQ.&<7</M?%>,3;U?
M?TA5I[P3G)\RXL1MXIZA!F=.W6-@^W'R'I.;1JS$_ORXX07)2G%02--/I"=D
M2"'E?@2Q%!@FB*0P"-. ,C]!*#*:BPTULC0-WL(<4^7U')$&JY@.Z)E8&W;,
M7%/ ]1Q%%DN #JB::1'OF#)'BVX7*!A<-CMW[WP+7Q?0[RU=7;IVG!/Z1=P_
MY 4IGG4(4=4<8"J;+?&5+\-4A,I?2B0)=9[L !(>(BBCD/E^3'Q.0CM_::"U
M97M+#^H]$LKI;Z-O;D#9Q(YD-7;P0[9I?V*9 '&(_H3&RF(=Q!KH58!$#>6$
M)S[DV$<<BQ1CLY@ Q^3/E!R^I;L.T6A#=-Q1:^:K.B)LXM%HBQ(T,-L(IO(2
M:=9NJ@$=+IW4H>9F=5$-[#YT4$UN&:?7GT1%LHW@;TFQR39?RUXMJC="9BRK
M5BAB6"BUAAXBREGU6 03YJNY+@ECGG@21W89)R\WN33YZ%=IXPU$.^TP8-E,
M0MQR-[&2=&!!AQ;\T&>R!>RPX)0Y.RZ%Q:#56?7%G(5#F;&XT\76Y$$QO)4?
M88(20J"0E$$<D!BFRC6$+$D2*1A#:4S&[U >M+8TC=EMQS5U.HNN:.2CKO\Q
M(@WN,-<1BX6?*)JYY^D#3JF )$ 8QK'>#D($H<BW\\6=L3V/-W[(MWN*S13=
M&6T3B_G1=O%Q5=.I-H[/D#+=_O%A@R^XC7S&]N'=Y',WC1/M7]284+ZO,TS<
M;=Y^UZT\9N4WO<IS)^M:XR@-4J*$! 8I5L+-E&8G/%8SRS1.DS0,O(1A&^&^
MV.+2Q%L#!C_H+!P_Z@++.GW?NDD/5)_5V<W[-_:[))?I-Q,:IZ1.+#8-G^\[
M/O?1:D[=UGTWIL:EY%QN=%;9,>;@4'K,;QQ9X%2H1XM]@>N*+#YW<3-O'L4'
M\;WZ\H=8/XE?\TWUK5RE5*D1CB*8ZGJ(.)$2$BXYE!Z-?2+].!%6JC06R-+$
M2KV/OF5=U+%=8*9,<Q [L6 U)MR (R]I:\<-J') =8QPQF_ ?PA2@+N-P[-^
MUY+HM%KK6"SSUG2]DK&CRJ_7/F_F))UWS<G@N\>JK,B&*\@?'IL=PSA.4L1B
M2&-,(?:49A(/(QCX4H@D)9X2UE63FO)S18K*3#Z=X[3Y_ _13J<$K\BZ/J1-
M*N6DL'I+#2#_!@2>GX[?UW'?R5'D!WZ81E *%$&,4@*3.%$]'1.21"2@+$1M
M)[_=\#]-%W=89^G@STIEVA[V= \'WI)ZV&SP?=$^FWA4=I# M;52_65GYPUH
M+%U (M=+G;"(;*YG0?XY4KI>XMA97M>+#5U;E>IGDA5U,H*VZI72REVU^E^5
MO_)8"'ZW^:2SS^GT!0IA5M:E9G1ZH#H[T$J&./"2&$$J20!Q$*@/Q_=]Z*F_
MXLB+?!D;U1>>!-W2IEJ=<7K)0IO7Y01IB[KIG"P]&T%GI%[SV)H):CO'%L%R
MT>6& \E+=>34@XBS/FQK;TV3:VL2^J>IU>4"X L5]'+([?FJ7RX;N6).V1^(
M5B*.B,1^#%.JIPL$Q6JZP'PH>$Q0$B%*2#!R3MAO9YESNM>];%LW@(JOV4;O
MCP/:3@6N<_KW>.:A+N(J/1B$A$,<IQZDPE=S,Q1(ST^"-([&3<NN8WGZ:=4^
MQZ+&.07!%K.BL93-,:O9GY$XGHF<,MSY3&*OD?EG J=L/.G)G[QPG*R^V[#\
M7F=J;I(J[CPL@46"8Q[ V.<88LDE3)%'%7^<1RD)9!I:I9L]U]#2_.,&I\YW
M;KLK>I9*L^_;!4$3?^8[;N9)UGJ)$I<"<+:M677@DL6'<G#Q^A$GQ+I]@9_S
MXKWX2M:O\[(J5X2&RI_"&!*FMRY3$4,B>01]DI)0H@ I3\SX?-C))I:F!)]$
M=D\?53OUXIO,"[#66 '38"U.09WF<U@4W+ TL1QT^.HL1#5"\-H)-Q;GPZ[F
M:*;38=9<V9T1&Z1A\(38Z3OG.Q\VB'SO=-CPE5=&_[[]KI=%1;GRL12,4*5S
M@NISL)*H^27ED&B!2RF6@9>N*ET/R<SO.6K!2N:V[4SW9C:UG?)ME(!H<8Z,
M.]T2:>;U7$7/Q/JVBYQX>XF3\>&DAW9/$D*Z;>1EPD8/;3P;*GITX<BO6F<S
MTSL=A?BFGI<]B<9/TB%A'T1U)[7#5"\BJ)\7.BCBC6C^ORTOXWDRQ<Q#$.$8
MZ8"#%*:<"\@3(7TOYM)+K/84KH>T-/>HMDAG?=^9!+)F@M"$G?[-4D&N[S1#
MR9FU*Z;6J+H7]JP![32M"5:] <HFO5&@K)JDJI [.IU*W_6HYM5*9RP>B:N[
M)[],--C;IG2$WDSH H7BF*C)J-+E) R4CY8DD% :0Y;$7L0Y]A)LE3?2.<*E
M:74/X-*"A(Y[UV(Y_*7Z;([E=$=!0CT[EQ<D=+83EA0D= SR3Q4D=)9CUT%"
MYQL:FSQ0;[_5V3$^DN*NJ,L1-)5+U'A50UE1XI/0QQZ,J1001SR%E*LQ06 <
MBXC+Q$-6;KI!FTO3]OU=R@=2@"<-MU9TGJ_7I"B!FE\UZFXI[B9=8";7CHF=
M6(!;3C\WG"K NOQ( [F)M=$)V!OY=9DCSY@BMYGR+C<[<[X\8QZ.L^:9WWK%
MTD(O]N6#LJG-PXM)S"3W ^C)1+FF?AQ!(I0JD21*><@0"Z/ >LG@9%-+DZ!F
M$KK9X@/K'>H1BP"GZ;68W%]-VBR3]AY*Y9EM<3J>F0]RX7S&?;JU^6?2@U:?
MG"$/WS$VN$*7-]1^4C/E5@_>KK.O.*=1F@84QBQ,(0Y"'Z9^H$^%IB&5J4BY
M3.W270PU9_/VSY/MXMU&29/"6X>KYO47T2P?WH#-0.(&>Z+-A,,5>1-+QPYF
MN\Q72\<6J<O8B\M\N(V_&&AOYAB,RY8?QV$8W#-.1'[.-CK@L*G)4*A/)'L@
MZVWECR",(Y(*! /L$X@%\V 2>@GTL9^&,L(\X72U$5^U'_3%W/<8;-3H<TB;
MS^&HZ0FWV#N<V]HJ.N!=-I8T*77L5&68>3-9N9[(F1+^MC1UA5>V7+HOP6)$
MB4MI&6YP5FTQLOU07,QN&EF>A?_G8R-<Y9?\EO-,+^7HIV?\W>8U><@JLJ[G
M3?1P8>B3^.=C5F:5^"R*IXR)9@_ADV#YUTW]E'K:M6(HB3R)"$Q37RJ!B@FD
MJI]@0A/U4E(A_-0J@]K4@)<VMZHGL^T:+^NO!;=Q&I8E9*;N;C-57%(G3BRL
MMQ_?O3:HN-WMO=5QACJR"?1L<E@!9R;BG=;2F1KSO%5Y9NJ!H_H^<[4[JCIP
MG=#S(RFJYR_JHR@)JW<4N@A<O:70A09]R?M7KV(F!&940A0+"G'$U,A"$O4.
M132*@X"QE'"+$L!C<2QMU.@CWD;TZ70_10-:[Q.8K\Y=VTG#@\*,U$^L]2TL
M4.,"?3-T==9>CW26Z%*N>S?-TQ]6)7CGZ)?9ZNQ.UC^V=72O9?5"L=S1CY^S
M(NZU'!R4O;WZ<2/79[JCT>TQ:/T>_URH,5-LV/.;_)YDFU60T"B4L1J;?(_I
MO'\44JH36=%(#51^@JAGE??/H,VEC4@]I& +%?S>@#4L*F1#N>'RC%LB)QY?
M1G)HOT)CSHK3=1J#9N==K3'GX6C-QN+6:S>7#L^;2A])[/$4IIAX$"/!8))(
M!",:)]S#*9;2*CSR;$M+TY@=4.NCN^>XM-T\6O+AW0[C7(=W+W RS>[1"Q_?
MO6#S^7TC-P=XN^>^:8M+U6?DVME]]E_*X2G$@YKQWVYXO>G=9'-YDY5LG6N5
MLCQ)<64K"_HX.DN:0YDWH&>,W@RIS;FI=ZJ;V(TVT]+.IDF.5CCBU^6'=BVD
M63]'1_P=?K2N'NNDG.'[3/V/UQ/GIJ2<<C#$BI$0QZ'$$/LXAEB$,:1^$,&0
MI"P*1.0):5E+Q:39Y069#!8X7.]L:'^IC;BJ!-_IWL Q%X01 9.(!KI+ IC2
M)("^B&+/$XD(<7)%F<.K^V(.WZP'$GR<DFRSH<LUA1./3\<5$"WYO+84XB!!
M$]9$/-WN2Q9''&3B0I7$X7OMQH.RJ%:?Q5?M._XB\J\%>?B6,;)NES\PC43,
MHABJ5\N'F.@T!G'LP9#&) I9+ )DM.(TV,K2-*:/T')I:9C-84UQQM'$(F)'
MC[%B&)D_(!'J_IX\J'\=2L-P [-H@9&-W<=O=O$5AVF/MFB/#VG1PT-:;[\_
M9$6C//7^[2H)8\$)0U#X.O[84^X)B0*DJ^_QP$.1^L\J,,<9LJ6IR@X?:#)/
MCC@@ZZ3'S#R;%^F'B97+P8'87B]^'.[%<:=@73+N_/2K$W#SGWIUR>G)TZY.
M&Q@IZ/J(FG[X^VPCWJF_EBL1</5?S*%' YUZ$R4P\2,.B2\"$?O(0\*JNO5Q
M$TN3V"U"\+O&"&J0EIN")X@T%,RKZ)E:^>R8L=>NL\8[%:'C5N95D[-6'LG"
M^2NO+75QNZDRGJT?J^Q)?-:)TNO#9F^_L_4C%_QG!5HKT6,3!',GNXK7W<'5
MW9Z4+V@<I7X _9@*B(4O(8V%GN4%2ATH2Q)NE(IS.HB+TY=>P82^C6!G).BL
M!/KU 3T[]4W;<O&7SWW/]188BMN+]NW4XNB^6V<JB.&Z,Z:IBN$,Y0N5QG#-
M\OGZ&,Y;&IDR94W*\D[69T;:I2N:^![7H6>4$PFQ3P-(PM2#.$))2(7T(SMG
M\KB)I8E]C5!_W37&D2%F)Y@T$]SK^)E8,&VIL<]A<M9ZIRE+CEN9-T/)62N/
M$I*<OW+<%_[;IA#-;K,N<JUS^-UM>F%/*^R+$'N)8@VG3'WN(H5$4A^2)"4!
M1Q$/&1EQ'OA"LT:O^/PG@E]_TY-YD&T 8:QX5$Y UB4=4.,_>2+96@_V4.8%
M+(D:]<NM=-NIQ:5>,9,.%R3/HR,[I$!#;5.-:E)-0O"L5<60&)<2<ZG)6?7&
MT/Y#\3&];9P2]0);WVV4:_-%/:8=*74>$Q0+#-/ 5R*4!B&D7D*@I)A1SZ,^
MCH6-SW&^J:7Y'OT([1HJT%A'^B ##)L)BAO>)M:2L919J\AE-EP*R$!KLVK'
M9:L/9</@CA%G/#_DF[?W#^O\68A?Z]RSJSA,, J4-G!*"<0R#F'J,0D3SQ=!
MB!,D J,-R-./7YHR*("P0VAQRN^8MN%/_WHR)O[<^SR WQMXAKIXAA"+TXQ7
M$3/3(46C%\7NN.%9LP=/$1[?-=_AP+.(]\[\G;_JRKVX>@UP16))O$A** /D
M08QCIK2I":*-0LX\I5!6;LS^XY<F4+V=IAK?V.VWACO+K3=K1N;;=KM QO@=
MMSV;)]EM:UIXF9VV/>O.[K+M7V4? /E)3_!OOV?E"J$PE#$*H/33"&*JOE@2
M4J&^6,F#2*^*))YIP./VJ4O\1K.RJ@/X^G[S[QJL1:3CCK;A[W0T&3-\GB-X
ML II/++[VA#&W0-G"UD\LJ$?HGC\R[%YVK=G+-X(6NVV/UK_#&'IT5"F,(FY
M#W&<1##% 8(I)8@%# <^L]JNOM#>TK[9_A$4C=<V _LPN8:;$NXHFWJ'XH"M
M_E;NQ=G"B)3K1KRX3;<^W.3,J=:-[#].LVYVVS@]^21*H6[Z=KOA;\236.</
M=>S=+C)/-5\?I/N2?Q2%S(O[G_.B/G%7OGK6BQ7UP$9BI/SW((!!2$.E.IC
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MN1L;TR@1L:YBC:@?0>R1%":8^9!AC_DT83+"5IG7AAI;VE?;P+/[7@?)-/N
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MW:LNDS02(8JAA_2:6H(#F/(@@EZ$?89#CR*[\_3#S2U-2_J%1C<:+GAH\-X
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M@"*,Y8]Z+[=-!5+?=%VZ(>,.,YTNNN^&R2>.-630QPPZT( ^5CIU"'@6%=#
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MBN)YD*8IA<H7]43DB41-A\WSU4R(=&F:M 4,]!FE$MQW>'5.3MM4.%/V\+#
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M(\O+]*/3X6EF$^8=XUZF?XX&RA>",>+(76],UPN<M^R?CUF9:11-+9DX]:A
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MTX<WA(]OFW$/^"SF_6W?\Y>-S "@L>E\E[JC/V7E/UX7@F>5_MLJ"&E <9)
MA.(08D$]2 (?P2 0*?510CW/*JW(0%M+$[0]J-I):* "C;57H$+_L_'??E/7
M%Q7)-O;;*T-=8.:@.2)V8D'<YU2#N^G3>@,^YNN,/8/?V_]/XHD94.7TR/]
M<_,>\K]L]]&Q?H-;QJ[&J&]8S5K;0CPKPN/8XZF$@9 $8B8H)!%!$$D1A2%A
MH8SBU:;.O,N_V%3,W6O&Z%-(FT_AJ+$I%V4:E$ T,&T+X^Y3:;IZ9<_,7$M4
M+1MO+[ Q8@'JI,UN5YGVFYAY*>FD?<?K1:<O&QDH1G0(6IUV2\E%F?%V4>.3
M8")[$OQNTSOONT(\1NH7"'*"]('<%$&*4@Q3QCC!+!8!)E;A8S:M+\W%T.$;
M#T7.A.!M.<<Z<9QR-J0HAFK%.^@(,Y68C-ZI9UZD.=/WN4G$MX<==.!UC$P/
MOL/@M#&L.0U9LP(P;R#;&&Z.PMM&/61L?<:'0K"LJ?$M'M:B74JZO<^+*ONO
M9AZ>AE'*TD@?/8C5'XH82*@G(4WB%(4QBY/$:+''IM&EJ5D?<STA(CVPMG45
M#3@W4S#73$XL7'VX>H.N!5SS>6O"YXB:A^8$N:UK:-#NS+4+S9DXKD]H<>^(
M!>;#))!:^MZ5Y:/@_1"K)C?D!_%'_:MRE40^(9''(<8TAIBKOQ%$4HA)*&F
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M7F<.(>N/)./O-J_)0U:1=;L1&$O*4TH$#"7U(8YU26XB?"@)BV-!)0X2HZ(
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M0T93'BO?'WO"7SV((LOYYXH4E:&8S(/>YOL[M&&Z3_$56=<;YZ12_C&K7P:
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M+MZNQ@@.M[UP\CNA]GM4AV2X;QO"_6+<1-V\8??+-_HWKO24RU2ET"A $1<
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MI72C8%<@<Z?[-HLKS.GQQM_/\^D#U9[IIU;YI,/\9-M_WB[XZL2XKWRFXOE
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M )1!#5S( Z!<%<#(-(.<\9P;KP/(JY+&1CU.O6WN0_*'4[%#'M1Y4#TWP&)
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M82M'1$?UI-1$? D=ZT.N'_3JXT(N'W7C2+NR9-M,7:(Q1I!SD&="NL(4KM4
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M]#_K ?]8 1VSA^AY^^.V##V2,7"'T/,6GC8$O7!=-^KZM%S\<-&U'ZO",76
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M$6RE73)OU M.N+R$9I$*HC M +)K#P!QBH!(E0:0<(4P*4CN>D#X-_^.@>8
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MT.B;Z(W"25EK[$J>U2H'^"M7L?;P"6,BV#-/;,#;ZIHTRB9O^P OP+>+">)
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M"ZSQ#]$[:?,*9^RWH';^"/ZF)W;(=/C[;*ZYJO*OOMIW_,$*W;0D0:DPU*3
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MB/ I@E*Z>&^ ,VG7H%1"0!&F(*>4I]"N0M,T"UF#GI4RSK6H:2*9YU788-P
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M&VV6=ETO[=OU7!4.>:>?5EK.JO?,WGKWZ!)"_JM^U7,[*PAJ9U=ITMRE(!6
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M19R#%%)L8T@@(!12P%-$>)81(1/L7/CDLHRI#?M6R:C2TN>,J@W%=N((A,W
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MK9O5;?>/MV/M8,71MK7+]?TFL[^MENKE-[;^A]J\W2YE<W2BN4IQKBC@"><
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MINDJ>UP'3D]$SEP[?>_OQULG87._SI?JP4QLBAG.%<X@XB 6,05($6IX2J>
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M]1<XRQ3B/$\AR#!) &($F5E\9D:U1.@<2H8$\SK6>@4;IC:X_5@5][J+&@-
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MV'*SGCJ,7'2V'T+GI6=[/J<?#1XLS\I=31O!8(6_9QM5[R:(1*1:Y! (G2N
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M_%]_>_,A?<;S -/9<A5FJ;Y@.?VGY?J';^8IK-8R_RY=/SSZB?H=7'T,ZH^
M"Y#\'_]8YK_\ZS_\\,-&'(OY&;['\D/]^[?WK^^\\N^+^6R^C-/Y/Z;Y^8_U
M$S^^G!,>WH5/E=[UOU]]^X+_\I?E]/S+V?7//B^P_,M?ZK^&JEA&RJAO_6\W
M__C'&P*^+'!)F%DS_(9^</F,^K8#B<$_5CC+N.'RZC5G\W3G0V=5QO/%U;\\
M"Q'/UC^=9)Q.UD]^$9>K14BK22D^:Z\#<,<MJ&P(AP$9"*631Y4$.GZ7]TKW
MD@A?JV2)Z1\_S;_^2 _^L<JC?K$6##!^J9#_]N"E&Q$=1OW5.OQ(GYUHJ5(V
M4@*+2,1KG<$+)4#1SY@T+F@5!B#^]COOTGY;P2\6Z8?Y(N."S,G52\,B/5#V
M72A??N+'+V%!#X+T>7J6K_YUM2M#Z&TU'T!^&^40N7_Y@;@NN%A@?K/1S:/,
MK3E;D9'%]2>'T/O_?1$6],2S;^_QRWRQFB3/)7<J0RZ,"$]!@6/:0PE%2<VX
M<$H,"(%[K]\)#:)_-!PCU4Z \0X7TWG^>99?T?8\B=Q%2]LE:$U245(A!#2"
M]DT>B\-BB;\!87'GY3N!0O8/BL,EV@DD/B[";#FM@K^$=3 L,5/)CS$1#RZ"
M\S:#E63HI$U%A$'WBWOOWPD8JG]@'"77D;'Q\VPU77W[97J&OUZ<1UQ,A'.*
MN1B@))]!\9))&$E 5ID9932/Z ; Q/WW[H0%W2\6CI)C%QAXCY^F50BSU:_A
M'"<FI\ <;71:*0(R<QF<L0A1<BP*M9#!#H:#N^_>"0NF=RP<(<\N\/":PO\%
MF;.UX#^0_/'E_&*V6GQ[.<\X8<49LF,>D E%\3I/X,FRD8!*Y-E'#($-!H\G
M2=D)+;9WM PG[2[ \S'\\3J3^*9ENLEO7%I%],8$JS@DGC1%6,1#X!1A2>65
ME$YP'H<(3YXD8B? N-X!,X2$NX#*BYQ)!<O+O]Y,9\@GUC@652*!9 *]0E)P
M\%X 2U'((@/MJVDPF&PA8">(^-XA<JQD.X6'F'#MDRRT>6H1.*CJ:3M--E%B
M4M8YXYT>(FYYE(#=DE[L^>%C/]'VA(^7].7;Q<?Y[[.)"AJM$0DP20FJ$!_1
M6 U"T%\>2T ^7 3SX/6[8:/CC.@08NT)&6MGZNWBW6+^=3I+.,F&HO*0'45B
M,E)P;@UXP32@RXXYE<B9&BZPV4[#;ACI.$\ZF(![ LJ[^7(5SOZ?Z9>URVV+
M]XIY#<461_%[CG7+=."S3")BC(GCT#"Y0\%N(.DX;SJ0<$>&2+6 +Q88UG1G
MVA!33K0Q^EA *8?@BZ/=T3J67<B%2S, *&Z_<S<8=)PE/5B (RN^GLR?O?L\
MGUUE] )M?XXS"2$CUHR>HLA*6Q!6B)!<C<+S ,J__][= -!Q:O0H08X,@@^8
M+A8$8"[BQ^GJ#"?2:69C\*"1O&)EE88H48 1A%Z3'3$SQ$':_??N!H*.<Z)'
M"7)D$'Q<A%H']>';>9R?35142FMG:]Q,A&O.Z:N0P*9$$;1W$MD0X<6=E^ZF
M_HZ3G(>+L!,#\/,?Z7.8?<)U+C_Z('C1#FSD8B,%G[B#PIA P8-*@YRF;WOW
M;DCH.'MYM$"["!E>7BRJN#;GO178I(.+Y<1YY 4I]$D\&0(V(SZB3E"T3H1M
M(]''P8*&[33L!I#N<Y<#"+@+H+R>T=-('-.O^"JLPB5;$V>YIA@Y@@M6@3+*
MTU=&@@\2L_5:D6LTX/'9-AIVJ]7J/HDY@("[ $HM'5B\#"O\-%]\FPB*CK.5
M"721#%0(!EQD 5!F&30ZIN5P2:H[K]X-%MWG+P\79Q=H^' >SLY^NEA.9[A<
M3HHN03C:#[.7#A0C-SDX4S59BL&8=1ZDKG?+JW=#0_>9RL/%V04:?C['Q2?:
M!/^ZF/^^^OQR?OXES+Y-I,0HG!.0>283IT0&1V*@@)J)4O,I6(:S$5M)V T=
MW:<HCQ=O'RCYXZ80<5.K.DE.A,Q4@"Q-!.6,@J#IJQA]5!IE80,:CH?OWPT?
M'><N!Q%L%^#X\!G/SJZ@'9)@W&<.7D5=ZU,%N"(EA*)%48Y\)S6<]WG[S;L!
MHN-<YI'"[ (*1/AYK3&;I[]_^$QR6[Z]6-6+:35!,S')FLRL !N0 BQ1 @0I
M"T2%(6J;C6%J,&@\1<EN4.DXXSFPL/N #DEN$<Y>SS+^\7_AMPF%5249Q<%I
M+2@<3T0[)@T<64*.R+P9,-]Q]^6[ :3CG.CQ(AW[:'03:_\R7:9P]A\8%E=W
M8ZRII<XB >V1E0>NP-MD:+,45MK,M)!#5'D^]O[=D-%QCG00P79RZ>B&B5_H
M)\N),YA0*0::F4PL2 K%M27#Y^@_$SE7N@R C4=>OQLT.LZ.#B'6KI"Q<:@W
M3,0BB-9DP64F:Q.  LZ1DQVRMR5([;T=HKSB40)VNZG8<4IT&-&.C(\7Q$%>
M<W$6/DV8U)%GU."U10*VLN"YY\"2">@QA,*'N&ARYZ6[X:#C'.CA(AQ,]__\
MXP/AO:$?'-&-@CRDV1+S3^&L-M&@& Q7R]]FX2)/5WBO7F37'A5//W*HSA5[
M$'YD/XN+)7P*X<MD79)9]?^V_#*=T5NG9 WFFPS&#;AT$,$J0^&&H>A#ED(
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MRU[*Y-'.9^L6WW],EQ,IR' C^1G,6K+GF9QC[Q.%4CH''U3D6C0Y)7F2JDX
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MUF7,2SM,9!8F'5',55U:)H W/H/G2CJ3A!2R377-?4K&Q<T VKU?-'.4J#O
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MUHB[0U OJ?&6Z#I< WTAJ9;(3O/E;:'WF'#Z%?/;.\N$)8I&9"2G4]9EPF*
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MXC 7BN5U%5V(X*2ET#[3]TY&Z4T3WZ\50^/F=1IA]HGP>#PT=-M[\99T#F]
M^_ A@UO-ALUF]\"A\<%FK6.MZRY &S #;U%"-DHDSUE@HDFQU2BV\^596"ZG
M98KYIV\44JT??Q'._A96]9W?7H45WNM&JA@/"BT"B<B!LB*#,]$ !5,^DVRD
M:3.:^QBBGXT-W =[3]C MEI]#G;NVNL-L_SB?+Y83?\+\\OY<G5$R]E]'C^X
M;=R/H=-;32V4BTIQX,D+BFZCI6A%.\B^J%2X#QB:Q(.GLYHW39W_#<_RQ_G5
M:KIYT^8PU7.?> P<<G"TE)BD""YA 5K81M)ODN5-)+$C?<_&%NZ#J,<;< ^G
MJPYR,H]=0C<^HC110DKU$#\%#T%[3?)RQG)4S)@VW8^/Z$+1#&)-=+]CCXE]
M%-$!G@:M7(Y2&&U2@%"$J\?A$J)UY$*(Z(OU0="J;0'"/W^/B;U0U;+'Q#XJ
M[@#>3]T=%ZH(*Z4 86,]&T+RN4T0X 5B]"9BL4WN=!U[X_]Y=)O8"RA[W/C?
M1VL] '#K/7)K>3%*(@ANB0GD'KQ)#J0+%&HH:P5O,M;T\!O_SZ/-Q%&@.UI3
M7<#MR7OCEENFK246>*"U8]:YA0+9N,0+RIS:[,_'W_A_'@TGCH/?4)KK (:[
MWQ /A0<5/3A;Y^DZ;2"@([XRMP:-E 8;W:L>\,;_\VA'<0PXF^BS"YP^>GO<
M8DY2D7RX2P64+10;<J% 9N=M"10P\B;GIT?>^'\>W2>.P^(@.NL ?4_<>5/H
M"V<A07!<@V*^)N/)Z<WDBV2AG)>F36^>XVZW-O,23Y'1&4@='0#KJ&MN5D:M
M= Z  9%6I""N65:@DA#,$^\L_N^[JTV ,^3=U7VTV %B'[D?J9C1@I&\D$5)
M!MTI<(5D:&-M/,F8YFVP^*>[N[H7'':[N[J/;CI V/=WD#?7=9?:",:-=E!D
M(M8X,1EYXF!M4"BU5=(T'JS[71K'C9I/L1VW4E@'6+R_4ZQ>AL7B&_G3Z^/]
M28E>:86QNK&T6#%G"%+3\LI<,.4*8]RW<OX>)ZOW([T#T;#%"1Q(-?L#S6^
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M[O@8F_YJ,3)OM'(0LR_U0DI4=Y+</_+V:K*-Y[H\YR'ML<ZXP#A5A?,V\NS
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M;?\UN[P ;&R^3I#ZV& ZX6K^4[C Y3^F],-J/L.-?";9!)7JH"V.K,[PJLV
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MC5IN]T.V6OE89V!C]%?3])QF$;0TR1D1A3!-'BA>A+LNK=HA*'U0$-,=)L[
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M>.8_9-6>[KA/@U=;@8^-I"JIV[UQ4Y&TYNM[F/V<& S&"N.@U.9L2H@ T:.
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M!"$+!29*:WC=*JG)L]Q.BKH:_7 <(IZ9_'"D],_&BIR00K7K4VUL2LNDJ=U
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MN+7?[Z] O;W;9$:6);\2.VEFG,=NTWUE$F]W]M,=B(0D-!2I$J1E]=??\P!
M\"%%WDTLV7&GD[4D$C@ SON%YW]Y_<NKR]_?O1'38I:(=[^^_/'M*[&W?W#P
MV]&K@X/7EZ_%/RY_^E$<]P=#<9G+U.A"9ZE,#@[>_+PG]J9%,3\_.%@L%OW%
M43_+)P>7[P]PJ..#),N,ZL=%O/?B.7X#_RH9O_B?YW_9WQ>OLZB<J;004:YD
MH6)1&IU.Q&^Q,A_%_KY]ZE4V7^9Z,BW$X>!P('[+\H_Z2O+OA2X2]<*-\_R
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MY*@W!$[>)N0_+%IJ>/4VU2@=Q+]@&$R\:,NWN@QB<8<#Y&HF=8KOE*D5LAU
M_FG)5!T3"2<OAT+A1"^&B;_P=-?"'L36'?%)O:$TR3>60VS%HKH ?%U)=,"+
M]&RF8@U(A>@;T#"%=3!!TPJ\+%5B:H-'P* B8NSH[7SL\'J53$%*4=<@HM()
M)4/AJ$[A6R&JUAAU@;;8*;F8V%V*:T],LP7(AMPFQ354YCJ<CCT'ZK_$/%(G
M7[F@KPZ,__$]_EC5":3 UZ\P2Z^^$@(BD7/#V](51C.8X53""<3*1+D>H68P
MRJX4G.6OQ!Z!#^M4NDJ#1JI;W<6(?C\OGS1PH2; K6.FO,6<G((K]PG/D$.#
MO)V-(>%/2FND9<8<>&'96)-[F\C-SQUHN M<+=YY9?PBBE2B*!+DQ-(66-L7
MS8HX&^PD;N@MX\99?WA(%0K 'BIM*70U!UQ+I[4(@C@6CP!2S .FI&#F5,X>
M"<=H^$ZL@KE& %E O/:(V;OE;.9Y)!8YD/0A.4.ZNW@D$=8Q+#=V^:)HXSQF
M%IU%$1A Q+N0:V-$EA.$+?.J5.V0W3*D!OE=.0(3A#*?;8V/JY'8N-KFZ4G_
MY#/I;[N*S=M&Y]/^&6$S&01D,[G8^TU/M2<<$K$AZO+5:\F%0 M.> /2H>3-
MRD*\DB4(P97HF-D"0_=B:U24QM]G68QYL0;]!O61'/4-AZ O/Z;<:*4I/O@0
MCM\@'+^"=&Z54"+4K4)6-%(3G9+)6G<'2\*QLP$:E:;.L!359: 'GYZ]*5/D
M<IIXU93#0[9=3<-X[9B!W&-V'6R)DZ/%UGZ@=0LX.FYB]6.2%H#<%X])-UTA
M?%A@A":-,]71B=ZC93QZR4-T&$5D + _H&8+(3 2A8[.*.@#.QS:[\U5NQUF
MCE*IZSV[8*L[TP[ 5I2I4X4[/0^\)G4]U[E:;]RDV2K'3^6K"[TT?O=I<"\M
MT4Z8R6L]*V<$_89*^'I*N0_2:MOBZKA_2JM^"\>44X)&)B9(TDS<^-%R>R..
MP8Y MQMA/+JZR(;LH6%6*U "! 0E#1$W<ZI3D:._K:J9L=5LE3_7DK!BTIMC
M@'$"@^<I#^A^D!2)RM4$_H._>++$<<<@A$KV<'I:MLZ LL/*M851PF:IQ66%
MKB!NBOT5CU<V)M&NZ0642ESH$[9TBDJG_X&7I7UH589,IQ+072:UB][EU6I)
M@T#:K+P-1+VUW1LIK![S++V"OLE;;L$E.),YB)U]*^>'I!WL?J[.R1W(U;G&
M^H(ME?Y?!IJNE7]Z-@+C1_F\4*Z&S6>8C58:E]>:*LR%I11S"S^21IES^ 8$
M;HY:IBLSW;3^EHD?1"-IV9'2\Z)1Y4VZ"T;>0+]!<KO*@!14;H*:V#R#9SS9
M(G0Q<1N>V:?C=7G@B+'Q>JJ=\&$C'_&;9V (+%UJ7;M"'8N!XFS>4:-^S\CK
M=/?)ZZ5*0:4MMD->%X9\R),R 5T1E=!]P@\6,DHU0L$H6(J$2\BH3#'2<\1Q
M9UO:M^!17I*M?N5R;<Z--RI%M=]G@3<IK+?*[^P#GYQW[F9 \<YT Z@_R>7,
MP*I>JP*FI'0+"ER1#A \XUWIOM6$]930XF&.*2BS=>9#<.&$8#-BAP<3Y8J5
MYJFUQ]G]C@(5Z)%D:25SV4XGD!F8+/>PA)83PN@,;[:/0"$"3<&5 DZ53(I@
M]3YBZ\TG:_ZT[2EB-K@N-%_(9&<NIE*J@EE,;0C;%Q<VZ].Y$=&F13*[R0Z>
M[#X[>(=5#]@;$*OVM\(37F'/$U-T-2;P(7X'H'A'DJ;GNAP0N5$\OJ/-0<5+
M,/X"1)Z7(!]EQ JN1^H1(#]F%X3<1E+=B@HHBFMD4,$&X8J-,QWQCFL!,B<1
M20820*:<H_IM,NXA@X%O;BY#@P0MK.8X6=$7O]IL\XX2,KMXW^$&<)P)TK>.
ML>;Y3*G"V=\HOZ-"\B0(@LU[MREB=M]\NR[06I*2NS4PQ5*2 [QNQA)S3+$0
M'=U\"<] 2?M9CHD7!@B/!P63'MFO_.B&P7TB!J=91>!)D'/C$SX1GXJ9<"7T
M)WH>L"JH4(F:3]'VB"1U&9QE(QQ_A@K7)%1C<.TSGW9:IIK/NB^^0P98YK#(
ME@1H[2YYZ=NGK#E$&?-Q(7RNS0\H9MDDI>2F*8Q!I@D61NOHHTB4Q%CE[^[$
M+!96OY%W/D3_H.@AD8N^^% ]:NL62F-[H.#!&96,R0053)6P*[,1[P3;AEI.
M@(]JV+:(<FC@:VS5ZDNUT+>C.9G"LGN/DRPVR(6+K!W?YY)O0"@]UFBUN3VM
MV<>K=]<) X1$BBO,HJ4.)3&ZE$'RP%<@[T <]&#$:]*MX8S+A%NH8/X(HM1&
MC44JRF]H$H"6L)49-3J!U1>+C/N;V#*QA5(?&4?<R3L)N6E?E/[M9_OOIOA[
MNOOB[[W"ZB38GH __B9S3 O;5O<YY!68F#6BP I#QYH:P]7,)]L\*>#VLI\.
M#_MG9[>,;7K+V,8^V)=+Y/%J[L5ODQ%RETS,<0L\:\BPJL/V[9THYS#-*F<C
M<'&./ &N3O7<$%ODC%HK>9W5[OIAH1C#AX@#VHP;GQ)*3Y/XST9PF)8&Z@45
MNUFF?GC2/QS>-H+M!H;][A"#A%Z)/BI\O@<B=F$;%29J@KJE:_B$NA1F$G-#
M095@%FEG&G#5VRSL@U:I5R&6((LB1NKTNFHL%(N ;66AV%1]"*W^\4KG6\5P
MPIL>YEV#44C9S-I&.?W!.UW'MHWJ 68!PD2*8VC8E<\4;)9U.%;0W"+'"N#,
MSY6U9)B+D2YE6"E=6M9E/._2MNS?&PMCEPN06?>.6H??6?Z'<'OK&7>@PQP?
MW3JCVQU.UZT"U4542V""SI]G)?K'Z@TL1^0T<%*O,0K)TM)X]^+JSI ]P=FD
M@,K:8F]L[Z_PZ$O-VYP[0MGND(B_"$?5NJ+FK*19*:FF)\HTP=B 7U0V*B0E
M(CC;PY74,%6RSYVMH-J\U@[49.&#I69<.U!<J?51LD^RJ(4^4(T FIPO79G.
M#4CA'ILT9[MOTKRJ7$J 4U7VPY;B:;I3Y45W"K?]G. G[H2*Z-ATXOE@0.5E
MNX'5<]]K/G:CG'[OA8VO5.I!T^HAP0N_O:- I2HP4/HV)?[J&Q2_3:]LN^(+
M[TL,-=1FNU.SDZU@7VZC%2SG4 $K)Q@,2(^@XA(Y/8HH;:(D,^7J0KIY<#BZ
M.AQ*LWJ@M]TI#=Y[X1SP+J%[)*./$U!Y,"_Q6OHD'JM3Y)0T2%J&=^1WT:JM
M"]Q%A]+76DZW]X)/;.G<2<W@#15%SF9Z8E/ 7&8I,M3WBMCN!78@9P[A.K-&
MA$#:3#DCPTPYC8HC02Y?Q$>8*;[C+C/H?^B3>DB?L8<BQSO&+I)+8;E*?C_Z
M(KM(XYSK C FVN PC5*W+BOV7N"=>O;JIN,G_ _>KU>:2)O^)+NB;_3^F4VH
MA>/@B RY#XE:Z2AZG(( XHXS&(&7ZXG&V%2<HZ7KV3?L!27J=#7#BF0>DX'#
MV8]@OAN#*7=KNNQ^5=2^&V5F>R\^$=@J*G7:DC(^'>=RD3;SPCJ+=5 WJ'2U
M37.Q[J\Y-QQLVYX[[-.5BQLU^]B7,#)%D8'"+ZMLUQWJ%8["A8'$;"]R_\%:
MDV5UV</JTIW6M13-5*6Q3;5F?09$FBQ,QAG_+D:+P5G[)]T $BF;TM3#BWKF
MR1*1'K^I)*J;#00:^E8HOBP^N%M]VA7$JQ=P0WA#8"-IM?0ZU,Z"=@<?!G_@
MG=2&M[F:''4_ZKJ(GE>W%H&6E&M=%6/W]L RX):H79>^P-)L/X]J>9P2AU:[
MK$IB:DY6RG4Q*E9!"*J*73EWTTP;97/U;+O59DJKV[8J-LNI9I2NHP#1QN&M
M,>BR=EXQ>!6/66_<E?6>A^"'6[\#[M,,[@.2!"+];K63[\A ME\5V;PC(WDS
M=_ZP?]LHL'4GT5G_R!7J-$I"0X:YOCRTP2$VJQ8EA=?>/;&N+G2DDFQA:^JX
M1<]F)#\</-U%FM]Z7?SA$UL8'QX9ZP=SN;27:E$B7$S9EV5*O;>#7N-H6F(
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M>//E!S&D"KH%)K'2_V'V\4Q6$N)</;Z*20\""I15].02#I%+: "DQ)0I*U#
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M;>E!VF,>+O?;(;U -'Q;HCAP'=>N-.OC"%>:C<8XK#:K7L6N>Z'=;.#*/PZ
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M+3(P,C P.3,P+GAS9%!+ 0(4 Q0    ( )M <E%3<]?\02,  (1U 0 5
M          "  7Y[ P!K<F]N+3(P,C P.3,P7V-A;"YX;6Q02P$"% ,4
M" ";0')1/$>5TN1D  "74 0 %0              @ 'RG@, :W)O;BTR,#(P
M,#DS,%]D968N>&UL4$L! A0#%     @ FT!R4=2D(J@,YP  $-4) !4
M         ( !"00$ &MR;VXM,C R,# Y,S!?;&%B+GAM;%!+ 0(4 Q0    (
M )M <E%ODE7929H  "\8!P 5              "  4CK! !K<F]N+3(P,C P
M.3,P7W!R92YX;6Q02P$"% ,4    " ";0')1#(W7FJLD  "UZ@  %0
M        @ '$A04 :W)O;G$S9GDR,#(P97@Q,#$N:'1M4$L! A0#%     @
MFT!R46X)G0F("   #4@  !4              ( !HJH% &MR;VYQ,V9Y,C R
M,&5X,S$Q+FAT;5!+ 0(4 Q0    ( )M <E':^<7C;0@  )9&   5
M      "  5VS!0!K<F]N<3-F>3(P,C!E>#,Q,BYH=&U02P$"% ,4    " ";
M0')1O/T/\-,%  !@+   %0              @ ']NP4 :W)O;G$S9GDR,#(P
?97@S,C$N:'1M4$L%!@     *  H E@(   /"!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
